

Friday, March 29, 2024

Volume 40 No. 3



NOTICE – Items in this issue will be listed online weekly and printed monthly.

NEW COMPANY DESCRIPTIONS

(For details on individual listings, see the News Section of this issue)

Blum Holdings Inc

AADI BIOSCIENCE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
License revenue	1,000,000
Product sales, net	24,354,000	15,216,000	...
Grant revenue	120,000
Total revenue	24,354,000	15,216,000	1,120,000
Selling, general & administrative	44,549,000	40,176,000	18,511,000
Research & development	48,929,000	32,662,000	19,670,000
Cost of goods sold	2,809,000	1,335,000	...
Impairment of acquired contract intangible asset	...	3,724,000	74,156,000
Total operating expenses	96,287,000	77,897,000	112,337,000
Income (loss) from operations	(71,933,000)	(62,681,000)	(111,217,000)
Change in fair value of convertible promissory notes	1,585,000
Gain upon extinguishment of debt	196,000
Interest income	6,400,000	2,398,000	13,000
Interest expense	231,000	230,000	665,000
Foreign exchange loss	(1,000)
Total other income (expense), net	...	2,168,000	1,129,000
Income (loss) before income tax expense	(65,765,000)	(60,513,000)	(110,088,000)
Income tax expense	2,000
Net income (loss)	(65,765,000)	(60,513,000)	(110,090,000)
Cumulative dividends on convertible preferred stock	647,000
Net income (loss) attributable to common stockholders	...	(60,513,000)	(110,737,000)
Weighted average shares outstanding - basic	26,917,967	22,511,237	8,923,369
Weighted average shares outstanding - diluted	26,917,967	22,511,237	8,923,369
Year end shares outstanding	24,554,205	24,435,007	20,894,695
Net income (loss) per share - basic	\$(2.44)	\$(2.69)	\$(12.41)
Net income (loss) per share - diluted	\$(2.44)	\$(2.69)	\$(12.41)
Full-Time Employees (Period End)	89
Total number of employees	89	79	39
Number of common stockholders	84	86	113

	2023	2022
EPS - Basic - excluding Extraordinary Items
Applicable to Common - Total	\$(2.44)	...
EPS - Diluted - excluding Extraordinary Items
Applicable to Common - Total	\$(2.44)	...

Reclassified to conform with 2022 presentation; Includes related party amounts - Research and development: \$200,000; Includes related party amounts - Interest expense: \$600,000; As of March 23, 2023; As of March 11, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	62,888,000	39,019,000
Short-term investments	45,957,000	133,541,000
Accounts receivable - Balancing value	5,688,000	...
Accounts receivable, net	5,488,000	1,862,000
Raw materials	4,640,000	944,000
Finished goods	421,000	917,000
Work in process	1,366,000	...
Inventory	6,427,000	1,861,000
Prepaid expenses & other current assets	3,826,000	3,746,000
Provision - Accounts & Notes Receivable - Trade	200,000	...
Total current assets	124,586,000	180,029,000
Computers & software	464,000	338,000
Construction in progress	4,389,000	77,000
Furniture & fixtures	...	65,000
Leasehold improvements	129,000	129,000
Furniture	65,000	...
Equipment	25,000	...
Total furniture & equipment	5,072,000	609,000
Less: accumulated depreciation	270,000	101,000
Property & equipment, net	4,802,000	508,000
Operating lease right-of-use assets	1,169,000	1,522,000
Other assets	1,866,000	2,178,000
Total assets	132,423,000	184,237,000
Accounts payable	5,898,000	3,519,000
Accrued bonus	3,081,000	5,463,000
Accrued clinical	1,416,000	2,399,000
Accrued professional fees	2,504,000	1,814,000
Advanced customer payments	...	1,571,000
Accrued salaries & payroll	1,590,000	1,299,000
Accrued contract manufacturing	4,315,000	405,000
Accrued other - sales related	772,000	1,435,000
Accrued other	...	536,000
Accrued liabilities	14,306,000	14,922,000
Operating lease liabilities, current portion	434,000	394,000
Accrued liabilities - Balancing value	628,000	...
Due to licensor payable	5,757,000	...

Total current liabilities	26,395,000	18,835,000
Operating lease liability, net of current portion	833,000	1,267,000
Due to licensor	...	5,757,000
Total liabilities	27,228,000	25,859,000
Common stock	2,000	2,000
Additional paid-in capital	374,129,000	361,689,000
Accumulated other comprehensive income (loss)	27,000	(115,000)
Retained earnings (accumulated deficit)	(268,963,000)	(203,198,000)
Total stockholders' equity (deficit)	105,195,000	158,378,000
Total Equity	105,195,000	...

Recent Dividends:

1. Aadi Bioscience Inc common.

No dividends paid.

Annual Dividends:

1. Aadi Bioscience Inc common.

No dividends paid.

AAON, INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

	2023	2022	2021 (revised)
Revenues	1,168,518
Net sales	1,168,518	888,788	534,517
Cost of sales	769,498	651,216	396,687
Gross profit	399,020	237,572	137,830
Selling, general & administrative expenses	171,539	110,823	68,598
Gain (loss) on disposal of assets & insurance recoveries	...	12	21
Income (loss) from operations	227,494	126,761	69,253
Interest expense	4,843
Interest income (expense), net	...	(2,627)	(132)
Other income (expense), net	503	399	61
Income (loss) before taxes	223,154	124,533	69,182
Current income tax provision (benefit)	52,058	37,489	6,755
Deferred income tax provision (benefit)	(6,527)	(13,332)	3,669
Income tax provision	45,531	24,157	10,424
Net income (loss)	177,623	100,376	58,758
Weighted average shares outstanding - basic	81,156	79,582	78,606
Weighted average shares outstanding - diluted	83,295	81,146	80,593
Year end shares outstanding	81,508	80,138	78,792
Net income (loss) per share - basic	\$2.19	\$1.26	\$0.75
Net income (loss) per share - diluted

per share - diluted	\$2.13	[Ⓐ] \$1.24	\$0.73
Cash dividends declared per common share	\$0.32	[Ⓐ] \$0.29	\$0.25
Full-Time Employees (Period End)	3,856		
Total number of employees	3,856	[Ⓐ] 3,666	[Ⓐ] 2,881
Number of common stockholders	1,030	[Ⓐ] 955	[Ⓐ] 955
Gain on disposal of assets	13		
Basic EPS Excluding ExtraOrdinary Items	\$2.19		
Diluted EPS Excluding ExtraOrd Items	\$2.13		

[Ⓐ] Adjusted for 3-for-2 stock split, August 17, 2023; [Ⓐ] As is; [Ⓐ] As of February 22, 2023; [Ⓐ] As of February 22, 2022; [Ⓐ] As of February 23, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	287	5,451
Restricted cash	8,736	498
Accounts receivable	138,431	127,635
Less: allowance for credit losses	323	477
Accounts receivable, net	138,108	127,158
Raw materials	211,259	194,159
Work in process	5,523	3,501
Finished goods	2,910	5,806
Inventories, gross	213,532	203,466
Less: allowance for excess & obsolete inventories	6,160	4,527
Inventories, net	207,372	198,939
Contract assets	45,194	15,151
Prepaid expenses & other current assets		1,919
Prepaid expenses and other	3,097	
Total current assets	408,954	349,116
Land	15,438	8,537
Buildings	205,841	169,156
Machinery & equipment	391,366	342,045
Furniture & fixtures	40,787	30,033
Total property, plant & equipment	653,432	549,771
Less: accumulated depreciation	283,485	245,026
Property, plant & equipment, net	369,947	304,745
Intangible assets, net	68,053	64,606
Goodwill	81,892	81,892
Right of use assets	11,774	7,123
Other long-term assets	816	6,421
Total assets	941,436	813,903
Accounts payable	27,484	45,513
Accrued warranty		15,682
Accrued due to representatives	14,428	15,545
Accrued payroll	11,901	
Accrued profit sharing		5,451
Accrued workers' compensation	338	367
Accrued medical self-insurance	1,460	1,178
Accrued customer prepayments		3,750
Accrued donations, short term		637
Accrued income taxes		12,472
Accrued employee vacation time	10,315	6,329
Accrued extended warranties, short term		1,330
Lease liability, short-term	2,021	1,254
Other accrued liabilities	6,559	2,734
Payroll	18,829	
Warranty	20,573	

Profit sharing	7,596	
Other	3,389	
Accrued liabilities	85,508	78,630
Contract liabilities	13,757	21,424
Total current liabilities	126,749	145,567
Revolving credit facility, long-term	38,328	71,004
Deferred tax liabilities	12,134	18,661
Long-term debt, less current	12,194	
Lease liability		5,993
Extended warranties		4,539
Donations & other long term liabilities		976
Other long-term liabilities	16,807	11,508
New market tax credit obligation		6,449
Common stock	326	214
Additional paid-in capital	122,063	98,735
Retained earnings (accumulated deficit)	612,835	461,765
Total stockholders' equity	735,224	560,714
Total stockholders equity	735,224	

Recent Dividends:

1. AAO, Inc. common.
No dividends paid.

Annual Dividends:

1. AAO, Inc. common.
No dividends paid.

AB INTERNATIONAL GROUP CORP

Earnings, 3 mos. to Nov 30 (Consol. - \$):

	2023	2022
Total revenues	801,747	236,812
Cost & expenses	318,096	517,417
Operating income	(28,158)	(1,204,104)
Gains or losses	85,000	
Net before taxes	43,600	(1,204,025)
Net income	43,600	(1,204,025)
Balance for common.	43,600	(1,209,790)
Earnings common share		
Common Shares:		
Full Diluted	2,008,456,325	481,889,485
Year-end	2,566,965,321	659,550,369

Consolidated Balance Sheet Items, as of (\$):

	2023	2022
Assets:		
Cash & equivalents	261,087	
Current assets	318,087	
Net property & equip.	7,146	
Total assets	2,656,363	
Liabilities:		
Current liabilities	1,115,714	
Stockholders' equity	993,467	
Net current assets	(797,627)	

ABEONA THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	[Ⓐ] 2021
Special charges/unusual items	(1,065,000)		
Product sales	3,500,000		
License & other revenues		1,414,000	3,000,000
Total revenues	3,500,000		
Royalty expenses		450,000	
Research & development expenses	31,091,000	28,965,000	38,726,000
Selling, general & administrative expense	1,605,000		
General & administrative expenses	19,004,000	17,256,000	21,644,000
Impairment of goodwill			32,466,000
Impairment of			

licensed technology			1,355,000	
Impairment of right-of-use lease assets			2,511,000	
Impairment of construction-in-progress			1,792,000	
Income (loss) from operations	(47,135,000)	(50,915,000)	(89,836,000)	
Gain on settlement with licensor			6,743,000	
Paycheck Protection Program ("PPP") loan payable forgiveness income			1,758,000	
Interest income	2,117,000	431,000	40,000	
Interest expense	418,000	736,000	3,656,000	
Change in fair value of warrant liabilities	(11,695,000)	11,383,000		
Other income	2,943,000	141,000	15,000	
Income (loss) before income taxes	(54,188,000)			
Net income (loss)	(54,188,000)	(39,696,000)	(84,936,000)	
Deemed dividends related to series A & series B convertible redeemable preferred stock			3,782,000	
Net income (loss) attributable to common shareholders	(54,188,000)	(43,478,000)	(84,936,000)	
Weighted average shares outstanding				
- basic	21,380,476	7,861,515	[Ⓐ] 3,937,676	
Weighted average shares outstanding - diluted	21,380,476	7,861,515	[Ⓐ] 3,937,676	
Year end shares outstanding	26,523,878	[Ⓐ] 17,719,720	[Ⓐ] 5,888,217	
Income (loss) per share - continuing operations - basic	\$(2.53)			
Net income (loss) per common share - basic	\$(2.53)	\$(5.53)	[Ⓐ] \$(21.57)	
Income (loss) per share - continuing operations - diluted	\$(2.53)			
Net income (loss) per common share - diluted	\$(2.53)	\$(5.53)	[Ⓐ] \$(21.57)	
Full-Time Employees (Period End)	84			
Number of full time employees	84			[Ⓐ] 90
Number of common stockholders	248	[Ⓐ] 39	[Ⓐ] 166	
Foreign currency translation adjustments		(3,000)		

	2023	2022
Cash & cash equivalents	14,473,000	14,217,000
Short-term investments	37,753,000	37,932,000
Restricted cash	338,000	338,000
Other receivables	2,444,000	188,000
Prepaid expenses & other current assets	729,000	424,000
Total current assets	55,737,000	53,099,000

[Ⓐ] Reclassified to conform with 2022 presentation; [Ⓐ] Adjusted for 1-for-25 stock split, July 5, 2022; [Ⓐ] Shares increased due to issuance of common shares with restricted share awards, under open market sale agreement & stock purchase warrants in connection with public offering; [Ⓐ] Shares increased due to issuance of common shares with exercise of stock options, restricted share awards, under open market sale agreement & stock purchase warrants in connection with public offering; [Ⓐ] As of March 21, 2022; [Ⓐ] Approximately; [Ⓐ] As of March 21, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	14,473,000	14,217,000
Short-term investments	37,753,000	37,932,000
Restricted cash	338,000	338,000
Other receivables	2,444,000	188,000
Prepaid expenses & other current assets	729,000	424,000
Total current assets	55,737,000	53,099,000

Laboratory equipment	6,935,000	7,636,000	Income (loss) from operations	(8,216,509)	(15,114,412)	(11,705,968)	Accounts receivable, net	1,530	98,325
Furniture, software & office equipment	986,000	1,379,000	Interest income	185,481	187,817	43,196	Accounts receivable - related parties, net	10,463	757,343
Leasehold improvements	8,603,000	8,605,000	Interest expense	2,493,340	293,968	227,210	Due from related parties	747,573	513,819
Subtotal property & equipment, gross	16,524,000	17,620,000	Impairment loss	...	110,125	...	Short-term investments	79,312	75,797
Less: accumulated depreciation	12,991,000	11,879,000	Operating sublease income	65,900	107,150	134,576	Prepaid expense & other current assets	101,051	150,235
Property & equipment, net	3,533,000	5,741,000	Operating sublease income - related parties	4,800	Total current assets	1,656,709	2,987,247
Right-of-use lease assets	4,455,000	5,331,000	Investment loss (income)	...	7,446	...	Software	174,797	...
Other assets	277,000	43,000	Gain (loss) on investment in equity securities	(221,888)	...	(269,844)	Land	363,416	361,193
Total assets	64,002,000	64,214,000	Other income	3,384	(24,149)	22,409	Buildings & leasehold improvements	2,227,431	2,226,687
Accounts payable	1,858,000	1,811,000	Government grant income	360,898	Machinery & equipment	1,138,675	1,116,789
Accrued employee compensation	3,688,000	2,593,000	Gain (loss) on foreign exchange changes	22,690	(259,463)	426,316	Office equipment	...	173,766
Accrued contracted services & other accrued expenses	...	1,398,000	Total other income (expenses)	(2,437,773)	(400,184)	495,141	Construction in Progress	7,400,000	...
Accrued expenses	5,985,000	3,991,000	Income (loss) before provision	(10,654,282)	(15,514,596)	(11,210,827)	- Gross
Current portion of lease liability	998,000	1,773,000	Current state income tax	...	2,400	...	Property & equipment, gross	11,304,319	3,878,435
Current portion of payable to licensor	4,580,000	...	Deferred foreign income taxes	...	795,378	...	Less: accumulated depreciation	3,335,041	3,304,457
Deferred revenue	1,000	...	Provision for income tax expense (benefit)	256,006	797,778	825,024	Property & equipment, net	7,969,278	573,978
Other current liabilities	...	204,000	Net income (loss) attributable to noncontrolling interests	394,632	(110,865)	(802,962)	Operating lease right-of-use assets	809,283	1,161,141
Accrued expenses - Balancing value	2,297,000	...	Net income (loss) attributable to American BriVision (Holding) Corporation & subsidiaries	(10,515,656)	(16,423,239)	(12,838,813)	Long-term investments	2,527,740	842,070
Total current liabilities	13,422,000	7,779,000	Weighted average shares outstanding - basic	4,335,650	3,166,466	2,505,352	Deferred tax assets	...	117,110
Payable to licensor	31,352,000	4,163,000	Weighted average shares outstanding - diluted	4,335,650	3,166,466	2,505,352	Prepaid expenses - noncurrent	78,789	135,135
Long-term lease liabilities	4,402,000	5,854,000	Year end shares outstanding	7,940,298	3,285,733	2,892,632	Security deposits	62,442	58,838
Warrant liabilities	...	19,657,000	Net income (loss) per share - basic	\$(2.43)	\$(5.20)	\$(5.10)	Prepayment for long-term investments	1,274,842	2,838,578
Total liabilities	49,176,000	37,453,000	Net income (loss) per share - diluted	\$(2.43)	\$(5.20)	\$(5.10)	Due from related parties - noncurrent	113,516	1,141,378
Common stock	265,000	177,000	Number of full time employees	16	19	28	Non-marketable Cost Method Investments, net	2,527,740	...
Additional paid-in capital	764,151,000	722,049,000	Number of part time employees	3	4	2	Total assets, net	14,492,599	9,855,475
Retained earnings (accumulated deficit)	(749,524,000)	(695,336,000)	Total number of employees	19	23	30	Short-term bank loans	...	1,893,750
Accumulated other comprehensive income (loss)	(66,000)	(129,000)	Number of common stockholders	656	666	706	Short-term loan	899,250	...
Total stockholders' equity (deficit)	14,826,000	26,761,000	Foreign currency translation adjustments	...	(22,532)	(25,200)	Accrued expenses and other current liabilities	3,696,380	...
Total Equity	14,826,000	...	Earnings per share from continuing operations	\$(2.43)	Notes payable	112,946	...

Recent Dividends:

- 1. Abeona Therapeutics Inc series B cumulative convertible preferred.**
No dividends paid.
- 2. Abeona Therapeutics Inc series A cumulative convertible preferred.**
No dividends paid.
- 3. Abeona Therapeutics Inc common.**
No dividends paid.

Annual Dividends:

- 1. Abeona Therapeutics Inc series B cumulative convertible preferred.**
No dividends paid.
- 2. Abeona Therapeutics Inc series A cumulative convertible preferred.**
No dividends paid.
- 3. Abeona Therapeutics Inc common.**
No dividends paid.

ABVC BIOPHARMA INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Revenues	152,430
Revenues	152,430	969,783	355,797
Cost of revenues	302,037	286,415	5,086
Gross profit (loss)	(149,607)	683,368	350,711
Selling, general & administrative expenses	5,368,278	6,067,545	5,746,119
Research & development expenses	1,062,916	2,693,457	1,003,805
Stock based compensation	1,635,708	7,036,778	5,306,755
Total operating expenses	8,066,902	15,797,780	12,056,679

Weighted average shares outstanding	4,335,650	3,166,466	2,505,352
Weighted average shares outstanding - diluted	4,335,650	3,166,466	2,505,352
Year end shares outstanding	7,940,298	3,285,733	2,892,632
Net income (loss) per share - basic	\$(2.43)	\$(5.20)	\$(5.10)
Net income (loss) per share - diluted	\$(2.43)	\$(5.20)	\$(5.10)
Number of full time employees	16	19	28
Number of part time employees	3	4	2
Total number of employees	19	23	30
Number of common stockholders	656	666	706
Foreign currency translation adjustments	...	(22,532)	(25,200)
Earnings per share from continuing operations	\$(2.43)

Adjusted for 1-for-10 stock split, July 25, 2023; As of March 30, 2022; Approximately; As of March 31, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	60,155	85,265
Restricted cash & cash equivalents	656,625	1,306,463

Accounts receivable, net	1,530	98,325
Accounts receivable - related parties, net	10,463	757,343
Due from related parties	747,573	513,819
Short-term investments	79,312	75,797
Prepaid expense & other current assets	101,051	150,235
Total current assets	1,656,709	2,987,247
Software	174,797	...
Land	363,416	361,193
Buildings & leasehold improvements	2,227,431	2,226,687
Machinery & equipment	1,138,675	1,116,789
Office equipment	...	173,766
Construction in Progress	7,400,000	...
- Gross
Property & equipment, gross	11,304,319	3,878,435
Less: accumulated depreciation	3,335,041	3,304,457
Property & equipment, net	7,969,278	573,978
Operating lease right-of-use assets	809,283	1,161,141
Long-term investments	2,527,740	842,070
Deferred tax assets	...	117,110
Prepaid expenses - noncurrent	78,789	135,135
Security deposits	62,442	58,838
Prepayment for long-term investments	1,274,842	2,838,578
Due from related parties - noncurrent	113,516	1,141,378
Non-marketable Cost Method Investments, net	2,527,740	...
Total assets, net	14,492,599	9,855,475
Short-term bank loans	...	1,893,750
Short-term loan	899,250	...
Accrued expenses and other current liabilities	3,696,380	...
Notes payable	112,946	...
Accrued expenses & other current liabilities	79,500	2,909,587
Advance from customers	...	10,985
Operating lease liabilities - current portion	401,826	369,314
Due to related parties	173,132	635,893
Convertible notes payable - current portion	569,456	...
Total current liabilities	5,932,490	5,819,529
Tenant security deposit	21,680	7,980
Operating lease liabilities - noncurrent portion	407,457	791,827
Total liabilities	6,361,627	6,619,336
Common stock	7,940	32,857
Additional paid-in capital	82,636,966	67,907,479
Stock subscription receivable	(451,480)	(1,354,440)
Retained earnings (accumulated deficit)	(65,420,095)	(54,904,439)
Accumulated other comprehensive income (loss)	516,387	517,128
Treasury stock	8,901,668	9,100,000
Total stockholders' equity (deficit)	8,388,050	3,098,585
Noncontrolling interest	(257,078)	137,554
Total equity (deficit)	8,130,972	3,236,139

Recent Dividends:

- 1. ABVC BioPharma Inc 5% cumulative convertible preferred.**
No dividends paid.
 - 2. ABVC BioPharma Inc common.**
No dividends paid.
- Annual Dividends:**
- 1. ABVC BioPharma Inc 5% cumulative convertible preferred.**
No dividends paid.
 - 2. ABVC BioPharma Inc common.**
No dividends paid.

ACORN ENERGY INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2023	2022	2021 (revised)
Revenues - products ..	8,059
Revenue	8,059	7,000	6,776
Cost of sales	2,055
Cost of sales	2,055	1,929	1,877
Gross profit	6,004	5,071	4,899
Research & development expenses	875	845	739
Selling, general & administrative expenses	5,055	4,804	4,168
Impairment of software	51	...
Total operating expenses	5,930	5,700	4,907
Operating income (loss)	74	(629)	(8)
Income (loss) before income taxes ..	138	(631)	(13)
Income tax expense (benefit)	9
Net income (loss)	129	(631)	(13)
Non-controlling interest share of income (loss)	(10)	(2)	(8)
Net income (loss) attributable to Acorn Energy, Inc. shareholders	119	(633)	(21)
Weighted average shares outstanding-basic	2,484	2,481	2,481
Weighted average shares outstanding-diluted ..	2,503	2,481	2,481
Year end shares outstanding	2,435	2,433	2,430
Income (loss) per share from continuing operations-basic	\$0.05
Net income (loss) per share-basic	\$0.05	\$(0.32)	\$0.00
Income (loss) per share from continuing operations-diluted	\$0.05
Net income (loss) per share-diluted	\$0.05	\$(0.32)	\$0.00
Number of full time employees	24	26	25
Number of part time employees	1	2	...
Total number of employees	25	...	25
Number of common stockholders	75	69	73
Number of beneficial stockholders	4,000	3,600

□ Adjusted for 1-for-16 stock split, September 8, 2023; □ As is; □ As of March 14, 2023; □ As of March 28, 2022; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	1,449	...
Cash	1,450
Accounts receivable, gross	607
Allowance for doubtful accounts	10
Accounts receivable, net	597
Accounts receivable-other	536	...
Raw materials	904	684

Finished goods	58	105
Inventory	962	...
Inventory, net	789
Deferred cost of goods sold	809	887
Total current assets	4,036	4,011
Computer hardware & software, cost	864
Less: accumulated depreciation & amortization-computer hardware & software	247
Equipment, cost	157	155
Less: accumulated depreciation & amortization-equipment	151
Leasehold improvements, cost	356	355
Less: accumulated depreciation & amortization-leasehold improvements	343
Intangible asset	21	20
Comp Software&Equip-grs	938	...
Property & equipment, gross	1,472	1,394
Plant/mach - acc depn	153	...
Acc Depr Leasehold Improvements	346	...
Comp Software&Equip-dep	403	...
Less: accumulated depreciation & amortization - property & equipment	902	741
Property & equipment, net	570	653
Right-of-use assets, net	193	298
Deferred cost of goods sold	476	807
Other assets	174	215
Total assets	5,449	5,984
Accounts payable	288	243
Accrued expenses	132	171
Deferred revenue	4,034	3,984
Current operating lease liabilities	123	116
Total current liabilities	4,607	4,572
Deferred revenue	1,550	2,187
Noncurrent operating lease liabilities	98	220
Other long-term liabilities	20	16
Total long-term liabilities	2,423
Total liabilities	6,275	...
Common stock	25	397
Additional paid-in capital	103,321	102,889
Retained earnings (accumulated deficit)	(101,148)	(101,267)
Treasury stock, at cost	3,036	3,036
Total Acorn Energy, Inc. shareholders' equity (deficit)	(838)	(1,017)
Non-controlling interests	12	6
Total stockholders' equity (deficit)	(826)	(1,011)

□ Approximately

Recent Dividends:

1. Acorn Energy Inc common.

No dividends paid.

Annual Dividends:

1. Acorn Energy Inc common.

No dividends paid.

ACURX PHARMACEUTICALS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
Research & development expenses	6,043,597	4,754,271	2,030,177

General & administrative expenses	8,534,171	7,338,505	10,784,023
Total operating expenses	14,577,768	12,092,776	12,814,200
Gain on forgiveness of paycheck protection program loan	66,503
Net income (loss)	(14,577,768)	(12,092,776)	(12,747,697)
Weighted average shares outstanding - basic	12,671,572	10,816,412	8,535,873
Weighted average shares outstanding - diluted	12,671,572	10,816,412	8,535,873
Year end shares outstanding	14,468,229	11,627,609	10,215,792
Net earnings (loss) per share - basic	\$(1.15)	\$(1.12)	\$(1.49)
Net earnings (loss) per share - diluted	\$(1.15)	\$(1.12)	\$(1.49)
Number of full time employees	4	3
Number of common stockholders	362	358	351
Income from cont operations before income tax	(14,577,768)

□ As of March 15, 2023; □ As of March 15, 2022; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	7,474,188	9,111,751
Prepaid expenses	105,776	264,955
Other Receivable	129,159	...
Total current assets	7,709,123	9,376,706
Total assets	7,709,123	9,376,706
Accrued compensation expenses	716,307	542,895
Accrued research & development	2,263,934	1,405,536
Accrued professional fees	58,388	83,715
Other accounts payable & accrued expenses	3,809	29,539
Accounts payable & accrued expenses	3,042,438	2,061,685
Total current liabilities	3,042,438	2,061,685
Total liabilities	3,042,438	2,061,685
Common stock	14,468	11,628
Additional paid-in capital	57,871,070	45,944,478
Retained earnings (accumulated deficit)	(53,218,853)	(38,641,085)
Total members' equity	4,666,685	7,315,021
Total Equity	4,666,685	...

Recent Dividends:

1. Acurx Pharmaceuticals Inc common.

No dividends paid.

Annual Dividends:

1. Acurx Pharmaceuticals Inc common.

No dividends paid.

ADAPTHEALTH CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021 (revised)
Net revenue	3,200,177,000	2,970,595,000	2,454,535,000
Grant income	10,595,000
Total	2,720,613,000
Cost of net revenue	2,553,169,000	2,008,925,000

General & administrative expenses	190,091,000	162,125,000	167,505,000
Depreciation, excluding patient equipment depreciation	24,487,000
Depreciation &			

amortization, excluding patient equipment depreciation	57,087,000	64,890,000	63,095,000
Total costs & expenses	3,798,578,000	2,780,184,000	2,239,525,000
Operating income (loss)	(598,401,000)	190,411,000	225,605,000
Interest expense, net	130,299,000	109,414,000	95,195,000
Gain (loss) on extinguishment of debt	(20,189,000)
Change in fair value of contingent consideration common shares liability	29,389,000
Change in fair value of warrant liability	34,482,000	17,158,000	53,181,000
Other income (loss), net	(29,566,000)	(253,000)	(1,832,000)
Income (loss) before income taxes	(723,784,000)	97,902,000	190,959,000
Current federal income tax expense (benefit)	5,689,000	(197,000)	2,356,000
Current state income tax expense (benefit)	7,902,000	6,930,000	8,070,000
Total current income tax expense (benefit)	13,591,000	6,733,000	10,426,000
Deferred federal income tax expense (benefit)	(42,720,000)	12,205,000	22,891,000
Deferred state income tax expense (benefit)	(19,875,000)	5,831,000	(511,000)
Total deferred income tax expense (benefit)	(62,595,000)	18,036,000	22,380,000
Income tax expense (benefit)	(49,004,000)	24,769,000	32,806,000
Net income (loss)	(674,780,000)	73,133,000	158,153,000
Income (loss) attributable to noncontrolling interests	(4,115,000)	(3,817,000)	(1,978,000)
Net income (loss) attributable to AdaptHealth Corp.	(678,895,000)	69,316,000	156,175,000
Less: earnings allocated to participating securities	...	5,867,000	14,379,000
Net income (loss) attributable to common stockholder	...	63,449,000	141,796,000
Weighted average shares outstanding - basic	134,156,000	134,175,000	126,306,000
Weighted average shares outstanding - diluted	134,156,000	138,988,000	133,034,000
Year end shares outstanding	132,634,850	134,435,119 ¹	133,843,732
Net income (loss) per common share - basic	\$(5.06)	\$0.47	\$1.12
Net income (loss) per common share - diluted	\$(5.06)	\$0.33	\$0.67
Full-Time Employees (Period End)	10,700
Total number of employees	10,700	² 10,900	³ 10,700
Number of common stockholders	41	⁴ 45	⁵ 89
Comprehensive (loss) income attributable to AdaptHealth Corp.	(683,232,000)

Goodwill impairment	830,787,000
Amortization of Intangibles excluding Goodwill	32,600,000

¹ Shares increased due to issuance of class A common stock for acquisitions, exchg of class B common stock & conversion of series B-1 & C-1 preferred stock to class A common stock, exercise of options; ² Approximately; ³ As of February 24, 2023; ⁴ As of February 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	77,132,000	46,272,000
Accounts receivable	388,910,000	359,146,000
Inventory	113,642,000	127,754,000
Prepaid & other current assets	69,338,000	52,136,000
Total current assets	649,022,000	585,308,000
Patient medical equipment	791,349,000	747,985,000
Delivery vehicles	35,021,000	35,326,000
Other equipment & other fixed assets	20,203,000	86,956,000
Computers and Software	85,509,000	...
Equipment & other fixed assets, gross	932,082,000	870,267,000
Less: accumulated depreciation	436,981,000	383,188,000
Equipment & other fixed assets, net	495,101,000	487,079,000
Operating lease right-of-use assets	110,465,000	129,506,000
Finance lease right-of-use assets	31,962,000	5,423,000
Goodwill	2,724,958,000	3,545,297,000
Identifiable intangible assets, net	130,160,000	162,773,000
Other assets	21,128,000	22,415,000
Deferred tax assets	345,854,000	281,786,000
Total assets	4,508,650,000	5,219,587,000
Accounts payable	211,504,000	222,505,000
Employee-related accruals	47,462,000	41,872,000
Accrued interest	29,327,000	28,877,000
Other accounts payable & accrued expenses	...	44,244,000
Accounts payable & accrued expenses	...	337,498,000
Litigation settlement	57,340,000	...
Current portion of finance lease obligations	9,122,000	2,211,000
Current portion of operating lease obligations	29,270,000	30,001,000
Current portion of long-term debt	53,368,000	35,000,000
Contract liabilities	38,570,000	31,641,000
Other liabilities	10,654,000	19,863,000
Current portion of contingent consideration common shares liability	4,021,000	...
Other	46,361,000	...
Accounts Payable and Accrued Expenses - Balancing value	391,994,000	...
Total current liabilities	536,999,000	456,214,000
Secured term loans	...	765,000,000
Senior unsecured notes	2,094,614,000	1,450,000,000
Unamortized deferred financing fees	...	(26,733,000)
Subtotal	...	2,188,267,000
Current portion Long-term debt, less current portion	...	2,153,267,000
Operating lease obligations, less current portion	85,529,000	104,394,000
Finance lease obligations, less current portion	22,746,000	3,950,000
Other long-term liabilities	302,093,000	305,501,000
Warrant liability	...	38,503,000
Total liabilities	3,041,981,000	3,061,829,000
Common stock	13,000	13,000

Preferred stock	1,000	1,000
Treasury stock, at cost	43,267,000	13,992,000
Additional paid-in capital	2,149,951,000	2,130,148,000
Retained earnings (accumulated deficit)	(652,600,000)	26,295,000
Accumulated other comprehensive income (loss)	4,356,000	8,693,000
Total stockholders' equity (deficit) attributable to AdaptHealth Corp.	1,458,454,000	2,151,158,000
Noncontrolling interests in subsidiaries	8,215,000	6,600,000
Total stockholders' equity (deficit)	1,466,669,000	2,157,758,000

Recent Dividends:

- 1. AdaptHealth Corp common (new).**
No dividends paid.
- 2. AdaptHealth Corp common.**
No dividends paid.
- 3. AdaptHealth Corp class B common.**
No dividends paid.
- 4. AdaptHealth Corp common shares subject to possible redemption.**
No dividends paid.

5. AdaptHealth Corp preferred.

No dividends paid.

Annual Dividends:

- 1. AdaptHealth Corp common (new).**
No dividends paid.
- 2. AdaptHealth Corp common.**
No dividends paid.
- 3. AdaptHealth Corp class B common.**
No dividends paid.
- 4. AdaptHealth Corp common shares subject to possible redemption.**
No dividends paid.
- 5. AdaptHealth Corp preferred.**
No dividends paid.

ADDENTAX GROUP CORP

Earnings, 9 mos. to Dec 31 (Consol. - \$):

	2023	2022
Total revenues	3,856,316	6,652,645
Cost & expenses	4,871,789	6,629,358
Operating income	(1,015,473)	23,287
Interest income	5,129	6,687
Interest expense	2,426,064	6,653
Other income (expense), net	(357,848)	93,288
Gains or losses	(172,001)	...
Net before taxes	(3,966,257)	116,609
Income taxes	7,726	18,939
Net income	(3,973,983)	97,670
Earnings common share		
Primary	\$(1.00)	\$.....
Fully Diluted	\$(1.00)	\$.....
Common Shares:		
Full Diluted	3,980,714	2,837,794
Year-end	4,494,979	3,169,300

ADMIRAL FINANCIAL CORP.

Earnings, 6 mos. to Dec 31 (Consol. - \$):

	2023	2022
Earnings common share		
Common Shares:		
Full Diluted	10,985,046	10,985,046
Year-end	10,985,046	10,985,046

ADTHEORENT HOLDINGS CO INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Revenue	170,809,000
Revenue	170,809,000	166,082,000	165,365,000
Platform operations expense	89,145,000	83,444,000	77,770,000
Sales & marketing expense	45,769,000	44,018,000	38,799,000
Technology & development expense	20,824,000	16,644,000	12,393,000

General & administrative expense	17,821,000	20,697,000	35,424,000	per share - basic	\$0.00	\$0.34	\$0.43	Retained earnings (accumulated deficit)	71,857,000	71,850,000
Total operating expenses	173,559,000	164,803,000	164,386,000	per share - diluted	\$0.00	\$0.32	\$0.39	Total stockholders' equity (deficit) attributable to AdTheorent Holding Company, Inc.	165,170,000	155,425,000
Income (loss) from operations	(2,750,000)	1,279,000	979,000	Number of full time employees	301	297	292	Total stockholders' equity (deficit)	165,170,000	155,425,000
Interest expense, net	(2,465,000)	(263,000)	2,404,000	Number of part time employees	3			
Gain (loss) on change in fair value of seller's earn-out	763,000	17,308,000	23,399,000	Total number of employees	301	...	295			
Gain (loss) on change in fair value of warrants	1,331,000	9,868,000	6,783,000	Number of common stockholders	...	88	72			
Gain on deconsolidation of SymmetryML Holdings	...	1,939,000	...	□ Shares increased due to the effect of options exercised and issuance of common stock upon the reverse recapitalization, net of offering costs; □ As of February 27, 2023; □ As of March 14, 2022						
Loss on change in fair value of simple agreement for future equity notes	...	(788,000)	...	Consolidated Balance Sheet, Years Ended Dec. 31 (\$):						
Loss on fair value of investment in SymmetryML Holdings	(161,000)	(72,000)	...		2023	2022				
Other income (expense), net	(49,000)	(21,000)	22,000	Cash	...	72,579,000	...			
Total other income (expense), net	4,349,000	28,497,000	27,800,000	Cash & cash equivalents	70,261,000			
Income (loss) from operations before income taxes	...	29,790,000	28,276,000	Accounts receivables, gross	72,057,000	56,243,000	...			
Income (loss) from operations before income taxes (benefit) - domestic	...	(14,000)	503,000	Other receivables	71,288,000	483,000	...			
Net income (loss) before provision for income taxes	1,599,000	29,776,000	28,779,000	Less: allowance for doubtful accounts	1,003,000	699,000	...			
Current federal income tax provision (benefit)	3,537,000	5,253,000	3,908,000	Accounts receivable, net	...	56,027,000	...			
Current state & local income tax provision (benefit)	1,604,000	2,261,000	2,325,000	Income tax recoverable	177,000	145,000	...			
Current foreign income tax provision (benefit)	64,000	2,000	18,000	Prepaid platform operations	...	876,000	...			
Current income tax provision (benefit)	5,205,000	7,516,000	6,251,000	Prepaid software	...	501,000	...			
Deferred federal income tax provision (benefit)	(2,744,000)	(4,473,000)	(2,054,000)	Other prepaid expenses	4,515,000	89,000	...			
Deferred state & local income tax provision (benefit)	(869,000)	(2,055,000)	(837,000)	Prepaid expenses	...	1,466,000	...			
Deferred income tax provision (benefit)	(3,613,000)	(6,528,000)	(2,891,000)	Other receivables	234,000			
Provision for income taxes (benefit)	1,592,000	988,000	3,360,000	Total current assets	146,241,000	130,217,000	...			
Net income (loss) attributable to noncontrolling interest	...	550,000	784,000	Computers & equipment, gross	906,000	949,000	...			
Net income (loss) attributable to AdTheorent Holding Company, Inc.	7,000	29,338,000	26,203,000	Less: accumulated depreciation - computers & equipment	...	429,000	...			
Weighted average shares outstanding - basic	87,984,917	86,222,972	60,510,847	Computers and equipment	906,000			
Weighted average shares outstanding - diluted	92,465,503	92,621,822	67,942,423	accumulated depreciation	449,000			
Year end shares outstanding	88,464,048	86,968,309	85,743,994	Property & equipment, net	457,000	520,000	...			
Net earnings (loss)				Operating lease right-of-use-assets	5,085,000	5,732,000	...			
				Investment in SymmetryML Holdings	628,000	789,000	...			
				Customer relationships, net	...	4,475,000	...			
				Other intangible assets, net	7,969,000	6,708,000	...			
				Goodwill	34,842,000	34,842,000	...			
				Deferred income taxes, net	10,575,000	6,962,000	...			
				Other assets	299,000	359,000	...			
				Total assets	206,096,000	190,604,000	...			
				Accounts payable	17,910,000	9,479,000	...			
				Accrued compensation	10,483,000	8,939,000	...			
				Accrued campaign costs	...	4,081,000	...			
				Deferred revenue	331,000	1,149,000	...			
				Accrued platform operations	...	401,000	...			
				Accrued income taxes	...	120,000	...			
				Accrued professional fees	...	68,000	...			
				Accrued sales & use taxes	...	14,000	...			
				Other accrued expenses	...	391,000	...			
				Accrued expenses	...	6,224,000	...			
				Operating lease liabilities, current	1,421,000	1,265,000	...			
				SubTotal	4,994,000			
				Other liabilities	382,000			
				Accrued expenses - Balancing value	4,281,000			
				Total current liabilities	34,808,000	25,907,000	...			
				Warrants	967,000	2,298,000	...			
				Seller's earn-out	10,000	773,000	...			
				Operating lease liabilities, non-current	5,141,000	6,201,000	...			
				Total liabilities	40,926,000	35,179,000	...			
				Common stock	9,000	9,000	...			
				Additional paid-in capital	93,304,000	83,566,000	...			

AERSALE CORP
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
			(revised)
Revenue - products	284,554,000	209,881,000	...
Revenue - leasing	28,732,000	30,657,000	...
Revenue - services	95,258,000	99,899,000	...
Services	102,535,000
Products	217,455,000
Leasing	14,513,000
Total revenue	334,503,000	408,544,000	340,437,000
Depreciation & Amortization in Cost of Revenues	4,597,000
Cost of leasing - Balancing value	2,000
Cost of products	155,376,000	176,074,000	139,475,000
Cost of leasing	4,599,000	6,929,000	9,804,000
Cost of services	82,107,000	74,147,000	71,766,000
Total cost of sales	242,082,000	257,150,000	221,045,000
Gross profit	92,421,000	151,394,000	119,392,000
Selling, general & administrative expense	103,191,000	96,348,000	77,498,000
Payroll support program proceeds	14,768,000
Income (loss) from operations	(10,770,000)	55,046,000	56,662,000
Interest income (expense), net	155,000	1,093,000	(980,000)
Other income, net	666,000	2,268,000	458,000
Unrealized gain (loss) on investment	(5,421,000)
Change in fair value of warrant liability	2,270,000	(525,000)	(2,945,000)
Total other income (expenses)	3,091,000	2,836,000	(8,888,000)
Income (loss) before income tax provision	(7,679,000)	57,882,000	47,774,000
Current income tax expense (benefit) - U.S. federal	(1,570,000)	10,537,000	11,003,000
Current income tax expense (benefit) - U.S. state	128,000	3,015,000	1,780,000
Current income tax expense (benefit) - foreign	242,000	2,856,000	2,068,000
Total current income tax expense (benefit)	...	16,408,000	14,851,000
Deferred income tax expense (benefit) - U.S. federal	(806,000)	(862,000)	(1,899,000)
Deferred income tax			

expense (benefit) - U.S. state	(110,000)	(405,000)	(402,000)	Aircraft, airframes, engines, & parts, net	151,398,000	66,042,000	Cost & expenses	770,136	942,622	
Deferred income tax expense (benefit) - foreign	...	(1,120,000)	(891,000)	Operating lease			Operating income	(770,136)	(942,622)	
Total deferred income tax expense (benefit)	...	(2,387,000)	(3,192,000)	right-of-use assets	27,519,000	31,624,000	Interest income	248	...	
Total income tax expense - Current	(1,200,000)	Deferred income taxes	12,203,000	11,287,000	Interest expense	13,851	...	
Total income tax expense - Deferred	(916,000)	Deferred financing costs, net	...	544,000	Other income (expense), net	198,371	...	
Income tax (expense) benefit	(2,116,000)	14,021,000	11,659,000	Deferred customer incentives & other assets, net	1,506,000	628,000	Net before taxes	(582,156)	(942,622)	
Net income (loss)	(5,563,000)	43,861,000	36,115,000	Goodwill	19,860,000	19,860,000	Net income	(582,156)	(942,622)	
Weighted average shares outstanding - basic	51,291,424	51,568,436	43,193,995	Other intangible assets, net	21,986,000	24,112,000	Earnings common share	Primary	\$(0.01)	\$(0.02)
Weighted average shares outstanding - diluted	51,291,424	53,145,639	47,310,100	Deferred customer incentives and other assets, net	525,000	...	Fully Diluted	\$(0.01)	\$(0.02)	
Year end shares outstanding	52,954,430	51,189,461	51,673,099	Total assets	553,938,000	531,579,000	Common Shares:	Full Diluted	40,066,951	38,995,307
Net earnings (loss) per share - basic	\$(0.11)	\$0.85	\$0.84	Accounts payable	29,899,000	21,131,000	Year-end	40,066,951	39,116,951	
Net earnings (loss) per share - diluted	\$(0.11)	\$0.83	\$0.76	Accrued compensation & related benefits	...	6,040,000	AGENTIX CORP			
Number of full time employees	...	606	509	Accrued legal fees	...	716,000	Earnings, 9 mos. to Dec 31 (Consol. - \$):			
Common Shareholders - Number	7,518	Commission fee accrual	...	251,000	Annual Report			
Number of stockholders	...	6,516	5,298	Accrued federal, state & local taxes & fees	...	142,000	Consolidated Income Statement, Years Ended Dec. 31 (\$):			
				Other accrued expenses	...	1,694,000	2023 2022 2021			
				Accrued expenses	5,478,000	8,843,000	(revised)			
				Lessee & customer purchase deposits	1,467,000	17,085,000	Product revenue	114,572,000
				Current operating lease liabilities	4,593,000	4,426,000	Service revenue	2,978,000	10,514,000	6,704,000
				Deferred revenue	2,998,000	1,355,000	Research & development revenue	38,764,000	16,975,000	244,422,000
				Current portion of long-term debt	1,278,000	...	Royalty sales milestone	...	25,250,000	...
				Total current liabilities	45,713,000	52,840,000	Other revenue	184,000
				Long-term lease deposits	102,000	152,000	Non-cash revenue related to the sale of future royalties & milestones	...	45,285,000	44,355,000
				Long-term operating lease liabilities	24,377,000	28,283,000	Total revenues	156,314,000	98,024,000	295,665,000
				Maintenance deposit payments & other liabilities	64,000	668,000	Cost of service revenue	3,111,000	10,568,000	3,470,000
				Warrant liability	2,386,000	4,656,000	Research & development expenses	234,569,000	186,691,000	178,608,000
				Long-term debt	7,281,000	...	General & administrative expenses	78,739,000	81,007,000	76,359,000
				Revolving credit facility	29,000,000	...	Contingent purchase price consideration fair value adjustment	(556,000)	(815,000)	11,481,000
				Total liabilities	108,923,000	86,599,000	Operating income (loss)	(159,549,000)	(179,427,000)	25,747,000
				Common stock	5,000	5,000	Gain (loss) on modification of debt	...	(1,937,000)	...
				Additional paid-in capital	311,739,000	306,141,000	Gain on extinguishment of debt	6,197,000
				Retained earnings (accumulated deficit)	133,271,000	138,834,000	Non-operating income (expense)	37,000	12,571,000	5,051,000
				Total stockholders' equity (deficit)	445,015,000	444,980,000	Interest expense, net	97,925,000	61,863,000	65,719,000
				Total Equity	445,015,000	...	Income (loss) before taxes	(257,437,000)
							Net income (loss)	(257,437,000)	(230,656,000)	(28,724,000)
							Dividends on series A-1 convertible preferred stock	213,000	212,000	211,000
							Less: net loss (income) attributable to non-controlling interest	11,676,000	10,582,000	4,798,000
							Net income (loss) attributable to Agentix Inc. common stockholders	(245,974,000)	(220,286,000)	(24,137,000)
							Weighted average shares outstanding - basic	357,889,000	281,743,000	228,919,000
							Weighted average shares outstanding - diluted	357,889,000	281,743,000	228,919,000
							Year end shares outstanding	394,373,240	305,573,397	256,897,910
							Income (loss) per share - continuing operations - basic	\$(0.69)
							Net income (loss) per common share -

basic	\$(0.69)	\$(0.78)	\$(0.11)
Income (loss) per share - continuing operations - diluted	\$(0.69)
Net income (loss) per common share - diluted	\$(0.69)	\$(0.78)	\$(0.11)
Total number of employees	...	^② 533	^③ 441
Number of common stockholders	46,464	^④ 488	^⑤ 512
Number of beneficiary stockholders	...	^⑥ 46,007	^⑦ 43,447
Foreign currency translation adjustments	...	(577,000)	(1,280,000)

^① Shares increased due to the effect of vesting of nonvested shares, shares sold, preferred stock conversion, payroll payment, issuance of shares, exercise of stock options and employee share purchases; ^② As of March 1, 2023; ^③ As of January 31, 2022; ^④ As of February 15, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	76,110,000	178,674,000
Short-term investments	...	14,684,000
Accounts receivable	25,836,000	2,741,000
Prepaid expenses	8,098,000	13,829,000
Other current assets	2,372,000	3,194,000
Total current assets	112,416,000	213,122,000
Land	...	12,286,000
Building & building improvements	5,837,000	5,654,000
Furniture, fixtures, & other property, plant & equipment	...	5,872,000
Laboratory & manufacturing equipment	64,276,000	...
Laboratory, manufacturing & transportation equipment	...	58,914,000
Leasehold improvements	95,645,000	28,758,000
Software & computer equipment	9,360,000	9,144,000
Construction in progress	1,512,000	66,464,000
Furniture, Fixtures, and other	6,448,000	...
Land- Gross	12,286,000	...
Property, plant & equipment, gross	195,364,000	187,092,000
Less accumulated depreciation & amortization	61,943,000	54,075,000
Property, plant & equipment, net	133,421,000	133,017,000
Operating lease right-of-use assets	29,606,000	31,269,000
Goodwill	24,723,000	25,467,000
Acquired intangible assets, gross	22,099,000	22,376,000
Accumulated amortization - acquired intangible assets	17,688,000	16,148,000
Acquired intangible assets, net	4,411,000	6,228,000
Other long-term assets	9,336,000	4,453,000
Total assets	313,913,000	413,556,000
Debentures	...	146,000
Other short-term borrowings	...	429,000
Current portion, long-term debt	146,000	575,000
Current portion, liability related to sale of future royalties & milestones	132,502,000	83,510,000
Current portion, deferred revenue	18,000	12,269,000
Current portion, operating lease

liabilities	2,587,000	1,943,000
Accounts payable	61,446,000	40,939,000
Accrued payroll	14,512,000	15,872,000
Accrued professional fees	7,101,000	6,946,000
Accrued contract manufacturing costs	7,613,000	1,848,000
Accrued research services	10,807,000	7,074,000
Other accrued liabilities	...	6,519,000
Other	5,250,000	...
Accrued liabilities	45,283,000	38,259,000
Other current liabilities	13,915,000	11,457,000
Total current liabilities	255,897,000	188,952,000
Subordinated notes	...	12,584,000
Long-term debt, net of current portion	12,768,000	12,584,000
Liability related to sale of future royalties & milestones, net of current portion	124,556,000	187,753,000
Deferred revenue, net of current portion	1,143,000	1,143,000
Operating lease liabilities, net of current portion	62,511,000	63,326,000
Contingent purchase price consideration	...	874,000
Other long-term liabilities	5,420,000	13,826,000
Common stock	3,944,000	3,056,000
Additional paid-in capital	1,792,348,000	1,644,658,000
Accumulated other comprehensive income (loss)	(955,000)	915,000
Retained earnings (accumulated deficit)	(1,955,668,000)	(1,709,907,000)
Total stockholders' equity (deficit) attributable to Agenus Inc.	(160,331,000)	(61,278,000)
Non-controlling interest	11,949,000	6,376,000
Total stockholders' equity (deficit)	(148,382,000)	(54,902,000)

Recent Dividends:			
1. Agenus Inc series A convertible preferred. No dividends paid.			
2. Agenus Inc series B1 convertible preferred. No dividends paid.			
3. Agenus Inc series C-1 convertible preferred.			
ExDate	Amt	Declared	Record Payable
04/26/2023	0.00		04/17/2023 05/01/2023
4. Agenus Inc common. No dividends paid.			
5. Agenus Inc series B2 convertible preferred. No dividends paid.			
6. Agenus Inc series A-1 convertible preferred. No dividends paid.			
Annual Dividends:			
1. Agenus Inc series A convertible preferred. No dividends paid.			
2. Agenus Inc series B1 convertible preferred. No dividends paid.			
3. Agenus Inc series C-1 convertible preferred.			
2023	0.00		
4. Agenus Inc common. No dividends paid.			
5. Agenus Inc series B2 convertible preferred. No dividends paid.			
6. Agenus Inc series A-1 convertible preferred. No dividends paid.			
AGILITI INC Annual Report			
Consolidated Income Statement, Years Ended Dec. 31 (\$000):			
	2023	2022	2021 (revised)
Revenue	1,174,604
Revenue	1,174,604	1,121,292	1,038,690
Cost of revenue	770,501	690,318	614,073

Gross margin	404,103	430,974	424,617
Selling, general & administrative expense	339,312	338,988	320,387
Operating income (loss)	64,791	91,986	104,230
Gain (loss) on extinguishment of debt	(4,527)	(1,418)	(10,116)
Interest expense	84,115	49,439	53,514
Tax indemnification expense	...	11,918	...
Income (loss) before income taxes & noncontrolling interest	(23,851)	29,211	40,600
Current federal provision (benefit) for income taxes	8,873	(6,555)	223
Current state provision (benefit) for income taxes	3,716	3,697	4,206
Total current provision (benefit) for income taxes	12,589	(2,858)	4,429
Deferred federal provision (benefit) for income taxes	(5,403)	1,730	11,823
Deferred state provision (benefit) for income taxes	(11,918)	(104)	181
Total deferred provision (benefit) for income taxes	(17,321)	1,626	12,004
Income tax expense (benefit)	(4,732)	(1,232)	16,433
Consolidated net income (loss)	(19,119)	30,443	24,167
Net income attributable to noncontrolling interest	(306)	(231)	(161)
Net income (loss) attributable to Agiliti, Inc. & subsidiaries	(19,425)	30,212	24,006
Weighted average shares outstanding - basic	134,647	132,603	120,877
Weighted average shares outstanding - diluted	134,647	138,381	128,497
Year end shares outstanding	135,352	133,608	^① 130,950
Net income (loss) per share - basic	\$(0.14)	\$0.23	\$0.20
Net income (loss) per share - diluted	\$(0.14)	\$0.22	\$0.19
Number of full time employees	5,800
Total number of employees	5,800	^② ^③ 5,500	^④ ^⑤ 5,000
Number of common stockholders	11	^⑥ ^⑦ 11	^⑧ ^⑨ 15
Comprehensive (loss) income attributable to Agiliti, Inc. and Subsidiaries	(24,263)

^① Shares increased due to the effect of issuance of common stock; ^② As is; ^③ Approximately; ^④ As of February 28, 2023; ^⑤ As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	20,037	5,577
Accounts receivables, gross	221,920	211,935
Less allowance for doubtful accounts	6,236	4,182
Accounts receivable	215,684	207,753
Raw materials	13,376	...

Work-in-process	400	...
Finished goods	60,708	...
Inventories	74,484	70,132
Prepaid expenses	20,231	23,458
Other current assets	7,307	9,393
Total current assets	337,743	316,313
Medical equipment	450,564	405,149
Less: accumulated depreciation - medical equipment	...	250,620
Medical equipment, net	...	154,529
Leasehold improvements	59,422	52,046
Office equipment & vehicles	200,560	165,737
Property & office equipment	710,546	217,783
Accumulated depreciation	417,862	98,354
Property & equipment, net	292,684	273,958
Goodwill	1,239,432	1,239,106
Operating lease right-of-use assets	78,157	79,975
Other intangibles, net	430,002	512,020
Other long-term assets	20,926	22,735
Total assets	2,398,944	2,444,107
Current portion of long-term debt - Balancing value	10,750	...
Current portion of long-term debt	18,468	17,752
Current portion of operating lease liability	25,603	23,607
Current portion of obligation under tax receivable agreement	12,796	34,694
Accounts payable	58,518	59,163
Accrued compensation	28,866	25,928
Accrued interest	21,451	5,039
Other current liabilities	30,906	31,198
Finance Lease - Current Portion	7,718	...
Total current liabilities	196,608	197,381
First lien term loan	...	1,054,549
Revolving loan	1,041,406	28,500
Finance lease liability	19,656	23,892
Long-term debt before unamortized deferred financing costs & debt discount	...	1,106,941
Less: unamortized deferred financing costs & debt discount	...	(11,896)
Less: current portion of long-term debt	...	17,752
Long-term debt, less current portion	1,061,062	1,077,293
Obligation under tax receivable agreement, pension & other long-term liabilities	10,467	9,161
Operating lease liability, less current portion	63,765	67,332
Deferred income taxes, net	126,219	146,615
Common stock	14	13
Additional paid-in capital	972,156	953,046
Retained earnings (accumulated deficit)	(33,699)	(14,274)
Unrealized gain (loss) on minimum pension liability adjustment, net of tax	1,069	502
Unrealized gain (loss) on cash flow hedge, net of tax	1,436	6,841
Accumulated other comprehensive income (loss)	2,505	7,343
Treasury stock, at cost	419	...
Total Agiliti, Inc. & subsidiaries equity (deficit)	940,557	946,128
Noncontrolling interest	266	197

Total equity (deficit)	940,823	946,325	
Recent Dividends:			
1. Agiliti Inc common.			
No dividends paid.			
Annual Dividends:			
1. Agiliti Inc common.			
No dividends paid.			
AILERON THERAPEUTICS INC			
Earnings, 9 mos. to Sep 30(Consol. - \$000):			
	2023	2022	
Cost & expenses	8,986	22,944	
Operating income	(8,986)	(22,944)	
Interest income	322	180	
Other income (expense), net	271	(18)	
Net before taxes	(8,393)	...	
Net income	(8,393)	(22,782)	
Earnings common share			
Primary	\$(1.85)	\$(5.00)	
Fully Diluted	\$(1.85)	\$(5.00)	
Common Shares:			
Full Diluted	4,541	4,539	
Year-end	4,541	4,541	
AINOS INC			
Annual Report			
Consolidated Income Statement, Years Ended Dec. 31 (\$):			
	2023	2022	²⁰²¹
Interferon sales	122,112
Revenues	122,112	3,519,627	594,563
Cost of revenues	375,845	2,114,284	184,181
Gross profits	(253,733)	1,405,343	410,382
Research & development expenses	7,317,388	6,845,964	1,920,645
Selling, general & administrative expenses	5,635,275	8,535,591	2,357,163
Total operating expenses	12,952,663	15,381,555	4,277,808
Operating income (loss)	(13,206,396)	(13,976,212)	(3,867,426)
Interest expense, net	144,193	53,528	18,689
Other income (expenses), net	12,276	23,050	(2,547)
Fair value change for senior secured convertible note	(94,207)
Issuance cost of convertible note measured at fair value	(525,643)
Total non-operating income (expenses), net	(563,353)	(30,478)	(21,236)
Income (loss) before income taxes	(13,769,749)
Income tax expense	800
Net income (loss)	(13,770,549)	(14,006,690)	(3,888,661)
Weighted average shares outstanding			
- basic	4,098,109	² 2,727,458	22,654,049
Weighted average shares outstanding - diluted	4,098,109	² 2,727,458	22,654,049
Year end shares outstanding	4,677,787	³ 4,002,320	⁴ 28,875,862
Net income (loss) per share - basic	\$(3.36)	³ \$(5.15)	\$(0.15)
Net income (loss) per share - diluted	\$(3.36)	³ \$(5.15)	\$(0.15)
Number of full time employees	46	43	34
Number of part time employees	1
Total number of employees	46
Basic EPS Excluding ExtraOrdinary Items	\$(3.36)
Diluted EPS

Excluding ExtraOrd Items			\$(3.36)	...
¹ Non-consolidated; ² As reported by the Company; ³ Adjusted for 1-for-5 stock split, December 14, 2023; ⁴ Shares increased due to the effect of conversion of convertible notes into common stock; and issuance of common stock for intangible assets, compensation and options				
Consolidated Balance Sheet, Years Ended Dec. 31 (\$):				
	2023	2022		
Cash & cash equivalents	1,885,628	1,853,362		
Accounts receivable	455	201,546		
Raw materials	92,708	...		
Work in process	1,208	...		
Finished goods	73,677	...		
Inventory	167,593	595,222		
Other current assets	419,521	195,787		
Total current assets	2,473,197	2,845,917		
Intangible assets, net	...	32,806,738		
Patents, net	28,283,208	...		
Furniture & equipment	669,502	620,064		
Machinery & equipment	1,137,352	1,063,765		
Property & equipment, cost	1,806,854	1,683,829		
Less: accumulated depreciation	930,282	308,153		
Property & equipment, net	876,572	1,375,676		
Other assets	208,827	80,683		
Total assets	31,841,804	37,109,014		
Convertible notes payable	...	376,526		
Notes payable	42,000	884,000		
Accrued expenses & other current liabilities	112,555	1,212,386		
Accrued expenses and other current liabilities	1,182,283	...		
Total current liabilities	1,336,838	2,472,912		
Operating lease liabilities - non-current	...	8,096		
Notes payable - related party, long term	270,000	...		
Senior secured convertible notes measured at fair value	2,651,556	...		
Other long-term liabilities	135,829	...		
Convertible notes payable - noncurrent (including amounts of related party of \$2,000,000 and nil as of 31, 2023 and 2022, respectively)	3,000,000	...		
Total liabilities	7,394,223	2,481,008		
Common stock	46,778	200,116		
Additional paid-in capital	62,555,808	58,745,149		
Retained earnings (accumulated deficit)	(37,886,155)	(24,115,606)		
Translation adjustment	270,473	201,653		
Common stock to be issued, 162,337 shares and nil as of 31, 2023 and 2022, respectively	1,623	...		
Total stockholders' equity (deficit)	24,447,581	34,628,006		
Total stockholders equity	24,447,581	...		
Recent Dividends:				
1. Ainos Inc series 2010-A 10% convertible preferred.				
No dividends paid.				
2. Ainos Inc common.				
No dividends paid.				
Annual Dividends:				
1. Ainos Inc series 2010-A 10% convertible preferred.				
No dividends paid.				
2. Ainos Inc common.				
No dividends paid.				
AIRGAIN INC				
Annual Report				
Consolidated Income Statement, Years Ended Dec. 31 (\$):				

Deferred collaboration revenue, long-term	6,000,000	...
Total liabilities	28,531,881	30,283,628
Common stock	59,196	58,560
Additional paid-in capital	513,994,982	507,770,045
Accumulated other comprehensive income (loss)	...	(103,938)
Retained earnings (accumulated deficit)	(394,259,148)	(356,716,638)
Total stockholders' equity (deficit)	119,795,030	151,008,029
Total Equity	119,795,030	...

Recent Dividends:

1. Aldeyra Therapeutics Inc common.

No dividends paid.

Annual Dividends:

1. Aldeyra Therapeutics Inc common.

No dividends paid.

ALTEROLA BIOTECH INC.

Earnings, 9 mos. to Dec 31(Consol. - \$):

	2023	2022
Cost & expenses	1,825,671	1,823,992
Operating income	(1,825,671)	(1,823,992)
Other income (expense), net	(1,039,538)	...
Net before taxes	(2,865,209)	...
Income taxes	...	(101,301)
Net income	(2,865,209)	(1,722,691)
Earnings common share
Common Shares:
Full Diluted	948,110,596	806,766,837
Year-end	1,353,646,959	807,047,948

ALTO INGREDIENTS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Net sales	1,222,940,000	1,335,621,000	1,207,892,000
Total revenues	1,222,940,000
Cost of revenue (price changes incurred at rep facility)	1,207,287,000
Cost of goods sold	...	1,363,171,000	1,140,108,000
Gross profit (loss)	15,653,000	(27,550,000)	67,784,000
Selling, general & administrative expenses	32,664,000	31,579,000	29,185,000
Gain (loss) on sale (disposal) of assets	(293,000)	(2,230,000)	4,571,000
Asset impairments	3,100,000
Asset impairments	6,544,000
Income (loss) from operations	(23,848,000)	(61,359,000)	40,070,000
Income from cash grant	2,812,000	22,652,000	...
Income from loan forgiveness	9,860,000
Interest expense, net	7,425,000	1,827,000	3,587,000
Other income (expense), net	553,000	862,000	1,208,000
Income (loss) before provision (benefit) for income taxes	(27,908,000)	(39,672,000)	47,551,000
Current provision (benefit)	97,000	1,925,000	1,469,000
Provision (benefit) for income taxes	97,000	1,925,000	1,469,000
Consolidated net income (loss)	(28,005,000)	(41,597,000)	46,082,000
Net income (loss) attributed to Alto Ingredients, Inc.	...	(41,597,000)	46,082,000
Preferred stock dividends	1,265,000	1,265,000	1,265,000
Income allocated to participating

securities	600,000
Income (loss) available to common stockholders	(29,270,000)	(42,862,000)	44,217,000
Weighted average shares outstanding - basic	73,339,000	71,944,000	71,098,000
Weighted average shares outstanding - diluted	73,339,000	71,944,000	72,219,000
Year end shares outstanding	75,703,996	75,155,391	72,778,590
Earnings (loss) per share from continuing operations - basic	\$(0.40)
Net earnings (loss) per share - basic	\$(0.40)	\$(0.60)	\$0.62
Earnings (loss) per share from continuing operations - diluted	\$(0.40)
Net earnings (loss) per share - diluted	\$(0.40)	\$(0.60)	\$0.61
Number of full time employees	...	439	415
Number of part time employees	2
Number of common stockholders	320	320	310
Number of non-voting common stockholders	...	896	1
Comprehensive loss attributed to Pacific Ethanol, Inc.	(27,346,000)

□ Approximately; □ As of March 13, 2023; □ As of March 11, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	30,014,000	36,456,000
Restricted cash	15,466,000	13,069,000
Accounts receivable, gross	58,814,000	68,760,000
Allowance for doubtful accounts	85,000	105,000
Accounts receivable, net	58,729,000	68,655,000
Finished goods	35,765,000	47,736,000
Work in progress	5,063,000	6,396,000
Raw materials	10,313,000	11,197,000
Other inventories	1,470,000	1,299,000
Inventories	52,611,000	66,628,000
Derivative instruments	2,412,000	4,973,000
Other current assets	9,538,000	9,340,000
Total current assets	168,770,000	199,121,000
Facilities & plant equipment	...	386,932,000
Land	3,687,000	3,687,000
Other equipment, vehicles & furniture	9,719,000	9,876,000
Construction in progress	50,505,000	37,538,000
Machinery & equipment	405,010,000	...
Less accumulated depreciation	220,173,000	198,964,000
Total Property/Plant/Equipment, net	468,921,000	...
Property & equipment, net	248,748,000	239,069,000
Right of use operating lease assets, net	22,597,000	18,937,000
Goodwill	...	5,970,000
Intangible assets, net	8,498,000	9,087,000
Other assets	5,628,000	6,137,000
Total assets	454,241,000	478,321,000
Accounts payable - trade	20,752,000	28,115,000
Accrued liabilities	20,205,000	26,556,000
Current portion - operating leases	4,333,000	3,849,000

Derivative instruments	13,849,000	6,732,000
Other current liabilities	6,149,000	12,765,000
Total current liabilities	65,288,000	78,017,000
Kinergy line of credit	...	18,076,000
Orion term loan	...	60,000,000
Less unamortized debt discount	...	(4,686,000)
Less unamortized debt financing costs	...	(5,034,000)
Operating leases, net of current portion	19,029,000	15,062,000
Other liabilities	8,270,000	8,797,000
Total liabilities	174,684,000	170,232,000
Series B preferred stock	1,000	1,000
Common stock	76,000	75,000
Additional paid-in capital	1,040,912,000	1,040,834,000
Accumulated other comprehensive income (loss)	2,481,000	1,822,000
Retained earnings (accumulated deficit)	(763,913,000)	(734,643,000)
Total stockholders' equity	279,557,000	308,089,000
Total stockholders' equity (deficit)	279,557,000	308,089,000

Recent Dividends:

1. Alto Ingredients Inc series A cumulative redeemable convertible preferred.

No dividends paid.

2. Alto Ingredients Inc series B cumulative redeemable convertible preferred.

No dividends paid.

3. Alto Ingredients Inc non voting common.

No dividends paid.

4. Alto Ingredients Inc common.

No dividends paid.

Annual Dividends:

1. Alto Ingredients Inc series A cumulative redeemable convertible preferred.

No dividends paid.

2. Alto Ingredients Inc series B cumulative redeemable convertible preferred.

No dividends paid.

3. Alto Ingredients Inc non voting common.

No dividends paid.

4. Alto Ingredients Inc common.

No dividends paid.

AMBASE CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021
Compensation & benefits	1,378	1,410	1,506
Professional & outside services	3,298	1,668	3,358
Property operating & maintenance	17	17	15
Insurance	259	257	261
Other operating expenses	79	72	68
Operating income (loss)	(5,031)	(3,424)	(5,208)
Interest income	2	9	1
Interest expense	241	57	...
Income (loss) before income taxes	(5,270)	(3,472)	(5,207)
State - current income tax expense (benefit)	1	1	1
Total current income tax expense (benefit)	1	1	1
Federal - deferred income tax expense (benefit)	(1,105)	(729)	(1,106)
State - deferred income tax expense (benefit)	(158)	(111)	(434)
Change in valuation

allowance	1,263	840	1,540
Income tax expense (benefit)	1	1	1
Net income (loss)	(5,271)	(3,473)	(5,208)
Weighted average common shares outstanding - basic	40,738	40,738	40,738
Weighted average common shares outstanding - diluted	40,738
Year end shares outstanding	40,738	40,738	40,738
Income (loss) per share from continuing operations - basic	\$(0.13)
Net income (loss) per common share - basic	\$(0.13)	\$(0.09)	\$(0.13)
Income (loss) per share from continuing operations - diluted	\$(0.13)
Net income (loss) per common share - diluted	\$(0.13)
Number of full time employees	4	4	4
Number of part time employees	2	2	2
Total number of employees	6
Number of beneficiary stockholders	5,900	6,000	6,200

□ As is; □ Approximately; □ As of February 28, 2023; □ As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):			
	2023	2022	
Cash & cash equivalents	78	349	
Other assets	...	61	
Total Current Assets	78	...	
Total assets	78	410	
Accounts payable & accrued liabilities	3,225	1,484	
Loans payable - related party	3,198	...	
Total liabilities	6,423	1,484	
Common stock	464	464	
Additional paid-in capital	548,304	548,304	
Retained earnings (accumulated deficit)	(549,945)	(544,674)	
Treasury stock, at cost	5,168	5,168	
Total stockholders' equity (deficit)	(6,345)	(1,074)	
Total stockholders' equity including non-controlling interest	(6,345)	...	

Recent Dividends:

1. Ambase Corp common.

No dividends paid.

Annual Dividends:

1. Ambase Corp common.

No dividends paid.

AMERICA GREAT HEALTH

Earnings, 6 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues	104,987	...
Net Sales	104,987	90,168
Cost & expenses	333,792	313,496
Operating income	(228,805)	(223,328)
Other income (expense), net	15	34,993
Net before taxes	(406,325)	(320,875)
Net income	(406,325)	(320,875)
Earnings common share
Common Shares:

Full Diluted	21,111,461	21,090,218	148
Year-end	21,120,507	21,090,218	148
AMERICAN BATTERY TECHNOLOGY CO			
Earnings, 6 mos. to Dec 31(Consol. - \$):			
	2023	2022	
Cost & expenses	14,614,790	8,757,685	
Operating income	(14,614,790)	(8,757,685)	
Other income (expense), net	...	27,342	
Gains or losses	(5,497)	98,919	
Net before taxes	(16,523,420)	...	
Net income	(16,523,420)	(8,631,424)	
Balance for common	...	(8,631,424)	
Earnings common share	
Primary	\$(0.35)	\$(0.15)	
Fully Diluted	\$(0.35)	\$(0.15)	
Common Shares:	
Full Diluted	47,357,879	43,152,476	
Year-end	49,343,225	43,341,063	

AMERICAN COASTAL INSURANCE CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
		(revised)	(revised)
Gross premiums written	670,043,000	572,343,000	1,329,445,000
Change in gross unearned premiums	34,079,000	36,974,000	(78,998,000)
Gross premiums earned	635,964,000	535,369,000	1,408,443,000
Ceded premiums earned	(354,080,000)	(266,023,000)	(818,682,000)
Net premiums earned	281,884,000	269,346,000	589,761,000
Fixed maturities	12,884,000
Equity securities	695,000
Cash & cash equivalents	280,000
Other investments	975,000
Other assets	24,000
Investment income	14,858,000
Investment expenses	(1,086,000)
Net investment income	10,574,000	7,673,000	13,772,000
Net realized investment gains (losses)	(6,808,000)	(6,483,000)	3,567,000
Net unrealized gains (losses) on equity securities	814,000	(1,968,000)	3,237,000
Other revenue	79,000	1,223,000	24,190,000
Total revenues	286,543,000	269,791,000	634,527,000
Losses & loss adjustment expenses	62,861,000	134,805,000	422,134,000
Policy acquisition costs	83,346,000	95,318,000	173,574,000
Operating expenses	10,240,000	13,729,000	56,257,000
General & administrative expenses	29,489,000	42,281,000	57,212,000
Interest expense	10,875,000	9,483,000	9,391,000
Total expenses	196,811,000	295,616,000	718,568,000
Income (loss) before other income (expenses)	89,732,000	(25,825,000)	(84,041,000)
Other income (expenses)	2,239,000	10,343,000	184,000
Income (loss) before income taxes	91,971,000	(15,482,000)	(83,857,000)
Current federal provision (benefit) for income taxes expense	(2,207,000)
Deferred federal provision (benefit) for income taxes expense	(18,830,000)
Total provision (benefit) for federal income taxes expense	(21,037,000)
Current state provision (benefit) for income taxes

expense	1,033,000
Deferred state provision (benefit) for income taxes expense	(3,985,000)
Total provision (benefit) for state income taxes expense	(2,952,000)
Provision (benefit) for income taxes	9,773,000	24,522,000	(23,989,000)
Income from continuing operations	82,198,000	(40,004,000)	...
Discontinued operations	227,713,000	(429,962,000)	...
Net income (loss)	309,911,000	(469,966,000)	(59,868,000)
Less: net income attributable to noncontrolling interests ("NCI")	...	111,000	1,949,000
Net income (loss) attributable to United Insurance Holdings Corp. ("UHC")	309,911,000	(469,855,000)	(57,919,000)
Weighted average shares outstanding - basic	43,596,432	43,052,070	42,948,850
Weighted average shares outstanding - diluted	44,388,804	43,052,070	42,948,850
Year end shares outstanding	46,777,006	43,280,173	43,370,442
Net earnings (loss) per share - basic	\$7.11	\$(10.91)	\$(1.35)
Net earnings (loss) per share - diluted	\$6.98	\$(10.91)	\$(1.35)
Dividends declared per share	\$0.24
Number of full time employees	71
Total number of employees	71	...	472
Number of common stockholders	5,049	...	4,560
Earnings per share-inc from discontinued oper	\$5.22	\$(9.99)	...
Earnings per share-total discontinued opers	\$5.22	\$(9.99)	...
Earn per share-inc from discont opers - diluted	\$5.13	\$(9.99)	...
Earning per share-total discont opers - diluted	\$5.13	\$(9.99)	...
Comprehensive income (loss) attributable to ACIC	322,717,000	(494,271,000)	...
Basic EPS Excluding ExtraOrdinary Items	\$1.89	\$(0.93)	...
Diluted EPS Excluding ExtraOrd Items	\$1.85	\$(0.93)	...

□ Restated to reflect correction of errors; □ As of March 7, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
		(revised)
Other investments	16,487,000	3,675,000
Fixed maturities	180,703,000	204,682,000
Equity securities	...	15,657,000
Total investments	197,190,000	224,014,000
Cash & cash equivalents	153,762,000	70,903,000
Restricted cash	18,070,000	45,988,000
Accrued investment income	2,104,000	1,605,000
Prepaid expenses	159,147,000	90,496,000
Reinsurance recoverable on paid and unpaid losses	341,102,000	796,546,000
Land	311,000	753,000
Computer hardware &

software	7,925,000	8,164,000
Office furniture & equipment	748,000	1,414,000
Leased vehicles	...	1,080,000
Total property & equipment, at cost	8,984,000	11,411,000
accumulated depreciation and amortization	5,326,000	6,118,000
Property & equipment, net	3,658,000	5,293,000
Premiums receivable, net	47,274,000	39,301,000
Goodwill	59,476,000	59,476,000
Deferred policy acquisition costs, net	25,041,000	52,369,000
Intangible assets, net	9,323,000	12,770,000
Other assets, net	36,141,000	3,920,000
Assets held for disposal	8,095,000	1,434,815,000
Intangible assets subject to amortization	8,125,000	11,371,000
Indefinite-lived intangible assets	1,198,000	1,399,000
Total assets	1,060,383,000	2,837,496,000
Unearned premiums	293,057,000	258,978,000
Reinsurance payable on premiums	317,000	30,503,000
Accounts payable & accrued expenses	75,284,000	74,386,000
Payments outstanding	2,116,000	2,000,000
Operating lease liability	776,000	1,689,000
Unpaid losses and loss adjustment expenses	370,221,000	842,958,000
Liabilities held for disposal	...	1,654,817,000
Other liabilities	1,159,000	5,849,000
Notes payable	148,688,000	148,355,000
Total liabilities	891,618,000	3,019,535,000
Common stock	5,000	4,000
Additional paid-in capital	423,717,000	395,631,000
Treasury shares	431,000	431,000
Accumulated other comprehensive income (loss)	(17,137,000)	(30,947,000)
Retained earnings (accumulated deficit)	(237,389,000)	(546,296,000)
Total stockholders' equity (deficit) attributable to United Insurance Holdings Corp. (UIHC) stockholders	168,765,000	(182,039,000)
Total stockholders' equity (deficit)	168,765,000	(182,039,000)

Recent Dividends:
1. American Coastal Insurance Corp common.
 No dividends paid.
Annual Dividends:
1. American Coastal Insurance Corp common.
 No dividends paid.

AMJ GLOBAL TECHNOLOGY
Annual Report

Consolidated Income Statement, Years Ended Nov. 30 (\$):

	2023	2022	2021
		(revised)	
General & administrative expenses	7,300	12,753	49,331
Professional fees	39,773
Total other income (expenses)	118,992	26,449	...
Total operating expenses	49,331
Operating income (loss)	(166,065)	(39,202)	(49,331)
Loss on settlement of debt - related party	(19,302)
Gain loss on settlement of debt	9,974	(105,404)	...
Net income (loss) from operation before taxes	(136,789)	(144,606)	...
Net income (loss)	(136,789)	(144,606)	(49,331)

Weighted average shares outstanding - basic	92,509,487	89,623,323	14,396,323
Weighted average shares outstanding - diluted	92,509,487	89,623,323	14,396,323
Year end shares outstanding	103,033,323	89,623,323	14,396,323
Net earnings (loss) per common share - basic	\$0.00
Net earnings (loss) per common share - diluted	\$0.00
Number of common stockholders	230

□ Restated to reflect correction of errors; □ As of March 11, 2022

Consolidated Balance Sheet, Years Ended Nov. 30 (\$):

	2023	2022	2021
		(revised)	
Prepaid expenses	9,140
Total current assets	9,140
Total assets	9,140
Accounts payable & accrued liabilities	750	5,655	11,098
Due to related parties
Accrued expenses - related party	110,000
Due to shareholder	16,465
Total current liabilities	127,215	16,753	89,623
Common stock	103,033	89,623	...
Additional paid-in capital	169,469	3,255,107	...
Retained earnings (accumulated deficit)	(390,577)	(3,361,483)	...
Total stockholders' equity (deficit)	(118,075)	(16,753)	...
Total Equity	(118,075)

Recent Dividends:

1. AMJ Global Technology common.
 No dividends paid.

Annual Dividends:

1. AMJ Global Technology common.
 No dividends paid.

AMMO INC

Earnings, 9 mos. to Dec 31 (Consol. - \$):

	2023	2022
Total revenues	104,633,425	147,756,079
Cost & expenses	106,935,251	137,579,374
Operating income	(12,418,827)	225,953
Interest expense	609,561	538,191
Other income (expense), net	376,186	28,193
Net before taxes	(12,652,202)	(284,045)
Income taxes	(2,419,883)	1,369,427
Net income	(10,232,319)	(1,653,472)
Balance for common	(12,571,729)	(3,992,881)
Earnings common share		
Primary	\$(0.11)	\$(0.03)
Fully Diluted	\$(0.11)	\$(0.03)
Common Shares:		
Full Diluted	118,110,943	116,950,013
Year-end	118,643,593	117,894,417

AMPLITUDE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021
			(revised)
Revenue	276,284
Revenue	276,284	238,067	167,261
Cost of revenue	71,923	70,442	51,764
Gross profit	204,361	167,625	115,497
Research & development	90,138	80,589	48,251
Sales & marketing	153,714	129,962	86,025
General & administrative	54,887	53,636	55,370
Restructuring and other related

charges	8,142
Total operating expenses	306,881	264,187	189,646
Other income (expense), net	13,426	3,981	195
Income (loss) before provision for income tax - United States	...	(97,047)	(79,354)
Income (loss) before provision for income tax - foreign	...	4,466	5,400
Income (loss) before provision for income tax	(89,094)	(92,581)	(73,954)
Current state income taxes	51	86	26
Current foreign income taxes	516	619	583
Total current income taxes	567	705	609
Deferred federal income taxes	(320)
Deferred state income taxes	(57)
Deferred foreign income taxes	702	91	797
Provision for income taxes	1,269	796	1,029
Net income (loss)	(90,363)	(93,377)	(74,983)
Weighted average shares outstanding - basic	116,938	111,437	51,360
Weighted average shares outstanding - diluted	116,938	111,437	51,360
Year end shares outstanding	120,010	114,199	109,876
Net income (loss) per share - basic	\$(0.77)	\$(0.84)	\$(1.46)
Net income (loss) per share - diluted	\$(0.77)	\$(0.84)	\$(1.46)
Total number of employees	737	612	612
Number of class A common stockholders	31	30	30
Number of class B common stockholders	37	48	48
Common Shareholders - Number	59

□ Shares increased due to the effect of conversion of redeemable convertible preferred stock to common stock upon direct listing; □ As is; □ As of December 31, 2021; □ As of February 8, 2023; □ As of February 9, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	248,491	218,494
Marketable securities, current	73,909	11,971
Accounts receivable, gross	30,597	23,406
Less: allowance for doubtful accounts	1,101	690
Accounts receivable, net	29,496	22,716
Prepaid hosting	6,074	9,759
Other prepaid expenses & other assets	10,550	10,576
Prepaid expenses & other current assets	16,624	20,335
Deferred commissions, current	11,444	10,918
Total current assets	379,964	284,434
Marketable securities, noncurrent	...	71,217
Office equipment	4,427	4,062
Furniture & fixtures	1,237	1,533
Leasehold improvements	1,299	1,012
Software	10,467	13
Internal-use software	...	6,825
Total property &		

equipment	17,430	13,445
Less: accumulated depreciation & amortization	7,362	4,037
Property & equipment, net	10,068	9,408
Intangible assets, net	609	2,022
Goodwill	4,073	4,073
Restricted cash, noncurrent	869	855
Deferred commissions, noncurrent	26,942	25,799
Operating lease right-of-use assets	6,856	9,593
Other noncurrent assets	4,303	6,354
Total assets	433,684	413,755
Accounts payable	3,063	490
Accrued commission	6,383	4,494
Accrued payroll & employee related taxes	2,468	1,580
Accrued sales tax	322	338
Liability from early exercised stock options	20	1,382
Employee stock purchase plan withholding	...	1,185
Operating lease liabilities, current	4,571	3,997
Other accrued expenses	...	5,723
Accrued expenses	26,657	18,699
Deferred revenue	102,573	89,993
Other accrued liabilities	5,370	...
2021 Employee stock purchase	1,017	...
Accrued Hosting	6,506	...
Total current liabilities	132,293	109,182
Operating lease liabilities, noncurrent	3,604	7,093
Noncurrent liabilities	3,034	2,511
Total liabilities	138,931	118,786
Class A common stock	1	1
Additional paid-in capital	658,463	568,889
Accumulated other comprehensive income (loss)	(181)	(754)
Retained earnings (accumulated deficit)	(363,530)	(273,167)
Total stockholders' equity (deficit)	294,753	294,969
Total Equity	294,753	...

Recent Dividends:

- 1. Amplitude Inc class B common.**
No dividends paid.
- 2. Amplitude Inc class A common.**
No dividends paid.

Annual Dividends:

- 1. Amplitude Inc class B common.**
No dividends paid.
- 2. Amplitude Inc class A common.**
No dividends paid.

ANIXA BIOSCIENCES INC**Earnings, 3 mos. to Jan 31(Consol. – \$):**

	2024	2023
Cost & expenses	3,609,000	2,556,000
Operating income	(3,609,000)	(2,556,000)
Interest income	319,000	202,000
Net before taxes	(3,290,000)	...
Net income	(3,290,000)	(2,354,000)
Balance for common	...	(2,322,000)
Earnings common share		
Primary	\$(0.10)	\$(0.08)
Fully Diluted	\$(0.10)	\$(0.08)
Common Shares:		
Full Diluted	31,446,000	30,921,000
Year-end	31,754,375	30,922,830

Consolidated Balance Sheet Items, as of (\$):

Assets:		2024
Cash & equivalents		998,000
Current assets		25,219,000
Total assets		25,372,000
Liabilities:		
Current liabilities		1,660,000

Stockholders' equity	24,605,000	
Net current assets	23,559,000	
ANTIAGING QUANTUM LIVING INC		
Earnings, 9 mos. to Dec 31(Consol. – \$):		
	2023	2022
Total revenues	7,499	12,400
Cost & expenses	158,698	41,797
Operating income	(151,199)	(29,397)
Interest income	1	...
Other income (expense), net	2	...
Net before taxes	(151,196)	(29,397)
Net income	(151,196)	(29,397)
Earnings common share		
Primary	\$(0.01)	...
Fully Diluted	\$(0.01)	...
Common Shares:		
Full Diluted	29,995,000	29,995,000
Year-end	29,995,000	29,995,000

ANYWHERE REAL ESTATE GROUP LLC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31**

(\$Millions):

	2023	2022	2021
			(revised)
Gross commission income	4,570	5,538	6,118
Service revenue	569	793	1,180
Franchise fees	351	417	521
Other revenues	146	160	164
Net revenues	5,636	6,908	7,983
Commission & other agent-related costs	3,664	4,415	4,753
Operating expenses	...	1,377	1,669
Marketing expenses	215	252	263
General & administrative expenses	422	388	441
Former parent legacy cost, net	18	1	1
Restructuring costs, net	49	32	17
Impairments	65	483	4
Depreciation & amortization	196	214	204
Interest expense, net	151	113	190
Gain (loss) on the early extinguishment of debt	169	(96)	(21)
Other income (expense), net	...	140	15
Total expenses	5,758	7,231	7,548
Income (loss) before income taxes, equity in earnings & noncontrolling interests	(122)	...	435
Current provision for federal income tax expense (benefit)	9	24	29
Current provision for state income tax expense (benefit)	5	...	30
Current provision for foreign income tax expense (benefit)	4	4	2
Total current provision for income tax expense (benefit)	18	28	61
Deferred provision for federal income tax expense (benefit)	(31)	(78)	70
Deferred provision for state income tax expense

(benefit)	(2)	(18)	2
Total deferred provision for income tax expense (benefit)	(33)	...	72
Income tax expense (benefit)	(15)	(68)	133
Equity in earnings (losses) of unconsolidated entities	9	(28)	48
Net income (loss)	(98)	(283)	350
Less: net income (loss) attributable to noncontrolling interests	1	(4)	(7)
Net income (loss) attributable to Realty Holdings Corp.	(97)	(287)	343
Weighted average shares outstanding - basic	110	114	116
Weighted average shares outstanding - diluted	110	114	120
Year end shares outstanding	110	109	117
Earnings (loss) per share from continuing operations - basic	\$(0.88)
Net earnings (loss) per share - basic	\$(0.88)	\$(2.52)	\$2.95
Earnings (loss) per share from continuing operations - diluted	\$(0.88)
Net earnings (loss) per share - diluted	\$(0.88)	\$(2.52)	\$2.85
Number of full time employees	7,965	8,890	9,665
Number of part time employees	125	135	165
Total number of employees	8,090
Number of common stockholders	49	50	47
Foreign currency translation adjustments	(1)
Operating Comprehensive (loss) income attributable to Anywhere and Anywhere Group	(93)

[□] Approximately; [■] As is; [▣] As of February 21, 2023; [▤] As of February 23, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$Millions):

	2023	2022
Cash & cash equivalents	106	214
Restricted cash	13	4
Trade receivables, gross	123	213
Allowance for doubtful accounts	18	12
Trade receivables, net	105	201
Relocation receivables	...	210
Other current assets	218	205
Relocation receivables	138	...
Other	61	...
Other Prepaid Expense, Current	78	...
Prepaid agent incentives	49	...
Franchise sales incentives	30	...
Total current assets	580	834
Furniture, fixtures & equipment	146	174

Capitalized software	530	492	No dividends paid.
Finance/capital lease assets	81	85	3. Anywhere Real Estate Group LLC class A common.
Buildings & leasehold improvements	1,044	290	No dividends paid.
Land	2	3	Annual Dividends:
Building and leasehold improvements	285	...	1. Anywhere Real Estate Group LLC class B common.
Property & equipment, gross	...	1,044	No dividends paid.
Less: accumulated depreciation	764	727	2. Anywhere Real Estate Group LLC common.
Property & equipment, net	280	317	No dividends paid.
Operating lease assets, net	380	422	3. Anywhere Real Estate Group LLC class A common.
Goodwill	2,499	2,523	No dividends paid.
Trademarks	586	611	
Franchise agreements, net	887	954	
Other intangibles, net	...	150	
Other non-current assets	500	572	
Other intangibles, net	127	...	
Total assets	5,839	6,383	
Accounts payable	99	184	
Securitization obligations	115	163	
Due to former parent	38	...	
Current portion of long-term debt	307	366	
Current portion of operating lease liabilities	113	122	
Accrued payroll & related employee costs	158	110	
Advances from clients	29	15	
Accrued volume incentives	28	39	
Accrued commissions	34	44	
Restructuring accruals	14	14	
Deferred income	53	62	
Accrued interest	34	40	
Current portion of finance lease liabilities	9	11	
Due to former parent	...	20	
Other accrued expenses & other current liabilities	...	115	
Other	176	...	
Accrued expenses and other current liabilities - Balancing value	573	...	
Total current liabilities	1,207	1,305	
Revolving credit facility	...	350	
Extended term loan A	...	221	
Senior notes	...	1,884	
Exchangeable senior notes	...	394	
Long-term debt, gross	...	2,849	
Less: current portion	...	366	
Long-term debt	2,235	2,483	
Long-term operating lease liabilities	333	371	
Deferred income taxes	207	239	
Other non-current liabilities	176	218	
Total liabilities	4,158	4,616	
Anywhere common stock	1	1	
Additional paid-in capital	4,813	4,805	
Retained earnings (accumulated deficit)	(3,091)	(2,994)	
Currency translation adjustment	(9)	(9)	
Minimum pension liability adjustment	(35)	(39)	
Accumulated other comprehensive income (loss)	(44)	(48)	
Total stockholder's equity (deficit)	1,679	1,764	
Noncontrolling interests	2	3	
Total equity (deficit)	1,681	1,767	

Recent Dividends:
1. Anywhere Real Estate Group LLC class B common.
 No dividends paid.
2. Anywhere Real Estate Group LLC common.

	2023	2022
Research & development	68,424	27,786
General & administrative	24,579	2,941
Total operating expenses	93,003	30,727
Income (loss) from operations	(93,003)	(30,727)
Interest income	9,018	92
Other financing expense	...	9,150
Net Income before Tax	(83,985)	...
Total other income (expense), net	9,018	(9,058)
Net income (loss)	(83,985)	(39,785)
Weighted average units outstanding - basic	48,339	2,462
Weighted average units outstanding - diluted	48,339	2,462
Year end units	48,339	5,000
Net income (loss) per unit - basic	\$(1.74)	\$(16.16)
Net income (loss) per unit - diluted	\$(1.74)	\$(16.16)
Number of full time employees	91	27
Common Shareholders - Number	8	...
Total number of employees	91	...

[□] From February 4, 2022 (inception); [□] Includes cash-based related-party amounts - research and development: \$23,326,000; [□] Includes equity-based related-party amounts - research and development: \$3,697,000; [□] Includes related-party amounts - general and administrative: \$317,000; [□] As of July 10, 2023

	2023	2022
Cash	...	151,890
Prepaid expenses	1,736	108
Other current assets	1,214	57
Prepaid expenses & other current assets	2,950	165
Cash and cash equivalents	118,316	...
Marketable securities	277,143	...
Total current assets	398,409	152,055
Property, Plant & Equipment - Net - Total	377	...
Right of Use Tangible Assets - Operating Lease - Net	2,217	...
Other Non-Current Assets	401	...
Total assets	401,404	152,055
Accounts payable	2,143	418
Accrued employee compensation & bonuses	167	9,047
Accrued external research & development costs	6,685	515
Accrued manufacturing expenses	9,219	...
Accrued other	1,243	...
Accrued expenses	17,314	9,562
Lease liability	1,101	...
Total current liabilities	20,558	9,980
Lease liability, net of current	933	...
Total liabilities	21,491	9,980
Series A preferred units	...	28,971
Series B preferred units	...	148,496

Common units	...	2,251
Incentive units	...	2,142
Retained earnings (accumulated deficit)	503,354	(39,785)
Accumulated deficit	(123,770)	...
Accumulated other comprehensive income	329	...
Total members' equity (deficit)	379,913	(35,392)
Total Equity	379,913	...

	2023	2022
Total revenues	5,798	31,039
Cost & expenses	1,183,602	1,500,273
Operating income	(1,177,804)	(1,469,234)
Interest expense	361,872	330,375
Other income (expense), net	388,579	250,672
Net before taxes	(1,151,097)	(1,548,937)
Net income	(1,151,097)	(1,548,937)
Earnings common share		
Primary	\$(0.02)	\$(0.03)
Fully Diluted	\$(0.02)	\$(0.03)
Common Shares:		
Full Diluted	60,543,635	53,076,511
Year-end	150,543,635	148,543,635

	2023	2022	2021 (revised)
Royalty revenue	...	3,114	12,292
Research & development	17,107	17,882	18,994
General & administrative	11,771	13,873	14,698
Income (loss) from operations	(28,878)	(28,641)	(21,400)
Other expense from continuing operations, net	(578)	4,027	8,008
Gain on extinguishment of liability related to sale of royalties	...	37,182	...
Milestone income related to sale of royalties	...	2,500	...
Gain related to sale of non-financial asset	9,650
Income (loss) before income taxes	(18,650)
Net income (loss) from continuing operations	(18,650)	7,014	(29,408)
Income (loss) from discontinued operations - Aptevo BioTherapeutics LLC	...	1,013	951
Income (loss) from discontinued operations	1,239	1,013	951
Net income (loss)	(17,411)	8,027	(28,457)
Weighted average shares outstanding			
- basic	12,235	116	107
Weighted average shares outstanding			
- diluted	12,235	116	107
Year end shares outstanding	19,468	147	111
Income (loss) per			

shre from continuing operations - basic	\$(1.42)	□\$60.28	\$(275.88)
Income (loss) per share from discontinued operations - basic	\$0.10	□\$8.80	\$8.80
Net income (loss) per share - basic	\$(1.42)	□\$69.08	\$(267.08)
Income (loss) per share from continuing operations - diluted	\$(1.42)	□\$60.28	\$(275.88)
Income (loss) per share from discontinued operations - diluted	\$0.10	□\$8.80	\$8.80
Net income (loss) per share - diluted	\$(1.42)	\$69.08	\$(267.08)
Number of full time employees	40	□45	□54
Number of common stockholders	111	□□115	□□162
Total number of employees	40

□ Adjusted for 1-for-44 stock split, March 6, 2024; □ Shares increased due to the effect of issuance of common stock upon vesting of stock units and exercised stock options, commitment shares issued pursuant to Lincoln Park Purchase Agreement; □ As is; □ As of March 30, 2023; □ As of March 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):			
	2023	2022	
Cash	3,732	...	
Cash equivalents	13,171	...	
Cash & cash equivalents	16,904	22,635	
Royalty & milestone receivable	...	2,500	
Prepaid expenses	1,473	1,571	
Other current assets	689	744	
Total current assets	19,066	27,450	
Leasehold improvements	2,228	2,228	
Furniture & equipment	12,260	12,260	
Property & equipment, gross	14,488	14,488	
Less: accumulated depreciation - property & equipment	13,593	13,026	
Property & equipment, net	895	1,462	
Operating lease right-of-use asset	4,881	5,303	
Total assets	24,842	34,215	
Accounts payable & other accrued liabilities	3,984	3,499	
Accrued compensation	2,098	2,105	
Current portion of long-term debt	...	2,000	
Other current liabilities	1,142	1,102	
Total current liabilities	7,224	8,706	
Long-term debt	...	1,456	
Operating lease liability	5,397	6,079	
Total liabilities	12,621	16,241	
Common stock	61	48	
Additional paid-in capital	235,607	223,962	
Retained earnings (accumulated deficit)	(223,447)	(206,036)	
Total stockholders' equity	12,221	17,974	
Total Equity	12,221	...	

Recent Dividends:

1. Aptevo Therapeutics Inc common.
No dividends paid.

Annual Dividends:

1. Aptevo Therapeutics Inc common.
No dividends paid.

ARCH THERAPEUTICS INC			
Annual Report			
Consolidated Income Statement, Years Ended Sept. 30 (\$):			
	2023	2022	2021
Revenue	75,724
Revenue	75,724	15,652	11,565
Cost of revenues	78,163	51,489	26,282
Selling, general & administrative expenses	4,371,164	4,519,636	5,009,323
Research & development expenses	670,880	1,153,333	1,353,084
Total costs & expenses	5,120,207	5,724,458	6,388,689
Income (loss) from operations	(5,044,483)	(5,708,806)	(6,377,124)
Decrease (increase) to fair value of derivative	...	1,000,000	108,944
Interest expense	3,096,550	567,048	150,531
Gain on forgiveness of loan	178,229
Change in fair value of derivative liability	1,158,197
Total other income (expense)	(1,938,353)	432,952	136,642
Income (loss) before income tax expense	(6,982,836)
Net income (loss)	(6,982,836)	(5,275,854)	(6,240,482)
Weighted average shares outstanding			
- basic	3,074,115	□1,199,574	1,100,007
Weighted average shares outstanding			
- diluted	3,074,115	□1,199,574	1,100,007
Year end shares outstanding	4,689,446	□1,249,682	□1,183,599
Net earnings (loss) per share - basic	\$(2.27)	□\$(4.00)	\$(6.00)
Net earnings (loss) per share - diluted	\$(2.27)	□\$(4.00)	\$(6.00)
Number of full time employees	8	8	10
Total number of employees	8
Number of common stockholders	130	□□100	□100
Basic EPS Excluding ExtraOrdinary Items	\$(2.27)
Diluted EPS Excluding ExtraOrd Items	\$(2.27)

□ Adjusted for 1-for-200 stock split, January 18, 2023; □ Shares increased due to the effect of issuance of common stock and warrants, and vesting of restricted stock issued; □ Approximately; □ As of December 28, 2022; □ As of December 16, 2021

Consolidated Balance Sheet, Years Ended Sept. 30 (\$):			
	2023	2022	
Cash	222,720	746,940	
Finished goods	40,969	9,063	
Goods-in-process	1,323,535	1,405,785	
Inventory	1,364,504	1,414,848	
Prepaid expenses & other current assets	362,866	436,407	
Total current assets	1,950,090	2,598,195	
Furniture & fixtures	...	9,357	
Leasehold improvements	...	8,983	
Computer equipment	...	14,416	
Lab equipment	...	1,000	
Property & equipment, gross	...	33,756	
Less - accumulated depreciation	...	31,712	
Property & equipment, net	4,599	2,044	
Other assets	3,500	3,500	
Total long-term assets	8,099	5,544	

Total assets	1,958,189	2,603,739
Accounts payable	2,304,207	1,328,000
Accrued expenses & other liabilities	467,496	318,505
Insurance premium financing	243,285	247,933
Current portion of Series 1 convertible notes	3,519,103	550,000
Current portion of accrued interest	823,128	127,781
Current portion of derivative liability	...	748,275
Convertible notes payable, unsecured, current portion, net of discount	1,658,702	...
Convertible notes payable, Series 2 unsecured, current portion	450,000	...
Total current liabilities	9,465,921	3,320,494
Series 2 convertible notes	...	450,000
Senior secured convertible notes, net of discount & issuance costs	...	2,362,273
Derivative liability	...	459,200
Accrued interest	...	204,575
Total long-term liabilities	...	3,476,048
Total liabilities	9,465,921	6,796,542
Common stock	4,689	249,886
Additional paid-in capital	54,543,188	50,630,084
Retained earnings (accumulated deficit)	(62,055,609)	(55,072,773)
Total stockholders' equity (deficit)	(7,507,732)	(4,192,803)
Total Equity	(7,507,732)	...

Recent Dividends:

1. Arch Therapeutics Inc common.
No dividends paid.

Annual Dividends:

1. Arch Therapeutics Inc common.
No dividends paid.

ARCH THERAPEUTICS INC**Earnings, 3 mos. to Dec 31 (Consol. - \$):**

	2023	2022
Total revenues	45,867	6,261
Cost & expenses	1,540,536	1,282,004
Operating income	(1,494,669)	(1,275,743)
Interest expense	1,186,983	524,313
Net before taxes	(2,681,652)	...
Net income	(2,681,652)	(1,800,056)
Earnings common share		
Primary	\$(0.57)	\$(1.44)
Fully Diluted	\$(0.57)	\$(1.44)
Common Shares:		
Full Diluted	4,707,473	1,249,432
Year-end	4,742,364	1,249,432

Consolidated Balance Sheet Items, as of (\$):

Assets:	2023	2022
Cash & equivalents	205,850	...
Inventories	1,335,849	...
Current assets	1,814,498	...
Net property & equip.	3,949	...
Total assets	1,821,947	...
Liabilities:		
Current liabilities	11,397,463	...
Stockholders' equity	(9,575,516)	...
Net current assets	(9,582,965)	...

ARENA GROUP HOLDINGS INC DEL**Earnings, 9 mos. to Sep 30 (Consol. - \$):**

	2023	2022
Total revenues	173,604,000	159,272,000
Net Sales	173,604,000	159,272,000
Cost & expenses	195,087,000	194,011,000
Operating income	(35,710,000)	(47,863,000)
Interest expense	...	8,510,000
Other income (expense), net	(455,000)	(639,000)

Gains or losses	(469,000)
Net before taxes	(49,859,000)	(57,012,000)
Income taxes	168,000	(1,180,000)
Net income	(50,027,000)	(50,027,000)
Balance for common	(50,027,000)
Earnings common share		
Primary	\$(2.33)	\$(3.30)
Fully Diluted	\$(2.33)	\$(3.30)
Common Shares:		
Full Diluted	21,567,166	17,339,882
Year-end	23,823,476	18,149,622

Net income (loss)	34,566	71,978	59,427
Less: net income attributable to non-controlling interests.....	(197)	(231)	(229)
Net income (loss) attributable to ARKO Corp.....	34,369	71,747	59,198
Less: series A redeemable preferred stock dividends.....	5,750	5,750	5,735
Net income (loss) attributable to common shareholders	28,619	65,997	53,463
Weighted average shares outstanding - basic.....	118,782	121,476	124,412
Weighted average shares outstanding - diluted.....	119,605	123,224	125,437
Year end shares outstanding.....	116,171	120,074	124,428
Net earnings (loss) per share - basic.....	\$0.24	\$0.54	\$0.43
Net earnings (loss) per share - diluted.....	\$0.24	\$0.53	\$0.42
Dividends per share	\$0.09
Full-Time Employees (Period End).....	13,481
Total number of employees.....	13,481	12,223	11,236
Total number of common stockholders	17	19	22
Dividends per common share.....	\$0.12
Income tax expense	12,166
Rent.....	183,845
Net income per share attributable to common shareholders - diluted.....	\$0.24
EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total.....	\$0.24

**ARKO CORP
Annual Report
Consolidated Income Statement, Years Ended Dec. 31**

(\$000):			
	2023	2022	2021 (revised)
Salaries and wages	341,381
Credit card fees	109,258
Utilities, upkeep, and taxes	75,927
Repairs and maintenance	52,906
Insurance	26,361
Other store operating expenses	70,456
Fuel revenue	7,464,372	7,401,090	5,714,333
Merchandise revenue	1,838,001	1,647,642	1,616,404
Other revenues, net	110,358	94,067	86,661
Total revenues	9,412,731	9,142,799	7,417,398
Fuel costs	6,876,084	6,856,651	5,275,907
Merchandise costs	1,252,879	1,146,423	1,143,494
Store operating expenses	12,729	721,174	630,518
General & administrative expenses	165,294	139,969	124,667
Depreciation & amortization	127,597	101,752	97,194
Total operating expenses	860,134	8,965,969	7,271,780
Other income (expense), net	...	(9,816)	(3,536)
Operating income	118,014	167,014	142,082
Interest & other financial income	20,273	3,178	3,005
Interest & other financial expenses	91,516	62,583	74,212
Income (loss) before income taxes - Domestic (U.S.)	...	106,365	73,338
Income (loss) before income taxes - Foreign (Israel)	...	1,170	(2,277)
Income (loss) before income taxes	46,771	107,609	70,875
Current domestic federal income taxes (benefit)	10,501	6,907	1,535
Current domestic state & local income taxes (benefit)	...	6,350	5,251
Current - Foreign state and local	6,345
Total current income taxes (benefit)	16,846	13,257	6,786
Deferred domestic federal income taxes (benefit)	(3,316)	19,830	7,550
Deferred domestic state & local income taxes (benefit)	...	2,470	(2,702)
Deferred - Foreign federal	(1,364)
Total deferred income taxes (benefit)	(4,680)	22,300	4,848
Income tax expense (benefit)	12,166	35,557	11,634
Income (loss) from equity investment	(39)	(74)	186

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	218,120	298,529
Restricted cash	23,301	18,240
Short-term investments	3,892	2,400
Credit card receivables	...	42,806
Fleet fueling customer credit accounts receivables, net	...	33,082
Independent dealers & customer credit accounts receivables, net	...	42,252
Trade receivables, net	134,735	118,140
Fuel inventory	91,720	80,004
Merchandise inventory	147,595	132,080
Lottery inventory	11,278	9,867
Inventory	250,593	221,951
Vendor receivables	53,926	42,711
Asset resulting from contingent consideration	3,930	4,533
Prepaid expenses	21,398	15,543
Environmental receivables	2,228	1,083
Income tax receivable	8,450	800
Due from related parties	935	1,151
Other current assets	27,605	22,052
Other current assets	118,472	87,873
Total current assets	749,113	747,133
Land	125,047	115,276
Buildings & leasehold

improvements	281,074	242,265
Equipment	775,472	633,511
Accumulated depreciation	438,983	345,243
Right-of-use assets under financing leases - Gross	215,174	...
Accumulated Depreciation of Right-of-use assets under financing leases	52,506	...
Property & equipment, net	742,610	645,809
Right-of-use assets under operating leases	1,384,693	1,203,188
Right-of-use assets under financing leases, net	162,668	182,113
Goodwill	292,173	217,297
Intangible assets, net	214,552	197,123
Equity investment	2,885	2,924
Deferred tax asset	52,293	22,728
Other non-current assets	49,377	36,855
Total assets	3,650,364	3,255,170
Long-term debt, current portion	16,792	11,944
Accounts payable	213,657	217,370
Accrued employee costs	22,015	28,298
Fuel & other taxes	40,392	30,491
Accrued insurance liabilities	10,464	9,881
Accrued expenses	50,798	42,955
Environmental liabilities	4,100	3,425
Deferred vendor income	13,134	12,101
Accrued income taxes payable	...	4,056
Due to related parties	25,291	...
Liabilities resulting from additional & contingent consideration	5,524	5,674
Ares put option	...	8,575
Other accrued liabilities	7,818	8,641
Other current liabilities	179,536	154,097
Operating leases, current portion	67,053	57,563
Financing leases, current portion	9,186	5,457
Total current liabilities	486,224	446,431
Senior notes	...	443,648
M&T debt	...	49,023
Capital One line of credit	...	256,430
Insurance premium notes	...	2,886
Less: current portion	...	11,944
Long-term debt, net obligation	828,647	740,043
Asset retirement obligation	84,710	64,909
Operating leases	1,395,032	1,218,045
Financing leases	213,032	225,907
Environmental liabilities	...	8,639
Deferred vendor income	...	26,715
Liabilities resulting from additional & contingent consideration	...	7,256
Public warrants	...	25,894
Private warrants	...	4,515
Deferred shares	...	1,436
Financial liability	...	96,864
Other non-current liabilities	...	7,626
Other non-current liabilities	266,602	178,945
Total liabilities	3,274,247	2,874,280
Series A redeemable preferred stock	100,000	100,000
Common stock	12	12
Treasury stock, at cost	74,134	40,042
Additional paid-in capital	245,007	229,995
Accumulated other comprehensive income (loss)	9,119	9,119
Retained earnings (accumulated deficit)	96,097	81,750
Total shareholders' equity	276,101	280,834
Non-controlling interest	16	56
Total equity	276,117	280,890

Recent Dividends:
1. ARKO Corp series A redeemable preferred.
 No dividends paid.
2. ARKO Corp common.
 No dividends paid.

Annual Dividends:
1. ARKO Corp series A redeemable preferred.
 No dividends paid.
2. ARKO Corp common.
 No dividends paid.

ARS PHARMACEUTICALS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31
(\$000):

	2023	2022	2021
Revenue under collaboration agreements	30	1,316	...
Total revenues	30
Research & development expenses	20,266	18,376	61,501
General & administrative expenses	47,284	18,456	28,083
Total operating expenses	67,550	36,832	89,584
Income (loss) from operations	(67,520)	(35,516)	(89,584)
Other income (expense), net	13,155	974	...
Change in fair value of financial instruments	...	(140)	...
Interest income (expense), net	106
Total other income (expense)	...	834	...
Net income (loss)	(54,365)	(34,682)	(89,478)
Weighted average shares outstanding - basic	95,215	39,956	34,926
Weighted average shares outstanding - diluted	95,215	39,956	34,926
Year end shares outstanding	96,415	93,943	35,108
Net earnings (loss) per share - basic	\$(0.57)	\$(0.87)	\$(2.56)
Net earnings (loss) per share - diluted	\$(0.57)	\$(0.87)	\$(2.56)
Number of full time employees	24	17	90
Number of part time employees	2	3	...
Number of common stockholders	20	29	78
Income from cont operations before income tax	(54,365)
Total number of employees	26

□ Non-consolidated; □ Including related party amounts - research & development: \$2,144,000; □ Including related party amounts - general & administrative: \$603,000; □ As is; □ As of March 17, 2023; □ Approximately; □ As of March 15, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022	2021
Cash & cash equivalents	70,971	210,518	...
Short-term investments	157,389	63,863	...
Prepaid insurance	...	1,539	...
Prepaid expenses	...	771	...
Interest receivable	...	796	...
Other receivables	...	213	...
Prepaid expenses & other current assets	3,366	3,319	...
Total current assets	231,726	277,700	...

Right-of-use assets	250	445	...
Equipment	...	377	...
Property & equipment, gross	695
Less accumulated depreciation	121	48	...
Fixed assets, net	574	329	...
Prepaid insurance	...	2,940	...
Security deposit	...	21	...
Other assets	638	2,961	...
Total assets	233,188	281,435	...
Accounts payable	759	1,659	...
Accrued legal & professional fees	174	908	...
Accrued clinical expenses	...	609	...
Accrued compensation	315	447	...
Accrued tax expenses	...	174	...
Accrued development expenses	190	133	...
Other accrued expenses	...	1,001	...
Accounts payable & accrued liabilities	2,154	4,931	...
Lease liability, current portion	237	230	...
Contract liability, current	...	283	...
Accounts payable and accrued liabilities - Balancing value	716
Total current liabilities	2,391	5,444	...
Lease liability, net of current portion	37	251	...
Contract liability	...	2,854	...
Total liabilities	2,428	8,549	...
Common stock	10	9	...
Additional paid-in capital	362,004	349,408	...
Accumulated other comprehensive gain (loss)	49	407	...
Retained earnings (accumulated deficit)	(131,303)	(76,938)	...
Total stockholders' equity (deficit)	230,760	272,886	...
Total Equity	230,760

□ Including related party amounts - accounts payable & accrued liabilities: \$16,000

Recent Dividends:
1. ARS Pharmaceuticals Inc common.
 No dividends paid.
Annual Dividends:
1. ARS Pharmaceuticals Inc common.
 No dividends paid.

ARTELO BIOSCIENCES INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
General & administrative expenses	4,234,000	5,963,000	2,098,000
Research & development expenses	5,696,000	4,324,000	1,944,000
Total operating expenses	9,930,000	10,287,000	4,042,000
Income (loss) from operations	(9,930,000)	(10,287,000)	(4,042,000)
Interest income	...	2,000	1,000
Interest expense	...	5,000	...
Net change in fair value of marketable securities	641,000	207,000	6,000
Total other income (expense)	641,000	204,000	7,000
Net income (loss)	(9,289,000)	(10,083,000)	(4,035,000)
Weighted average shares outstanding - basic	2,960,000	2,833,000	2,230,000
Weighted average shares outstanding - diluted	2,960,000	2,833,000	2,230,000
Year end shares

outstanding	3,188,959	2,855,688	2,820,068
Net earnings (loss) per common share - basic	\$(3.14)	\$(3.56)	\$(1.81)
Net earnings (loss) per common share - diluted	\$(3.14)	\$(3.56)	\$(1.81)
Number of full time employees	6
Total number of employees	6	7	5
Number of common stockholders	165	165	165
Foreign currency translation adjustments	...	(212,000)	(31,000)
Income from cont operations before income tax	(9,289,000)
Earnings per share from continuing operations	\$(3.14)
Earnings per share from continuing operations	\$(3.14)

□ From September 1, 2022; □ Reclassified to conform with 2022 presentation; □ Adjusted for 1-for-15 stock split, August 10, 2022; □ Shares increased due to common shares issued for cash; □ As of March 27, 2023; □ As of March 18, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	2,815,000	6,888,000
Trading marketable securities	...	9,150,000
Available-for-sale securities	7,611,000	1,495,000
Prepaid expenses & other current assets	554,000	789,000
Total current assets	10,980,000	18,322,000
Operating lease right-of-use asset	21,000	60,000
Intangible asset	2,039,000	2,039,000
Other assets	3,000	3,000
Total assets	13,043,000	20,424,000
Accounts payable & accrued liabilities	1,238,000	905,000
Due to related party	30,000	53,000
Operating lease liabilities - current portion	23,000	40,000
Total current liabilities	1,291,000	998,000
Operating lease liabilities	...	23,000
Total liabilities	1,291,000	1,021,000
Common stock	3,000	3,000
Additional paid-in capital	52,262,000	50,675,000
Retained earnings (accumulated deficit)	(40,310,000)	(31,021,000)
Accumulated other comprehensive income (loss)	(203,000)	(254,000)
Total stockholders' equity (deficit)	11,752,000	19,403,000
Total Equity	11,752,000	...

□ Amortized cost - available-for-sale securities: \$1,502,000

Recent Dividends:
1. Artelo Biosciences Inc common.
 No dividends paid.
Annual Dividends:
1. Artelo Biosciences Inc common.
 No dividends paid.

ARTISAN CONSUMER GOODS INC
Earnings, 6 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues	7,434	7,434
Cost & expenses	18,898	32,291
Operating income	(20,398)	(26,357)

Other income (expense), net		15	
Net before taxes	(20,398)		
Net income	(20,398)	(26,342)	
Earnings common share			
Primary	\$(0.01)		
Fully Diluted	\$(0.01)		
Common Shares:			
Full Diluted	4,400,048	4,400,048	
Year-end	4,400,048	4,400,048	

Number of common stockholders			
Discontinued operations	(495,820)	(276,324)	
Earnings per share-total discontinued opers	\$(0.10)	\$(0.06)	
Earning per share-total discount opers - diluted	\$(0.10)	\$(0.06)	

liabilities	13,774	24,016
Long-term portion of finance lease liabilities	722,200	602,131
Bank Midwest loan payable		2,510,486
U.S. small business administration loan payable	2,629,862	491,433
Less: current portion of term debt		97,678
Long-term debt, excluding current portion		2,904,241
Total liabilities	12,760,859	12,797,677
Common stock	51,069	50,137
Additional paid-in capital	4,838,425	4,547,172
Retained earnings (accumulated deficit)	7,021,253	6,754,284
Treasury stock	269,492	200,956
Total stockholders' equity	11,641,255	11,150,637
Total Equity	11,641,255	

ARTS WAY MANUFACTURING CO INC

Annual Report

Consolidated Income Statement, Years Ended Nov. 30 (\$):

	2023	2022	2021
		(revised)	(revised)
Total revenues	30,280,957	25,646,152	
Sales	30,280,957	25,646,152	24,965,086
Cost of goods sold	21,697,075	18,707,496	18,368,596
Gross profit (loss)	8,583,882	6,938,656	6,596,490
Engineering	598,065	580,537	505,085
Selling	2,132,101	1,904,573	2,014,149
General & administrative	4,322,475	3,848,828	3,553,848
Total expenses	7,052,641	6,333,938	6,073,082
Income (loss) from operations	1,531,241	604,718	523,408
Interest expense	590,005	404,188	313,485
Other income (expense)	147,512	240,414	56,967
Total other income (expense)	(442,493)	(163,774)	(256,518)
Income (loss) before income taxes	1,088,748	440,944	266,890
Total current income tax expense (benefit)	11,284	2,712	8,459
Benefit of utilization of operating loss carryforward	212,493	47,620	
Total deferred income tax expense (benefit)	102,182	16,491	45,800
Income tax expense (benefit)	325,959	66,823	54,259
Income (loss) from continuing operations	762,789	374,121	
Net income (loss)	266,969	97,797	212,631
Weighted average shares outstanding - basic	5,002,238	4,707,384	4,515,229
Weighted average shares outstanding - diluted	5,002,238	4,707,384	4,515,229
Year end shares outstanding	5,012,666	4,949,097	4,538,972
Income (loss) per share from continuing operations - basic	\$0.15	\$0.08	
Income (loss) per share from discontinued operations - basic	\$(0.10)	\$(0.06)	
Net income (loss) per share - basic	\$0.05	\$0.02	\$0.05
Income (loss) per share from continuing operations - diluted	\$0.15	\$0.08	
Income (loss) per share from discontinued operations - diluted	\$(0.10)	\$(0.06)	
Net income (loss) per share - diluted	\$0.05	\$0.02	\$0.05
Number of full time employees	120		131
Number of part time employees	4		8
Total number of employees	124		139

□ Restated to reflect discontinued operations; □ As of February 4, 2022

Consolidated Balance Sheet, Years Ended Nov. 30 (\$):

	2023	2022
		(revised)
Cash	4,014	5,055
Accounts receivable - customers, gross	3,464,353	2,756,997
Less: allowance for doubtful accounts	32,137	34,699
Accounts receivable - customers, net	3,432,216	2,722,298
Raw materials	8,860,296	8,700,719
Work in process	281,760	624,781
Finished goods	3,472,354	3,029,099
Total gross inventory	11,031,362	12,354,599
Less: reserves		1,743,047
Less: inventories classified as noncurrent	(1,583,048)	
Inventories, net		10,611,552
Cost & profit in excess of billings	289,282	450,906
Other current assets	296,662	343,618
Assets of discontinued operations	31,958	
Total current assets	15,085,494	14,133,429
Land	70,503	220,503
Buildings & improvements	7,332,416	8,235,981
Construction in progress		357,644
Manufacturing machinery & equipment	10,386,044	11,721,908
Trucks & automobiles	576,704	567,563
Furniture & fixtures		115,059
Patterns & dies	115,059	
Property, plant & equipment, gross	18,480,726	21,218,658
Less accumulated depreciation	13,420,131	15,039,741
Property, plant & equipment, net	5,060,595	6,178,917
Modular Buildings		400,325
Assets held for lease, net	145,494	400,325
Deferred income taxes	2,503,213	2,605,395
Other assets	583,752	630,248
Other assets of discontinued operations	1,023,566	
Total assets	24,402,114	23,948,314
Accounts payable	2,256,502	2,630,966
Customer deposits	416,044	828,565
Billings in excess of cost & profit	351,289	328,041
Income taxes payable	5,000	3,500
Salaries, wages & commissions	805,908	755,708
Accrued warranty expense	295,113	193,301
Other accrued expenses		334,195
Other	298,211	
Other - Balancing value	289,558	
Accrued expenses	1,399,232	1,283,204
Line of credit	4,413,520	3,924,500
Current portion of finance lease liabilities	257,454	170,835
Current portion of long-term debt	109,193	97,678
Liabilities of discontinued operations	186,789	
Operating Lease Liabilities - Current Portion/Short-Term	8,653	
Total current liabilities	9,395,023	9,267,289
Long-term portion of operating lease		

Recent Dividends:

1. Arts Way Manufacturing Co Inc common.

No dividends paid.

Annual Dividends:

1. Arts Way Manufacturing Co Inc common.

No dividends paid.

ASCEND WELLNESS HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
			(revised)
Revenue, net	518,590,000		
Revenue, net	518,590,000	405,926,000	332,381,000
Cost of goods sold	363,470,000		
Cost of goods sold	363,470,000	271,363,000	196,409,000
Gross profit	155,120,000	134,563,000	135,972,000
Compensation		61,503,000	55,773,000
Rent & utilities	158,739,000	21,974,000	18,993,000
Professional services		17,110,000	16,057,000
Depreciation & amortization		14,095,000	10,036,000
Insurance		5,586,000	5,126,000
Marketing		3,445,000	2,968,000
Gain (loss) on sale of assets		(345,000)	(605,000)
Other general & administrative expenses		13,031,000	7,107,000
General & administrative expenses		137,089,000	116,665,000
Settlement expense		5,000,000	36,511,000
Total operating expenses	158,739,000	142,089,000	153,176,000
Operating profit (loss)	(3,619,000)	(7,526,000)	(17,204,000)
Cash interest		24,524,000	17,638,000
Accretion		3,576,000	9,710,000
Loss on extinguishment of debt		2,180,000	6,637,000
Interest on financing liability		2,113,000	2,643,000
Interest on finance leases		43,000	
Non-cash interest related to beneficial conversion feature			27,361,000
Interest expense	36,984,000	32,436,000	63,989,000
Other income (expense), net	25,843,000	756,000	256,000
Total other income (expense)	(11,141,000)	(31,680,000)	(63,733,000)
Income (loss) before income taxes	(14,760,000)	(39,206,000)	(80,937,000)
Current federal income taxes	43,143,000	35,067,000	31,747,000
Current state income taxes	2,561,000	12,381,000	13,609,000

Deferred federal income taxes	(7,916,000)	(3,685,000)	(2,502,000)
Deferred state income taxes	(4,334,000)	(2,070,000)	(1,134,000)
Income tax expense	33,454,000	41,693,000	41,720,000
Net income (loss)	(48,214,000)	(80,899,000)	(122,657,000)
Net income (loss) attributable to Ascend Wellness Holdings, Inc.	(80,899,000)	(122,657,000)	
Weighted average shares outstanding - basic	199,154,000	183,381,000	149,434,000
Weighted average shares outstanding - diluted	199,154,000	183,381,000	149,434,000
Year end shares outstanding	206,875,000	188,064,000	171,586,000
Net income (loss) per share - basic	\$(0.24)	\$(0.44)	\$(0.82)
Net income (loss) per share - diluted	\$(0.24)	\$(0.44)	\$(0.82)
Full-Time Employees (Period End)	2,300
Total number of employees	2,300	220	1,500
Number of stockholders	228
Number of class A common stockholders	...	135	...

¹ Reclassified to conform with 2022 presentation; ² Approximately; ³ As of March 7, 2022; ⁴ As of March 13, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	72,508,000	74,146,000
Accounts receivable, gross	...	14,594,000
Less: allowance for doubtful accounts	...	493,000
Accounts receivable, net	28,298,000	14,101,000
Materials & supplies	16,824,000	16,115,000
Work in process	36,612,000	49,586,000
Finished goods	41,858,000	31,831,000
Inventory	95,294,000	97,532,000
Notes receivable	13,116,000	3,423,000
Prepaid expenses	...	4,765,000
Deposits & other receivables	...	3,170,000
Construction deposits	...	863,000
Tenant improvement allowance	...	500,000
Other current assets	...	243,000
Other current assets	19,644,000	9,541,000
Total current assets	228,860,000	198,743,000
Leasehold improvements	192,807,000	174,099,000
Construction in progress	6,511,000	9,633,000
Furniture, fixtures, & equipment	71,474,000	63,974,000
Buildings	72,204,000	71,951,000
Land	5,242,000	6,505,000
Property & equipment, gross	348,238,000	326,162,000
Less: accumulated depreciation	80,156,000	46,302,000
Property & equipment, net	268,082,000	279,860,000
Operating lease right-of-use assets	130,556,000	108,810,000
Intangible assets, net	221,452,000	221,093,000
Goodwill	47,538,000	44,370,000
Other noncurrent assets	23,062,000	19,284,000
Total assets	919,550,000	872,160,000
Fixed asset purchases	5,738,000	6,777,000
Accrued payroll & related expenses	21,306,000	7,549,000
Accounts payable	34,687,000	17,065,000
Acquisition-related liabilities	9,381,000	15,943,000
Accrued interest	...	1,100,000
Other payables & accrued liabilities	71,112,000	8,161,000

Accounts payable & accrued liabilities	...	56,595,000
Current portion of debt, net - Balancing value	10,652,000	...
Current portion of debt, net	11,148,000	11,329,000
Operating lease liabilities, current	3,660,000	2,633,000
Income taxes payable	...	34,678,000
Other current liabilities	6,766,000	5,714,000
Capitalized Leases - Current Portion	496,000	...
Total current liabilities	92,686,000	110,949,000
Credit facility	...	275,000,000
Sellers' notes	297,565,000	27,606,000
Financing agreement	...	19,364,000
Finance liabilities	296,369,000	18,100,000
Finance leases	1,196,000	902,000
Total debt	...	340,972,000
Less: current portion of debt	...	11,347,000
Long-term debt	...	329,625,000
Less: unamortized deferred financing costs	...	(10,328,000)
Long-term debt, net	...	319,297,000
Operating lease liabilities, noncurrent	261,087,000	229,816,000
Deferred tax liabilities, net	35,745,000	33,607,000
Other non-current liabilities	89,595,000	15,076,000
Total liabilities	776,678,000	708,745,000
Class A common stock	207,000	188,000
Additional paid-in capital	458,027,000	430,375,000
Retained earnings (accumulated deficit)	(315,362,000)	(267,148,000)
Total stockholders' equity	142,872,000	163,415,000
Total Equity	142,872,000	...

Recent Dividends:

- 1. Ascend Wellness Holdings Inc class B common. No dividends paid.
 - 2. Ascend Wellness Holdings Inc class A common. No dividends paid.
- Annual Dividends:**
- 1. Ascend Wellness Holdings Inc class B common. No dividends paid.
 - 2. Ascend Wellness Holdings Inc class A common. No dividends paid.

ASCENT SOLAR TECHNOLOGIES INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
			(revised)
Products	397,886	694,286	607,783
Milestone & engineering	60,374	528,500	...
Total revenues	458,260	1,222,786	607,783
Costs of revenue	1,892,341	2,011,459	1,902,414
Research, development & manufacturing operations	3,222,283	5,975,921	4,140,319
Selling, general & administrative expenses	5,364,523	4,736,562	3,297,982
Share-based compensation	2,243,445	5,478,734	...
Depreciation & amortization	95,238	75,645	57,314
Impairment loss	3,283,715
Total costs & expenses	16,101,545	18,278,321	9,398,029
Income (loss) from operations	(15,643,285)	(17,055,535)	(8,790,246)
Other income (expense), net	747,739	33,100	(169,423)
Interest expense	2,174,118	2,704,909	1,088,327
Change in fair value of derivatives & gain

(loss) on extinguishment of liabilities, net	4,047,993
Income/(Loss) on Equity Method Investment	(232)
Total other income (expense)	...	(2,671,809)	2,790,243
Income (loss) on equity method investment	...	(27,361)	...
Down round deemed dividend	17,980,678
Net income (loss)	(17,069,896)	(19,754,705)	(6,000,003)
Net income (loss) applicable to common stockholders	(35,050,574)
Weighted average shares outstanding - basic	1,025,097	149,016	19,470
Weighted average shares outstanding - diluted	1,025,097	149,016	19,470
Year end shares outstanding	3,583,846	170,004	23,934
Net income (loss) per share - basic	\$(34.19)	\$(132.00)	\$(308.00)
Net income (loss) per share - diluted	\$(34.19)	\$(132.00)	\$(308.00)
Number of full time employees	16	60	51
Number of part time employees	2	2	3
Total number of employees	18
Number of common stockholders	34	29	25
Income from cont operations before income tax	(17,069,896)
Earnings per share from continuing operations	\$(34.19)
Earnings per share from continuing operations	\$(34.19)
Depreciation	76,069
Amortization of Intangibles
excluding Goodwill	19,169

¹ Adjusted for 1-for-200 stock split, September 12, 2023; ² Adjusted for 1-for-5,000 stock split, January 31, 2022; ³ Shares increased due to the effect issuance of shares for conversion of TubeSolar Series 1A & Crowdex Series 1A Preferred Stock, BD1 Note, Nanyang Note, Fleur Note, Sabby Note & private placement; ⁴ Shares increased due to the effect issuance of common shares, conversion of Global Ichiban note, conversion of TubeSolar Series 1A preferred stock, conversion of Nanyang note and conversion of Crowdex

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	1,048,733	11,483,018
Trade receivables, gross	...	27,769
Allowance for doubtful accounts	...	26,000
Trade receivables, net	...	1,769
Raw materials	445,721	577,799
Work in process	1,775	37,351
Finished goods	...	133
Inventories	447,496	615,283
Prepaid & other current assets	39,279	344,110
Total current assets	1,535,508	12,444,180
Furniture, fixtures, computer hardware & computer software	468,588	482,235
Leasehold improvements	15,995	87,957
Manufacturing machinery & equipment	20,661,222	21,739,504
Manufacturing machinery & equipment, in progress	32,087	280,473

Property, plant & equipment, gross	21,177,892	22,590,169
Less accumulated depreciation	20,131,008	22,038,508
Property, plant & equipment, net	1,046,884	551,661
Operating lease right-of-use assets, net	2,364,672	4,324,514
Patents, net	53,978	79,983
Equity method investment	...	61,379
Investment in joint venture	68,867	...
Other non-current assets	1,228,797	1,214,985
Total assets	6,298,706	18,676,702
Accounts payable	579,237	595,157
Related party payables	4,231	67,164
Accrued expenses	1,354,159	888,869
Accrued payroll	160,477	490,185
Severance payable	...	437,079
Accrued professional services fees	849,282	952,573
Accrued interest	628,145	559,060
Current portion of operating lease liability	491,440	733,572
Other payable	250,000	250,000
Current portion of convertible note payable, net	354,936	...
Conversions payable	1,089,160	...
Total current liabilities	5,761,067	4,973,659
Non-current operating lease liabilities	2,043,025	3,827,878
Non-current convertible notes, net	...	5,268,399
Accrued warranty liability	21,225	21,225
Total liabilities	7,825,317	14,091,161
Series A preferred stock	...	5
Common stock	358	3,400
Additional paid in capital	480,942,526	452,135,653
Retained earnings (accumulated deficit)	(482,478,436)	(447,537,493)
Accumulated other comprehensive income (loss)	8,936	(16,024)
Preferred stock	5	...
Total stockholders' equity (deficit)	(1,526,611)	4,585,541
Total Equity	(1,526,611)	...

Recent Dividends:

- 1. Ascent Solar Technologies Inc series J-1 preferred.**
No dividends paid.
- 2. Ascent Solar Technologies Inc series D preferred.**
No dividends paid.
- 3. Ascent Solar Technologies Inc series F preferred.**
No dividends paid.
- 4. Ascent Solar Technologies Inc series J preferred.**
No dividends paid.
- 5. Ascent Solar Technologies Inc series A preferred.**
No dividends paid.
- 6. Ascent Solar Technologies Inc series K redeemable preferred.**
No dividends paid.
- 7. Ascent Solar Technologies Inc series E preferred.**
No dividends paid.
- 8. Ascent Solar Technologies Inc series G preferred.**
No dividends paid.
- 9. Ascent Solar Technologies Inc common.**
No dividends paid.
- 10. Ascent Solar Technologies Inc series B-1 preferred.**
No dividends paid.

Annual Dividends:

- 1. Ascent Solar Technologies Inc series J-1 preferred.**
No dividends paid.
- 2. Ascent Solar Technologies Inc series D preferred.**
No dividends paid.
- 3. Ascent Solar Technologies Inc series F preferred.**
No dividends paid.
- 4. Ascent Solar Technologies Inc series J preferred.**
No dividends paid.
- 5. Ascent Solar Technologies Inc series A preferred.**
No dividends paid.

- 6. Ascent Solar Technologies Inc series K redeemable preferred.**
No dividends paid.
- 7. Ascent Solar Technologies Inc series E preferred.**
No dividends paid.
- 8. Ascent Solar Technologies Inc series G preferred.**
No dividends paid.
- 9. Ascent Solar Technologies Inc common.**
No dividends paid.
- 10. Ascent Solar Technologies Inc series B-1 preferred.**
No dividends paid.

ASSERTIO HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Product sales, net	149,451,000	155,121,000	109,420,000
Royalties & milestones	2,433,000	2,403,000	2,579,000
Other revenue	185,000	(1,290,000)	(985,000)
Total revenues	152,069,000	156,234,000	111,014,000
Cost of sales	27,020,000	18,748,000	15,832,000
Selling, general & administrative expenses	78,638,000	46,786,000	56,555,000
Fair value of contingent consideration	2,843,000	18,687,000	28,114,000
Amortization of intangible assets	27,527,000	32,608,000	...
Loss on impairment of intangible asset	279,639,000
Restructuring charges	5,476,000	...	1,089,000
Total costs & expenses	395,605,000	116,829,000	101,590,000
Income (loss) from operations	(243,536,000)	39,405,000	9,424,000
Gain (loss) on debt extinguishment	(9,918,000)
Interest payable on convertible notes	...	1,592,000	...
Interest payable on secured notes	...	6,065,000	10,020,000
Amortization of royalty rights	2,925,000	68,000	185,000
Amortization of debt issuance costs	455,000	236,000	15,000
Interest expense	3,380,000	7,961,000	10,220,000
Other gain (loss)	2,780,000	(278,000)	243,000
Net income (loss) before income taxes - United States	(254,054,000)	30,734,000	(574,000)
Net income (loss) before income taxes - outside the United States	...	432,000	21,000
Net income (loss) before income taxes	(254,054,000)	31,166,000	(553,000)
Current federal income tax provision (benefit)	829,000	1,023,000	124,000
Current state income tax provision (benefit)	858,000	893,000	387,000
Total current income tax provision (benefit)	1,687,000	1,916,000	511,000
Deferred federal income tax provision (benefit)	62,883,000	(61,077,000)	...
Deferred state income tax provision (benefit)	13,318,000	(19,298,000)	217,000
Total deferred income tax provision (benefit)	76,201,000	(80,375,000)	217,000
Income tax expense (benefit)	77,888,000	(78,459,000)	728,000
Net income (loss)	(331,942,000)	109,625,000	(1,281,000)
Weighted average shares outstanding - basic	71,031,000	47,004,000	43,169,000
Weighted average			

shares outstanding - diluted	71,031,000	54,669,000	43,169,000
Year end shares outstanding	94,668,523	48,319,838	44,640,444
Net income (loss) per share - basic	\$(4.67)	\$2.33	\$(0.03)
Net income (loss) per share - diluted	\$(4.67)	\$2.03	\$(0.03)
Number of full time employees	53	30	19
Number of common stockholders	264	26	24
Change in fair value of contingent consideration	(25,538,000)
Basic EPS Excluding ExtraOrdinary Items	\$(4.67)
Diluted EPS Excluding ExtraOrd Items	\$(4.67)
Total number of employees	53

Reclassified to conform with 2022 presentation; Shares increased due to the effect of exercise of options, stock offering, vesting of restricted stock units, and vesting of performance stock units; Shares increased due to the effect of issuance under employee stock purchase plan, and exercise of warrant; As of March 6, 2023; As of March 1, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	73,441,000	64,941,000
Receivables related to product sales, net	...	45,357,000
Receivables from Collegium Pharmaceutical, Inc. (Collegium)	48,563,000	...
Accounts receivable, net	47,663,000	45,357,000
Raw materials	10,537,000	1,367,000
Work-in-process	2,239,000	2,735,000
Finished goods	24,910,000	9,594,000
Inventories, net	37,686,000	13,696,000
Prepaid & other current assets	299,000	8,268,000
Prepaid and other current assets - Balancing value	11,973,000	...
Provision - Accounts & Notes Receivable - Trade	900,000	...
Total current assets	171,062,000	132,262,000
Furniture & office equipment	...	1,712,000
Laboratory equipment	20,000	20,000
Leasehold improvements	2,945,000	2,945,000
Construction in progress	528,000	...
Property and equipment, gross - Balancing value	1,908,000	...
Property & equipment, gross	5,401,000	4,677,000
Less: accumulated depreciation	4,631,000	...
Less: accumulated depreciation & amortization	...	3,933,000
Property & equipment, net	770,000	744,000
Intangible assets, net	111,332,000	197,996,000
Deferred tax assets	...	80,202,000
Investments, net	...	268,000
Operating lease right-of-use assets	1,269,000	137,000
Prepaid asset & deposits	1,289,000	1,607,000
Other long-term assets	...	697,000
Other long-term assets - Balancing value	697,000	...
Total assets	286,419,000	413,913,000
Accounts payable	13,439,000	5,991,000
Accrued rebates, returns & discounts	58,137,000	49,426,000
Accrued compensation	2,438,000	3,117,000

Accrued restructuring	4,378,000	...
Other accrued liabilities	...	6,561,000
Interest payable	...	1,593,000
Accrued royalties	1,038,000	910,000
Accrued liabilities	18,213,000	12,181,000
Contingent consideration liability	2,700,000	...
Interest payable	867,000	...
Liability related to the sale of future royalties & milestones	26,000	...
Current portion of long-term debt	...	470,000
Contingent consideration, current portion	...	26,300,000
Other current liabilities	954,000	948,000
Accrued liabilities - Balancing value	9,492,000	...
Current operating lease liabilities	928,000	...
Total current liabilities	93,443,000	95,316,000
Senior secured notes	...	70,000,000
Royalty rights obligation	38,514,000	470,000
Plus: derivative liability for embedded conversion feature	...	252,000
Less: unamortized debt issuance costs	...	(3,849,000)
Long-term debt, carrying value	...	66,873,000
Less: current portion of long-term debt	...	(470,000)
Long-term debt	...	66,403,000
Contingent consideration	...	22,200,000
Other long-term liabilities	16,459,000	4,269,000
Total liabilities	148,416,000	188,188,000
Common stock	9,000	5,000
Additional paid-in capital	789,537,000	545,321,000
Retained earnings (accumulated deficit)	(651,543,000)	(319,601,000)
Total shareholders' equity (deficit)	138,003,000	225,725,000
Total Equity	138,003,000	...

Recent Dividends:

- 1. Assertio Holdings Inc series A convertible preferred. No dividends paid.
 - 2. Assertio Holdings Inc common. No dividends paid.
- Annual Dividends:**
- 1. Assertio Holdings Inc series A convertible preferred. No dividends paid.
 - 2. Assertio Holdings Inc common. No dividends paid.

ASTRANA HEALTH INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):			
	2023	2022	2021
		(revised)	(revised)
Capitation, net	1,215,614,000	930,131,000	593,224,000
Risk pool settlements & incentives	63,468,000	117,254,000	111,627,000
Management fee income	38,677,000	41,094,000	35,959,000
Fee-for-service, net	59,658,000	49,517,000	26,564,000
Other income	6,541,000
Other revenue	9,244,000	6,167,000	...
Total revenue	1,386,661,000	1,144,163,000	773,915,000
Cost of services, excluding depreciation & amortization	596,142,000
Cost of services	1,171,703,000	944,685,000	...
General & administrative expenses	112,597,000	77,670,000	62,077,000
Depreciation & amortization expenses	17,748,000	17,543,000	17,517,000

Total expenses	1,302,048,000	1,039,898,000	675,736,000
Income (loss) from operations	84,613,000	104,265,000	98,179,000
Income (loss) from equity method investments	5,579,000	5,622,000	(4,306,000)
Interest expense	16,102,000	7,920,000	5,394,000
Interest income	14,208,000	1,976,000	1,571,000
Unrealized gain (loss) on investments	(4,581,000)	(21,271,000)	(10,745,000)
Gain on sale of equity method investment	2,193,000
Other income (loss)	6,121,000	3,944,000	(3,750,000)
Total other income (expense), net	5,225,000	(17,649,000)	(20,431,000)
Income (loss) before provision (benefit) for income taxes	89,838,000	86,616,000	77,748,000
Current federal provision (benefit) for income taxes	35,434,000	35,365,000	22,801,000
Current state provision (benefit) for income taxes	8,999,000	19,788,000	11,605,000
Total current provision (benefit) for income taxes	44,433,000	55,153,000	34,406,000
Deferred federal provision (benefit) for income taxes	(3,638,000)	...	(3,794,000)
Deferred state provision (benefit) for income taxes	(8,806,000)	...	(2,158,000)
Total deferred provision (benefit) for income taxes	(12,444,000)	(14,278,000)	(5,952,000)
Provision (benefit) for income taxes	31,989,000	40,875,000	28,454,000
Net income (loss)	57,849,000	45,741,000	49,294,000
Net loss (income) attributable to noncontrolling interests	2,868,000	(570,000)	24,564,000
Net income (loss) attributable to Apollo Medical Holdings, Inc.	60,717,000	45,171,000	73,858,000
Weighted average shares outstanding - basic	46,553,256	44,971,143	43,828,664
Weighted average shares outstanding - diluted	46,943,140	45,602,415	45,403,085
Year end shares outstanding	46,843,743	46,575,699	44,630,873
Net earnings (loss) per share - basic	\$1.30	\$1.00	\$1.69
Net earnings (loss) per share - diluted	\$1.29	\$0.99	\$1.63
Number of full time employees	1,800
Total number of employees	1,800	...	1,133
Number of common stockholders	599	...	575
Earnings per share	\$1.30	\$1.00	...
Earnings per share diluted	\$1.29	\$0.99	...

Restated to reflect correction of errors; Approximately; As of February 16, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):		
	2023	2022
		(revised)
Cash & cash equivalents	293,807,000	288,027,000
Investment in marketable securities	2,498,000	5,567,000
Receivables, net	76,780,000	52,629,000
Receivables, net - related parties	58,980,000	65,147,000
Income taxes receivable	10,657,000	4,015,000

Other receivables	1,335,000	1,834,000
Prepaid expenses & other current assets	17,450,000	14,798,000
Loans receivable	...	996,000
Loan receivable - related party	...	2,125,000
Total current assets	461,507,000	435,138,000
Land	...	32,288,000
Buildings	...	58,451,000
Computer software	4,923,000	4,731,000
Furniture & equipment	18,854,000	17,161,000
Construction in progress	340,000	12,801,000
Leasehold improvements	5,930,000	7,151,000
Land, property & equipment, gross	30,047,000	132,583,000
Less accumulated depreciation	22,876,000	...
Less accumulated depreciation & amortization	...	24,047,000
Land, property & equipment, net	7,171,000	108,536,000
Intangible assets, net	71,648,000	76,861,000
Goodwill	278,831,000	275,675,000
Loans receivable	15,943,000	...
Investments in other entities - equity method	25,774,000	40,299,000
Investments in privately held entities	6,396,000	896,000
Restricted cash	345,000	...
Operating lease right-of-use assets	37,396,000	20,444,000
Other assets	1,877,000	6,056,000
Loans receivable	26,473,000	...
Total non-current assets	471,854,000	528,767,000
Total assets	933,361,000	963,905,000
Accounts payable trade	9,075,000	...
Accounts payable & other accruals	...	10,473,000
Capitation payable	4,503,000	4,229,000
Subcontractor independent practice association ("IPA") payable	...	2,415,000
Accrued professional fees	4,407,000	2,709,000
Due to related parties	9,271,000	3,304,000
Contract liabilities	744,000	531,000
Accrued compensation	20,098,000	15,301,000
Other provider payable	9,322,000	10,600,000
Fiduciary accounts payable	7,737,000	8,065,000
Medical liabilities	106,657,000	84,253,000
Dividend payable	638,000	664,000
Stock issuable	18,940,000	...
Due to officers	2,529,000	...
Finance lease liabilities	646,000	594,000
Operating lease liabilities	4,607,000	3,572,000
Current portion of long term debt	19,500,000	619,000
Accounts payable and accrued expenses - Balancing value	59,949,000	...
Total current liabilities	218,674,000	147,329,000
Deferred tax liability	4,072,000	3,042,000
Finance lease liabilities, net of current portion	1,033,000	1,275,000
Operating lease liabilities, net of current portion	36,289,000	19,915,000
Revolver loan	...	180,000,000
Real estate loans	...	23,168,000
Construction loan	...	4,159,000
Total debt	...	207,327,000
Less: current portion of debt	...	619,000
Less: unamortized financing costs	...	(3,319,000)
Long-term debt, net of current portion & deferred financing costs	258,939,000	203,389,000
Other long-term liabilities	3,586,000	20,260,000
Total non-current

liabilities	247,881,000	
Total liabilities	395,210,000	
Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation ("APC")	(205,883,000)	13,682,000
Common stock	47,000	47,000
Additional paid-in capital	371,037,000	360,097,000
Retained earnings (accumulated deficit)	243,134,000	192,678,000
Stockholders' equity (deficit) attributable to parent	614,218,000	552,822,000
Noncontrolling interest	2,433,000	2,191,000
Total stockholders' equity (deficit)	616,651,000	555,013,000

Recent Dividends:**1. Astrana Health Inc series B preferred.**

No dividends paid.

2. Astrana Health Inc series A preferred.

No dividends paid.

3. Astrana Health Inc common.

No dividends paid.

Annual Dividends:**1. Astrana Health Inc series B preferred.**

No dividends paid.

2. Astrana Health Inc series A preferred.

No dividends paid.

3. Astrana Health Inc common.

No dividends paid.

ASTROTECH CORP**Earnings, 6 mos. to Dec 31(Consol. - \$000):**

	2023	2022
Total revenues	1,540	301
Cost & expenses	7,943	5,879
Operating income	(6,403)	(5,578)
Other income (expense), net	850	631
Net before taxes	(5,553)	(4,947)
Net income	(5,553)	(4,947)
Earnings common share		
Primary	\$(3.40)	\$(3.07)
Fully Diluted	\$(3.40)	\$(3.07)
Common Shares:		
Full Diluted	1,631	1,613
Year-end	1,702	1,690

ASURE SOFTWARE INC.**Annual Report****Consolidated Income Statement, Years Ended Dec. 31**

(\$000):

	2023	2022	2021
			(revised)
Recurring revenue	86,222	71,078	71,078
Professional services, hardware & other revenue	9,606	4,986	4,986
Revenues - products	99,734
Revenues - services	19,348
Total revenue	119,082	95,828	76,064
Cost of sales	33,545	33,318	29,500
Gross profit	85,537	62,510	46,564
Sales & marketing	28,734	20,260	15,448
Research & development expenses	6,846	6,147	5,410
General & administrative	39,333	33,924	27,720
Amortization of intangible assets	13,623	13,486	10,948
Total operating expenses	88,536	73,817	59,526
Income (loss) from operations	(2,999)	(11,307)	(12,962)
Interest expense & other, net	4,297	4,438	2,038
Gain on extinguishment of debt	(1,517)	...	8,312
Employee retention tax credit	10,533

Other income (expense), net	(292)	1,391	150
Income (loss) from continuing operations before income taxes	(9,105)	(14,354)	3,995
Current federal provision (benefit) for income taxes	(57)
Current state provision (benefit) for income taxes	(59)	204	95
Total current provision (benefit) for income taxes	(116)	204	95
Deferred federal provision (benefit) for income taxes	184	187	292
Deferred state provision (benefit) for income taxes	41	(279)	415
Total deferred provision (benefit) for income taxes	225	(92)	707
Income tax expense (benefit)	109	112	802
Net income (loss)	(9,214)	(14,466)	3,193
Weighted average shares outstanding - basic	22,138	20,117	19,313
Weighted average shares outstanding - diluted	22,138	20,117	19,509
Year end shares outstanding	24,998	20,244	20,028
Income (loss) per share - continuing operations - basic	\$(0.42)
Net income (loss) per share - basic	\$(0.42)	\$(0.72)	\$0.17
Income (loss) per share - continuing operations - diluted	\$(0.42)
Net income (loss) per share - diluted	\$(0.42)	\$(0.72)	\$0.16
Number of full time employees	564	493	508
Number of part time employees	17	8	9
Total number of employees	581	501	517
Number of common stockholders	370	253	253

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	30,317	17,010
Accounts receivable, gross	18,989	15,371
Less: allowance for doubtful accounts	4,787	3,248
Accounts receivable, net	...	12,123
Accounts receivable, net of allowance for doubtful accounts of \$182 and \$19 at December 31, 2012 and 2011, respectively	14,202	...
Inventory	155	251
Prepaid expenses & other current assets	219,075	10,304
Total current assets before funds held for clients	...	39,688
Funds held for clients	...	203,588
Prepaid expenses and other current assets	3,471	...
Total current assets	267,220	243,276
Furniture & equipment	7,950	7,552

Software development costs	25,242	18,678
Software	2,808	2,808
Leasehold improvements	2,516	1,878
Gross property & equipment	38,516	30,916
Less: accumulated depreciation	23,999	...
Less: accumulated depreciation & amortization	...	19,477
Property & equipment, net	14,517	11,439
Goodwill	86,011	86,011
Intangible assets, net	62,082	66,594
Operating lease assets, net	4,991	7,065
Other assets, net	9,047	5,523
Total assets	443,868	419,908
Current portion of notes payable	27	4,106
Accounts payable	2,570	2,194
Accrued compensation & benefits	6,519	5,791
Operating lease liabilities, current	1,490	1,860
Accrued warranty expense	3,862	...
Other accrued liabilities	...	3,728
Contingent purchase consideration	...	2,955
Deferred revenue	6,853	8,461
Total current liabilities before client fund obligations	...	29,095
Client fund obligations	220,019	206,088
Total current liabilities	241,340	235,183
Deferred revenue	16	788
Deferred tax liability	1,728	1,503
Gross notes payable	...	32,780
Debt issuance costs & debt discount	4,282	(1,985)
Notes payable, net of current portion	...	30,795
Operating lease liabilities, noncurrent	4,638	6,459
Other liabilities	209	114
Total long-term liabilities	10,873	39,659
Total liabilities	252,213	274,842
Common stock	254	206
Treasury stock at cost	5,017	5,017
Additional paid-in capital	487,973	433,586
Retained earnings (accumulated deficit)	(290,440)	(281,226)
Accumulated other comprehensive income (loss)	(1,115)	(2,483)
Total stockholders' equity	191,655	145,066
Total Equity	191,655	...

Recent Dividends:**1. Asure Software Inc. common.**

No dividends paid.

Annual Dividends:**1. Asure Software Inc. common.**

No dividends paid.

ATERIAN INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31**

(\$000):

	2023	2022	2021
			(revised)
Net Revenue	142,566
Net revenues	142,566	221,170	247,767
Cost of goods sold	72,281	115,652	125,904
Gross profit (loss)	70,285	105,518	121,863
Research & development expenses	4,616	6,012	9,837
Sales & distribution	81,911	121,139	127,369

General & administrative expenses	20,220	38,239	45,099	Net earnings (loss) per share - diluted	\$(0.95)	\$(2.95)	\$(6.67)	Additional paid-in capital	736,675	728,339
Impairment loss on goodwill	...	120,409	...	Full-Time Employees (Period End)	114	Retained earnings (accumulated deficit)	(699,815)	(625,251)
Impairment loss on intangibles	39,728	3,118	...	Total number of employees	114	178	159	Accumulated other comprehensive income (loss)	(838)	(1,144)
Settlement of a contingent earn-out liability	4,164	Number of common stockholders	136	167	152	Total stockholders' equity (deficit)	36,031	101,952
Change in fair value of contingent earn-out liabilities	...	(5,240)	(30,529)	Foreign currency translation adjustments	...	(676)	...	Total Equity	36,031	...
Total operating expenses	146,475	283,677	155,940	Benefit for income taxes	(867)	Recent Dividends:		
Operating income (loss)	(76,190)	(178,159)	(34,077)	□ Shares increased due to issuance of common shares, issuance of restricted share awards, issuance of restricted common shares and warrants exercised; □ Shares increased due to issuance of common shares, issuance of restricted share awards and issuance of restricted common shares; □ As Is; □ Approximately			1. Aterian Inc common. No dividends paid.			
Interest expense	2,125	2,696	13,250	Consolidated Balance Sheet, Years Ended Dec. 31 (\$'000):			Annual Dividends:			
Interest income	704	93	595	2023			1. Aterian Inc common. No dividends paid.			
Interest income (expense), net	(1,421)	(2,603)	(12,655)	2022			ATLANTA BRAVES HOLDINGS INC			
Gain on extinguishment of seller note	...	2,012	...	Cash	20,023	43,574	Annual Report			
Loss on initial issuance of equity	...	18,669	...	Trade accounts receivable	4,225	4,882	Consolidated Income Statement, Years Ended Dec. 31 (\$'000):			
Change in fair value of derivative liability	(3,254)	Less: allowance for doubtful accounts	131	367	2023			
Gain (loss) on extinguishment of debt	(138,859)	Trade accounts receivable	4,356	...	Year end shares outstanding			
Change in fair market value of warrant liability	2,440	470	(26,455)	Accounts receivable - net	...	4,515	Baseball revenue			
Gain (loss) on initial issuance of warrants	(20,147)	Inventory on-hand	18,980	34,374	Mixed-Use Development revenue			
Other income (expense), net	(260)	281	(45)	Inventory in-transit	1,410	9,292	Total revenues			
Income (loss) before income taxes - Domestic	...	(196,166)	(233,846)	Inventory	20,390	43,666	Baseball operating costs			
Income (loss) before income taxes - International	...	(502)	(1,646)	Prepaid inventory	...	1,342	Mixed-Use Development costs			
Income (loss) before income taxes - Current state	(75,431)	(196,668)	(235,492)	Restricted cash	...	2,926	Selling, general and administrative, including stock-based compensation			
Income tax expense (benefit)	...	101	72	Prepaid insurance	...	1,991	Operating income			
Current foreign income tax expense (benefit)	213	69	265	Amazon global logistics	...	576	Income from cont operations before income tax			
Income Taxes - State- Current	73	Other prepaid & other current assets	...	1,426	Net income (consolidated)			
Current income tax expense (benefit)	286	170	337	Prepaid & other current assets	4,998	8,261	Weighted average shares outstanding - diluted			
Deferred federal income tax expense (benefit)	...	(270)	253	Total current assets	49,636	100,016	Earnings per share - net income - diluted			
Deferred state income tax expense (benefit)	...	(35)	32	Computer equipment & software	1,273	1,109	Impairment of long-lived assets and other related costs			
Deferred foreign income tax expense (benefit)	(1,153)	(241)	(90)	Furniture, fixtures & equipment	23	91	Depreciation and amortization			
Deferred income tax expense (benefit)	(1,153)	(546)	195	Leasehold improvements	2	56	Interest expense			
Provision for income taxes (benefit)	(867)	(376)	532	Building	796	638	Share of earnings (losses) of affiliates, net			
Net income (loss)	(74,564)	(196,292)	(236,024)	Computer equipment and software	452	...	Unrealized gains (losses) on intergroup interests			
Weighted average shares outstanding - basic	78,156	66,530	35,379	Total property & equipment, gross	...	1,894	Realized and unrealized gains (losses) on financial instruments, net			
Weighted average shares outstanding - diluted	78,156	66,530	35,379	Less: accumulated depreciation & amortization	498	1,041	Gains (losses) on dispositions, net			
Year end shares outstanding	90,097	80,752	55,090	Property & equipment - net	775	853	Other, net			
Net earnings (loss) per share - basic	\$(0.95)	\$(2.95)	\$(6.67)	Other intangibles - net	11,320	54,757	Current - Federal			
				Other non-current assets	138	813	Current - State			
				Total assets	61,869	156,439	Foreign			
				Credit facility	11,098	21,053	Total current			
				Seller notes	1,049	1,693	Deferred - Federal			
				Accounts payable	4,190	16,035	Deferred - State			
				Accrued compensation costs	140	53	Total deferred			
				Accrued professional fees & consultants	310	461	Income tax benefit (expense)			
				Accrued logistics costs	149	609	Total operating costs			
				Product related accruals	644	1,248	Common Shareholders - Number			
				Sales tax payable	1,019	711	Full-Time Employees (Period End)			
				Sales return reserve	233	646	Total number of employees			
				Accrued fulfillment expense	...	755	Consolidated Balance Sheet, Years Ended Dec. 31 (\$'000):			
				Accrued insurance	...	356	2023			
				Federal payroll taxes payable	...	1,467	Cash and cash equivalents			
				Accrued interest payable	146	190	Restricted cash			
				Warrant liability	1,033	3,473	Accounts receivable and contract assets, net of allowance for credit losses			
				All other accruals	3,185	4,285	Other current assets			
				Accrued & other current liabilities	9,110	14,254	Property and equipment, at cost			
				Withholding tax	2,251	...	Accumulated depreciation			
				Total current liabilities	25,447	53,035	Investments in affiliates, accounted for using the equity method			
				Other liabilities	391	1,452	Goodwill			
				Total liabilities	...	54,487	Franchise rights			
				Common stock	9	8	Other assets, net			
							Provision - Accounts & Notes Receivable - Trade			
							Contract Assets			

Accounts & Notes Receivable - Trade - Net	27,838
Accounts & Notes Receivable - Trade - Net - Balancing value	28,170
Total Current Assets	218,019
Property and equipment - Net	766,747
Total assets	1,504,330
Retained earnings (deficit)	(554,376)
Accumulated other comprehensive earnings (loss), net of taxes	(7,271)
Common stock value	103
Additional paid-in capital	1,089,625
Series B common stock, \$01 par value Authorized 7,500,000 shares; issued and outstanding 977,795 and zero at 30, 2023 and 31, 2022, respectively	10
Series C common stock, \$01 par value Authorized 200,000,000 shares; issued and outstanding 50,427,249 and zero at 30, 2023 and 31, 2022, respectively	506
Stockholders' equity	528,597
Accounts payable and accrued liabilities	73,096
Deferred revenue and refundable tickets	111,985
Current portion of debt	42,153
Other current liabilities	6,439
Long-term debt	527,116
Finance lease liabilities	103,586
Deferred income tax liabilities	50,415
Pension liability	15,222
Other noncurrent liabilities	33,676
Noncontrolling interests in equity of subsidiaries	12,045
Total Equity	540,642
Total Current Liabilities	233,673
Total liabilities	963,688

Recent Dividends:

- Atlanta Braves Holdings Inc series C common.**
No dividends paid.
- Atlanta Braves Holdings Inc series A common.**
No dividends paid.
- Atlanta Braves Holdings Inc series B common.**
No dividends paid.

Annual Dividends:

- Atlanta Braves Holdings Inc series C common.**
No dividends paid.
- Atlanta Braves Holdings Inc series A common.**
No dividends paid.
- Atlanta Braves Holdings Inc series B common.**
No dividends paid.

ATYR PHARMA INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Total revenues	353	10,386	...
License & collaboration agreement revenues	353	10,386	...
Research & development	42,293	42,808	23,264
General & administrative	12,979	13,982	10,751
Total operating expenses	...	56,790	34,015
Income (loss) from operations	(54,919)	(46,404)	(34,015)
Other income (expense), net	4,522
Total other income (expense), net	...	1,061	238
Income (loss) before income taxes	(50,397)
Net Income After Extraordinary Items applicable to Common	(50,389)
Net income (loss)	(50,397)	(45,343)	(33,777)
Net loss attributable to noncontrolling interest in Pangu BioPharma Limited	8	5	9

Net income (loss) attributable to common stockholders	(45,338)	(33,768)	...
Weighted average shares outstanding - basic	53,606	28,420	19,081
Weighted average shares outstanding - diluted	53,606	28,420	19,081
Year end shares outstanding	63,286	29,498	27,793
Net income (loss) per share - basic	\$(0.94)	\$(1.60)	\$(1.77)
Net income (loss) per share - diluted	\$(0.94)	\$(1.60)	\$(1.77)
Number of full time employees	56	65	49
Number of part time employees	3	5	4
Total number of employees	59	70	53
Number of Common Shareholders	31
Number of stockholders	...	31	32
Comprehensive loss attributable to aTyr Pharma, Inc. common stockholders	(50,030)

Reclassified to conform with 2022 presentation; Shares increased due to the effect of issuance of common stock upon release of restricted stock units, exercise of stock options, pursuant to employee stock purchase plan and at-the-market offerings; As Is; Approximately; As of March 10, 2023; As of March 10, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	22,544	9,981
Available-for-sale investments	75,622	56,165
Other receivables	2,436	11,775
Prepaid expenses	2,390	2,950
Total current assets	102,992	80,871
Restricted cash	3,484	3,165
Computer & office equipment	448	620
Scientific & laboratory equipment	4,051	4,379
Tenant improvements	10,152	4,414
Tenant improvements - Property & equipment, net	5,653	...
Property & equipment, gross	...	9,413
Less: accumulated depreciation & amortization	4,621	6,354
Property & equipment, net	5,531	3,059
Operating lease, right-of-use assets	6,727	7,250
Financing lease, right-of-use assets	1,788	1,248
Other assets	131	193
Total assets	120,653	95,786
Accounts payable	3,529	3,106
Accrued salaries, wages & benefits	2,706	2,781
Accrued clinical studies costs	...	5,151
Other accrued expenses	1,100	1,930
Accrued expenses - Balancing value	11,559	...
Accrued clinical and manufacturing	7,753	...
Accrued expenses	...	9,862
Current portion of operating lease liability	831	630
Current portion of financing lease liability	497	264
Total current liabilities	16,416	13,862
Long-term operating lease liability, net of current

portion	12,339	9,633
Long-term financing lease liability, net of current portion	1,428	1,007
Common stock	63	29
Additional paid-in capital	558,692	489,502
Accumulated other comprehensive income (loss)	(74)	(433)
Retained earnings (accumulated deficit)	(468,023)	(417,634)
Total aTyr Pharma stockholders' equity	90,658	71,464
Non-controlling interests	(188)	(180)
Total stockholders' equity (deficit)	90,470	71,284

Recent Dividends:

- aTyr Pharma Inc class X convertible preferred.**
No dividends paid.
- aTyr Pharma Inc common.**
No dividends paid.

Annual Dividends:

- aTyr Pharma Inc class X convertible preferred.**
No dividends paid.
- aTyr Pharma Inc common.**
No dividends paid.

AUDIOEYE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Revenue	31,316,000	29,913,000	24,503,000
Total revenues	31,316,000
Cost of revenue	...	7,219,000	6,121,000
Cost of services	6,974,000
Gross profit (loss)	24,342,000	22,694,000	18,382,000
Selling & marketing expenses	11,781,000	13,657,000	14,621,000
Research & development expenses	6,989,000	6,085,000	5,304,000
General & administrative expenses	11,537,000	13,381,000	13,970,000
Total operating expenses	30,307,000	33,123,000	33,895,000
Operating income (loss)	(5,965,000)	(10,429,000)	(15,513,000)
Gain on loan forgiveness	1,316,000
Interest expense, net	(93,000)	4,000	12,000
Total other income (expense)	...	(4,000)	1,304,000
Net income (loss)	(5,872,000)	(10,433,000)	(14,209,000)
Dividends on series A convertible preferred stock	69,000
Net income (loss) available to common stockholders	...	(10,433,000)	(14,278,000)
Weighted average shares outstanding - basic	11,766,000	11,477,000	11,040,000
Weighted average shares outstanding - diluted	11,766,000	11,477,000	11,040,000
Year end shares outstanding	11,711,000	11,551,000	11,435,000
Net income (loss) per common share - basic	\$(0.50)	\$(0.91)	\$(1.29)
Net income (loss) per common share - diluted	\$(0.50)	\$(0.91)	\$(1.29)
Number of full time employees	114	120	111
Total number of employees	114
Number of common stockholders	148	149	139

Income from cont operations before income tax	(5,872,000)
Basic EPS Excluding ExtraOrdinary Items	\$(0.50)
Diluted EPS Excluding ExtraOrd Items	\$(0.50)

□ As of February 28, 2023; □ As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	9,236,000	6,904,000
Accounts receivable, gross	5,324,000	5,886,000
Allowance for doubtful accounts	496,000	468,000
Accounts receivable, net	4,828,000	5,418,000
Deferred costs, short term	...	49,000
Prepaid expenses & other current assets	712,000	595,000
Total current assets	14,776,000	12,966,000
Property & equipment, gross	469,000	415,000
Less accumulated depreciation	251,000	254,000
Property & equipment, net	218,000	161,000
Right of use assets	611,000	1,154,000
Deferred costs, long term	...	12,000
Intangible assets, at cost	...	12,019,000
Less: accumulated amortization	...	5,978,000
Intangible assets, net	5,783,000	6,041,000
Goodwill	4,001,000	4,001,000
Other assets	106,000	93,000
Total assets	25,495,000	24,428,000
Accounts payable & accrued expenses	2,339,000	2,452,000
Finance lease liabilities	7,000	38,000
Operating lease liabilities	312,000	468,000
Deferred revenue	6,472,000	7,125,000
Contingent consideration	2,399,000	979,000
Total current liabilities	11,529,000	11,062,000
Finance lease liabilities	...	7,000
Operating lease liabilities	417,000	745,000
Deferred revenue	10,000	73,000
Contingent consideration, long term	105,000	1,952,000
Convertible notes & loans payable, net	6,727,000	...
Total liabilities	18,788,000	13,839,000
Common stock	1,000	1,000
Additional paid-in capital	96,182,000	93,070,000
Retained earnings (accumulated deficit)	(89,476,000)	(82,482,000)
Total stockholders' equity (deficit)	6,707,000	10,589,000
Total stockholders' equity (deficit)	6,707,000	...

Recent Dividends:

- 1. AudioEye Inc common.**
No dividends paid.
- 2. AudioEye Inc series A convertible preferred.**
No dividends paid.

Annual Dividends:

- 1. AudioEye Inc common.**
No dividends paid.
- 2. AudioEye Inc series A convertible preferred.**
No dividends paid.

AUTO PARTS 4LESS GROUP INC

Earnings, 9 mos. to Oct 31(Consol. - \$):			
	2023	2022	
Total revenues	339,116	4,089,037	
Net Sales	339,116	...	
Cost & expenses	1,381,869	8,636,115	

Operating income	(1,073,063)	(4,585,665)	
Other income (expense), net	(2,140,669)	19,539	
Gains or losses	9,468	(841,772)	
Net before taxes	(7,173,870)	...	
Net income	(7,173,870)	(12,228,775)	
Earnings common share			
Primary	\$(2.17)	\$(7.76)	
Fully Diluted	\$(2.17)	\$(7.76)	
Common Shares:			
Full Diluted	3,302,841	1,576,024	
Year-end	7,082,421	1,823,708	

AVALON GLOBOCARE CORP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Total revenues	...	905,842
Cost & expenses	6,897,191	7,465,454
Operating income	(5,962,831)	(9,773,867)
Other income (expense), net	(328,985)	517,186
Invest. income	(18,564)	(33,809)
Net before taxes	(7,151,876)	(9,513,166)
Net income	(7,151,876)	(9,513,166)
Earnings common share		
Primary	\$(0.69)	\$(1.00)
Fully Diluted	\$(0.69)	\$(1.00)
Common Shares:		
Full Diluted	10,372,447	9,152,168
Year-end	10,929,534	9,921,521

AVENUE THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

	2023	2022	□2021
Research & development expenses	6,131	2,698	1,254
Research & development expenses - licenses acquired	4,230
General & administrative expenses	4,179	5,345	2,484
Income (loss) from operations	(14,540)	(8,043)	(3,738)
Interest income	126	20	7
Financing costs - warrant liabilities	332	1,160	...
Change in fair value of warrant liabilities	4,258	5,580	...
Net income (loss)	(10,488)	(3,603)	(3,731)
Net income (loss) attributable to non-controlling interests			
	111	51	...
Net income (loss) attributable to common stockholders			
	(10,377)	(3,552)	...
Weighted average shares outstanding			
- basic	10,592	2,185	□1,133
Weighted average shares outstanding - diluted	10,592	2,185	□1,133
Year end shares outstanding	25,598	□4,774	□□1,406
Net income (loss) per share - basic	\$(0.98)	\$(1.63)	□\$(3.30)
Net income (loss) per share - diluted	\$(0.98)	\$(1.63)	□\$(3.30)
Number of full time employees			
	3	□2	□4
Total number of employees			
	3
Number of common stockholders			
	32	□□35	□□38
Income from cont operations before income tax			
	(10,488)
EPS - Basic -			

excluding Extraordinary Items Applicable to Common - Total	\$(0.98)
EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total	\$(0.98)

□ Non-consolidated; □ Adjusted for 1-for-15 stock split, September 26, 2022; □ Shares increased due to the effect of share based compensation, issuance of common shares & pre-funded warrants at private placement, exercise of warrants; □ Shares increased due to the issuance of common shares, issuance pursuant to cashless exercise of warrants and share based compensation; □ As is; □ As of March 28, 2023; □ March 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

2023 2022

Cash & cash equivalents	1,783	6,708
Prepaid expenses & other current assets	67	137
Total current assets	1,850	...
Total assets	1,850	6,845
Accounts payable	78	129
Accrued employee compensation	11	199
InvaGen Pharmaceuticals Inc. contingent fee	...	208
Accrued contracted services & other accrued expenses	198	413
Accounts payable & accrued expenses	...	949
Accounts payable & accrued expenses - related party	323	21
Warrant liability	...	2,609
Licenses payable	287	...
Derivative warrant liability	586	...
Total current liabilities	1,196	3,579
Total liabilities	1,196	3,579
Common shares	3	...
Additional paid-in capital	92,507	84,456
Retained earnings (accumulated deficit)	(90,928)	(80,551)
Total stockholders' equity (deficit) attributed to the Company	1,582	3,905
Non-controlling interests	(928)	(639)
Total stockholders' equity	654	3,266

Recent Dividends:

- 1. Avenue Therapeutics Inc class A preferred.**
No dividends paid.
- 2. Avenue Therapeutics Inc common.**
No dividends paid.

Annual Dividends:

- 1. Avenue Therapeutics Inc class A preferred.**
No dividends paid.
- 2. Avenue Therapeutics Inc common.**
No dividends paid.

AVINGER INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

	2023	2022	□2021
Revenues	7,652
Revenues	7,652	8,273	10,130
Cost of revenues	5,649	5,619	6,706
Gross profit (loss)	2,003	2,654	3,424
Research & development	4,540	4,390	5,900
Selling, general & administrative	14,098	14,221	15,625
Total operating expenses	18,638	18,611	21,525

Income (loss) from operations	(16,635)	(15,957)	(18,101)	Balancing value	78	...	Total operating expenses	...	59,100,000	27,054,000
Interest expense	1,719	1,665	1,648	Total property & equipment, gross	4,594	4,658	Operating income (loss)	(42,655,000)	(27,505,000)	(14,423,000)
Other income, net	34	(1)	2,337	Less: accumulated depreciation & amortization	4,107	3,956	Interest expense	1,143,000	16,000	17,000
Income (loss) before provision (benefit) for income taxes	(18,320)	Property & equipment, net	487	702	Other income	8,483,000	892,000	38,000
Net income (loss)	(18,320)	(17,623)	(17,412)	Other assets	19	312	Income (loss) from continuing operations before income taxes - U.S.	...	(26,764,000)	(14,490,000)
Accretion of preferred stock dividends	...	4,510	4,175	Total assets	13,770	24,195	Income (loss) from continuing operations before income taxes - foreign	...	135,000	88,000
Deemed dividend arising from beneficial conversion feature of convertible preferred stock	...	5,111	...	Accounts payable	777	631	Income (loss) before income taxes - Current state	(35,315,000)	(26,629,000)	(14,402,000)
Net income (loss) applicable to common stockholders	(18,320)	(27,244)	(21,587)	Accrued compensation	2,311	1,401	Income tax expense (benefit)	...	36,000	25,000
Weighted average shares outstanding - basic	786	417	315	Deferred revenues	...	141	Income Taxes - State	66,000
Weighted average shares outstanding - diluted	786	417	315	Accrued travel & entertainment expenses	...	129	Income tax expense (benefit)	...	36,000	25,000
Year end shares outstanding	1,280	522	319	Accrued product warranty costs	817	109	Income tax relating to ordinary activities	66,000
Net earnings (loss) per share - basic	\$(23.31)	\$(65.40)	\$(68.55)	Accrued clinical trial costs	105	106	Net income (loss)	(35,381,000)	(26,665,000)	(14,427,000)
Net earnings (loss) per share - diluted	\$(23.31)	\$(65.40)	\$(68.55)	Accrued professional fees	152	60	Weighted average shares outstanding - basic	25,331,264	25,000,180	24,915,414
Number of full time employees	68	67	68	Accrued sales & use tax	...	40	Weighted average shares outstanding - diluted	25,331,264	25,000,180	24,915,414
Number of part time employees	4	4	6	Other accrued liabilities	63	72	Year end shares outstanding	25,682,078	25,208,436	24,925,743
Total number of employees	72	71	74	Leasehold liability, current portion	1,102	1,092	Net income (loss) per share - basic	\$(1.40)	\$(1.07)	\$(0.58)
Number of common stockholders	128	123	123	Borrowings, current portion	14,293	14,165	Net income (loss) per share - diluted	\$(1.40)	\$(1.07)	\$(0.58)
Earnings per share from continuing operations	\$(23.31)	Total current liabilities	19,300	17,946	Part-Time Employees (Period End)	207
Earnings per share from continuing operations	\$(23.31)	Leasehold liability, long-term portion	...	1,102	Total number of employees	207	126	416

Recent Dividends:
1. Avinger Inc series B convertible preferred. No dividends paid.
2. Avinger Inc series C convertible preferred. No dividends paid.
3. Avinger Inc common. No dividends paid.
4. Avinger Inc series A convertible preferred. No dividends paid.
Annual Dividends:
1. Avinger Inc series B convertible preferred. No dividends paid.
2. Avinger Inc series C convertible preferred. No dividends paid.
3. Avinger Inc common. No dividends paid.
4. Avinger Inc series A convertible preferred. No dividends paid.

Reclassified to conform with 2022 presentation; Adjusted for 1-for-15 stock split, September 13, 2023; Shares issued due to the effect of issuance common stock in public offerings, vesting of stock units, conversion of preferred stock, exercise of warrants, reclassification and adjustment due to split; As is; As of March 10, 2023; As of March 18, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	5,275	14,603
Accounts receivable, gross	1,055	1,130
Less: allowance for doubtful accounts	41	73
Accounts receivable, net	1,014	1,057
Raw materials	3,203	3,374
Work-in-process	25	17
Finished products	2,070	1,574
Inventories - Balancing value	5,298	...
Inventories	...	4,965
Prepaid expenses & other current assets	575	362
Total current assets	12,162	20,987
Right of use asset	1,102	2,194
Equipment held by customers & field sales personnel	2,495	2,566
Machinery & equipment	1,379	1,372
Computer software	122	122
Computer equipment	200	200
Furniture & fixture	...	78
Leasehold improvements	320	320
Property and Equipment -		

AVITA MEDICAL INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Revenues	50,143,000	34,421,000	13,956,000
Cost of sales	7,780,000	6,041,000	1,905,000
Gross profit (loss)	42,363,000	28,380,000	12,051,000
Biomedical Advance Research & Development Authority ("BARDA") income	1,428,000	3,215,000	580,000
Sales & marketing expenses	37,291,000	21,913,000	8,472,000
General & administrative expenses	28,334,000	23,330,000	10,996,000
Research & development expenses	20,821,000	13,857,000	7,586,000
Cost of sales of listed & unlisted shares	7,780,000

For six months due to fiscal year end change; Approximately; As of January 31, 2023; As of January 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	22,118,000	18,164,000
Marketable securities	66,939,000	61,178,000
Accounts receivable, gross	7,712,000	3,539,000
Less: allowance for doubtful accounts	48,000	24,000
Accounts receivable, net	7,664,000	3,515,000
Biomedical Advance Research & Development Authority ("BARDA") receivables	...	898,000
Prepaid expenses	1,376,000	921,000
Lease deposits	38,000	110,000
Accrued investment income	227,000	168,000
BARDA contract costs	...	252,000
Other receivables	18,000	127,000
Prepaid & other current assets	1,659,000	1,578,000
Raw materials	3,683,000	1,131,000
Work in process	878,000	384,000
Finished goods	1,035,000	610,000
Inventory	5,596,000	2,125,000
BARDA receivables	30,000	...

Income (loss) from operations	(21,462,000)	(29,707,000)	(25,416,000)
Investment income	(437,000)	569,000	93,000
Interest expense	2,835,000	624,000	1,356,000
Change in fair value of derivatives	1,531,000	1,044,000	(28,000)
Other expense	...	230,000	278,000
Dividend income	1,487,000
Total other income (expense), net	(254,000)	759,000	(1,569,000)
Net income (loss)	(21,716,000)	(28,948,000)	(26,985,000)
Weighted average shares outstanding - basic	42,878,543	42,083,125	41,214,889
Weighted average shares outstanding - diluted	42,878,543	42,083,125	41,214,889
Year end shares outstanding	43,124,496	42,445,517	41,736,950
Net income (loss) per common share - basic	\$(0.51)	\$(0.69)	\$(0.65)
Net income (loss) per common share - diluted	\$(0.51)	\$(0.69)	\$(0.65)
Number of full time employees	...	2394	2428
Number of part time employees	...	2	23
Total number of employees	...	2396	2451
Number of common stockholders	...	226	231

Accounts payable & accrued expenses	28,883,000	22,443,000	...
Accrued deferred compensation	13,929,000
Current maturities of long-term lease obligations	1,547,000	1,310,000	...
Total current liabilities	30,430,000	23,753,000	...
Oberland facility	...	50,000,000	...
Less: unamortized debt discount & deferred financing fees	...	(4,288,000)	...
Long-term debt, net of debt discount & financing fees	46,603,000	45,712,000	...
Long-term lease obligations	21,142,000	20,405,000	...
Debt derivative liabilities	2,987,000	4,518,000	...
Total liabilities	101,162,000	94,388,000	...
Common stock	431,000	424,000	...
Additional paid-in capital	376,530,000	360,155,000	...
Retained earnings (accumulated deficit)	(281,296,000)	(259,580,000)	...
Total shareholders' equity (deficit)	95,665,000	100,999,000	...

Current state tax expense (benefit)	116,715	58,601	40,000
Current tax expense (benefit)	155,407	58,601	40,000
Deferred tax expense (benefit)	27,593	117,586	79,174
Total tax provision (benefit)	183,000	176,187	119,174
Net income (loss)	467,321	431,992	651,122
Net income (loss) available to common shareholders	...	431,992	651,122
Weighted average shares outstanding - basic	7,263,508	7,263,508	7,263,508
Weighted average shares outstanding - diluted	7,263,508	7,263,508	7,263,508
Year end shares outstanding	7,263,508	8,466,953	7,263,508
Net income (loss) per share - basic	\$0.06	\$0.06	\$0.09
Net income (loss) per share - diluted	\$0.06	\$0.06	\$0.09
Cash distributions declared per share	\$0.04	\$0.04	\$0.04
Number of full time employees	11	12	13
Total number of employees	11
Number of common stockholders	116	119	125
Number of beneficial stockholders	...	1,100	1,100
Special DPS - by Period End Date - Gross	\$0.01
Diluted EPS Excluding ExtraOrd Items	\$0.06
Basic EPS Excluding ExtraOrdinary Items	\$0.06

Recent Dividends:
1. Axogen Inc common.
 No dividends paid.
Annual Dividends:
1. Axogen Inc common.
 No dividends paid.

BAB INC Annual Report

	Consolidated Income Statement, Years Ended Nov. 30 (\$):		
	2023	2022	2021 (revised)
Royalty fees from franchised stores	1,944,894	1,838,276	1,678,970
Net sales by Company-owned stores	1,243,890
Franchise fees	...	53,149	49,595
Licensing fees & other income	294,062	314,342	362,943
Marketing fund revenue	26,999	1,081,320	980,630
Total revenues	3,509,845	3,287,087	3,072,138
Store food, beverage & paper costs	108,977
Payroll & payroll-related expenses	1,012,913	969,796	970,465
Occupancy expenses	139,095	133,089	133,247
Advertising & promotion expenses	12,186	14,800	22,980
Professional service fees	...	112,608	101,168
Travel expenses	...	16,332	9,930
Employee benefit expenses	147,191	145,245	133,132
Depreciation & amortization expenses	3,807	4,440	5,116
Marketing fund expenses	1,243,890	1,081,320	980,630
Other operating expenses	203,682	201,690	173,746
Travel	23,331
Total operating expenses	2,895,072	2,679,320	2,530,414
Income (loss) from operations	614,773	607,767	541,724
Interest income	35,548	412	417
Loan forgiveness	228,155
Income (loss) before provision for income taxes	650,321	608,179	770,296
Current federal tax expense (benefit)	38,692

Reclassified to conform with 2022 presentation; As of February 24, 2023; As of February 24, 2022; Approximately

	Consolidated Balance Sheet, Years Ended Nov. 30 (\$):	
	2023	2022
Cash and cash equivalents	1,888,728	...
Cash	...	1,623,256
Restricted cash	183,944	279,405
Trade accounts & notes receivable, gross	100,554	84,845
Less: allowance for doubtful accounts - trade accounts & notes receivable	28,873	10,873
Trade accounts & notes receivable, net	71,681	73,972
Marketing fund contributions receivable from franchisees & stores	14,995	12,811
Lease receivable	5,900	5,827
Prepaid expenses & other current assets	...	159,226
Prepaid expenses and other current assets	96,544	...
Total current assets	2,261,792	2,154,497
Property, plant & equipment, gross	159,414	...
Less: accumulated depreciation - property, plant & equipment	159,414	...
Lease receivable	32,406	38,305
Trademarks	461,445	461,445
Goodwill	1,493,771	1,493,771
Definite lived intangible assets, gross	154,886	153,705
Less: accumulated amortization - definite lived intangible assets	138,541	134,733

Reclassified to conform with 2022 presentation; Approximately; As of March 10, 2023; As of February 22, 2022

	Consolidated Balance Sheet, Years Ended Dec. 31 (\$):	
	2023	2022
Cash & cash equivalents	31,024,000	15,284,000
Restricted cash	6,002,000	6,251,000
Investments	...	33,505,000
Accounts receivables, gross	...	22,836,000
Less: allowance for doubtful accounts	...	650,000
Accounts receivable, net	...	22,186,000
Total receivables	25,147,000	...
Finished goods	13,545,000	12,651,000
Work in process	2,120,000	1,026,000
Raw materials	7,355,000	5,228,000
Inventory	23,020,000	18,905,000
Prepaid expenses & other current assets	...	1,944,000
Prepaid expenses and other	2,811,000	...
Total current assets	88,004,000	98,075,000
Building & improvements	60,679,000	...
Furniture & equipment	8,741,000	5,316,000
Leasehold improvements	15,348,000	15,482,000
Processing equipment	13,116,000	4,227,000
Land	...	731,000
Projects in process	3,674,000	63,703,000
Finance lease right-of-use assets	...	131,000
Property & equipment, at cost	102,427,000	89,590,000
Less: accumulated depreciation & amortization	13,697,000	10,296,000
Property & equipment, net	88,730,000	79,294,000
Operating lease right-of-use assets	15,562,000	14,369,000
Finance lease right-of-use assets	138,000	...
Land- Gross	731,000	...
Intangible assets, net	4,531,000	3,649,000
Total assets	196,827,000	195,387,000
Accounts payable	11,774,000	8,964,000
Accrued expenses	3,180,000	4,520,000
Accrued compensation	...	8,959,000

	2023	2022 (revised)	2021 (revised)			
Definite lived intangible assets, net	16,345	18,972		Total revenues	397,991,000	365,876,000
Operating lease right of use	32,745	127,617		Net sales	397,991,000	365,876,000
Total noncurrent assets	2,036,712	2,140,110		Cost of sales	242,878,000	117,097,000
Total assets	4,298,504	4,294,607		Gross profit	155,113,000	248,779,000
Accounts payable	3,042	5,803		Selling & marketing	144,496,000	160,076,000
Income tax payable	47,334	...		Research & development	10,102,000	8,444,000
Accrued expenses & other current liabilities	325,880	324,718		General & administrative	131,432,000	106,100,000
Unexpended marketing fund contributions	201,824	291,387		Total operating expenses	286,030,000	274,620,000
Deferred franchise fee revenue	30,094	33,487		Income (loss) from operations	(130,917,000)	(25,841,000)
Deferred licensing revenue	...	298		Interest expense, net	13,649,000	13,392,000
Current portion operating lease liability	39,818	113,883		Interest income	23,173,000	9,175,000
Total current liabilities	647,992	769,576		Other income (expense), net	5,200,000	(1,650,000)
Operating lease liability	...	39,819		Change in fair value of warrant liabilities	11,919,000	78,343,000
Deferred franchise revenue	162,026	128,465		Change in fair value of earn-out shares liability	...	(47,100,000)
Deferred tax liability	309,293	281,700		Foreign currency transaction loss (gain), net	2,385,000	(1,296,000)
Contract Liabilities - Long-Term - Advance Consideration & Progress Billings in Excess of Unbilled Revenue	162,026	...		Income (loss) before provision for income taxes - domestic	(104,161,000)	42,080,000
Total long-term liabilities	471,319	449,984		Income (loss) before provision for income taxes - Foreign	2,272,000	3,259,000
Total liabilities	1,119,311	1,219,560		Income (loss) before provision for income taxes	(101,889,000)	45,339,000
Common stock	13,508,257	13,508,257		Current federal income tax expense (benefit)	34,000	407,000
Additional paid-in capital	987,034	987,034		Current state income tax expense (benefit)	216,000	306,000
Treasury stock	222,781	222,781		Current foreign income tax expense (benefit)	3,793,000	2,189,000
Retained earnings (accumulated deficit)	(11,093,317)	(11,197,463)		Current income tax expense (benefit)	4,043,000	2,902,000
Total stockholders' equity (deficit)	3,179,193	3,075,047		Deferred federal income tax expense (benefit)	(4,137,000)	(257,000)
Total Equity	3,179,193	...		Deferred state income tax expense (benefit)	(633,000)	(166,000)
				Deferred foreign income tax expense (benefit)	(1,046,000)	(1,364,000)
				Deferred income tax expense (benefit)	(5,816,000)	(1,787,000)
				Income tax expense (benefit)	(1,773,000)	1,115,000
				Net income (loss)	(100,116,000)	44,224,000
				Weighted average shares outstanding - basic	131,680,605	147,554,090
				Weighted average shares outstanding - diluted	131,680,605	148,506,312
				Year end shares outstanding	122,899,002	132,214,695
				Net income (loss) per share - basic	\$(0.76)	\$0.30
				Net income (loss) per share - diluted	\$(0.76)	\$(0.23)
				Full-Time Employees (Period End)	881	...
				Total number of employees	881	...
				Number of class A common stockholders	51	...
						74

Foreign currency translation adjustments ... (1,499,000)

Earnings per share from continuing operations ... \$(0.76) \$0.30 ...

Earnings per share from continuing operations ... \$(0.76) \$(0.23) ...

Restated to reflect correction of errors; Reclassified to conform with 2022 presentation; As of February 18, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022 (revised)
Cash & cash equivalents	523,025,000	568,197,000
Accounts receivable, gross	61,301,000	79,423,000
Less: allowances for estimated credit losses	6,604,000	2,929,000
Accounts receivable, net	54,697,000	76,494,000
Prepaid expenses & other current assets	28,877,000	26,698,000
Income tax receivable	332,000	1,280,000
Raw materials	24,406,000	38,373,000
Finished goods	66,915,000	78,057,000
Inventories	91,321,000	116,430,000
Total current assets	698,252,000	789,099,000
Furniture & fixtures	5,903,000	5,364,000
Computer & equipment	5,479,000	4,901,000
Machinery & equipment	8,597,000	6,427,000
Auto & trucks	242,000	161,000
Tooling	887,000	638,000
Leasehold improvements	12,323,000	11,812,000
Property & equipment, gross	34,179,000	29,303,000
Less: Accumulated depreciation	19,953,000	...
Less: accumulated depreciation & amortization	...	12,494,000
Construction in progress	748,000	1,375,000
Property & equipment, net	14,226,000	18,184,000
Right-of-use assets, net	12,120,000	15,637,000
Intangible assets, net	62,123,000	46,386,000
Goodwill	125,818,000	124,593,000
Deferred income tax assets, net	531,000	815,000
Other assets	16,043,000	14,193,000
Total assets	929,113,000	1,008,907,000
Accounts payable	44,768,000	30,335,000
Accrued compensation	...	4,154,000
Accrued payroll taxes	...	1,357,000
Accrued benefits	...	5,643,000
Accrued sales commissions	...	10,523,000
Accrued payroll-related expenses	22,028,000	21,677,000
Sales & VAT tax payables	4,971,000	4,904,000
Accrued interest	2,344,000	2,344,000
Note payable due seller	...	1,819,000
Royalty liabilities	3,914,000	2,348,000
Other accrued expenses	...	3,768,000
Other accrued expenses	19,846,000	15,183,000
Lease liabilities, current	4,598,000	4,958,000
Income tax payable	2,759,000	962,000
Syndeo Program reserves	21,009,000	...
Other accrued expenses - Balancing value	8,617,000	...
Total current liabilities	115,008,000	73,115,000
Other long-term liabilities	2,767,000	...
Lease liabilities, non-current	9,319,000	12,689,000
Deferred income tax liabilities, net	702,000	2,011,000
Warrant liabilities	3,555,000	15,473,000
Convertible senior notes, net	738,372,000	734,143,000
Total liabilities	869,723,000	837,431,000
Class A common stock	12,000	14,000
Additional paid-in capital	541,281,000	550,320,000

Recent Dividends:**1. BAB Inc common.**

ExDate	Amt	Declared	Record	Payable
02/09/2021	0.01	01/27/2021	02/10/2021	02/24/2021
03/31/2021	0.01	03/17/2021	04/01/2021	04/22/2021
06/18/2021	0.01	06/03/2021	06/21/2021	07/12/2021
09/24/2021	0.01	09/10/2021	09/27/2021	10/18/2021
12/21/2021	0.01	12/06/2021	12/22/2021	01/11/2022
03/28/2022	0.01	03/07/2022	03/29/2022	04/18/2022
06/21/2022	0.01	06/03/2022	06/22/2022	07/11/2022
09/27/2022	0.01	09/09/2022	09/28/2022	10/20/2022
12/21/2022	0.01	12/07/2022	12/22/2022	01/11/2023
12/21/2022	0.01	12/07/2022	12/22/2022	01/11/2023
03/29/2023	0.01	03/13/2023	03/30/2023	04/19/2023
06/21/2023	0.01	06/06/2023	06/22/2023	07/11/2023
09/27/2023	0.01	09/12/2023	09/28/2023	10/18/2023
12/26/2023	0.01	12/11/2023	12/27/2023	01/16/2024
12/26/2023	0.01	12/11/2023	12/27/2023	01/16/2024

Annual Dividends:**1. BAB Inc common.**

2021	0.04	2022	0.04	2023	0.05
2024	0.02				

BANGFU TECHNOLOGY GROUP CO LTD**Earnings, 6 mos. to Dec 31(Consol. - \$):**

	2023	2022
Cost & expenses	33,049	28,150
Operating income	(33,049)	(28,150)
Net before taxes	(33,049)	(28,150)
Net income	(33,049)	(28,150)
Earnings common share		
Primary	\$(0.00)	\$(0.00)
Fully Diluted	\$(0.00)	\$(0.00)
Common Shares:		
Full Diluted	7,950,500	7,950,500
Year-end	7,950,500	7,950,500

BEAUTY HEALTH CO (THE)**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

Accumulated other comprehensive income (loss)	(3,036,000)	(4,530,000)
Retained earnings (accumulated deficit)	(478,867,000)	(374,328,000)
Total stockholders' equity (deficit)	59,390,000	171,476,000
Total Equity	59,390,000	...

Recent Dividends:

1. Beauty Health Co (The) class A common.
No dividends paid.

2. Beauty Health Co (The) class A common subject to possible redemption.
No dividends paid.

3. Beauty Health Co (The) class B common.
No dividends paid.

Annual Dividends:

1. Beauty Health Co (The) class A common.
No dividends paid.

2. Beauty Health Co (The) class A common subject to possible redemption.
No dividends paid.

3. Beauty Health Co (The) class B common.
No dividends paid.

BIO-PATH HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Stock-based Compensation in SGA	551,000
General and administrative	4,235,000
Research & development expenses	11,608,000	9,165,000	5,910,000
General & administrative expenses	3,684,000	4,736,000	4,533,000
Selling, general & administrative expenses	11,425,000
Stock-based Compensation in R&D	183,000
Total operating expenses	15,843,000	13,901,000	10,443,000
Net operating income (loss)	(15,843,000)	(13,901,000)	(10,443,000)
Change in fair value of warrant liability	(271,000)
Interest income	36,000	33,000	3,000
Total other income (expense)	(235,000)	33,000	3,000
Net income (loss) before income taxes	(16,078,000)
Net income (loss)	(16,078,000)	(13,868,000)	(10,440,000)
Weighted average shares outstanding - basic	478,000	363,800	336,250
Weighted average shares outstanding - diluted	478,000	363,800	336,250
Year end shares outstanding	618,000	398,008	358,000
Net income (loss) per share - basic	\$(33.63)	\$(38.20)	\$(31.00)
Net income (loss) per share - diluted	\$(33.63)	\$(38.20)	\$(31.00)
Number of full time employees	10	10	10
Number of common stockholders	187	190	196
Basic EPS Excluding ExtraOrdinary Items	\$(33.63)
Diluted EPS Excluding ExtraOrd Items	\$(33.63)
Total number of employees	10

Adjusted for 1-for-20 stock split, February 23, 2024; Shares increased due to the effect of issuance of common stock, and exercise of warrants; Approximately; As of March 23, 2023; As of March 3, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	1,052,000	10,384,000
Prepaid drug product	632,000	3,587,000
Other current assets	1,358,000	1,644,000
Total current assets	3,042,000	15,615,000
Leasehold improvements	463,000	463,000
Computers & office equipment	93,000	83,000
Furniture & fixtures	...	93,000
Scientific equipment	481,000	481,000
Computers and office equipment	83,000	...
Furniture, fixtures & equipment, gross	1,120,000	1,120,000
Less: accumulated depreciation	1,044,000	962,000
Fixed assets, net	76,000	158,000
Right of use operating assets	102,000	198,000
Total assets	3,220,000	15,971,000
Accounts payable	457,000	667,000
Accrued salaries & payroll taxes	200,000	...
Accrued expense	...	909,000
Current portion of lease liabilities	103,000	108,000
Other Accrued Liabilities	100,000	...
Accrued Clinical And Preclinical Expenses	800,000	...
Accrued expenses - Balancing value	246,000	...
Total current liabilities	1,906,000	1,684,000
Noncurrent lease liabilities	10,000	113,000
Warranty liability	863,000	...
Total liabilities	2,779,000	1,797,000
Common stock	1,000	8,000
Additional paid in capital	108,047,000	105,695,000
Retained earnings (accumulated deficit)	...	(91,529,000)
Accumulated deficit	(107,607,000)	...
Total shareholders' equity (deficit)	441,000	14,174,000
Total Equity	441,000	...

Recent Dividends:

1. Bio-Path Holdings Inc common.
No dividends paid.

Annual Dividends:

1. Bio-Path Holdings Inc common.
No dividends paid.

BIOFRONTERA INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021
Products revenues, net	34,005	28,541	24,043
Revenues, related party	66	133	57
Total revenues, net	34,071	28,674	24,100
Cost of revenues, related party	16,789	14,618	12,222
Cost of revenues, other	655	567	520
Selling, general & administrative	38,975	35,137	36,512
Selling, general & administrative, related party	152	733	697
Restructuring costs	77	...	752
Change in fair value of contingent consideration	100	(3,800)	(1,402)
Total operating

expenses	56,748	47,255	49,301
Income (loss) from operations	(22,677)	(18,581)	(25,201)
Change in fair value of warrant liabilities	6,456	16,388	(12,801)
Change in fair value of investments	(7,421)	1,747	...
Related party interest expense	22
Interest expense	220	12	2
Contract asset interest expense	358	358	358
Interest income, related party	...	165	...
Interest income, other	132	10	16
Interest income (expense), net	(468)	(195)	(344)
Other income, net	(75)	33	...
Other income, net	(1,045)	33	689
Gain on legal settlement	(7,385)
Excess of warrant fair value over offering proceeds	(2,272)
Total other income (expense)	2,560	17,973	(12,456)
Income (loss) before income taxes	(20,117)	(608)	(37,657)
Income tax expense	14	32	56
Net income (loss)	(20,131)	(640)	(37,713)
Weighted average shares outstanding - basic	1,546	1,057	440
Weighted average shares outstanding - diluted	1,546	1,057	440
Year end shares outstanding	1,518	1,335	855
Net income (loss) per share - basic	\$(13.02)	\$(0.60)	\$(85.60)
Net income (loss) per share - diluted	\$(13.02)	\$(0.60)	\$(85.60)
Number of full time employees	85	81	69
Total number of employees	85
Number of common stockholders	...	3	2

Non-consolidated; Adjusted for 1-for-20 stock split, July 5, 2023; Shares increased due to the effect of issuance of common stock and warrants under initial public offering and private placement offering, and exercise of common and pre-funded warrants; As is; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	1,343	17,208
Investment in equity securities	78	10,548
Accounts receivable, gross	5,162	3,848
Less: allowance for doubtful accounts	0	100
Accounts receivable, net	5,162	3,748
Other receivables, related party	5,159	3,658
Inventories	10,908	7,168
Prepaid expenses	305	439
Security deposits	...	85
Other prepaid expenses & other current assets	...	286
Prepaid expenses & other current assets	425	810
Other Current Assets	120	...
Total current assets	23,075	43,140
Other receivables long term, related party	...	2,813
Computer equipment	94	89

Computer software	27	27
Furniture & fixtures	81	81
Leasehold improvement	368	368
Machinery & equipment	121	145
Property and equipment, gross - Balancing value	81	...
Property & equipment, gross	691	710
Less: accumulated depreciation	557	506
Property & equipment, net	134	204
Operating lease right-of-use assets	1,612	1,375
Intangible asset, net	2,629	3,032
Other assets	482	320
Total assets	27,932	50,884
Accounts payable	3,308	1,278
Accounts payable, related parties	5,698	1,312
Acquisition contract liabilities, net	6,942
Operating lease liabilities, non-current	691	498
Legal settlement	6,207
Employee compensation & benefits	2,185	2,850
Professional fees	1,353
Product revenue allowances & reserves	82
Other accrued expenses & other current liabilities	372
Accrued expenses & other current liabilities	1,616	10,864
Accrued expenses and other current liabilities - Balancing value	4,487	...
Short term debt	3,904	...
Other	686	...
Total current liabilities	18,088	20,894
Acquisition contract liabilities, net	2,400
Warrant liabilities	4,210	2,843
Operating lease liabilities, non-current	804	848
Other long-term liabilities	21
Other liabilities	37	21
Total liabilities	23,139	27,006
Common stock	2	27
Additional paid-in capital	104,441	103,370
Retained earnings (accumulated deficit)	(99,650)	(79,519)
Total stockholder's equity (deficit)	4,793	23,878
Total Equity	4,793	...

Recent Dividends:**1. Biofrontera Inc common.**

No dividends paid.

Annual Dividends:**1. Biofrontera Inc common.**

No dividends paid.

BIOLASE INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
			(revised)
Net sales	49,164,000
Net revenue	49,164,000	48,462,000	39,188,000
Cost of revenue	32,440,000	32,551,000	22,659,000
Gross profit (loss)	16,724,000	15,911,000	16,529,000
Sales & marketing	18,441,000	21,675,000	15,339,000
General & administrative	10,216,000	12,309,000	11,258,000
Engineering & development	6,004,000	7,265,000	6,048,000
Gain (loss) on patent litigation settlement	315,000
Income (loss) from operations	(17,937,000)	(25,338,000)	(16,431,000)

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):			
	2023	2022	
Cash & cash equivalents	6,566,000	4,181,000	
Accounts receivable, gross	5,727,000	8,005,000	
Less: allowance for accounts receivable	244,000	2,164,000	

[¶] Adjusted for 1-for-100 stock split, July 28, 2023; ^{¶¶} Adjusted for 1-for-25 stock split, April 29, 2022; ^{¶¶¶} Shares increased due to the effect of sale of common stock, exercise of stock option, issuance of common stock for settlement of liability, issuance of restricted shares, conversion of series F conver; ^{¶¶¶} As of March 21, 2023; ^{¶¶¶} As of March 10, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):			
	2023	2022	
Cash & cash equivalents	6,566,000	4,181,000	
Accounts receivable, gross	5,727,000	8,005,000	
Less: allowance for accounts receivable	244,000	2,164,000	

Accounts receivable	5,483,000	5,841,000
Raw materials	6,168,000	6,697,000
Work-in-process	1,299,000	1,871,000
Finished goods	3,966,000	7,316,000
Inventory	11,433,000	15,884,000
Prepaid inventory	1,225,000
Prepaid insurance	662,000
Other prepaid expenses & other current assets	1,166,000
Prepaid expenses & other current assets	1,381,000	3,053,000
Total current assets	24,863,000	28,959,000
Building	205,000	199,000
Leasehold improvements	1,251,000	464,000
Equipment & computers	519,000	8,566,000
Furniture & fixtures	475,000
Construction in progress	92,000	2,957,000
Demonstration units	16,695,000	...
Equipment and Computers	14,628,000	...
Total property, plant, & equipment before depreciation & land	12,661,000
Less: accumulated depreciation	11,330,000	8,538,000
Total property, plant, & equipment, net before land	4,123,000
Land	160,000	155,000
Property, plant & equipment, net	5,525,000	4,278,000
Goodwill	2,926,000	2,926,000
Right of use asset	1,519,000	1,768,000
Other assets	268,000	255,000
Total assets	35,101,000	38,186,000
Accounts payable	6,065,000	5,786,000
Payroll & benefits	3,343,000	4,674,000
Warranty accrual, current portion	1,321,000	1,293,000
Lease liability	888,000	638,000
Accrued professional services	422,000	591,000
Accrued insurance premium	473,000	490,000
Accrued taxes	432,000
Other accrued liabilities	1,092,000
Deferred revenue, current portion	2,452,000	2,111,000
Current portion of term loans, net of discount	2,265,000	700,000
Taxes	452,000	...
Other	619,000	...
Accrued Liabilities - Balancing value	1,363,000	...
Total current liabilities	19,663,000	17,807,000
Deferred revenue	256,000	418,000
Warranty accrual	593,000	360,000
Notes payable & long-term debt, less current portion	11,782,000	...
Non current term loans, net of discount	13,091,000
Non current operating lease liability	772,000	1,259,000
Other liabilities	79,000	362,000
Total liabilities	33,145,000	33,297,000
Preferred Stock - Convertible - Non-Redeemable	1,857,000	...
Preferred Stock - Series H Convertible Preferred stock - Non-Redeemable	346,000	...
Common stock	3,000	8,000
Additional paid-in capital	317,103,000	301,782,000
Accumulated other comprehensive gain (loss)	(553,000)	(733,000)
Retained earnings (accumulated deficit)	(316,800,000)	(296,168,000)
Total stockholders' equity (deficit)	1,956,000	4,889,000
Total Equity	1,956,000	...

Recent Dividends:**1. Biolase Inc series J convertible redeemable preferred.**

No dividends paid.

2. Biolase Inc series F convertible preferred.	No dividends paid.
3. Biolase Inc common.	No dividends paid.
4. Biolase Inc series E convertible preferred stock.	No dividends paid.
5. Biolase Inc series H convertible redeemable preferred.	No dividends paid.
Annual Dividends:	
1. Biolase Inc series J convertible redeemable preferred.	No dividends paid.
2. Biolase Inc series F convertible preferred.	No dividends paid.
3. Biolase Inc common.	No dividends paid.
4. Biolase Inc series E convertible preferred stock.	No dividends paid.
5. Biolase Inc series H convertible redeemable preferred.	No dividends paid.

BIOLIFE SOLUTIONS INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):			
	2023	2022	2021
			(revised)
Product sales	117,695,000	136,000,000	101,913,000
Rental revenue	...	10,451,000	7,426,000
Service revenue	17,551,000	15,308,000	9,817,000
Total product, rental & service revenue	143,271,000	161,759,000	119,156,000
Consulting revenue	8,025,000
Cost of product revenue (exclusive of intangible assets amortization)	15,586,000	88,519,000	69,676,000
Cost of rental revenue (exclusive of intangible assets amortization)	75,751,000	7,058,000	7,051,000
Cost of service revenue (exclusive of intangible assets amortization)	5,182,000	12,360,000	5,381,000
Research & development expenses	18,796,000	14,798,000	11,821,000
Sales & marketing expenses	24,583,000	21,570,000	14,006,000
General & administrative expenses	55,725,000	47,670,000	33,668,000
Impairment of intangible asset	15,485,000	110,364,000	...
Intangible asset amortization	5,181,000	9,697,000	8,202,000
Acquisition costs	...	18,000	1,636,000
Change in fair value of contingent consideration	(2,193,000)	(4,754,000)	2,875,000
Total operating expenses	214,096,000	307,300,000	154,316,000
Operating income (loss)	(70,825,000)	(145,541,000)	(35,160,000)
Change in fair value of warrant liability	(121,000)
Change in fair value of investments	...	697,000	...
Interest income (expense), net	...	(687,000)	(485,000)
Interest expense	1,812,000
Other income (expense)	1,264,000	704,000	289,000
Gain on acquisition of Sexton Biotechnologies, Inc.	6,451,000
Write off of deferred financing costs	(5,115,000)

Total other income (expense), net	4,567,000	714,000	6,134,000
Income (loss) before income taxes	...	(146,091,000)	(28,590,000)
- domestic
- foreign	...	1,264,000	(436,000)
Income (loss) before income tax expense (benefit)	(66,258,000)	(144,827,000)	(29,026,000)
Current state income tax provision (benefit)	46,000	11,000	...
Current foreign income tax provision	185,000	205,000	9,000
Total current income tax provision (benefit)	231,000	216,000	9,000
Deferred federal income tax provision (benefit)	(62,000)	(2,924,000)	(17,703,000)
Deferred state income tax provision (benefit)	...	(2,314,000)	(2,424,000)
Total deferred income tax provision (benefit)	(62,000)	(5,238,000)	(20,127,000)
Income tax expense (benefit)	169,000	(5,022,000)	(20,118,000)
Net income (loss)	(66,427,000)	(139,805,000)	(8,908,000)
Net income (loss) attributable to common stockholders	...	(139,805,000)	(8,908,000)
Weighted average shares outstanding - basic	43,719,185	42,481,027	38,503,944
Weighted average shares outstanding - diluted	43,719,185	42,481,027	38,503,944
Year end shares outstanding	45,167,225	42,832,231	41,817,503
Income (loss) per share from continuing operations - basic	\$(1.52)
Net income (loss) per common share - basic	\$(1.52)	\$(3.29)	\$(0.23)
Income (loss) per share from continuing operations - diluted	\$(1.52)
Net income (loss) per common share - diluted	\$(1.52)	\$(3.29)	\$(0.23)
Number of full time employees	409	466	...
Number of part time employees	5	1	...
Total number of employees	414
Number of common stockholders	256	202	...
Foreign currency translation adjustments	...	(347,000)	...

□ Restated to reflect correction of immaterial errors related to sales tax liability and associated expenses; □ Shares increased due to the effect of stock issued as consideration, stock options exercises, cashless exercise of warrants, and stock issued on vested RSAs; □ Approximately; □ As of March 21, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	35,407,000	19,442,000
Restricted cash	31,000	31,000
Available-for-sale securities, current portion	...	43,260,000
Accounts receivable,		

trade, gross	20,367,000	34,675,000
Less: allowance for doubtful accounts	1,710,000	739,000
Accounts receivable, trade, net	18,657,000	33,936,000
Raw materials	26,219,000	20,950,000
Work in progress	7,128,000	5,680,000
Finished goods	10,109,000	8,274,000
Inventories	...	34,904,000
Prepaid expenses & other current assets	16,288,000	6,879,000
Prepaid expenses and other current assets	6,765,000	...
Total current assets	120,604,000	138,452,000
Assets held for rent, net	94,000	9,064,000
Leasehold improvements	5,913,000	5,249,000
Furniture & computer equipment	820,000	1,908,000
Manufacturing & other equipment	19,893,000	20,557,000
Construction in-progress	3,953,000	5,095,000
Subtotal property & equipment	30,579,000	32,809,000
Less: accumulated depreciation	9,502,000	9,171,000
Net property & equipment	21,077,000	23,638,000
Operating lease right-of-use assets, net	11,446,000	15,292,000
Accumulated depreciation	6,272,000	...
Assets held for rent, net - Balancing value	13,985,000	...
Financing lease right-of-use assets, net	7,713,000	272,000
Intangible assets, net	21,149,000	32,088,000
Equity investments	...	5,069,000
Long-term deposits & other assets	273,000	281,000
Available-for-sale securities, long term	5,069,000	1,332,000
Goodwill	224,741,000	224,741,000
Available-for-sale securities, long-term	548,000	...
Total assets	412,714,000	450,229,000
Accounts payable	6,940,000	15,367,000
Accrued expenses	...	3,128,000
Accrued taxes	...	975,000
Accrued compensation	3,800,000	5,080,000
Deferred revenue, current	661,000	548,000
Other accrued expenses & other current liabilities	...	51,000
Accrued expenses & other current liabilities	7,471,000	9,782,000
Sales taxes payable	5,442,000	4,151,000
Warranty liability	...	8,312,000
Lease liabilities, operating, current portion	2,797,000	2,860,000
Lease liabilities, financing, current portion	376,000	158,000
Debt, current portion	6,833,000	1,814,000
Warrant liability	7,858,000	...
Contingent consideration, current portion	...	2,138,000
Accrued warranty costs	11,932,000	...
Total current liabilities	42,178,000	44,582,000
Contingent consideration, long term	...	2,318,000
Lease liabilities, operating, long-term	13,205,000	14,962,000
Lease liabilities, financing, long-term	1,169,000	126,000
Term loan - secured	...	22,896,000
Insurance premium financing	...	1,074,000
Freezer equipment loan	...	466,000
Manufacturing equipment loans	...	266,000
Freezer installation loan	...	1,078,000
Other loans	...	6,000
Total debt, excluding unamortized debt issuance costs	...	25,786,000
Less: unamortized debt		

issuance costs	...	(179,000)	before income taxes				expenses	...	439,000
Total debt	...	25,607,000	- domestic	(235,852,000)	(131,237,000)	(78,356,000)	Other current assets	...	2,412,000
Less: current portion of debt	...	1,814,000	Income before income taxes - foreign	3,421,000	525,000	204,000	Prepaid expenses & other current assets	6,019,000	7,329,000
Debt, long-term	...	23,793,000	Income (loss) before income taxes	(232,431,000)	(130,712,000)	(78,152,000)	Total current assets	140,118,000	157,298,000
Notes payable - LDC loan - long term portion	18,311,000	...	Current foreign income taxes	63,000	123,000	39,000	Restricted cash	400,000	400,000
Deferred tax liabilities	188,000	250,000	Current state & local income taxes	(1,000)	1,000	21,000	Computer & office equipment	2,984,000	1,622,000
Other long-term liabilities	...	10,000	Total current income tax provision (benefit)	62,000	124,000	60,000	Lab equipment	18,438,000	15,080,000
Total liabilities	75,051,000	86,041,000	Deferred federal income taxes	...	(277,000)	(4,055,000)	Service equipment placed at customer sites	17,254,000	10,403,000
Common stock	45,000	43,000	Deferred state & local income taxes	...	2,037,000	(1,722,000)	Leasehold improvements	3,746,000	4,001,000
Additional paid-in capital	651,305,000	611,739,000	Total deferred income tax provision (benefit)	...	1,760,000	(5,777,000)	Total property & equipment, gross	42,422,000	31,106,000
Accumulated other comprehensive income (loss), net of taxes	(345,000)	(679,000)	Provision (benefit) for income taxes	62,000	1,884,000	(5,717,000)	Less accumulated depreciation	19,077,000	...
Retained earnings (accumulated deficit)	(313,342,000)	(246,915,000)	Net income (loss)	(232,493,000)	(132,596,000)	(72,435,000)	Less accumulated depreciation & amortization	...	13,077,000
Total shareholders' equity	337,663,000	364,188,000	Weighted average shares outstanding - basic	34,150,000	² 28,921,000	27,678,200	Property & equipment, net	23,345,000	18,029,000
Total shareholders' equity (deficiency)	337,663,000	...	Weighted average shares outstanding - diluted	34,150,000	² 28,921,000	27,678,200	Operating lease right-of-use assets	5,633,000	7,222,000

Recent Dividends:**1. Biolife Solutions Inc series A preferred.**

No dividends paid.

2. Biolife Solutions Inc series F convertible preferred.

No dividends paid.

3. Biolife Solutions Inc common.

No dividends paid.

Annual Dividends:**1. Biolife Solutions Inc series A preferred.**

No dividends paid.

2. Biolife Solutions Inc series F convertible preferred.

No dividends paid.

3. Biolife Solutions Inc common.

No dividends paid.

BIONANO GENOMICS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	¹ 2021 (revised)
Revenue - product revenue	20,425,000	12,686,000	...
Revenue - other revenue	7,377,000	5,295,000	...
Product revenue	26,727,000
Service and other revenue	9,389,000
Total revenue	36,116,000	27,802,000	17,981,000
Cost of product revenue	20,415,000	15,966,000	10,524,000
Cost of service & other revenue	6,135,000	5,891,000	3,583,000
Total cost of revenue	21,857,000	14,107,000	...
Research & development	54,032,000	49,047,000	22,485,000
Selling, general & administrative	93,499,000	88,596,000	58,490,000
Goodwill Impairment	77,280,000
Total operating expenses	137,643,000	80,975,000	...
Income (loss) from operations	(215,245,000)	(131,698,000)	(77,101,000)
Interest income	3,311,000	1,507,000	236,000
Interest expense	5,119,000	298,000	927,000
Gain on forgiveness of paycheck protection program loan	1,775,000
Change in fair value of preferred stock warrants & expirations	(18,827,000)
Gain (loss) on debt extinguishment	(2,076,000)
Other income (expenses)	3,449,000	(223,000)	(59,000)
Total other income (expense)	(17,186,000)	986,000	(1,051,000)
Income (loss)

¹ Reclassified to conform with 2022 presentation; ² Adjusted for 1-for-10 stock split, August 4, 2023; ³ Shares increased due to the effect of stock option exercises, issue common stock, warrant exercises, employee stock purchase plan, vesting of restricted stock units & stock for acquisition; ⁴ Approximately; ⁵ As of March 6, 2023; ⁶ As of February 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	17,948,000	5,091,000
Investments	48,823,000	...
Investments	35,117,000	108,095,000
Accounts receivable, gross	9,802,000	7,315,000
Less allowance for doubtful accounts	483,000	293,000
Accounts receivable, net	9,319,000	7,022,000
Raw materials	7,567,000	5,319,000
Work in process	10,245,000	7,055,000
Finished goods	...	17,387,000
Work in process	9,790,000	...
Inventories non-current (included in other long-term assets)	(4,710,000)	...
Inventory - Balancing value	22,892,000	...
Inventory	...	29,761,000
Prepayment to supplier	...	245,000
Prepaid insurance	...	948,000
Interest receivable	...	474,000
Prepaid employee related expenses	...	680,000
Internal use cloud computing arrangement software development costs	...	530,000
Prepaid software subscriptions	...	1,601,000
Prepaid marketing

Other current assets	...	2,412,000
Prepaid expenses & other current assets	6,019,000	7,329,000
Total current assets	140,118,000	157,298,000
Restricted cash	400,000	400,000
Computer & office equipment	2,984,000	1,622,000
Lab equipment	18,438,000	15,080,000
Service equipment placed at customer sites	17,254,000	10,403,000
Leasehold improvements	3,746,000	4,001,000
Total property & equipment, gross	42,422,000	31,106,000
Less accumulated depreciation	19,077,000	...
Less accumulated depreciation & amortization	...	13,077,000
Property & equipment, net	23,345,000	18,029,000
Operating lease right-of-use assets	5,633,000	7,222,000
Finance lease right-of-use assets, related party	3,503,000	3,707,000
Intangible assets, net	33,974,000	41,143,000
Goodwill	...	77,289,000
Other long-term assets	7,431,000	2,414,000
Total assets	214,404,000	307,502,000
Accounts payable	10,384,000	12,534,000
Compensation expenses	5,030,000	7,002,000
Accrued taxes payable	...	825,000
Accrued insurance	...	613,000
Professional fees & royalties	387,000	210,000
Warranty liabilities	391,000	489,000
Accrued clinical study fees	138,000	250,000
Customer deposits	17,000	17,000
Other accrued expenses	...	1,146,000
Accrued other	515,000	...
Taxes payable	1,099,000	...
Insurance	512,000	...
Accrued expenses - Balancing value	8,089,000	...
Accrued expenses	...	10,552,000
Contract liabilities	783,000	871,000
Operating lease liability	2,163,000	2,260,000
Finance lease liability, related party	272,000	285,000
Contingent consideration	...	9,382,000
Preferred stock warrant liability	8,534,000	...
Convertible notes payable (at fair value)	69,803,000	...
Total current liabilities	100,028,000	35,884,000
Operating lease liability, net of current portion	3,590,000	5,504,000
Finance lease liability, net of current portion, related party	3,585,000	3,619,000
Contingent consideration, net	10,890,000	12,970,000
Long-term contract liabilities	154,000	127,000
Total liabilities	118,247,000	58,104,000
Common stock	5,000	30,000
Additional paid-in capital	677,337,000	599,207,000
Retained earnings (accumulated deficit)	(581,208,000)	(348,715,000)
Accumulated other comprehensive income (loss)	23,000	(1,124,000)
Total stockholders' equity (deficit)	96,157,000	249,398,000
Total Equity	96,157,000	...

Recent Dividends:**1. BioNano Genomics Inc common.**

No dividends paid.

Annual Dividends:

1. BioNano Genomics Inc common.

No dividends paid.

BIOTRICITY INC
Earnings, 9 mos. to Dec 31(Consol. – \$):

	2023	2022
Total revenues	8,885,034	6,896,622
Cost & expenses	14,668,967	18,852,728
Operating income	(5,783,933)	(11,956,106)
Other income (expense), net	(1,924,020)	(824,467)
Net before taxes	(9,911,813)	(13,985,915)
Net income	(9,911,813)	(13,985,915)
Balance for common	(10,528,856)	(14,676,245)
Earnings common share		
Primary	\$(1.19)	\$(1.70)
Fully Diluted	\$(1.19)	\$(1.70)
Common Shares:		
Full Diluted	8,842,890	8,635,900
Year-end	9,419,629	8,707,012

Year end shares
 outstanding 29,930 28,147 27,980

Net earnings (loss)
 per share - basic \$(6.15) \$(5.92) \$(4.05)
 Net earnings (loss)
 per share - diluted \$(6.15) \$(5.92) \$(4.05)

Number of full time employees 74 183 ...

Total number of employees 74 ... 89

Number of common stockholders 12 11 10

Net Income before Tax (179,053) ...

□ Non-consolidated; □ As is; □ As of March 13, 2023; □ As of February 20, 2022

BITMIS CORP

Earnings, 6 mos. to Dec 31(Consol. – \$):

	2023	2022
Total revenues	868,445	286,273
Cost & expenses	528,695	531,587
Operating income	339,750	(254,768)
Other income (expense), net	37,487	20,054
Net before taxes	377,237	(234,714)
Net income	377,237	(234,714)
Earnings common share		
Primary	\$0.05	\$(0.03)
Fully Diluted	\$0.05	\$(0.03)
Common Shares:		
Full Diluted	7,250,750	7,250,750
Year-end	7,250,750	7,250,750

BIOXCEL THERAPEUTICS INC

Annual Report
Consolidated Income Statement, Years Ended Dec. 31
 (\$000):

	2023	2022	2021
Total revenues	1,380
Product revenue, net	1,380	375	...
Cost of goods sold	1,260	20	...
Direct external costs - BXCL501	...	52,044	...
Direct external costs - BXCL701	...	9,631	...
Other research & development programs	...	2,687	...
Total direct external costs	...	64,362	...
Internal personnel costs	...	22,831	...
Sub-total direct costs	...	87,193	...
Indirect costs & overhead	...	4,213	...
Research & development tax credit	...	(167)	...
Research & development expenses	...	91,239	52,708
General & administrative expense	54,227
Personnel & related costs	...	20,690	...
Non-cash stock-based compensation	...	12,779	...
Professional fees	...	14,313	...
Commercial & marketing	83,413	13,006	...
Insurance	...	2,370	...
Travel & other costs	...	5,603	...
Selling, general & administrative expenses	84,326	68,761	...
Restructuring costs	4,163
Total operating expenses	106,935
Total operating expenses	173,162	160,020	...
Income (loss) from operations	(171,782)	(159,645)	(106,935)
Interest income	5,649	2,528	44
Interest expense	13,314	8,213	40
Other expense, net	(394)	427	...
Net income (loss)	(179,053)	(165,757)	(106,931)
Weighted average shares outstanding - basic	29,129	28,015	26,373
Weighted average shares outstanding - diluted	29,129	28,015	26,373

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	65,221	193,725
Accounts receivable, net	71	248
Raw materials	935	682
Work in process	651	708
Finished goods	...	595
Inventories - Finished Goods	405	...
Inventory	1,991	1,985
Prepaid expenses	2,782	3,067
Other current assets	2,078	3,843
Total current assets	72,143	202,868
Computers & related equipment	202	213
Furniture	575	575
Leasehold improvements	1,200	1,181
Total property & equipment, gross	1,977	1,969
Less: accumulated depreciation	1,193	885
Property & equipment, net	784	1,084
Operating lease right-of-use assets	688	976
Other assets	87	925
Total assets	73,702	205,853
Accounts payable	13,654	10,228
Accrued research & development expenses	6,406	8,659
Accrued compensation & benefits	163	6,370
Accrued professional expenses	5,562	2,738
Accrued taxes	116	82
Other accrued expenses	177	820
Accrued expenses	12,424	18,669
Due to related parties	107	422
Accrued interest	736	3,175
Other current liabilities	346	404
Operating lease liabilities current portion	346	...
Total current liabilities	27,267	32,898
Long-term portion of operating lease liabilities	440	786
Derivative liabilities	1,905	2,343
Long-term debt	100,598	93,051
Total liabilities	130,210	129,078
Common stock	30	28
Additional paid-in-capital	534,060	488,292
Retained earnings (accumulated deficit)	(590,598)	(411,545)
Total stockholders' equity (deficit)	(56,508)	76,775
Total Equity	(56,508)	...

Recent Dividends:

1. BioXcel Therapeutics Inc common.
 No dividends paid.

Annual Dividends:
1. BioXcel Therapeutics Inc common.
 No dividends paid.

BLINK CHARGING CO
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Charging service revenue - company-owned	469,000	6,866,000	2,978,000
Product sales	109,416,000	46,018,000	15,480,000
Grant & rebate revenue	...	296,000	400,000
Warranty revenue	...	928,000	220,000
Network fees	7,481,000	4,370,000	667,000
Ride sharing services revenue	3,302,000	1,268,000	769,000
Equipment sales	3,258,000
Other revenues	15,646,000	1,393,000	426,000
Other	1,026,000
Total revenues	140,598,000	61,139,000	20,940,000
Cost of revenues - cost of charging services - company-owned charging stations	...	1,466,000	707,000
Cost of revenues - host provider fees	...	3,935,000	1,386,000
Cost of revenues - cost of product sales	...	31,428,000	11,670,000
Cost of revenues - network costs	...	1,463,000	454,000
Cost of revenues - warranty & repairs & maintenance	...	2,795,000	892,000
Cost of revenues - ride sharing services	...	2,137,000	1,458,000
Cost of revenues - depreciation & amortization	4,250,000	3,113,000	1,531,000
Cost of revenues - inventory obsolescence charge	3,540,000
Cost of product sales	72,532,000
Network costs	1,969,000
Warranty and repairs and maintenance	4,605,000
Host provider fees	9,140,000
Ride-sharing services	4,356,000
Total cost of revenues	100,392,000	46,337,000	18,098,000
Gross profit (loss)	40,206,000	14,802,000	2,842,000
Compensation	92,669,000	60,602,000	38,389,000
Other operating expenses	17,825,000	15,645,000	9,606,000
General & administrative expenses	35,170,000	27,826,000	10,516,000
Impairment of goodwill	89,087,000
Impairment of intangible assets	5,143,000
Total operating expenses	239,894,000	104,073,000	58,511,000
Income (loss) from			

operations	(199,688,000)	(89,271,000)	(55,669,000)
Interest income			
(expense)	(3,546,000)	(1,529,000)	9,000
Dividend & interest income	...	454,000	294,000
Foreign transaction loss	140,000	(600,000)	(124,000)
Gain on forgiveness of PPP loan	856,000
Change in fair value of derivative & other accrued liabilities	(8,000)	(66,000)	(69,000)
Other (expense) income, net	(22,000)	(372,000)	(554,000)
Dividend income	1,909,000
Loss on extinguishment of notes payable	(1,000,000)
Total other income (expense)	(2,511,000)	(1,981,000)	550,000
Income (loss) before income taxes	(202,199,000)	(91,252,000)	(55,119,000)
Federal: Deferred	(7,129,000)
State: Deferred	426,000
Foreign: Current	1,493,000
Foreign: Deferred	(7,995,000)
Income Taxes - Change in valuation allowance	14,699,000
Provision for income taxes	1,494,000	308,000	...
Net income (loss)	(203,693,000)	(91,560,000)	(55,119,000)
Weighted average shares outstanding - basic	63,466,398	46,922,434	41,905,340
Weighted average shares outstanding - diluted	63,466,398	46,922,434	41,905,340
Year end shares outstanding	92,818,233	51,476,445	42,423,514
Net income (loss) per share - basic	\$(3.21)	\$(1.95)	\$(1.32)
Net income (loss) per share - diluted	\$(3.21)	\$(1.95)	\$(1.32)
Number of full time employees	684	564	191
Number of part time employees	...	56	7
Total number of employees	684	620	198
Number of common stockholders	388	393	293
Number of beneficiary stockholders	547
Foreign currency translation adjustments	...	(1,262,000)	...
Basic EPS Excluding ExtraOrdinary Items	\$(3.21)
Diluted EPS Excluding ExtraOrd Items	\$(3.21)

¹ Reclassified to conform with 2022 presentation; ² Shares increased due to the effect issuance of shares for public offering, purchase consideration, options, warrants exercised and stock compensation; ³ Approximately; ⁴ As of March 10, 2023; ⁵ As of March 10, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):		
	2023	2022
Cash	...	36,562,000
Cash & cash equivalents	121,691,000	...
Accounts receivable & other receivables, net	45,447,000	...
Accounts receivable, net	...	23,581,000
Inventory, gross	47,942,000	...
Inventory, net	...	34,740,000
Prepaid expenses & other current asset	...	4,399,000
Total current assets	221,734,000	99,282,000

Restricted cash	79,000	71,000
Machinery & equipment, net	32,140,000	...
EV charging stations	2,503,000	22,718,000
Building	6,847,000	4,718,000
Software	2,455,000	2,137,000
Automobiles	3,339,000	2,993,000
Office & computer equipment	...	1,371,000
Leasehold improvements	986,000	536,000
Machinery & equipment	1,065,000	712,000
Property & equipment, gross	49,335,000	35,185,000
Less: accumulated depreciation	14,208,000	9,323,000
Property & equipment, net	35,127,000	25,862,000
Operating lease right-of-use asset	9,731,000	4,174,000
Intangible assets, net	16,298,000	26,582,000
Goodwill	144,881,000	203,710,000
Total assets	428,519,000	362,542,000
Accounts payable	31,193,000	24,585,000
Current portion of notes payable	6,792,000	...
Accrued host fees	...	130,000
Accrued professional, board & other fees	...	451,000
Accrued wages	...	5,456,000
Accrued commissions	...	827,000
Accrued warranty payable	...	176,000
Accrued income, property & sales taxes payable	...	371,000
Accrued issuable equity	...	433,000
Accrued purchases	...	549,000
Internal use software liability	...	372,000
Accrued warrants payable	14,143,000	...
Accrued interest	...	1,871,000
Other accrued expenses	...	2,473,000
Accrued expenses & other current liabilities	...	13,109,000
Notes payable	...	10,000
Current portion of operating lease liabilities	3,448,000	1,738,000
Current portion of financing lease liabilities	512,000	306,000
Current portion of deferred revenue	13,613,000	10,572,000
Total current liabilities	69,701,000	50,320,000
Contingent consideration	...	1,316,000
Consideration payable	49,434,000	40,608,000
Operating lease liabilities, non-current portion	7,025,000	3,030,000
Financing lease liabilities, non-current portion	163,000	408,000
Other liabilities	337,000	645,000
Deferred revenue, non-current portion	12,462,000	5,258,000
Total liabilities	139,122,000	101,585,000
Common stock	93,000	51,000
Additional paid-in-capital	829,563,000	597,982,000
Accumulated other comprehensive income (loss)	(2,536,000)	(3,046,000)
Retained earnings (accumulated deficit)	(537,723,000)	(334,030,000)
Total stockholders' equity	289,397,000	260,957,000
Total stockholders' equity (deficiency)	289,397,000	...

Recent Dividends:

- 1. Blink Charging Co series A convertible preferred.**
No dividends paid.
- 2. Blink Charging Co common.**
No dividends paid.
- 3. Blink Charging Co series B convertible preferred.**
No dividends paid.

4. Blink Charging Co series D convertible preferred.

No dividends paid.

5. Blink Charging Co series C convertible preferred.

No dividends paid.

6. Blink Charging Co series B convertible preferred.

No dividends paid.

Annual Dividends:

1. Blink Charging Co series A convertible preferred.

No dividends paid.

2. Blink Charging Co common.

No dividends paid.

3. Blink Charging Co series B convertible preferred.

No dividends paid.

4. Blink Charging Co series D convertible preferred.

No dividends paid.

5. Blink Charging Co series C convertible preferred.

No dividends paid.

6. Blink Charging Co series B convertible preferred.

No dividends paid.

BLUEONE CARD INC

Earnings, 9 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues	4,000	...
Cost & expenses	1,219,435	676,025
Operating income	(1,215,435)	(676,025)
Interest income	11,120	...
Net before taxes	(1,204,356)	(679,535)
Net income	(1,204,356)	(679,535)
Earnings common share		
Primary	\$(0.10)	\$(0.07)
Fully Diluted	\$(0.10)	\$(0.07)
Common Shares:		
Full Diluted	11,822,147	10,279,092
Year-end	12,041,204	10,336,004

BLUM HOLDINGS INC

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, Marcum LLP, as it appeared in Co.'s 2022 10-K Report: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Unrivaled Brands, Inc. (the "Company") as of December 31, 2022 and 2021, the related consolidated statements of income operations, stockholders' (deficit) equity and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America. Explanatory Paragraph - Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company has a significant working capital deficiency, has incurred significant losses, and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

BLUM HOLDINGS INC

History: Incorporated in Nevada on July 22, 2008 as Private Secretary, Inc. Name changed to Terra Tech Corp. on Jan. 27, 2012; to Unrivaled Brands, Inc. on July 7, 2021. Reincorporated in Delaware on Sept. 28, 2023. Present name adopted on Jan. 12, 2024.

On Feb. 9, 2012, Co. acquired all of the issued and outstanding shares of GrowOp Technology Ltd., a Nevada corporation (GrowOp Technology) through a reverse-triangular merger its subsidiary, TT Acquisitions, Inc. with GrowOp Technology. As a result, GrowOp Technology became a new subsidiary of Co. Co. acquired all of the issued and outstanding shares of GrowOp Technology in exchange for (i) 33,998,520 shares of Co.'s common stock, (ii) 100 shares of to-be-created Series A Preferred Stock, convertible into shares of common stock on a one-for-one basis, and 14,750,000 shares of to-be-created Series B Preferred Stock convertible into shares of common stock on a 1-for-5.384325537 basis, which represents approximately 50.3% of Co.'s total shares

outstanding, assuming the conversion of all shares of Series A Preferred Stock and Series B Preferred Stock into shares of common stock.

On May 6, 2013, Co. acquired Edible Garden, LLC as Co.'s new subsidiary. Terms of the transaction were not disclosed.

On Mar. 19, 2014, Co. formed MediFarm, LLC (MediFarm). Co. owns 60% of the membership interests in MediFarm. The remaining membership interests are owned by Camden Goorjian (20%) and by Richard Vonfeldt (20%), two otherwise unaffiliated individuals.

On July 18, 2014, Co. formed MediFarm I, LLC (MediFarm I). Co. owns 50% of the membership interests in MediFarm I. The remaining membership interests are owned by Forever Green NV, LLC (50%), an otherwise unaffiliated entity that also owns certain membership interests in MediFarm II, LLC.

On July 30, 2014, Co. formed MediFarm II, LLC (MediFarm II). Co. owns 55% of the membership interests in MediFarm II. The remaining membership interests are owned by Nevada MF, LLC (30%) and by Forever Green NV, LLC (15%), two otherwise unaffiliated entities.

On Sept. 16, 2014, Co. formed IVXX Inc. and IVXX, LLC (together IVXX).

On Oct. 14, 2015, Co. formed MediFarm I RE, LLC (MediFarm I RE). Co. owns 50% of the membership interests in MediFarm I RE. The remaining membership interests are owned by Forever Young Investments, LLC (50%), an otherwise unaffiliated entity.

On Apr. 1, 2016, Co. acquired Black Oak Gallery (Black Oak) through the merger of Generic Merger Sub, Inc. (Merger Sub), a subsidiary of Co. with and into Black Oak, with Black Oak as the surviving corporation, and became a new subsidiary of Co. (the Acquisition). As a result of the Acquisition, the outstanding shares of common stock of Black Oak held by (i) two of the shareholders of Black Oak (the Group A Shareholders) were converted into the right to receive approximately 8,166 shares of Co.'s Series Z Preferred Stock, of which approximately 1,175 shares of Series Z Preferred Stock were issued and paid at closing, and approximately 8,668,700 shares of Co.'s Series B Preferred Stock, of which approximately 1,248,300 shares of Series B Preferred Stock were issued and paid at closing and (ii) the remaining shareholders of Black Oak (the Group B Shareholders) were converted into the right to receive approximately 21,378 shares of Co.'s Series Q Preferred Stock, of which approximately 3,695 shares of Series Q Preferred Stock were issued and paid at closing. The aggregate fair market value of the securities issued in the Acquisition was approximately \$22,900,000.

On Sept. 13, 2017, Co.'s wholly-owned subsidiary, MediFarm So Cal, Inc., substantially all of the assets of Tech Center Drive Management, LLC (the Seller), other than certain intellectual property rights that remained with the Seller, for aggregate consideration paid for the assets was \$7,000,000 plus the value of the Seller's inventory, \$4,000,000 plus the value of the Seller's inventory was paid in cash and \$3,000,000 was paid in shares of Co.'s common stock, of which \$700,000 in shares of common stock would be held in escrow for six months to satisfy the Seller's indemnity obligations.

On Oct. 31, 2017, Co. formed 1815 Carnegie LLC, a wholly owned subsidiary.

On Oct. 31, 2017, Co. formed 620 Dyer LLC, a wholly owned subsidiary.

On Nov. 22, 2017, Co.'s wholly-owned subsidiary, 1815 Carnegie LLC, acquired certain commercial property located at 1815 Carnegie Avenue, Santa Ana, CA, from AHVA Properties-Carnegie, LLC for \$7,346,247.

On Jan. 18, 2018, Co.'s wholly-owned subsidiary, 620 Dyer LLC, sold certain commercial property located at 620 East Dyer Road, Santa Ana, CA 92705, to Modernize, Inc. for a purchase price of \$11,000,000.

On Oct. 5, 2018, Co.'s wholly-owned subsidiary, 121 North Fourth Street, LLC, acquired a real property located at 121 North Fourth Street, Las Vegas, NV, from North Fourth LLC for \$2,700,000.

On Oct. 22, 2018, Co.'s wholly-owned subsidiary, MediFarm LLC, sold substantially all the assets of Co. related to Co.'s dispensary located at 1921 Western Ave., Las Vegas, NV 89102, to Exhale Brands Nevada III, LLC, a company that operates as a marijuana dispensary, for aggregate consideration of \$6,250,000 in cash plus the value of any inventory of the Business on the closing date.

On June 12, 2019, Co. acquired 50% of the membership interest of MediFarm I LLC (MediFarm I) and 15% of the membership interest of MediFarm II, LLC (MediFarm II) from Forever Green NV (Forever Green) and 50% of the membership interest of MediFarm I Real Estate, LLC (MediFarm I RE) from Forever Young Investments, LLC (Forever Young) for aggregate consideration of

\$6,250,000. MediFarm I owns Co.'s Blum dispensary located at 1085 S. Virginia St. Suite A, Reno, NV 89502, and MediFarm I RE owns the building which houses the dispensary. As a result, Co. owned 100% of MediFarm I, 100% of MediFarm RE and 70% of MediFarm II. Forever Green and Forever Young, were affiliates of Heidi Loeb Hegerich, co-owner of Blum dispensary.

On Sept. 16, 2019, Co.'s Board of Directors authorized the repurchase of up to \$20,000,000 of Co.'s common stock. This share buyback program is in addition to the previously announced purchase of shares of Co.'s common stock in connection with the settlement of litigation with members of the Vande Vrede family. Co. anticipates to receive approximately \$36,000,000 upon the closing of previously announced asset sales. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. Any shares acquired will be held by Co. as treasury shares. As of Aug. 2, 2019, Co. had 109,278,898 shares of common stock outstanding.

On Feb. 14, 2020, Co.'s wholly owned subsidiary, TT Merger Sub, Inc., merged with and into OneQor Technologies, Inc. ("OneQor"), an innovative, cannabinoid-focused pharmaceutical company, concentrating on the development, manufacturing, and delivery of patented, proprietary OTC products to established suppliers and consumer brands, with OneQor continuing as the surviving corporation and became a wholly owned subsidiary of Co. As the result of the merger, each outstanding share of OneQor capital stock was converted into the right to receive 44.9727 shares of Co. common stock for each share of OneQor common stock outstanding immediately prior to the Merger.

On Feb. 14, 2020, Co. announced that Mr. Derek Peterson resigned as Chief Executive Officer, following his appointment as Chief Strategy Officer.

On Feb. 14, 2020, Co. announced the appointment of Mr. Matthew Morgan as Chief Executive Officer.

On Mar. 30, 2020, Co.'s wholly owned subsidiary, Edible Garden Corp. sold substantially all of its asset to Edible Garden Incorporated for a five-year \$3,000,000 secured promissory note bearing interest at 3.5% per annum.

On Mar. 30, 2020, Co. announced the resignation of Michael James from its Board of Directors.

On Mar. 30, 2020, Co. appointed Megan Jimenez to the position of Chief Financial Officer.

On July 29, 2020, Co.'s wholly owned subsidiary, 1815 Carnegie LLC sold its real property located at 1815 E. Carnegie, Santa Ana, CA to Dyer 18 LLC for \$9,200,000 in cash.

On July 1, 2021, Co. acquired 100% of the outstanding membership interests in Halladay Holding, LLC, the owner of real property located at 3242 S. Halladay Street, Santa Ana, CA 92705, where Co. operates a cannabis dispensary and maintains its principal office space, from Mr. Nicholas Kovacevich, the Chairman of Co.'s Board of Directors and Mr. Dallas Imbimbo, a Director of Co. As the result, Co. paid Mr. Kovacevich and Mr. Imbimbo an aggregate purchase price of \$4,600,495.39 in cash.

On July 1, 2021, Co.'s wholly owned subsidiary, Phoenix Merger Sub Corp., merged with and into UMBRLA, Inc. ("UMBRLA"), a diversified cannabis company with distribution, manufacturing and dispensary operations, which was owned by Mr. Dallas Imbimbo, a Director of Co., with UMBRLA continuing as the surviving corporation and became a wholly owned subsidiary of Co. As the result of the merger, each share of UMBRLA common stock outstanding was converted into the right to receive 1.5386 shares of Co.'s common stock.

On Oct. 1, 2021, Co. acquired from Sterling Harlan and Matthew Guild (collectively, the "Sellers") all the issued and outstanding shares of common stock (the "Shares") of Silverstreak Solutions, Inc., a cannabis delivery service based in Sacramento, CA (the "Acquisition"). As a result of the Acquisition, Co. paid the Sellers on a pro rata basis a total of \$8,500,000 (the "Purchase Price"). The Purchase Price is comprised of (i) \$1,500,000 in cash, (ii) 9,051,412 shares of restricted common stock, par value \$0.001 per share, of Co. (the "Purchaser Shares"), which is equal to the quotient obtained by dividing (a) \$2,500,000, by (b) the volume-weighted average price of the Purchaser Shares as reported through Bloomberg for the ten consecutive trading days ending on the business day prior to the closing, (iii) \$2,000,000 in unsecured promissory notes with an interest rate of 3% and due six months after the closing, and (iv) \$2,500,000 in unsecured promissory notes with an interest rate of 3% and due twelve months after the closing.

On Nov. 22, 2021, Co. acquired all outstanding equity of People's First Choice, LLC, a wholly owned subsidiary of People's California, LLC, a California limited liability company, for a purchase price of \$76,000,000 (the "Consideration"). The Consider-

ation which consisted of \$24,000,000 in cash and the issued of a secured promissory note in a principal amount of \$30,568,623.67, in each case, reduced by certain outstanding indebtedness and expenses, and 40,000,000 shares of Co.'s common stock, valued at \$0.40 per share.

On Feb. 4, 2022, Co. sold its non-operating real property and building located on Dyer Road in Santa Ana, CA to CREF3 Dyer Owner LLC for \$13,400,000.

On Sept. 12, 2022, Co. appointed Ms. Patty Chan as Co.'s Interim Chief Financial Officer and Principal Financial Officer.

On Sept. 12, 2022, Mr. Jeffrey Batliner step down as Co.'s Chief Financial Officer.

On Dec. 23, 2022, Co. appointed Mr. Sabas Carrillo, Co.'s Interim Chief Executive Officer as its Chief Executive Officer and Board of Directors.

On Dec. 23, 2022, Co. appointed Mr. James Miller as Chief Operating Officer.

On Jun. 12, 2023, Co. appointed Ms. Patty Chan, Co.'s Interim Chief Financial Officer as Chief Financial Officer.

On Jun. 26, 2023, Co. appointed Mr. Chris Rivera as Co.'s Interim Chief Financial Officer and Principal Financial Officer.

On Jul. 1, 2023, Mr. Nicholas Kovacevich and Mr. Eric Baum resigned from Co.'s Board of Directors.

On July 1, 2023, Co. appointed Mr. James Miller to its Board of Directors.

On July 1, 2023, Co. appointed Mr. Sabas Carrillo as its Chairman of the Board.

On Aug. 1, 2023, Co. appointed Mr. Matt Barron to its Board of Directors.

On Jan. 12, 2024, pursuant to a reorganization, Co. becomes a wholly-owned subsidiary of Blum Holdings, Inc., a Delaware corporation ("Newco") and all outstanding shares of Co. exchanged for shares of Issuer on a one-for-one basis. Upon completion of the Reorganization, Newco will, in effect, replace Co. as the publicly held corporation. In the Reorganization, Co. existing shares of common stock, par value \$0.001 per share (the "Co. Common Stock" or the "Common Stock") and Co. preferred stock, par value \$0.001 per share (the "Co. Preferred Stock" or the "Preferred Stock") (in each case, other than shares held by stockholders that properly exercise dissenters' rights) will be converted automatically into shares of Newco common stock, par value \$0.001 per share (the "Newco Common Stock") and Newco preferred stock, par value \$0.001 per share (the "Newco Preferred Stock"), respectively.

Business Summary: Blum is a holding company. Through its subsidiaries, Co. is engaged in the retail, production, distribution, and cultivation of cannabis throughout California and adult use cannabis dispensaries in California. Co. is home to Korova, a brand of products available in California. Co. operates four cannabis dispensaries in California: People's in Santa Ana, The Spot in Santa Ana, Blum in Oakland, and Blum in San Leandro. Co.'s segments are cannabis retail, which includes cannabis-focused retail in physical stores and non-store front delivery; and cannabis cultivation and distribution, which includes cannabis cultivation and distribution operations.

Property: Co. maintains its principal executive offices in Santa Ana, CA.

The table below sets forth information regarding Co.'s offices and properties as of Dec. 31, 2022:

Location	Owned/Leased
Oakland, CA (2)	Leased
San Leandro, CA	Leased
Santa Ana, CA	Leased
Costa Mesa, CA	Leased
Los Angeles, CA	Leased
Santa Ana, CA	Owned

Subsidiaries

- Unrivaled Brands, Inc.
- Black Oak Gallery
- Blum San Leandro
- Halladay Holding, LLC
- People's First Choice, LLC
- People's Costa Mesa, LLC
- 3242 Enterprises, Inc
- 3242 Holdings, LLC
- IVXX Gardens I, Inc.

Officers

- Sabas Carrillo, Chairman; Chief Executive Officer
- Patty Chan, Chief Financial Officer
- Christopher Rivera, Interim Chief Financial Officer; Principal Financial Officer

James Miller, Chief Operating Officer
Robert Baca, Chief Legal Officer; Secretary

Directors

Sabas Carrillo, Chairman; Director
James Miller, Director
Matthew Barron, Director

Auditors: Marcum LLP

Annual Meeting: In December

Shareholder Relations: Jason Assad Tel: 678-570-6791

No. of Stockholders: Oct. 16, 2023, 53,633, common

No. of Employees: Sept. 30, 2023, 151

Address: 3242 S. Halladay Street Suite 202, Santa Ana, CA 92705

Tel: 888 909-5564

Web: www.unrivaledbrands.com

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2022	2021 (revised)	2020 (revised)
Revenue	52,015,000	42,120,000	6,161,000
Cost of goods sold	35,118,000	31,101,000	3,518,000
Gross profit	16,897,000	11,019,000	2,643,000
Selling, general & administrative expenses	54,156,000	46,314,000	19,319,000
Impairment loss	163,698,000	6,171,000	...
Impairment of assets	19,910,000
Gain (loss) on disposal of assets	7,194,000	3,133,000	...
Total operating expenses	210,660,000	49,352,000	...
Income (loss) from operations	(193,763,000)	(38,333,000)	(36,586,000)
Gain (loss) on extinguishment of debt	542,000	(5,976,000)	...
Interest expense, net	4,173,000	1,775,000	1,394,000
Unrealized gain (loss) on investments	29,045,000
Gain on sale of investments	...	5,337,000	...
Unrealized gain on investments	210,000
Other income (expense)	1,550,000	(433,000)	929,000
Total other income (expense), net	(1,871,000)	(2,847,000)	28,580,000
Income (loss) from operations before provision for income taxes	(195,634,000)	(41,180,000)	(8,006,000)
Provision for income tax benefit for continuing operations	(2,784,000)	885,000	...
Net income (loss) from continuing operations	(192,850,000)	(42,065,000)	(8,006,000)
Income from (loss) discontinued operations before provision for income taxes	4,194,000	11,107,000	(22,865,000)
Provision for income tax for discontinued operations	...	(917,000)	...
Net income (loss) from discontinued operations	4,194,000	10,190,000	(22,865,000)
Net income (loss)	(188,656,000)	(31,875,000)	(30,871,000)
Less: net income (loss) from discontinued operations attributable to non-controlling interest	(275,000)	...	754,000

Less: net income (loss) from continuing operations attributable to non-controlling interest	...	604,000	...
Net income (loss) attributable to Unrivaled Brands, Inc.	(188,931,000)	(31,271,000)	(30,117,000)
Weighted average shares outstanding - basic	5,896,062	3,766,253	1,919,782
Weighted average shares outstanding - diluted	5,896,062	3,766,253	1,919,782
Year end shares outstanding	6,772,051	4,962,379	1,942,045
Net earnings (loss) per share from continuing operations - basic	\$(33.00)	\$(11.00)	\$(4.00)
Net earnings (loss) per share - basic	\$(32.00)	\$(8.00)	\$(16.00)
Net earnings (loss) per share from continuing operations - diluted	\$(33.00)	\$(11.00)	\$(4.00)
Net earnings (loss) per share - diluted	\$(32.00)	\$(8.00)	\$(16.00)
Total number of employees	151
Number of common stockholders	53,633
Number of preferred stockholders	17

□ Restatement due to discontinued operations of 50% membership interests of NuLeaf Reno Production, LLC and NuLeaf Sparks Cultivation, LLC; □ Restated to reflect the discontinued operations of NuLeaf operations; □ Adjusted for 1-for-100 stock split, January 16, 2024; □ Shares increased due to the effect issuance of shares for warrants exercised, stock compensation, option exercised, debt conversion, issuance for cash, UMBRLA holdback and stock option purchase; □ Shares increased due to the effect of debt diversion, shares issued for cash, Umbrla Acquisition, People's Acquisition, Silverstreak Acquisition, stock compensations, and stock option exercises; □ Shares increased as a result of the conversion of debt & the issuance of stock for the OneQor acquisition

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2022	2021 (revised)
Cash & cash equivalents	1,200,000	6,700,000
Accounts receivable, gross	313,000	7,013,000
Less: allowance	...	3,000,000
Accounts receivable	313,000	4,013,000
Raw materials	524,000	2,258,000
Work-in-progress	284,000	1,077,000
Finished goods	1,131,000	2,845,000
Inventory	1,939,000	6,180,000
Assets held for sale	...	6,406,000
Prepaid expenses & other current assets	498,000	1,215,000
Notes receivable	625,000	750,000
Total current assets	4,575,000	25,264,000
Land & building	7,581,000	7,787,000
Furniture & equipment	1,336,000	3,205,000
Computer hardware	299,000	348,000
Leasehold improvements	8,009,000	14,357,000
Vehicles	103,000	1,027,000
Construction in progress	2,565,000	1,832,000
Property, equipment & leasehold improvements, gross	19,893,000	28,556,000
Less accumulated depreciation	6,893,000	5,392,000
Property, equipment & leasehold improvements,		

net	13,000,000	23,164,000
Intangible assets, net	2,859,000	129,637,000
Goodwill	3,585,000	48,132,000
Other assets	16,279,000	26,426,000
Investments	210,000	164,000
Long-term assets held for sale	...	19,037,000
Total assets	40,508,000	271,824,000
Accounts payable	12,990,000	15,629,000
Tax liabilities	1,018,000	4,865,000
Accrued payroll & benefits	628,000	1,327,000
Current lease liabilities	1,996,000	3,041,000
Accrued interest	2,113,000	833,000
Other accrued expenses	665,000	4,543,000
Current portion of notes payable	29,662,000	45,451,000
Income taxes payable	10,071,000	7,969,000
Liabilities held for sale	...	4,050,000
Total current liabilities	59,143,000	87,708,000
Promissory note	9,896,000	17,016,000
Unsecured promissory notes	154,000	1,140,000
Convertible promissory note	3,450,000	3,500,000
Secured promissory note	21,569,000	31,069,000
Line of credit agreement	...	4,500,000
Total notes payable - promissory notes	35,069,000	57,225,000
Vehicle loans	76,000	178,000
Less short-term portion	29,662,000	45,451,000
Less: debt discount	(669,000)	(1,946,000)
Notes payable, net of current portion & discounts	4,814,000	10,006,000
Deferred tax liabilities	...	6,123,000
Long-term liabilities held for sale	...	591,000
Lease liabilities	13,088,000	20,909,000
Total liabilities	77,045,000	125,337,000
Common stock	701,000	521,000
Additional paid-in capital	403,619,000	392,930,000
Treasury stock	808,000	808,000
Retained earnings (accumulated deficit)	(440,049,000)	(250,015,000)
Total equity attributable to stockholders of Unrivaled Brands, Inc.	(36,537,000)	142,628,000
Non-controlling interest	...	3,859,000
Total stockholders' equity (deficit)	(36,537,000)	146,487,000

□ Restatement due to discontinued operations of 50% membership interests of NuLeaf Reno Production, LLC and NuLeaf Sparks Cultivation, LLC

Auditor's Report:

The following is an excerpt from the Report of the Independent Auditors, Marcum LLP, as it appeared in Co.'s 2022 10-K Report: "Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Unrivaled Brands, Inc. (the "Company") as of December 31, 2022 and 2021, the related consolidated statements of income operations, stockholders' (deficit) equity and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

Explanatory Paragraph - Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company has a significant working capital deficiency, has incurred significant losses, and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

Long-Term Debt: Dec. 31, 2022, \$35,145,000 (including current portion of \$29,662,000 and debt discount of \$669,000) comprised of:

- (1) \$14,000 (classified as current) promissory note, bearing interest at 1.0%, due May 4, 2022.
- (2) \$3,450,000 (classified as current) convertible promissory note, bearing interest at 3.0%, due July 22, 2022.
- (3) \$2,500,000 promissory note, bearing interest at 8%, due July 26, 2024.
- (4) \$154,000 unsecured promissory note, bearing interest at 1%, due Dec. 28, 2027.
- (5) \$2,000,000 (classified as current) promissory note, bearing interest at 3%, due Apr. 1, 2022.
- (6) \$2,500,000 (classified as current) promissory note, bearing interest at 3%, due Oct. 1, 2022.
- (7) \$21,569,000 (classified as current) secured promissory note, bearing interest at 8%, due Nov. 22, 2023.
- (8) \$2,882,000 promissory note, bearing interest at 9.89%, due May 15, 2039.
- (9) \$76,000 vehicle loans.

Capital Stock: 1. Blum Holdings Inc series A convertible preferred; par \$ 0.001.
 AUTHORIZED—100 shs.
 OUTSTANDING—Dec. 31, 2020, 8 shs; par \$ 0.001.(Converted in 2021)

2. Blum Holdings Inc series B convertible preferred; par \$ 0.001.
 AUTHORIZED—49,999,900 shs.
 OUTSTANDING—Dec. 31, 2016, 36,825,953 shs; par \$ 0.001.(Converted in 2017)

3. Blum Holdings Inc common; par \$ 0.001.
 AUTHORIZED—990,000,000 shs.
 OUTSTANDING—Dec. 31, 2022, 677,205,144 shs; par \$ 0.001.
 TREASURY—2,308,412 shs.
 STOCK SPLITS—\$0.001 par shares split 150-for-1 Aug. 24, 2011; split 1-for-15 Mar. 13, 2018.

OPTIONS—Dec. 31, 2017, outstanding, 1,177,732; available for grant, 28,822,268; authorized for issuance, 30,000,000.
 PRIMARY EXCHANGE—National Bulletin Board (NBB): BLMH.

4. Blum Holdings Inc series V preferred; par \$ 0.001.
 AUTHORIZED—25,000,000 shs.
 OUTSTANDING—Oct. 16, 2023, 14,071,431 shs; par \$ 0.001.

BONE BIOLOGICS CORP
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):			
	2023	2022	2021 (revised)
Research & development expenses	6,907,824	1,579,298	82,044
General & administrative expenses	2,520,479	2,085,875	1,021,032
Total operating expenses	9,428,303	3,665,173	1,103,076
Income (loss) from operations	(9,428,303)	(3,665,173)	(1,103,076)
Finance cost related to public offering	...	731,714	...
Change in fair value of warrant liability	...	2,912,267	...
Interest expense - related party	805,109
Gain on forgiveness of deferred compensation	297,500
Gain (loss) on disposal of assets	892,693
Interest income	1,868
Legal settlement, net of insurance	414,989
Total other income (expenses)	479,572	2,180,553	(507,609)
Income (loss) before provision (benefit) for income taxes	(8,948,731)	(1,484,620)	...
Provision (benefit) for income taxes	...	0	...
Net income (loss)	(8,948,731)	(1,484,620)	(1,610,685)
Weighted average			

shares outstanding - basic	263,137	263,137	263,137
Weighted average shares outstanding - diluted	263,137	263,137	263,137
Year end shares outstanding	534,238	534,238	534,238
Net income (loss) per share - basic	\$(34.01)	\$(34.01)	\$(34.01)
Net income (loss) per share - diluted	\$(34.01)	\$(34.01)	\$(34.01)
Number of full time employees	2	2	2
Number of common stockholders	...	31	25
Total number of employees	2

Reclassified to conform with 2022 presentation; Adjusted for 1-for-30 stock split, June 7, 2023; Adjusted for 1-for-8 stock split, December 20, 2023; Shares increased due to the effect of proceeds from sale of common stock units in public offering and exercise of warrants; As of March 28, 2023; As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	3,026,569	7,538,312
Prepaid expenses	10,000	956,925
Deferred financing fees	328,844	...
Prepaid insurance	372,350	...
Total current assets	3,737,763	8,495,237
Total assets	3,737,763	8,495,237
Accounts payable & accrued expenses	360,662	888,461
Warrant liability	...	1,659,468
Shares to be issued	55,751	...
Accrued legal settlement	414,989	...
Total current liabilities	831,402	2,547,929
Total liabilities	831,402	2,547,929
Common stock	534	15,300
Additional paid-in capital	83,814,785	77,892,235
Retained earnings (accumulated deficit)	(80,908,958)	(71,960,227)
Total stockholders' equity (deficit)	2,906,361	5,947,308
Total Equity	2,906,361	...

Recent Dividends:
1. Bone Biologics Corp common.
 No dividends paid.

Annual Dividends:
1. Bone Biologics Corp common.
 No dividends paid.

BOXLIGHT CORP
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):			
	2023	2022	2021 (revised)
Impairment of intangible assets	25,195,000
Revenues	176,721,000
Revenues, net	...	221,781,000	185,177,000
Cost of revenues	113,419,000	156,913,000	138,652,000
Gross profit	63,302,000	64,868,000	46,525,000
General & administrative expenses	61,252,000	59,337,000	47,270,000
Research & development expenses	3,155,000	2,482,000	1,826,000
Total operating expense	...	61,819,000	49,096,000
Income (loss) from operations	(26,300,000)	3,049,000	(2,571,000)
Interest expense, net	10,840,000	9,923,000	3,382,000
Other income (expense), net	(417,000)	(267,000)	(20,000)
Gain (loss) on

settlement of liabilities, net	...	856,000	(4,532,000)
Change in fair value of derivative liabilities	267,000	2,591,000	13,000
Total other income (expense)	(10,990,000)	(6,743,000)	(7,921,000)
Income (loss) before income taxes - U.S.	...	(2,569,000)	(18,130,000)
Income (loss) before income taxes - foreign	...	(2,707,000)	6,032,000
Income (loss) before income taxes - other foreign jurisdictions	...	1,582,000	1,606,000
Income (loss) before income taxes	(37,290,000)	(3,694,000)	(10,492,000)
Current federal income tax expense (benefit)	855,000	1,491,000	...
Current state income tax expense (benefit)	93,000	138,000	62,000
Current foreign income tax expense (benefit)	1,589,000	1,399,000	2,722,000
Total current income tax expense (benefit)	2,537,000	3,028,000	2,784,000
Deferred federal income tax expense (benefit)	81,000	(85,000)	...
Deferred foreign income tax expense (benefit)	(752,000)	(2,894,000)	526,000
Total deferred income tax expense (benefit)	(671,000)	(2,979,000)	526,000
Income tax expense (benefit)	1,866,000	49,000	3,310,000
Net income (loss)	(39,156,000)	(3,743,000)	(13,802,000)
Fixed dividends - series B preferred	1,269,000	1,269,000	1,269,000
Deemed contribution - series B preferred	(367,000)
Net income (loss) attributable to common stockholders	(40,425,000)	(5,012,000)	(14,704,000)
Weighted average shares outstanding - basic	9,455,000	8,644,125	7,356,125
Weighted average shares outstanding - diluted	9,455,000	8,644,125	7,356,125
Year end shares outstanding	9,704,496	9,339,587	7,977,738
Net income (loss) per common share - basic	\$(4.28)	\$(0.56)	\$(1.84)
Net income (loss) per common share - diluted	\$(4.28)	\$(0.56)	\$(1.84)
Full-Time Employees (Period End)	228
Total number of employees	228	187	183
Number of common stockholders	378	378	378
Foreign currency translation adjustments	...	(4,642,000)	...
Earnings per share from continuing operations	\$(4.28)
Earnings per share from continuing operations	\$(4.28)

Adjusted for 1-for-8 stock split, June 15, 2023; As of March 13, 2023; As of March 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):			Total mezzanine equity			Information processing & communication		
	2023	2022		2023	2022		2023	2022
Cash & cash equivalents	17,253,000	14,591,000	Common stock	1,000	7,000	Additional paid-in capital	301,000	274,000
Accounts receivable - trade	33,089,000	33,198,000	Retained earnings (accumulated deficit)	119,724,000	117,843,000	Marketing expenses	161,000	180,000
Allowance for doubtful accounts	3,566,000	414,000	Accumulated other comprehensive income (loss)	(104,275,000)	(65,043,000)	Depreciation & amortization	116,000	113,000
Allowance for sales returns & volume rebates	...	1,775,000	Total stockholders' equity	16,751,000	51,893,000	Other non-interest expenses	219,000	227,000
Accounts receivable - trade, net of allowances	29,523,000	31,009,000				Total non-interest expenses	2,092,000	1,932,000
Finished goods	45,461,000	56,583,000				Income (loss) from continuing operations before income taxes	968,000	300,000
Spare parts	1,221,000	775,000				Income tax expense (benefit) - current - federal	262,000	280,000
Reserve for inventory obsolescence	2,551,000	531,000				Income tax expense (benefit) - current - state	37,000	41,000
Advanced shipping costs	...	1,384,000				Total income tax expense (benefit) - current	299,000	321,000
Inventories, net of reserves	44,131,000	58,211,000				Income tax expense (benefit) - deferred - federal	(66,000)	(201,000)
Prepayments to vendors	3,176,000	4,131,000				Income tax expense (benefit) - deferred - state	(2,000)	(44,000)
Prepaid licenses & other current assets	...	3,302,000				Total deferred income taxes (benefit)	(68,000)	(245,000)
Prepaid expenses & other current assets	9,471,000	7,433,000				Provision (benefit) for income taxes	231,000	76,000
Prepaid licenses and other	6,295,000	...				Income (loss) from continuing operations	737,000	224,000
Total current assets	100,378,000	111,244,000				Income (loss) from discontinued operations, net of taxes	(19,000)	(1,000)
Building	200,000	200,000				Net income (loss)	718,000	223,000
Building improvements	14,000	14,000				Weighted average shares outstanding - basic	49,800	49,900
Leasehold improvements	544,000	450,000				Weighted average shares outstanding - diluted	50,000	50,000
Office equipment	...	1,057,000				Year end shares outstanding	49,300	49,900
Software	88,000	88,000				Income (loss) per share - continuing operations - basic	\$14.79	\$4.48
Other equipment	705,000	678,000				Income (loss) per share - discontinued operations - basic	\$(0.40)	\$(0.01)
Construction in process	1,029,000	14,000				Net income (loss) per share - basic	\$14.39	\$4.47
Property and equipment - Gross - Balancing value	1,242,000	...				Income (loss) per share - continuing operations - diluted	\$14.74	\$4.47
Property & equipment, at cost	3,822,000	2,501,000				Income (loss) per share - discontinued operations - diluted	\$(0.40)	\$(0.01)
Less: accumulated depreciation	1,345,000	768,000				Net income (loss) per share - diluted	\$14.34	\$4.46
Property & equipment, net of accumulated depreciation	2,477,000	1,733,000				Dividends declared per share	\$0.84	\$0.84
Operating lease right of use asset	8,846,000	4,350,000				Full-Time Employees (Period End)	7,000	...
Intangible assets, net of accumulated amortization	45,964,000	52,579,000				Total number of employees	7,000	7,500
Goodwill	...	25,092,000				Number of common stockholders	93	99
Other assets	906,000	397,000				Foreign currency translation adjustments	...	17,000
Total assets	158,571,000	195,395,000						
Accounts payable	27,448,000	30,719,000						
Accrued expense	5,106,000	5,306,000						
Other accounts payable & accrued expenses	...	541,000						
Accounts payable & accrued expenses	32,899,000	36,566,000						
Short-term debt	1,037,000	845,000						
Operating lease liabilities, current	1,827,000	1,898,000						
Deferred revenues, current	8,698,000	8,308,000						
Derivative liabilities	205,000	472,000						
Other short-term liabilities	1,566,000	386,000						
Other	345,000	...						
Total current liabilities	46,232,000	48,475,000						
Deferred revenues, non-current	16,347,000	15,603,000						
Notes payable	39,134,000	49,906,000						
Paycheck protection program	...	127,000						
Total debt	...	50,033,000						
Less: discount & issuance cost	...	(5,410,000)						
Less: current portion of debt	...	845,000						
Long-term debt	...	43,778,000						
Deferred tax liabilities, net	4,316,000	4,680,000						
Operating lease liabilities, non-current	7,282,000	2,457,000						
Total liabilities	113,311,000	114,993,000						
Preferred series B	16,146,000	16,146,000						
Preferred series C	12,363,000	12,363,000						

Consolidated Income Statement, Years Ended Dec. 31 (\$'000):		
	2023	2022
Interest & fees on loans	4,961,000	4,615,000
Interest on cash & investment securities	184,000	69,000
Total interest income	5,145,000	4,684,000
Interest expense on direct-to-consumer deposits (retail)	251,000	81,000
Interest expense on wholesale deposits	290,000	162,000
Interest on deposits	541,000	243,000
Interest expense on secured borrowings	227,000	153,000
Interest expense on unsecured borrowings	111,000	107,000
Interest on borrowings	338,000	260,000
Total interest expense	879,000	503,000
Net interest income	4,266,000	4,181,000
Non-interest income - interchange revenue, net of retailer share arrangements	(335,000)	(469,000)
Gain on portfolio sale	230,000	...
Other non-interest income	128,000	114,000
Total non-interest income	23,000	(355,000)
Provision for credit losses	1,229,000	1,594,000
Total net interest & non-interest income, after provision for credit losses	3,060,000	2,232,000
Employee compensation & benefits	867,000	779,000
Card & processing expenses	428,000	359,000
	323,000	

Information processing & communication	301,000	274,000	216,000
Marketing expenses	161,000	180,000	160,000
Depreciation & amortization	116,000	113,000	92,000
Other non-interest expenses	219,000	227,000	222,000
Total non-interest expenses	2,092,000	1,932,000	1,684,000
Income (loss) from continuing operations before income taxes	968,000	300,000	1,044,000
Income tax expense (benefit) - current - federal	262,000	280,000	218,000
Income tax expense (benefit) - current - state	37,000	41,000	49,000
Total income tax expense (benefit) - current	299,000	321,000	267,000
Income tax expense (benefit) - deferred - federal	(66,000)	(201,000)	(13,000)
Income tax expense (benefit) - deferred - state	(2,000)	(44,000)	(7,000)
Total deferred income taxes (benefit)	(68,000)	(245,000)	(20,000)
Provision (benefit) for income taxes	231,000	76,000	247,000
Income (loss) from continuing operations	737,000	224,000	797,000
Income (loss) from discontinued operations, net of taxes	(19,000)	(1,000)	4,000
Net income (loss)	718,000	223,000	801,000
Weighted average shares outstanding - basic	49,800	49,900	49,700
Weighted average shares outstanding - diluted	50,000	50,000	50,000
Year end shares outstanding	49,300	49,900	49,800
Income (loss) per share - continuing operations - basic	\$14.79	\$4.48	\$16.02
Income (loss) per share - discontinued operations - basic	\$(0.40)	\$(0.01)	\$0.07
Net income (loss) per share - basic	\$14.39	\$4.47	\$16.09
Income (loss) per share - continuing operations - diluted	\$14.74	\$4.47	\$15.95
Income (loss) per share - discontinued operations - diluted	\$(0.40)	\$(0.01)	\$0.07
Net income (loss) per share - diluted	\$14.34	\$4.46	\$16.02
Dividends declared per share	\$0.84	\$0.84	\$0.84
Full-Time Employees (Period End)	7,000
Total number of employees	7,000	7,500	6,000
Number of common stockholders	93	99	101
Foreign currency translation adjustments	17,000

□ As is; □ Approximately; □ As of February 22, 2023; □ As of February 18, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):			(loss)	(19,000)	(21,000)	outstanding	21,566	20,853	19,586
	2023	2022	Total stockholders'	equity	2,918,000	2,265,000	Income (loss) per		
			Total Equity	2,918,000	common share from		
Cash & cash equivalents	3,590,000	3,891,000					continuing		
Trade receivables, gross	19,333,000	...					operations - basic	\$0.36	...
Accounts receivable, net	17,005,000	...					Net income (loss)		
Credit card loans	...	21,065,000					per common share -		
Installment loans	...	300,000					basic	\$0.36	\$(0.48)
Allowance for credit losses	2,328,000	2,464,000					Income (loss) per		
Investment securities	253,000	221,000					common share from		
Internal-use computer software & development	...	305,000					continuing		
Furniture & equipment	...	96,000					operations -		
Land & leasehold improvements	...	72,000					diluted	\$0.36	...
Construction in progress	...	9,000					Net income (loss)		
Total property & equipment, gross	...	482,000					per common share -		
Less: accumulated depreciation	343,000	...					diluted	\$0.36	\$(0.48)
Less: accumulated depreciation & amortization	...	287,000					Full-Time Employees		
Property and equipment - Balancing value	510,000	...					(Period End)	444	...
Property & equipment, net	167,000	195,000					Total number of		
Goodwill & intangible assets, net	762,000	799,000					employees	444	499
Restricted cash	26,000	36,000					Number of common		
Deferred contract costs	285,000	344,000					stockholders	50	49
Deferred tax asset, net	629,000	552,000							
Accounts receivable, net	144,000	164,000							
Right of use assets - operating	98,000	88,000							
Investment in Loyalty Ventures Inc.	...	6,000							
Other assets	1,364,000	210,000							
Other assets	182,000	1,400,000							
Total assets	23,141,000	25,407,000							
Savings accounts - direct-to-consumer	...	2,782,000							
Savings accounts - wholesale	...	3,954,000							
Certificates of deposit - direct-to-consumer	...	2,684,000							
Certificates of deposit - wholesale	...	4,367,000							
Cardholder credit balances	...	39,000							
Deposits	...	13,826,000							
Current portion of deposits	13,620,000	...							
Debt issued by consolidated variable interest entities	3,898,000	6,115,000							
Term loans	...	556,000							
Senior notes	...	1,350,000							
Bridge loan	1,394,000	...							
Less: unamortized discount & debt issuance costs	...	(14,000)							
Accounts payable & other brand partner liabilities	...	398,000							
Accrued liabilities	...	306,000							
Operating lease liabilities	...	126,000							
Long-term tax reserves	...	306,000							
Other liabilities	1,311,000	173,000							
Other liabilities	...	1,309,000							
Total liabilities	20,223,000	23,142,000							
Common stock	1,000	1,000							
Additional paid-in capital	2,169,000	2,192,000							
Retained earnings (accumulated deficit)	767,000	93,000							
Net unrealized gain (loss) on available for sale securities	(16,000)	(18,000)							
Foreign currency translation adjustment	(3,000)	(3,000)							
Accumulated other comprehensive income							

Recent Dividends:						
1. Bread Financial Holdings Inc common.						
ExDate	Amt	Declared	Record	Payable		
05/12/2022	0.21	04/28/2022	05/13/2022	06/17/2022		
08/11/2022	0.21	07/28/2022	08/12/2022	09/16/2022		
11/10/2022	0.21	10/27/2022	11/14/2022	12/16/2022		
02/09/2023	0.21	01/26/2023	02/10/2023	03/17/2023		
05/11/2023	0.21	04/27/2023	05/12/2023	06/16/2023		
08/10/2023	0.21	07/27/2023	08/11/2023	09/15/2023		
11/09/2023	0.21	10/26/2023	11/13/2023	12/15/2023		
02/08/2024	0.21	01/25/2024	02/09/2024	03/15/2024		

Annual Dividends:			
1. Bread Financial Holdings Inc common.			
2022	2023	2024	
0.63	0.84	0.21	

BROADWIND INC			
Annual Report			
Consolidated Income Statement, Years Ended Dec. 31 (\$000):			
	2023	2022	2021 (revised)
Total revenues	203,477
Revenues	203,477	176,759	145,619
Cost of sales	170,969	166,049	140,108
Gross profit (loss)	32,508	10,710	5,511
Selling, general & administrative	20,705	16,592	17,372
Intangible amortization	664	725	733
Total operating expenses	21,369	17,317	18,105
Operating income (loss)	11,139	(6,607)	(12,594)
Paycheck Protection Program loan forgiveness	9,151
Interest income (expense), net	(3,201)	(3,218)	(1,129)
Other income (expense), net	(48)	130	7,444
Total other income (expense), net	(3,249)	(3,088)	15,466
Net income (loss) before provision (benefit) for income taxes	7,890	(9,695)	2,872
Current state provision (benefit) for income taxes	...	48	21
Total current provision (benefit) for income taxes	251	48	21
Deferred federal provision (benefit) for income taxes	(1,758)	(2,102)	(1,636)
Deferred state provision (benefit) for income taxes	(209)	(460)	(304)
Total provision (benefit) for deferred income taxes	(1,967)	(2,562)	(1,940)
Increase (decrease) in deferred tax valuation allowance	1,957	2,549	1,944
Provision (benefit) for income taxes	241	35	25
Net income (loss)	7,649	(9,730)	2,847
Weighted average shares outstanding - basic	21,189	20,299	18,726
Weighted average shares outstanding - diluted	21,491	20,299	19,388
Year end shares			

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):		
	2023	2022
Cash	1,099	12,732
Accounts receivable, gross	19,330	17,035
Allowance for doubtful accounts	99	17
Accounts receivable, net	19,231	17,018
Contract assets	1,460	1,955
Raw materials	24,651	27,644
Work-in-process	10,390	13,843
Finished goods	4,595	4,916
Gross inventories	37,405	46,403
Less: reserve	...	2,141
Reserve	(2,231)	...
Inventories, net	...	44,262
Prepaid expenses & other current assets	3,500	3,291
AMP credit receivable	7,051	...
Total current assets	69,746	79,258
Land	1,423	1,423
Buildings	22,111	20,792
Machinery & equipment	125,107	120,893
Office furniture & equipment	5,962	5,705
Leasehold improvements	9,068	9,040
Construction in progress	3,526	2,360
Property & equipment, gross	167,197	160,213
Less: accumulated depreciation	120,074	...
Less: accumulated depreciation & amortization	...	114,894
Property & equipment, net	47,123	45,319
Operating lease right-of-use assets	15,593	16,396
Intangible assets, net	...	2,728
Other intangible assets, net	2,064	...
Other assets	630	839
Total assets	135,156	144,540
Line of credit & current portion of long-term debt	...	1,170
Current maturities of long-term debt	5,903	...
Current portion of finance lease obligations	2,153	2,008
Current portion of operating lease obligations	1,851	1,882
Accounts payable	20,728	26,255
Accrued payroll & benefits	5,051	3,110
Accrued property taxes	...	17
Income taxes payable	254	26
Accrued professional fees	140	118
Accrued warranty

□ As is; □ As of March 6, 2023; □ As of February 22, 2022

liability	322	149	Gain (loss) on loan extinguishment	6,980,932	Current portion of lease liability	353,526	...
Accrued self-insured workers compensation reserve	21	30	Loss on debt settlement	170,941	Total current liabilities	7,472,326	10,155,582
Long term incentive plan accrual	...	619	Loss on debt settlement	491,643	Loan payable	...	4,684,446
Other accrued liabilities	...	244	Loss on revaluation of stream debenture	3,128,956	Series 1 convertible debenture	5,244,757	5,537,360
Accrued other	6,477	...	Income (loss) before income tax	(10,843,949)	Series 2 convertible debenture	13,458,570	14,063,525
Accrued tax	310	...	Deferred tax expense	2,588,590	Royalty convertible debenture	...	10,285,777
Accrued other	379	...	Net income (loss) for the year	(13,432,539)	898,591	(6,402,277)	Lease liability	71,808	...
Accrued liabilities	...	4,313	Weighted average shares outstanding - basic	280,354,631	205,950,811	161,868,334	Environment protection agency cost recovery liability net of discount	6,574,140	7,941,466
Customer deposits	16,500	34,550	Weighted average shares outstanding - diluted	280,354,631	269,801,281	161,868,334	Derivative warrant liability	1,808,649	6,438,679
Total current liabilities	53,612	70,178	Year end shares outstanding	322,661,482	229,501,661	164,435,442	Deferred tax liability	2,588,590	...
Other notes payable	...	1,094	Net income (loss) per common share - basic	\$(0.05)	\$0.00	\$(0.04)	Stream debenture	51,138,000	...
Long-term debt	...	7,217	Net income (loss) per common share - diluted	\$(0.05)	\$0.00	\$(0.04)	Total liabilities	88,356,840	59,106,835
Less: current portion	...	1,170	Number of full time employees	20	Common shares	321	228
Long-term finance lease obligations, net of current portion	3,372	4,226	Total number of employees	20	10	4	Additional paid-in capital	57,848,953	45,161,513
Long-term operating lease obligations, net of current portion	15,888	16,696	Number of common stockholders	160	157	102	Accumulated other comprehensive income (loss)	808,662	253,875
Other long-term liabilities	15	26	Foreign currency translation adjustments	...	(237,546)	...	Retained earnings (accumulated deficit)	(85,025,098)	(71,592,559)
Total long-term liabilities	25,525	28,089	Basic EPS Excluding ExtraOrdinary Items	\$(0.05)	Total shareholders' equity (deficiency)	(26,367,162)	(26,176,943)
Common stock	22	21	Net income per common share	\$(0.05)	Total Equity	(26,367,162)	...
Treasury stock	1,842	1,842							
Additional paid-in capital	399,336	397,240							
Retained earnings (accumulated deficit)	(341,497)	(349,146)							
Total stockholders' equity	56,019	46,273							
Total Equity	56,019	...							

Recent Dividends:**1. Broadwind Inc common.**

No dividends paid.

Annual Dividends:**1. Broadwind Inc common.**

No dividends paid.

BUNKER HILL MINING CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021 (revised)
Operation & administration expense	6,146,322	2,033,879	2,651,954
Exploration expense	13,530,819
Mine preparation expense	...	7,827,656	...
Legal & accounting expense	1,848,879	1,147,861	1,035,777
Consulting & wages expense	3,605,373	5,477,765	1,533,954
Income (loss) from operations	(11,600,574)	(16,487,161)	(18,752,504)
Change in derivative liability	2,360,025	15,696,391	12,300,453
Gain (loss) on foreign exchange	4,821	(237,546)	208,660
Gain (loss) on fair value of convertible debentures	...	(1,140,537)	...
Gain (loss) on environmental protection agency debt extinguishment	(99,569)	8,614,103	...
Interest income	1,107,093
Interest expense	7,124,527	3,382,559	102,740
Debtenture finance costs	...	1,230,540	...
Financing costs	934,502	945,507	...
Other income	23,520	18,626	...
Other expense	...	6,679	...
Loss on debt settlement	(214,714)	...	56,146
Share issuance costs	1,673,776

Reclassified to conform with 2022 presentation; Shares increased due to the effect of issuance of shares for interest payable, restricted share units vested and process plant purchase, issuance of non brokered, special warrant and contractor shares; Approximately; As of April 17, 2023; As of March 30, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	20,102,596	...
Cash	...	708,105
Restricted cash	6,476,000	6,476,000
Prepaid expenses	...	386,218
Environment protection agency overpayment	...	170,729
Accounts receivable & prepaid expenses	598,401	556,947
Total current assets	27,176,997	7,741,052
Spare parts inventory	341,004	341,004
Accumulated depreciation	513,714	...
Equipment	1,460,375	920,571
Total equipment, gross	...	920,571
Less accumulated depreciation	...	369,367
Right-of-use assets	625,022	...
Long term deposit	249,265	269,015
Bunker Hill Mine & Mining interests	15,198,259	15,896,645
Process plant	17,452,470	8,130,972
Total assets	61,989,678	32,929,892
Accounts payable	1,788,950	4,523,502
Accrued liabilities	1,225,525	1,500,164
Interest payable	534,998	1,154,477
Derivative warrant liability	...	903,697
DSU liability	...	573,742
Promissory notes payable	...	1,500,000
Environment protection agency cost recovery payable (note 8)	3,000,000	...
Deferred share units liability	569,327	...

Current portion of lease liability	353,526	...
Total current liabilities	7,472,326	10,155,582
Loan payable	...	4,684,446
Series 1 convertible debenture	5,244,757	5,537,360
Series 2 convertible debenture	13,458,570	14,063,525
Royalty convertible debenture	...	10,285,777
Lease liability	71,808	...
Environment protection agency cost recovery liability net of discount	6,574,140	7,941,466
Derivative warrant liability	1,808,649	6,438,679
Deferred tax liability	2,588,590	...
Stream debenture	51,138,000	...
Total liabilities	88,356,840	59,106,835
Common shares	321	228
Additional paid-in capital	57,848,953	45,161,513
Accumulated other comprehensive income (loss)	808,662	253,875
Retained earnings (accumulated deficit)	(85,025,098)	(71,592,559)
Total shareholders' equity (deficiency)	(26,367,162)	(26,176,943)
Total Equity	(26,367,162)	...

Recent Dividends:**1. Bunker Hill Mining Corp common.**

No dividends paid.

Annual Dividends:**1. Bunker Hill Mining Corp common.**

No dividends paid.

BUTLER NATIONAL CORP.**Earnings, 9 mos. to Jan 31 (Consol. - \$000):**

	2024	2023
Total revenues	55,746	55,093
Cost & expenses	47,215	43,772
Deprec., depl. & amort.	...	2,309
Operating income	8,531	9,012
Interest income	199	...
Interest expense	1,869	2,107
Gains or losses	4,169	69
Net before taxes	11,030	6,974
Income taxes	2,978	...
Net income	8,052	5,091
Earnings common share		
Primary	\$0.11	\$0.07
Fully Diluted	\$0.11	\$0.07
Common Shares:		
Full Diluted	70,985	76,634
Year-end	68,851	75,896

BYRNA TECHNOLOGIES INC**Annual Report****Consolidated Income Statement, Years Ended Nov. 30 (\$):**

	2023	2022 (revised)	2021 (revised)
Sales	42,644,000	48,036,000	...
Net revenue	42,644,000	48,036,000	42,160,000
Cost of goods sold	18,997,000	21,758,000	19,270,000
Gross profit	23,647,000	26,278,000	22,890,000
Operating expenses	31,437,000	34,009,000	26,181,000
Total operating expenses	31,437,000	34,009,000	...
Income (loss) from operations	(7,790,000)	(7,731,000)	(3,291,000)
Foreign currency transaction gain (loss)	(270,000)	(87,000)	(210,000)
Interest income (expense), net	693,000	201,000	(34,000)
Forgiveness of paycheck protection program loan	190,000
Other expenses	57,000	34,000	98,000
Income (loss) before income taxes
- U.S.	(2,911,000)

depreciation)	6,498,000	6,584,000
Cash & cash equivalents	1,476,000
Cash	652,000	...
Prepaid & other assets	387,000	224,000
Prepaid income taxes	57,000	21,000
Deferred income taxes, discontinued operations	110,000
Assets held for sale	109,000	...
Investments	1,244,000	...
Total assets	8,947,000	8,415,000
Property taxes	340,000	260,000
Accrued professional fees	157,000	155,000
Deposits & prepaid rent	146,000	93,000
Accrued payroll & related costs	75,000
Other liabilities	43,000
Other liabilities	366,000
Deferred income taxes, net	465,000	271,000
Environmental remediation accrual, discontinued operations	402,000	406,000
Other	330,000	...
Other Non-Current Liabilities	27,000	...
Deferred Tax - Debit - Liability	(181,000)	...
Deferred Tax - Liability - Net	284,000	...
Total liabilities	1,356,000	1,303,000
Class A common stock	66,000	66,000
Capital in excess of par	782,000	782,000
Retained earnings (accumulated deficit)	6,743,000	6,264,000
Total shareholders' equity (deficit)	7,591,000	7,112,000
Total Equity	7,591,000	...

Recent Dividends:

- 1. Capital Properties, Inc. class B common.**
No dividends paid.
- 2. Capital Properties, Inc. class A common.**

ExDate	Amt	Declared	Record	Payable
02/11/2021	0.07	01/27/2021	02/12/2021	02/26/2021
05/13/2021	0.07	04/28/2021	05/14/2021	05/28/2021
08/12/2021	0.07	07/28/2021	08/13/2021	08/27/2021
11/10/2021	0.07	10/27/2021	11/12/2021	11/24/2021
02/10/2022	0.07	01/26/2022	02/11/2022	02/25/2022
05/12/2022	0.07	04/27/2022	05/13/2022	05/27/2022
08/11/2022	0.07	07/27/2022	08/12/2022	08/26/2022
11/09/2022	0.07	10/26/2022	11/11/2022	11/23/2022
02/09/2023	0.07	01/25/2023	02/10/2023	02/24/2023
05/11/2023	0.07	04/26/2023	05/12/2023	05/26/2023
08/10/2023	0.07	07/26/2023	08/11/2023	08/25/2023
11/09/2023	0.07	10/25/2023	11/10/2023	11/20/2023
02/08/2024	0.07	01/24/2024	02/09/2024	02/23/2024

Annual Dividends:

- 1. Capital Properties, Inc. class B common.**
No dividends paid.
- 2. Capital Properties, Inc. class A common.**

2021	0.28	2022	0.28	2023	0.28
2024	0.07				

CAPITAL PROPERTIES, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2023	2022
Cost & expenses	1,666,000	1,942,000
Operating income	2,390,000	1,879,000
Net before taxes	2,390,000	1,879,000
Income taxes	516,000	...
Income contin. oper	1,728,000	...
Net income	1,706,000	1,363,000
Earnings common share		
Primary	\$0.26	\$0.21
Fully Diluted	\$0.26	\$0.21
Common Shares:		
Full Diluted	6,599,912	...
Year-end	6,599,912	6,599,912

CAPRICOR THERAPEUTICS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
Revenue	25,178,066	2,551,469	244,898
Total revenue	25,178,066	2,551,469	244,898
Research & development	36,448,039	21,816,949	13,571,045
General & administrative	12,807,886	10,431,903	7,612,295
Total operating expenses	49,255,925	32,248,852	21,183,340
Income (loss) from operations	(24,077,859)	(29,697,383)	(20,938,442)
Other income	67,657	190,582	548,207
Investment income	1,728,701	521,535	57,460
Forgiveness of debt	318,160
Gain (loss) on disposal of fixed asset	(6,041)	(34,266)	(7,905)
NET LOSS	(22,287,542)
Total other income (expense)	1,790,317	677,851	915,922
Net income (loss)	(22,287,542)	(29,019,532)	(20,022,520)
Weighted average shares outstanding			
- basic	26,778,360	24,552,688	23,089,323
Weighted average shares outstanding - diluted	26,778,360	24,552,688	23,089,323
Year end shares outstanding	31,148,320	25,241,402	24,185,001
Net income (loss) per share - basic	\$(0.83)	\$(1.18)	\$(0.87)
Net income (loss) per share - diluted	\$(0.83)	\$(1.18)	\$(0.87)
Number of full time employees	101	74	48
Total number of employees	101
Number of common stockholders	126	134	136
Net income (loss) per share - diluted	\$(0.83)
Diluted EPS Excluding ExtraOrd Items	\$(0.83)

As of March 16, 2023; As of March 9, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	14,694,857	9,603,242
Marketable securities	24,792,846	31,818,020
Receivables	10,371,993	547,580
Prepaid expenses & other current assets	995,776	919,892
Total current assets	50,855,472	42,888,734
Furniture & fixtures	139,336
Laboratory equipment	5,449,597	4,237,089
Leasehold improvements	2,129,102	1,393,230
Furniture & equipment	187,997	...
Total property & equipment, gross	7,766,696	5,769,655
Less accumulated depreciation	2,206,055	1,181,625
Property & equipment, net	5,560,641	4,588,030
Lease right-of-use assets, net	2,050,042	2,349,974
Other assets	268,172	268,172
Total assets	58,734,327	50,094,910
Accounts payable & accrued expenses	6,222,762	4,834,683
Accounts payable & accrued expenses, related party	27,479	89,234
Deferred revenue, current	24,270,465	17,980,599
Lease liabilities, current	749,112	682,039
Total current liabilities	31,269,818	23,586,555
Note payable, net of current	3,376,259	...
Deferred revenue, net of current portion	9,467,932
California Institute for		

Regenerative Medicine (CIRM) liability	3,376,259
Lease liabilities, net of current	1,486,783	1,878,070
Total long-term liabilities	4,863,042	14,722,261
Total liabilities	36,132,860	38,308,816
Common stock	31,148	25,241
Additional paid-in capital	181,701,859	148,735,420
Accumulated other comprehensive income (loss)	235,813	105,244
Retained earnings (accumulated deficit)	(159,367,353)	(137,079,811)
Total stockholders' equity (deficit)	22,601,467	11,786,094
Total Equity	22,601,467	...

Recent Dividends:

- 1. Capricor Therapeutics Inc common.**
No dividends paid.

Annual Dividends:

- 1. Capricor Therapeutics Inc common.**
No dividends paid.

CARDIFF ONCOLOGY INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
Stock-based Compensation	3,230,000
Salaries and staff costs	3,531,000
Royalty revenues	488,000	386,000	359,000
Facilities and other	23,686,000
Research & development	32,857,000	27,107,000	17,376,000
Selling, general & administrative	13,043,000	13,181,000	11,838,000
Selling & marketing	4,133,000
General & administrative	2,149,000
Total operating expenses	(45,900,000)	40,288,000	29,214,000
Income (loss) from operations	(45,412,000)	(39,902,000)	(28,855,000)
Interest income, net	4,069,000	1,581,000	264,000
Other income (expense), net	(98,000)	(383,000)	15,000
Gain (loss) from changes in fair value of derivative financial instruments - warrants	285,000
Total other income (expense), net	3,971,000	1,198,000	564,000
Net income (loss)	(41,441,000)	(38,704,000)	(28,291,000)
Preferred stock dividend	24,000
Preferred stock dividend payable on series A convertible preferred stock	24,000	24,000
Net income (loss) attributable to common stockholders	(41,465,000)	(38,728,000)	(28,315,000)
Weighted average shares outstanding			
- basic	44,677,000	43,600,000	39,030,000
Weighted average shares outstanding - diluted	44,677,000	43,600,000	39,030,000
Year end shares outstanding	44,677,000	44,677,000	41,964,000
Net earnings (loss) per common share - basic	\$(0.93)	\$(0.89)	\$(0.73)

Net earnings (loss) per common share - diluted	\$(0.93)	\$(0.89)	\$(0.73)
Number of full time employees	25	22	22
Number of part time employees	1	1	1
Total number of employees	26	23	23
Number of common stockholders	58	58	58
Income from cont operations before income tax	(41,441,000)
Federal	(8,300,000)
Income Taxes - Local - Deferred	(789,000)
Total deferred (benefit) expense	(9,089,000)
Earnings per share from continuing operations	\$(0.93)
Earnings per share from continuing operations	\$(0.93)
Stock-based Compensation in R&D	1,962,000
Salaries and staff costs	5,930,000
Valuation allowance	9,089,000
Comprehensive loss attributable to common stockholders	(41,137,000)
Stock-based Compensation in R&D	1,279,000

□ As of February 23, 2023; □ As of February 17, 2022; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):		
	2023	2022
Cash & cash equivalents	21,655,000	16,347,000
Short-term investments	53,168,000	88,920,000
Accounts receivable & unbilled receivable	288,000	771,000
Prepaid expenses & other assets	2,301,000	5,246,000
Total current assets	77,412,000	111,284,000
Furniture & office equipment	1,067,000	1,066,000
Leasehold improvements	2,568,000	2,560,000
Laboratory equipment	4,990,000	1,056,000
Laboratory equipment, gross	1,355,000	...
Property & equipment, net - accumulated depreciation	3,752,000	3,413,000
Property & equipment, net	1,238,000	1,269,000
Operating lease right-of-use assets	1,708,000	2,251,000
Other assets	1,279,000	1,387,000
Total assets	81,637,000	116,191,000
Accounts payable	1,966,000	1,956,000
Accrued compensation	2,737,000	1,849,000
Accrued clinical trials	...	2,333,000
Accrued research agreements & services	530,000	509,000
Accrued director fees	...	125,000
Accrued patent, license & other fees	...	24,000
Other accrued liabilities	207,000	337,000
Accrued liabilities - Balancing value	7,783,000	...
Clinical trials	4,309,000	...
Accrued liabilities	...	5,177,000
Operating lease liabilities	691,000	675,000
Total current liabilities	10,440,000	7,808,000
Operating lease liabilities, net of		

current portion	1,458,000	2,040,000
Total liabilities	11,898,000	9,848,000
Common stock	4,000	4,000
Additional paid-in capital	409,343,000	404,834,000
Accumulated other comprehensive income (loss)	(67,000)	(395,000)
Retained earnings (accumulated deficit)	(339,541,000)	(298,100,000)
Total stockholders' equity (deficiency)	69,739,000	106,343,000
Total Equity	69,739,000	...

Recent Dividends:

1. Cardiff Oncology Inc series A convertible preferred.

No dividends paid.

2. Cardiff Oncology Inc common.

No dividends paid.

3. Cardiff Oncology Inc series E convertible preferred.

No dividends paid.

Annual Dividends:

1. Cardiff Oncology Inc series A convertible preferred.

No dividends paid.

2. Cardiff Oncology Inc common.

No dividends paid.

3. Cardiff Oncology Inc series E convertible preferred.

No dividends paid.

CARO HOLDINGS INC

Earnings, 9 mos. to Dec 31 (Consol. - \$):

	2023	2022
Total revenues	521	...
Cost & expenses	255,851	139,403
Operating income	(443,520)	(139,403)
Interest income	1,219	...
Interest expense	192,455	75,218
Foreign currency	3,046	1,607
Net before taxes	(443,520)	(213,014)
Net income	(443,520)	(213,014)
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	42,394,348	40,000,000
Year-end	36,505,000	40,000,000

CASSAVA SCIENCES INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Research & development expenses, net of grant reimbursement	89,423,000	68,032,000	24,813,000
General & administrative expenses	16,534,000	11,988,000	8,055,000
Total operating expenses	105,957,000	80,020,000	32,868,000
Operating income (loss)	(105,957,000)	(80,020,000)	(32,868,000)
Interest income	7,833,000	2,777,000	49,000
Other income, net	907,000	997,000	434,000
Income (loss) before provision for (benefit from) income taxes	(97,217,000)
Net income (loss)	(97,217,000)	(76,246,000)	(32,385,000)
Weighted average shares outstanding - basic	41,932,000	40,202,000	39,405,000
Weighted average shares outstanding - diluted	41,932,000	40,202,000	39,405,000
Year end shares outstanding	42,236,919	41,735,557	40,016,792
Net income (loss) per share - basic	\$(2.32)	\$(1.90)	\$(0.82)
Net income (loss) per share - diluted	\$(2.32)	\$(1.90)	\$(0.82)
Number of full time employees	29	26	24

Total number of employees	29
Number of common stockholders	28	25	30
Earnings per share from continuing operations	\$(2.32)
Earnings per share from continuing operations	\$(2.32)

□ Approximately; □ As of February 20, 2023; □ As of February 23, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

2023 2022

Cash & cash equivalents	121,136,000	201,015,000
Receivables	962,000	...
Prepaid insurance	759,000	874,000
Contract research organization & other deposits	6,489,000	9,177,000
Other prepaid expenses & current assets	8,497,000	160,000
Prepaid expenses & other current assets	287,000	10,211,000
Total current assets	129,633,000	211,226,000
Operating lease right-of-use assets	...	122,000
Land	3,734,000	3,734,000
Buildings	15,980,000	15,980,000
Site improvements	494,000	470,000
Tenant improvements	3,062,000	3,016,000
Furniture & equipment	868,000	851,000
Construction in progress	...	13,000
Gross property & equipment	24,138,000	24,064,000
Less: accumulated depreciation - property & equipment	2,284,000	1,200,000
Property & equipment, net	21,854,000	22,864,000
Intangible assets, net	176,000	622,000
Total assets	151,663,000	234,834,000
Accounts payable and other accrued expenses	10,573,000	...
Accounts payable	...	4,017,000
Accrued development expense	3,037,000	2,280,000
Accrued compensation & benefits	200,000	170,000
Operating lease liabilities, current	...	104,000
Other current liabilities	385,000	492,000
Total current liabilities	14,195,000	7,063,000
Operating lease liabilities, non-current	...	35,000
Other non-current liabilities	...	197,000
Total liabilities	14,195,000	7,295,000
Common stock	42,000	42,000
Additional paid-in capital	518,195,000	511,049,000
Retained earnings (accumulated deficit)	(380,769,000)	(283,552,000)
Total stockholders' equity (deficiency)	137,468,000	227,539,000
Total Equity	137,468,000	...

Recent Dividends:

1. Cassava Sciences Inc common.

ExDate	Amt	Declared	Record	Payable
12/21/2023	0.00	12/18/2023	12/22/2023	01/03/2024

Annual Dividends:

1. Cassava Sciences Inc common.

2024 0.00

CATALYST PHARMACEUTICALS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	[□] 2021 (revised)								
Product revenue, net.....	396,502,000	213,938,000	137,997,000	Other prepaid expenses & other current assets.....	...	577,000		Net revenues.....	204,438,365
License & other revenue.....	1,702,000	265,000	2,836,000	Total current assets.....	219,329,000	320,797,000		Net revenues.....	204,438,365	248,725,485	52,669,733
Total revenues.....	398,204,000	214,203,000	140,833,000	Operating lease right-of-use asset.....	2,508,000	2,770,000		Cost of revenues.....	172,714,042	230,630,161	47,559,243
Cost of sales.....	51,967,000	34,393,000	21,884,000	Computer equipment.....	...	51,000		Gross profit (loss)....	31,724,323	18,095,324	5,110,490
Research & development.....	93,150,000	19,789,000	16,936,000	Furniture & equipment.....	494,000	222,000		Research & development expenses.....	11,928,070	10,635,486	5,274,316
Selling, general & administrative.....	133,710,000	58,183,000	49,628,000	Leasehold improvements.....	991,000	980,000		Sales & marketing expenses.....	4,903,926	2,007,812	2,301,720
Total operating costs & expenses.....	311,392,000	112,365,000	88,448,000	Software.....	433,000	...		General & administrative expenses.....	13,789,108	9,737,711	10,027,349
Amortization of intangible assets.....	32,565,000	Property & equipment, gross.....	1,918,000	...		Impairment charge on long-lived assets.....	7,070,236	4,831,708	...
Operating income (loss).....	86,812,000	101,838,000	52,385,000	Less: accumulated depreciation.....	723,000	406,000		Impairment charge on goodwill.....	...	1,556,078	...
Other income, net.....	7,699,000	2,881,000	282,000	Property & equipment, net.....	1,195,000	847,000		Provision for (recovery) of doubtful accounts....	1,284,795	831,132	(780,389)
Net income (loss) before income taxes..	94,511,000	104,719,000	52,667,000	License & acquired intangibles, net.....	194,049,000	32,471,000		Total operating expenses.....	38,976,135	29,599,927	16,822,996
Current federal income taxes (benefit).....	5,931,000	12,858,000	2,455,000	Deferred tax assets, net.....	36,544,000	18,736,000		Operating income (loss).....	(7,251,812)	(11,504,603)	(11,712,506)
Current state income taxes (benefit).....	34,975,000	3,877,000	1,414,000	Deposits.....	...	9,000		Finance income (expense), net.....	432,900	491,060	784,880
Deferred federal income taxes (benefit).....	(1,712,000)	4,739,000	8,620,000	Investment in equity securities.....	16,489,000	...		Other income (expenses), net.....	3,023,238	(7,252,475)	3,644,363
Deferred state income taxes (benefit).....	(16,093,000)	166,000	696,000	Total assets.....	470,114,000	375,630,000		Impairment of non-marketable equity securities.....	692,639
Income tax provision (benefit)....	23,101,000	21,640,000	13,185,000	Accounts payable.....	14,795,000	3,975,000		Changes in fair value of warrants liability.....	136,000	5,710,000	61,802,000
Net income (loss).....	71,410,000	83,079,000	39,482,000	Accrued preclinical & clinical trial expenses.....	1,015,000	479,000		Income (loss) before income tax....	(6,053,182)	(12,556,018)	53,826,098
Weighted average shares outstanding				Accrued professional fees.....	4,730,000	1,619,000		Current taxes expense (benefit).....	(7,713,191)
- basic.....	106,279,736	103,374,606	103,379,349	Accrued compensation & benefits.....	8,883,000	5,132,000		Deferred taxes expense (benefit).....	...	(1,228,207)	(19,855)
Weighted average shares outstanding - diluted.....	113,753,154	111,375,631	107,795,585	Accrued license fees.....	24,437,000	20,444,000		Income tax expenses..	2,486,145	(1,228,207)	(7,733,046)
Year end shares outstanding.....	107,121,549	105,263,031	102,992,913	Accrued purchases.....	192,000	154,000		Net income (loss).....	(8,539,327)	(11,327,811)	61,559,144
Net income (loss) per share - basic.....	\$0.67	\$0.80	\$0.38	Operating lease liability, net of current portion.....	6,877,000	3,381,000		Less: net income (loss) attributable to non-controlling interests.....	6,090,270	1,879,365	(73,092)
Net income (loss) per share - diluted....	\$0.63	\$0.75	\$0.37	Accrued income tax.....	729,000	8,702,000		Net income (loss) attributable to shareholders of CBAK Energy Technology, Inc.	(2,449,057)	(9,448,446)	61,486,052
Total number of employees.....	...	[□] 82	[□] 76	Due to licensor.....	12,540,000	13,127,000		Weighted average shares outstanding-basic....	89,252,085	88,927,671	87,605,493
Number of common stockholders.....	17	[□] 32	[□] 31	Other accrued expenses & other current liabilities.....	...	238,000		Weighted average shares outstanding-diluted...	89,252,085	88,927,671	87,884,357
Basic EPS Excluding ExtraOrdinary Items..	\$0.67	Other.....	465,000	...		Year end shares outstanding.....	89,919,190	88,990,858	88,705,016
Diluted EPS Excluding ExtraOrd Items.....	\$0.63	Accrued interest payable.....	1,031,000	...		Income (loss) per share from continuing operations - basic....	\$(0.03)
				Total current liabilities.....	76,063,000	57,588,000		Net income (loss) per share-basic.....	\$(0.03)	\$(0.11)	\$0.70

[□] Reclassified to conform with 2022 presentation; [□] Approximately; [□] As of March 15, 2023; [□] As of March 14, 2022; [□] As of March 13, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents.....	137,636,000	298,395,000
Accounts receivable, net.....	53,514,000	10,439,000
Raw materials.....	1,910,000	...
Work-in-process.....	4,573,000	5,543,000
Finished goods.....	9,161,000	1,262,000
Inventory.....	15,644,000	6,805,000
Prepaid manufacturing costs.....	...	1,147,000
Prepaid tax.....	...	44,000
Prepaid insurance.....	...	1,224,000
Prepaid subscriptions fees.....	...	1,202,000
Prepaid research fees.....	...	178,000
Prepaid commercialization expenses.....	...	198,000
Due from collaborative & licensing arrangements.....	...	354,000
Prepaid conference & travel expenses.....	...	234,000

Recent Dividends:

1. Catalyst Pharmaceuticals Inc common.

No dividends paid.

Annual Dividends:

1. Catalyst Pharmaceuticals Inc common.

No dividends paid.

CAVITATION TECHNOLOGIES, INC.

Earnings, 6 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues.....	192,000	320,000
Cost & expenses.....	456,000	660,000
Operating income.....	(264,000)	(340,000)
Other income (expense), net.....	...	(29,000)
Net before taxes.....	(267,000)	...
Net income.....	(267,000)	(372,000)
Earnings common share Common Shares:		
Full Diluted.....	284,289,740	276,698,831
Year-end.....	284,289,740	276,698,831

CBAK ENERGY TECHNOLOGY INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	[□] 2021 (revised)
Income.....	(5,896,816)
Share of loss of

Net income (loss) per share from continuing operations - basic....	\$(0.03)
Net income (loss) per share-basic.....	\$(0.03)	\$(0.11)	\$0.70
Income (loss) per share from continuing operations - basic....	\$(0.03)
Net income (loss) per share-diluted....	\$(0.03)	\$(0.11)	\$0.70
Full-Time Employees (Period End).....	1,456
Total number of employees.....	1,456	[□] 1,063	[□] 1,054
Number of common stockholders.....	...	[□] 50	[□] 47
Foreign currency translation adjustments.....	...	(11,189,175)	...
Reported Comprehensive Income.....	(5,896,816)
Share of loss of

equity investee	(27,428)
Impairment charges on equity investee	2,366,080

⊠ Reclassified to conform with 2022 presentation; ⊡ Approximately; ⊢ As of April 10, 2023; ⊣ As of April 13, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	4,643,267	6,519,212
Pledged deposits	54,179,549	30,836,864
Trade accounts receivable	29,368,296	23,422,733
Less: allowance for doubtful accounts	3,198,249	2,274,513
Trade accounts & bills receivable, net	28,653,047	21,148,220
Bills receivable	2,483,000	6,265,355
Trade & bills receivable, net	...	27,413,575
Raw materials	3,779,414	7,101,426
Work-in-progress	9,525,568	17,274,033
Finished goods	20,108,440	25,070,832
Inventories, before provision for obsolete inventories	33,413,422	...
Inventories	...	49,446,291
Receivables from former subsidiary	74,946	5,518,052
Income tax recoverable	...	57,934
Value added tax recoverable	5,248,210	4,234,082
Prepayments to suppliers	...	220,671
Deposits	108,492	43,914
Staff advances	113,336	51,826
Prepaid operating expenses	645,390	706,190
Receivables from sales of vehicles	...	371,105
Other prepayments & other receivables	...	294,292
Prepayments & other receivables, gross	...	5,922,080
Less: allowance for doubtful accounts	290,228	7,000
Prepaid land use rights, current portion	1,341,596	...
Others	292,458	...
Total current assets	128,423,485	125,707,008
Buildings	45,843,428	47,086,680
Leasehold Improvements	7,214,436	5,156,705
Machinery & equipment	83,625,645	71,665,842
Office equipment	1,983,601	1,545,026
Motor vehicles	727,452	507,882
Less: impairment	...	13,025,161
Less: accumulated depreciation	30,407,634	22,932,447
Impairment	17,358,096	...
Property, plant & equipment, net	91,628,832	90,004,527
Construction in progress	37,797,862	9,954,202
Long-term investments, net	...	945,237
Non-marketable equity securities	2,565,005	...
Prepaid land use rights	11,712,704	12,361,163
Operating lease right-of-use assets, net	1,084,520	1,264,560
Deferred tax assets, net	...	2,486,979
Deposit paid for acquisition of long-term investments	7,101,492	...
Total assets	281,155,260	244,032,734
Trade accounts payable	...	32,516,445
Bills payable - bank acceptance bills	...	34,974,990
Trade & bills payable	82,429,575	67,491,435
Short-term bank borrowings	32,587,676	14,907,875
Other short-term loans	339,552	689,096
Officers advances	15,571,808	...
Construction costs payable	...	2,143,730
Equipment purchase payable	13,665,499	9,710,187

Liquidated damages	1,210,119	1,210,119
Accrued staff costs	...	2,961,781
Product warranty	2,781,730	...
Customer deposits	2,875,131	4,845,382
Deferred revenue, current portion	3,386,142	1,869,525
Accrued expenses	...	2,476,605
Dividend payable to non-controlling interest to Hitrans	1,256,745	1,290,942
Other payable	461,366	182,915
Deferred revenues	784,000	(1,085,525)
Payable to a former subsidiary, net	411,111	358,067
Deferred government grants, current	375,375	1,299,715
Product warranty provisions	23,870	26,215
Warrants liability	...	136,000
Operating lease liability, current	691,992	575,496
Finance lease liability, current	1,643,864	844,297
Accrued expenses and other payables - Balancing value	41,992,540	...
Total current liabilities	160,495,555	111,933,857
Deferred government grants, non-current	...	5,577,020
Product warranty provisions	522,574	450,613
Operating lease liability, non-current	475,302	607,222
Accrued expenses & other payables, non-current	6,203,488	1,085,525
Total liabilities	...	119,654,237
Common stock	90,063	89,135
Donated shares	14,101,689	14,101,689
Additional paid-in capital	247,465,817	246,240,998
Statutory reserves	1,230,511	1,230,511
Retained earnings (accumulated deficit)	(134,395,762)	(131,946,705)
Accumulated other comprehensive income (loss)	(11,601,403)	(8,153,644)
Less: treasury shares	4,066,610	4,066,610
Total shareholders' equity (deficit)	112,824,305	117,495,374
Non-controlling interests	634,036	6,883,123
Total equity	113,458,341	124,378,497

Recent Dividends:
1. CBAK Energy Technology Inc common.
No dividends paid.

Annual Dividends:
1. CBAK Energy Technology Inc common.
No dividends paid.

CELL MEDX CORP
Earnings, 6 mos. to Nov 30(Consol. - \$):

	2023	2022
Total revenues	...	2,466
Cost & expenses	93,616	279,519
Operating income	(137,500)	(297,498)
Interest expense	43,884	20,445
Net before taxes	(137,500)	(297,498)
Net income	(137,500)	(297,498)
Earnings common share
Common Shares:
Full Diluted	62,923,063	62,923,063
Year-end	62,923,063	62,923,063

CELLEX THERAPEUTICS, INC.
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Product development & licensing agreements	...	56,000	31,000
Contracts & grants	6,605,000	2,301,000	4,620,000
Product sales	...	278,000	...
Total revenue	6,883,000	2,357,000	4,651,000

Research & development expense	118,011,000	82,258,000	53,311,000
General & administrative expense	30,914,000	27,195,000	20,488,000
Intangible asset impairment	3,500,000
Gain on fair value remasurement of contingent consideration	...	6,862,000	1,405,000
Litigation settlement related loss	12,500,000	15,000,000	...
Operating income (loss)	(154,542,000)	(115,234,000)	(71,243,000)
Investment & other income, net	13,113,000	2,909,000	505,000
Net income (loss) before income taxes	(141,429,000)	(112,325,000)	(70,738,000)
Income tax provision (benefit) - federal	...	(17,484,000)	(18,513,000)
Income tax provision (benefit) - state	...	(9,606,000)	(7,082,000)
Expiration of NOLs & R&D credit	...	16,862,000	14,210,000
Deferred tax valuation allowance	...	10,228,000	11,158,000
Income tax expense (benefit)	(227,000)
Net income (loss)	(141,429,000)	(112,325,000)	(70,511,000)
Weighted average shares outstanding - basic	48,449,000	46,888,000	42,870,000
Weighted average shares outstanding - diluted	48,449,000	46,888,000	42,870,000
Year end shares outstanding	55,883,377	47,200,695	46,730,198
Income (loss) per share before cumulative effect of change in accounting principle - basic	\$(2.92)
Net income (loss) per share - basic	\$(2.92)	\$(2.40)	\$(1.64)
Income (loss) per share before cumulative effect of change in accounting principle - diluted	\$(2.92)
Net income (loss) per share - diluted	\$(2.92)	\$(2.40)	\$(1.64)
Number of full time employees	160	148	132
Number of part time employees	2
Total number of employees	160	...	134
Number of common stockholders	133	⊠⊡154	⊠⊢158

⊠ Approximately; ⊡ As of February 13, 2023; ⊢ As of February 17, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	34,814,000	29,429,000
Short-term investments	388,784,000	...
Marketable securities	...	275,523,000
Accounts & other receivables	2,628,000	347,000
Prepaid & other current assets	5,467,000	12,394,000
Total current assets	431,693,000	317,693,000
Laboratory equipment	9,848,000	9,250,000
Manufacturing equipment	2,419,000	2,558,000
Office furniture & equipment	3,738,000	3,454,000
Leasehold improvements	9,653,000	9,613,000

No dividends paid.

4. Celsius Holdings Inc series D preferred.
No dividends paid.

5. Celsius Holdings Inc 5% series A convertible preferred.
No dividends paid.

6. Celsius Holdings Inc series C preferred.
No dividends paid.

7. Celsius Holdings Inc preferred.
No dividends paid.

Annual Dividends:

1. Celsius Holdings Inc preferred.
No dividends paid.

After 3-for-1 split: No dividends paid.

3. Celsius Holdings Inc common.
No dividends paid.

4. Celsius Holdings Inc series D preferred.
No dividends paid.

5. Celsius Holdings Inc 5% series A convertible preferred.
No dividends paid.

6. Celsius Holdings Inc series C preferred.
No dividends paid.

7. Celsius Holdings Inc preferred.
No dividends paid.

CENTREX INC

Earnings, 3 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues	16,878,166	11,970,242
Cost & expenses	17,616,538	13,921,678
Operating income	(738,372)	(1,951,436)
Interest expense	583,683	1,128,234
Other income (expense), net	78,411	(17,083)
Net before taxes	(1,243,644)	(3,096,753)
Income taxes	70,751	...
Income contin. oper.	(1,314,395)	(3,096,753)
Net income	(1,303,903)	(6,336,374)
Earnings common share		
Primary	\$(1.16)	\$(8.24)
Fully Diluted	\$(1.16)	\$(8.24)
Common Shares:		
Full Diluted	1,047,624	761,571
Year-end	1,055,636	793,727

Consolidated Balance Sheet Items, as of (\$):

	2023	2022
Assets:		
Cash & equivalents	2,835,216	7,938,617
Inventories	7,938,617	26,411,336
Current assets	26,411,336	9,170,376
Net property & equip.	9,170,376	45,298,305
Total assets	45,298,305	...
Liabilities:		
Current liabilities	28,696,123	6,760,418
Long-term debt	6,760,418	6,755,441
Stockholders' equity	6,755,441	(2,284,787)
Net current assets	(2,284,787)	...

CENTURY CASINOS INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Gaming	412,388,000	365,986,000	331,877,000
Pari-mutuel, sports betting & iGaming	20,165,000	19,607,000	18,848,000
Hotel	42,269,000	9,628,000	8,286,000
Food & beverage	50,262,000	24,097,000	17,788,000
Other	25,122,000	11,211,000	11,707,000
Net operating revenue	550,206,000	430,529,000	388,506,000
Gaming	216,475,000	183,841,000	161,119,000
Pari-mutuel, sports betting & iGaming	21,752,000	22,149,000	19,735,000
Hotel	14,379,000	2,815,000	2,360,000
Food & beverage	45,065,000	22,631,000	16,523,000
Other	9,722,000
General & administrative	140,505,000	105,467,000	93,489,000
Depreciation & amortization	41,043,000	27,109,000	26,762,000
(Gain) on sale of casino operations	1,660,000
Loss on sale of assets	...	(2,154,000)	...
Earnings (loss) from equity investment	1,121,000	3,249,000	...

Earnings (loss) from operations	64,046,000	67,612,000	68,518,000
Interest income	2,114,000	851,000	174,000
Interest expense	93,925,000	65,831,000	42,832,000
Gain (loss) on foreign currency transactions, cost recovery income & other	3,933,000	3,378,000	2,289,000
Non-operating income (expense), net	(87,878,000)	(61,602,000)	(40,369,000)
Earnings (loss) before income taxes - United States	(30,793,000)	(10,142,000)	29,715,000
Earnings (loss) before income taxes - foreign	6,961,000	16,152,000	(1,566,000)
Earnings (loss) before income taxes	(23,832,000)	6,010,000	28,149,000
Provision (benefit) for U.S. federal income taxes - current	...	3,176,000	5,160,000
Provision (benefit) for U.S. federal income taxes - deferred	...	(14,981,000)	...
Total provision (benefit) for U.S. federal income taxes	...	(11,805,000)	5,160,000
Provision (benefit) for foreign income taxes - current	...	4,291,000	866,000
Provision (benefit) for foreign income taxes - deferred	...	(146,000)	345,000
Total provision (benefit) for foreign income taxes	...	4,145,000	1,211,000
US - Current	1,088,000
Foreign - Current	17,085,000
US - Deferred	(6,504,000)
Foreign - Deferred	(17,012,000)
Income tax expense (benefit)	(5,343,000)	(7,660,000)	6,371,000
Earnings (loss) from continuing operations before minority interest	(18,489,000)
Net earnings (loss)	(18,489,000)	13,670,000	21,778,000
Net earnings (loss) attributable to non-controlling interests	(9,709,000)	(5,694,000)	(1,156,000)
Net earnings (loss) attributable to Century Casinos, Inc. shareholders	(28,198,000)	7,976,000	20,622,000
Weighted average shares outstanding - basic	30,274,000	29,809,000	29,593,000
Weighted average shares outstanding - diluted	30,274,000	31,480,000	31,388,000
Year end shares outstanding	30,359,931	29,870,547	29,624,814
Earnings (loss) per share from continuing operations - basic	\$(0.93)
Net earnings (loss) per share - basic	\$(0.93)	\$0.27	\$0.70
Earnings (loss) per share from continuing operations - diluted	\$(0.93)
Net earnings (loss) per share - diluted	\$(0.93)	\$0.25	\$0.66
Number of full time employees	3,243	2,292	2,287

Number of part time employees	910	512	439
Number of common stockholders	144	124	141
Foreign currency translation adjustments	...	(9,739,000)	...
Total number of employees	4,153

□ Approximately; □ As of March 3, 2023; □ As of March 3, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	171,327,000	101,785,000
Receivables, net	18,253,000	9,085,000
Prepaid expenses	11,859,000	13,780,000
Inventories	4,652,000	1,530,000
Restricted cash	...	100,151,000
Other current assets	926,000	1,688,000
Total current assets	207,017,000	228,019,000
Land	44,662,000	43,654,000
Buildings & improvements	839,793,000	436,207,000
Gaming equipment	57,750,000	43,590,000
Furniture & non-gaming equipment	75,499,000	47,166,000
Property & equipment held under finance leases	1,028,000	764,000
Capital projects in process	53,072,000	18,954,000
Less: accumulated depreciation	158,243,000	125,685,000
Property & equipment, net	913,561,000	464,650,000
Leased right-of-use assets, net	25,973,000	27,190,000
Goodwill	80,583,000	9,583,000
Intangible assets, net	93,207,000	44,771,000
Equity investment	...	93,260,000
Deferred income taxes	37,646,000	15,579,000
Note receivable, net of current portion & unamortized discount	316,000	336,000
Deposits & other assets	1,359,000	1,579,000
Total assets	1,359,662,000	884,967,000
Current portion of long-term debt	8,468,000	5,322,000
Current portion of operating lease liabilities	3,395,000	3,947,000
Current portion of finance lease liabilities	199,000	150,000
Accounts payable	15,279,000	15,341,000
Accrued commissions (Alberta Gaming & Liquor Commission)	...	2,436,000
Progressive slot, table & on track liability	...	3,719,000
Player point liability	...	1,047,000
Chip liability	...	639,000
Racing-related liabilities	...	814,000
Deposit liability	...	368,000
Construction liability	2,297,000	3,562,000
Other accrued liabilities	...	6,427,000
Accrued payroll	16,221,000	11,840,000
Accrued property taxes	...	1,478,000
Gaming taxes payable	...	6,787,000
Other taxes payable	...	1,536,000
Taxes payable	21,001,000	9,801,000
Accrued liabilities - Balancing value	26,759,000	...
Total current liabilities	93,619,000	65,413,000
Credit agreement - Goldman	...	347,375,000
UniCredit term loans	...	4,661,000
Financing obligation - Century Downs Racetrack & Casino land lease	...	14,388,000
Deferred financing costs	...	(16,844,000)
Total long-term debt	...	349,580,000
Less: current portion	...	5,322,000
Long-term debt, net of

current portion & deferred financing costs	344,258,000	
Long-term debt, net of current portion & deferred financing costs	324,212,000	
Long-term financing obligation to VICI Properties, Inc. subsidiaries	658,007,000	284,904,000
Operating lease liabilities, net of current portion	25,834,000	26,016,000
Finance lease liabilities, net of current portion	427,000	399,000
Taxes payable & other liabilities	41,758,000	6,965,000
Deferred income taxes	1,364,000	2,813,000
Total liabilities	1,145,221,000	730,768,000
Common stock	304,000	299,000
Additional paid-in capital	124,094,000	121,653,000
Retained earnings (accumulated deficit)	9,067,000	37,265,000
Accumulated other comprehensive income (loss)	(12,073,000)	(15,189,000)
Total Century Casinos, Inc. shareholders' equity (deficit)	121,392,000	144,028,000
Non-controlling interests	93,049,000	10,171,000
Total equity	214,441,000	154,199,000

Recent Dividends:**1. Century Casinos Inc. common.**

No dividends paid.

2. Century Casinos Inc. Austrian Depository Certificate.

No dividends paid.

Annual Dividends:**1. Century Casinos Inc. common.**

No dividends paid.

2. Century Casinos Inc. Austrian Depository Certificate.

No dividends paid.

CEREVEL THERAPEUTICS HOLDINGS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021 (revised)
Research & development expenses	334,641,000	280,259,000	161,855,000
General & administrative expenses	112,624,000	87,589,000	58,243,000
Total operating expenses	447,265,000	367,848,000	220,098,000
Income (loss) from operations	(447,265,000)	(367,848,000)	(220,098,000)
Interest income, net	13,537,000	157,000	
Interest expense	3,918,000		
Interest income (expense), net	9,619,000	157,000	
Interest income, net	43,865,000		
Contractual interest expense	8,625,000		
Amortization of debt issuance costs	1,942,000		
Interest expense	10,567,000		
Gain (loss) on fair value remeasurement of financing liability, related party	(9,173,000)	3,438,000	(751,000)
Gain (loss) on fair value remeasurement of financing liability	(9,173,000)	3,438,000	(751,000)
Gain (loss) on fair value remeasurement of private placement warrants			(3,881,000)

Other income (expense), net	(18,372,000)	2,000	(10,000)
Other income (expense), net	(26,000)	(6,878,000)	5,393,000
Income (loss) before income taxes	(432,339,000)	(351,351,000)	(225,334,000)
Current state income tax provision (benefit)	503,000	160,000	2,000
Deferred federal income tax provision (benefit)			(2,000)
Income tax provision (benefit), net	503,000	160,000	
Net income (loss)	(432,842,000)	(351,511,000)	(225,334,000)
Net income (loss) attributable to common stockholders		(351,511,000)	(225,334,000)
Weighted average shares outstanding - basic	162,056,405	151,265,635	136,576,536
Weighted average shares outstanding - diluted	162,056,405	151,265,635	136,576,536
Year end shares outstanding	181,362,064	156,502,285	147,719,523
Net income (loss) per share - basic	\$(2.67)	\$(2.32)	\$(1.65)
Net income (loss) per share - diluted	\$(2.67)	\$(2.32)	\$(1.65)
Full-Time Employees (Period End)	334		
Total number of employees	334	298	200
Number of common stockholders	3	206	209
Earnings per share from continuing operations	\$(2.67)		
Earnings per share from continuing operations	\$(2.67)		

□ Reclassified to conform with 2022 presentation; □ Approximately; □ As of February 10, 2023; □ As of February 18, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	416,465,000	136,521,000
Marketable securities	574,500,000	755,509,000
Prepaid clinical trial services	1,717,000	2,872,000
Prepaid research & development expenses	1,821,000	1,228,000
Prepaid insurance	2,608,000	2,460,000
Other prepaid expenses	3,973,000	3,556,000
Interest receivable	5,291,000	2,046,000
Other current assets	563,000	1,459,000
Prepaid expenses & other current assets	15,973,000	13,621,000
Total current assets	1,006,938,000	905,651,000
Marketable securities	185,199,000	58,126,000
Computer equipment & software	459,000	996,000
Furniture & fixtures		459,000
Laboratory equipment	13,212,000	9,489,000
Leasehold improvements	23,481,000	23,461,000
Construction in progress	16,000	321,000
Less: accumulated depreciation	12,566,000	7,259,000
Computer equipment and software	1,045,000	
Property & equipment, net	25,647,000	27,467,000
Operating lease assets	20,125,000	21,820,000
Restricted cash	1,960,000	1,867,000
Other prepaid expenses, net of current portion	1,886,000	1,792,000
Deferred expenses associated with financing activities	122,000	286,000
Other long-term assets	3,429,000	813,000
Other long-term assets	1,421,000	2,891,000

Total assets	1,243,298,000	1,017,822,000
Accounts payable	11,863,000	10,061,000
Accrued external research & development services		33,967,000
Accrued compensation & personnel costs	19,423,000	19,057,000
Accrued property & equipment		40,000
Accrued professional fees & consulting services		2,187,000
Accrued interest	3,234,000	3,210,000
Other accrued expenses & other current liabilities		1,143,000
Accrued expenses & other current liabilities	53,086,000	59,604,000
Operating lease liabilities, current portion	3,404,000	2,899,000
Other	1,169,000	
Accrued expenses and other current liabilities - Balancing value	76,912,000	
Total current liabilities	92,179,000	72,564,000
Operating lease liabilities, net of current portion	27,786,000	31,190,000
Financing liability, related party	56,082,000	28,674,000
Financing liability	56,082,000	28,674,000
Convertible senior notes, net	337,424,000	335,482,000
Total liabilities	569,553,000	496,584,000
Common stock	18,000	16,000
Additional paid-in capital	2,072,553,000	1,485,880,000
Accumulated other comprehensive income (loss)	1,771,000	3,097,000
Retained earnings (accumulated deficit)	(1,400,597,000)	(967,755,000)
Total stockholders' equity (deficit)	673,745,000	521,238,000
Total Equity	673,745,000	

Recent Dividends:**1. Cerevel Therapeutics Holdings Inc class B ordinary.**

No dividends paid.

2. Cerevel Therapeutics Holdings Inc common.

No dividends paid.

3. Cerevel Therapeutics Holdings Inc class A ordinary.

No dividends paid.

Annual Dividends:**1. Cerevel Therapeutics Holdings Inc class B ordinary.**

No dividends paid.

2. Cerevel Therapeutics Holdings Inc common.

No dividends paid.

3. Cerevel Therapeutics Holdings Inc class A ordinary.

No dividends paid.

CFSB BANCORP INC (MD)**Earnings, 6 mos. to Dec 31 (Consol. - \$000):**

	2023	2022
Cost & expenses	5,846	4,417
Operating income	22	1,221
Net before taxes	22	1,221
Income taxes	109	235
Net income	(87)	986
Earnings common share		
Primary	\$(0.01)	\$0.16
Fully Diluted	\$(0.01)	\$0.16
Common Shares:		
Full Diluted	6,283	6,273
Year-end	6,633	6,522

CHAMPIONS ONCOLOGY INC**Earnings, 9 mos. to Jan 31 (Consol. - \$000):**

	2024	2023
Total revenues	36,153	
Cost & expenses	43,238	43,534
Operating income	(7,085)	(2,735)
Other income (expense), net	(33)	9
Net before taxes	(7,118)	(2,726)
Income taxes	49	48
Net income	(7,167)	(2,774)

Balance for common.....	(2,774)	- Number.....	64	Weighted average shares outstanding			
Earnings common share						- basic.....	74,985,000	69,729,000	67,185,000
Primary.....	\$(0.53)	\$(0.20)				Weighted average shares outstanding			
Fully Diluted.....	\$(0.53)	\$(0.20)				- diluted.....	74,985,000	69,729,000	67,185,000
Common Shares:						Year end shares outstanding.....	74,981,000	74,567,000	68,126,000
Full Diluted.....	13,538	13,533				Net income (loss) per common share from continuing operations - basic.....	\$(0.07)
Year-end.....	13,594	13,559				Net income (loss) per common share - basic.....	\$(0.07)	\$(0.24)	\$(0.40)

CHASE GENERAL CORP.

Earnings, 6 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues.....	2,449,291	2,442,221
Net Sales.....	2,449,291	2,442,221
Cost & expenses.....	2,368,176	2,124,154
Operating income.....	81,115	318,067
Interest expense.....	13,784	6,993
Other income (expense), net.....	803	774
Net before taxes.....	68,134	311,848
Income taxes.....	23,802	...
Net income.....	44,332	311,848
Balance for common.....	(19,704)	247,812
Earnings common share		
Primary.....	\$(0.02)	\$0.26
Fully Diluted.....	\$(0.02)	\$0.16
Common Shares:		
Full Diluted.....	969,834	2,003,168
Year-end.....	969,834	969,834

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents.....	4,928	12,068
Prepaid expenses & other assets.....	450	1,149
Other receivables - related party.....	...	73
Total current assets.....	5,378	13,290
Total assets.....	5,378	13,290
Accounts payable.....	6,570	11,535
Accrued compensation.....	1,206	1,195
Research & development.....	2,815	7,289
Other payables & accrued expenses.....	15,485	278
Accounts payable & accrued expenses - related party.....	...	20,297
Common stock warrant liabilities.....	...	1,306
Research and development.....	7,123	...
Other.....	586	...
Total current liabilities.....	18,425	32,773
Total liabilities.....	18,425	32,773
Common shares.....	...	1
Common stock issuable.....	3	1,885
Additional paid-in capital.....	297,864	241,117
Retained earnings (accumulated deficit).....	(314,333)	(262,486)
Common stock issuable.....	3,419	...
Total stockholders' equity (deficit).....	(13,047)	(19,483)
Total Equity.....	(13,047)	...

CHECKPOINT THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021
			(revised)
Revenue - related party.....	103
Revenue - related party.....	103	192	268
Research & development.....	43,566	49,825	48,453
General & administrative.....	8,685	8,700	8,538
Total operating expenses.....	52,251	58,525	56,991
Income (loss) from operations.....	(52,148)	(58,333)	(56,723)
Interest income.....	84	160	53
Gain (loss) on common stock warrant liabilities.....	(217)	4,451	...
Total other income (expense).....	301	(4,291)	53
Net income (loss).....	(51,847)	(62,624)	(56,670)
Weighted average shares outstanding			
- basic.....	18,742	8,836	7,603
Weighted average shares outstanding			
- diluted.....	18,742	8,836	7,603
Year end shares outstanding.....	27,742	10,287	8,457
Net earnings (loss) per share - basic.....	\$(3.17)	\$(7.09)	\$(7.45)
Net earnings (loss) per share - diluted.....	\$(3.17)	\$(7.09)	\$(7.45)
Number of full time employees.....	23
Total number of employees.....	23	24	14
Number of common shareholders.....	...	68	83
Number of class A common shareholders.....	...	1	1
Income from cont operations before income tax.....	(51,847)
Earnings per share from continuing operations.....	\$(3.17)
Earnings per share from continuing operations.....	\$(3.17)
Common Shareholders			

Recent Dividends:

1. Checkpoint Therapeutics Inc class A common.

No dividends paid.

2. Checkpoint Therapeutics Inc common.

No dividends paid.

Annual Dividends:

1. Checkpoint Therapeutics Inc class A common.

No dividends paid.

2. Checkpoint Therapeutics Inc common.

No dividends paid.

CHROMADEX CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
			(revised)
Total revenues.....	83,570,000
Sales, net.....	83,570,000	72,050,000	67,449,000
Cost of sales.....	32,790,000	29,253,000	25,959,000
Gross profit.....	50,780,000	42,797,000	41,490,000
Sales & marketing expense.....	26,438,000	28,313,000	28,352,000
Research & development expense.....	4,958,000	4,826,000	3,832,000
General & administrative expense.....	24,983,000	28,286,000	36,379,000
Total operating expenses.....	56,379,000	61,425,000	68,563,000
Operating income (loss).....	(5,599,000)	(18,628,000)	(27,073,000)
Other income, net - employee retention tax credit.....	...	2,085,000	...
Interest income (expense), net.....	661,000	3,000	(55,000)
Income (loss) before income taxes.....	(4,938,000)
Net income (loss).....	(4,938,000)	(16,540,000)	(27,128,000)

Net income (loss) per common share from continuing operations - basic.....	\$(0.07)
Net income (loss) per common share from continuing operations - diluted.....	\$(0.07)
Net income (loss) per common share - diluted.....	\$(0.07)
Number of full time employees.....	106	113	115
Total number of employees.....	106
Number of common stockholders.....	40	40	41

Reclassified to conform with 2022 presentation; Approximately As of March 6, 2023; As of March 9, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash - Balancing value.....	27,173,000	...
Cash.....	27,325,000	...
Cash & cash equivalents.....	...	20,441,000
Trade receivables, gross.....	2,502,000	6,504,000
Allowances.....	68,000	122,000
Receivables from related party.....	2,800,000	2,100,000
Trade receivables, net.....	5,234,000	8,482,000
Bulk ingredients.....	4,478,000	3,284,000
Reference standards.....	548,000	500,000
Consumer products - finished goods.....	5,962,000	7,901,000
Consumer products - work in process.....	3,537,000	2,992,000
Inventories, gross.....	14,525,000	...
Inventories.....	...	14,677,000
Prepaid expenses & other assets.....	2,450,000	2,967,000
Restricted cash.....	152,000	...
Total current assets.....	49,534,000	46,567,000
Laboratory equipment.....	3,272,000	3,268,000
Leasehold improvements.....	2,148,000	2,060,000
Computer equipment.....	...	602,000
Implementation costs - Cloud computing arrangements.....	665,000	1,075,000
Furniture & fixtures.....	...	176,000
Construction in progress.....	5,000	172,000
Leasehold improvements & equipment, gross.....	7,547,000	7,353,000
Leasehold improvements and equipment, gross.....	322,000	...
Implementation costs- cloud computing arrangements.....	1,135,000	...
Less accumulated depreciation.....	5,410,000	4,554,000
Leasehold improvements & equipment, net.....	2,137,000	2,799,000
Intangible assets, net.....	510,000	671,000
Right of use assets.....	2,400,000	3,523,000
Other long-term assets.....	383,000	497,000
Total assets.....	54,964,000	54,057,000
Accounts payable.....	10,232,000	9,679,000
Accrued expenses.....	9,493,000	7,337,000
Current maturities of operating lease obligations.....	691,000	680,000
Current maturities of		

finance lease obligations	11,000	16,000
Customer deposits	195,000	157,000
Total current liabilities	20,622,000	17,869,000
Deferred revenue	3,311,000	3,955,000
Operating lease obligations, less current maturities	2,563,000	3,539,000
Finance lease obligations, less current maturities	12,000	22,000
Total liabilities	26,508,000	25,385,000
Common stock	75,000	74,000
Additional paid-in capital	218,845,000	214,094,000
Retained earnings (accumulated deficit)	(190,460,000)	(185,493,000)
Cumulative translation adjustments	4,000	3,000
Total stockholders' equity	28,456,000	28,672,000
Total Equity	28,456,000	...

Year end shares outstanding	23,710	24,977	775
Net income (loss) per share - basic	\$(25.95)	\$(18.50)	\$(39.00)
Net income (loss) per share - diluted	\$(25.95)	\$(18.50)	\$(39.00)
Full-Time Employees (Period End)	183
Total number of employees	183	548	555
Number of common stockholders	482	589	584
Income tax benefit (expense)	(4)
Goodwill and intangible assets impairment	249,419
Comprehensive loss attributable to Cibus, Inc.	(267,619)

Financing lease obligations	113	...
Operating lease obligations	17,025	13,447
Long-term debt	536	...
Other non-current liabilities	1,868	79
Royalty liability - related parties	165,252	...
Total liabilities	206,117	15,188
Redeemable noncontrolling interest	44,824	...
Common stock	8	5
Additional paid-in capital	775,017	220,422
Common stock in treasury, at cost	1,785	1,043
Retained earnings (accumulated deficit)	(479,778)	(212,151)
Accumulated other comprehensive income (loss)	8	...
Total stockholders' equity (deficit)	293,470	7,233
Total Equity	293,470	...

Recent Dividends:**1. ChromaDex Corp common.**

No dividends paid.

Annual Dividends:**1. ChromaDex Corp common.**

No dividends paid.

CIBUS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31**

(\$000):

	2023	2022	2021 (revised)
Revenue	1,817
Revenue	1,817	157	25,987
Costs of goods sold	28,557
Gross margin	...	157	(2,570)
Research & development	...	11,553	11,335
Selling, general, & administrative expense	42,367	10,974	15,427
Selling & supply chain	28,914
Total operating expenses	(320,700)	(22,527)	(26,762)
Income (loss) from operations	(318,883)	(22,370)	(29,332)
Gain upon extinguishment of Payroll Protection Program loan	1,528
Interest expense	18,892	75	1,431
Interest income	...	60	17
Common stock warrants - financing cost amortization	527	(72)	...
Interest, net	...	(87)	(1,414)
Non-operating expenses (income)	...	(5,566)	(19)
Foreign currency transaction gain (loss)	(395)
Income (loss) before income taxes	(337,643)	(16,891)	(29,199)
Net loss attributable to redeemable noncontrolling interest	70,012
Net Income After Extraordinary Items applicable to Common	(267,627)
Net income (loss)	(337,639)	(16,891)	(29,199)
Weighted average shares outstanding - basic	10,315	920	750
Weighted average shares outstanding - diluted	10,315	920	750

Reclassified to conform with 2022 presentation; Adjusted for 1-for-10 stock split, April 25, 2023; Adjusted for 1-for-5 stock split, May 31, 2023; Shares increased due to the effect issuance of shares and exercise of pre-funded warrants; As is; As of February 28, 2023; As of March 3, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	32,699	3,427
Restricted cash	...	99
Accounts receivable	530	...
Prepaid expenses & other current assets	1,991	606
Total current assets	35,220	4,132
Buildings	900	900
Leasehold improvements	3,912	364
Office furniture & equipment	15,102	7,803
Office furniture & equipment under capital lease	373	414
Computer equipment & software	3,761	912
Construction in progress	704	...
Total land, buildings, & equipment	24,752	10,393
Less: accumulated depreciation	8,977	...
Less accumulated depreciation & amortization	...	5,877
Land, buildings, & equipment	15,775	4,516
Operating lease right-of-use assets	21,685	13,615
Other non-current assets	1,422	158
Goodwill	434,898	...
Intangible Assets - excluding Goodwill - Net
- Total	35,411	...
Total assets	544,411	22,421
Accounts payable	6,127	340
Accrued expenses	1,747	173
Accrued compensation	3,858	107
Due to related parties	...	175
Deferred revenue	1,210	...
Current portion of financing lease obligations	187	97
Common stock warrants	1,418	291
Other current liabilities	16	479
Current portion of notes payable	833	...
Current portion of operating lease obligations	5,927	...
Accrued consulting and professional fees	631	...
Accrued field trials	505	...
Other	611	...
Total current liabilities	21,323	1,662

Recent Dividends:**1. Cibus Inc common.**

No dividends paid.

2. Cibus Inc class B common.

No dividends paid.

3. Cibus Inc class A common.

No dividends paid.

Annual Dividends:**1. Cibus Inc common.**

No dividends paid.

2. Cibus Inc class B common.

No dividends paid.

3. Cibus Inc class A common.

No dividends paid.

CIBUS INC**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, Ernst & Young LLP, as it appeared in Co.'s 2023 10-K Report: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheet of Cibus, Inc. (the "Company") as of December 31, 2023, the related consolidated statements of operations, comprehensive loss, redeemable noncontrolling interest and stockholders' equity, and cash flows for the year then ended, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Going Concern Uncertainty The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has incurred recurring losses from operations and negative cash flows from operations. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

CITIUS PHARMACEUTICALS INC**Earnings, 3 mos. to Dec 31 (Consol. - \$):**

	2023	2022
Cost & expenses	9,340,823	7,249,883
Operating income	(9,340,823)	(7,249,883)
Interest income	253,638	214,549
Gains or losses	...	3,585,689
Net before taxes	(9,087,185)	(3,449,645)
Income taxes	144,000	144,000
Net income	(9,231,185)	(3,593,645)
Earnings common share		
Primary	\$(0.06)	\$(0.02)
Fully Diluted	\$(0.06)	\$(0.02)
Common Shares:		
Full Diluted	158,955,935	146,211,130
Year-end	158,966,576	146,211,130

Consolidated Balance Sheet Items, as of (\$):

Assets:	2023
Cash & equivalents	20,345,618
Current assets	28,210,114
Net property & equip.	854
Total assets	97,399,822
Liabilities:	
Current liabilities	5,578,819
Stockholders' equity	84,734,254
Net current assets	22,631,295

current assets	1,910,000	1,723,000
Provision - Accounts & Notes Receivable - Trade	1,400,000	...
Total current assets	36,172,000	51,180,000
Equipment	1,108,000	1,511,000
Furniture & fixtures	...	112,000
Leasehold improvements	485,000	201,000
Computer equipment & software	...	150,000
Loaned systems	741,000	601,000
Property & equipment, gross	2,334,000	2,575,000
Less accumulated depreciation & amortization	945,000	1,769,000
Property & equipment, net	1,389,000	806,000
Operating lease rights of use	3,564,000	1,895,000
Software license inventory	386,000	450,000
Licensing rights	1,041,000	1,028,000
Other assets	109,000	131,000
Total assets	42,661,000	55,490,000
Accounts payable	393,000	272,000
Accrued compensation	2,947,000	2,824,000
Other accrued liabilities	1,053,000	2,065,000
Operating lease liabilities, current portion	424,000	561,000
Deferred product & service revenue, current portion	2,613,000	1,066,000
Total current liabilities	7,430,000	6,788,000
Related party deferred revenue	541,000	...
Operating lease liabilities, net of current portion	3,568,000	1,532,000
Note payable	9,949,000	...
Deferred product & service revenue, net of current portion	...	390,000
2020 senior secured convertible note payable, net	...	9,893,000
Total liabilities	21,488,000	18,603,000
Common stock	247,000	246,000
Additional paid-in capital	193,382,000	187,008,000
Retained earnings (accumulated deficit)	(172,456,000)	(150,367,000)
Total stockholders' equity (deficit)	21,173,000	36,887,000
Total Equity	21,173,000	...

Inventories	27,646
Current assets	1,465,040
Net property & equip.	15,168
Total assets	1,625,532
Liabilities:	
Current liabilities	1,534,471
Stockholders' equity	22,844
Net current assets	(69,431)

CLEARPOINT NEURO INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):			
	2023	2022	¹ 2021 (revised)
Product revenue	10,603,000	12,789,000	11,913,000
Service & other revenue	13,352,000	7,762,000	4,386,000
Total revenue	23,955,000	20,551,000	16,299,000
Cost of revenues	10,341,000	7,020,000	5,176,000
Gross profit	13,614,000	13,531,000	11,123,000
Research & development costs	11,709,000	10,894,000	9,281,000
Selling & marketing expenses	...	9,358,000	7,217,000
General & administrative expenses	11,756,000	9,611,000	7,999,000
Selling, general & administrative expense	12,595,000
Operating income (loss)	(22,446,000)	(16,332,000)	(13,374,000)
Other income (expense), net	(29,000)	(22,000)	(63,000)
Interest expense, net	(386,000)	81,000	973,000
Income (loss) before taxes	(22,089,000)
Net income (loss)	(22,089,000)	(16,435,000)	(14,410,000)
Average shares outstanding-basic	24,605,212	24,181,854	20,734,236
Weighted average shares outstanding-diluted	24,605,212	24,181,854	20,734,236
Year end shares outstanding	24,652,729	24,578,983	² 23,665,991
Net income (loss) per share - basic	\$(0.90)	\$(0.68)	\$(0.69)
Net income (loss) per share - diluted	\$(0.90)	\$(0.68)	\$(0.69)
Number of full time employees	...	³ 108	⁴ 80
Number of common stockholders	230	⁵ 230	⁶ 225
Basic EPS Excluding ExtraOrdinary Items	\$(0.90)
Diluted EPS Excluding ExtraOrd Items	\$(0.90)

Recent Dividends:

- 1. ClearPoint Neuro Inc common.**
No dividends paid.
- 2. ClearPoint Neuro Inc series A convertible preferred.**
No dividends paid.

Annual Dividends:

- 1. ClearPoint Neuro Inc common.**
No dividends paid.
- 2. ClearPoint Neuro Inc series A convertible preferred.**
No dividends paid.

CLEARTRONIC, INC.

Earnings, 3 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues	606,047	506,650
Cost & expenses	635,423	489,035
Operating income	17,667	17,084
Other income (expense), net	44,052	...
Net before taxes	17,667	17,084
Net income	17,667	17,084
Balance for common	7,324	6,740
Earnings common share		
Common Shares:		
Full Diluted	599,482,330	599,331,678
Year-end	229,160,695	228,780,695

Consolidated Balance Sheet Items, as of (\$):

Assets:	2023
Cash & equivalents	818,525

CLENE INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	¹ 2021 (revised)
Product revenue	498,000	329,000	570,000
Royalty revenue	156,000	144,000	153,000
Total revenue	654,000	473,000	723,000
Cost of revenue	121,000	26,000	289,000
Research & development	26,655,000	31,920,000	28,416,000
General & administrative	14,418,000	16,936,000	21,996,000
Total operating expenses	41,194,000	48,882,000	50,701,000
Operating income (loss)	...	(48,409,000)	(49,978,000)
Interest income	1,389,000
Interest expense	4,558,000	3,296,000	870,000
Gain (loss) on extinguishment of notes payable	648,000
Gain on termination of lease	10,000	420,000	...
Change in fair value of common stock warrant liability	6,337,000	169,000	983,000
Change in fair value of Clene Nanomedicine contingent earn-out liability	2,189,000	15,836,000	33,953,000
Change in fair value of Initial Stockholders contingent earn-out liability	281,000	2,026,000	3,589,000
Australia research & development credit	(402,000)
Research & development tax credits & unrestricted grants	963,000	3,079,000	1,519,000
Other income (expense), net	...	257,000	(12,000)
Loss on initial issuance of equity	(14,840,000)
Issuance costs for common stock warrant liability	(333,000)
Total other income (expense), net	(8,964,000)	18,491,000	39,810,000
Income (loss) before income taxes - United States	(48,578,000)	(26,941,000)	(6,269,000)
Income before income taxes - Foreign	(926,000)	(2,977,000)	(3,899,000)
Income (loss) before income taxes	(49,504,000)	(29,918,000)	(10,168,000)
Current foreign income taxes	(146,000)
Current income taxes	(146,000)
Deferred foreign income taxes	(282,000)
Deferred income taxes	(282,000)
Income tax benefit (expense)	(428,000)
Net income (loss)	(49,504,000)	(29,918,000)	(9,740,000)
Net income (loss) attributable to Tottenham			

¹ Reclassified to conform with 2022 presentation; ² Shares increased due to the effect of conversion of 2020 senior secured convertible notes; and issuances of common stock for public offering compensation, share-based compensation and warrant exercise; ³ As of February 15, 2023; ⁴ As of March 3, 2022; ⁵ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	23,140,000	27,615,000
Short-term investments	...	9,874,000
Accounts receivable - Balancing value	4,611,000	...
Accounts receivable, net	3,211,000	2,665,000
Raw materials & work in process	6,466,000	6,513,000
Software licenses	211,000	210,000
Finished goods	1,234,000	2,580,000
Inventory	7,911,000	...
Inventory, net	...	9,303,000
Prepaid expenses & other

Acquisition I Limited	(29,918,000)	(9,740,000)	
Weighted average shares outstanding - basic	104,938,819	65,204,663	61,558,455
Weighted average shares outstanding - diluted	104,938,819	65,204,663	61,558,455
Year end shares outstanding	128,422,851	74,759,591	62,312,097
Net earnings per share (loss) - basic	\$(0.47)	\$(0.46)	\$(0.16)
Net earnings per share (loss) - diluted	\$(0.47)	\$(0.46)	\$(0.16)
Number of full time employees	82	75	95
Number of part time employees	...	11	7
Total number of employees	82	86	102
Common Shareholders - Number	65
Number of stockholders	...	70	80
Foreign currency translation adjustments	...	(16,000)	(92,000)

□ Reclassified to conform with 2022 presentation; □ As of March 9, 2023; □ As of March 8, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	28,821,000	18,332,000
Marketable securities	6,179,000	4,983,000
Accounts receivable	143,000	189,000
Raw materials	...	29,000
Finished goods	...	14,000
Inventories - Raw
Materials - Net	23,000	...
Inventories - Finished
Goods	14,000	...
Inventory	37,000	43,000
Research & development tax credits receivable	1,195,000	2,777,000
Metals to be used in research & development	1,909,000	2,290,000
Other prepaid expenses & current assets	...	581,000
Prepaid expenses & other current assets	3,672,000	5,648,000
Other	568,000	...
Total current assets	38,852,000	29,195,000
Restricted cash	58,000	58,000
Right-of-use assets	4,168,000	4,602,000
Lab equipment	4,092,000	3,934,000
Office equipment	178,000	177,000
Computer software	459,000	459,000
Leasehold improvements	9,983,000	5,677,000
Construction in progress	1,438,000	5,664,000
Property, plant & equipment, gross	16,150,000	15,911,000
Less: Accumulated depreciation	6,887,000	5,273,000
Property & equipment, net	9,263,000	10,638,000
Total assets	52,341,000	44,493,000
Accounts payable	1,504,000	3,014,000
Accrued compensation & benefits	2,120,000	2,007,000
Accrued CRO & clinical fees	...	1,297,000
Deferred grant funds	...	520,000
Other accrued liabilities	...	39,000
Accrued liabilities - Balancing value	1,600,000	...
Accrued liabilities	3,720,000	3,863,000
Operating lease obligations, current portion	576,000	488,000
Finance lease obligations, current

portion	27,000	74,000
Notes payable, current portion	14,627,000	6,418,000
Convertible notes payable, current portion	4,876,000	...
Total current liabilities	25,330,000	13,857,000
Operating lease obligations, net of current portion	4,903,000	5,557,000
Finance lease obligations, net of current portion	...	34,000
Notes payable	1,894,000	...
Notes payable, net of current portion	...	9,483,000
Convertible notes payable	5,258,000	9,770,000
Common stock warrant liability	1,481,000	...
Clene Nanomedicine contingent earn-out liability	75,000	2,264,000
Initial Shareholders contingent earn-out	10,000	291,000
Total liabilities	38,951,000	41,256,000
Common stock	13,000	7,000
Additional paid-in capital	255,901,000	196,246,000
Retained earnings (accumulated deficit)	(242,723,000)	(193,219,000)
Accumulated other comprehensive income	199,000	203,000
Total stockholders' equity	13,390,000	3,237,000
Total Equity	13,390,000	...

Recent Dividends:

1. Clene Inc common.
No dividends paid.

Annual Dividends:

1. Clene Inc common.
No dividends paid.

CO-DIAGNOSTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Grant revenue	5,820,565
Net sales	991,473
Revenue	6,812,038	34,218,209	97,885,603
Cost of revenue	4,184,949	5,481,092	11,574,944
Gross profit	2,627,089	28,737,117	86,310,659
Selling & marketing	6,860,815	7,344,628	13,397,813
General & administrative	14,279,441	14,262,963	11,550,615
Research & development	22,962,593	17,438,098	14,961,916
Depreciation & amortization	1,230,474	1,282,718	335,363
Goodwill impairment charges	...	15,388,546	...
Total operating expenses	45,333,323	55,716,953	40,245,707
Income (loss) from operations	(42,706,234)	(26,979,836)	46,064,952
Interest income	1,161,913	704,044	45,631
Gain (loss) on disposition of assets	2,243,059	(138,117)	(44,355)
Change in fair value of acquisition contingencies	...	7,899,644	...
Gain (loss) from equity method investment	...	(332,969)	(430,433)
Gain (loss) on equity method investment in joint venture	100,703
Loss on disposition of assets	(2,578)
Gain on

remeasurement of acquisition contingencies	(1,092,581)
Total other income (expense), net	4,595,678	8,132,602	(429,157)
Income (loss) before income taxes	(38,110,556)	(18,847,234)	45,635,795
Current state income tax provision	84,435	(266,248)	886,173
Current federal income tax provision	(540,240)	563,821	6,092,730
Total current income tax provision	(455,805)	297,573	6,978,903
Deferred federal income tax provision	(2,068,509)	(3,945,090)	1,394,686
Deferred state income tax provision	(7,228,611)	(961,468)	603,642
Change in valuation allowance	6,975,234
Total deferred income tax provision	(2,321,886)	(4,906,558)	1,998,328
Income tax provision (benefit)	(2,777,691)	(4,608,985)	8,977,231
Net income (loss)	(35,332,865)	(14,238,249)	36,658,564
Weighted average shares outstanding - basic	29,346,599	31,479,028	28,874,555
Weighted average shares outstanding - diluted	29,346,599	31,479,028	29,903,686
Year end shares outstanding	31,259,668	30,872,607	33,819,862
Net income (loss) per common share - basic	\$(1.20)	\$(0.45)	\$1.27
Net income (loss) per common share - diluted	\$(1.20)	\$(0.45)	\$1.23
Number of full time employees	155
Total number of employees	155	145	101
Number of common stockholders	154	154	154

□ Approximately; □ As of March 14, 2023; □ As of March 22, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	14,916,878	22,973,803
Marketable investment securities	43,631,510	58,289,066
Account receivables, gross	504,264	6,552,249
Allowance for uncollectable accounts	200,338	3,098,526
Accounts receivable, net	303,926	3,453,723
Finished goods	700,467	1,327,264
Raw materials	964,258	3,983,209
Inventory	1,664,725	5,310,473
Income taxes receivable	26,955	1,870,419
Note receivable	...	75,000
Prepaid expenses & other current assets	1,597,114	761,186
Total current assets	62,141,108	92,733,670
Lab equipment	4,545,908	3,574,730
Leasehold improvements	548,648	224,957
Office equipment, furniture & other	173,668	112,044
Less: Accumulated depreciation	2,232,495	...
Less accumulated depreciation & amortization	...	1,372,248
Property & equipment, net	3,035,729	2,539,483
Operating right use of

				Consolidated Balance Sheet, Years Ended Oct. 31 (\$):					
				2023		2022			
Other income, net	330,000	88,000	117,000	Cash & cash equivalents	15,861,000	7,482,000	Operating lease obligations, non-current	20,458,000	20,984,000
Total other income (expense)	(20,890,000)	(15,909,000)	(50,477,000)	Trade receivables, gross	63,954,000	63,782,000	Finance lease obligations, non-current	50,000	169,000
Income (loss) before income taxes - United States	32,252,000	(13,162)		Less: allowance for doubtful accounts	978,000	900,000	Deferred income taxes	80,791,000	74,223,000
Income (loss) before income taxes - foreign	1,950,000	731		Trade receivables, net	62,976,000	62,882,000	Warrant liability	7,030,000	
Income (loss) before income taxes	40,562,000	34,202,000	(12,431,000)	Inventory	6,732,000		Other liabilities, non-current	14,142,000	
Current tax provision (benefit) - federal	1,945,000			Inventory, net	5,532,000		Total liabilities	571,285,000	583,162,000
Current tax provision (benefit) - foreign	(113,000)	(375,000)		Income taxes receivable	485,000		Zero-dividend convertible perpetual preferred stock	25,000,000	25,000,000
Current tax provision (benefit) - state & local	690,000	434,000	470,000	Prepaid insurance	1,550,000		Common stock	6,000	6,000
Current tax provision (benefit)	2,635,000	321,000	95,000	Prepaid licenses & deposits	751,000		Additional paid-in capital	383,286,000	379,395,000
Deferred tax provision (benefit) - federal	4,567,000	4,575,000	483,000	Prepaid rent	402,000		Treasury stock	15,114,000	4,609,000
Deferred tax provision (benefit) - foreign	753,000	70,000	2,134,000	Other current assets & prepaids	2,472,000		Accumulated other comprehensive income (loss)	(5,491,000)	(9,228,000)
Deferred tax provision (benefit) - state & local	817,000	560,000	(70,000)	Prepaid expenses & other current assets	8,701,000	5,175,000	Retained earnings (accumulated deficit)	(54,447,000)	(86,237,000)
Deferred income tax provision (benefit)	6,137,000	5,205,000	2,547,000	Total current assets	94,270,000	81,556,000	Total stockholders' equity	308,240,000	279,327,000
Income tax expense (benefit)	8,772,000	5,526,000	2,642,000	Land, building & improvements	29,338,000	28,528,000	Total Equity	308,240,000	
Net income (loss)	31,790,000	28,676,000	(15,073,000)	Finance leases - land & buildings	828,000				
Less accretion of liquidation preference on preferred stock	1,750,000	1,750,000	1,750,000	Machinery & equipment	517,514,000	478,162,000			
Undistributed earnings allocated to participating securities	1,017,000			Transportation equipment	9,306,000	7,133,000			
Income (loss) available to common shareholders	29,023,000	26,926,000	(16,823,000)	Furniture & office equipment	3,817,000	3,870,000			
Weighted average common shares outstanding - basic	53,276,450	53,914,311	53,413,594	Capital leases - land & buildings	828,000				
Weighted average common shares outstanding - diluted	54,173,731	54,851,308	53,413,594	Property, plant & equipment, gross	560,803,000	518,521,000			
Year end shares outstanding	54,757,445	56,226,191	56,564,642	Less: accumulated depreciation	133,155,000	99,144,000			
Net income (loss) per common share - basic	\$0.54	\$0.48	\$(0.31)	Property, plant & equipment, net	427,648,000	419,377,000			
Net income (loss) per common share - diluted	\$0.54	\$0.47	\$(0.31)	Intangible assets, net	120,244,000	137,754,000			
Full-Time Employees (Period End)	1,720			Goodwill	221,517,000	220,245,000			
Total number of employees	1,720	1,650	1,300	Right-of-use operating lease assets	24,815,000	24,833,000			
Number of common stockholders	134	129	126	Other non-current assets	14,250,000	2,026,000			
Foreign currency translation adjustments	(12,899,000)		4,277,000	Deferred financing costs	1,781,000	1,698,000			
EPS - Basic - excluding Extraordinary Items				Total assets	904,525,000	887,489,000			
Applicable to Common - Total	\$0.54			Revolving loan	18,954,000	52,133,000			
EPS - Diluted - excluding Extraordinary Items				Operating lease obligations, current portion	4,739,000	4,001,000			
Applicable to Common - Total	\$0.54			Finance lease obligations, current portion	125,000	109,000			
				Accounts payable	8,906,000	8,362,000			
				Accrued vacation	2,705,000				
				Accrued payroll	2,763,000				
				Accrued bonus	4,835,000				
				Accrued employee-related taxes	2,760,000				
				Other accrued payroll & payroll expenses	14,524,000	278,000			
				Accrued payroll & payroll expenses	13,341,000				
				Accrued insurance	12,133,000				
				Accrued interest	5,775,000	5,996,000			
				Accrued equipment purchases	7,644,000				
				Accrued sales & use tax	846,000				
				Accrued property taxes	825,000				
				Accrued professional fees	831,000				
				Other accrued expenses & other current liabilities	3,881,000				
				Accrued expenses & other current liabilities	130,000	32,156,000			
				Income taxes payable	178,000				
				Franchise tax payable	1,848,000				
				Accrued expenses and other current liabilities - Balancing value	28,975,000				
				Accrued expenses and other current liabilities - Balancing value	34,750,000				
				Total current liabilities	83,976,000	110,280,000			
				Long term debt, net of discount for deferred financing costs	371,868,000				
				Long-term debt, net	370,476,000				

Recent Dividends:

- Concrete Pumping Holdings Inc series A zero-dividend convertible perpetual preferred.**
No dividends paid.
- Concrete Pumping Holdings Inc common.**
No dividends paid.
- Concrete Pumping Holdings Inc class A common.**
No dividends paid.
- Concrete Pumping Holdings Inc class A common - shares subject to possible redemption.**
No dividends paid.
- Concrete Pumping Holdings Inc redeemable preferred.**
No dividends paid.
- Concrete Pumping Holdings Inc class B common.**
No dividends paid.

Annual Dividends:

- Concrete Pumping Holdings Inc series A zero-dividend convertible perpetual preferred.**
No dividends paid.
- Concrete Pumping Holdings Inc common.**
No dividends paid.
- Concrete Pumping Holdings Inc class A common.**
No dividends paid.
- Concrete Pumping Holdings Inc class A common - shares subject to possible redemption.**
No dividends paid.
- Concrete Pumping Holdings Inc redeemable preferred.**
No dividends paid.
- Concrete Pumping Holdings Inc class B common.**
No dividends paid.

CORCEPT THERAPEUTICS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Product sales, net	482,375		
Product revenue, net		401,858	365,978
Cost of sales	6,481	5,385	5,281
Research & development	184,353	130,991	113,864
Selling, general & administrative	184,259	152,848	122,356
Settlement expense related to Melucci litigation		14,000	
Insurance recovery related to Melucci litigation		14,000	
Total operating expenses	375,093	289,224	241,501
Income (loss) from operations	107,282	112,634	124,477
Interest & other income	17,275	3,557	529
Income (loss) before income taxes - U.S.		116,871	126,308

Reclassified to conform with 2022 presentation; Approximately: As of January 30, 2023

notes	12,965,480	
Deferred collaboration revenue	574,685	
Total liabilities	5,626,665	16,789,111
Series A convertible preferred stock	8,793,637	
Common stock	1,441	259
Additional paid-in capital	61,501,801	681,106
Retained earnings (accumulated deficit)	(25,856,383)	(17,868,547)
Subscription receivables	(11,250)	
Total stockholders' equity (deficit)	35,635,609	(8,393,545)
Total Equity	35,635,609	

Recent Dividends:
1. Coya Therapeutics Inc common.
 No dividends paid.

Annual Dividends:
1. Coya Therapeutics Inc common.
 No dividends paid.

CPI CARD GROUP INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Products (exclusive of depreciation and amortization shown below)	161,374		
Services (exclusive of depreciation and amortization shown below)	117,397		
Net sales - products	249,354	281,190	199,586
Net sales - services	195,193	194,555	175,533
Total net sales	444,547	475,745	375,119
Cost of sales - products (exclusive of depreciation & amortization)		171,017	121,601
Cost of sales - services (exclusive of depreciation & amortization)		119,930	103,255
Depreciation & amortization	10,287	9,031	8,837
Total cost of sales	289,058	299,978	233,693
Gross profit	155,489	175,767	141,426
Selling, general & administrative (exclusive of depreciation & amortization)	88,255	90,782	75,701
Depreciation & amortization	5,644	5,855	6,261
Total operating expenses	93,899	96,637	81,962
Income (loss) from operations	61,590	79,130	59,464
Interest expense, net	26,913	29,616	30,608
Gain (loss) on debt extinguishment		(474)	(5,048)
Other income (expense), net	(215)	107	14
Total other income (expense), net	(27,128)	(29,983)	(35,642)
Income (loss) before income taxes - domestic	34,400	49,108	23,761
Income (loss) before income taxes - foreign	62	39	61
Income (loss) before income taxes	34,462	49,147	23,822
Current domestic income tax expense (benefit)	10,126	11,047	10,038

Current foreign income tax expense (benefit)	20	5	(1)
Total current income tax expense (benefit)	10,146	11,052	10,037
Deferred domestic income tax expense (benefit)	331	1,554	(2,154)
Deferred foreign income tax expense (benefit)		1	(2)
Total deferred income tax expense (benefit)	331	1,555	(2,156)
Income tax expense (benefit)	10,477	12,607	7,881
Net income (loss)	23,985	36,540	15,941
Weighted average shares outstanding - basic	11,426	11,291	11,239
Weighted average shares outstanding - diluted	11,918	11,749	11,764
Year end shares outstanding	11,446	11,390	11,255
Earnings (loss) per share - continuing operations - basic	\$2.10		
Net earnings (loss) per share - basic	\$2.10	\$3.24	\$1.42
Earnings (loss) per share - continuing operations - diluted	\$2.01		
Net earnings (loss) per share - diluted	\$2.01	\$3.11	\$1.36
Number of full time employees	1,448	1,375	1,150
Number of common stockholders	23	25	27
Total number of employees	1,448		

[□] Reclassified to conform with 2022 presentation; [□] As is; [□] Approximately; [□] As of March 1, 2023; [□] As of February 22, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	12,413	11,037
Trade accounts receivable	69,245	68,886
Unbilled accounts receivable	73,724	11,915
Accounts receivable, gross	4,725	80,801
Less allowance for doubtful accounts	246	218
Accounts receivable, net		80,583
Raw materials	66,210	61,434
Finished goods	7,162	10,300
Inventory reserve	(2,778)	(3,335)
Inventories	70,594	68,399
Prepaid expenses & other current assets	8,647	7,379
Income taxes receivable		172
Total current assets	165,378	167,570
Machinery & equipment	67,506	64,786
Machinery & equipment under financing leases	23,774	15,717
Furniture, fixtures & computer equipment	107	3,072
Leasehold improvements	16,335	14,703
Construction in progress	1,778	3,304
Plant, equipment, leasehold improvements & operating lease right-of-use assets, gross	129,489	101,582
Less accumulated depreciation & amortization	66,436	55,109
Operating right-of-use assets	19,989	

Operating lease right-of-use assets, net of accumulated amortization		10,705
Plant, equipment, leasehold improvements & operating lease right-of-use assets, net	63,053	57,178
Intangible assets, net	14,122	17,988
Goodwill	47,150	47,150
Other assets	3,980	6,780
Total assets	293,683	296,666
Accounts payable	12,802	24,371
Other	5,989	
Accrued employee performance bonuses	667	
Employer payroll taxes	298	
Accrued Expenses - Balancing value	35,803	
Accrued payroll and related employee expenses	11,431	
Accrued rebates	2,919	
Estimated sales tax liability	351	
Accrued expenses		40,070
Deferred revenue & customer deposits	840	3,571
Accrued Interest	6,830	
Current Portion of Finance Leases	4,779	
Operating Lease Liabilities - Current Portion/Short-Term	2,539	
Current operating and financing lease liabilities	7,318	
Total current liabilities	49,445	68,012
Senior notes		285,000
ABL revolver		5,000
Unamortized deferred financing costs		(4,478)
Total long-term debt		285,522
Deferred income taxes	7,139	6,808
Other long-term liabilities	24,038	18,401
Total liabilities	345,619	378,743
Common stock	11	11
Additional paid-in capital (capital deficiency)	(102,223)	(108,379)
Retained earnings (accumulated loss)	50,276	26,291
Total stockholders' equity (deficit)	(51,936)	(82,077)
Total Equity	(51,936)	

Recent Dividends:
1. CPI Card Group Inc common.
 No dividends paid.
Annual Dividends:
1. CPI Card Group Inc common.
 No dividends paid.

CPS TECHNOLOGIES CORP

Annual Report

Consolidated Income Statement, Years Ended (\$):

	12/30/23	12/31/22	12/25/21
Product sales	27,550,646	26,586,926	22,449,065
Total revenues	27,550,646		
Cost of product sales	20,725,237	19,285,846	17,659,347
Gross margin	6,825,409	7,301,080	4,789,718
administrative expense	5,126,046		
Selling, general & administrative expenses		5,066,660	4,276,751
Income (loss) from operations	1,699,363	2,234,420	512,967
Other income (expense)	27,261	653,248	(4,068)
Interest income (expense)	225,757		

Income (loss) before income tax	1,952,381	2,887,668	508,899
Current federal income tax provision (benefit)	81,919	1,270	...
Current state income tax provision (benefit)	456	456	11,967
Current income tax provision (benefit)	82,375	1,726	11,967
Deferred federal income tax provision (benefit)	357,507	577,866	(2,156,278)
Deferred state income tax provision (benefit)	142,203	176,676	(562,667)
Deferred income tax provision (benefit), net	499,710	754,542	(2,718,945)
Income tax provision (benefit)	582,085	756,268	(2,706,978)
Net income (loss)	1,370,296	2,131,400	3,215,877
Weighted average shares outstanding - basic	14,495,709	14,424,381	14,061,320
Weighted average shares outstanding - diluted	14,628,811	14,675,646	14,590,725
Year end shares outstanding	14,519,215	14,450,470	14,350,451
Net income (loss) per common share - basic	\$0.09	\$0.15	\$0.23
Net income (loss) per common share - diluted	\$0.09	\$0.15	\$0.22
Number of full time employees	100	86	90
Total number of employees	100
Number of common stockholders	80	100	100
Basic EPS Excluding ExtraOrdinary Items	\$0.09
Diluted EPS Excluding ExtraOrd Items	\$0.09
Income tax provision	582,085

Approximately

Consolidated Balance Sheet, Years Ended (\$):

12/30/23 12/31/22

Cash & cash equivalents	8,813,626	8,266,753
Accounts receivable - trade, gross	...	3,787,975
Allowance for doubtful accounts	...	10,000
Accounts receivable - trade, net	4,389,155	3,777,975
Accounts receivable - other	83,191	685,668
Raw materials	2,861,333	2,645,442
Work in process	1,493,582	1,863,512
Finished goods	537,975	525,872
Gross inventory	4,581,930	5,034,826
Less: reserve for obsolescence	310,960	158,925
Inventories	...	4,875,901
Prepaid expenses & other current assets	276,349	211,242
Total current assets	18,144,251	17,817,539
Production equipment	11,271,982	10,770,427
Furniture & office equipment	952,883	952,883
Leasehold improvements	985,649	985,649
Total cost property & equipment	13,210,514	12,708,959
Accumulated depreciation & amortization	11,936,004	11,446,901
Construction in progress	281,629	64,910
Net property & equipment	1,556,139	1,326,968
Right-of-use lease asset	332,000	466,000

Deferred taxes, net	1,569,726	2,069,436
Total assets	21,602,116	21,679,943
Notes payable, current portion	46,797	43,711
Accounts payable	2,535,086	1,836,865
Accrued legal & accounting	86,000	35,398
Accrued payroll & related costs	649,201	760,305
Accrued other expenses	...	25,153
Accrued other	339,936	...
Accrued expenses	1,075,137	820,856
Deferred revenue	251,755	2,521,128
Current lease liability	160,000	157,000
Total current liabilities	4,068,775	5,379,560
Notes payable less current portion	8,090	54,847
Long term lease liability	172,000	309,000
Deferred revenue - long term	31,277	231,020
Total liabilities	4,280,142	5,974,427
Common stock	146,015	144,605
Additional paid-in capital	40,180,893	39,726,851
Retained earnings (accumulated deficit)	(22,754,796)	(24,125,092)
Less cost of common shares repurchased	250,138	40,848
Total stockholders' equity (deficit)	17,321,974	15,705,516
Total Equity	17,321,974	...

Recent Dividends:

1. CPS Technologies Corp common.

No dividends paid.

Annual Dividends:

1. CPS Technologies Corp common.

No dividends paid.

CRAWFORD UNITED CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

2023 2022 2021 (revised)

Total sales	143,885,934	127,754,927	104,162,227
Cost of sales	106,239,852	100,722,146	82,249,762
Gross profit	37,646,082	27,032,781	21,912,465
Selling, general & administrative expenses	19,713,611	18,499,309	14,922,213
Operating income (loss)	17,932,471	8,533,472	6,990,252
Interest charges	1,255,984	1,138,224	881,741
PPP loan forgiveness	1,453,837
Unrealized gain (loss) on investments	...	(860,273)	(188,615)
Realized gain (loss) on investments	152,761
Other expense, net	(480,331)	(1,197,218)	163,552
Loss (Gain) on investments in equity securities	7,330
Total other income (expenses), net	(768,323)	(801,279)	372,690
Income (loss) before provision for income taxes	17,164,148	7,732,194	7,362,942
Provision for (recovery of) income taxes - current	4,817,023	2,629,560	1,183,145
Provision for (recovery of) income taxes - deferred	(947,668)	(1,458,769)	526,499
Total provision for (recovery of) income taxes	3,869,355	1,170,791	1,709,644
Net income (loss)	13,294,793	6,561,403	5,653,298
Net income to common stockholders	...	6,561,403	5,653,298

Weighted average shares outstanding - basic	3,507,883	3,462,868	3,405,061
Weighted average shares outstanding - diluted	3,526,836	3,462,868	3,405,061
Year end shares outstanding	3,510,740	3,475,885	3,410,791
Income (loss) per common share - continuing operations - basic	\$3.79
Net income (loss) per common share - basic	\$3.79	\$1.89	\$1.66
Income (loss) per common share - continuing operations - diluted	\$3.77
Net income (loss) per common share - diluted	\$3.77	\$1.89	\$1.66
Number of full time employees	405	387	451
Total number of employees	405
Number of class A common stockholders	...	162	154
Number of class B common stockholders	...	7	7
Total Revenue	143,885,934
Number of Common Shareholders	147

As reported by the Company; Approximately; As of February 18, 2023; As of March 18, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

2023 2022

Cash & cash equivalents	1,647,175	1,247,627
Short-term investments - available for sale	665,301	...
Accounts receivable, gross	19,777,056	22,028,438
Less: allowance for doubtful accounts	105,223	143,631
Accounts receivable less allowance for doubtful accounts	19,671,833	21,884,807
Contract assets	4,822,347	3,284,301
Raw materials & component parts	3,989,444	2,892,820
Work-in-process	4,514,263	5,158,252
Finished products	9,846,694	13,483,017
Total inventory	(677,779)	21,534,089
Less: inventory reserves	...	1,357,947
Inventories less allowance for obsolete inventory	17,672,622	20,176,142
Investments	...	657,971
Prepaid expenses & other current assets	1,303,780	1,522,516
Total current assets	45,783,058	48,773,364
Land	...	231,034
Land & improvements	231,034	...
Buildings	3,760,203	...
Buildings & improvements	28,842,940	3,222,243
Machinery & equipment	24,851,703	23,301,660
Total property, plant & equipment	...	26,754,937
Less accumulated depreciation	14,156,750	11,541,494
Property, plant & equipment, net	14,686,190	15,213,443
Operating right of use assets, net	8,356,903	9,524,280
Goodwill	16,453,049	16,231,938
Intangibles, net of accumulated amortization	8,252,600	9,492,560
Other non-current assets	107,798	362,489
Total assets	93,639,598	99,598,074
Notes payable - current	...	1,303,972

Bank debt - current	222,222	
Leases payable	1,705,224	
Accounts payable	11,168,308	14,017,973
Unearned revenue	5,596,706	4,354,868
Current portion of long-term debt	824,226	
Accrued income taxes	539,876	1,239,289
Accrued expenses	3,292,787	3,224,188
Operating lease liabilities - current	1,714,174	
Total current liabilities	23,136,077	26,067,736
Notes payable	5,096,672	1,846,405
Term debt		222,222
Revolving debt		19,281,119
Total bank debt		19,503,341
Less: current portion		222,222
Non-current bank debt		19,281,119
Less: unamortized debt costs	(56,801)	
Bank debt	19,224,318	
Leases payable	8,060,152	
Deferred income taxes	310,250	1,384,558
Convertible notes payable - related party	470,209	
Operating lease liabilities - noncurrent	6,901,043	
Total long-term liabilities	12,778,174	30,515,433
Class A shares	8,878,986	7,351,563
Class B shares	1,465,522	1,465,522
Contributed capital	1,741,901	1,741,901
Treasury shares	2,237,026	2,125,252
Retained earnings (accumulated deficit)	47,875,964	34,581,171
Total stockholders' equity	57,725,347	43,014,905
Total Equity	57,725,347	

Recent Dividends:

- 1. Crawford United Corp class B common. No dividends paid.
- 2. Crawford United Corp class A common. No dividends paid.

Annual Dividends:

- 1. Crawford United Corp class B common. No dividends paid.
- 2. Crawford United Corp class A common. No dividends paid.

CREATIVE REALITIES INC

Annual Report

	Consolidated Income Statement, Years Ended Dec. 31 (\$):		
	2023	2022	2021 (revised)
Hardware sales	20,303,000	19,895,000	9,450,000
Software sales	24,863,000		
Services & other sales		23,455,000	8,987,000
Total sales	45,166,000	43,350,000	18,437,000
Cost of sales - hardware	15,280,000	16,613,000	6,914,000
Cost of software sales	7,703,000		
Cost of sales - services & other		8,998,000	3,166,000
Total cost of sales	22,983,000	25,611,000	10,080,000
Gross profit (loss)	22,183,000	17,739,000	8,357,000
Sales & marketing	5,247,000	3,651,000	1,153,000
Research & development	1,574,000	1,251,000	550,000
General & administrative	10,795,000	11,892,000	7,321,000
Depreciation & amortization	3,221,000	2,833,000	1,364,000
Deal & transaction costs		592,000	518,000
Total operating expenses	20,837,000	20,219,000	10,906,000
Operating income (loss)	1,346,000	(2,480,000)	(2,549,000)
Interest expense, including amortization of debt discount	2,992,000	2,743,000	805,000

Change in fair value of equity guarantee	1,074,000	
Gain (loss) on debt modification	(1,419,000)	
Change in fair value of warrant liability	7,902,000	
Gain on settlement of obligations	(237,000)	3,449,000
Gain (loss) on fair value of debt		166,000
Gain (loss) on debt waiver consent	(1,212,000)	
Gain (loss) on warrant amendment	(345,000)	
Other income (expense), net	211,000	(4,000)
Total other income (expense)	(4,200,000)	4,435,000
Net income (loss) before income taxes	(2,854,000)	1,955,000
State income tax	39,000	51,000
Deferred tax benefit (expense) - federal	9,000	30,000
Deferred tax benefit (expense) - state	35,000	(2,000)
Income tax expense (benefit)	83,000	79,000
Net income (loss)	(2,937,000)	1,876,000
Weighted average shares outstanding - basic	8,479,000	6,664,000
Weighted average shares outstanding - diluted	8,479,000	6,664,000
Year end shares outstanding	10,409,027	7,266,382
Net income (loss) per share - basic	\$(0.35)	\$0.28
Net income (loss) per share - diluted	\$(0.35)	\$0.28
Number of full time employees	152	
Total number of employees	152	120
Number of common stockholders	378	395
Basic EPS Excluding ExtraOrdinary Items	\$(0.35)	
Diluted EPS Excluding ExtraOrd Items	\$(0.35)	

Leasehold improvements	298,000	197,000
Furniture & fixtures	205,000	199,000
Other depreciable assets	135,000	124,000
Total property & equipment	972,000	658,000
Less accumulated depreciation	473,000	
Less: accumulated depreciation & amortization		457,000
Property & equipment, net	499,000	201,000
Intangibles, net	24,062,000	23,752,000
Goodwill	26,453,000	26,453,000
Other assets	112,000	43,000
Total assets	70,777,000	66,015,000
Current maturities of long-term obligations	3,690,000	
Accounts payable	7,876,000	3,757,000
Accrued expenses		3,828,000
Deferred revenues	1,132,000	1,223,000
Customer deposits	3,233,000	2,478,000
Current maturities of operating leases	505,000	711,000
Current maturities of financing leases	42,000	
Short-term portion of secured promissory note		1,248,000
Short-term portion of related party consolidation term loan		1,251,000
Short-term related party term loan (2022)		2,000,000
Accrued expenses and other current liabilities	3,761,000	
Accrued expenses and other current liabilities - Balancing value	3,719,000	
Total current liabilities	20,197,000	16,496,000
Long-term secured promissory note		208,000
Long-term related party acquisition term loan		8,516,000
Long-term related party consolidation term loan		4,349,000
Long-term Payroll Protection Program note payable	9,213,000	
Loans payable, net	616,000	
Long-term obligations under operating leases	536,000	873,000
Contingent acquisition consideration, at fair value	11,208,000	9,789,000
Other liabilities	176,000	205,000
Total liabilities	41,946,000	40,436,000
Common stock	104,000	218,000
Additional paid-in capital	82,073,000	75,770,000
Retained earnings (accumulated deficit)	(53,346,000)	(50,409,000)
Total shareholders' equity (deficit)	28,831,000	25,579,000
Total Equity	28,831,000	

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	2,910,000	1,633,000
Accounts receivable, gross	13,169,000	9,247,000
Allowance for doubtful receivables	701,000	984,000
Accounts receivable, net	12,468,000	8,263,000
Raw materials	2,063,000	1,671,000
Work-in-process	504,000	596,000
Work-in-process and inventories	2,567,000	
Inventories, net		2,267,000
Prepays & other current assets		1,819,000
Total current assets	18,610,000	13,982,000
Operating lease right-of-use assets	1,041,000	1,584,000
Equipment	334,000	138,000

Reclassified to conform with 2022 presentation; Adjusted for 1-for-3 stock split, March 27, 2023; Shares increased due to issuance of shares and exercise of warrants in private investment in public entity, issuance of shares in Reflect Systems, Inc. Merger and share based compensation to vendors; Approximately; As of March 29, 2023; As of March 22, 2022

Net of reserve - raw material: \$1,777,000; Net of discount - Short-term portion of related party consolidation term loan: \$745,000; Net of discount - Long-term related party acquisition term loan: \$1,484,000; Net of discount - Long-term related party consolidation term loan: \$840,000

Recent Dividends:

- 1. Creative Realities Inc common. No dividends paid.

Annual Dividends:

- 1. Creative Realities Inc common. No dividends paid.

CREDITRISKMONITOR.COM, INC.

Annual Report

	Consolidated Income Statement, Years Ended Dec. 31 (\$):		
	2023	2022	2021 (revised)
Operating revenues	18,931,931		

Less: accumulated depreciation	2,891,000	2,721,000
Property & equipment, net	670,000	3,315,000
Operating lease right-of-use assets	1,009,000	1,081,000
Intangible assets, net	23,556,000	26,725,000
Goodwill	9,454,000	9,454,000
Contract costs, net of current portion	2,273,000	1,304,000
Other long-term assets	139,000	150,000
Total assets	56,160,000	55,634,000
Accounts payable	769,000	1,206,000
Accrued wages & benefits	2,884,000	2,427,000
Accrued accounts payable	1,297,000	987,000
Accrued sales & telecommunications taxes	...	846,000
Product warranty liability	25,000	55,000
Other accrued expenses	398,000	575,000
Finance leases	75,000	95,000
Notes payable	457,000	420,000
Operating lease liabilities	566,000	363,000
Contract liabilities	2,390,000	3,338,000
Income tax payable	53,000	79,000
Credit Cards	1,234,000	...
Credit Cards	113,000	...
Total current liabilities	10,261,000	10,391,000
Contract liabilities, net of current portion	198,000	247,000
Finance leases, net of current portion	23,000	98,000
Operating lease liabilities, net of current portion	473,000	752,000
Notes payable, net of current portion	592,000	2,605,000
Line of credit	...	82,000
Total liabilities	11,547,000	14,175,000
Common stock	26,000	26,000
Additional paid-in capital	132,888,000	129,192,000
Retained earnings (accumulated deficit)	(88,467,000)	(87,946,000)
Accumulated other comprehensive income (loss)	166,000	187,000
Total stockholders' equity (deficit)	44,613,000	41,459,000
Rep Total Equity & Minority Interest	44,613,000	...

service fees paid to Leucadia National Corporation	17,762
Net gain (loss) on disposal of property & equipment	(37)	(306)	(1,029)
Income (loss) from operations	1,975	1,969	244
Interest expense, net	826	926	1,015
Gain (loss) on extinguishment of debt	3,863
Other income (expense), net	3,123	415	359
Total other income (expense), net	2,297	(511)	3,207
Income (loss) before income taxes	4,272	1,458	3,451
Current state income tax provision (benefit)	...	10	28
Deferred state income taxes	936	49	356
Total state income taxes	...	59	384
Deferred federal income tax provision (benefit)	...	322	(98)
Total federal income tax provision (benefit)	...	322	(98)
Current	12
Deferred Tax -State income taxes	201
Income tax expense (benefit)	1,149	381	286
Net income (loss)	3,123	1,077	3,165
Weighted average shares outstanding - basic	21,307	22,294	22,806
Weighted average shares outstanding - diluted	21,307	22,294	22,807
Year end shares outstanding	21,034	21,448	22,524
Net income (loss) per share - basic	\$0.15	\$0.05	\$0.14
Net income (loss) per share - diluted	\$0.15	\$0.05	\$0.14
Number of full time employees	164	164	156
Number of common stockholders	1,256	1,293	1,332
Basic EPS Excluding ExtraOrdinary Items	\$0.15
Diluted EPS Excluding ExtraOrd Items	\$0.15
Total number of employees	164

Total current assets	98,617	97,596
Land & improvements	44,912	44,912
Buildings & improvements	66,083	61,260
Vineyards & improvements	34,812	35,998
Winery & vineyard equipment	40,242	34,221
Caves	5,639	5,639
Vineyards under development	3,892	2,489
Construction in progress	1,053	3,479
Property & equipment, gross	196,633	187,998
Less: accumulated depreciation & amortization	80,173	74,577
Property & equipment, net	116,460	113,421
Goodwill	1,262	1,262
Intangible assets & other non-current assets, net	5,750	6,481
Total non-current assets	123,472	121,164
Total assets	222,089	218,760
Accounts payable & accrued grape expenses	...	5,120
Accrued compensation related expenses	...	3,287
Sales & marketing	575	227
Acquisition of property & equipment	210	709
Accrued interest	235	250
Depletion allowance	675	1,176
Production & farming	318	202
Other accrued expenses	341	489
Accounts payable & accrued liabilities	...	11,460
Accrued compensation related expenses	2,965	...
Customer deposits	666	392
Current portion of long-term debt, net of unamortized loan fees	1,129	1,128
Accounts payable and accrued liabilities	7,524	...
Accounts payable and accrued liabilities - Balancing value	12,843	...
Total current liabilities	14,638	12,980
Senior secured term loan agreements	...	18,895
Unamortized loan fees	...	(96)
Total debt	...	18,799
Less current portion of long-term debt	...	1,128
Long-term debt, net of current portion & unamortized loan fees	16,542	17,671
Deferred tax liability, net	2,742	1,100
Other non-current liabilities	9	9
Total non-current liabilities	19,293	18,780
Total liabilities	33,931	31,760
Common shares	210	214
Additional paid-in capital	278,580	278,083
Accumulated other comprehensive income (loss)	88	(49)
Retained earnings (accumulated deficit)	(90,720)	(91,248)
Total equity	188,158	187,000
Total Equity	188,158	...

Recent Dividends:

1. Crexendo Inc common.

ExDate	Amt	Declared	Record	Payable
02/17/2022	0.01	02/08/2022	02/18/2022	02/28/2022
05/26/2022	0.01	05/18/2022	05/30/2022	06/10/2022
08/22/2022	0.01	08/09/2022	08/23/2022	09/02/2022
11/25/2022	0.01	11/10/2022	11/28/2022	12/08/2022
03/30/2023	0.01	03/14/2023	03/31/2023	04/11/2023

Annual Dividends:

1. Crexendo Inc common.

2022	0.02	2023	0.01
------	------	------	------

CRIMSON WINE GROUP LTD.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):	2023	2022	2021 (revised)
Total revenues	72,402
Net sales	72,402	74,244	68,918
Cost of sales	38,719	41,453	38,865
Gross profit	33,683	32,791	30,053
Sales & marketing expenses	...	17,414	15,658
General & administrative expenses	13,909	13,102	13,122
Administrative

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	22,777	25,705
Investments available for sale	8,002	11,673
Accounts receivable, gross	7,885	7,049
Allowance for doubtful accounts	200	200
Accounts receivable, net	7,685	6,849
Finished goods	23,921	17,896
In-process goods	33,856	32,849
Packaging & bottling supplies	317	971
Inventory	58,094	51,716
Other current assets	2,059	1,653

Recent Dividends:

1. Crimson Wine Group Ltd. common.

No dividends paid.

Annual Dividends:

1. Crimson Wine Group Ltd. common.

No dividends paid.

CRONA CORP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Cost & expenses	132,886	25,847
Operating income	(166,922)	(26,347)
Net before taxes	(166,922)	
Net income	(166,922)	(26,347)
Earnings common share		
Primary	\$(0.03)	\$
Fully Diluted	\$(0.03)	\$
Common Shares:		
Full Diluted	6,087,500	6,087,500
Year-end	6,087,500	6,087,500

CRYO-CELL INTERNATIONAL INC**Annual Report****Consolidated Income Statement, Years Ended Nov. 30 (\$):**

	2023	2022	2021 (revised)
--	------	------	-------------------

Processing & storage fees	30,796,091	29,771,123	28,397,401
Public banking revenue	481,148	461,626	376,101
Product revenue	66,456	104,000	111,400
Total revenue	31,343,695	30,336,749	28,884,902
Cost of sales	8,442,310	8,792,358	8,989,736
Selling, general & administrative expenses	17,115,514	15,580,274	14,610,200
Impairment of public inventory	13,108,064		1,164,499
Change in fair value of contingent consideration	(1,050,978)	435,333	(782,481)
Research, development & related engineering	1,171,456	384,789	49,870
Depreciation & amortization	1,124,228	1,119,528	834,845
Non-recurring charges	3,737,133		
Total costs & expenses	43,647,727	26,312,282	24,866,669
Operating income (loss)	(12,304,032)	4,024,467	4,018,233
Gains (losses) on marketable securities	50,777	(38,972)	(13,064)
Gain on interest rate swap	122,113	446,200	
Loss (gain) on sale of property & equipment		407,344	(15,111)
Other income		1,676	99
Interest expense	1,236,794	1,521,767	1,378,926
Other income (expense)	3,441		
Income (loss) before income tax expense (benefit)	(13,364,495)	3,318,948	2,611,231
Current federal income taxes	1,862,000	1,714,000	1,468,000
Current state income taxes	1,046,000	566,000	740,000
Current foreign income taxes			(34,000)
Total current income taxes	2,280,000	2,170,000	2,170,000
Deferred federal income taxes	(4,945,000)	(1,218,000)	(1,024,000)
Deferred state income taxes	(1,806,000)	(514,000)	(622,000)
Total deferred income taxes	(1,732,000)	(1,646,000)	(1,646,000)
Income tax expense (benefit)	(3,842,826)	547,540	527,710
Net income (loss)	(9,521,669)	2,771,408	2,083,521
Weighted average shares outstanding - basic	8,340,839	8,465,568	8,137,342
Weighted average shares outstanding - diluted	8,340,839	8,483,994	8,361,720
Year end shares outstanding	8,286,785	8,500,511	8,551,816
Income (loss) per			

share from continuing operations - basic	\$(1.14)		
Net income (loss) per share - basic	\$(1.14)	\$0.33	\$0.26
Income (loss) per share from continuing operations - diluted	\$(1.14)		
Net income (loss) per share - diluted	\$(1.14)	\$0.33	\$0.25
Dividends per share		\$0.90	
Number of full time employees	82	80	83
Number of part time employees	6	8	10
Total number of employees	88		
Number of common stockholders	1,644	144	152
Number of beneficiary stockholders		1,500	1,500
Dividends per common share	\$0.90		

[□] Reclassified to conform with 2022 presentation; [□] Rounding difference, breakdown taken from the notes; [□] Approximately

Consolidated Balance Sheet, Years Ended Nov. 30 (\$):

	2023	2022
Cash & cash equivalents	406,067	1,703,958
Marketable securities	574,183	17,620
Accounts receivable, gross	10,398,540	9,572,060
Less: allowance for doubtful accounts	3,822,300	3,528,119
Accounts receivable, net	6,576,240	6,043,941
Prepaid expenses	615,407	566,557
Inventory, current portion		851,230
Other current assets	389,950	426,879
Inventory, net	768,877	
Swap contract	122,113	
Total current assets	9,452,837	9,610,185
Building	11,215,134	11,215,134
Vehicle	172,697	172,697
Furniture & equipment	8,573,555	7,570,067
Leasehold improvements	1,262,238	1,258,738
Computer software - internal use	1,194,038	1,194,038
Construction in progress	6,712,329	
Property & equipment, gross	29,129,991	21,410,674
Less: accumulated depreciation	8,133,108	7,807,559
Property & equipment - net	20,996,883	13,603,115
Investment - Tianhe Stem Cell Biotechnologies Inc., stock		308,000
Duke University ("Duke") license agreement, net		13,691,028
Intangible assets, net	989,121	1,463,312
Inventory, net of current portion	5,260,119	9,275,344
Goodwill	1,941,411	1,941,411
Deferred tax assets	20,492,749	13,742,399
Operating lease right-of-use asset	1,033,157	606,034
Deposits & other assets, net	746,493	647,226
Investment - Tianhe stock	308,000	
Total assets	61,220,770	64,888,054
Accounts payable	3,174,584	1,605,301
Accrued state income & franchise taxes	1,426,477	
Accrued professional fees	78,964	238,188
Accrued payroll & payroll taxes	2,061,595	1,515,680
Accrued interest expense	1,111,853	1,038,799
Accrued general expenses		451,037
Accrued federal & state		

taxes		342,106
Accrued expenses	5,170,809	3,585,810
Note payable		150,527
Line of credit	1,222,728	2,272,728
Current portion of operating lease liability	225,686	297,691
Current portion of Duke license agreement liability	165,641	1,983,036
Deferred revenue	9,704,553	9,586,327
Due to officers	491,920	
Current portion of Duke license agreement liability	1,200,000	
Total current liabilities	20,864,001	19,481,420
Deferred revenue, net of current portion	41,186,800	36,000,059
Contingent consideration	44,226	1,162,704
Note payable, net of current portion & debt issuance costs	8,430,037	8,579,875
Operating lease long-term liability	851,938	313,298
Long-term liability - revenue sharing agreements	875,000	875,000
Total other liabilities	51,388,001	
Total liabilities	72,252,002	66,412,356
Common stock	148,492	148,480
Additional paid-in-capital	43,411,143	42,597,380
Treasury stock, at cost	23,431,685	22,632,649
Retained earnings (accumulated deficit)	(31,159,182)	(21,637,513)
Total stockholder's equity (deficit)	(11,031,232)	(1,524,302)
Rep Total Equity & Minority Interest	(11,031,232)	

Recent Dividends:**I. Cryo-Cell International Inc common.**

ExDate	Amt	Declared	Record	Payable
09/01/2022	0.90	08/19/2022	09/02/2022	09/09/2022

Annual Dividends:**I. Cryo-Cell International Inc common.**

2022.....0.90

CRYOPORT INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021 (revised)
Total revenues	233,255,000	237,277,000	222,608,000
Product revenues	89,168,000	103,398,000	103,543,000
Service revenues	144,087,000	133,879,000	119,065,000
Cost of product revenues	52,103,000	58,217,000	56,734,000
Cost of service revenues	81,820,000	75,187,000	69,297,000
Total cost of revenues	133,923,000	133,404,000	126,031,000
Gross margin	99,332,000	103,873,000	96,577,000
Selling, general & administrative expenses	146,880,000	120,055,000	97,563,000
Engineering & development expenses	18,040,000	15,722,000	16,843,000
Goodwill impairment	49,569,000		
Total operating costs & expenses	214,489,000	135,777,000	114,406,000
Income (loss) from operations	(115,157,000)	(31,904,000)	(17,829,000)
Investment income	10,577,000	8,474,000	3,253,000
Interest expense	5,503,000	6,142,000	4,689,000
Other income (expense), net	5,056,000	(5,522,000)	(2,823,000)
Gain (loss) on extinguishment of debt	5,679,000		(251,754,000)
Total other income			

(expense), net	15,809,000	(3,190,000)	(256,013,000)
Income (loss) before provision for income taxes - U.S.	(70,227,000)	(34,854,000)	(273,531,000)
Income (loss) before provision for income taxes - foreign	(29,121,000)	(240,000)	(311,000)
Income (loss) before provision for income taxes	(99,348,000)	(35,094,000)	(273,842,000)
Current state provision for (benefit from) income taxes	73,000	70,000	112,000
Current foreign provision for (benefit from) income taxes	2,263,000	2,634,000	1,783,000
Total current provision for (benefit from) income taxes	2,336,000	2,704,000	1,895,000
Deferred federal provision for (benefit from) income taxes	(278,000)	(7,712,000)	(11,646,000)
Deferred state provision for (benefit from) income taxes	(423,000)	(191,000)	(1,564,000)
Deferred foreign provision for (benefit from) income taxes	(1,396,000)	(1,545,000)	(1,126,000)
Change in valuation allowance	...	8,983,000	14,127,000
Total deferred provision for (benefit from) income taxes	(2,097,000)	(465,000)	(209,000)
Provision for (benefit from) income taxes	239,000	2,239,000	1,686,000
Net income (loss)	(99,587,000)	(37,333,000)	(275,528,000)
Paid-in-kind dividend on series C convertible preferred stock	8,000,000	8,000,000	8,196,000
Net income (loss) attributable to common stockholders	(107,587,000)	(45,333,000)	(283,724,000)
Weighted average shares outstanding - basic	48,737,377	48,987,295	45,927,591
Weighted average shares outstanding - diluted	48,737,377	48,987,295	45,927,591
Year end shares outstanding	48,971,026	48,334,280	49,616,154
Net income (loss) per share - basic	\$(2.21)	\$(0.93)	\$(6.18)
Net income (loss) per share - diluted	\$(2.21)	\$(0.93)	\$(6.18)
Number of full time employees	1,019	960	791
Number of part time employees	11	8	15
Number of temporary employees	...	56	41
Total number of employees	1,030	1,024	...
Number of common stockholders	158	163	158
Basic EPS Excluding ExtraOrdinary Items	\$(2.21)
Diluted EPS Excluding ExtraOrd Items	\$(2.21)

Reclassified to conform with 2022 presentation; Shares increased due to the issuance of common stock for compensation, public offering, direct placement, conversion of Series C preferred

shares and exercise of stock options and warrants; As of February 17, 2023; As of February 18, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	40,979,000	...
Cash & cash equivalents	46,346,000	36,595,000
Short-term investments	410,409,000	486,728,000
Accounts receivable, gross	44,066,000	45,158,000
Less: allowance for doubtful accounts	1,992,000	1,300,000
Accounts receivable, net	42,074,000	43,858,000
Raw materials	15,335,000	18,287,000
Work-in-process	1,375,000	895,000
Finished goods	9,496,000	8,496,000
Inventories	26,206,000	27,678,000
Prepaid expenses & other current assets	10,077,000	9,317,000
Money market mutual fund	5,367,000	...
Total current assets	535,112,000	604,176,000
Cryogenic shippers	1,878,000	...
Cryogenic shippers & data loggers	14,237,000	11,373,000
Freezers	6,351,000	7,320,000
Furniture & fixtures	...	3,760,000
Computers & software	4,908,000	2,824,000
Machinery & equipment	19,760,000	16,492,000
Trucks & autos	...	853,000
Leasehold improvements	33,688,000	27,083,000
Buildings	6,652,000	4,473,000
Land	813,000	813,000
Fixed assets in process	24,224,000	15,947,000
Trucks and autos, Freezers	8,934,000	...
Property & equipment, gross	121,445,000	90,938,000
Less: accumulated depreciation & amortization	36,588,000	27,335,000
Property & equipment, net	84,858,000	63,603,000
Operating lease right-of-use assets	32,653,000	26,877,000
Intangible assets, net	194,382,000	191,009,000
Goodwill	108,403,000	151,117,000
Other long-term assets	656,000	...
Deposits	1,680,000	1,017,000
Deferred tax assets	...	947,000
Total assets	957,744,000	1,038,746,000
Accounts payable & other accrued expenses	26,995,000	28,046,000
Accrued salaries & wages	...	6,007,000
Accrued paid time off	...	2,451,000
Current portion of operating lease liabilities	5,371,000	3,720,000
Deferred revenue	1,308,000	439,000
Current portion of finance lease liabilities	286,000	128,000
Current portion of notes payable	149,000	60,000
Current portion of contingent consideration	92,000	...
Total current liabilities	45,610,000	40,851,000
Convertible senior notes, net	378,553,000	406,708,000
Notes payable, net	1,335,000	355,000
Operating lease liabilities, net of current portion	29,355,000	24,721,000
Deferred tax liability	2,816,000	4,929,000
Other long-term liabilities	601,000	451,000
Finance lease liabilities, net of current portion	954,000	216,000
Contingent consideration	9,497,000	4,677,000
Total liabilities	468,721,000	482,908,000
Class C convertible preferred stock	26,275,000	18,275,000
Common stock	49,000	48,000
Additional paid-in capital	1,131,183,000	1,114,896,000

Retained earnings (accumulated deficit) (642,419,000) (542,832,000)

Accumulated other comprehensive income (loss) (26,065,000) (34,549,000)

Total stockholders' equity (deficit) 489,023,000 555,838,000

Total Equity 489,023,000

Net of discount - Convertible senior notes: \$10,100,000

Recent Dividends:

- 1. CryoPort Inc common.**
No dividends paid.
- 2. CryoPort Inc class B convertible preferred.**
No dividends paid.
- 3. CryoPort Inc class C convertible preferred.**
No dividends paid.
- 4. CryoPort Inc class A convertible preferred.**
No dividends paid.

Annual Dividends:

- 1. CryoPort Inc common.**
No dividends paid.
- 2. CryoPort Inc class B convertible preferred.**
No dividends paid.
- 3. CryoPort Inc class C convertible preferred.**
No dividends paid.
- 4. CryoPort Inc class A convertible preferred.**
No dividends paid.

CRYOPORT INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Total revenues	175,995,000	176,919,000
Cost & expenses	221,281,000	197,788,000
Operating income	(45,286,000)	(20,869,000)
Interest expense	4,197,000	4,686,000
Other income (expense), net	5,921,000	(7,377,000)
Gains or losses	7,962,000	5,797,000
Net before taxes	(35,600,000)	(27,135,000)
Income taxes	1,598,000	762,000
Net income	(37,198,000)	(27,897,000)
Balance for common	(43,198,000)	(33,897,000)
Earnings common share		
Primary	\$(0.89)	\$(0.69)
Fully Diluted	\$(0.89)	\$(0.69)
Common Shares:		
Full Diluted	48,660,646	49,148,558
Year-end	48,963,717	48,558,431

CVD EQUIPMENT CORP.

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Total revenues	19,998,000	18,579,447
Net Sales	19,998,000	...
Cost & expenses	22,408,000	20,181,295
Operating income	(2,410,000)	(1,601,848)
Other income (expense), net	91,000	11,057
Foreign currency	42,000	(250,000)
Net before taxes	(1,895,000)	(1,772,314)
Income taxes	11,000	890
Net income	(1,906,000)	(1,773,204)
Earnings common share		
Primary	\$(0.28)	\$(0.26)
Fully Diluted	\$(0.28)	\$(0.26)
Common Shares:		
Full Diluted	6,787,415	6,730,263
Year-end	6,820,665	6,760,938

CYCLACEL PHARMACEUTICALS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Product revenue	420
Total revenues	420
Research & development	19,155	20,274	15,477
General & administrative	6,718	7,382	7,461
Total operating expenses	25,873	27,656	22,938
Operating income (loss)	(25,453)	(27,656)	(22,938)

Foreign exchange gains (losses)	(414)	233	44	of purchase	4,547	CYCLO THERAPEUTICS INC			
Interest income	266	210	16	Cash & cash equivalents	3,378	18,345	Annual Report			
Other income (expense), net	50	1,298	144	Research & development tax credit receivable	2,933	4,664	Consolidated Income Statement, Years Ended Dec. 31 (\$):			
Total other income (expense), net	(98)	1,741	204	Prepayments & VAT receivable	792	976	2023	2022	2021	
Income (loss) from continuing operations before taxes - domestic	(1,981)	(1,622)	Other current assets	341	426	(revised)			
Income (loss) from continuing operations before taxes - foreign	(23,934)	(21,112)	Total current assets	7,444	24,411	Revenues - product sales	1,076,405	1,375,760	1,585,756
Income (loss) before taxes	(25,551)	(25,915)	(22,734)	Leasehold improvements	6	6	Total revenues	1,076,405
Current - domestic	2	Office equipment & furniture	423	409	Personnel expenses	3,968,681	3,838,477
Current income tax expense (benefit) - domestic	2	2	Property, plant & equipment, gross	429	415	Cost of products sold (exclusive of direct & indirect overhead & handling costs)	84,367	138,929	156,080
Current income tax expense (benefit) - foreign	(2,998)	(4,719)	(3,849)	Less: accumulated depreciation & amortization	420	383	Gross profit	992,038
Current income tax expense (benefit) - total	(2,996)	(4,717)	(3,847)	Property & equipment, net	9	32	Research & development expenses	14,181,769	8,999,543	9,153,780
Net loss	(22,555)	Right-of-use lease asset	93	142	Repairs & maintenance expenses	14,091
Income tax expense (benefit)	(2,996)	(4,717)	(3,847)	Non-current deposits	1,259	2,916	Repairs & maintenance expenses	11,019	10,708
Net income (loss)	(22,555)	(21,198)	(18,887)	Total assets	8,805	27,501	Professional fees	1,943,757	2,417,017	1,474,911
Dividends on preferred ordinary shares	201	Accounts payable	3,543	2,561	Office & other expenses	1,025,635	1,061,937
Dividend on convertible exchangeable preferred shares	201	201	Accrued research & development	3,668	3,611	Board of directors fees & costs	335,268	394,009	122,833
Net income (loss) applicable to common shareholders	(22,756)	(21,399)	(19,088)	Accrued legal & professional fees	570	333	Depreciation expenses	19,276	19,481	16,827
Weighted average shares outstanding - basic	851	750	595	Other current liabilities	380	887	Freight & shipping expenses	3,902	13,060	18,336
Weighted average shares outstanding - diluted	851	750	595	Total current liabilities	8,161	7,392	Bad debt expense	10,272	21,927
Year end shares outstanding	1,059	836	666	Lease liability	37	106	Selling, general & administrative expenses	1,161,094
Income (loss) per share from continuing operations - basic	\$(26.75)	Total liabilities	8,198	7,498	Personnel	3,382,938
Net income (loss) per share - basic	\$(26.75)	\$(28.50)	\$(32.10)	Redeemable common stock	4,494	Total operating expenses	16,997,646	15,875,816
Income (loss) per share from continuing operations - diluted	\$(26.75)	Common stock	1	9	Income (loss) from operations	(20,050,057)	(15,621,886)	(14,290,060)
Net income (loss) per share - diluted	\$(26.75)	\$(28.50)	\$(32.10)	Additional paid-in capital	429,796	422,973	Investment & other income	(7,245)	12,474	3,405
Number of common stockholders	11	19	19	Accumulated other comprehensive income (loss)	(908)	(1,316)	Gain on forgiveness of Paycheck Protection Program ("PPP") loan	158,524	...
Foreign currency translation adjustments	20,598	...	Retained earnings (accumulated deficit)	(428,282)	(406,157)	Income (loss) before provision for income taxes	(20,057,302)	(15,450,888)	(14,286,655)
Dividends Per Share - Common - Gross - by Period End Date	\$0.60	Total stockholders' equity (deficit)	607	15,509	Net income (loss)	(20,057,302)	(15,450,888)	(14,286,655)
				Total Equity	607	...	Weighted average shares outstanding - basic	16,329,713	8,439,177	6,370,073
Recent Dividends:							Weighted average shares outstanding - diluted			
1. Cyclacel Pharmaceuticals Inc series B convertible preferred.							Year end shares outstanding			
No dividends paid.							28,556,072			
2. Cyclacel Pharmaceuticals Inc 6% convertible exchangeable preferred.							8,481,848			
ExDate	Amt	Declared	Record	Payable			8,403,869			
01/14/2021	0.15	12/11/2020	01/15/2021	02/01/2021			Net income (loss) per common share - basic			
04/15/2021	0.15	03/24/2021	04/16/2021	05/01/2021			\$(1.23)			
07/15/2021	0.15	06/21/2021	07/16/2021	08/01/2021			\$(1.83)			
10/14/2021	0.15	09/08/2021	10/15/2021	11/01/2021			\$(2.24)			
01/13/2022	0.15	12/13/2021	01/14/2022	02/01/2022			...			
04/13/2022	0.15	03/17/2022	04/14/2022	05/01/2022			...			
07/14/2022	0.15	06/14/2022	07/15/2022	08/01/2022			...			
10/13/2022	0.15	09/07/2022	10/14/2022	11/01/2022			...			
01/12/2023	0.15	12/06/2022	01/13/2023	02/01/2023			...			
04/20/2023	0.15	03/08/2023	04/21/2023	05/01/2023			...			
07/20/2023	0.15	06/13/2023	07/21/2023	08/01/2023			...			
10/19/2023	0.15	09/06/2023	10/20/2023	11/01/2023			...			
01/19/2024	0.15	01/12/2024	01/22/2024	02/01/2024			...			
3. Cyclacel Pharmaceuticals Inc 6% preferred convertible series A.							...			
No dividends paid.							...			
4. Cyclacel Pharmaceuticals Inc common.							...			
No dividends paid.							...			
Annual Dividends:							...			
1. Cyclacel Pharmaceuticals Inc series B convertible preferred.							...			
No dividends paid.							...			
2. Cyclacel Pharmaceuticals Inc 6% convertible exchangeable preferred.							...			
2021	0.60	2022	0.60	2023	0.60		...			
2024	0.15						...			
3. Cyclacel Pharmaceuticals Inc 6% preferred convertible series A.							...			
No dividends paid.							...			
4. Cyclacel Pharmaceuticals Inc common.							...			
No dividends paid.							...			

Adjusted for 1- for -15 stock split, December 18, 2023; Shares increased due to the effect of issuance of common stock and associated warrants on underwritten offering; market issuance sales agreement; and warrant and stock option exercises; Approximately; As of March 6, 2023; As is; As of March 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):
2023 2022

Cash

Investments with original maturity of less than three months at the time

2021

2024

3. Cyclacel Pharmaceuticals Inc 6% preferred convertible series A.
No dividends paid.
4. Cyclacel Pharmaceuticals Inc common.
No dividends paid.

Shares increased due to the effect of stock issued to employees and non employees; exercise of warrants and sale of common stock; Approximately; As of March 10, 2023; As of March 10, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	9,246,592	1,543,418
Provision for doubtful accounts	10,272	...
Accounts receivable - Balancing value	132,651	...
Accounts receivable	122,379	54,991
Inventory, gross	254,352	...
Inventory, net	...	254,491
Prepaid insurance & services	384,889	101,135
Prepaid clinical expenses	2,310,045	2,204,520
Total current assets	12,318,257	4,158,555
Machinery & equipment	75,137	75,137
Office furniture	...	81,590
Less: accumulated depreciation - furniture & equipment	120,815	101,539
Equipment not in service	84,010	...
Furniture & equipment, net	38,332	55,188
Right-to-use lease asset, net	890,949	1,470
Total assets	13,247,538	4,215,213
Current portion of lease liability	1,010,631	...
Accounts payable & accrued expenses	7,457,416	3,480,669
Accounts Payable	4,856,530	...
Accrued bonus compensation	1,590,776	...
Accrued board expense	92,110	...
Accounts payable and accrued expenses - Balancing value	918,000	...
Total current liabilities	8,468,047	3,480,669
Accrued stock compensation	22,484	...
Total long-term liabilities	22,484	...
Common stock	2,856	849
Additional paid-in capital	88,610,832	64,533,074
Retained earnings (accumulated deficit)	(83,856,681)	(63,799,379)
Total stockholders' equity	4,757,007	734,544
Total Equity	4,757,007	...

Recent Dividends:

1. **Cyco Therapeutics Inc series A preferred.**
No dividends paid.

2. **Cyco Therapeutics Inc common.**
No dividends paid.

Annual Dividends:

1. **Cyco Therapeutics Inc series A preferred.**
No dividends paid.

2. **Cyco Therapeutics Inc common.**
No dividends paid.

CYNGN INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Revenue	1,489,317
Revenue	1,489,317	262,000	...
Cost of revenue	1,222,321	186,823	...
Research & development	12,719,983	9,481,329	4,990,407
General & administrative	10,892,955	9,994,575	4,409,651
Total costs & expenses	24,835,259	19,662,727	9,400,058
Income (loss) from operations	(23,345,942)	(19,400,727)	(9,400,058)
Interest income	137,887
Interest income (expense)	...	44,100	(9,580)
Other income (expense)	396,825	120,118	7,173
Paycheck protection

program note forgiveness	1,602,936
Loss before income taxes	(22,811,230)
Total other income (expense), net	534,712	164,218	1,600,529
Net income (loss)	(22,811,230)	(19,236,509)	(7,799,529)
Net income (loss) attributable to common stockholders	...	(19,236,509)	(7,799,529)
Weighted average shares outstanding - basic	39,987,864	34,356,378	6,447,903
Weighted average shares outstanding - diluted	39,987,864	34,356,378	6,447,903
Year end shares outstanding	64,773,756	37,053,350	29,136,448
Net earnings (loss) per share - basic	\$(0.57)	\$(0.56)	\$(1.21)
Net earnings (loss) per share - diluted	\$(0.57)	\$(0.56)	\$(1.21)
Number of full time employees	81	66	42
Common Shareholders - Number	58
Number of stockholders	...	89	72
Total number of employees	81

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	3,591,623	...
Cash	...	10,536,273
Restricted cash	...	50,000
Short-term investments	4,561,928	12,064,337
Prepaid expenses & other current assets	1,316,426	1,126,137
Total current assets	9,469,977	23,776,747
Automobiles	616,947	397,816
Furniture & fixtures	...	176,402
Computer & equipment	178,491	380,457
Leasehold improvement	458,406	93,120
Construction work in progress	208,848	359,289
Computer and Equipment	517,181	...
Property and equipment, gross	2,322,009	1,407,084
Software Development	342,136	...
Property & equipment, gross	2,322,009	1,407,084
Less: accumulated depreciation	835,337	523,084
Property & equipment, net	1,486,672	884,000
Right of use asset, net	992,292	371,189
Intangible Assets - excluding Goodwill - Net	1,084,415	...
Intangible assets, net	...	473,076
Total assets	13,033,356	25,505,012
Accounts payable	196,963	155,943
Credit card payable	1,103	5,194
Accrued expenses	214,286	283,118
Accrued payroll	985,753	566,608
Accrued expenses & other current liabilities	...	854,920
Operating lease liability	682,718	376,622
Accrued expenses and other current liabilities - Balancing value	1,201,142	...
Total current liabilities	2,080,823	1,387,485
Non-current operating

lease liability	317,344	...
Total liabilities	2,398,167	1,387,485
Common stock	648	337
Additional paid-in capital	170,652,160	159,847,229
Retained earnings (accumulated deficit)	(160,017,619)	(135,730,039)
Total stockholders' equity	10,635,189	24,117,527
Total Equity	10,635,189	...

Recent Dividends:

1. **Cyngn Inc common.**

No dividends paid.

Annual Dividends:

1. **Cyngn Inc common.**

No dividends paid.

CYTOSORBENTS CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
CytoSorb sales	...	28,572,709	39,996,700
Other sales	69,685	787,201	111,867
Total product sales	31,015,268	29,359,910	40,108,567
Grant income	5,264,426	5,328,899	3,056,960
Total revenue	36,349,379	34,688,809	43,165,527
Cost of revenue	13,957,356	13,955,752	11,047,350
Gross profit (loss)	22,392,023	20,733,057	32,118,177
Research & development expenses	15,728,915	15,118,907	16,380,930
Legal, financial & other consulting expenses	...	2,847,899	2,731,515
Selling, general & administrative expenses	33,600,065	34,288,130	35,750,477
General & administrative expenses	4,272,296
Total operating expenses	53,601,276	52,254,936	54,862,922
Income (loss) from operations	(31,209,253)	(31,521,879)	(22,744,745)
Interest income (expense), net	(157,891)	132,597	28,007
Gain (loss) on foreign currency transactions	1,949,257	(2,448,583)	(2,577,913)
Miscellaneous expense	(96,754)	67,303	...
Total other income (expense), net	1,888,120	(2,383,289)	(2,549,906)
Income (loss) before provision for (benefit from) income taxes - domestic	...	(21,155,203)	(18,829,797)
Income (loss) before provision for (benefit from) income taxes - foreign	...	(12,749,965)	(6,464,854)
Income (loss) before provision for (benefit from) income taxes	(29,321,133)	(33,905,168)	(25,294,651)
State tax, including sale of New Jersey losses & credits	...	(1,092,585)	(736,003)
Provision for (benefit from) income taxes	(813,739)	(1,092,585)	(736,003)
Net income (loss)	(28,507,394)	(32,812,583)	(24,558,648)
Net income (loss) attributable to common stockholders	(28,507,394)	(32,812,583)	(24,558,648)
Weighted average shares outstanding - basic	44,656,391	43,573,215	43,359,186
Weighted average

	2023	2022	2021
shares outstanding			
- diluted	44,656,391	43,573,215	43,359,186
Year end shares outstanding	54,240,265	43,635,715	43,478,487
Income (loss) per share from continuing operation - basic	\$(0.64)
Net earnings (loss) per common share - basic	\$(0.64)	\$(0.75)	\$(0.57)
Income (loss) per share from continuing operations - diluted	\$(0.64)
Net earnings (loss) per common share - diluted	\$(0.64)	\$(0.75)	\$(0.57)
Total number of employees	...	198	221
Number of common stockholders	11,100	11,200	13,000
Foreign currency translation adjustments	...	1,803,610	...
As of March 7, 2023; As of March 1, 2022; Approximately, As of February 13, 2023; As of February 15, 2022			
Consolidated Balance Sheet, Years Ended Dec. 31 (\$):			
	2023	2022	
Cash & cash equivalents	14,131,137	22,144,567	
Grants & accounts receivable, gross	6,106,735	5,740,982	
Allowance for doubtful accounts	49,663	76,041	
Grants & accounts receivable, net	...	5,664,941	
Receivables, net	6,057,072	...	
Finished goods	2,155,457	...	
Work in process	838,871	...	
Raw materials	685,801	...	
Inventories	3,680,129	3,461,586	
Prepaid expenses & other current assets	...	2,488,597	
Prepaid expenses and other current assets	1,834,485	...	
Total current assets	25,702,823	33,759,691	
Furniture & fixtures	...	1,306,267	
Equipment & computers	1,462,778	5,131,934	
Leasehold improvements	6,224,863	6,201,523	
Equipment and Computers	5,404,743	...	
Property & equipment, gross	13,092,384	12,639,724	
Less: accumulated depreciation & amortization	3,036,030	1,896,692	
Property & equipment - net	10,056,354	10,743,032	
Restricted cash	1,483,958	1,687,459	
Right of use asset	12,058,896	12,603,901	
Patent applications pending	1,945,532	2,466,341	
Patents issued	2,982,253	2,773,191	
Less accumulated amortization of patents issued	1,021,233	848,999	
Patents, net	3,906,552	4,390,533	
Security deposits	52,051	46,914	
Total assets	53,260,634	63,231,530	
Accounts payable	3,802,170	1,655,173	
Accrued salaries & commissions	3,344,080	2,862,930	
Deferred revenue	1,380,821	1,516,772	
Clinical studies	...	1,115,123	
Accrued accounts payable	497,627	850,630	
Accrued royalties	513,338	592,398	
Professional fees	686,908	622,353	
Customer rebates	181,284	166,065	
Sales, payroll & income taxes payable	56,423	21,871	
Travel & entertainment	...	99,316	
Interest	34,444	5,556	2023
Board of director fees	84,610	97,426	2022
Accrued expenses & other current liabilities	1,090,614	7,950,440	2021 (revised)
Current maturities of long-term debt	2,500,000	...	
Lease liability - current portion	373,636	108,939	
Accrued expenses and other current liabilities - Balancing value	7,870,149	...	
Total current liabilities	14,545,955	9,714,552	
Lease liability, net of current portion	12,896,659	13,142,005	
Long-term debt - principal amount	...	5,000,000	
Long-term debt	2,542,857	5,000,000	
Total liabilities	29,985,471	27,856,557	
Common stock	54,240	43,635	
Additional paid-in capital	305,196,874	287,000,021	
Foreign Currency Translation Adjustment - Accumulated	529,321	...	
Accumulated other comprehensive income (loss)	529,321	2,329,195	
Retained earnings (accumulated deficit)	(282,505,272)	(253,997,878)	
Total stockholders' equity (deficiency)	23,275,163	35,374,973	
Total Equity	23,275,163	...	
Recent Dividends:			
1. Cytosorbents Corp 10% series A preferred (stated value: \$1.00).			
No dividends paid.			
2. Cytosorbents Corp common.			
No dividends paid.			
3. Cytosorbents Corp 10% series B cumulative convertible preferred (stated value: \$100).			
No dividends paid.			
Annual Dividends:			
1. Cytosorbents Corp 10% series A preferred (stated value: \$1.00).			
No dividends paid.			
2. Cytosorbents Corp common.			
No dividends paid.			
3. Cytosorbents Corp 10% series B cumulative convertible preferred (stated value: \$100).			
No dividends paid.			
CYTTA CORP			
Earnings, 3 mos. to Dec 31(Consol. - \$):			
	2023	2022	
Total revenues	2,411	5,706	
Cost & expenses	990,452	1,106,443	
Operating income	(988,041)	(1,100,737)	
Interest income	200	55	
Interest expense	71,287	26	
Net before taxes	(1,059,128)	(1,100,708)	
Net income	(1,059,128)	(1,100,708)	
Earnings common share			
Common Shares:			
Full Diluted	428,575,956	380,882,100	
Year-end	434,718,920	383,685,670	
Consolidated Balance Sheet Items, as of (\$):			
Assets:		2023	
Cash & equivalents		390,262	
Current assets		1,030,026	
Net property & equip.		66,982	
Total assets		1,553,451	
Liabilities:			
Current liabilities		1,430,816	
Long-term debt		1,222,141	
Stockholders' equity		(1,099,506)	
Net current assets		(400,790)	
DALLASNEWS CORP			
Annual Report			
Consolidated Income Statement, Years Ended Dec. 31 (\$000):			
	2023	2022	2021
Advertising	59,038
Net operating revenue - advertising & marketing services	...	69,667	73,271
Net operating revenue - circulation	...	65,191	64,943
Net operating revenue - printing, distribution & other operating revenue	15,309	15,793	16,160
Circulation	65,349
Total net operating revenue	139,696	150,651	154,374
Employee compensation & benefits expense	69,445	67,096	69,078
Other production, distribution & operating costs	68,008	78,638	81,041
Newsprint, ink & other supplies expense	8,793	11,035	9,878
Depreciation expense	1,520	2,709	4,002
Amortization expense	64
Gain (loss) on sale or disposal of assets, net	...	(58)	(29)
Asset impairments expense	...	102	232
Total operating costs & expense	147,766	159,638	164,324
Operating income (loss)	(8,070)	(8,987)	(9,950)
Other income (expense), net	1,422
Total other income (expense), net	...	(241)	7,332
Income (loss) before income taxes	(6,648)	(9,228)	(2,618)
Current federal income tax provision (benefit)	(66)	...	(2,575)
Current state income tax provision (benefit)	519	583	604
Total current income tax provision (benefit)	453	583	(1,971)
Deferred federal income tax provision (benefit)	(1,324)	(1,985)	(571)
Deferred state income tax provision (benefit)	8	(28)	(180)
Total deferred income tax provision (benefit)	(1,316)	(2,013)	(751)
Valuation allowance	1,327	1,988	571
Income tax provision (benefit)	464	558	(2,151)
Net income (loss)	(7,112)	(9,786)	(467)
Net income (loss) available to common shareholders	...	(9,786)	(467)
Weighted average shares outstanding - basic	5,352	5,352	5,352
Weighted average shares outstanding - diluted	5,352	5,352	5,352
Year end shares outstanding	5,352	5,352	5,352
Earnings (loss) per share from continuing operations - basic	\$(1.33)
Net income (loss)			

per share - basic	\$(1.33)	\$(1.83)	\$(0.09)
Earnings (loss) per share from continuing operations - diluted	\$(1.33)
Net income (loss) per share - diluted	\$(1.33)	\$(1.83)	\$(0.09)
Dividends per common share	\$0.64	\$2.14	\$0.64
Number of full time employees	601
Total number of employees	601	663	656
Number of series A common stockholders	...	279	291
Number of series B common stockholders	...	68	64
Number of Shareholders A Series	277
Number of Shareholders B Series	67

Defined benefit pension plans	(40,578)	(41,777)	
Other post-employment benefit plans	331	397	
Accumulated other comprehensive income (loss)	(40,247)	(41,380)	
Retained earnings (accumulated deficit)	(437,973)	(427,435)	
Total shareholders' equity	2,958	12,363	
Total shareholders' equity	2,958	...	

Recent Dividends:
1. DallasNews Corp series B common.
 No dividends paid.
2. DallasNews Corp series A common.

ExDate	Amt	Declared	Record	Payable
08/12/2021	0.16	05/13/2021	08/13/2021	09/03/2021
11/10/2021	0.16	09/22/2021	11/12/2021	12/03/2021
02/10/2022	0.16	12/02/2021	02/11/2022	03/04/2022
05/12/2022	0.16	03/03/2022	05/13/2022	06/03/2022
08/11/2022	0.16	05/12/2022	08/12/2022	09/02/2022
09/08/2022	1.50	08/22/2022	09/09/2022	09/30/2022
11/09/2022	0.16	09/22/2022	11/10/2022	12/02/2022
02/09/2023	0.16	12/01/2022	02/10/2023	03/03/2023
05/11/2023	0.16	03/09/2023	05/12/2023	06/02/2023
08/10/2023	0.16	05/11/2023	08/11/2023	09/01/2023
11/09/2023	0.16	09/21/2023	11/10/2023	12/01/2023
02/08/2024	0.16	12/07/2023	02/09/2024	03/01/2024

Annual Dividends:
1. DallasNews Corp series B common.
 No dividends paid.
2. DallasNews Corp series A common.

2021	2022	2023
0.32	2.14	0.64
0.16		

Interest income	4,600,000	2,800,000	300,000
Interest expense	52,200,000	35,400,000	33,500,000
Change in fair value of warrant liability	...	4,700,000	1,600,000
Other income (expense)	1,000,000	(700,000)	800,000
Total other income (expense)	(46,600,000)	(28,600,000)	(30,800,000)
Income (loss) before income taxes	(10,400,000)	69,800,000	82,000,000
Current federal tax expense (benefit)	5,000,000	6,200,000	4,600,000
Current state tax expense (benefit)	3,700,000	1,600,000	5,400,000
Current foreign tax expense (benefit)	500,000	1,200,000	900,000
Total current tax expense (benefit)	9,200,000	9,000,000	10,900,000
Deferred federal tax expense (benefit)	(2,200,000)	8,700,000	11,000,000
Deferred state tax expense (benefit)	(1,900,000)	200,000	3,400,000
Deferred foreign tax expense (benefit)	2,200,000	1,700,000	700,000
Total deferred tax expense (benefit)	(1,900,000)	10,600,000	15,100,000
Income tax expense (benefit)	7,300,000	19,600,000	26,000,000
Net income (loss)	(17,700,000)	50,200,000	56,000,000
Less dividends to series A convertible preferred stockholders	5,000,000	5,000,000	5,000,000
Less dividends to series B perpetual preferred stockholders	4,300,000	700,000	...
Net income (loss) attributable to common stockholders	(27,000,000)	44,500,000	51,000,000
Weighted average shares outstanding - basic	45,822,936	60,459,451	63,744,456
Weighted average shares outstanding - diluted	45,822,936	63,283,502	65,409,258
Year end shares outstanding	46,566,542	45,028,041	62,489,278
Net earnings (loss) per share - basic	\$(0.59)	\$0.73	\$0.79
Net earnings (loss) per share - diluted	\$(0.59)	\$0.70	\$0.77
Number of full time employees	4,182
Total number of employees	4,182	4,123	4,006
Number of common stockholders	41	47	50
Foreign currency translation adjustments	...	(400,000)	...
EPS - Basic - excluding Extraordinary Items
Applicable to Common - Total	\$(0.59)
EPS - Diluted - excluding Extraordinary Items
Applicable to Common - Total	\$(0.59)

As is; Approximately; As of March 6, 2023; As of March 3, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	11,697	27,825
Accounts receivable, gross	10,130	14,513
Less: allowance	207	490
Accounts receivable, net	9,923	14,023
Inventories	1,930	2,725
Prepays & other current assets	2,602	3,352
Short-Term Investments	10,781	...
Total current assets	36,933	47,925
Land	1,971	...
Buildings & improvements	85,718	85,714
Publishing equipment	173,994	173,646
Other property, plant & equipment	45,528	51,336
Construction in process	225	773
Property, plant & equipment, at cost	307,436	313,440
Less accumulated depreciation	300,337	306,002
Property, plant & equipment, net	7,099	7,438
Operating lease right-of-use assets	16,141	14,811
Deferred income taxes, net	271	282
Other assets	1,790	1,809
Total assets	62,234	72,265
Accounts payable	3,963	5,041
Accrued compensation & benefits	3,901	4,154
Other accrued expenses	6,548	4,060
Contract liabilities	9,511	9,504
Operating Lease Liabilities - Current
Portion/Short-Term	1,809	...
Other accrued expense - Balancing value	4,739	...
Total current liabilities	23,923	22,759
Long-term pension liabilities	17,353	19,455
Long-term operating lease liabilities	16,924	16,546
Other post employment benefits	996	982
Other liabilities	80	160
Total liabilities	59,276	59,902
Series A common stock	52	52
Series B common stock	6	6
Treasury stock, series A	13,443	13,443
Additional paid-in capital	494,563	494,563

DASEKE INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Purchased freight	542,000,000
Impairment of tangible assets	17,900,000
Brokerage	242,100,000	321,200,000	269,000,000
Company freight	654,900,000	650,300,000	629,700,000
Owner operator freight	422,300,000	509,900,000	486,500,000
Logistics	59,900,000	53,800,000	39,200,000
Fuel surcharge	190,200,000	238,100,000	132,400,000
Total revenue	1,569,400,000	1,773,300,000	1,556,800,000
Salaries, wages & employee benefits	412,400,000	402,400,000	378,300,000
Fuel	139,800,000	159,600,000	107,300,000
Operations & maintenance	...	162,500,000	147,800,000
Purchased freight	168,900,000	698,000,000	598,500,000
Administrative expenses	...	72,400,000	64,700,000
Taxes & licenses	16,100,000	15,900,000	14,800,000
Insurance & claims	61,400,000	76,700,000	61,300,000
Acquisition-related transaction expenses	1,500,000	3,800,000	...
Depreciation & amortization	106,500,000	92,800,000	88,100,000
Gain on disposition of property & equipment	12,300,000	21,000,000	17,100,000
Impairment	...	9,400,000	...
Restructuring charges	500,000	2,400,000	300,000
General & administrative expenses	78,500,000
Total operating expenses	1,533,200,000	1,674,900,000	1,444,000,000
Income (loss) from operations	36,200,000	98,400,000	112,800,000

Reclassified to conform with 2022 presentation; Shares decreased due to the effect of common stock repurchased and retired; As of February 10, 2023; As of February 11, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	76,600,000	153,400,000

diluted	\$0.00	...	\$0.76
Net earnings (loss) per share Dell Technologies common stock - diluted	\$4.36	...	\$7.02
Earn per share-inc from discount opers - diluted	\$0.00
Dividends declared per common share	\$1.48	\$1.32	...
Number of full time employees	120,000	[Ⓐ] 133,000	[Ⓐ] 133,000
Number of Class V common stockholders	3,865
Number of Class A common stockholders	...	[Ⓐ] 6	[Ⓐ] 6
Number of Class B common stockholders	...	[Ⓐ] 6	[Ⓐ] 6
Number of Class C common stockholders	...	[Ⓐ] 3,982	[Ⓐ] 4,369
Foreign currency translation adjustments	...	(222,000)	(385,000)
Comprehensive income attributable to Dell Technologies Inc	3,412,000
Total number of employees	120,000

[Ⓐ] 53 weeks; [Ⓑ] Includes related party cost of net revenue - products cost: \$1,634,000,000; [Ⓒ] Includes related party cost of net revenue - products cost: \$1,577,000,000; [Ⓓ] Includes related party cost of net revenue - services cost: \$3,065,000,000; [Ⓔ] Includes related party cost of net revenue - services cost: \$2,487,000,000; [Ⓕ] Approximately; [Ⓖ] As is; [Ⓗ] As of March 27, 2023; [Ⓘ] As of March 22, 2022

Consolidated Balance Sheet, Years Ended (\$000):

	02/02/24	02/03/23
Cash & cash equivalents	7,366,000	8,607,000
Accounts receivables, gross	9,414,000	12,560,000
Allowance for doubtful accounts	71,000	78,000
Allowance for customer returns	9,343,000	...
Accounts receivable, net	...	12,482,000
Due from related party, net	...	378,000
Short-term financing receivables, net	4,643,000	[Ⓐ] 5,281,000
Production materials	2,321,000	3,225,000
Work in process	607,000	708,000
Finished goods	694,000	843,000
Inventories	3,622,000	4,776,000
Other current assets	10,973,000	10,827,000
Total current assets	35,947,000	42,351,000
Computer equipment	3,552,000	6,899,000
Land & buildings	2,877,000	3,059,000
Machinery & other equipment	...	3,134,000
Property, Plant & Equipment - Other - Gross	5,022,000	...
Internal use software	2,166,000	...
Total property, plant, & equipment	13,617,000	13,092,000
Accumulated depreciation & amortization	7,185,000	6,883,000
Property, plant & equipment, net	6,432,000	6,209,000
Long-term investments	1,316,000	1,518,000
Long-term financing receivables, net	5,877,000	[Ⓐ] 5,638,000
Goodwill	19,700,000	19,676,000
Intangible assets, net	5,701,000	6,468,000
Due from related party, net	...	440,000
Other non-current assets	7,116,000	7,311,000
Total assets	82,089,000	89,611,000
Short-term debt	6,982,000	6,573,000
Accounts payable	19,389,000	18,598,000

Due to related party	...	2,067,000
Current operating lease liabilities	253,000	...
Accrued & other current liabilities	...	8,874,000
Short-term deferred revenue	15,318,000	15,542,000
Accrued and other - Accrued and other - Balancing value	6,552,000	...
Total current liabilities	48,494,000	51,654,000
Senior notes	19,012,000	18,300,000
Legacy notes & debentures	...	952,000
DFS debt	10,290,000	...
Other debt	...	325,000
Total debt, principal amount	...	29,867,000
Unamortized discount, net of unamortized premium	...	(133,000)
Debt issuance costs	...	(146,000)
Total debt, carrying value	...	29,588,000
Less: short-term debt	...	6,573,000
Long-term debt	...	23,015,000
Long-term deferred revenue	13,827,000	14,744,000
Other non-current liabilities	3,065,000	3,223,000
Total liabilities	84,398,000	92,636,000
Common stock & capital	8,926,000	8,424,000
Common stock	7,050	...
Treasury stock at cost	5,900,000	3,813,000
Retained earnings (accumulated deficit)	(4,630,000)	(6,732,000)
Foreign currency translation adjustments	(755,000)	(747,000)
Cash flow hedges	(30,000)	(222,000)
Pension & other postretirement plans	(15,000)	(32,000)
Accumulated other comprehensive income (loss)	(800,000)	(1,001,000)
Common stock and capital in excess - Balancing value	8,918,950	...
Total Dell Technologies Inc. stockholders' equity	(2,404,000)	(3,122,000)
Non-controlling interests	95,000	97,000
Total stockholders' equity (deficit)	(2,309,000)	(3,025,000)

[Ⓐ] Net of allowance - short term financing receivables: \$142,000,000; [Ⓑ] Net of allowance - long-term financing receivables: \$59,000,000

Recent Dividends:

- Dell Technologies Inc class C common - DHI Group.**
No dividends paid.
 - Dell Technologies Inc series A common.**
No dividends paid.
 - Dell Technologies Inc class V common.**
No dividends paid.
 - Dell Technologies Inc class A common - DHI Group.**
No dividends paid.
 - Dell Technologies Inc series B common.**
No dividends paid.
 - Dell Technologies Inc class B common - DHI Group.**
No dividends paid.
- Annual Dividends:**
- Dell Technologies Inc class C common - DHI Group.**
No dividends paid.
 - Dell Technologies Inc series A common.**
No dividends paid.
 - Dell Technologies Inc class V common.**
No dividends paid.
 - Dell Technologies Inc class A common - DHI Group.**
No dividends paid.
 - Dell Technologies Inc series B common.**
No dividends paid.
 - Dell Technologies Inc class B common - DHI Group.**
No dividends paid.

DENNY'S CORP Annual Report

Consolidated Income Statement, Years Ended (\$000):

	12/27/23	12/28/22	[Ⓐ] 12/29/21 (revised)
Company restaurant sales	215,532	199,753	175,017
Net company sales	13,882
Royalties	120,131	113,891	103,425
Advertising revenue - Initial & other fees	78,494	75,926	69,957
Occupancy revenue	...	28,262	8,009
Total operating revenue	463,922	456,429	398,174
Product costs	55,789	53,617	42,982
Payroll & benefits	80,666	76,412	65,337
Occupancy	17,080	15,154	11,662
Utilities	7,848	7,273	5,814
Repairs & maintenance	3,661	3,874	2,743
Marketing	5,603	5,294	4,594
Legal expenses	2,302	4,224	2,134
Other direct costs	14,650	13,610	11,666
Costs of franchise & license revenue	122,452	135,327	109,140
Corporate administrative expenses	...	52,115	44,367
Share-based compensation	...	11,400	13,602
Incentive compensation	...	5,811	8,628
Deferred compensation valuation adjustments	...	(2,153)	2,089
Depreciation of property & equipment	10,720	11,118	11,441
Amortization of finance right-of-use assets	1,451	1,704	1,895
Amortization of intangible & other assets	2,214	2,040	2,110
Goodwill impairment charges	6,363
Impairment charges	2,214
Gains on disposition of assets & other gains, net	2,220
Gains (losses) on sales of assets & other gains (losses), net	...	3,378	47,822
Severance & other restructuring charges	2,346
Restructuring charges & exit costs	...	1,410	1,275
Impairment charges	190	963	442
Total operating costs & expenses, net	411,099	395,815	294,099
Operating income (loss)	52,823	60,614	104,075
Interest on credit facilities	18,929	8,478	5,478
Interest on interest rate swaps	(5,028)	1,310	4,023
Interest on finance lease liabilities	2,139	2,350	2,960
Letters of credit & other fees	738	1,053	1,438
Interest income	171	87	25
Amortization of deferred financing costs	635	634	1,105
Amortization of interest rate swap losses	...	29	167
Interest accretion on other

Total liabilities	1,623,616	922,634
Common stock	393	1,232
Additional paid-in capital	59,742,503	51,613,810
Retained earnings (accumulated deficit)	(53,387,878)	(45,593,188)
Total stockholders' (deficit)	6,355,018	6,021,854
Total Equity	6,355,018	...

Recent Dividends:

1. Dermata Therapeutics Inc common.

No dividends paid.

Annual Dividends:

1. Dermata Therapeutics Inc common.

No dividends paid.

DERMTECH INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Assay revenue	14,384,000	13,790,000	11,023,000
Contract revenue	912,000	728,000	815,000
Total revenues	15,296,000	14,518,000	11,838,000
Cost of assay revenue	14,792,000	13,702,000	10,464,000
Cost of contract revenue	228,000	169,000	100,000
Cost of revenues	15,020,000	13,871,000	10,564,000
Gross profit (loss)	276,000	647,000	1,274,000
Formation & operating costs	15,020,000
Sales & marketing expenses	44,995,000	58,674,000	37,575,000
Research & development expenses	15,239,000	24,052,000	16,261,000
General & administrative expenses	43,781,000	36,086,000	24,836,000
Total operating expenses	104,015,000	118,812,000	78,672,000
Income (loss) from operations	(103,739,000)	(118,165,000)	(77,398,000)
Interest income, net	...	1,341,000	151,000
Change in fair value of warrant liability	5,000	141,000	(1,088,000)
Interest income (expense)	2,846,000
Total other income (expense)	2,851,000	1,482,000	(937,000)
Net income (loss)	(100,888,000)	(116,683,000)	(78,335,000)
Weighted average shares outstanding - basic	32,641,376	30,038,959	28,884,874
Weighted average shares outstanding - diluted	32,641,376	30,038,959	28,884,874
Year end shares outstanding	34,524,677	30,297,408	29,772,922
Net earnings (loss) per share - basic	\$(3.09)	\$(3.88)	\$(2.71)
Net earnings (loss) per share - diluted	\$(3.09)	\$(3.88)	\$(2.71)
Number of full time employees	206	278	255
Number of part time employees	...	1	3
Total number of employees	206	279	258
Number of common stockholders	163	166	172
Income from cont operations before income tax	(100,888,000)
Earnings per share from continuing operations	\$(3.09)
Earnings per share from continuing operations	\$(3.09)

Reclassified to conform with 2022 presentation; Shares increased due to the effect of issuance of common stock, through at-the-market offering; option and warrant exercises, restricted stock unit releases and Employee Stock Purchase Plan; Approximately; As of February 24, 2023; As of March 8, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	36,741,000	77,757,000
Short-term marketable securities	19,123,000	48,411,000
Accounts receivable - Balancing value	2,484,000	...
Accounts receivable, net	2,584,000	4,172,000
Inventory	1,004,000	1,757,000
Prepaid insurance	...	1,285,000
Prepaid trade shows	...	907,000
Prepaid software fees	...	831,000
Deferred issuance costs	100,000	...
Prepaid employee compensation	...	184,000
Other current assets	581,000	733,000
Prepaid expenses & other current assets	2,300,000	3,940,000
Prepaid expenses	1,719,000	...
Total current assets	61,752,000	136,037,000
Laboratory equipment	6,100,000	6,250,000
Computer equipment	831,000	872,000
Furniture & fixtures	1,248,000	913,000
Leasehold improvements	604,000	1,344,000
Total property & equipment, gross	8,783,000	9,379,000
Less: accumulated depreciation	3,795,000	3,004,000
Property & equipment, net	4,988,000	6,375,000
Operating lease right-of-use assets	51,722,000	56,007,000
Other assets	...	168,000
Restricted cash	3,468,000	3,488,000
Total assets	121,930,000	202,075,000
Accounts payable	1,484,000	2,419,000
Accrued bonus & commissions	3,534,000	3,257,000
Accrued salaries & wages	3,130,000	2,199,000
Accrued paid time off	...	1,835,000
Other accrued compensation	6,664,000	603,000
Accrued compensation	...	7,894,000
Accrued consulting services	262,000	894,000
Customer refund liability	1,008,000	980,000
Other accrued expenses	737,000	1,590,000
Accrued liabilities	...	3,464,000
Short-term deferred revenue	196,000	109,000
Current portion of operating lease liabilities	3,069,000	1,634,000
Current portion of finance lease obligations	17,000	116,000
Restructuring liability	10,000	...
Accrued liabilities - Balancing value	2,017,000	...
Total current liabilities	13,447,000	15,636,000
Warrant liability	...	5,000
Long-term finance lease obligations, less current portion	38,000	53,000
Operating lease liabilities, long-term	51,270,000	54,028,000
Total liabilities	64,755,000	69,722,000
Common stock	3,000	3,000
Additional paid-in capital	480,929,000	456,171,000
Accumulated other comprehensive income (loss)	178,000	(774,000)
Retained earnings (accumulated deficit)	(423,935,000)	(323,047,000)
Total stockholders' equity (deficit)	57,175,000	132,353,000
Total Equity	57,175,000	...

Recent Dividends:

1. DermTech Inc series A convertible preferred.

No dividends paid.

2. DermTech Inc ordinary.

No dividends paid.

3. DermTech Inc ordinary subject to possible redemption.

No dividends paid.

4. DermTech Inc common.

No dividends paid.

Annual Dividends:

1. DermTech Inc series A convertible preferred.

No dividends paid.

2. DermTech Inc ordinary.

No dividends paid.

3. DermTech Inc ordinary subject to possible redemption.

No dividends paid.

4. DermTech Inc common.

No dividends paid.

DIANTHUS THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
License revenue-related party	2,826
Total revenues	2,826
Research & development	32,841	55,141	46,766
Personnel related expenses (including stock-based compensation)	...	13,165	13,902
Professional & consultant expenses	...	5,308	6,555
Facility related & other expenses	...	7,288	7,469
General & administrative expenses	18,159	25,761	27,926
Total operating expenses	51,000	80,902	74,692
Income (loss) from operations	(48,174)	(80,902)	(74,692)
Interest & other income, net	(60)	4,440	3,556
Interest income	4,764
Foreign Exchange Gain/Loss - Non-Business	(85)
Net Income before Tax	(43,555)
Net income (loss)	(43,555)	(76,462)	(71,136)
Weighted average shares outstanding - basic	5,153	3,711	3,434
Weighted average shares outstanding - diluted	5,153	3,711	3,434
Year end shares outstanding	14,818	3,790	3,675
Net earnings (loss) per share - basic	\$(8.45)	\$(20.64)	\$(20.64)
Net earnings (loss) per share - diluted	\$(8.45)	\$(20.64)	\$(20.64)
Number of full time employees	53	67	75
Number of common stockholders	50	3	...
Total number of employees	53

Adjusted for 1-for-16 stock split, September 12, 2023; Shares increased due to the effect of issuance of common stock upon private investment, vesting restricted stock, exercise of stock options, employee stock purchase plan; As is; As of January 31, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022							
Cash & cash equivalents	132,325	57,626				operation per share			
Marketable securities	...	54,415				- basic	\$(0.04)	\$(0.09)	...
Prepaid expenses & other current assets	3,255	3,561				Net income (loss)			
Short-term investments	41,393	...				per share - basic	\$(0.04)	\$(0.09)	\$(0.02)
Receivable from related party	294	...				Net income (loss)			
Unbilled receivable from related party	184	...				from continued operation per share			
U.S. treasury securities	36,418	...				- diluted	\$(0.01)	\$(0.00)	...
U.S. government agency securities	4,975	...				Earn per share-inc			
Prepaid materials, supplies and research and development	2,155	...				from discount ops			
Prepaid insurance	596	...				- diluted	\$(0.04)	\$(0.09)	...
Prepaid subscriptions, software and other administrative	504	...				Net income (loss)			
Total current assets	177,451	115,602				from discontinued operation per share			
Restricted cash	1,154	1,780				- diluted	\$(0.04)	\$(0.09)	...
Operating lease, right-of-use asset	615	23,168				Net income (loss)			
Laboratory & computer equipment	282	6,954				per share - diluted	\$(0.04)	\$(0.09)	...
Furniture & fixtures	48	826				Net income (loss)			
Leasehold improvements	...	6,905				per share - diluted	\$(0.04)	\$(0.09)	\$(0.02)
Computer Software & Equipment - Tangible Assets - Gross	234	...				Number of full time employees	1
Total property & equipment, gross	...	14,685				Total number of employees	1	...	30
Less accumulated depreciation & amortization	97	8,590				Loss from discontinued operations	(967,497)	(2,303,777)	...
Property & equipment, net	185	6,095				Net Income Before Extraordinary and Preferred Dividends	(185,747)	(125,449)	...
Total assets	179,405	146,645							
Accounts payable	2,610	2,454							
Accrued payroll & related expenses	5,361	4,162							
Accrued external research & development expenses	456	3,091							
Deferred rent, current portion	100	...							
Accrued professional fees	422	...							
Other accrued expenses	6,504	1,018							
Accrued other	265	...							
Accrued expenses & other current liabilities	...	8,271							
Operating lease liability	417	3,824							
Total current liabilities	9,631	14,549							
Operating lease liability, net of current portion	168	26,138							
Deferred rent	736	...							
Total liabilities	10,535	40,687							
Common stock	15	61							
Additional paid-in capital	258,231	508,107							
Accumulated other comprehensive income (loss)	47	(181)							
Retained earnings (accumulated deficit)	(89,423)	(402,029)							
Total stockholders' equity (deficit)	168,870	105,958							
Total Equity	168,870	...							
Recent Dividends:									
1. Dianthus Therapeutics Inc common.									
No dividends paid.									
2. Dianthus Therapeutics Inc series A redeemable convertible preferred.									
No dividends paid.									
3. Dianthus Therapeutics Inc series B redeemable convertible preferred.									
No dividends paid.									
Annual Dividends:									
1. Dianthus Therapeutics Inc common.									
No dividends paid.									
2. Dianthus Therapeutics Inc series A redeemable convertible preferred.									
No dividends paid.									
3. Dianthus Therapeutics Inc series B redeemable convertible preferred.									
No dividends paid.									
Annual Dividends:									
1. Dianthus Therapeutics Inc common.									
No dividends paid.									
2. Dianthus Therapeutics Inc series A redeemable convertible preferred.									
No dividends paid.									
3. Dianthus Therapeutics Inc series B redeemable convertible preferred.									
No dividends paid.									
Annual Dividends:									
1. Dianthus Therapeutics Inc common.									
No dividends paid.									
2. Dianthus Therapeutics Inc series A redeemable convertible preferred.									
No dividends paid.									
3. Dianthus Therapeutics Inc series B redeemable convertible preferred.									
No dividends paid.									
Annual Dividends:									
1. Dianthus Therapeutics Inc common.									
No dividends paid.									
2. Dianthus Therapeutics Inc series A redeemable convertible preferred.									
No dividends paid.									
3. Dianthus Therapeutics Inc series B redeemable convertible preferred.									
No dividends paid.									
Annual Dividends:									
1. Dianthus Therapeutics Inc common.									
No dividends paid.									
2. Dianthus Therapeutics Inc series A redeemable convertible preferred.									
No dividends paid.									
3. Dianthus Therapeutics Inc series B redeemable convertible preferred.									
No dividends paid.									
Annual Dividends:									
1. Dianthus Therapeutics Inc common.									
No dividends paid.									
2. Dianthus Therapeutics Inc series A redeemable convertible preferred.									
No dividends paid.									
3. Dianthus Therapeutics Inc series B redeemable convertible preferred.									
No dividends paid.									

No dividends paid.
4. DLT Resolution Inc series A convertible preferred.
 No dividends paid.
Annual Dividends:
1. DLT Resolution Inc common.
 No dividends paid.
2. DLT Resolution Inc series B convertible preferred.
 No dividends paid.
3. DLT Resolution Inc series A convertible preferred.
 No dividends paid.
4. DLT Resolution Inc series A convertible preferred.
 No dividends paid.

DOCGO INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
General & administrative expenses	137,152,512	103,403,416	74,892,828
Sales of Goods & Services - Net	624,288,642
Revenue, net	624,288,642	440,515,746	318,718,580
Cost of revenues	428,906,225	285,794,520	208,971,062
Depreciation & amortization	16,431,892	10,565,578	7,511,579
Legal & regulatory	13,082,569	8,780,590	3,907,660
Technology & development	10,858,724	5,384,853	3,320,183
Sales, advertising & marketing	2,801,740	4,755,161	4,757,970
Depreciation	4,829,780
Amortization of Intangibles excluding Goodwill	5,249,358
Depreciation of Financial Lease Right-of-Use Assets	6,352,754
Total expenses	609,233,662	418,684,118	303,361,282
Income (loss) from operations	15,054,980	21,831,628	15,357,298
Interest income (expense), net	1,684,399	762,685	(763,030)
Gain from PPP loan forgiveness	1,437,525	...	142,667
Gain (loss) on disposal of fixed assets	(852,544)	(21,173)	(34,342)
Goodwill impairment	...	2,921,958	...
Gain on remeasurement of warrant liabilities	(866)	1,127,388	5,199,496
Loss (gain) on equity method investment	(343,336)	8,919	(66,818)
Gain on remeasurement of finance leases	...	1,388,273	...
Gain on bargain purchase	...	1,593,612	...
Other income (expenses)	(686,865)	(987,482)	(40,086)
Total other income (expense)	1,238,313	950,264	4,437,887
Net income (loss) before income tax benefit (expense)	16,293,293	22,781,892	19,795,185
Current federal income tax	...	1,493,772	295,956
Current state & local income tax	...	502,872	319,741
Deferred federal income tax	...	(7,683,475)	...
Deferred state & local income tax	...	(2,649,791)	...
Deferred foreign income tax	...	375,301	...
Provision (benefit) for income tax	6,244,965	(7,961,321)	615,697
Net loss attributable to noncontrolling interests	(3,189,873)	3,841,285	4,564,270
Net income (loss)			

attributable to stockholders of DocGo Inc. & Subsidiaries	6,858,455	34,584,498	23,743,758
Net income (loss)	10,048,328	30,743,213	19,179,488
Weighted average shares outstanding - basic	103,511,299	101,228,369	80,293,959
Weighted average shares outstanding - diluted	105,617,817	102,975,831	94,863,613
Year end shares outstanding	104,055,168	102,411,162	100,133,953
Net income (loss) per share - basic	\$0.07	\$0.34	\$0.30
Net income (loss) per share - diluted	\$0.06	\$0.34	\$0.25
Number of full time employees	2,915	2,064	1,706
Number of part time employees	1,249	1,188	1,218
Total number of employees	4,164	3,252	2,924
Number of common stockholders	64	103	103
Foreign currency translation adjustments	...	773,707	...

As of March 14, 2023; As of March 11, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	59,286,147	157,335,323
Accounts receivable, gross	268,359,916	110,814,099
Less: allowance	6,276,454	7,818,702
Accounts receivable, net of allowance of \$ 7,377,389 and \$ 3,193,048 as of 31, 2021 and 2020, respectively	262,083,462	...
Accounts receivable, net	...	102,995,397
Prepaid expenses & other current assets	17,499,953	6,269,841
Assets held for sale	...	4,480,344
Total current assets	338,869,562	271,080,905
Office equipment & furniture	7,104,161	2,686,065
Buildings	527,283	527,283
Land	37,800	37,800
Transportation equipment	17,438,072	20,773,862
Medical equipment	3,701,657	5,177,520
Leasehold improvements	709,619	579,658
Property & equipment, gross	29,518,592	29,782,188
Less: accumulated depreciation	12,683,108	8,524,013
Right of Use Tangible Assets - Capital/Finance Lease - Accumulated Depreciation	11,679,823	...
Property & equipment, net	16,835,484	21,258,175
Intangibles, net	37,682,928	22,969,246
Goodwill	47,539,929	38,900,413
Restricted cash	12,931,839	6,773,751
Operating lease right-of-use assets	9,580,535	9,074,277
Finance lease right-of-use assets	12,003,919	9,039,663
Equity method investment	553,573	597,977
Deferred tax assets	11,888,539	9,957,967
Other assets	2,565,649	3,625,254
Finance lease right-of-use assets - Balancing value	23,683,742	...
Total assets	490,451,957	393,277,628
Accounts payable	19,827,258	21,582,866
Accrued bonus	4,784,005	1,500,717
Accrued lab fees	...	584,203
Accrued payroll	12,881,902	4,245,838
FICA/Medicare liability	...	555,166
Accrued general expenses	...	11,436,462

Accrued subcontractors	...	8,101,150
Accrued fuel & maintenance	...	253,243
Accrued workers compensation & insurance liabilities	6,464,192	3,766,469
Accrued legal fees	...	344,417
Credit card payable	...	78,838
Other current liabilities	2,350,523	706,528
Accrued liabilities	91,340,609	31,573,031
Line of credit	25,000,000	...
Notes payable, current	28,131	664,913
Due to seller	7,823,009	26,244,133
Contingent consideration	19,792,982	10,555,540
Operating lease liability, current	2,773,020	2,325,024
Liabilities held for sale	...	4,480,344
Finance lease liability, current	3,534,073	2,732,639
Accrued liabilities - Balancing value	64,859,987	...
Total current liabilities	170,119,082	100,158,490
Notes payable, non-current	41,586	1,236,601
Operating lease liability, non-current	7,223,941	7,040,982
Finance lease liability, non-current	7,896,392	5,914,164
Total liabilities	185,281,001	114,350,237
Class A common stock	10,406	10,241
Additional paid-in capital	320,693,866	301,451,435
Retained earnings (accumulated deficit)	(21,394,310)	(28,972,216)
Accumulated other comprehensive income (loss)	1,484,905	741,206
Total stockholders' equity attributable to DocGo Inc. & subsidiaries	300,794,867	273,230,666
Noncontrolling interests	4,376,089	5,696,725
Total stockholders' equity	305,170,956	278,927,391

Recent Dividends:

1. DocGo Inc class A common subject to possible redemption.

No dividends paid.

2. DocGo Inc class A common.

No dividends paid.

3. DocGo Inc class B common.

No dividends paid.

Annual Dividends:

1. DocGo Inc class A common subject to possible redemption.

No dividends paid.

2. DocGo Inc class A common.

No dividends paid.

3. DocGo Inc class B common.

No dividends paid.

DOLPHIN ENTERTAINMENT INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Total revenues	31,100,867	29,366,748
Cost & expenses	41,616,187	29,726,661
Operating income	(12,128,096)	(1,608,534)
Interest income	309,424	...
Other income (expense), net	(6,444)	682,522
Gains or losses	5,000	...
Equity earnings	1,467,356	143,623
Net before taxes	(13,233,293)	(1,326,896)
Income taxes	91,243	21,672
Net income	(14,791,892)	(1,492,191)
Balance for common	...	(1,492,191)
Earnings common share		
Primary	\$(1.11)	\$(0.16)
Fully Diluted	\$(1.11)	\$(0.23)
Common Shares:		
Full Diluted	13,328,138	9,437,807
Year-end	14,225,487	9,999,052

DRIVEITAWAY HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Sept. 30 (\$):			
	2023	2022	2021
Royalties fees	773,592
Initial franchise fees	1,257,217
Technology fees	143,614
Merchandise sales	307,284	...	20,771
Insurance revenue	...	33,393	...
Rental revenue	...	69,343	...
Initial fee revenue	...	15,797	...
Miscellaneous revenue	...	42,960	...
Vehicle owner share	...	(66,438)	...
Driver & dealer insurance cost	...	(39,546)	...
Total revenues	307,284	55,509	2,195,194
Cost of goods sold	238,763	38,898	...
Gross profit	68,521	16,611	2,195,194
Salaries & payroll taxes	297,625	388,100	...
Salaries, payroll taxes & stock-based compensation	452,258
Professional, legal & consulting fees	423,631
Professional fees	...	644,189	...
General & administrative	92,749	74,053	...
Software development	56,529	61,542	...
Selling expense	345,101	33,883	...
Loss on legal settlements	290,000
Bad debt expense	(48,621)
Other general & administrative expenses	293,831
Franchise commissions	298,389
Depreciation & amortization	114,543
General advertising	38,972	...	45,997
Total operating expenses	830,976	1,201,767	1,870,028
Operating income (loss)	(762,455)	(1,185,156)	325,166
Gain on change in fair value of the derivative	169,723	435,188	...
Gain on Paycheck Protection Program loan forgiveness	(36,313)	24,148	...
Amortization debt discount	...	677,561	...
Interest expense	173,895	70,346	...
Interest expense - related parties	4,918	2,296	...
Interest income	...	12	...
Other income	(122,279)	646	...
Other income (expense)	(264)
Total other income (expense)	(167,682)	(290,209)	...
Income (loss) before income taxes	(930,137)	(1,475,365)	324,902
Net income (loss)	(930,137)	(1,475,365)	324,902
Weighted average common shares outstanding - basic	106,458,571	50,013,328	13,278,388
Weighted average common shares outstanding - diluted	106,458,571	50,013,328	13,503,269
Year end shares outstanding	106,536,622	105,286,622	13,525,838
Income (loss) per share from continuing operations - basic	\$(0.01)
Net income (loss) per share - basic	\$(0.01)	\$(0.03)	\$0.02

Income (loss) per share from continuing operations - diluted			
	2023	2022	2021
Net income (loss) per share - diluted	\$(0.01)	\$(0.03)	\$0.02
Number of full time employees	...	26	4
Number of part time employees	...	21	...
Number of common stockholders	144	143	130

2021 and prior years for Creative Learning Corporation prior to reverse recapitalization of DriveItAway, Inc.; 2022 As of January 13, 2023; 2023 As of January 9, 2023; 2024 As of December 31, 2021

Consolidated Balance Sheet, Years Ended Sept. 30 (\$):

	2023	2022
Cash	4,632	127,109
Accounts receivable, gross	11,584	6,082
Less: allowance for doubtful accounts	...	0
Accounts receivable, net	11,584	6,082
Prepaid website development	...	10,498
Restricted cash	18,559	...
Total current assets	34,775	143,689
Vehicles, net	184,228	149,428
Vehicles - Balancing value	224,903	...
Less: accumulated depreciation	40,675	...
Intangibles-Website development cost	11,787	...
Total assets	230,790	293,117
Accounts payable	...	198,065
Accrued liabilities	...	29,044
SBA loan	...	5,840
Deferred revenue	7,233	2,101
Due to related party	...	80
Convertible note payable	1,082,654	750,000
Derivative liability	1,317	115,009
Customer deposits	2,234	...
Due to shareholder	25,080	...
Accrued interest-related parties	4,918	...
Accounts payable and accrued liabilities	664,707	...
Promissory notes payable, net of debt discount	50,000	...
Promissory notes payable, in default	12,500	...
Promissory notes payable, net of debt discount	27,437	...
Total current liabilities	1,878,080	1,100,139
SBA loan - noncurrent	114,700	108,860
Convertible note payable - noncurrent, net	...	183,340
Notes payables - net of current portion	175,720	...
Promissory notes payable - noncurrent	16,649	...
Total liabilities	2,185,149	1,392,339
Common stock	10,656	10,531
Additional paid-in capital	1,364,007	1,289,132
Treasury stock, at cost	18,126	18,126
Retained earnings (accumulated deficit)	(3,310,896)	(2,380,759)
Total stockholders' equity (deficit)	(1,954,359)	(1,099,222)
Total equity (deficit)	(1,954,359)	...

Recent Dividends:**1. DriveItAway Holdings Inc common.**

No dividends paid.

Annual Dividends:**1. DriveItAway Holdings Inc common.**

No dividends paid.

DRIVEITAWAY HOLDINGS INC**Earnings, 3 mos. to Dec 31 (Consol. - \$):**

	2023	2022
Total revenues	96,503	48,083
Cost & expenses	291,689	263,516
Operating income	(195,186)	(215,433)
Other income (expense), net	(370,684)	(454,655)
Net before taxes	(715,429)	(721,008)
Net income	(715,429)	(721,008)
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	106,551,722	106,119,657
Year-end	106,536,622	106,536,622

Consolidated Balance Sheet Items, as of (\$):

Assets:	2023	2022
Cash & equivalents	61,167	...
Current assets	68,699	...
Net property & equip.	176,129	...
Total assets	255,243	...
Liabilities:		
Current liabilities	2,805,998	...
Long-term debt	119,033	...
Stockholders' equity	(2,669,788)	...
Net current assets	(2,737,299)	...

DYNAVAX TECHNOLOGIES CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2023	2022	2021
Product revenue, net	213,295	713,645	437,099
Other revenue	18,989	9,038	2,343
Total revenues	232,284	722,683	439,442
Cost of sales - product	...	262,153	173,572
Cost of sales - amortization of intangible assets	50,167
Research & development expenses	54,886	46,600	32,228
Selling, general & administrative expenses	152,946	131,408	100,156
Gain (loss) on sale of assets	1,000	1,000	1,000
Unoccupied facility expense	12,313
Total operating expenses	269,312	439,161	304,956
Income (loss) from operations	(37,028)	283,522	134,486
Interest income	31,993	7,912	140
Interest expense	6,757	6,732	11,176
Sublease income	7,577	7,685	7,735
Change in fair value of warrant liability	...	(1,801)	49,354
Other income (expense)	(152)	111	922
Gain (loss) on extinguishment of debt	(5,232)
Income (loss) before provision for income taxes - U.S.	...	292,460	75,954
Income (loss) before provision for income taxes - non-U.S.	...	1,839	1,567
Income (loss) before income taxes	(4,367)	294,299	77,521
Current income tax expense - federal	(178)	(165)	345
Current income tax expense - state	1,533	897	260
Current income tax expense - non-U.S.	667	411	203
Total current tax

expense	2,022	1,143	808
Provision for income taxes	2,022	1,143	808
Net income (loss)	(6,389)	293,156	76,713
Undistributed earnings allocated to participating securities	...	283	4,569
Net income (loss) allocable to common stockholders	(6,389)	292,873	72,144
Weighted average shares outstanding - basic	128,733	126,398	116,264
Weighted average shares outstanding - diluted	128,733	150,797	133,006
Year end shares outstanding	129,530	127,604	122,945
Net income (loss) per share - basic	\$(0.05)	\$2.32	\$0.62
Net income (loss) per share - diluted	\$(0.05)	\$1.97	\$0.57
Number of full time employees	408
Total number of employees	408	311	311
Number of common stockholders	39	41	40
Foreign currency translation adjustments	...	(1,765)	(2,509)
Basic EPS Excluding ExtraOrdinary Items	\$(0.05)
Diluted EPS Excluding ExtraOrd Items	\$(0.05)

□ As is; □ Approximately; □ As of February 21, 2023; □ As of February 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	150,279	202,004
Marketable securities available-for-sale	592,023	422,391
Accounts receivables, net - Balancing value	52,920	...
Accounts receivables, net	40,607	145,130
Other receivables	3,926	2,385
Raw materials	27,256	25,517
Work-in-process	18,954	23,934
Finished goods	7,080	9,995
Inventories, net	53,290	59,446
Prepaid expenses & other current assets	18,995	85,629
Provision - Doubtful	12,313	...
Accounts	859,120	916,985
Total current assets	15,752	15,139
Manufacturing equipment	2,827	2,360
Lab equipment	5,060	4,720
Computer equipment	2,467	2,464
Furniture & fixtures	37,201	28,822
Leasehold improvements	5,822	11,613
Assets in progress	69,129	65,118
Property, plant & equipment, gross	31,832	27,522
Less accumulated depreciation & amortization	37,297	37,596
Property & equipment, net	24,287	25,745
Operating lease right-of-use assets	2,006	2,006
Goodwill	...	207
Restricted cash	74,325	3,311
Other assets	997,096	985,850
Total assets	5,245	3,211
Accounts payable	2,982	4,775
Accrued research & development	...	107,738
Coalition for Epidemic Preparedness Innovations ("CEPI") accrual

Payroll & related expenses	17,069	14,261
Revenue reserve accruals	21,004	10,552
Accrued inventory	4,456	2,209
Other accrued liabilities	6,919	3,697
Other current liabilities	4,520	3,631
Total current liabilities	62,195	150,074
Convertible notes, net	222,698	221,578
Long-term portion of lease liabilities	29,720	32,801
Other long-term liabilities	74	384
CEPI accrual long-term	60,337	...
Total liabilities	375,024	404,837
Common stock	130	128
Additional paid-in capital	1,554,634	1,510,518
Accumulated other comprehensive gain (loss)	(2,108)	(5,438)
Retained earnings (accumulated deficit)	(930,584)	(924,195)
Total stockholders' equity (deficit)	622,072	581,013
Total stockholders' equity	622,072	...

Recent Dividends:

- Dynavax Technologies Corp series B convertible preferred.**
No dividends paid.
- Dynavax Technologies Corp series B convertible preferred.**
No dividends paid.
- Dynavax Technologies Corp common.**
No dividends paid.

Annual Dividends:

- Dynavax Technologies Corp series B convertible preferred.**
No dividends paid.
- Dynavax Technologies Corp series B convertible preferred.**
No dividends paid.
- Dynavax Technologies Corp common.**
No dividends paid.

EARTH SCIENCE TECHNOLOGIES INC

Earnings, 9 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues	5,937,766	2,533
Cost & expenses	5,189,344	819,893
Operating income	633,864	(817,360)
Other income (expense), net	7,798	724,062
Net before taxes	580,315	(129,896)
Net income	580,315	(129,896)
Earnings common share		
Primary	\$0.00	\$0.00
Fully Diluted	\$0.00	\$0.00
Common Shares:		
Full Diluted	314,850,730	...
Year-end	314,850,730	257,964,406

EBET INC

Earnings, 3 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues	4,284,055	14,407,964
Net Sales	4,284,055	...
Cost & expenses	6,818,785	16,562,883
Operating income	(2,534,730)	(2,154,919)
Interest expense	1,586,388	3,031,348
Gains or losses	...	(142,187)
Foreign currency	301,741	(2,229,311)
Net before taxes	(3,819,377)	(7,557,765)
Net income	(3,819,377)	(7,557,765)
Balance for common	(3,819,377)	(9,094,734)
Earnings common share		
Primary	\$(0.25)	\$(15.90)
Fully Diluted	\$(0.25)	\$(15.90)
Common Shares:		
Full Diluted	14,979,642	570,282
Year-end	14,979,642	575,844

Consolidated Balance Sheet Items, as of (\$):

	2023
Assets:	2023
Cash & equivalents	539,327
Current assets	2,469,307

Net property & equip.	132,120
Total assets	15,479,790
Liabilities:	
Current liabilities	67,394,297
Long-term debt	572,888
Stockholders' equity	(52,487,395)
Net current assets	(64,924,990)

EKSO BIONICS HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Engineering services	18,279,000
Revenue	18,279,000	12,912,000	11,246,000
Cost of Revenue	9,200,000
Cost of revenue	9,200,000	6,698,000	4,497,000
Gross profit (loss)	9,079,000	6,214,000	6,749,000
Website expenses	8,472,000
Sales & marketing expenses	...	7,157,000	7,305,000
Research & development expenses	5,025,000	3,626,000	2,549,000
General & administrative expenses	10,694,000	10,987,000	10,723,000
Total operating expenses	24,191,000	21,770,000	20,577,000
Income (loss) from operations	(15,112,000)	(15,556,000)	(13,828,000)
Interest expense	302,000	156,000	113,000
Gain (loss) on revaluation of warrant liabilities	(133,000)	1,317,000	3,962,000
Gain on forgiveness of note payable	1,099,000
Unrealized loss on foreign exchange	412,000	(655,000)	(867,000)
Other income (expense), net	(63,000)	(30,000)	(17,000)
Total other income (expense), net	(86,000)	476,000	4,064,000
Net income (loss)	(15,198,000)	(15,080,000)	(9,764,000)
Net income (loss) applicable to common shareholders	(15,198,000)
Weighted average shares outstanding - basic	13,867,000	12,962,000	12,193,000
Weighted average shares outstanding - diluted	13,867,000	12,962,000	12,269,000
Year end shares outstanding	14,848,000	13,203,000	12,693,000
Net income (loss) per share - basic	\$(1.10)	\$(1.16)	\$(0.80)
Net income (loss) per share - diluted	\$(1.10)	\$(1.16)	\$(0.88)
Number of full time employees	70	72	55
Number of part time employees	2	1	1
Total number of employees	72	73	56
Number of common stockholders	175	175	179
Foreign currency translation adjustments	...	580,000	830,000
Income from cont operations before income tax	(15,198,000)
Basic EPS Excluding ExtraOrdinary Items	\$(1.10)
Diluted EPS Excluding ExtraOrd Items	\$(1.10)

□ Reclassified to conform with 2022 presentation; □ Shares increased due to issuance of common stock under equity financing, equity incentive plan, exercise of warrants and matching contribu-

tion to 401(k) plan; [□] As of March 23, 2023; [□] As of February 18, 2022; [□] Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):		
	2023	2022
Cash and restricted cash	8,638,000	...
Cash	...	20,525,000
Accounts receivable, gross	5,724,000	4,665,000
Less: allowances	79,000	40,000
Accounts receivable, net	5,645,000	4,625,000
Raw materials	4,298,000	3,837,000
Work in progress	290,000	487,000
Finished goods	462,000	863,000
Subtotal	5,050,000	...
Inventories, net	...	5,187,000
Prepaid expenses & other current assets	875,000	700,000
Total current assets	20,208,000	31,037,000
Company owned fleet	2,828,000	3,468,000
Computer software	234,000	234,000
Leasehold improvement	179,000	142,000
Furniture & office equipment	279,000	...
Furniture, office & leased equipment	...	279,000
Machinery & equipment	236,000	207,000
Tools, molds, dies & jigs	1,418,000	1,347,000
Property & equipment, net, gross	5,174,000	5,677,000
Less: accumulated depreciation - property & equipment	3,156,000	...
Less: accumulated depreciation & amortization - property & equipment	...	2,997,000
Property & equipment, net	2,018,000	2,680,000
Right-of-use assets	977,000	1,307,000
Intangible assets, net	4,892,000	5,217,000
Goodwill	431,000	431,000
Other assets	392,000	231,000
Total assets	28,918,000	40,903,000
Accounts payable	1,847,000	3,151,000
Accrued salaries, benefits & related expenses	2,058,000	1,843,000
Accrued device warranty	2,664,000	274,000
Accrued warranty expense	461,000	...
Other accrued expenses	...	161,000
Device warranty	145,000	...
Accrued liabilities	...	2,278,000
Deferred revenues, current	1,993,000	1,121,000
Note payable, current	1,250,000	2,310,000
Lease liabilities, current	363,000	341,000
Total current liabilities	8,117,000	9,201,000
Deferred revenues	2,169,000	1,032,000
Note payable	4,832,000	3,767,000
Lease liabilities	723,000	1,087,000
Warrant liabilities	366,000	233,000
Other non-current liabilities	105,000	141,000
Total liabilities	16,312,000	15,461,000
Common stock	15,000	13,000
Additional paid-in capital	251,580,000	248,813,000
Foreign currency translation	156,000	563,000
Accumulated other comprehensive income (loss)	156,000	563,000
Retained earnings (accumulated deficit)	(239,145,000)	(223,947,000)
Total stockholders' equity	12,606,000	25,442,000
Total Equity	12,606,000	...

Recent Dividends:

1. Ekso Bionics Holdings Inc common.

No dividends paid.

Annual Dividends:

1. Ekso Bionics Holdings Inc common.

No dividends paid.

ELECTRO-SENSORS, INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Net sales	8,555,000	9,029,000	8,607,000
Cost of goods sold	4,310,000	4,188,000	3,930,000
Gross profit (loss)	4,245,000	4,841,000	4,677,000
Selling & marketing expense	1,332,000	1,516,000	1,373,000
General & administrative expense	1,968,000	2,526,000	1,987,000
Research & development expense	973,000	836,000	876,000
Total operating expenses	4,273,000	4,878,000	4,236,000
Operating income (loss)	(28,000)	(37,000)	441,000
Interest expense	1,000	1,000	1,000
Interest income	407,000	110,000	5,000
Other income (expense)	...	0	14,000
Total non-operating income, net	406,000	109,000	18,000
Income (loss) before income taxes	378,000	72,000	459,000
Current income taxes - federal	201,000	19,000	10,000
Current income taxes - state	1,000	1,000	1,000
Deferred income taxes (benefits) - federal	(99,000)	(48,000)	38,000
Deferred income taxes (benefits) - state	...	0	0
Income taxes expense (benefit)	103,000	(28,000)	49,000
Net income (loss)	275,000	100,000	410,000
Weighted average shares outstanding - basic	3,428,021	3,401,137	3,395,521
Weighted average shares outstanding - diluted	3,428,021	3,432,843	3,444,939
Year end shares outstanding	3,428,021	3,428,021	3,395,521
Income (loss) per share from continuing operations-basic	\$0.08
Net income (loss) per share - basic	\$0.08	\$0.03	\$0.12
Income (loss) per share from continuing operations-diluted	\$0.08
Net income (loss) per share - diluted	\$0.08	\$0.03	\$0.12
Number of full time employees	35	...	33
Number of part time employees	2
Total number of employees	35	35	...
Number of common stockholders	61	64	63
Number of beneficial stockholders	...	1,250	1,300
Total revenues	8,555,000

[□] As of February 28, 2023; [□] As of February 24, 2022; [□] Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	9,870,000	7,646,000

Treasury bills	...	1,980,000
Equity securities	...	56,000
Available-for-sale securities	56,000	...
Trade receivables, gross	1,294,000	1,172,000
Less allowance for doubtful accounts	11,000	11,000
Trade receivables	1,283,000	1,161,000
Raw materials	1,172,000	1,162,000
Work in process	301,000	278,000
Finished goods	288,000	315,000
Reserve for obsolescence	10,000	10,000
Inventories	1,751,000	1,745,000
Other current assets	179,000	214,000
Income tax receivable	...	11,000
Total current assets	13,139,000	12,813,000
Deferred income tax asset	355,000	256,000
Intangible assets, net	...	0
Equipment	282,000	282,000
Furniture & fixtures	463,000	491,000
Right-of-use asset	63,000	30,000
Building	1,373,000	1,373,000
Land	415,000	415,000
Right-of-Use Asset	30,000	...
Property & equipment, gross	2,626,000	2,654,000
Autos	...	63,000
Less accumulated depreciation	1,675,000	1,679,000
Property & equipment, net	951,000	975,000
Total assets	14,445,000	14,044,000
Current maturity of financing lease	...	6,000
Accounts payable	291,000	274,000
Accrued wages & commissions	255,000	328,000
Other accrued expenses	...	22,000
Accrued income taxes	76,000	...
Other	68,000	...
Total current liabilities	690,000	630,000
Financing lease, net of current maturities	...	0
Total long-term liabilities	...	0
Common stock	342,000	342,000
Additional paid-in capital	2,230,000	2,163,000
Retained earnings (accumulated deficit)	11,183,000	10,908,000
Accumulated other comprehensive gain (unrealized gain on available-for-sale securities, net of income tax)	...	1,000
Total stockholders' equity	13,755,000	13,414,000
Total Equity	13,755,000	...

Recent Dividends:

1. Electro-Sensors, Inc. common.

No dividends paid.

Annual Dividends:

1. Electro-Sensors, Inc. common.

No dividends paid.

ELECTRONIC SYSTEMS TECHNOLOGY, INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Sales - net	1,544,821	1,910,061	1,512,028
Cost of sales	749,107	881,409	744,246
Gross profit	795,714	1,028,652	767,782
Advertising	...	8,895	7,979
Dues & subscriptions	...	3,547	2,011
Depreciation	...	444	5,169
Insurance	...	13,485	13,242
Materials & supplies	...	10,370	12,668
Office & administration	...	4,890	4,097

Printing	2,658	3,318	Dies/Molds	73,607	...	for income taxes	(41,221)	(32,863)	(24,777)
Professional services	91,096	138,357	Property & equipment - gross	661,854	647,554	Income tax expense (benefit)	28	34	55
Services purchased in lieu of payroll	45,875	81,250	Accumulated depreciation	643,599	...	Net income (loss)	(37,656)	(32,897)	(24,832)
Rent & utilities	50,308	49,662	Less: accumulated depreciation & amortization	...	646,640	Net income (loss) attributable to common stockholders	(24,832)
Repair & maintenance	4,259	8,096	Property & equipment - net	18,255	914	Weighted average shares outstanding - basic	18,161	13,833	10,445
Salaries & benefits	696,665	614,337	Right of use - asset, net of amortization	30,298	69,419	Weighted average shares outstanding - diluted	18,161	13,833	10,445
Taxes, licenses & health insurance	194,839	183,546	Total assets	1,731,038	2,046,457	Year end shares outstanding	23,198	16,137	13,559
Telephone	5,372	5,968	Accounts payable	37,355	138,996	Net earnings (loss) per share - basic	\$(2.07)	\$(2.38)	\$(2.38)
Warranty expenses	2,897	2,867	Accrued wages	4,188	24,777	Net earnings (loss) per share - diluted	\$(2.07)	\$(2.38)	\$(2.38)
Trade shows	12,199	7,631	Operating lease liability - current	30,773	39,120	Number of full time employees	54	164	176
Travel expenses	15,984	18,955	Accrued vacation payable	21,243	16,846	Number of class A common stockholders	...	16	26
Expenses allocated to cost of sales	(213,445)	(201,499)	Other accrued liabilities	10,221	8,913	Number of class B common stockholders	...	2	2
Operating	979,648	...	Total current liabilities	103,780	228,652	Income from continuing operations	(41,249)
Operating expenses	979,648	950,338	Operating lease liability	...	30,457	Discontinued operations	3,593
Operating income (loss)	(183,934)	78,314	Total liabilities	103,780	259,109	Earnings per share from continuing operations	\$(2.27)
Interest income	23,151	5,217	Common stock	4,947	4,947	Earnings per share-inc from discontinued oper	\$0.20
Gain (loss) on employee retention credit	...	63,000	Additional paid-in capital	933,105	932,412	Earnings per share-total discontinued opers	\$0.20
Gain (loss) on forgiveness of CARES act loan	Retained earnings (accumulated deficit)	689,206	849,989	Earnings per share from continuing operations	\$(2.27)
Total other income (expense)	23,151	68,217	Total stockholders' equity	1,627,258	1,787,348	Earn per share-inc from discount opers - diluted	\$0.20
Net income (loss) before income taxes	(160,783)	146,531	Total Equity	1,627,258	...	Earning per share-total discount opers - diluted	\$0.20
Net income (loss)	(160,783)	146,531				Total number of employees	54
Weighted average shares outstanding - basic	4,946,502	4,946,502							
Weighted average shares outstanding - diluted	4,946,502	4,946,502							
Year end shares outstanding	4,946,502	4,946,502							
Net income (loss) per share - basic	\$(0.03)	\$0.03							
Net income (loss) per share - diluted	\$(0.03)	\$0.03							
Number of full time employees	8	8							
Total number of employees	8	...							
Number of common stockholders	329	335							
Total Revenue	1,544,821	...							
Basic EPS Excluding ExtraOrdinary Items	\$(0.03)	...							
Diluted EPS Excluding ExtraOrd Items	\$(0.03)	...							

Recent Dividends:

1. Electronic Systems Technology, Inc. common.

No dividends paid.

Annual Dividends:

1. Electronic Systems Technology, Inc. common.

No dividends paid.

ELITE PHARMACEUTICALS INC

Earnings, 9 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues	38,676,061	25,513,551
Cost & expenses	30,616,817	20,517,119
Operating income	7,060,185	4,062,901
Interest income	16,085	187
Other income (expense), net	(8,235,073)	561,070
Gains or losses	...	1,000,000
Net before taxes	(1,530,281)	4,841,937
Income taxes	(18,313,045)	50,837
Net income	16,782,764	4,791,100
Balance for common	16,782,764	4,791,100
Earnings common share		
Fully Diluted	\$	\$0.01
Common Shares:		
Full Diluted	1,019,511,813	1,012,480,115
Year-end	1,017,781,199	1,013,915,081

ELUTIA INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

	2023	2022	2021 (revised)
Total revenues	24,745
Net sales	24,745	49,187	47,390
Cost of goods sold	13,692	29,965	28,368
Gross profit	11,053	19,222	19,022
Sales & marketing	13,087	20,195	18,825
General & administrative	14,104	16,627	13,687
Research & development	4,399	8,940	9,266
Fiber Viable Bone Matrix ("FiberCel") litigation costs, net	9,989	5,200	276
Total operating expenses	41,579	50,962	42,054
Income (loss) from operations	(30,526)	(31,740)	(23,032)
Interest expense	5,796	5,282	5,324
Other income (expense), net	(4,899)	4,159	3,579
Income (loss) before provision			

Cash and cash equivalents 19,276 | ... | ... |

Cash ... | 16,989 | ... |

Accounts receivable, gross 3,963 | 6,930 | ... |

Allowance for doubtful accounts 700 | 100 | ... |

Accounts receivable, net 3,263 | 6,830 | ... |

Raw materials 242 | 1,716 | ... |

Work in process 286 | 623 | ... |

Finished goods 3,325 | 7,713 | ... |

Inventory 3,853 | 10,052 | ... |

Receivables of Fiber Viable Bone Matrix ("FiberCel") litigation costs ... | 13,813 | ... |

Prepaid expenses & other current assets 2,165 | 3,015 | ... |

Receivables of FiberCel litigation costs 2,696 | ... | ... |

Total current assets 31,253 | 50,699 | ... |

Processing & research equipment 381 | 4,348 | ... |

Leasehold improvements 92 | 613 | ... |

Office equipment & furniture 86 | 188 | ... |

Reclassified to conform with 2022 presentation; Shares increased due to the effect of issuance of common stock through Employee Stock Purchase Plan and private placement; As is; Approximately; As of March 6, 2023; As of March 4, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash and cash equivalents	19,276	...
Cash	...	16,989
Accounts receivable, gross	3,963	6,930
Allowance for doubtful accounts	700	100
Accounts receivable, net	3,263	6,830
Raw materials	242	1,716
Work in process	286	623
Finished goods	3,325	7,713
Inventory	3,853	10,052
Receivables of Fiber Viable Bone Matrix ("FiberCel") litigation costs	...	13,813
Prepaid expenses & other current assets	2,165	3,015
Receivables of FiberCel litigation costs	2,696	...
Total current assets	31,253	50,699
Processing & research equipment	381	4,348
Leasehold improvements	92	613
Office equipment & furniture	86	188

As of February 14, 2023; As of February 15, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	486,252	751,118
Certificates of deposit	...	251,699
Available-for-sale investments	400,000	...
Accounts receivable, net	52,592	141,394
Parts	...	172,190
Work in progress	313,597	336,298
Finished goods	290,388	216,990
Inventory Parts	118,472	...
Inventories, net	722,457	725,478
Other prepaid expenses	19,278	...
Prepaid expenses	...	42,627
Employee retention tax credit receivable	...	63,000
Accrued interest receivable	1,906	808
Total current assets	1,682,485	1,976,124
Laboratory equipment	554,740	522,575
Software	18,245	35,028
Furniture & fixtures	...	16,344
Dies & molds	15,262	73,607

Computer hardware & software	753	998	Cost & expenses	251,371	178,360	current assets	10,000	1,438
Computer hardware and software	194	...	Operating income	(409,748)	(178,360)	Marketable securities	153,007	...
Property & equipment, gross	...	6,147	Other income (expense), net	(12,877)	(267,262)	Prepaid expenses and other current assets	2,949	...
Less: accumulated depreciation & amortization	581	4,744	Gains or losses	183,690	Restricted cash	54	...
Property & equipment, net	172	1,403	Invest. income	(327,784)	Total current assets	266,151	89,636
Intangible assets, net	11,671	15,069	Foreign currency	(1,406)	(1,212)	Leasehold improvements	1,191	...
Operating lease right-of-use assets & other assets	332	1,670	Net before taxes	(409,748)	Computer equipment	222	...
Total assets	43,428	68,841	Net income	(409,748)	(446,834)	Property & equipment, gross	1,413	...
Accounts payable	2,285	2,328	Earnings common share	Less: accumulated depreciation - property & equipment	671	...
Accrued expenses	9,485	10,103	Common Shares:	Property & equipment, net	742	...
Payables to tissue suppliers	906	3,152	Full Diluted	155,166,088	155,116,088	Right of use assets - operating leases	320	...
Current portion of long-term debt	3,321	...	Year-end	155,166,088	155,116,088	Other assets	4,091	2,323
Current portion of revenue interest obligation	...	8,990	Consolidated Balance Sheet Items, as of (\$):	Deferred offering costs	563	...
Contingent liability for FiberCel litigation	15,024	17,360	Assets:	Total assets	271,867	91,959
Current operating lease liabilities & other current liabilities	11,741	682	Cash & equivalents	248,186	Accounts payable	532	149
Current operating lease liabilities	275	...	Current assets	923,198	Accrued research & development expenses	10,433	85
Total current liabilities	43,037	42,615	Total assets	933,698	Accrued compensation & benefits	3,328	127
Long-term debt	20,356	24,260	Liabilities:	Accrued professional services	...	1,100
Long-term revenue interest obligation	5,360	5,916	Current liabilities	317,838	Accrued other expenses	...	369
Long-term operating lease liabilities	...	956	Stockholders' equity	616,833	Accrued expenses & other current liabilities	10,000	1,681
Other long-term liabilities	515	127	Net current assets	605,360	Operating lease liability, current	335	...
Warrant liability	12,760	...	ENLIVEN THERAPEUTICS INC Annual Report	Accrued expenses and other current liabilities	15,362	...
Total liabilities	82,028	73,874	Consolidated Income Statement, Years Ended Dec. 31 (\$000):	Accrued legal and professional fees	902	...
Class A common stock	4	12	2023	2022	2021 (revised)	Accrued other	364	...
Class B common stock	19	4	Research & development expense	64,574	18,940	Total current liabilities	25,894	1,830
Additional paid-in capital	137,021	132,939	General & administrative expense	18,955	15,330	Long-term liabilities	67	...
Retained earnings (accumulated deficit)	(175,644)	(137,988)	Total operating expenses	83,529	34,270	Total liabilities	25,961	1,830
Total stockholders' equity (deficit)	(38,600)	(5,033)	Gain on asset sale	...	35,000	Common stock	41	27
Total Equity	(38,600)	...	Income (loss) from operations	...	730	Additional paid-in capital	400,172	236,111
□ Approximately	Interest income	11,967	943	Accumulated other comprehensive income (loss)	141	...
Recent Dividends:	Other income (expense)	(22)	(97)	Retained earnings (accumulated deficit)	(154,448)	(146,009)
1. Elutia Inc class A common.	Total other income (expense), net	11,945	846	Total stockholders' equity (deficit)	245,906	90,129
No dividends paid.	Net income (loss) before income tax provision	(71,584)	1,576	Total Equity	245,906	...
2. Elutia Inc class B common.	Income tax provision	...	88			
No dividends paid.	Net income (loss)	(71,584)	1,488			
Annual Dividends:	Net income (loss) attributable to common stockholders	...	1,488	Recent Dividends:		
1. Elutia Inc class A common.	Weighted average shares outstanding - basic	35,546	□6,572	1. Enliven Therapeutics Inc common.		
No dividends paid.	Weighted average shares outstanding - diluted	35,546	□6,596	No dividends paid.		
2. Elutia Inc class B common.	Year end shares outstanding	41,292	□6,572	Annual Dividends:		
No dividends paid.	Net income (loss) per share - basic	\$(2.01)	□\$0.24	1. Enliven Therapeutics Inc common.		
Annual Dividends:	Net income (loss) per share - diluted	\$(2.01)	□\$0.24	No dividends paid.		
1. Elutia Inc class A common.	Number of full time employees	46	□6	ENSYSCOE BIOSCIENCES INC Annual Report		
No dividends paid.	Number of common stockholders	24	□□15	Consolidated Income Statement, Years Ended Dec. 31 (\$):		
2. Elutia Inc class B common.	Total number of employees	46	...	2023	2022	2021 (revised)
No dividends paid.	□ Reclassified to conform with 2022 presentation; □ Adjusted for 1-for-4 stock split, February 24, 2023; □ Shares increased due to issuance of shares and exercise of stock options; □ As is; □ As of February 3, 2023; □ As of January 15, 2022	Total revenues	2,230,520	...
ENCISION INC. Earnings, 9 mos. to Dec 31(Consol. - \$):				Federal grants	2,230,520	2,523,383
2023	2022				Research & development	7,587,473	19,835,875
Total revenues	5,061,338	5,542,722				General & administrative	5,361,234	6,909,603
Cost & expenses	5,372,589	5,765,691				Total operating expenses	12,948,707	26,745,478
Operating income	(311,251)	(222,969)				Income (loss) from operations	(10,718,187)	(24,222,095)
Interest expense	8,758	8,758				Change in fair value of derivative liabilities	...	673,314
Other income (expense), net	8,287	674				Loss on issuance of convertible notes	...	3,609,944
Net before taxes	(355,112)	(231,053)				Issuance costs for convertible notes	1,137,740	1,920,158
Net income	(355,112)	(231,053)				Change in fair value of convertible notes	146,479	5,756,787
Earnings common share				(2,993,060)		
Primary	\$(0.03)	\$(0.02)						
Fully Diluted	\$(0.03)	\$(0.02)						
Common Shares:						
Full Diluted	11,769,543	11,760,820						
Year-end	11,769,543	11,769,543						
ENERTOPIA CORP Earnings, 3 mos. to Nov 30(Consol. - \$):						
2023	2022						
Cash & cash equivalents	100,141	88,198						
Prepaid expenses & other						

Issuance of liability classified warrants ...	(3,737,371)	(1,865,403)	
Change in fair value of liability classified warrants ...	283,958	6,730,613	(1,438,186)
Loss on debt conversions	3,964,633	154,391	
Interest expense, net	353,945	109,525	1,295,307
Other income & expense, net	15,420	86,223	(282,279)
Total other income (expense), net	91,912	14,410	(9,275,470)
Income (loss) before provision for income taxes	(10,626,275)		
Net income (loss)	(10,626,275)	(24,207,685)	(29,145,901)
Net income (loss) attributable to noncontrolling interests	13,201	35,393	62,190
Deemed dividend related to warrants down round provision	12,937	913,204	803,140
Net income (loss) attributable to common stockholders	(10,626,011)	(25,085,496)	(29,886,851)
Weighted average shares outstanding - basic	2,264,060	179,932	84,019
Weighted average shares outstanding - diluted	2,264,060	179,932	84,019
Year end shares outstanding	3,146,076	534,506	102,680
Net earnings (loss) per share - basic	\$(4.69)	139.44	355.68
Net earnings (loss) per share - diluted	\$(4.69)	139.44	355.68
Number of full time employees	7	7	6
Number of part time employees	5	6
Total number of employees	7
Number of common stockholders	71	150	161

Adjusted for 1-for-12 stock split, March 31, 2023; Adjusted for 1-for-20 stock split, October 28, 2022; Approximately; As of March 27, 2023; As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	1,123,604	3,147,702
Unbilled receivable	97,561	276,821
Right-of-use asset	27,165
Prepaid expenses	72,358	...
Prepaid expenses & other current assets	1,067,703	1,847,481
Prepaid insurance	441,871	...
Prepaid research and development	535,474	...
Other current assets	18,000	...
Total current assets	2,288,868	5,299,169
Other assets	419,217	585,883
Total assets	2,708,085	5,885,052
Accounts payable	1,936,007	2,943,791
Accrued expenses & other liabilities	542,260	2,226,494
Lease liability	27,315
Notes payable & accrued interest	854,697	4,266,610
Professional fees	110,202	...
Accrued research and development	329,228	...
Other accrued liabilities	102,830	...
Total current liabilities	3,332,964	9,464,210
Notes payable, net of current portion (at fair		

value)	140,148
Other long-term liabilities	26,388	310,346
Total long-term liabilities	26,388	450,494
Total liabilities	3,359,352	9,914,704
Common stock	315	642
Additional paid-in capital	121,233,901	107,215,977
Retained earnings (accumulated deficit)	(121,557,074)	(110,931,063)
Total Ensysce Biosciences, Inc. stockholders' equity (deficit)	(322,858)	(3,714,444)
Noncontrolling interest in stockholders' equity (deficit)	(328,409)	(315,208)
Total stockholders' equity (deficit)	(651,267)	(4,029,652)

Fair value - Notes payable & accrued expenses: \$4,063,431

Recent Dividends:

1. Ensysce Biosciences Inc common subject to possible redemption.
No dividends paid.

2. Ensysce Biosciences Inc common.
No dividends paid.

Annual Dividends:

1. Ensysce Biosciences Inc common subject to possible redemption.
No dividends paid.

2. Ensysce Biosciences Inc common.
No dividends paid.

ENTERGY TEXAS INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Electric	2,028,586	2,288,905	1,902,511
Fuel, fuel-related expenses, & gas purchased for resale	403,111	443,765	335,742
Purchased power expenses	468,511	717,501	588,941
Other operation & maintenance expenses	323,797	312,340	281,713
Taxes other than income taxes	117,852	101,673	94,989
Other Depreciation and Amortization	278,311
Depreciation & amortization expenses	230,692	214,838
Other regulatory charges (credits) - net	7,324	49,175	59,581
Total operating expenses	1,598,906	1,855,146	1,575,804
Operating income	429,680	433,759	326,707
Allowance for equity funds used during construction	28,193	13,527	9,892
Interest & investment income (loss)	11,116	4,141	837
Miscellaneous - net	(10,411)	(6,572)	721
Interest expense	114,978	95,454	87,787
Allowance for borrowed funds used during construction	10,545	4,547	3,980
Total interest expense	104,433	90,907	83,807
Income before income taxes	354,145	353,948	254,350
Current federal income taxes expense (benefit)	2,851	37,471	(189)
Current state income taxes			

expense (benefit)	3,719	2,260	1,261
Total current income taxes expense (benefit)	6,570	39,731	1,072
Deferred & non-current income taxes expense (benefit) - net	57,066	11,520	25,087
Investment tax credits, net	764	630	633
Income taxes	62,872	50,621	25,526
Distribution for Preferred Shares	2,072
Net income (loss)	291,273	303,327	228,824
Preference dividend requirements	2,072	1,909
Earnings (loss) applicable to common stock	289,201	301,255	226,915
Year end shares outstanding	46,525	46,525	46,525
Full-Time Employees (Period End)	704
Total number of employees	704	648	669
Number of common stockholders	1	1
Shares used to calculate Basic EPS - Total	46,525
Basic (in usd per share)	\$6.22
EPS - Basic - excluding Extraordinary Items Applicable to Common - Total	\$6.22
Shares used to calculate Diluted EPS - Total	46,525
Diluted EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total	\$6.22
Dividends Per Share - Common - Gross - by Period End Date ..	\$1.34

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash	1,497	500
Temporary cash investments	20,489	2,997
Total cash & cash equivalents	21,986	3,497
Securitization recovery trust account	5,195	10,879
Accounts receivable - customer	88,468	115,955
Accounts receivable - allowance for doubtful accounts	1,484	2,352
Accounts receivable - associated companies	115,549
Accounts receivable - other receivable	24,416	21,587
Accounts receivable - accrued unbilled revenues	72,771	69,208
Associated companies	329,941	...
Deferred fuel costs	139,019	258,115
Fuel inventory - at average cost	50,847	26,750
Materials & supplies - at average cost	123,020	93,031
Prepayments & other current assets	20,568
Prepaid Expense and Other Assets	35,232	...
Total current assets	889,411	732,787
Investments in affiliates		

- at equity	214	250
Non-utility property - at cost (less accumulated depreciation)	376	376
Other property & investments	...	18,975
Electric	7,931,340	7,409,461
Construction work in progress	857,707	339,139
Total utility plant	8,789,047	7,748,600
Less - accumulated depreciation & amortization	2,363,919	2,135,400
Utility plant - net	6,425,128	5,613,200
Other regulatory assets	596,606	578,682
Other deferred debits & other assets	...	99,694
Other	129,769	...
Other	15,068	...
Total assets	8,056,572	7,043,964
Accounts payable - associated companies	...	70,321
Accounts payable - other payable	...	201,982
Customer deposits	39,999	38,764
Taxes accrued	78,887	93,033
Interest accrued	31,285	23,928
Other current liabilities	16,237	16,963
Accounts payable	74,423	...
Other Payables	195,703	...
Total current liabilities	436,534	444,991
Accumulated deferred income taxes & taxes accrued	814,905	744,227
Accumulated deferred investment tax credits	7,963	8,711
Regulatory liability for income taxes - net	114,759	132,647
Other regulatory liabilities	43,013	45,247
Asset retirement cost liabilities	11,743	11,121
Accumulated provisions	...	7,593
Mortgage bonds	...	2,630,000
Securitization bonds	...	278,593
Unamortized premium & discount - net	...	11,528
Unamortized debt issuance costs	...	(24,208)
Long-term debt	3,225,092	2,895,913
Other non-current liabilities	...	74,053
Loss Contingency Accrual	9,480	...
Deferred Credits and Other Liabilities	274,421	...
Total non-current liabilities	4,501,376	3,919,512
Common stock	49,452	49,452
Paid-in capital	1,200,125	1,050,125
Retained earnings	1,830,335	1,541,134
Total common shareholder's equity	...	2,640,711
Preferred stock without sinking fund	38,750	38,750
Total equity	3,118,662	2,679,461
Total Equity	3,118,662	...

□ Includes securitization property - Other regulatory assets: \$269,523,000; □ Includes securitization bonds - Long-term debt: \$275,064,000

Recent Dividends:

1. Entergy Texas Inc common.

No dividends paid.

Annual Dividends:

1. Entergy Texas Inc common.

No dividends paid.

ENTERGY TEXAS INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2023	2022
Total revenues	1,588,531	...
Cost & expenses	982,779	1,161,052
Deprec., depl. & amort.	202,288	171,781
Operating income	403,464	363,796

Other income (expense), net	5,006	7,618
Net before taxes	349,234	307,535
Income taxes	69,015	41,645
Net income	280,219	265,890
Balance for common	278,665	264,336
Earnings common share		
Primary	\$5.99	\$5.99
Fully Diluted	\$5.99	\$5.99
Common Shares:		
Full Diluted	46,525	46,525
Year-end	46,525	46,525

ENVVENO MEDICAL CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
			(revised)
Selling, general & administrative expenses	11,655,000	15,018,000	11,165,000
Research & development expenses	13,583,000	9,914,000	5,728,000
Income (loss) from operations	(25,238,000)	(24,932,000)	(16,893,000)
Gain on extinguishment of note payable	313,000
Realized gain from sales of trading securities	1,074,000	53,000	...
Unrealized gain from trading securities	468,000	49,000	...
Interest income (expense), net	180,000	161,000	19,000
Other income (expense)	33,000
Total other income (expense)	1,722,000	263,000	365,000
Net income (loss)	(23,516,000)	(24,669,000)	(16,528,000)
Net income (loss) attributable to common shareholders	...	(24,669,000)	(16,528,000)
Weighted average shares outstanding - basic	12,301,000	11,230,000	8,680,000
Weighted average shares outstanding - diluted	12,301,000	11,230,000	8,680,000
Year end shares outstanding	13,317,000	9,471,932	9,469,850
Earnings per share (loss) from continuing operations - basic	\$(1.91)
Net earnings (loss) per common share - basic	\$(1.91)	\$(2.20)	\$(1.90)
Earnings per share (loss) from continuing operations - diluted	\$(1.91)	\$(2.20)	\$(1.90)
Number of full time employees	...	30	24
Number of common stockholders	72	68	76
Income from cont operations before income tax	(23,516,000)

□ Reclassified to conform with 2022 presentation; □ Shares increased due to the effect of issuance common stock for public offering, exercised warrants, trade payable, at the market transaction, registered direct offering and stock based compensation; □ As of February 27, 2023; □ As of March 24, 2022; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
--	------	------

Cash & cash equivalents	3,620,000	4,555,000
Short-term investments	42,792,000	34,489,000
Prepaid expenses & other current assets	511,000	392,000
Total current assets	46,923,000	39,436,000
Laboratory equipment	548,000	524,000
Furniture & fixtures	...	160,000
Computer software & equipment	373,000	...
Computer equipment	...	222,000
Leasehold improvements	...	213,000
Software	482,000	251,000
Total property & equipment	1,403,000	1,370,000
Less: accumulated depreciation	1,069,000	849,000
Property & equipment, net	334,000	521,000
Operating lease right-of-use assets, net	1,347,000	1,673,000
Security deposits & other assets	31,000	31,000
Total assets	48,635,000	41,661,000
Accounts payable	427,000	648,000
Accrued compensation costs	478,000	391,000
Accrued professional fees	...	62,000
Accrued research & development	...	56,000
Other accrued expenses	128,000	59,000
Accrued expenses & other current liabilities	1,033,000	568,000
Current portion of operating lease liabilities	338,000	314,000
Total current liabilities	1,371,000	1,530,000
Long-term operating lease liabilities	1,064,000	1,402,000
Total liabilities	2,435,000	2,932,000
Common stock	133	...
Additional paid-in capital	176,236,000	145,249,000
Retained earnings (accumulated deficit)	(130,036,000)	(106,520,000)
Total stockholders' equity (deficiency)	46,200,000	38,729,000
Total Equity	46,200,000	...

Recent Dividends:

1. enVveno Medical Corp common.

No dividends paid.

Annual Dividends:

1. enVveno Medical Corp common.

No dividends paid.

ENZON PHARMACEUTICALS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
			(revised)
Royalties & milestones, net	...	26,000	701,000
Total revenues	...	26,000	701,000
General & administrative expenses	1,044,000	1,058,000	1,170,000
Total operating expenses	1,044,000	1,058,000	1,170,000
Operating income (loss)	(1,044,000)	(1,032,000)	(469,000)
Other income	2,261,000	646,000	7,000
Income (loss) before income tax expense (benefit)	1,217,000	(386,000)	(462,000)
Current state income tax provisions (benefit)	1,000
Current state & foreign income tax provisions (benefit)	...	2,000	7,000
Total current

income tax provisions (benefit)	1,000	2,000	7,000
Deferred federal income tax provisions (benefit)	(117,000)	(151,000)	...
Deferred state income tax provisions (benefit)	(40,000)	(51,000)	...
Total deferred income tax provisions (benefit)	(157,000)	(202,000)	...
Income tax expense (benefit)	(156,000)	(200,000)	7,000
Net income (loss)	1,373,000	(186,000)	(469,000)
Dividends on series C preferred stock	1,275,000	1,275,000	2,023,000
Net income (loss) available to common shareholders	98,000	(1,461,000)	(2,492,000)
Weighted average shares outstanding - basic	74,215,000	74,215,000	74,215,000
Weighted average shares outstanding - diluted	74,215,000	74,215,000	74,215,000
Year end shares outstanding	74,214,603	74,214,603	74,214,603
Net income (loss) per share - basic	\$0.00	\$(0.02)	\$(0.03)
Net income (loss) per share - diluted	\$0.00	\$(0.02)	\$(0.03)
Number of common stockholders	...	758	758

As of February 11, 2023; As of February 11, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	47,012,000	46,982,000
Other current assets	331,000	405,000
Total current assets	47,343,000	47,387,000
Deferred tax assets	359,000	202,000
Total assets	47,702,000	47,589,000
Accounts payable	331,000	331,000
Accrued professional & consulting fees	...	87,000
Other accrued expenses & current liabilities	...	6,000
Dividends payable on series C preferred stock	1,275,000	1,275,000
Total current liabilities	1,714,000	1,699,000
Series C preferred stock	42,483,000	42,483,000
Common stock	742,000	742,000
Additional paid-in capital	73,433,000	74,708,000
Retained earnings (accumulated deficit)	(70,670,000)	(72,043,000)
Total stockholders' equity (deficit)	3,505,000	3,407,000
Total Equity	3,505,000	...

Recent Dividends:

- Enzon Pharmaceuticals Inc common.**
No dividends paid.
 - Enzon Pharmaceuticals Inc series C non-convertible redeemable preferred.**
No dividends paid.
- Annual Dividends:**
- Enzon Pharmaceuticals Inc common.**
No dividends paid.
 - Enzon Pharmaceuticals Inc series C non-convertible redeemable preferred.**
No dividends paid.

EO ENERGY ENTERPRISES INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Revenues	16,378,000

Revenue	16,378,000	17,924,000	4,598,000
Cost of goods sold	89,798,000	153,260,000	46,483,000
Research & development expenses	18,708,000	18,469,000	19,154,000
General & administrative expenses	53,650,000
Selling, general & administrative expense	...	60,623,000	42,998,000
Loss on pre-existing agreement	30,368,000
Loss from write-down of property, plant & equipment	7,159,000	6,846,000	50,000
Grant expense (income), net	...	(16,000)	269,000
Total costs & expenses	169,315,000	239,182,000	139,322,000
Operating income (loss)	(152,937,000)	(221,258,000)	(134,724,000)
Interest expense, net	18,770,000	7,915,000	604,000
Interest expense - related party	37,466,000	10,898,000	4,597,000
Remeasurement of equity method investment	(7,480,000)
Gain on change in fair value of derivatives - related parties	...	11,728,000	19,282,000
Change in fair value, embedded derivative	9,983,000
Income (loss) from equity in unconsolidated joint venture	440,000
Gain (loss) on debt forgiveness (extinguishment)	(3,510,000)	(942,000)	1,273,000
Other income (expense) income	(1,795,000)	(477,000)	2,194,000
Sale of state tax attributes	(24,980,000)
Income (loss) before income taxes	(229,475,000)	(229,762,000)	(124,216,000)
Non-US -Current	31,000
Total current income tax (benefit) provision	31,000
Income tax expense	31,000	51,000	...
Net income (loss)	(229,506,000)	(229,813,000)	(124,216,000)
Weighted average shares outstanding - basic	126,967,756	62,439,857	52,664,349
Weighted average shares outstanding - diluted	126,967,756	62,439,857	52,664,349
Year end shares outstanding	199,133,827	82,653,781	53,786,632
Net earnings (loss) per share - basic	\$(1.81)	\$(3.68)	\$(2.36)
Net earnings (loss) per share - diluted	\$(1.81)	\$(3.68)	\$(2.36)
Number of full time employees	420	333	251
Total number of employees	420	...	251
Number of common stockholders	260	258	253
Number of warrant holders	...	3	3
Foreign currency translation adjustments	...	6,000	...

Reclassified to conform with 2022 presentation; Shares increased due to the effect of exercise of warrant, stock units, cancellation of shares used to settle payroll tax withholding, promissory

note, ATM & SEPA program and commitment fee for SEPA; As of February 22, 2023; As of February 16, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	69,473,000	17,076,000
Restricted cash	3,439,000	2,725,000
Accounts receivable - Balancing value	3,413,000	...
Accounts receivable, net	3,387,000	1,666,000
Grants receivable	3,256,000	...
Raw materials	15,487,000	22,899,000
Work-in-process	1,105,000	361,000
Finished goods	478,000	...
Inventory	17,070,000	...
Inventory, net	...	23,260,000
Vendor deposits	7,161,000	4,789,000
Notes receivable, net	...	36,000
Contract assets, current	6,386,000	1,859,000
Prepaid expenses	1,082,000	2,289,000
Other current assets	3,577,000	1,447,000
Other receivables	7,500,000	...
Provision - Accounts & Notes Receivable - Trade	26,000	...
Total current assets	122,331,000	55,147,000
Equipment	20,559,000	23,653,000
Finance lease	504,000	379,000
Furniture	2,103,000	1,868,000
Leasehold improvements	7,718,000	6,303,000
Tooling	7,045,000	6,926,000
Construction in Progress
- Gross	17,958,000	...
Property, plant, & equipment, gross	55,887,000	39,129,000
Less: accumulated depreciation & amortization	18,032,000	11,960,000
Property, plant & equipment, net	37,855,000	27,169,000
Intangible assets, net	295,000	240,000
Goodwill	4,331,000	4,331,000
Notes receivable, net	...	827,000
Operating lease right-of-use asset, net	4,033,000	4,316,000
Long-term restricted cash	11,755,000	11,422,000
Other assets, net	5,892,000	3,336,000
Total assets	186,492,000	106,788,000
Accounts payable	20,540,000	34,669,000
Accrued payroll	4,553,000	2,706,000
Warranty reserve	6,197,000	3,836,000
Accrued legal & professional expenses	10,710,000	840,000
Provision for contract losses	3,351,000	2,561,000
Insurance premium payable, current	2,605,000	2,607,000
Other accrued expenses	...	2,809,000
Other	4,916,000	...
Accrued expenses	32,332,000	15,359,000
Operating lease liability, current	1,496,000	1,106,000
Capital lease, current portion	100,000	...
Long term debt, current portion	3,332,000	2,872,000
Convertible notes payable - related party	...	2,688,000
Other current liabilities	100,000	32,000
Contract liabilities, current	3,070,000	3,850,000
Total current liabilities	60,870,000	60,576,000
Operating lease liability	3,350,000	4,130,000
Long-term debt	88,002,000	87,321,000
Convertible notes payable - related party	112,525,000	82,950,000
Contract liabilities, long-term	3,540,000	956,000
Warrants - related party	...	78,000
Other liabilities	1,544,000	3,488,000
Warrants	27,461,000	...
Total long term liabilities	236,422,000	178,923,000
Total liabilities	297,292,000	239,499,000
Common stock	21,000	9,000

Additional paid in capital	765,018,000	513,614,000
Retained earnings (accumulated deficit)	(875,846,000)	(646,340,000)
Accumulated other comprehensive income	7,000	6,000
Total stockholders' equity (deficit)	(110,800,000)	(132,711,000)
Total Equity	(110,800,000)	...

Recent Dividends:**1. EOS Energy Enterprises Inc class B common.**

No dividends paid.

2. EOS Energy Enterprises Inc common.

No dividends paid.

Annual Dividends:**1. EOS Energy Enterprises Inc class B common.**

No dividends paid.

2. EOS Energy Enterprises Inc common.

No dividends paid.

ESCALON MEDICAL CORP**Earnings, 6 mos. to Dec 31(Consol. - \$):**

	2023	2022
Total revenues	5,814,237	5,610,305
Cost & expenses	5,900,408	5,926,199
Operating income	(86,171)	(315,894)
Interest expense	11,347	10,873
Net before taxes	(97,518)	...
Net income	(97,518)	(326,767)
Balance for common	(123,530)	(352,779)
Earnings common share		
Primary	\$(0.02)	\$(0.05)
Fully Diluted	\$(0.02)	\$(0.05)
Common Shares:		
Full Diluted	7,415,329	7,415,329
Year-end	7,415,329	7,415,329

EVENTIKO INC**Earnings, 9 mos. to Jan 31(Consol. - \$):**

	2024	2023
Total revenues	10,250	10,250
Cost & expenses	10,309	16,092
Operating income	(10,309)	(5,842)
Net before taxes	(10,309)	...
Net income	(10,309)	(5,842)
Earnings common share		
Common Shares:		
Full Diluted	4,192,500	4,192,500
Year-end	4,192,500	4,192,500

EVOKE PHARMA INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021 (revised)
Net product sales	5,180,630	2,508,645	1,618,076
Total revenues	5,180,630
Research & development	181,907	300,789	590,476
Cost of goods sold	201,879	370,394	328,118
Selling, general & administrative	12,227,735	9,623,599	8,851,129
Total operating expenses	12,611,521	10,294,782	9,769,723
Income (loss) from operations	(7,430,891)	(7,786,137)	(8,151,647)
Forgiveness of paycheck protection loan & accrued interest	105,130
Interest income	138,596	62,007	8,615
Interest expense	500,000	500,000	500,050
Total other income (expense)	(361,404)	(437,993)	(386,305)
Net income (loss)	(7,792,295)	(8,224,130)	(8,537,952)
Weighted average shares outstanding			
- basic	3,343,070	3,143,626	2,682,145
Weighted average shares outstanding - diluted	3,343,070	3,143,626	2,682,145
Year end shares outstanding	3,343,070	3,343,070	2,721,373

Net earnings (loss) per common share - basic	\$(2.33)	\$(2.62)	Ⓜ\$(3.18)
Net earnings (loss) per common share - diluted	\$(2.33)	\$(2.62)	Ⓜ\$(3.18)
Number of full time employees	4	4	Ⓜ4
Number of common stockholders	5	Ⓜ5	Ⓜ8
Income from cont operations before income tax	(7,792,295)
Earnings per share from continuing operations	\$(2.33)
Earnings per share from continuing operations	\$(2.33)
Total number of employees	4

Ⓜ Reclassified to conform with 2022 presentation; Ⓜ Adjusted for 1-for-12 stock split, May 23, 2022; Ⓜ Shares increased due to the effect of issuance of common shares from At the Market Equity Offering Program; Ⓜ Shares increased due to the effect of issuance of common stock, stock option exercised and ATM offering; Ⓜ As of February 28, 2022; Ⓜ As of February 28, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	4,739,426	9,843,699
Accounts receivable, net	673,071	624,832
Prepaid expenses	885,040	952,954
Inventory	481,840	...
Inventory, net	...	289,378
Other current assets	47,532	11,551
Total current assets	6,826,909	11,722,414
Operating lease right-of-use asset	...	129,074
Deferred offering costs	241,637	...
Total assets	7,068,546	11,851,488
Accounts payable & accrued expenses	...	934,312
Accrued compensation	1,324,010	591,158
Operating lease liability	...	129,074
Milestone payable	1,711,778	...
Total current liabilities	3,035,788	1,654,544
Note payable	5,000,000	5,000,000
Accrued interest payable	1,612,295	1,112,295
Total long-term liabilities	6,612,295	6,112,295
Total liabilities	9,648,083	7,766,839
Common stock	334	334
Additional paid-in capital	120,859,567	119,731,458
Retained earnings (accumulated deficit)	(123,439,438)	(115,647,143)
Total stockholders' equity (deficit)	(2,579,537)	4,084,649
Total Equity	(2,579,537)	...

Recent Dividends:**1. Evoke Pharma Inc common.**

No dividends paid.

Annual Dividends:**1. Evoke Pharma Inc common.**

No dividends paid.

EVOLV TECHNOLOGIES HOLDINGS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
Product revenue	21,977,000	31,985,000	13,917,000
Subscription revenue	37,247,000	17,569,000	7,855,000
Service revenue	16,141,000	5,641,000	1,920,000
License fee and other revenue	5,053,000
Total revenue	80,418,000	55,195,000	23,692,000
Cost of product revenue	26,667,000	41,575,000	12,471,000

Cost of subscription revenue	14,991,000	7,469,000	3,644,000
Cost of service revenue	3,982,000	4,422,000	936,000
Cost of license fee and other revenue	949,000
Total cost of revenue	46,589,000	53,466,000	17,051,000
Gross profit	33,829,000	1,729,000	6,641,000
Research & development expenses	24,455,000	18,771,000	11,416,000
Sales & marketing expenses	55,223,000	46,639,000	27,404,000
Personnel related	...	17,369,000	7,731,000
Professional fees	...	8,715,000	6,241,000
Director & officer insurance	2,187,000
Insurance costs	...	4,514,000	...
Non-income taxes	...	540,000	...
Sales tax contingencies	1,091,000
Facilities related & other	2,763,000
Other general & administrative expenses	...	6,581,000	...
General & administrative expenses	42,091,000	37,719,000	20,013,000
Loss from impairment of property & equipment	322,000	1,161,000	1,869,000
Total operating expenses	122,091,000	104,290,000	60,702,000
Income (loss) from operations	(88,262,000)	(102,561,000)	(54,061,000)
Interest expense	654,000	712,000	...
Interest income	6,227,000	3,165,000	...
Other expense, net	(84,000)	(64,000)	...
Interest expense, net	6,095,000
Gain (loss) on disposal of property & equipment	(617,000)
Gain (loss) on extinguishment of debt	(626,000)	...	(12,685,000)
Change in fair value of derivative liability	(1,745,000)
Change in fair value of contingent earn-out liability	(14,901,000)	6,988,000	46,212,000
Change in fair value of contingently issuable common stock liability	(3,138,000)	1,872,000	6,406,000
Change in fair value of public warrant liability	(4,765,000)	4,906,000	12,606,000
Change in fair value of common stock warrant liability	(879,000)
Total other income (expense), net	(17,941,000)	16,155,000	43,203,000
Income (loss) before provision for income tax	(106,203,000)
Net income (loss)	(106,254,000)	(86,406,000)	(10,858,000)
Net income (loss) attributable to common stockholders	...	(86,406,000)	(10,858,000)
Weighted average shares outstanding			
- basic	149,168,105	143,858,668	71,662,694
Weighted average shares outstanding - diluted	149,168,105	143,858,668	71,662,694

Year end shares outstanding	151,310,080	145,204,974	142,745,021
Net earnings (loss) per share - basic	\$(0.71)	\$(0.60)	\$(0.15)
Net earnings (loss) per share - diluted	\$(0.71)	\$(0.60)	\$(0.15)
Full-Time Employees (Period End)	293
Total number of employees	293	225	173
Number of common stockholders	60	95	177
Foreign currency translation adjustments	...	(10,000)	...
State	27,000
Foreign	24,000
Income Taxes - Total - Current	51,000
Provision for income taxes	51,000

December 31, 2021 & prior financials for the NewHold Investment Corp prior to reverse acquisition with Evolv Technologies, Inc. dba Evolv Technology, Inc. ("Legacy Evolv"); Approximately; As of March 23, 2023; As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	67,162,000	229,783,000
Restricted cash	275,000	...
Marketable securities	51,289,000	...
Accounts receivable, gross	23,193,000	32,120,000
Less: allowance for doubtful debt	582,000	200,000
Accounts receivable, net	22,611,000	31,920,000
Raw materials	1,869,000	2,334,000
Finished goods	7,638,000	7,923,000
Inventory	9,507,000	10,257,000
Current portion of contract assets	3,707,000	2,852,000
Current portion of commission asset	4,339,000	3,384,000
Prepaid deposits	12,177,000	9,666,000
Prepaid subscriptions	1,868,000	897,000
Current portion of net investment in sales-type leases	367,000	337,000
Prepaid insurance	1,208,000	2,374,000
Other current assets	1,334,000	1,114,000
Prepaid expenses & other current assets	16,954,000	14,388,000
Total current assets	175,844,000	292,584,000
Cash & investments held in trust account	451,000	...
Restricted cash, noncurrent	...	275,000
Contract assets, noncurrent	...	1,386,000
Commission asset, noncurrent	7,107,000	5,655,000
Computers & telecom equipment	1,331,000	599,000
Lab equipment	1,171,000	871,000
Furniture & fixtures	111,000	111,000
Leasehold improvements	566,000	542,000
Leased equipment	80,206,000	35,983,000
Internal-use software	8,629,000	4,150,000
Sales demo equipment	2,758,000	2,340,000
Equipment held for lease	32,910,000	7,826,000
Construction in progress	2,493,000	71,000
Less: accumulated depreciation & amortization	17,254,000	7,786,000
Property & equipment, net	112,921,000	44,707,000
Operating lease right-of-use assets	1,195,000	1,673,000
Other assets	1,202,000	1,835,000
Total assets	298,720,000	348,115,000
Accounts payable	17,400,000	18,194,000
Accrued employee

compensation & benefits expense	7,780,000	7,225,000
Accrued professional services & consulting	1,579,000	722,000
Accrued sales tax	1,643,000	1,680,000
Accrued interest	...	54,000
Other current liabilities	...	1,864,000
Accrued expenses & other current liabilities	15,578,000	11,545,000
Current portion of deferred revenue	47,677,000	18,273,000
Current portion of deferred rent	1,188,000	...
Current portion of long-term debt	...	10,000,000
Current portion of operating lease liabilities	1,391,000	1,114,000
Other	3,388,000	...
Total current liabilities	82,046,000	59,126,000
Deferred revenue, noncurrent	23,813,000	17,695,000
Term loans payable	...	30,000,000
Less: unamortized discount	...	(317,000)
Long-term debt, gross	...	29,683,000
Less: current portion of long-term debt	...	10,000,000
Long-term debt, noncurrent	...	19,683,000
Operating lease liabilities, noncurrent	...	892,000
Contingent earn-out liability	29,119,000	14,218,000
Contingently issuable common stock liability	6,530,000	3,392,000
Public warrant liability	10,889,000	6,124,000
Total liabilities	152,397,000	121,130,000
Common stock	15,000	15,000
Additional paid-in capital	444,825,000	419,190,000
Accumulated other comprehensive income (loss)	(53,000)	(10,000)
Retained earnings (accumulated deficit)	(298,464,000)	(192,210,000)
Stockholders' equity (deficit)	146,323,000	226,985,000
Total Equity	146,323,000	...

Recent Dividends:

- 1. Evolv Technologies Holdings Inc common.**
No dividends paid.
 - 2. Evolv Technologies Holdings Inc class A common.**
No dividends paid.
 - 3. Evolv Technologies Holdings Inc class B common.**
No dividends paid.
- Annual Dividends:**
- 1. Evolv Technologies Holdings Inc common.**
No dividends paid.
 - 2. Evolv Technologies Holdings Inc class A common.**
No dividends paid.
 - 3. Evolv Technologies Holdings Inc class B common.**
No dividends paid.

EXACT SCIENCES CORP.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Product revenue	2,499,766,000
Revenue	2,499,766,000	2,084,279,000	1,767,087,000
Cost of sales (exclusive of amortization of acquired intangibles)	654,248,000	574,394,000	458,757,000
Research & development expense	425,882,000	393,418,000	385,646,000
General & administrative expense	893,204,000	737,304,000	801,262,000
Amortization of acquired intangible

assets	92,160,000	97,450,000	95,001,000
Impairment of long-lived assets	621,000	15,969,000	20,210,000
Sales & marketing expense	...	846,011,000	861,889,000
Selling, general & administrative expense	727,090,000
Total operating expenses	...	2,664,546,000	2,622,765,000
Other operating income (loss)	78,427,000	(13,244,000)	...
Income (loss) from operations	(215,012,000)	(593,511,000)	(855,678,000)
Investment income (loss), net	...	(19,425,000)	31,778,000
Interest expense	19,447,000	19,634,000	18,606,000
Investment income	32,713,000
Total other income (expenses)	13,266,000	(39,059,000)	13,172,000
Net income (loss) before tax	(201,746,000)	(632,570,000)	(842,506,000)
Current state income taxes	2,266,000	2,170,000	1,388,000
Current foreign income taxes	2,561,000	1,131,000	4,898,000
Deferred federal income taxes	2,395,000	(3,292,000)	(222,693,000)
Deferred state income taxes	(1,829,000)	(8,926,000)	(30,528,000)
Deferred foreign income taxes	(2,990,000)	(147,000)	54,000
Income tax expense (benefit)	2,403,000	(9,064,000)	(246,881,000)
Net income (loss)	(204,149,000)	(623,506,000)	(595,625,000)
Weighted average shares outstanding - basic	180,144,000	176,351,000	171,348,000
Weighted average shares outstanding - diluted	180,144,000	176,351,000	171,348,000
Year end shares outstanding	181,364,180	177,925,631	173,674,067
Net income (loss) per share - basic	\$(1.13)	\$(3.54)	\$(3.48)
Net income (loss) per share - diluted	\$(1.13)	\$(3.54)	\$(3.48)
Number of full time employees	6,500	6,300	6,420
Number of part time employees	100	100	80
Total number of employees	6,600	6,400	6,500
Number of common stockholders	179	182	201
Foreign currency translation adjustments	...	30,000	23,000
Basic EPS Excluding ExtraOrdinary Items	\$(1.13)
Diluted EPS Excluding ExtraOrd Items	\$(1.13)

Reclassified to conform with 2022 presentation; Approximately; As of February 20, 2023; As of February 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash and money market	530,100,000	...
Cash equivalents	75,278,000	...
Cash & cash equivalents	605,378,000	242,493,000
Marketable securities	172,266,000	389,564,000
Accounts receivable, net	203,623,000	158,043,000
Raw materials	58,593,000	61,207,000
Semi-finished & finished goods	68,882,000	57,052,000
Inventory	127,475,000	...
Inventory, net	...	118,259,000
Prepaid expenses & other current assets	85,627,000	73,898,000
Total current assets	1,194,369,000	982,257,000
Land	4,716,000	4,716,000

Leasehold & building improvements	200,588,000	
Leasehold improvements	214,562,000	
Land improvements	6,729,000	6,417,000
Buildings	290,777,000	288,941,000
Computer equipment & computer software	168,131,000	142,896,000
Laboratory equipment	290,294,000	246,344,000
Furniture & fixtures	35,756,000	34,047,000
Assets under construction	104,592,000	68,398,000
Property, plant & equipment, at cost	1,115,557,000	992,347,000
Less: accumulated depreciation	417,203,000	307,591,000
Net property & equipment	698,354,000	684,756,000
Operating lease right-of-use assets	143,708,000	167,003,000
Goodwill	2,367,120,000	2,346,040,000
Intangibles, net	1,890,396,000	1,956,240,000
Other long-term assets, net	177,387,000	90,577,000
Total assets	6,471,334,000	6,226,873,000
Accounts payable	78,816,000	74,916,000
Accrued compensation	247,619,000	201,252,000
Accrued assets under construction	11,210,000	10,462,000
Accrued professional fees	45,405,000	43,715,000
Accrued research & trial related expenses	14,219,000	17,455,000
Other accrued expenses		22,329,000
Accrued licenses		4,003,000
Other	17,274,000	
Licenses	5,956,000	
Accrued liabilities	341,683,000	299,216,000
Operating lease liabilities, current portion	29,379,000	28,366,000
Debt, current portion	50,000,000	
Other current liabilities	14,823,000	10,249,000
Total current liabilities	514,701,000	412,747,000
Convertible notes, net	2,314,276,000	2,186,106,000
Long-term debt		50,000,000
Other long-term liabilities	335,982,000	352,459,000
Operating lease liabilities, less current portion	161,070,000	182,399,000
Total liabilities	3,326,029,000	3,183,711,000
Common stock	1,815,000	1,780,000
Additional paid-in capital	6,611,237,000	6,311,644,000
Cumulative translation adjustment	1,374,000	53,000
Unrealized gain (loss) on securities	54,000	(5,289,000)
Accumulated other comprehensive income (loss)	1,428,000	(5,236,000)
Retained earnings (accumulated deficit)	(3,469,175,000)	(3,265,026,000)
Total stockholders' equity (deficit)	3,145,305,000	3,043,162,000
Total Equity	3,145,305,000	

Recent Dividends:**1. EXACT Sciences Corp. common.**

No dividends paid.

Annual Dividends:**1. EXACT Sciences Corp. common.**

No dividends paid.

EXCEED WORLD INC**Earnings, 3 mos. to Dec 31(Consol. - \$):**

	2023	2022
Total revenues	4,827,149	6,031,803
Cost & expenses	5,107,494	5,843,631
Operating income	(280,345)	188,172
Interest expense	490	508
Other income (expense), net	10,063	27,042
Net before taxes	(270,772)	214,706
Income taxes	7,174	122,247
Net income	(277,946)	92,459
Earnings common share		
Primary	\$(0.01)	\$

Fully Diluted	\$(0.01)	\$
Common Shares:		
Full Diluted	32,700,000	32,700,000
Year-end	32,700,000	32,700,000
Consolidated Balance Sheet Items, as of (\$):		
Assets:	2023	
Cash & equivalents	17,963,261	
Inventories	1,689,804	
Current assets	21,126,004	
Net property & equip.	314,858	
Total assets	23,305,837	
Liabilities:		
Current liabilities	5,665,879	
Long-term debt	26,805	
Stockholders' equity	17,352,462	
Net current assets	15,460,125	

**EYENOVIA INC
Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
			(revised)
Revenue	3,787		14,000,000
Cost of revenue	3,787		1,600,000
Gross profit			12,400,000
Research & development expenses	12,975,832	13,378,680	14,850,874
General & administrative expenses	12,430,614	13,532,835	10,569,653
Total operating expenses	25,406,446	26,911,515	25,420,527
Income (loss) from operations	(25,406,446)	(26,911,515)	(13,020,527)
Extinguishment of Paycheck Protection Program loan			463,353
Other income, net	(176,411)	197,090	164,027
Interest expense	2,371,851	1,380,058	387,756
Interest income	693,612	83,326	2,516
Total other income (expense)	(1,854,650)		
Net income (loss)	(27,261,096)	(28,011,157)	(12,778,387)
Weighted average shares outstanding - basic	41,032,970	33,649,747	26,324,081
Weighted average shares outstanding - diluted	41,032,970	33,649,747	26,324,081
Year end shares outstanding	45,553,026	36,668,980	28,426,616
Net earnings (loss) per share - basic	\$(0.66)	\$(0.83)	\$(0.49)
Net earnings (loss) per share - diluted	\$(0.66)	\$(0.83)	\$(0.49)
Number of full time employees		41	43
Number of part time employees			2
Total number of employees		41	45
Number of common stockholders	36	37	34
Income from cont operations before income tax	(27,261,096)		
Earnings per share from continuing operations	\$(0.66)		
Earnings per share from continuing operations	\$(0.66)		

Shares increased due to the effect of issuance of common stock and warrants in direct offering, at the Market offering, debt financing, related to vested RSU, and stock warrants exercised; As of March 30, 2023; As of March 15, 2022; Approximately; As of March 28, 2023; As of March 30, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
--	------	------

Cash & cash equivalents	14,849,057	22,863,520
Deferred clinical supply costs	4,256,793	2,284,931
License fee & expense reimbursements receivable	123,833	1,183,786
Security deposits, current	1,506	119,550
Payroll tax receivable		660,891
Prepaid insurance expenses		201,082
Prepaid general & administrative expenses		87,982
Prepaid patent expenses		38,796
Prepaid rent & security deposit		74,959
Prepaid conference expenses		97,743
Prepaid research & development expenses		2,521
Other prepaid expenses & other current assets		26,745
Prepaid expenses & other current assets	1,365,731	1,190,719
Inventories	109,798	
Total current assets	20,706,718	27,642,506
Equipment	3,038,651	1,271,372
Equipment not yet placed in service	4,793,430	90,411
Leasehold improvements	1,754,779	569,170
Property & equipment, gross		1,930,953
Less: accumulated depreciation & amortization	1,419,046	635,838
Property & equipment, net	3,374,384	1,295,115
Security deposits, non-current	197,168	80,874
Operating lease right-of-use asset	1,666,718	1,291,592
Equipment deposits	711,441	726,326
Intangible assets	2,122,945	
Total assets	28,779,374	31,036,413
Accounts payable	1,753,172	1,428,283
Accrued bonus expenses		1,447,643
Accrued payroll expenses		299,548
Accrued compensation	1,658,613	1,747,191
Accrued research & development expenses	89,872	35,524
Accrued consulting & professional services		320,000
Accrued leasehold improvements		92,528
Credit card payable	27,193	50,639
Accrued professional services	63,028	
Other accrued expenses & other current liabilities		4,385
Accrued expenses & other current liabilities	287,928	503,076
Operating lease liabilities - current portion	501,250	484,882
Notes payable - current portion, net		174,448
Convertible notes payable - current portion, net	5,329,419	174,448
Other	7,835	
Accrued rework of clinical supply returns	100,000	
Total current liabilities	9,530,382	4,512,328
Operating lease liabilities - non-current portion	1,292,667	907,644
Notes payable - non-current portion, net	4,355,800	4,190,938
Convertible notes payable - non-current portion, net		4,190,938
Convertible notes payable non-current portion, net of debt discount of \$813,229 and \$0 as of 31, 2022 and 2021,		

respectively	4,601,431	...
Total liabilities	19,780,280	13,801,848
Common stock	4,555	3,667
Additional paid-in capital	154,486,098	135,461,361
Retained earnings (accumulated deficit)	(145,491,559)	(118,230,463)
Total stockholders' equity	8,999,094	17,234,565
Total Equity	8,999,094	...

□ Net of debt discount - notes payable - current portion: \$33,885; □ Net of debt discount - convertible notes payable - current portion: \$33,885; □ Net of debt discount - notes payable - non-current portion: \$813,229; □ Net of debt discount - convertible notes payable - non-current portion: \$813,229

Recent Dividends:

- 1. Eyenovia Inc series B preferred.**
No dividends paid.
- 2. Eyenovia Inc series A convertible preferred.**
No dividends paid.
- 3. Eyenovia Inc series A-2 convertible preferred.**
No dividends paid.
- 4. Eyenovia Inc common.**
No dividends paid.

Annual Dividends:

- 1. Eyenovia Inc series B preferred.**
No dividends paid.
- 2. Eyenovia Inc series A convertible preferred.**
No dividends paid.
- 3. Eyenovia Inc series A-2 convertible preferred.**
No dividends paid.
- 4. Eyenovia Inc common.**
No dividends paid.

FAT BRANDS INC

Annual Report

Consolidated Income Statement, Years Ended (\$000):

	12/31/23	12/25/22	□ 12/26/21 (revised)
Revenues - royalties	...	87,921	42,658
Revenues - restaurant sales	...	241,001	41,563
Revenues - advertising fees	...	37,997	16,728
Revenues - factory revenues	...	33,504	13,470
Revenues - franchise fees	...	3,706	4,023
Revenues - management fees & other income	...	3,095	439
Royalties	94,036
Franchise fees	4,979
Other revenue	4,940
Advertising fees	39,490
Restaurant sales	299,029
Factory revenues	37,983
Total revenue	480,457	407,224	118,881
General & administrative expense	282,887	113,313	41,775
Cost of restaurant & factory revenues	...	221,627	44,242
Depreciation & amortization expenses	31,131	27,015	8,474
Impairment of goodwill & other intangible assets	500	14,000	1,037
Refranchising loss	2,873	4,178	314
Acquisition costs	...	383	4,242
Advertising fees	47,619	44,612	17,973
Compensation	93,117
Total costs & expenses	458,127	425,128	118,057
Income (loss) from operations	22,330	(17,904)	824
Interest expense, net	99,342	78,477	26,864
Interest expense related to preferred shares	18,189	16,372	2,193

Gain (loss) on extinguishment of debt	(2,397)	...	(7,637)
Other income (expense), net	1,233	5,375	750
Total other income (expense), net	(118,695)	(89,474)	(35,944)
Income (loss) before income tax	(96,365)	(107,378)	(35,120)
Current state income tax expense (benefit)	800	400	1,000
Current foreign income tax expense (benefit)	1,300	1,000	800
Total current income tax expense (benefit)	...	1,400	1,800
Deferred federal income tax expense (benefit)	(6,300)	8,200	(5,100)
Deferred state income tax expense (benefit)	(2,100)	9,200	(200)
Total deferred income tax expense (benefit)	...	17,400	(5,300)
Income tax provision (benefit)	(6,255)	□ 18,810	□ (3,537)
Net income (loss)	(90,110)	(126,188)	(31,583)
Dividends on preferred shares	7,007
Net income to common	(97,117)
Weighted average shares outstanding - basic	16,599	16,476	14,657
Weighted average shares outstanding - diluted	16,599	16,476	14,657
Year end shares outstanding	16,900	16,572	□ 16,381
Net income (loss) per common share - basic	\$(5.85)	\$(7.66)	\$(2.15)
Net income (loss) per common share - diluted	\$(5.85)	\$(7.66)	\$(2.15)
Cash dividends declared per common share	\$0.56	\$0.54	\$0.52
Number of full time employees	2,600	□ 1,100	□ 1,100
Number of part time employees	4,790	□ 4,300	□ 4,100
Total number of employees	7,390	□ 5,400	□ 5,200
Number of common stockholders	78
Number of class A common stockholders	...	□ 45	□ 47
Number of class B common stockholders	...	□ 42	□ 44

Consolidated Balance Sheet, Years Ended (\$000):

	12/31/23	12/25/22
Cash and restricted cash	37,044	...
Cash	...	28,668
Restricted cash	39,271	25,375
Accounts receivables, gross	24,846	48,080
Allowance for doubtful accounts	3,700	24,200

Accounts receivable, net of allowance for \$679 for doubtful accounts	21,146	...
Accounts receivable, net	...	23,880
Inventory	9,306	6,925
Assets classified as held-for-sale	3,756	4,767
Other current assets	10,486	6,086
Total current assets	121,009	95,701
Non-current restricted cash	15,588	14,720
Operating lease right-of-use assets	220,035	101,114
Goodwill	305,089	293,282
Other intangible assets, net	620,622	625,294
Real estate, gross	83,500	67,700
Equipment, gross	44,900	26,500
Property & equipment, gross	128,400	94,200
Less: accumulated depreciation	27,900	15,000
Property & equipment, net	100,524	□ 79,189
Other assets	5,371	4,003
Total assets	1,388,238	1,213,303
Accounts payable	21,809	18,328
Accrued expenses & other liabilities	58,903	52,800
Deferred income, current portion	2,490	2,019
Accrued advertising	7,992	14,819
Accrued interest payable	24,961	13,241
Dividend payable on preferred shares	1,325	1,467
Liabilities related to assets classified as held- for-sale	3,421	4,084
Current portion of operating lease liability	17,254	14,815
Current portion of redeemable preferred stock	...	91,836
Current portion of long-term debt	42,611	49,611
Current portion of acquisition purchase price payable	...	4,000
Other current liabilities	91,836	...
Acquisition purchase price payable	4,000	...
Total current liabilities	276,602	267,020
Deferred income, net of current portion	21,958	21,698
Deferred income tax liabilities, net	18,805	27,181
Operating lease liability, net of current portion	211,744	95,620
Senior debt	...	636,500
Senior subordinated debt	...	198,000
Subordinated debt	...	168,100
Elevation note	...	3,900
Equipment notes	...	1,300
Twin Peaks Buyer, LLC construction loan	...	400
Total debt	...	1,008,200
Less: current portion of long-term debt	...	49,600
Long-term debt, net of current portion	1,110,308	□ 958,630
Other liabilities	4,684	2,332
Total liabilities	1,644,101	1,372,481
Preferred stock	44,103	45,504
Common Stock - Class A	2	...
Common stock	(31,189)	...
Class A & class B common stock & additional paid-in capital	...	(26,015)
Retained earnings (accumulated deficit)	(268,777)	(178,667)
Additional paid-in capital	(31,191)	...
Total stockholders'

income taxes	3	358	347	Long-term investments	4,348	
Provision for (benefit from) income taxes	3	358	347	Leasehold improvements	102,109	102,580
Investment loss in unconsolidated variable interest entity	2,638	1,573	1,007	Building shell	6,184	...
Net income (loss)	(284,232)	(293,654)	(290,023)	Laboratory equipment	22,757	21,175
Weighted average shares outstanding - basic	97,303	93,582	92,349	Machinery	9,454	9,642
Weighted average shares outstanding - diluted	97,303	93,582	92,349	Computer equipment	9,490	9,486
Year end shares outstanding	98,770	94,166	92,881	Furniture & fixtures	6,200	6,200
Net income (loss) per share - basic	\$(2.92)	\$(3.14)	\$(3.14)	Construction in progress	62	204
Net income (loss) per share - diluted	\$(2.92)	\$(3.14)	\$(3.14)	Total property & equipment	150,056	149,287
Number of full time employees	486	Less: accumulated depreciation	136,930	128,682
Total number of employees	486	592	566	Property & equipment, net	13,126	20,605
Number of Common Shareholders	105	Right of Use Tangible Assets - Accumulated amortization	34,917	...
Number of stockholders	...	113	118	Right of Use Tangible Assets - Operating Lease	103,010	...
Foreign currency translation adjustments	...	75	1,235	- Gross	5,290	5,061
EPS - Basic - excluding Extraordinary Items	Equity method investment in unconsolidated variable interest entity	5,290	5,061
Applicable to Common - Total	\$(2.92)	Operating lease right-of-use assets	68,093	79,893
EPS - Diluted - excluding Extraordinary Items	Other assets	3,803	5,282
Applicable to Common - Total	\$(2.92)	Total assets	423,529	610,087
				Accounts payable	17,960	30,758
				Preclinical & clinical trial accruals	27,663	57,780
				Active pharmaceutical ingredient & bulk drug product price true-up	...	75,055
				Payroll & related accruals	20,267	22,562
				Contract liabilities to pharmaceutical distributors	...	390
				Accrued co-promotion expenses - current	10,309	36,677
				Roxadustat profit share to AstraZeneca	7,084	7,280
				Property taxes & other taxes	6,615	7,691
				Professional services	7,103	5,480
				Other accrued liabilities	...	6,858
				Accrued and other liabilities - Balancing	32,197	...
				API and bulk drug product price true-up	50,978	...
				Other	5,021	...
				Other - Balancing value	4,981	...
				Current portion of liability related to sale of future revenues	5,654	...
				Accrued and other liabilities - Balancing	172,891	...
				Accrued & other current liabilities	...	219,773
				Deferred revenue	12,740	12,739
				Finance lease liabilities, current	40	...
				Operating lease liabilities, current	14,077	10,292
				Total current liabilities	217,668	273,562
				Product development obligations	17,763	16,917
				Deferred revenue, net of current	157,555	185,722
				Operating lease liabilities, non-current	66,537	79,593
				Liability related to sale of future revenues, non-current	51,413	49,333
				Other long-term liabilities	2,858	6,440
				Senior secured term loan facilities, non-current	71,934	...
				Total liabilities	585,728	611,567
				Common stock	988	942
				Additional paid-in capital	1,643,641	1,541,019
				Accumulated other comprehensive income

(loss)	(6,875)	(5,720)
Retained earnings (accumulated deficit)	(1,841,920)	(1,557,688)
Redeemable non-controlling interests	21,480	...
Total stockholders' equity (deficit)	(182,686)	(21,447)
Non-controlling interests	20,487	19,967
Total equity (deficit)	(162,199)	(1,480)

From a related party - accounts receivable: \$12,088,000; To a related party - accrued and other current liabilities: \$63,886,000; To a related party - deferred revenue: \$9,259,000; To a related party - deferred revenue, net of current: \$31,044,000

Recent Dividends:

1. FibroGen Inc common.

No dividends paid.

Annual Dividends:

1. FibroGen Inc common.

No dividends paid.

FIRST AMERICA RESOURCES CORP

Earnings, 6 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues	3,920	...
Cost & expenses	29,052	11,246
Operating income	(25,132)	(11,246)
Net before taxes	(25,132)	(11,246)
Net income	(25,132)	(11,246)
Earnings common share		
Common Shares:		
Full Diluted	7,964,090	7,964,090
Year-end	7,964,090	7,964,090

FORTE BIOSCIENCES INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

	2023	2022	2021 (revised)
Research & development	21,862	5,594	13,853
General & administrative	10,624	8,302	7,633
Total operating expenses	32,486	13,896	21,486
Income (loss) from operations	(32,486)	(13,896)	(21,486)
Other income (expenses), net	(114)	17	(222)
Interest income	1,124
Income (loss) before income taxes	(31,476)
Net income (loss)	(31,476)	(13,879)	(21,708)
Weighted average shares outstanding - basic	31,571	17,384	13,968
Weighted average shares outstanding - diluted	31,571	17,384	13,968
Year end shares outstanding	36,335	21,000	14,754
Net income (loss) per common share - basic	\$(1.00)	\$(0.80)	\$(1.55)
Net income (loss) per common share - diluted	\$(1.00)	\$(0.80)	\$(1.55)
Number of full time employees	...	6	5
Number of common stockholders	227	229	5
Earnings per share from continuing operations	\$(1.00)
Earnings per share from continuing operations	\$(1.00)

Reclassified to conform with 2022 presentation; Shares increased due to the effect of issuance of common stock through public equity offering, issuance of common stock upon vesting of restricted stock units & issuance of common stock under ESPP;

Includes from a related party - license revenue: \$22,590,000;

Includes from a related party - license revenue: \$108,434,000;

Includes from a related party - development and other revenue:

\$9,908,000; Includes from a related party - development and other revenue: \$21,928,000;

Includes from a related party - product revenue, net: \$71,167,000;

Includes from a related party - product revenue, net: \$35,568,000;

Includes from a related party - drug product revenue: \$11,086,000;

Includes from a related party - drug product revenue: \$3,186,000;

As Is; As of January 31, 2023;

As of January 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash	63,396	135,819
Commercial paper	1,988	...
Money market funds	36,016	19,881
U.S. government bonds	12,288	...
Cash & cash equivalents	113,688	155,700
Short-term investments	121,898	266,308
Other - Accounts Receivable	18,632	...
Other - Accounts Receivable	12,553	...
Accounts receivable, net	...	16,299
Raw materials	1,376	...
Work-in-progress	34,614	...
Finished goods	5,575	...
Inventories	41,565	40,436
Prepaid expenses & other current assets	6,711	14,083
Prepaid assets	6,644	...
Prepaid Expenses and Other Current Assets	41,855	...
Astellas - Related party	(6,079)	...
Insurance proceeds receivable for litigation settlement	28,500	...
Total current assets	331,559	492,826
Restricted time deposits	1,658	2,072

As is; [□] As of March 24, 2023; [□] As of March 15, 2022; [□] As of March 10, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	37,125	41,100
Prepaid manufacturing & clinical expenses	306	...
Prepaid insurance	...	341
Prepaid license	413	...
Other	318	70
Prepaid expenses & other current assets	165	411
Prepaid expenses and other current assets	1,202	...
Total current assets	38,327	41,511
Property & equipment, net	109	...
Other assets	544	486
Other	53	...
Prepaid insurance	280	...
Prepaid professional fees	211	...
Total assets	38,980	41,997
Accounts payable	1,424	1,153
Accrued legal & professional fees	276	643
Accrued compensation	947	890
Accrued manufacturing & clinical expenses	1,016	485
Other accrued liabilities	...	8
Accrued other expenses	3	...
Accrued liabilities	2,242	2,026
Total current liabilities	3,666	3,179
Common stock	36	21
Additional paid-in capital	153,794	125,841
Retained earnings (accumulated deficit)	(118,520)	(87,044)
Accumulated other comprehensive income (loss)	4	...
Total stockholders' equity (deficit)	35,314	38,818
Total Equity	35,314	...

Recent Dividends:

1. Forte Biosciences Inc common.
No dividends paid.

Annual Dividends:

1. Forte Biosciences Inc common.
No dividends paid.

**FORTITUDE GOLD CORP
Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	[□] 2021 (revised)
Total revenues	73,073
Sales, net	73,073	74,379	82,109
Production costs	19,997	25,443	26,661
Depreciation & amortization	11,557	13,294	14,728
Reclamation & remediation	288	247	156
Total mine cost of sales	...	38,984	41,545
Mine gross profit	41,231	35,395	40,564
General & administrative expenses	5,003	5,787	11,443
Exploration expenses	17,217	11,591	5,396
Interest expense (income)	...	(71)	129
Charitable contributions	145	134	71
Other income	21	8	10
Other expense, net	(1,961)	55	190
Realized/unrealized gold and silver rounds/bullion (gain) loss, net	105
Total costs &			

expenses	...	17,433	17,029		
Income (loss) before income & mining taxes	20,972	17,962	23,535		
Current taxes - federal	3,216	1,739	3,000		
Current taxes - state	2,317	2,312	2,219		
Total current taxes	5,533	4,051	5,219		
Deferred taxes - federal	(1,578)	(773)	450		
Total deferred taxes	(1,578)	(773)	450		
Mining & income tax expense	3,955	3,278	5,669		
Net income (loss)	17,017	14,684	17,866		
Weighted average shares outstanding - basic	24,079	24,017	23,876		
Weighted average shares outstanding - diluted	24,206	24,197	24,108		
Year end shares outstanding	24,085	24,025	23,961		
Net earnings (loss) per share - basic	\$0.71	\$0.61	\$0.75		
Net earnings (loss) per share - diluted	\$0.70	\$0.61	\$0.74		
Dividends Per Share - Special - Gross - by Period End Date	\$0.48		
Dividends per share	...	\$0.48	\$0.30		
Number of full time employees	68	[□] 60	[□] 68		
Number of common stockholders	231	[□] 238	[□] 252		
Dividends per common share	\$0.04		
Interest (income) expense	1,980		
Total number of employees	68		

[□] Reclassified to conform with 2022 presentation; [□] As is; [□] As of February 27, 2023; [□] As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	48,678	45,054
Accounts receivable	42	...
Stockpiles	3,874	5,832
Leach pad	19,579	40,786
Dore	...	32
Subtotal - product inventories	23,848	46,650
Materials & supplies	373	505
Golden	22	...
Inventories	...	47,155
Prepaid taxes	355	710
Contractor advances	100	273
Prepaid insurance	208	309
Other current assets	148	148
Prepaid expenses & other current assets	811	730
Gold and silver rounds/bullion	1,532	...
Interest receivable	355	...
Total current assets	75,266	93,649
Asset retirement costs	5,488	5,171
Construction-in-progress	13,615	9,522
Furniture & office equipment	...	590
Leach pad & ponds	3,732	3,732
Land	41	25
Light vehicles & other mobile equipment	654	544
Machinery & equipment	16,547	15,698
Process facilities & infrastructure	8,913	8,856
Mineral interests & mineral rights	18,968	18,953
Mine development	24,365	24,365
Software & licenses	105	105

Light vehicles and other mobile equipment	558	...
Property, plant & mine development, gross	92,986	87,561
Less: accumulated depreciation & amortization	67,621	56,980
Property, plant & mine development, net	25,365	30,581
Operating lease assets, net	631	3,826
Deferred tax assets	2,860	1,282
Other non-current assets	344	1,818
Leach pad inventories	30,533	...
Total assets	134,999	131,156
Accounts payable	3,881	2,524
Operating lease liabilities, current	631	3,826
Mining taxes payable	2,309	1,857
Accrued royalty payments	333	547
Accrued property & excise taxes	798	721
Other accrued expenses	2	56
Other current liabilities	1,133	1,324
Total current liabilities	7,954	9,531
Asset retirement obligations	6,500	5,863
Other non-current liabilities	...	3
Total liabilities	14,454	15,397
Common stock	241	240
Additional paid-in capital	104,020	103,731
Retained earnings (accumulated deficit)	16,284	11,788
Total stockholders' equity	120,545	115,759
Total Equity	120,545	...

Recent Dividends:

1. Fortitude Gold Corp common.
No dividends paid.

Annual Dividends:

1. Fortitude Gold Corp common.
No dividends paid.

FORTREA HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021
Revenues	3,109,000
Revenues	3,109,000	3,096,100	3,057,500
Direct costs, exclusive of depreciation & amortization	2,588,600	[□] 2,447,400	[□] 2,453,100
Selling, general & administrative expenses, exclusive of depreciation & amortization	336,600	279,800	303,100
Depreciation & amortization	96,400	92,700	166,300
Goodwill & other asset impairments	200	9,800	...
Restructuring & other charges	24,300	30,500	20,700
Total costs & expenses	(3,045,900)	2,860,200	2,943,200
Operating income (loss)	63,100	235,900	114,300
Foreign exchange gain (loss)	900	(900)	20,200
Other income (expenses), net	6,900	2,000	1,900
Income (loss) before income taxes
- Domestic	(123,300)	114,900	22,800
Income (loss) before income taxes
- Foreign	124,400	122,100	113,600
Income (loss)

before income taxes . . .	1,100	237,000	136,400	Property, plant & equipment, net	220,900	164,900	Interest expense	2,894	3,064
Current federal income taxes	3,600	18,600	23,900	Goodwill, net	2,029,300	1,997,300	Net before taxes	(3,254)	(5,199)
Current state income taxes	900	10,700	8,900	Intangible assets, net	771,200	823,300	Net income	(3,254)	(5,199)
Current foreign income taxes	40,500	31,300	35,800	Deferred income taxes	3,200	1,200	Earnings common share		
Total current income taxes	45,000	60,600	68,600	Other assets, net	79,500	54,300	Common Shares:		
Deferred federal income taxes	(24,300)	(8,000)	(27,900)	Total assets	4,357,200	4,287,900	Full Diluted	55,308,825	9,308,825
Deferred state income taxes	(4,000)	(5,900)	(4,700)	Accounts payable	132,800	81,500	Year-end	55,308,825	9,308,825
Deferred foreign income taxes	(12,200)	(2,600)	2,400	Employee compensation & benefits	118,000	123,000	Consolidated Balance Sheet Items, as of (\$):		
Total deferred income taxes	(40,500)	(16,500)	(30,200)	Accrued pass through expenses	133,100	Assets:		2023
Provision for income taxes	4,500	44,100	38,400	Accrued taxes	39,500	Cash & equivalents	93	
Net income (loss)	(3,400)	192,900	98,000	Other accrued expenses & other current liabilities	27,100	Current assets	93	
EPS - Basic - including Extraordinary Items Applicable to Common - Total	\$(0.04)	Accrued expenses & other current liabilities	202,800	322,700	Total assets	93	
Diluted	\$(0.04)	Unearned revenue	241,400	271,500	Liabilities:		
Interest expense	69,800	Short-term operating lease liabilities	19,500	23,300	Current liabilities	288,886	
Common Shares - Outstanding - Total	88,800	Prepaid expenses	35,300	...	Long-term debt	126,350	
Restructuring charges	23,900	Accrued expenses and other current liabilities - Balancing value	356,100	...	Stockholders' equity	(415,143)	
Restructuring charges allocated from Parent	200	Current portion of long-term debt	26,100	...	Net current assets	(288,793)	
Depreciation	32,600	Total current liabilities	775,900	699,000	FRESH TRACKS THERAPEUTICS INC		
Amortization of Intangibles excluding Goodwill	63,800	Operating lease liabilities	66,500	40,100	Annual Report		
Shares used to calculate Basic EPS - Total	88,800	Deferred income taxes & other tax liabilities	148,800	184,500	Consolidated Income Statement, Years Ended Dec. 31 (\$):		
Shares used to calculate Diluted EPS - Total	88,800	Other liabilities	61,300	21,700	2023	2022	2021
Common Shareholders - Number	1,748	Long-term debt, less current portion	1,565,900	...	Contract revenue	6,851,000	(revised)
Full-Time Employees (Period End)	18,000	Total liabilities	2,618,400	945,300	Royalty revenue	92,000	...
Total number of employees	18,000	Net parent investment	3,618,600	Sale of technology	8,006,000	...
				Foreign currency translation adjustments	(209,600)	(267,200)	Total revenue	8,006,000	6,943,000
				Net benefit plan adjustments	(7,400)	(8,800)	Research & development	3,182,000	14,043,000
				Unrealized Gain (Loss) on Derivatives Instrument	(1,400)	...	General & administrative	11,184,000	14,434,000
				Accumulated other comprehensive income (loss)	(218,400)	(276,000)	Total operating expenses	14,366,000	28,477,000
				Common stock	100	...	Income (loss) from operations	(6,360,000)	(21,534,000)
				Additional paid-in capital	2,006,200	...	Investment & other income, net	671,000	441,000
				Accumulated deficit	(49,100)	...	Interest expense	5,000	9,000
				Total equity	1,738,800	3,342,600	Net income (loss)	(5,694,000)	(21,102,000)
				Total equity	1,738,800	3,342,600	Weighted average shares outstanding - basic	5,394,551	2,808,075
							Weighted average shares outstanding - diluted	5,394,551	2,808,075
							Year end shares outstanding	5,973,306	3,018,940
							Income (loss) per share from continuing operations - basic	\$(1.06)	...
							Net income (loss) per share - basic	\$(1.06)	\$(7.51)
							Income (loss) per share from continuing operations - diluted	\$(1.06)	...
							Net income (loss) per share - diluted	\$(1.06)	\$(7.51)
							Number of full time employees	4	13
							Number of common stockholders	130	119
							Income from cont operations before income tax	(5,694,000)	...
							Total number of employees	4	...

¹ Including costs incurred from related parties - Direct costs: \$87,100,000; ² Including costs incurred from related parties - Direct costs: \$70,100,000

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	108,600	112,000
Accounts receivable	1,084,400	449,200
Unbilled services	1,052,100	585,700
Less: allowance for credit losses	32,300	12,700
Accounts receivable & unbilled services, net	1,022,200
Prepaid expenses	35,300	...
Research & development tax credit receivables	22,000	29,200
Other prepaid expenses & other	35,100	83,500
Prepaid expenses & other	92,400	112,700
Total current assets	1,253,100	1,246,900
Land, buildings, & building improvements	6,000	14,600
Machinery & equipment	77,300	74,400
Software	95,100	74,600
Leasehold improvements	72,100	30,000
Furniture & fixtures	15,200	8,600
Construction in progress	45,900	41,400
Operating lease ROU assets	78,200	50,000
Property, plant & equipment, gross	389,800	293,600
Less: accumulated depreciation	168,900	128,700

Recent Dividends:

1. Fortrea Holdings Inc common.

No dividends paid.

Annual Dividends:

1. Fortrea Holdings Inc common.

No dividends paid.

FRANKLIN WIRELESS CORP

Earnings, 6 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues	18,503,325	...
Net Sales	18,503,325	17,092,583
Cost & expenses	20,643,783	19,074,816
Operating income	(2,140,458)	(1,982,233)
Interest income	405,768	122,737
Other income (expense), net	334,141	240,396
Gains or losses	148,472	124,222
Net before taxes	(1,252,077)	(1,494,878)
Income taxes	(265,217)	15,483
Net income	(986,860)	(1,510,361)
Earnings common share		
Primary	\$(0.09)	\$(0.13)
Fully Diluted	\$(0.09)	\$(0.13)
Common Shares:		
Full Diluted	11,784,280	11,689,715
Year-end	11,784,280	...

FREEDOM HOLDINGS INC

Earnings, 3 mos. to Dec 31(Consol. - \$):

	2023	2022
Cost & expenses	360	2,135
Operating income	(360)	(2,135)

Income (loss) per share from continuing operations - basic	\$(1.06)
Net income (loss) per share - basic	\$(1.06)	\$(7.51)	2 \$(22.12)
Income (loss) per share from continuing operations - diluted	\$(1.06)
Net income (loss) per share - diluted	\$(1.06)	\$(7.51)	2 \$(22.12)
Number of full time employees	4	13	16
Number of common stockholders	130	119	188
Income from cont operations before income tax	(5,694,000)
Total number of employees	4

¹ Reclassified to conform with 2022 presentation; ² Adjusted for 1-for-45 stock split, July 5, 2022; ³ Shares increased due to the effect of common stock issued, issuance of common stock upon exercise of warrants; under license agreement; to settle accrued liabilities; for cash under ESPP; ⁴ Reclassified to conform with 2022 presentation; ⁵ As of March 23, 2023; ⁶ As of March 3, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	10,868,000	8,680,000
Prepaid insurance	545,000	521,000

Contract asset	254,000	Deferred federal income tax expense (benefit)	(2)	19	net	358	397				
Prepaid research & development expenses	254,000	Deferred state income tax expense (benefit)	...	19	Right-of-use operating lease assets	609	197				
Accounts receivable	45,000	250,000	Deferred foreign income tax expense (benefit)	(3)	Long-term investments	3,664	6,360				
Other prepaid expenses	117,000	117,000	Total deferred income tax expense (benefit)	(5)	38	5	5	5	Other assets	781	794
Other current assets	7,000	7,000	Income tax expense (benefit)	69	54	14	14	14	Total assets	50,388	50,124
Prepaid expenses & other current assets	684,000	1,403,000	Net income (loss)	(1,538)	(1,442)	54	54	54	Accounts payable	2,421	2,710
Other	94,000	94,000	Weighted average shares outstanding - basic	30,348	30,289	29,585	29,585	29,585	Operating lease liabilities - current	81	125
Total current assets	11,552,000	10,083,000	Weighted average shares outstanding - diluted	30,348	30,289	29,694	29,694	29,694	Accrued employee compensation	1,252	1,105
Property & equipment, net	34,000	75,000	Year end shares outstanding	30,385	30,296	30,264	30,264	30,264	Contract liabilities	1,279	372
Contract asset, net of current portion	64,000	64,000	Income (loss) per share from continuing operations - basic	\$(0.05)	Warranty reserve	159	159
Operating lease right-of-use asset	49,000	49,000	Net income (loss) per common share - basic	\$(0.05)	\$(0.05)	\$0.00	\$0.00	\$0.00	Other accrued liabilities	292	295
Total assets	11,586,000	10,271,000	Income (loss) per share from continuing operations - diluted	\$(0.05)	Other accrued liabilities	1,934	826
Accounts payable	406,000	571,000	Full-Time Employees (Period End)	72	Deferred revenue	103	...
Accrued compensation	232,000	1,320,000	Total number of employees	72	66	73	73	73	Other accrued liabilities
Accrued professional fees	705,000	705,000	Number of common stockholders	56	62	74	74	74	Total current liabilities	5,688	4,766
Accrued research & development expenses	432,000	432,000	Foreign currency translation adjustments	...	(124)	(234)	(234)	(234)	Operating lease liabilities - non-current	533	66
Accrued liabilities	2,457,000	2,457,000							Deferred income taxes	172	177
Lease liability, current portion	49,000	49,000							Other liabilities	281	274
Accrued liabilities - Balancing value	1,250,000	1,250,000							Total liabilities	6,674	5,283
Accrued severance	1,018,000	1,018,000							Common stock	313	313
Total current liabilities	1,656,000	3,077,000							Additional paid-in capital	164,853	164,422
Total liabilities	3,077,000	3,077,000							Retained earnings (accumulated deficit)	(117,529)	(115,991)
Common stock	60,000	30,000							Foreign currency translation	(1,748)	(1,728)
Additional paid-in capital	182,033,000	173,633,000							Accumulated other comprehensive income (loss)	(1,748)	(1,728)
Retained earnings (accumulated deficit)	(172,163,000)	(166,469,000)							Nil coupon perpetual loan notes	76	76
Total stockholders' equity (deficit)	9,930,000	7,194,000							Treasury stock, at cost	2,251	2,251
Total Equity	9,930,000	9,930,000							Total stockholders' equity	43,714	44,841

Recent Dividends:

1. Fresh Tracks Therapeutics Inc common.
No dividends paid.

Annual Dividends:

1. Fresh Tracks Therapeutics Inc common.
No dividends paid.

FUEL TECH INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2023	2022	2021 (revised)
Net sales	27,081
Revenues	27,081	26,941	24,261
Cost of sales	15,425	15,298	12,363
Selling, general & administrative	12,803	12,275	12,055
Research & development expense	1,511	895	1,332
Operating income (loss) from continuing operations	(2,658)	(1,527)	(1,489)
Interest expense	21	17	19
Interest income	1,300	202	6
Other income (expense), net	(90)	(46)	1,570
Income (loss) before income taxes - United States	(17,722)	(1,262)	798
Income (loss) before income taxes - foreign	(1,772)	(126)	(730)
Income (loss) before income taxes - Current state	(1,469)	(1,388)	68
Current state income tax expense (benefit)	19	6	9
Current foreign income tax expense (benefit)	55	10	...
Total current income tax expense (benefit)	74	16	9

Reclassified to conform with 2022 presentation; As is; As of February 28, 2023; As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Cash & cash equivalents	17,578	23,328	2023
Marketable securities	12,136
Short-term investments	...	2,981	...
Accounts receivable, gross	6,840	7,839	7,839
Allowance for doubtful accounts	111	110	110
Accounts receivable, net	6,729	7,729	7,729
Inventories, net	439	392	392
Prepaid expenses & other current assets	1,439	1,395	1,395
Total current assets	38,321	35,825	35,825
Land	1,050	1,050	1,050
Building	3,950	3,950	3,950
Building & leasehold improvements	2,655	2,626	2,626
Field equipment	12,100	11,882	11,882
Computer equipment & software	2,049	2,117	2,117
Furniture & fixtures	1,307	1,306	1,306
Vehicles	32	32	32
Construction in progress	99	29	29
Total property & equipment, cost	23,242	22,992	22,992
Less: accumulated depreciation	18,703	18,557	18,557
Property & equipment, net	4,539	4,435	4,435
Goodwill	2,116	2,116	2,116
Other intangible assets,

Recent Dividends:

1. Fuel Tech Inc common.
No dividends paid.

Annual Dividends:

1. Fuel Tech Inc common.
No dividends paid.

FULL HOUSE RESORTS, INC.**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021 (revised)
Casino	176,933,000	113,876,000	130,431,000
Food & beverage	241,060,000	26,494,000	27,347,000
Hotel	...	9,282,000	9,624,000
Other operations	20,719,000
Other operations, including contracted sports wagering	...	13,629,000	12,757,000
Food and beverage	33,980,000
Revenue Hotel	9,428,000
Net revenues	241,060,000	163,281,000	180,159,000
Casino	68,061,000	39,788,000	43,765,000
Food & beverage	33,240,000	26,372,000	23,757,000
Hotel	4,840,000	4,806,000	4,444,000
Other operations	3,498,000	2,168,000	1,980,000
Project development costs, net	53,000	228,000	782,000
Advertising Expense	8,500,000
Selling, general & administrative	85,746,000	59,706,000	59,965,000
Preopening costs	15,685,000	9,558,000	17,000
General & administrative expenses	68,078,000
Depreciation & amortization	31,092,000	7,930,000	7,219,000
Loss (gain) on disposal of assets, net	(7,000)	(42,000)	(676,000)
Total operating costs & expenses	242,222,000	150,598,000	142,605,000
Gain on settlements	(384,000)

Operating income (loss)	(1,162,000)	12,683,000	37,554,000	gross	6,521,000	4,331,000	current portion	16,075,000	...
Interest expense (excluding bond fee amortization & premium)	39,860,000	33,496,000	24,179,000	Less: allowance for doubtful accounts	1,189,000	249,000	Total liabilities	610,609,000	495,538,000
Amortization of debt issuance costs, discounts & premiums	2,793,000	1,649,000	1,349,000	Accounts receivable, net	5,332,000	4,082,000	Common stock	4,000	4,000
Capitalized interest	15,938,000	10,802,000	1,871,000	Restricted cash	37,639,000	134,587,000	Additional paid-in capital	113,329,000	110,590,000
Interest income & other	3,738,000	1,355,000	...	Inventories	1,839,000	1,479,000	Treasury stock	869,000	1,091,000
Interest expense, net	22,977,000	22,988,000	23,657,000	Prepaid expenses & other current assets	6,184,000	Retained earnings (deficit)	(34,616,000)	(9,712,000)
Adjustment to fair value of warrants	(1,347,000)	Prepaid expenses and other	3,674,000	...	Total Full House Resorts, Inc. stockholders' equity (deficit)	77,848,000	99,791,000
Loss on modification & extinguishment of debt, net	(4,530,000)	(409,000)	Total current assets	84,639,000	202,921,000	Total stockholders' equity (deficit)	77,848,000	99,791,000
Total other income (expense)	(22,593,000)	(27,518,000)	(25,413,000)	Land & improvements	37,601,000	26,477,000			
Income (loss) before income taxes ..	(23,755,000)	(14,835,000)	12,141,000	Buildings & improvements	256,722,000	120,732,000			
Current provision for state income taxes	489,000	Furniture & equipment	88,522,000	51,336,000			
Total current income taxes	489,000	Construction in progress	188,841,000	227,006,000			
Deferred provision (benefit) for federal income taxes	(5,007,000)	(4,077,000)	2,421,000	Property & equipment, gross	571,686,000	425,551,000			
Deferred provision (benefit) for state income taxes	(3,108,000)	(1,279,000)	(744,000)	Less accumulated depreciation	113,779,000	86,494,000			
Increase in valuation allowance ..	8,775,000	5,325,000	(1,242,000)	Property & equipment, net	457,907,000	339,057,000			
Total deferred income taxes (benefit)	660,000	(31,000)	435,000	Operating lease right-of-use assets, net	44,704,000	15,771,000			
Income tax expense (benefit)	1,149,000	(31,000)	435,000	Finance lease right-of-use assets, net	2,318,000	3,808,000			
Net income (loss)	(24,904,000)	(14,804,000)	11,706,000	Goodwill	21,286,000	21,286,000			
Weighted average shares outstanding - basic	34,519,993	34,354,847	32,516,758	Other intangible assets, net	76,271,000	10,869,000			
Weighted average shares outstanding - diluted	34,519,993	34,354,847	34,945,951	Deposits & other assets	1,332,000	1,617,000			
Year end shares outstanding	34,590,150	34,407,654	34,242,581	Total assets	688,457,000	595,329,000			
Income (loss) per share - continuing operations - basic	\$(0.72)	Accounts payable	12,794,000	4,602,000			
Net income (loss) per share - basic	\$(0.72)	\$(0.43)	\$0.36	Income taxes payable	489,000	...			
Income (loss) per share - continuing operations - diluted	\$(0.72)	Construction payable	20,667,000	30,279,000			
Net income (loss) per share - diluted	\$(0.72)	\$(0.43)	\$0.33	Accrued payroll & related expenses	4,097,000	3,784,000			
Number of full time employees	1,281	893	Accrued interest	12,966,000			
Number of part time employees	259	265	Player club points & progressive jackpots	3,010,000			
Number of common stockholders	70	72	74	Outstanding chip liability	416,000			
Operating leases				Unpaid wagers & other	122,000			
Cost	9,168,000	Other gaming-related accruals	421,000			

□ Reclassified to conform with 2022 presentation; □ Shares increased due to the effect of equity offering; □ As of March 1, 2023; □ As of March 1, 2022; □ As of March 13, 2023; □ As of March 11, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & equivalents	36,155,000	56,589,000
Accounts receivables,		

Recent Dividends:
1. Full House Resorts, Inc. common.
 No dividends paid.
2. Full House Resorts, Inc. cumulative preferred.
 No dividends paid.

Annual Dividends:
1. Full House Resorts, Inc. common.
 No dividends paid.
2. Full House Resorts, Inc. cumulative preferred.
 No dividends paid.

GEN RESTAURANT GROUP INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31
(\$000):

	2023	2022	2021
Revenue	181,007
Revenue	181,007	163,729	140,561
Food cost	58,322	54,357	44,688
Payroll & benefits	56,889	48,866	40,710
Occupancy expenses ..	14,653	12,110	10,151
Operating expenses ..	18,043	15,019	12,533
Depreciation & amortization	4,808	4,314	4,337
Pre-opening costs	3,680	1,455	...
Total restaurant operating expenses	136,121	112,419
General & administrative	12,937	7,988	4,882
Consulting fees - related party	2,325	4,897	4,269
Management fees	1,176	2,332	2,280
Depreciation & amortization - corporate	84	39	26
Total costs & expenses	172,917	151,377	123,876
Income (loss) from operations	8,090	12,352	16,685
Gain on extinguishment of Paycheck Protection Program ("PPP") debt	387	22,285
Restaurant revitalization fund grant	12,963
Employee retention credits	3,532	...
Aborted deferred initial public offerings costs written off	4,036	...
Other income (expense)	2,483	(835)	22
Interest cost capitalized	0	0
Interest expense	617	817	668
PPP interest expense forgiveness	(4)	(215)
Interest income	964	179	256
Interest expense, net	347	(634)	(197)
Equity in income of investee	535	966	1,086
Net income (loss)	11,434	11,732	52,844
Net income attributable to			

noncontrolling interest	(3,028)	(1,451)	(2,985)	Obligations under finance leases, current	124	134	warrant & earn-out contingent liabilities	1,170,000	70,229,000	198,401,000
Net income attributable to GEN Restaurant Group	8,406	10,281	49,859	Operating lease liabilities, current	4,535	4,096	Interest income	2,541,000	79,000	2,835,000
Full-Time Employees (Period End)	2,500	Deferred restaurant revitalization fund grant	3,806	3,806	Interest expense	3,207,000	2,835,000	5,114,000
Total number of employees	2,500	□□2,350	...	Advances from members	2,704	4,442	Other income, net	1,619,000	57,000	5,114,000
Net income before income taxes	11,455	Sales tax payable	...	1,468	Interest Expense/Income - Net	1,114,000
Net income attributable to Class A common stock per share - basic and diluted	\$2.03	Accrued percentage rent	...	1,246	Total other income, net	3,903,000	69,620,000	200,759,000
Net income per share of Class A common stock - diluted	\$1.99	Miscellaneous accrued expenses	...	1,910	Income (loss) before income taxes	...	104,000	...
Shares used to calculate Basic EPS - Total	4,140	Other current liabilities	5,366	4,624	- Foreign	...	(598,136,000)	(245,390,000)
Shares used to calculate Diluted EPS - Total	4,233	Total current liabilities	31,303	37,266	Income (loss) before income taxes	(176,693,000)	(598,032,000)	(245,390,000)
Income Taxes - Domestic - Current	61	Notes payable, net of current portion	4,547	5,316	Current foreign income taxes	164,000	72,000	...
Income Taxes - Local - Current	47	Notes payable to related parties, net of current portion	...	500	Total current income taxes	164,000	72,000	...
Income Taxes - Total - Current	108	Obligations under finance leases, net of current portion	1	185	Deferred federal income taxes	942,000	(40,828,000)	...
Income Taxes - Domestic - Deferred	(71)	Operating lease liabilities, net of current portion	110,501	100,872	Deferred state & local income taxes	(2,032,000)	(8,296,000)	...
Income Taxes - Local - Deferred	(16)	Total liabilities	146,352	144,139	Total deferred domestic income taxes	(1,090,000)
Income Taxes - Total - Deferred	(87)	EB-5 members' equity	1,500	1,500	Income taxes	(926,000)	(49,052,000)	...
Provision for income taxes	21	Additional paid-in capital	7,112	...	Net income (loss)	(175,767,000)	(548,980,000)	(245,390,000)
Common Shareholders - Number	4	Retained Earnings	322	...	Weighted average class A shares outstanding - basic	...	□10,236,960	3,275,074
Common Shares - Outstanding - Total	4,140	Class A common stock, \$0.00 par value, 75,000,000 shares authorized, 4,40,000 shares issued and outstanding as of , 202	4	...	Weighted average shares outstanding - basic	24,311,989
				Class B common stock, \$0.00 par value, 50,000,000 shares authorized; 28,4,566 shares issued and outstanding as of , 202	28	...	Weighted average class A shares outstanding - diluted	24,311,989	□10,236,960	3,275,074
				Members' equity (deficit)	...	(10,011)	Year end shares outstanding	25,978,863	□□11,773,065	7,352,958
				Noncontrolling interest	28,552	3,250	Net earnings (loss) per share - class A - basic	\$(7.23)	□\$(53.79)	\$(74.91)
				Total permanent equity (deficit)	36,018	(6,761)	Net earnings (loss) per share - class A - diluted	\$(7.23)	□\$(53.79)	\$(74.91)

□ As is; □ As of May 12, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	32,631	11,195
Inventories	461	2,542
Prepaid expenses & other current assets	3,726	994
Total current assets	36,818	14,731
Equity method investment	523	618
Equipment	...	9,578
Furniture & fixtures	5,467	4,050
Leasehold improvements	43,022	32,157
Other assets	...	448
Construction in progress	4,894	2,435
Equipment - Gross	12,387	...
Other assets- Gross	414	...
Property, plant & equipment, gross	66,184	48,668
Less: accumulated depreciation & amortization	32,277	27,385
Property & equipment, net	33,907	21,283
Operating lease assets	99,255	90,713
Notes receivable from related party, net of current portion	...	10,850
Other assets	749	683
Deferred tax asset	12,618	...
Total assets	183,870	138,878
Accounts payable	10,704	7,474
Accrued salaries & benefits	2,660	1,976
Accrued interest	42	175
Notes payable, current	165	624
Line of credit	...	6,894
Notes payable to related parties, current	1,197	3,021

Recent Dividends:**1. GEN Restaurant Group Inc class A common.**

No dividends paid.

2. GEN Restaurant Group Inc class B common.

No dividends paid.

Annual Dividends:**1. GEN Restaurant Group Inc class A common.**

No dividends paid.

2. GEN Restaurant Group Inc class B common.

No dividends paid.

GENEDX HOLDINGS CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	□2021 (revised)
Impairment of tangible assets	10,402,000
Diagnostic test revenue	195,654,000	□227,334,000	□205,100,000
Other revenue	6,912,000	□7,360,000	□7,095,000
Total revenue	202,566,000	234,694,000	212,195,000
Cost of services	112,560,000	□261,444,000	□228,797,000
Gross (loss) profit	90,006,000	(26,750,000)	(16,602,000)
Research & development	58,266,000	86,203,000	105,162,000
Selling & marketing	60,956,000	134,913,000	112,738,000
General & administrative expenses	133,755,000	203,329,000	205,988,000
Related party expenses	7,223,000	6,312,000	5,659,000
Impairment loss	...	210,145,000	...
Income (loss) from operations	(180,596,000)	(667,652,000)	(446,149,000)
Change in fair market value of

□ Reclassified to conform with 2022 presentation; □ Including related party revenue - diagnostic test revenue: \$2,209,000; □ Including related party revenue - diagnostic test revenue: \$90,000; □ Including related party revenue - other revenue: \$353,000; □ Including related party revenue - other revenue: \$232,000; □ Including related party expenses - cost of services: \$4,169,000; □ Including related party expenses - cost of services: \$3,975,000; □ Adjusted for 1-for-33 stock split, May 4, 2023; □ Shares increase due to the effect of common stock issued pursuant to stock option exercises, shares issued for PIPE, acquisition & vested restricted stock units converted to common stock; □ As of January 20, 2023; □□ Approximately; □□ As of March 6, 2023; □□ As of March 07, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	99,681,000	123,933,000
Restricted cash	...	13,470,000
Accounts receivable, net	32,371,000	42,634,000
Due from related parties	445,000	708,000
Inventory, gross	...	14,765,000
Less: obsolete inventory	...	1,100,000
Inventory	8,777,000	...

Inventory, net	13,665,000	
Prepaid expenses	11,822,000	
Other current assets	6,390,000	
Prepaid Expenses and other current assets	10,598,000	
Marketable securities	30,467,000	
Total current assets	182,339,000	212,622,000
Laboratory equipment	15,538,000	41,255,000
Equipment under capital leases	2,604,000	21,384,000
Leasehold improvements	14,614,000	35,561,000
Capitalized software	32,171,000	32,171,000
Building under capital lease	4,529,000	6,276,000
Construction-in-progress	3,106,000	3,386,000
Computer equipment	5,819,000	9,177,000
Furniture, fixtures & other equipment	550,000	3,777,000
Total property & equipment	78,931,000	152,987,000
Less: accumulated depreciation & amortization	46,452,000	101,460,000
Property & equipment, net	32,479,000	51,527,000
Intangible assets, net	172,625,000	186,650,000
Operating lease right-of-use assets	26,900,000	32,758,000
Long-term restricted cash		900,000
Other assets	4,413,000	6,485,000
Total assets	418,756,000	490,942,000
Accounts payable	10,238,000	46,017,000
Accrued purchases	12,154,000	20,314,000
Reserves for refunds to insurance carriers	15,039,000	17,001,000
Other accrued expenses	25,000	1,546,000
Accrued expenses		38,861,000
Due to related parties	1,379,000	3,593,000
Contract liabilities		40,000
Current portion of lease liabilities	3,647,000	6,121,000
Accrued bonus	3,784,000	8,429,000
Accrued payroll	1,745,000	3,905,000
Accrued benefits	6,409,000	1,529,000
Accrued commissions	527,000	1,656,000
Accrued severance	1,853,000	4,770,000
Current portion of long-term debt	497,000	4,750,000
Indemnification liabilities		13,470,000
Current portion of the contingent consideration liabilities		6,019,000
Current portion of debt issuance costs	(802,000)	
Other current liabilities	2,323,000	5,137,000
Other current liabilities	16,336,000	49,665,000
Accounts payable & accrued expenses	37,456,000	
Total current liabilities	58,818,000	144,297,000
Long-term debt, net of current portion	52,688,000	6,250,000
Long-term lease liabilities	62,938,000	60,013,000
Other liabilities	14,735,000	22,000,000
Deferred taxes	1,560,000	2,659,000
Warrant liability	2,735,000	418,000
Earn-out contingent liability		1,600,000
Third party payor reserve	12,000,000	
Total liabilities	190,739,000	237,237,000
Class A common stock	2,000	38,000
Additional paid-in capital	1,527,778,000	1,378,088,000
Retained earnings (accumulated deficit)	(1,300,188,000)	(1,124,421,000)
Accumulated other comprehensive income	425,000	
Total stockholders' equity (deficit)	228,017,000	253,705,000
Total Equity	228,017,000	

Recent Dividends:

1. GeneDx Holdings Corp class A common.

No dividends paid.
2. GeneDx Holdings Corp class B common.
 No dividends paid.
Annual Dividends:
 1. GeneDx Holdings Corp class A common.
 No dividends paid.
 2. GeneDx Holdings Corp class B common.
 No dividends paid.

GENUFOOD ENERGY ENZYMES CORP

Earnings, 3 mos. to Dec 31 (Consol. - \$):

	2023	2022
Cost & expenses	95,616	205,245
Operating income	(95,616)	(205,245)
Other income (expense), net	(750)	(750)
Foreign currency		(43)
Net before taxes	(96,410)	(206,038)
Income taxes	1,600	
Net income	(98,010)	(206,038)
Earnings common share		
Primary	\$(0.00)	\$.....
Fully Diluted	\$(0.00)	\$.....
Common Shares:		
Full Diluted	808,900,041	299,686,921
Year-end	808,900,041	299,686,921

Consolidated Balance Sheet Items, as of (\$):

Assets:	2023	2022
Cash & equivalents	19,617	
Current assets	27,617	
Net property & equip.	96,142	
Total assets	123,759	
Liabilities:		
Current liabilities	116,323	
Stockholders' equity	(25,540)	
Net current assets	(88,706)	

GEOVAX LABS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	²⁰²¹
			(revised)
Grant revenue		81,526	385,501
Research & development expenses	20,720,766	9,123,479	15,554,171
General & administrative expenses	6,022,173	4,986,611	3,577,153
Total operating expenses	26,742,939	14,110,090	19,131,324
Income (loss) from operations	(26,742,939)	(14,028,564)	(18,745,823)
Interest income	776,177	7,439	4,736
Interest expense			1,286
Gain on debt extinguishment			172,056
Total other income (expense)		7,439	175,506
Income (loss) before income taxes	(25,966,762)		
Net income (loss)	(25,966,762)	(14,021,125)	(18,570,317)
Weighted average shares outstanding			
- basic	1,817,282	² 1,131,546	406,662
Weighted average shares outstanding			
- diluted	1,817,282	² 1,131,546	406,662
Year end shares outstanding	1,977,152	² 1,755,664	³ 425,436
Income (loss) per common share - continuing operations - basic	\$(14.29)		
Net income (loss) per common share - basic	\$(14.29)	² \$(12.45)	\$(45.60)
Income (loss) per common share - continuing operations - diluted	\$(14.29)		
Net income (loss) per common share - diluted	\$(14.29)	² \$(12.45)	\$(45.60)

Number of full time employees	17	14	11
Total number of employees	17		
Number of common stockholders	14	⁵ 15	⁶ 12

¹ Reclassified to conform with 2022 presentation; ² Adjusted for 1-for-15 stock split, January 31, 2024; ³ Shares increased due to the effect of sale of common stock and warrants for cash, issuance of common stock upon warrant exercise and services; ⁴ Shares increased due to the effects of sale of common stock for cash, issuance of common stock upon warrant exercise & common stock for services; ⁵ As of March 15, 2022; ⁶ As of March 9, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	6,452,589	27,612,732
Prepaid clinical trial costs (current portion)		1,171,077
Prepaid insurance premiums		107,876
Prepaid rent		13,045
Other prepaid expenses		34,000
Prepaid expenses	1,433,153	1,325,998
Total current assets	7,885,742	28,938,730
Equipment & furnishings	774,758	725,812
Leasehold improvements	115,605	115,605
Total property & equipment, gross	890,363	841,417
Accumulated depreciation & amortization	680,674	606,505
Property & equipment, net	209,689	234,912
Prepaid clinical trial costs (noncurrent portion)	1,106,778	2,083,276
Prepaid technology license fees	70,000	80,000
Deposits	11,010	11,010
Other assets	1,187,788	2,174,286
Total assets	9,283,219	31,347,928
Accounts payable	2,802,950	1,747,682
Accrued license fees (current portion)		2,000,000
Payroll-related liabilities	114,337	550,810
Other accrued expenses	602,594	449,402
Accrued expenses	716,931	3,000,212
Total current liabilities	3,519,881	4,747,894
Total liabilities		4,747,894
Common stock	1,977	26,335
Additional paid-in capital	110,125,146	104,970,722
Retained earnings (accumulated deficit)	(104,363,785)	(78,397,023)
Total stockholders' equity (deficit)	5,763,338	26,600,034
Total Equity	5,763,338	

Recent Dividends:

1. GeoVax Labs Inc series H convertible preferred.
 No dividends paid.
 2. GeoVax Labs Inc series I convertible preferred.
 No dividends paid.
 3. GeoVax Labs Inc series C convertible preferred (stated value: \$1,000).
 No dividends paid.
 4. GeoVax Labs Inc series B convertible preferred (stated value: \$1,000).
 No dividends paid.
 5. GeoVax Labs Inc common.
 No dividends paid.
 6. GeoVax Labs Inc series D convertible preferred (stated value: \$1,000).
 No dividends paid.
 7. GeoVax Labs Inc series A convertible preferred (stated value: \$1,000).
 No dividends paid.
 8. GeoVax Labs Inc series E convertible preferred (stated value: \$1,000).
 No dividends paid.

Annual Dividends:

1. GeoVax Labs Inc series H convertible preferred.	No dividends paid.
2. GeoVax Labs Inc series I convertible preferred.	No dividends paid.
3. GeoVax Labs Inc series C convertible preferred (stated value: \$1,000).	No dividends paid.
4. GeoVax Labs Inc series B convertible preferred (stated value: \$1,000).	No dividends paid.
5. GeoVax Labs Inc common.	No dividends paid.
6. GeoVax Labs Inc series D convertible preferred (stated value: \$1,000).	No dividends paid.
7. GeoVax Labs Inc series A convertible preferred (stated value: \$1,000).	No dividends paid.
8. GeoVax Labs Inc series E convertible preferred (stated value: \$1,000).	No dividends paid.

GHST WORLD INC**Earnings, 6 mos. to Dec 31(Consol. – \$):**

	2023	2022
Total revenues	39,695	39,695
Net Sales	39,695	39,695
Cost & expenses	476,161	72,221
Operating income	(436,800)	(72,221)
Net before taxes	(436,800)	(72,221)
Net income	(436,800)	(72,221)
Earnings common share		
Common Shares:		
Full Diluted	127,914,437	124,834,016
Year-end	130,201,179	125,222,070

GLIMPSE GROUP INC (THE)**Earnings, 6 mos. to Dec 31(Consol. – \$):**

	2023	2022
Total revenues	5,181,305	6,901,571
Cost & expenses	5,505,442	10,117,131
Operating income	(983,293)	(4,201,241)
Interest income	125,483	126,879
Net before taxes	(857,810)	(4,074,362)
Net income	(857,810)	(4,074,362)
Earnings common share		
Primary	\$(0.05)	\$(0.30)
Fully Diluted	\$(0.05)	\$(0.30)
Common Shares:		
Full Diluted	15,699,563	13,548,573
Year-end	16,722,146	13,966,007

GLOBAL SELF STORAGE INC**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2023	2022
Total revenues	9,214,345	8,886,141
Cost & expenses	5,558,496	4,992,571
Deprec., depl. & amort.	1,224,624	1,214,344
Operating income	2,431,225	2,679,226
Interest expense	619,550	572,174
Other income (expense), net	(165,266)	(582,675)
Net before taxes	1,841,369	1,617,271
Net income	1,841,369	1,617,271
Balance for common	1,841,369	1,599,316
Earnings common share		
Primary	\$0.17	\$0.15
Fully Diluted	\$0.16	\$0.15
Common Shares:		
Full Diluted	11,084,684	10,842,515
Year-end	11,142,970	11,100,842

GLOBESTAR THERAPEUTICS CORP**Annual Report****Consolidated Income Statement, Years Ended Sept. 30 (\$):**

	2023	2022	2021
Cost of goods sold	2,412
Gross profit (loss)	(2,412)
General & administrative expenses	1,864,370	1,265,065	9,091,817
Total operating expenses	1,864,370	1,265,065	9,091,817
Income (loss) from			

operations	(1,864,370)	(1,265,065)	(9,094,229)
Loss on conversion of preferred stock liability	...	5,939	...
Loss on settlement of liabilities, related party	(6,724)	146,460	419,900
Interest expense	91,603	70,346	287,499
Net Income before Tax	(1,949,249)
Total other income (expense)	(84,879)	(222,745)	(707,399)
Net income (loss)	(1,949,249)	(1,487,810)	(9,801,628)
Weighted average shares outstanding - basic	827,324,789	628,539,782	482,090,099
Weighted average shares outstanding - diluted	827,324,789	628,539,782	482,090,099
Year end shares outstanding	996,119,530 ²	722,326,669 ³	561,495,726
Net income (loss) per share - basic	\$0.00	\$0.00	\$(0.02)
Net income (loss) per share - diluted	\$0.00	\$0.00	\$(0.02)
Number of common stockholders	42	42	28

¹ Reclassified to conform with 2022 presentation; ² Shares increased due to the effect of common stock issued for conversion of convertible note payable and accrued interest, stock payable, settlement liability & conversion of series G preferred stock; ³ Shares increased due to the effect of conversion of note payable and accrued interest, stock-based compensation, issuance of common stock and retirement of accrued compensation with related party; ⁴ As of January, 9, 2023; ⁵ As of January 5, 2022

Consolidated Balance Sheet, Years Ended Sept. 30 (\$):

	2023	2022
Cash & cash equivalents	...	6,365
Prepaid expenses	...	3,550
Total current assets	...	9,915
Total assets	...	9,915
Accounts payable & accrued liabilities	59,650	380,735
Accounts payable to related party	454,665	379,126
Related party advances	6,295	12,400
Advances payable	328,178	59,650
Current portion of convertible notes payable	59,710	20,000
Series G preferred stock liability, net	...	126,294
Accrued interest payable	225,363	226,270
Note payable	300,000	...
Total current liabilities	1,433,861	1,204,475
Total liabilities	1,433,861	1,204,475
Common stock	996,119	722,325
Series D preferred stock	...	510
Series E preferred stock	1,000	1,000
Series F preferred stock	129	129
Additional paid-in capital	18,022,916	16,581,252
Stock payable	...	5,000
Retained earnings (accumulated deficit)	(20,454,025)	(18,504,776)
Total stockholders' equity (deficit)	(1,433,861)	(1,194,560)
Total stockholders deficit	(1,433,861)	...

¹ Net of discount - Series G preferred stock liability: \$12,581

Recent Dividends:

- 1. Globestar Therapeutics Corp series E preferred.**
No dividends paid.
- 2. Globestar Therapeutics Corp series G preferred.**
No dividends paid.
- 3. Globestar Therapeutics Corp series D preferred.**
No dividends paid.
- 4. Globestar Therapeutics Corp series A preferred.**
No dividends paid.
- 5. Globestar Therapeutics Corp series F preferred.**

No dividends paid.

6. Globestar Therapeutics Corp common.

No dividends paid.

7. Globestar Therapeutics Corp series B preferred.

No dividends paid.

Annual Dividends:**1. Globestar Therapeutics Corp series E preferred.**

No dividends paid.

2. Globestar Therapeutics Corp series G preferred.

No dividends paid.

3. Globestar Therapeutics Corp series D preferred.

No dividends paid.

4. Globestar Therapeutics Corp series A preferred.

No dividends paid.

5. Globestar Therapeutics Corp series F preferred.

No dividends paid.

6. Globestar Therapeutics Corp common.

No dividends paid.

7. Globestar Therapeutics Corp series B preferred.

No dividends paid.

GLOBESTAR THERAPEUTICS CORP**Earnings, 3 mos. to Dec 31(Consol. – \$):**

	2023	2022
Cost & expenses	155,871	155,241
Operating income	(155,871)	(155,241)
Interest expense	7,888	10,668
Net before taxes	(163,759)	(165,909)
Net income	(163,759)	(165,909)
Balance for common	(196,100)	...
Earnings common share		
Common Shares:		
Full Diluted	1,004,027,756	755,602,522
Year-end	1,049,750,653	770,360,616

Consolidated Balance Sheet Items, as of (\$):

Assets:	2023
Current liabilities	1,532,533
Stockholders' equity	(1,532,533)
Net current assets	(1,532,533)

GRAYSCALE BITCOIN TRUST (BTC)**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
Sponsor's fee, related party	360,561,000	360,683,000	615,420,000
Net investment loss	(360,561,000)	(360,683,000)	(615,420,000)
Net realized gain on investment in bitcoin	218,806,000	216,064,000	470,168,000
Net change in unrealized appreciation (depreciation) on investment in Bitcoin	16,027,962,000	(18,967,171,000)	10,099,600,000
Net realized & unrealized gain (loss) on investment	16,246,768,000	(18,751,107,000)	10,569,768,000
Net increase (decrease) in net assets resulting from operations	15,886,207,000	(19,111,790,000)	9,954,348,000
Year end shares outstanding	692,370,100	692,370,100	692,370,100
Net earnings (loss) per share - basic	\$(0.52)	\$(0.52)	\$(0.89)
Number of common stockholders	46	65	94
Shares used to calculate Basic EPS			
-Total	692,370,100
Shares used to calculate Diluted EPS - Total	692,370,100
EPS - Diluted - including Extraordinary Items			
Applicable to Common - Total	\$(0.52)

□ Approximately
Consolidated Balance Sheet, Years Ended Dec. 31 (\$):
 2023 2022

Investments in bitcoin, at fair value	26,350,470,000	□10,464,263,000
Total assets	26,350,470,000	10,464,263,000
Net assets	...	10,464,263,000
Paid-in-capital	7,513,961,000	7,513,961,000
Accumulated net investment loss	(1,511,004,000)	(1,150,443,000)
Accumulated net realized gain on investment in Bitcoin	1,013,949,000	795,143,000
Accumulated net change in unrealized appreciation (depreciation) on investments in Bitcoin	19,333,564,000	3,305,602,000
Net assets	26,350,470,000	10,464,263,000
Net assets value per share	\$38.06	\$15.11
Total Equity	26,350,470,000	...

□ Cost - investments in bitcoin, at fair value: \$7,158,661,000

Recent Dividends:

1. Grayscale Bitcoin Trust (BTC) common.

No dividends paid.

Annual Dividends:

1. Grayscale Bitcoin Trust (BTC) common.

No dividends paid.

GRAYSCALE BITCOIN TRUST (BTC)

Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2023	2022
Cost & expenses	247,093,000	302,945,000
Net income	(247,093,000)	302,945,000
Earnings common share		
Primary	\$(0.36)	\$(0.44)
Fully Diluted	\$(0.36)	\$.....
Common Shares:		
Full Diluted	692,370,100
Year-end	692,370,100	692,370,100

GRAYSCALE ETHEREUM CLASSIC TRUST (ETC)

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):
 2023 2022 2021

Sponsor fee, related party	5,476,000	8,638,000	15,574,000
Net investment income (loss)	(5,476,000)	(8,638,000)	(15,574,000)
Net realized gain on investment in ETC	3,269,000	6,261,000	12,791,000
Net change in unrealized appreciation (depreciation) on investment in Ethereum Classic	68,838,000	(217,762,000)	337,929,000
Net realized & unrealized gain (loss) on investment	72,107,000	(211,501,000)	350,720,000
Net increase (decrease) in net assets resulting from operations	66,631,000	(220,139,000)	335,146,000
Year end shares outstanding	13,993,800	13,993,800	13,993,800
Net investment gain (loss) per share	\$(0.39)	\$(0.62)	\$(1.12)
Income from operations per share	\$4.76	\$(15.73)	\$24.04
Common Shareholders - Number	13
Number of stockholders	...	□17	□21
Shares used to calculate Basic EPS - Total	13,993,800

Shares used to calculate Diluted EPS - Total 13,993,800

□ Approximately
Consolidated Balance Sheet, Years Ended Dec. 31 (\$):
 2023 2022

Investments in Ethereum Classic, at fair value	...	□187,327,000
Investment in Ethereum Classic, at fair value (cost \$91,793 and \$91,860 as of 31, 2021 and 2020, respectively)	253,958,000	...
Total assets	253,958,000	187,327,000
Net assets	...	187,327,000
Paid-in-capital	100,243,000	100,243,000
Accumulated net investment loss	(35,912,000)	(30,436,000)
Accumulated net realized gain on investment in Ethereum Classic	22,878,000	19,609,000
Accumulated net change in unrealized appreciation (depreciation) on investment in Ethereum Classic	166,749,000	97,911,000
Net assets	253,958,000	187,327,000
Net asset value per share	\$18.15	\$13.39
Total Equity	253,958,000	...

□ Cost - Investment in Grayscale Ethereum Classic Trust ("ETC"): \$89,416,000

Recent Dividends:

1. Grayscale Ethereum Classic Trust (ETC) common.

No dividends paid.

Annual Dividends:

1. Grayscale Ethereum Classic Trust (ETC) common.

No dividends paid.

GRAYSCALE STELLAR LUMENS TRUST (XLM)

Earnings, 3 mos. to Dec 31 (Consol. - \$):

	2023	2022
Cost & expenses	55,000	46,000
Net income	(55,000)	(46,000)
Earnings common share		
Primary	\$1.37	\$(0.06)
Fully Diluted	\$1.37	\$.....
Common Shares:		
Full Diluted	831,100
Year-end	831,100	824,600

Consolidated Balance Sheet Items, as of (\$):

Assets:	2023
Total assets	9,448,000
Liabilities:	
Stockholders' equity	9,448,000
Net current assets	0

GRID DYNAMICS HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):
 2023 2022 2021

Revenues	312,910,000
Revenue	312,910,000	310,482,000	211,280,000
Cost of revenue	199,764,000	189,892,000	123,552,000
Gross profit (loss)	113,146,000	120,590,000	87,728,000
Engineering, research & development	14,741,000	15,772,000	8,459,000
Sales & marketing	24,151,000	19,808,000	14,457,000
General & administrative	79,834,000	106,018,000	64,762,000
Total operating expenses	118,726,000	141,598,000	87,678,000
Income (loss) from operations	(5,580,000)	(21,008,000)	50,000
Other income (expenses), net	10,418,000	555,000	(2,502,000)
Income (loss) before income taxes	...	(23,490,000)	(11,530,000)
- United States	...	(23,490,000)	(11,530,000)

Income (loss) before income taxes - International 3,037,000 9,078,000

Income (loss) before income taxes .. 4,838,000 (20,453,000) (2,452,000)

Current income tax provision (benefit) - federal 3,619,000 6,951,000 71,000

Current income tax provision (benefit) - state 941,000 1,774,000 80,000

Current income tax provision (benefit) - international 6,183,000 3,681,000 2,164,000

Total current income taxes 10,743,000 12,406,000 2,315,000

Deferred income tax provision (benefit) - federal (2,265,000) (2,740,000) 2,752,000

Deferred income tax provision (benefit) - state (474,000) (315,000) (59,000)

Deferred income tax provision (benefit) - foreign (1,401,000) (590,000) 240,000

Total deferred income taxes (4,140,000) (3,645,000) 2,933,000

Provision (benefit) for income taxes 6,603,000 8,761,000 5,248,000

Net income (loss) (1,765,000) (29,214,000) (7,700,000)

Weighted average shares outstanding - basic 75,193,000 69,197,000 58,662,000

Weighted average shares outstanding - diluted 75,193,000 69,197,000 58,662,000

Year end shares outstanding 75,887,475 74,156,458 □66,850,941

Net earnings (loss) per share - basic \$(0.02) \$(0.42) \$(0.13)

Net earnings (loss) per share - diluted \$(0.02) \$(0.42) \$(0.13)

Full-Time Employees (Period End) 3,920

Total number of employees 3,920 3,798 3,274

Common Shareholders - Number 13

Total number of common stockholders □□13 □14

Foreign currency translation adjustments (722,000) (122,000)

EPS - Basic - excluding Extraordinary Items Applicable to Common - Total \$(0.02)

EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total \$(0.02)

□ Shares increased due to the effect of exchange of warrants, exercise of stock options, issuance of common stock; □ Approximately; □ As of February 15, 2023; □ As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):
 2023 2022

Cash & cash equivalents	257,227,000	256,729,000
Accounts receivable, gross	51,187,000	48,801,000
Less: allowance for doubtful accounts	1,363,000	443,000
Accounts receivable, net	49,824,000	48,358,000
Unbilled receivables	3,735,000	5,591,000
Prepaid income taxes	3,998,000	4,294,000
Prepaid expenses & other current assets	9,196,000	8,154,000
Total current assets	323,980,000	323,126,000
Computers & equipment	13,837,000	11,679,000
Machinery & automobiles	570,000	349,000

Furniture & fixtures	1,732,000	1,614,000
Software	1,236,000	1,053,000
Leasehold improvements	1,343,000	646,000
Property & equipment, gross before capitalized software	18,718,000	15,341,000
Less: accumulated depreciation & amortization	12,441,000	8,614,000
Property & equipment, net before capitalized software	6,277,000	6,727,000
Capitalized software development costs	9,050,000	6,210,000
Less: accumulated amortization	3,969,000	4,722,000
Intangible property and equipment, net	5,081,000	...
Property and equipment, net - Balancing value	6,277,000	...
Property & equipment, net	11,358,000	8,215,000
Operating lease right-of-use assets, net	10,446,000	7,694,000
Intangible assets, net	26,546,000	20,375,000
Deferred tax assets	6,418,000	4,998,000
Goodwill	53,868,000	45,514,000
Other noncurrent assets	2,549,000	1,224,000
Total assets	435,165,000	411,146,000
Accounts payable	3,621,000	3,897,000
Accrued compensation & benefits	19,263,000	13,065,000
Accrued income taxes	8,828,000	10,718,000
Operating lease liabilities, current	4,235,000	2,505,000
Contingent consideration payable	...	3,288,000
Value added tax payable	993,000	1,345,000
Accrued expenses	2,943,000	1,302,000
Deferred revenue	577,000	1,124,000
Customer deposits	756,000	754,000
Other liabilities	1,007,000	712,000
Other current liabilities	600,000	...
Accrued expenses & other current liabilities	...	8,525,000
Accrued expenses and other current liabilities - Balancing value	6,276,000	...
Other Liabilities - Balancing value	407,000	...
Total current liabilities	42,223,000	38,710,000
Deferred tax liabilities	3,274,000	3,756,000
Operating lease liabilities, noncurrent	6,761,000	5,636,000
Total liabilities	52,258,000	48,102,000
Common stock	8,000	7,000
Additional paid-in capital	397,511,000	378,006,000
Retained earnings (accumulated deficit)	(15,886,000)	(14,121,000)
Accumulated other comprehensive income (loss)	1,274,000	(848,000)
Total stockholders' equity (deficit)	382,907,000	363,044,000
Total Equity	382,907,000	...

Recent Dividends:

- 1. Grid Dynamics Holdings Inc class B common.**
No dividends paid.
- 2. Grid Dynamics Holdings Inc class A common.**
No dividends paid.
- 3. Grid Dynamics Holdings Inc common.**
No dividends paid.
- 4. Grid Dynamics Holdings Inc common stock subject to possible redemption.**
No dividends paid.

Annual Dividends:

- 1. Grid Dynamics Holdings Inc class B common.**
No dividends paid.
- 2. Grid Dynamics Holdings Inc class A common.**
No dividends paid.
- 3. Grid Dynamics Holdings Inc common.**
No dividends paid.

4. Grid Dynamics Holdings Inc common stock subject to possible redemption.

No dividends paid.

GROWGENERATION CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021 (revised)
Total revenues	225,882,000
Sales, net	225,882,000	278,166,000	422,489,000
Cost of sales (exclusive of depreciation & amortization shown below)	164,624,000	207,903,000	304,248,000
Gross profit	61,258,000	70,263,000	118,241,000
Store operations & other operational expenses	48,082,000	54,680,000	49,742,000
Selling, general, & administrative	...	36,758,000	39,469,000
General & administrative expense	29,799,000
Bad debt expense	955,000	1,737,000	1,428,000
Impairment of intangible assets	15,659,000
Depreciation & amortization expense	16,607,000	17,132,000	12,600,000
Impairment loss	...	127,831,000	...
Total operating expenses	111,102,000	238,138,000	103,239,000
Income (loss) from operations	(49,844,000)	(167,875,000)	15,002,000
Miscellaneous income (expense)	781,000	684,000	(216,000)
Interest income	2,696,000	580,000	486,000
Interest expense	97,000	21,000	43,000
Total non-operating income (expense), net	3,380,000	1,243,000	227,000
Net income (loss) before income tax	(46,464,000)	(166,632,000)	15,229,000
Current federal tax expense	(115,000)	(471,000)	(115,000)
Current state tax expense	147,000	(55,000)	949,000
Deferred federal tax expense	...	(2,179,000)	1,473,000
Deferred state tax expense	...	(180,000)	136,000
Provision (benefit) for income taxes	32,000	(2,885,000)	2,443,000
Net income (loss)	(46,496,000)	(163,747,000)	12,786,000
Weighted average shares outstanding - basic	61,181,000	60,813,000	59,223,000
Weighted average shares outstanding - diluted	61,181,000	60,813,000	60,464,000
Year end shares outstanding	61,483,762	61,010,155	59,928,564
Net income (loss) per share - basic	\$(0.76)	\$(2.69)	\$0.22
Net income (loss) per share - diluted	\$(0.76)	\$(2.69)	\$0.21
Number of full time employees	372	429	634
Number of part time employees	28	26	53
Total number of employees	400	455	687
Number of common stockholders	75	84	136

□ Reclassified to conform with 2022 presentation; □ As of March 1, 2023; □ As of February 23, 2022; □ Approximately; □ As of February 27, 2023; □ As of February 18, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

Cash & cash equivalents	29,757,000	40,054,000
Marketable securities	35,212,000	31,852,000
Accounts receivable, gross	10,295,000	9,036,000
Less: allowance for doubtful accounts	1,400,000	700,000
Notes receivable, current, net of allowance for doubtful accounts of \$292,050	193,000	...
Notes receivable, current, net of allowance for doubtful accounts of \$292,050 - Balancing value	1,893,000	...
Accounts receivable, net	8,895,000	8,336,000
Notes receivable, net	...	1,214,000
Inventory	64,905,000	77,091,000
Prepaid income taxes	516,000	5,679,000
Prepaid expenses & other current assets	7,973,000	6,455,000
Provision - Accounts & Notes Receivable - Trade	1,700,000	...
Total current assets	147,451,000	170,681,000
Vehicle	2,558,000	2,176,000
Building	2,121,000	2,121,000
Leasehold improvements	11,920,000	12,562,000
Furniture, fixtures & equipment	14,364,000	13,195,000
Capitalized software	16,085,000	2,644,000
Construction in progress	...	9,569,000
Property & equipment, gross	47,048,000	42,267,000
Less: accumulated depreciation & amortization	19,996,000	13,598,000
Property & equipment, net	27,052,000	28,669,000
Operating leases right-of-use assets	39,933,000	46,433,000
Notes receivables, net of current portion	106,000	...
Intangible assets, net	16,180,000	30,878,000
Goodwill	7,525,000	15,978,000
Other assets	843,000	803,000
Total assets	239,090,000	293,442,000
Accounts payable	11,666,000	15,728,000
Accrued liabilities	2,530,000	1,535,000
Payroll & payroll tax liabilities	2,169,000	4,671,000
Customer deposits	5,359,000	4,338,000
Sales tax payable	1,185,000	1,341,000
Current maturities of operating lease liability	8,021,000	8,131,000
Current portion of long-term debt	...	50,000
Total current liabilities	30,930,000	35,794,000
Operating lease liability, net of current maturities	34,448,000	40,659,000
Other long-term liabilities	317,000	593,000
Total liabilities	65,695,000	77,046,000
Common stock	61,000	61,000
Additional paid-in capital	373,433,000	369,938,000
Retained earnings (accumulated deficit)	(200,099,000)	(153,603,000)
Total stockholders' equity	173,395,000	216,396,000
Total Equity	173,395,000	...

□ Allowance for doubtful accounts - notes receivable, current: \$1,268,000

Recent Dividends:**1. GrowGeneration Corp common.**

No dividends paid.

Annual Dividends:**1. GrowGeneration Corp common.**

No dividends paid.

HALL OF FAME RESORT & ENTERTAINMENT CO Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Total revenues	17,992,539	12,919,088
Cost & expenses	41,637,835	33,332,117
Operating income	(34,131,631)	(29,833,614)
Other income (expense), net	819,646	260,686
Gains or losses	1,683,246	9,011,000
Net before taxes	(48,850,138)	(27,977,976)
Net income	(48,850,138)	(27,977,976)
Balance for common	(49,582,489)	(28,438,810)
Earnings common share		
Primary	\$(8.77)	\$(5.57)
Fully Diluted	\$(8.77)	\$(5.57)
Common Shares:		
Full Diluted	5,654,184	5,105,744
Year-end	5,674,969	5,509,242

Year end shares outstanding	34,052	32,983	30,785
Earnings (loss) per share from continuing operations - basic	\$1.35
Net income (loss) per share - basic	\$1.35	\$0.57	\$(0.12)
Earnings (loss) per share from continuing operations - diluted	\$1.25
Net income (loss) per share - diluted	\$1.25	\$0.55	\$(0.12)
Total number of full-time employees	936	...	805
Total number of employees	936	980	...
Number of common stockholders	215	249	275
Number of beneficiary stockholders	...	5,000	5,000

Accounts payable - trade	43,636	...
Other	1,631	...
Accounts payable and accrued liabilities - Balancing value	62,908	...
Operating Lease Liabilities - Current
Portion/Short-Term	58	...
Current portion of lease financing	3,933	...
Total current liabilities	157,595	239,602
Bank debt, net	63,453	49,713
Convertible notes payable	...	10,000
- related party	9,000	9,000
Convertible debt to related parties	10,000	...
Deferred income taxes	9,235	4,606
Asset retirement obligations	14,538	17,254
Contract liability - power purchase agreement	47,425	84,096
Other long-term liabilities	1,789	1,259
Long-term lease financing	8,157	...
Total long-term liabilities	163,597	175,928
Total liabilities	321,192	415,530
Common stock	341	330
Additional paid-in capital	127,548	118,788
Retained earnings (accumulated deficit)	140,699	95,906
Total stockholders' equity	268,588	215,024
Total equity	268,588	...

HALLADOR ENERGY CO

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

	2023	2022	2021 (revised)
Coal sales	361,926	289,376	243,903
Electric sales	...	66,252	...
Other revenues	4,627	6,363	3,763
Prospect sale	267,927
Total sales & operating revenues	634,480	361,991	247,666
Cost of coal sales	473,390
Operating expenses	...	266,608	198,840
Depreciation, depletion & amortization	67,211	46,875	39,973
Asset retirement obligations accretion	1,804	1,010	1,504
Asset retirement obligations change in estimate	(3,510)
Exploration costs	904	651	482
General & administrative	26,159	16,417	14,833
Total operating expenses	...	(331,561)	(253,710)
Income (loss) from operations	...	30,430	(6,044)
Gain on extinguishment of debt	(1,491)	...	10,000
Equity method investment income	(552)	443	364
Interest on bank debt	...	7,563	8,510
Other interest expense	...	715	...
Payments on interest rate swap, net of changes in value	...	(867)	(3,026)
Amortization of debt issuance costs	...	3,601	2,564
Interest expense	13,711	11,012	8,048
Asset impairment	1,588
Income (loss) before income taxes	49,258	19,861	(3,728)
Current income tax expense (benefit)	(164)
Deferred income tax expense (benefit)	4,629	1,756	26
Total income tax expense (benefit)	4,465	1,756	26
Net income (loss)	44,793	18,105	(3,754)
Less: earnings (loss) allocated to restricted stock units	(1,201)
Net income (loss) allocated to common shareholders	45,994	18,105	(3,754)
Weighted average shares outstanding - basic	33,133	32,043	30,614
Weighted average shares outstanding - diluted	36,827	33,649	30,614

Reclassified to conform with 2022 presentation; As is; As of March 10, 2023; As of March 23, 2022; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	2,842	3,009
Restricted cash	4,281	3,417
Accounts receivable	...	29,889
Accounts receivable	19,937	...
Coal inventory	38,877	49,796
Parts & supplies	...	28,295
Contract asset - coal purchase agreement	...	19,567
Prepaid expenses	2,262	4,546
Inventory	23,075	...
Total current assets	91,274	138,519
Land & material rights	115,486	115,595
Buildings & equipment	537,131	534,129
Mine development	158,642	140,108
Total property, plant & equipment, at cost	823,605	789,832
Less - accumulated depreciation, depletion, & amortization	...	309,370
Total property, plant & equipment, net	488,634	480,462
Building And Equipment Gross - Balancing value	536,431	...
Finance lease right-of-use assets	12,346	...
Investment in Sunrise Energy LLC	2,811	3,988
Advance coal royalties	...	5,967
Other long-term assets	...	1,618
Right of Use Tangible Assets - Operating Lease - Gross	700	...
Total assets	589,780	630,554
Current portion of bank debt, net	24,438	33,031
Accounts payable	...	62,306
Accrued property taxes	2,987	1,917
Accrued payroll	6,575	5,933
Workers' compensation reserve	3,629	3,440
Group health insurance	...	2,250
Asset retirement obligation - current portion	43,254	3,580
Other accounts payable & accrued liabilities	...	3,546
Accounts payable & accrued liabilities	4,392	82,972
Deferred revenue	23,062	35,485
Contract liability - power purchase agreement & capacity payment reduction	...	88,114

Recent Dividends:

1. Hallador Energy Co common.

No dividends paid.

Annual Dividends:

1. Hallador Energy Co common.

No dividends paid.

HAMMER FIBER OPTICS HOLDINGS CORP

Annual Report

Consolidated Income Statement, Years Ended Jul. 31 (\$):

	2023	2022 (revised)	2021 (revised)
Revenues	3,256,611	2,602,115	2,199,127
Cost of sales	2,426,456	2,022,190	1,568,357
Selling, general & administrative expenses	1,359,339	1,062,163	694,389
Depreciation expense	60,283	65,487	55,398
Operating loss	(589,467)	(547,725)	...
Total operating expenses	3,846,078	3,149,840	2,318,144
Income (loss) from operations	(119,017)
Other income	262,259	...	213,026
Interest expenses	20,618	89,926	30,797
Financing expenses	255,532	635,812	...
Other expenses	175,559	12,040	2,475
Loss of asset impairment	18,000	57,000	...
Warrant financing expense	145,725	125,025	...
Income (loss) From Discontinued Operations	(906,642)	(1,353,528)	...
Total other income (expenses)	(317,175)	(805,803)	179,754
Income (loss) before discontinued operations	60,737
Income (loss) from discontinued operations	(1,013,600)	...	2,412,877
Net income (loss)	(1,920,242)	(1,353,528)	2,473,614
Weighted average shares outstanding - basic	62,205,947	61,565,841	60,853,341

Weighted average shares outstanding - diluted	62,205,947	61,565,841	60,853,341
Year end shares outstanding	60,452,612	59,812,506	54,920,506
Net income (loss) per share - continuing operations - basic	\$(0.01)	\$(0.02)	...
Earnings per share-inc from discontinued oper	\$(0.02)	\$0.00	...
Net income (loss) per share - discontinued operations - basic	\$(0.02)	\$0.00	\$0.04
Net income (loss) per share - basic	\$(0.03)	\$(0.02)	\$0.04
Net income (loss) per share - continuing operations - diluted	\$(0.01)	\$(0.02)	...
Earn per share-inc from discount opers - diluted	\$(0.02)	\$0.00	...
Net income (loss) per share - discontinued operations - diluted	\$(0.02)	\$0.00	\$0.04
Net income (loss) per share - diluted	\$(0.03)	\$(0.02)	\$0.04
Number of full time employees	15	...	13
Number of part time employees	3	...	2
Total number of employees	18
Total Revenue	3,256,611	2,602,115	...
Net Income Before Extraordinary and Preferred Dividends	(906,642)	(1,353,528)	...

□ Restated to reflect correction of errors; □ Reclassified to conform with 2022 presentation

Consolidated Balance Sheet, Years Ended Jul. 31 (\$):

	2023	2022	2021
Cash & cash equivalents	66,688	482,910	...
Account receivable	238,820	216,834	...
Security deposits	7,316	11,082	...
Prepaid expenses	18,675	14,746	...
Total current assets	331,499	725,572	...
Property & equipment, gross	1,275,031
Less: accumulated depreciation	1,185,319
Property & equipment, net	89,712	137,345	...
Intangible assets	7,406,827	7,464,702	...
Assets from discontinued operations	...	1,243,960	...
Total assets	7,828,038	9,571,579	...
Accounts payable & accrued expenses	1,205,995	1,342,287	...
Loans payable	1,443,294	1,314,693	...
Deferred revenue	172,900	321,074	...
Rent concessions	195,750
Unissued Stock	105,925
Warrant Liabilities	...	213,750	...
Liabilities from discontinued operations	545,994	546,304	...
Total liabilities	3,669,858	3,738,108	...
Common stock	62,206	61,566	...
Additional paid-in capital	27,808,440	27,564,129	...
Retained earnings (accumulated deficit)	(23,712,466)	(21,792,224)	...
Total stockholders' equity (deficit)	4,158,180	5,833,471	...
Total Equity	4,158,180	5,833,471	...

Recent Dividends:

1. Hammer Fiber Optics Holdings Corp common.

No dividends paid.

Annual Dividends:

1. Hammer Fiber Optics Holdings Corp common.

No dividends paid.

HARTFORD GREAT HEALTH CORP

Earnings, 6 mos. to Jan 31(Consol. - \$):

	2024	2023
Total revenues	62,443	...
Cost & expenses	97,639	76,010
Operating income	(35,196)	(76,010)
Other income (expense), net	74	(91)
Gains or losses	...	539,230
Net before taxes	(45,453)	454,951
Income contin. oper.	...	454,951
Net income	(45,453)	454,951
Earnings common share
Common Shares:
Full Diluted	100,108,000	100,108,000
Year-end	100,108,000	100,108,000

HEALTHCARE TRIANGLE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Total revenues	33,203,000
Net revenue	33,203,000	45,886,000	35,270,000
Cost of revenue (exclusive of depreciation & amortization)	26,426,000	34,591,000	24,748,000
Sales & marketing	4,670,000	6,808,000	4,761,000
General & administrative	5,424,000	5,575,000	4,440,000
Research & development
expenses	799,000	5,953,000	5,257,000
Depreciation & amortization	7,232,000	3,374,000	1,422,000
Total operating expenses	...	21,711,000	15,880,000
Operating income (loss) before other income (expenses)	(11,348,000)	(10,416,000)	(5,358,000)
Other income (Paycheck Protection Program loan forgiveness)	12,000	1,081,000	...
Interest expense	968,000	212,000	567,000
Net income (loss) before income tax expenses	(12,304,000)	(9,547,000)	(5,925,000)
State income tax	35,000
Total income tax expense (benefit)	35,000	63,000	24,000
Net income (loss)	(12,339,000)	(9,610,000)	(5,949,000)
Net income (loss) attributable to common stockholders	...	(9,609,000)	(5,949,000)
Weighted average shares outstanding - basic	4,228,741	3,674,065	2,942,786
Weighted average shares outstanding - diluted	4,228,741	3,674,065	2,942,786
Year end shares outstanding	4,308,822	4,170,953	3,526,083
Net income (loss) per common share - basic	\$(2.92)	\$(2.62)	\$(2.02)
Net income (loss) per common share - diluted	\$(2.92)	\$(2.62)	\$(2.02)
Number of full time employees	33	51	77
Number of part time employees	...	225	272
Number of common stockholders	49	49	57
Total number of employees	33

□ Reclassified to conform with 2022 presentation; □ As reported by the Company; □ Adjusted for 1-for-10 stock split, May 26, 2023; □ Shares increased due to the effect of issuance of shares for services, IPO proceeds, note conversion and issuance of shares towards Devcool, Inc. acquisition; □ As of March 2, 2023; □ As of March 2, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	1,234,000	1,341,000
Accounts receivable, gross	...	5,814,000
Less: allowance for doubtful debts	...	222,000
Accounts receivable	3,236,000	5,592,000
Other current assets	1,259,000	816,000
Total current assets	5,729,000	7,749,000
Furniture & equipment	132,000	119,000
Less: accumulated depreciation	88,000	39,000
Net Fixed Assets	44,000	...
Property & equipment, net	44,000	80,000
Goodwill	...	1,289,000
Intangible assets, net	3,972,000	10,570,000
Due from affiliates	304,000	1,075,000
Total assets	10,049,000	20,763,000
Accounts payable	1,953,000	1,481,000
Other current liabilities	1,787,000	2,200,000
Warrant liability	954,000	55,000
Payroll protection program loan	3,429,000	...
Short term borrowing	...	2,412,000
Total current liabilities	8,123,000	6,148,000
Contingent consideration	500,000	2,227,000
Convertible Notes	888,000	...
Total current & long-term liabilities	9,511,000	8,375,000
Series A. super voting preferred stock	...	0
Common stock	43	0
Additional paid-in capital	25,443,000	24,956,000
Retained earnings (accumulated deficit)	(24,905,000)	(12,568,000)
Total stockholders' equity	538,000	12,478,000
Total Equity	538,000	...

□ As reported by the Company

Recent Dividends:

1. Healthcare Triangle Inc series A super voting preferred.

No dividends paid.

2. Healthcare Triangle Inc common.

No dividends paid.

Annual Dividends:

1. Healthcare Triangle Inc series A super voting preferred.

No dividends paid.

2. Healthcare Triangle Inc common.

No dividends paid.

HEART TEST LABORATORIES INC

Earnings, 9 mos. to Jan 31(Consol. - \$):

	2024	2023
Total revenues	18,600	5,150
Cost & expenses	4,444,580	4,519,455
Operating income	(4,425,980)	(4,514,305)
Interest expense	333,143	209,217
Other income (expense), net	79	1,593
Net before taxes	(4,759,044)	...
Net income	(4,759,044)	(4,721,929)
Earnings common share
Primary	\$(0.19)	\$(0.64)
Fully Diluted	\$(0.19)	\$(0.64)
Common Shares:
Full Diluted	25,201,024	7,371,764
Year-end	63,611,630	8,349,859

HEARTBEAM INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	^① 2021 (revised)
General & administrative	8,516	7,354	2,030
Research & development	6,798	5,677	255
Total operating expenses	15,314	13,031	2,285
Income (loss) from operations	(15,314)	(13,031)	(2,285)
Interest income	675
(expense)	...	66	(2,165)
Other income	...	3	22
Total other income (expense)	675	69	(2,143)
Income (loss) before provision (benefit) for income taxes	(14,639)	(12,962)	(4,428)
Net income (loss)	(14,639)	(12,962)	(4,428)
Weighted average shares outstanding - basic	20,333	8,169	4,285
Weighted average shares outstanding - diluted	20,333	8,169	4,285
Year end shares outstanding	26,329	8,010	^② 7,810
Net income (loss) per share - basic	\$(0.72)	\$(1.59)	\$(1.03)
Net income (loss) per share - diluted	\$(0.72)	\$(1.59)	\$(1.03)
Total number of employees	15
Number of full time employees	15	^③ 15	^④ 5
Number of common stockholders	84	^⑤ 50	^⑥ 77
EPS - Basic - excluding Extraordinary Items
Applicable to Common - Total	\$(0.72)
EPS - Diluted - excluding Extraordinary Items
Applicable to Common - Total	\$(0.72)

^① Reclassified to conform with 2022 presentation; ^② Shares increased due to issuance of common stock upon vesting and exercise of stock option and upon conversion of 2015 notes, and sale of common stock & warrants; ^③ As Is; ^④ Approximately; ^⑤ As of March 14, 2023; ^⑥ As of March 23, 2022

Recent Dividends:

^① Includes related party - accounts payable and accrued expenses: \$2,000

1. Heartbeam Inc common.			
No dividends paid.			
Annual Dividends:			
1. Heartbeam Inc common.			
No dividends paid.			
HERITAGE GLOBAL INC			
Annual Report			
Consolidated Income Statement, Years Ended Dec. 31 (\$):			
	2023	2022	^① 2021 (revised)
Services revenue	39,480,000	23,419,000	19,954,000
Asset sales	...	23,495,000	5,838,000
Total revenues	60,545,000	46,914,000	25,792,000
Cost of services revenue	8,007,000	4,654,000	4,499,000
Cost of asset sales	12,724,000	16,256,000	2,929,000
Selling, general & administrative	26,040,000	21,326,000	14,811,000
Depreciation & amortization	514,000	536,000	460,000
Total operating costs & expenses	...	(42,772,000)	(22,699,000)
Earnings of equity method investments	1,059,000	6,978,000	(79,000)
Operating income (loss)	14,319,000	11,120,000	3,014,000
Interest expense, net	...	113,000	22,000
Interest & other expense, net	324,000
Income (loss) before income tax expense (benefit)	13,995,000	11,007,000	2,992,000
Income Taxes - Local - Current	1,188,000
Current income tax expense (recovery)	1,188,000
Income Taxes - Domestic - Deferred	465,000
Income Taxes - Local - Deferred	(133,000)
Deferred income tax expense (recovery)	332,000
Income tax expense (benefit)	1,520,000	(4,486,000)	(61,000)
Net income (loss)	12,475,000	15,493,000	3,053,000
Weighted average shares outstanding - basic	36,677,098	36,016,619	35,458,938
Weighted average shares outstanding - diluted	37,587,308	37,097,270	36,901,390
Year end shares outstanding	37,157,616	36,932,177	36,574,702
Income (loss) per common share - continuing operations - basic	\$0.34
Net income (loss) per share - basic	\$0.34	\$0.43	\$0.09
Income (loss) per common share - continuing operations - diluted	\$0.33
Net income (loss) per share - diluted	\$0.33	\$0.42	\$0.08
Number of full time employees	82	75	63
Total number of employees	82	75	63
Number of common stockholders	338	^② 341	^③ 340
Net sales	21,065,000

^① Reclassified to conform with 2022 presentation; ^② Approximately; ^③ As of March 1, 2023; ^④ As of March 1, 2022

Recent Dividends:

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):		
	2023	2022
Cash & cash equivalents	12,279,000	12,667,000
Non-trade accounts receivable	1,910,000	...

Accounts receivables, gross	2,042,000	1,110,000
Less: allowance for doubtful accounts - accounts receivable	132,000	122,000
Accounts receivable	...	988,000
Current portion of notes receivable, net	6,581,000	4,505,000
Inventory - equipment	5,074,000	4,619,000
Other current assets	448,000	1,113,000
Total current assets	26,292,000	23,892,000
Non-current portion of notes receivable, net	10,890,000	4,245,000
Equity method investments	21,361,000	13,973,000
Right-of-use asset	2,539,000	2,776,000
Building	985,000	985,000
Land	...	397,000
Furniture, fixtures & office equipment	...	223,000
Software & technology assets	...	173,000
Vehicles	11,000	11,000
In-process system development costs	372,000	...
Property and equipment, gross	2,051,000	1,789,000
Fixtures	286,000	...
Land/Improvements - Gross	397,000	...
Property, plant & equipment, gross	2,051,000	1,789,000
Less: accumulated depreciation - property, plant & equipment	346,000	218,000
Property, plant & equipment, net	1,705,000	1,571,000
Intangible assets, net	3,753,000	4,144,000
Goodwill	7,446,000	7,446,000
Deferred tax assets	9,115,000	9,449,000
Other assets	67,000	64,000
Total assets	83,168,000	67,560,000
Remuneration & benefits	4,423,000	4,660,000
Accrued auction & liquidation expenses	...	2,573,000
Due to joint venture partners	...	793,000
Deferred revenue	...	279,000
Sales & other taxes	626,000	220,000
Accrued asset liquidation expenses	1,840,000	...
Accounting, auditing & tax consulting	189,000	204,000
Other accounts payable & accrued liabilities	...	195,000
Payables to sellers	7,237,000	3,188,000
Current portion of third party debt	1,733,000	3,411,000
Current portion of lease liabilities	789,000	703,000
Other	159,000	...
Payables to sellers	4,975,000	...
Total current liabilities	14,734,000	16,226,000
Non-current portion of third party debt	...	871,000
Non-current portion of lease liabilities	1,859,000	2,164,000
Notes payable, less current portion	5,495,000	...
Total liabilities	22,088,000	19,261,000
Preferred stock	6,000	6,000
Common stock	372,000	369,000
Additional paid-in capital	294,522,000	293,589,000
Retained earnings (accumulated deficit)	(233,026,000)	(245,270,000)
Treasury stock at cost	794,000	395,000
Total stockholders' equity (deficit)	61,080,000	48,299,000
Total stockholders' equity	61,080,000	...

Recent Dividends:

1. Heritage Global Inc common.
No dividends paid.
2. Heritage Global Inc series N preferred.

No dividends paid.
Annual Dividends:
1. Heritage Global Inc common.
 No dividends paid.
2. Heritage Global Inc series N preferred.
 No dividends paid.

HERON THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Net product sales	127,044,000	107,672,000	86,346,000
Total revenues	127,044,000
Cost of product sales	65,105,000	54,874,000	46,021,000
Gross profit (loss)	61,939,000
Research & development	55,897,000	107,506,000	130,821,000
General & administrative	49,014,000	37,437,000	40,153,000
Sales & marketing	67,643,000	82,513,000	87,179,000
Total operating expenses	172,554,000
Total operating expenses	...	282,330,000	304,174,000
Income (loss) from operations	(110,615,000)	(174,658,000)	(217,828,000)
Interest income	3,364,000	1,638,000	433,000
Interest expense	3,868,000	2,474,000	2,410,000
Other income (expense)	560,000	(6,530,000)	(878,000)
Total other income (expense), net	56,000	(7,366,000)	(2,855,000)
Income (loss) from continuing operations before income taxes	(110,559,000)
Net income (loss)	(110,559,000)	(182,024,000)	(220,683,000)
Weighted average shares outstanding - basic	138,135,000	108,876,000	98,471,000
Weighted average shares outstanding - diluted	138,135,000	108,876,000	98,471,000
Year end shares outstanding	150,285,044	119,155,000	102,005,000
Income (loss) per share from continuing operations - basic	\$(0.80)
Net income (loss) per share - basic	\$(0.80)	\$(1.67)	\$(2.24)
Income (loss) per share from continuing operations - diluted	\$(0.80)
Net income (loss) per share - diluted	\$(0.80)	\$(1.67)	\$(2.24)
Number of full time employees	126	203	302
Number of common stockholders	88	190	95
Total number of employees	126

¹ As of March 14, 2023; ² As of February 4, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	28,677,000	15,364,000
Short-term investments	51,732,000	69,488,000
Accounts receivable, net	...	52,049,000
Receivables, net	60,137,000	...
Raw materials	17,643,000	15,137,000
Work in process	14,550,000	20,723,000
Finished goods	9,917,000	18,713,000
Total inventory before reserve	42,110,000	...
Inventory	...	54,573,000
Prepaid expenses & other current assets	6,118,000	13,961,000
Total current assets	188,774,000	205,435,000

Scientific equipment	34,027,000	33,318,000	
Leasehold improvements	647,000	647,000	
Computer equipment & software	37,194,000	1,506,000	
Furniture, fixtures & office equipment	1,014,000	982,000	
Computer equipment and software	1,506,000	...	
Property & equipment, gross	...	36,453,000	
Less: accumulated depreciation & amortization	...	14,293,000	
Accumulated depreciation	17,028,000	...	
Property & equipment, net	20,166,000	22,160,000	
Right-of-use lease assets	5,438,000	7,645,000	
Other assets	8,128,000	15,711,000	
Total assets	222,506,000	250,951,000	
Accounts payable	3,240,000	3,225,000	
Accrued bonus	2,354,000	...	
Accrued salaries	9,224,000	...	
Accrued clinical & manufacturing liabilities	22,291,000	24,468,000	
Accrued employee salaries & benefits	1,371,000	2,134,000	
Accrued bonuses	5,499,000	7,783,000	
Accrued vacation	...	3,499,000	
Accrued payroll & employee liabilities	...	13,416,000	
Accrued product sales allowances	36,529,000	33,317,000	
Accrued consulting & professional fees	3,940,000	4,236,000	
Accrued accounts payable	559,000	363,000	
Other accrued liabilities	...	636,000	
Other accrued liabilities	41,855,000	38,552,000	
Current lease liabilities	3,075,000	2,694,000	
Other current liabilities	415,000	...	
Accrued interest	412,000	...	
Total current liabilities	79,685,000	82,355,000	
Non-current lease liabilities	2,800,000	5,499,000	
Non-current convertible notes payable, net	24,263,000	149,284,000	
Promissory note payable to related party	149,490,000	...	
Other long-term liabilities	241,000	241,000	
Total liabilities	256,479,000	237,379,000	
Common stock	1,503,000	1,191,000	
Additional paid-in capital	1,870,525,000	1,807,855,000	
Accumulated other comprehensive income (loss)	13,000	(19,000)	
Retained earnings (accumulated deficit)	(1,906,014,000)	(1,795,455,000)	
Total stockholders' equity	(33,973,000)	13,572,000	
Rep Total Equity & Minority Interest	(33,973,000)	...	

Recent Dividends:

1. Heron Therapeutics Inc common.

No dividends paid.

Annual Dividends:

1. Heron Therapeutics Inc common.

No dividends paid.

HUDSON TECHNOLOGIES INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Product & related sales	...	319,019	187,799
RefrigerantSide services	289,025	6,206	4,949
Revenues	289,025	325,225	192,748
Cost of sales	177,518	162,332	121,084
Gross profit	111,507	162,893	71,664
Selling, general & administrative
Amortization
Total operating expenses
Operating income (loss)
Interest expense
Other income
Total other income (expense)	(8,352)	(14,327)	(8,906)
Income (loss) before income taxes	69,820	117,182	33,399
Current federal income tax expense (benefit)	10,319	11,995	453
Current state & local income tax expense (benefit)	2,940	2,835	350
Total current income tax expense (benefit)	...	14,830	803
Deferred federal income tax expense (benefit)	3,667	(323)	267
Deferred state & local income tax expense (benefit)	647	(1,126)	70
Total deferred income tax expense (benefit)	4,314	(1,449)	337
Current Tax - Total	13,259
Income tax expense (benefit)	17,573	13,381	1,140
Net income (loss)	52,247	103,801	32,259
Weighted average shares outstanding - basic	45,385	44,990	43,765
Weighted average shares outstanding - diluted	47,338	47,109	46,641
Year end shares outstanding	45,502	45,288	44,759
Net earnings (loss) per share - basic	\$1.15	\$2.31	\$0.74
Net earnings (loss) per share - diluted	\$1.10	\$2.20	\$0.69
Number of full time employees	...	232	217
Number of common stockholders	87	104	104
Number of beneficiary stockholders	...	4,000	4,000
Basic EPS Excluding ExtraOrdinary Items	\$1.15
Diluted EPS Excluding ExtraOrd Items	\$1.10

¹ As is; ² As of February 23, 2023; ³ As of March 4, 2022; ⁴ Approximately; ⁵ As of March 8, 2023; ⁶ As of March 10, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	12,446	5,295
Trade accounts receivable - gross	27,163	22,799
Reserve for doubtful accounts	1,994	1,927
Trade accounts receivable - net	25,169	20,872
Refrigerants & cylinders	159,654	152,840
Less: net realizable value adjustments	5,204	7,463
Inventories - Balancing value	154,450	...
Inventories	...	145,377
Income tax receivable	5,438	...
Prepaid expenses & other current assets	7,492	5,289
Total current assets	204,995	176,833
Land	1,255	1,255
Land improvements	319	319

Buildings	1,446	1,446	leach pads	1,051,000	7,990,000
Building improvements	3,467	3,396	Write-down of		
Cylinders	13,220	13,315	materials &		
Equipment	29,397	27,258	supplies		
Equipment under capital			inventories		5,888,000
lease	315	315	Total cost of sales	53,589,000	163,338,000
Vehicles	1,790	1,773	General &		
Lab & computer			administrative		
equipment, software	3,233	3,103	expenses	12,673,000	14,367,000
Furniture & fixtures	933	840	Projects,		
Leasehold improvements	865	852	exploration &		
Construction-in-progress	2,844	3,533	development	20,637,000	18,355,000
Property, plant &			Write-off of		
equipment, gross	59,084	57,405	deposit		916,000
Accumulated depreciation	39,709	36,837	Reduction in asset		
Property, plant &			retirement		
equipment, less			obligation	(1,151,000)	
accumulated depreciation	19,375	20,568	Accretion	1,087,000	408,000
Goodwill	47,803	47,803	Impairment loss on		
Intangible assets, less			assets held for		
accumulated amortization	14,771	17,564	sale		1,777,000
Right of use asset	6,591	7,339	Income (loss) from		
Other assets	3,137	2,386	operations	(45,554,000)	(53,490,000)
Total assets	296,672	272,493	Sprott credit		
Trade accounts payable	23,399	14,165	agreement	5,310,000	6,349,000
Accrued expenses		11,696	Subordinated notes	9,620,000	8,803,000
Cylinder deposits	17,225	13,638	Amortization of		
Lease obligations	1,898	1,669	debt issuance costs	689,000	4,648,000
Other current liabilities	163	905	Amortization of		
Accrued expenses & other			original issue		
current liabilities	12,251	27,908	discount	2,840,000	1,394,000
Accrued payroll	3,615	6,303	Other interest		
Current maturities of			expense	18,467,000	22,000
long-term debt		4,250	Capitalized		
Accrued expenses and			interest		654,000
other current liabilities			Interest expense,		
- Balancing value	31,537		net of capitalized		
Total current liabilities	58,551	52,626	interest	18,481,000	20,593,000
Deferred tax liability	4,558	244	Fair value		
Long-term lease			adjustment to		
liabilities	4,790	5,763	warrants	175,000	(159,000)
Term loan facility- net			Gain (loss) on sale		
of current portion of			of equipment &		
long-term debt		27,563	supplies		
Frst in last out ("FILO")			inventories, net of		
term loan		15,000	commissions	544,000	3,948,000
Less: deferred financing			Interest income	8,278,000	2,313,000
costs on term loan		(3,578)	Gain on		
Total liabilities	67,899	97,618	extinguishment of		
Common stock	455	453	debt	5,041,000	
Additional paid-in			Income (loss)		
capital	118,091	116,442	before income taxes	(55,024,000)	(60,828,000)
Retained earnings			Current federal		
(accumulated deficit)	110,227	57,980	income tax		
Total stockholders'			provision (benefit)		(1,530,000)
equity (deficit)	228,773	174,875	Deferred federal		
Total Equity	228,773		income tax		
			provision (benefit)	(11,428,000)	(17,719,000)
			Change in valuation		
			allowance	11,428,000	17,719,000
			Income tax expense		
			(benefit)		(1,530,000)
			Net income (loss)	(55,024,000)	(60,828,000)
			Weighted average		
			shares outstanding		
			- basic	21,113,516	16,977,306
			Weighted average		
			shares outstanding		
			- diluted	21,113,516	16,977,306
			Year end shares		
			outstanding	20,736,612	20,027,060
			Net earnings (loss)		
			per share - basic	\$(2.61)	\$(3.60)
			Net earnings (loss)		
			per share - diluted	\$(2.61)	\$(3.60)
			Full-Time Employees		
			(Period End)	78	
			Total number of		
			employees	78	74
			Number of common		
			stockholders	244	233

for 1- for -10 stock split, November 15, 2023; [Ⓛ] Shares increased due to the effect of issuance of common stock and warrants, vesting of restricted stock units and other stock issuance; [Ⓜ] Approximately; [Ⓟ] As of March 27, 2023; [Ⓠ] As of March 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	106,210,000	141,984,000
Accounts receivable		2,771,000
Income tax receivable	1,530,000	1,530,000
Interest receivable	667,000	459,000
Materials & supplies		2,808,000
Inventories	1,834,000	2,808,000
Prepays - insurance		1,221,000
Prepays - mining claims & permitting fees		940,000
Prepays - license fees		287,000
Prepays - other prepaids		154,000
Deposits	204,000	238,000
Prepays & deposits, net	3,326,000	2,840,000
Prepaid expenses	3,122,000	
Total current assets	113,567,000	152,392,000
Royalty - advance payment		600,000
Other assets		600,000
Leach pads	713,000	
Production leach pads	11,190,000	11,190,000
Test leach pads	6,241,000	6,241,000
Process equipment	17,556,000	17,302,000
Buildings & leasehold improvements	9,419,000	9,280,000
Mine equipment	4,732,000	4,872,000
Vehicles	1,700,000	1,578,000
Furniture & office equipment		370,000
Mineral properties	50,000	
Construction in progress & other plant & equipment		35,721,000
Construction in progress and other	35,504,000	
Plant, equipment & mine development, gross	87,105,000	86,554,000
Less: accumulated depreciation & amortization	34,014,000	31,722,000
Plant & equipment, net	53,091,000	54,832,000
Restricted cash	26,340,000	33,982,000
Assets held for sale	7,148,000	7,148,000
Prepaid Expenses - Long-Term	1,547,000	
Total assets	201,693,000	248,954,000
Accounts payable & accrued expenses	1,631,000	5,644,000
Contract liabilities	1,550,000	1,050,000
Sprott credit agreement		2,200,000
Note payable		128,000
Debt, net	2,330,000	2,328,000
Accrued compensation	3,000,000	2,868,000
Excise tax liability		96,000
Accrued directors' fees	38,000	36,000
Operating lease liability	25,000	11,000
Other liabilities	3,063,000	3,011,000
Royalty obligation, current	3,172,000	
Total current liabilities	11,746,000	12,033,000
Warrant liabilities	26,000	786,000
Sprott credit agreement		42,503,000
Subordinated notes		92,080,000
Notes payable	142,617,000	205,000
Less, debt issuance costs		(2,098,000)
Debt, net		132,690,000
Deferred gain on sale of royalty	29,839,000	29,837,000
Asset retirement obligation	4,801,000	10,302,000
Operating lease liability	8,000	
Other liabilities	8,000	
Total liabilities	189,037,000	185,648,000
Common stock	21,000	20,000
Additional paid-in capital	737,810,000	733,437,000
Retained earnings (accumulated deficit)	(725,175,000)	(670,151,000)
Total stockholders'		

Recent Dividends:

1. Hudson Technologies Inc common.

No dividends paid.

Annual Dividends:

1. Hudson Technologies Inc common.

No dividends paid.

HYCROFT MINING HOLDING CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	[Ⓛ] 2021 (revised)
Special charges/unusual items	495,000		
Revenues	33,229,000	110,734,000	
Production costs	30,756,000	102,750,000	
Depreciation & amortization	2,814,000	3,361,000	8,544,000
Mine site period costs	11,886,000	13,720,000	38,166,000
Asset retirement obligation adjustments	(2,887,000)	4,701,000	
Write-down of non-current ore on			

[Ⓛ] Reclassified to conform with 2022 presentation; [Ⓜ] Adjusted

equity (deficit)	12,656,000	63,306,000
Total Equity	12,656,000	...

Recent Dividends:**1. Hycroft Mining Holding Corp class B common.**

No dividends paid.

2. Hycroft Mining Holding Corp common subject to possible redemption.

No dividends paid.

3. Hycroft Mining Holding Corp class A common.

No dividends paid.

Annual Dividends:**1. Hycroft Mining Holding Corp class B common.**

No dividends paid.

2. Hycroft Mining Holding Corp common subject to possible redemption.

No dividends paid.

3. Hycroft Mining Holding Corp class A common.

No dividends paid.

IDAHO COPPER CORP**Earnings, 9 mos. to (Consol. - \$):**

	10/31/23	09/30/22
Cost & expenses	1,236,821	50,644
Operating income	(1,236,821)	(50,644)
Other income (expense), net	(203,812)	...
Net before taxes	(1,742,991)	(50,644)
Net income	(1,742,990)	(50,644)
Earnings common share		
Primary	\$(0.01)	\$.....
Fully Diluted	\$(0.01)	\$.....
Common Shares:		
Full Diluted	210,175,251	20,054,000
Year-end	213,181,524	20,054,000

INDIE SEMICONDUCTOR INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021 (revised)
Product revenue	195,624,000	89,457,000	43,796,000
Contract revenue	27,545,000	21,340,000	4,616,000
Total revenue	223,169,000	110,797,000	48,412,000
Cost of goods sold	133,606,000	60,491,000	28,703,000
Research & development	154,507,000	121,197,000	58,117,000
Selling, general, & administrative	70,479,000	48,237,000	36,384,000
Total operating expenses	358,592,000	229,925,000	123,204,000
Income (loss) from operations	(135,423,000)	(119,128,000)	(74,792,000)
Interest income	7,801,000	2,567,000	49,000
Interest expense	8,650,000	1,692,000	1,239,000
Gain (loss) from change in fair value of simple agreements for future equity (SAFEs)	21,600,000
Gain (loss) from change in fair value of warrants	...	55,069,000	(26,060,000)
Gain (loss) from change in fair value of earn-out liabilities	(38,758,000)
Gain (loss) from change in fair value of contingent considerations	...	9,468,000	(80,000)
Gain (loss) from extinguishment of debt	304,000
Other income (expense)	(1,175,000)	(107,000)	42,000
Unrealized gain in securities held in trust	7,066,000
Gain (loss) from change in fair value of contingent considerations and acquisition related

holdbacks	(2,985,000)
Total other income (expense), net	2,057,000	65,305,000	(44,142,000)
Income before income taxes - United States	...	(49,948,000)	(117,761,000)
Income before income taxes - foreign	...	(3,875,000)	(1,173,000)
Net income (loss) before income taxes	(133,366,000)	(53,823,000)	(118,934,000)
Current state income taxes	23,000	224,000	8,000
Current foreign income taxes	766,000	818,000	181,000
Income Taxes - Domestic - Current	96,000
Total current income tax expense	885,000	1,042,000	189,000
Deferred foreign income taxes	(3,414,000)	(2,077,000)	(516,000)
Income Taxes - Domestic - Deferred	(2,000,000)
Income Taxes - Local - Deferred	(5,000)
Total deferred income tax expense (benefit)	(5,419,000)	(2,077,000)	(516,000)
Income tax provision (benefit)	(4,534,000)	(1,035,000)	(327,000)
Net income (loss)	(128,832,000)	(52,788,000)	(118,607,000)
Less: net loss attributable to noncontrolling interest	11,207,000	9,388,000	30,563,000
Net income (loss) available to indie Semiconductor, Inc.	(117,625,000)	(43,400,000)	(88,044,000)
Net income (loss) attributable to common shares	(117,625,000)	(43,400,000)	(88,044,000)
Weighted average shares outstanding - basic	145,188,867	118,660,785	70,012,112
Weighted average shares outstanding - diluted	145,188,867	118,660,785	70,012,112
Year end shares outstanding	181,887,610	148,205,941	138,629,862
Net income (loss) per common share - basic	\$(0.81)	\$(0.37)	\$(1.26)
Net income (loss) per common share - diluted	\$(0.81)	\$(0.37)	\$(1.26)
Full-Time Employees (Period End)	900
Total number of employees	900	600	400
Number of class A common stockholders Reported	169	91	82
Comprehensive Income	(111,506,000)
EPS - Basic - excluding Extraordinary Items
Applicable to Common - Total	\$(0.81)
EPS - Diluted - excluding Extraordinary Items
Applicable to Common - Total	\$(0.81)

□ Reclassified to conform with 2022 presentation; □ Approximately; □ As of March 21, 2023; □ As of April 1, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	151,678,000	321,629,000
Restricted cash	...	250,000
Accounts receivable,		

gross	63,794,000	26,487,000
Allowance for doubtful accounts	192,000	46,000
Accounts receivable, net	63,602,000	26,441,000
Raw materials	7,360,000	5,718,000
Work-in-process	12,423,000	6,846,000
Finished goods	15,896,000	2,484,000
Product inventory	33,141,000	15,048,000
Less: inventory reserves	2,538,000	1,792,000
Inventory, net	...	13,256,000
Prepaid expenses & other current assets	23,399,000	12,290,000
Total current assets	271,820,000	373,866,000
Production tooling	16,428,000	10,851,000
Lab equipment	12,887,000	6,382,000
Office equipment	6,539,000	4,736,000
Leasehold improvements	1,898,000	1,216,000
Construction in progress	3,867,000	1,763,000
Property & equipment, gross	41,619,000	24,948,000
Less: accumulated depreciation	14,653,000	9,119,000
Property & equipment, net	26,966,000	15,829,000
Intangible assets, net	208,134,000	63,117,000
Goodwill	295,096,000	136,463,000
Operating lease right-of-use assets	13,790,000	12,055,000
Other assets & deposits	3,070,000	2,021,000
Total assets	818,876,000	603,351,000
Accounts payable	18,405,000	14,186,000
Accrued payroll liabilities	6,621,000	11,541,000
Contingent considerations	83,903,000	2,500,000
Operating lease liabilities, current	2,653,000	1,955,000
Deferred revenue	2,473,000	1,739,000
Accrued interest	1,672,000	900,000
Other accrued expenses & other current liabilities	...	6,065,000
Accrued expenses & other current liabilities	14,613,000	13,159,000
Intangible asset contract liability	4,429,000	9,377,000
Current debt obligations	4,106,000	15,700,000
Accrued expenses and other current liabilities - Balancing value	21,411,000	...
Total current liabilities	138,875,000	63,963,000
Long-term debt, net of current portion	156,735,000	155,699,000
Warrant liability	...	45,398,000
Intangible asset contract liability, net of current portion	...	4,177,000
Deferred tax liabilities, non-current	13,696,000	7,823,000
Operating lease liability, non-current	10,850,000	10,115,000
Other long-term liabilities	21,695,000	1,844,000
Total liabilities	341,851,000	289,019,000
Class A common stock	16,000	13,000
Class V common stock	2,000	2,000
Additional paid-in capital	813,742,000	568,564,000
Retained earnings (accumulated deficit)	(361,441,000)	(243,816,000)
Accumulated other comprehensive income (loss)	(6,170,000)	(11,951,000)
indie Semiconductor, Inc.'s stockholder's equity (deficit)	446,149,000	312,812,000
Noncontrolling interest	30,876,000	1,520,000
Total stockholders' equity (deficit)	477,025,000	314,332,000

Recent Dividends:**1. indie Semiconductor Inc ordinary shares subject to possible redemption.**

No dividends paid.

2. indie Semiconductor Inc class A common.

No dividends paid.

3. indie Semiconductor Inc class B common.
No dividends paid.
4. indie Semiconductor Inc class V common.
No dividends paid.

Annual Dividends:

1. indie Semiconductor Inc ordinary shares subject to possible redemption.
No dividends paid.

2. indie Semiconductor Inc class A common.
No dividends paid.

3. indie Semiconductor Inc class B common.
No dividends paid.

4. indie Semiconductor Inc class V common.
No dividends paid.

INNOVATIVE DESIGNS INC

Annual Report

Consolidated Income Statement, Years Ended Oct. 31 (\$):

	2023	2022	2021 (revised)
REVENUES - NET ..	347,763
Revenues - net	347,763	258,734	225,601
Cost of sales	167,788	146,912	96,728
Selling, general & administrative expenses	464,065	666,239	411,716
Total operating expenses	631,853	813,151	508,444
Income (loss) from operations	(284,090)	(554,417)	(282,843)
Other income	371,000	33,652
Loss on disposal of equipment	7,519	...	(24,429)
Interest expense	24,807	42,072	49,112
NET LOSS	(301,378)
Total other income (expense)	(17,288)	328,928	(39,889)
Net income (loss)	(301,378)	(225,489)	(322,732)
Weighted average shares outstanding - basic	35,487,572	34,650,560	32,263,560
Weighted average shares outstanding - diluted	35,487,572	35,330,560	32,313,560
Year end shares outstanding	36,532,560	34,650,560	33,315,560
Net earnings (loss) per share - basic	\$(0.01)	\$(0.01)	\$(0.01)
Net earnings (loss) per share - diluted	\$(0.01)	\$(0.01)	\$(0.01)
Number of full time employees	2	2	2
Total number of employees	2
Number of common stockholders	249	249	247
Basic EPS Excluding ExtraOrdinary Items	\$(0.01)
Diluted EPS Excluding ExtraOrd Items	\$(0.01)

¹ As of January 30, 2023; ² As of February 8, 2021

Consolidated Balance Sheet, Years Ended Oct. 31 (\$):

	2023	2022
Cash & cash equivalents	238,677	263,293
Accounts receivable, gross	31,050	17,063
Allowance for doubtful accounts	5,860
Accounts receivable - net	31,050	11,203
Inventory, gross	570,048
Less: obsolete inventory reserve	75,468
Inventory - net of obsolete inventory	549,277	...
Inventory Valuation Reserves	(65,600)	...
Inventory - net of obsolete inventory - Balancing value	483,677	...
Inventory, net	494,580
Total current assets	819,004	769,076

Equipment	1,500	1,500	Warrant fair value gains (losses)	(1,696,000)	...
Containers	11,093	14,900	Other income, net	355,000	...
Automobile	8,111	Income (loss) before income taxes
Containers	24,400	...	- United States	(53,885,000)	...
Property & equipment, gross	36,993	24,511	Income (loss) before income taxes
Less accumulated depreciation	13,514	18,551	- Foreign	3,603,000	...
Property & equipment - net	23,479	5,960	Income (loss) before income tax expense	(93,138,000)	(50,282,000)
Inventory on consignment	1,625	Current federal income taxes	799,000	...
Advance to employees	8,200	13,200	Foreign	692,000	...
Deposits on inventory	80,000	State	29,000	...
Deposits on equipment	652,944	607,370	Total current income taxes	721,000	799,000
Total other assets	702,195	Income tax expense	721,000	799,000
Total assets	1,503,627	1,477,231	Net income (loss) attributable to noncontrolling interests	(93,859,000)	(51,081,000)
Accounts payable	216,626	162,063	Net loss (income) attributable to noncontrolling interests	42,104,000	27,024,000
Current portion of notes payable	20,397	20,128	Net income (loss) attributable to Inspirato Incorporated	(51,755,000)	(24,057,000)
Accrued interest expense	46,345	Weighted average class A shares outstanding - basic	862,500
Due to stockholders	110,631	Weighted average class B shares outstanding - basic	215,625
Accrued expenses	3,778	Weighted average shares outstanding - basic	3,380,000	2,615,500
Accrued interest on stockholder loans	42,873	...	Weighted average class A shares outstanding - diluted	862,500
Current portion of stockholder loans	70,668	...	Weighted average class B shares outstanding - diluted	3,380,000	2,615,500
Total current liabilities	350,564	342,945	Year end shares outstanding	6,444,000	6,203,800
Long-term portion of due to stockholders	66,667	Net earnings (loss) per class A common stock - basic	\$(4.60)
Total long term liabilities	44,429	131,214	Net earnings (loss) per class B common stock - basic	\$(4.60)
Total liabilities	474,159	Net earnings (loss) per share - basic	\$(15.31)	\$(9.20)
Common stock	3,656	3,467	Net earnings (loss) per class A common stock - diluted	\$(4.60)
Additional paid-in capital	11,741,935	11,335,184	Net earnings (loss) per class B common stock - diluted	\$(4.60)
Retained earnings (accumulated deficit)	(10,636,957)	(10,335,579)	Net earnings (loss) per share - diluted	\$(15.31)	\$(9.20)
Total stockholders' equity (deficit)	1,108,634	1,003,072	Full-Time Employees (Period End)	630	...
Total Equity	1,108,634	...	Total number of employees	630	900
			Number of class A common stockholders	32	1
			Number of class V common stockholders	39	...
			Number of class B common stockholders	70	6
			Interest, net	1,133,000	...
			(Gain) loss on fair value instruments	2,368,000	...
			Income tax expense (benefit)	721,000	...

Recent Dividends:

1. Innovative Designs Inc common.

No dividends paid.

Annual Dividends:

1. Innovative Designs Inc common.

No dividends paid.

INSPIRATO INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Operations	28,125,000
Revenue	329,100,000
Revenue	329,100,000	345,530,000	...
Asset impairments	40,844,000
Cost of revenue	233,942,000
Cost of revenue	229,287,000	...
Gross margin	54,314,000	116,243,000	...
General & administrative expenses	72,117,000	68,383,000	5,155,793
Franchise tax expense	152,376
Sales & marketing expenses	32,884,000	38,540,000	...
Operations expenses	457,000	41,267,000	...
Technology & development expenses	11,330,000	13,615,000	...
Depreciation & amortization expenses	3,773,000	3,191,000	...
Income (loss) from operations	(5,308,169)
Interest earned on investments held in trust account	42,056
Interest expense, net	188,000	...
Change in fair value of derivative warrant liabilities	387,750

¹ 2021 and prior periods for Thayer Ventures Acquisition Cor-

poration prior to reverse recapitalization with Inspirato LLC; [Ⓔ]
Adjusted for 1-for-20 stock split, October 17, 2023; [Ⓔ] Approximately: [Ⓔ] As of February 1, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):		
	2023	2022
Cash & cash equivalents	36,566,000	80,278,000
Restricted cash	5,700,000	1,661,000
Accounts receivable, net	3,306,000	3,140,000
Accounts receivable, net - related parties	842,000	663,000
Prepaid subscriber travel	20,547,000	19,915,000
Prepaid expenses	6,135,000	10,922,000
Other current assets	1,744,000	302,000
Total current assets	74,840,000	116,881,000
Residence leasehold improvements	21,372,000	15,302,000
Internal-use software	16,510,000	13,559,000
Corporate office leasehold improvements	5,323,000	5,156,000
Computer equipment	1,114,000	1,436,000
Furniture, fixtures, & equipment	1,214,000	1,208,000
Residence vehicles	689,000	806,000
Property & equipment, gross	46,222,000	37,467,000
Accumulated depreciation & amortization	26,718,000	19,169,000
Property & equipment, net	19,504,000	18,298,000
Goodwill	21,233,000	21,233,000
Right-of-use assets	209,702,000	271,702,000
Other noncurrent assets	5,448,000	2,253,000
Total assets	330,727,000	430,367,000
Accounts payable	11,644,000	30,611,000
Compensation accruals	3,786,000	...
Occupancy taxes payable	6,823,000	...
Accrued liabilities	...	5,475,000
Franchise tax payable	495,000	...
Deferred revenue, current	160,493,000	167,733,000
Lease liabilities, current	61,953,000	74,299,000
Accounts payable and accrued liabilities	22,748,000	...
Total current liabilities	245,194,000	278,118,000
Deferred revenue, noncurrent	17,026,000	18,321,000
Lease liabilities, noncurrent	196,875,000	208,159,000
Warrants	48,000	759,000
Convertible note	23,854,000	...
Other noncurrent liabilities	2,428,000	...
Total liabilities	485,425,000	505,357,000
Class A common stock	6,000	6,000
Class V common stock	7,000	6,000
Additional paid-in capital	255,527,000	245,652,000
Retained earnings (accumulated deficit)	(285,782,000)	(233,931,000)
Total equity excluding noncontrolling interest	(30,242,000)	11,733,000
Noncontrolling interests	(124,456,000)	(86,723,000)
Total equity	(154,698,000)	(74,990,000)

Recent Dividends:

- Inspirato Inc class B common.**
No dividends paid.
- Inspirato Inc class A common.**
No dividends paid.
- Inspirato Inc class V common.**
No dividends paid.

Annual Dividends:

- Inspirato Inc class B common.**
No dividends paid.
- Inspirato Inc class A common.**
No dividends paid.
- Inspirato Inc class V common.**
No dividends paid.

INSPIRED ENTERTAINMENT INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Total revenues	241,800,000	206,800,000
Net Sales	241,800,000	...
Cost & expenses	181,400,000	141,600,000
Operating income	30,600,000	36,500,000
Other income (expense), net	300,000	900,000
Gains or losses	...	900,000
Net before taxes	10,400,000	19,600,000
Income taxes	2,800,000	400,000
Net income	7,600,000	19,200,000
Earnings common share		
Primary	\$0.27	\$0.72
Fully Diluted	\$0.26	\$0.66
Common Shares:		
Full Diluted	29,149,285	29,308,455
Year-end	26,214,739	25,912,781

INSPIREMD INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	[Ⓔ] 2021
			(revised)
REVENUES	6,205,000
Revenues	6,205,000	5,171,000	4,495,000
Cost of revenues	4,398,000	4,054,000	3,741,000
Gross profit (loss)	1,807,000	1,117,000	754,000
Research & development	7,981,000	7,810,000	5,158,000
Selling & marketing	3,865,000	3,664,000	2,907,000
General & administrative expenses	11,104,000	8,356,000	7,405,000
Total operating expenses	22,950,000	19,830,000	15,470,000
Income (loss) from operations	(21,143,000)	(18,713,000)	(14,716,000)
Change in fair value of warrants, embedded derivatives & anti-dilution rights	1,292,000
Income (loss) before tax expenses	(19,851,000)	(18,463,000)	(14,873,000)
Tax expenses	65,000	28,000	45,000
Net income (loss)	(19,916,000)	(18,491,000)	(14,918,000)
Weighted average ordinary shares outstanding - basic	24,268,181	7,871,814	7,346,022
Weighted average ordinary shares outstanding - diluted	24,268,181	7,871,814	7,346,022
Year end shares outstanding	21,841,215	8,330,918	8,296,256
Net income (loss) per share - basic	\$(0.82)	\$(2.35)	\$(2.03)
Net income (loss) per share - diluted	\$(0.82)	\$(2.35)	\$(2.03)
Number of full time employees	65	55	50
Number of part time employees	1	1	2
Total number of employees	66	56	52
Number of common stockholders	278	[Ⓔ] 268	[Ⓔ] 267
Net loss per share basic and diluted	\$(0.82)
Diluted EPS Excluding ExtraOrd Items	\$(0.82)

[Ⓔ] Reclassified to conform with 2022 presentation; [Ⓔ] Reclassified to conform with 2022 presentation; [Ⓔ] As of March 4, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	9,640,000	4,632,000
Short-term bank deposits	...	13,171,000
Accounts receivable - trade, net	...	1,034,000
Other accounts receivable	1,804,000	213,000

Prepaid expenses	578,000	655,000
Finished goods	210,000	179,000
Work in process	562,000	510,000
Raw materials & supplies	1,334,000	932,000
Other	648,000	...
Marketable securities	29,383,000	...
Total current assets	44,159,000	21,326,000
Computer equipment	425,000	396,000
Office furniture & equipment	249,000	231,000
Machinery & equipment	1,702,000	1,704,000
Leasehold improvements	724,000	494,000
Property, plant & equipment, gross	3,100,000	2,825,000
Less - accumulated depreciation & amortization	2,040,000	1,908,000
Property, plant & equipment, net	1,060,000	917,000
Operating lease right of use assets	1,473,000	1,554,000
Fund in respect of employee rights upon retirement	951,000	856,000
Total assets	47,643,000	24,653,000
Accounts payable & accruals - trade	939,000	659,000
Employees & employee institutions	2,188,000	1,853,000
Accrued vacation & recreation pay	287,000	197,000
Clinical trial accrual	744,000	1,258,000
Accrued expenses	1,115,000	554,000
Current operating lease liabilities	557,000	419,000
Other accounts payable & accruals	...	130,000
Advances from an officer	190,000	...
Other	5,081,000	...
Total current liabilities	6,020,000	5,070,000
Operating lease liabilities	1,038,000	1,195,000
Liability for employee rights upon retirement	1,084,000	995,000
Total long-term liabilities	2,122,000	2,190,000
Total liabilities	8,142,000	7,260,000
Common stock	2,000	1,000
Additional paid-in capital	261,000,000	218,977,000
Retained earnings (accumulated deficit)	...	(201,585,000)
Accumulated deficit	(221,501,000)	...
Total equity (deficit)	39,501,000	17,393,000
Total Equity	39,501,000	...

Recent Dividends:

- InspireMD Inc series B convertible preferred.**
No dividends paid.
 - InspireMD Inc common.**
No dividends paid.
 - InspireMD Inc series D convertible preferred.**
No dividends paid.
 - InspireMD Inc series C convertible preferred.**
No dividends paid.
- #### Annual Dividends:
- InspireMD Inc series B convertible preferred.**
No dividends paid.
 - InspireMD Inc common.**
No dividends paid.
 - InspireMD Inc series D convertible preferred.**
No dividends paid.
 - InspireMD Inc series C convertible preferred.**
No dividends paid.

INTERNATIONAL MEDIA ACQUISITION CORP

Earnings, 6 mos. to Sep 30(Consol. - \$):

	2023	2022
Cost & expenses	685,981	1,190,225
Operating income	(685,981)	(1,190,225)
Other income (expense), net	207,969	119,535
Net before taxes	47,834	(392,014)
Income taxes	119,474	131,283
Net income	(71,640)	(523,297)

Earnings common share			
Primary	\$(0.01)	\$(0.02)	
Fully Diluted	\$(0.01)	\$(0.02)	
Common Shares:			
Full Diluted	8,500,164	21,868,367	
Year-end	8,500,164	29,546,900	

INTERNATIONAL MONEY EXPRESS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	[□] 2021 (revised)
Wire transfer & money order fees, net	561,540,000	469,162,000	393,241,000
Foreign exchange gain, net	87,908,000	72,920,000	62,832,000
Other income	9,287,000	4,723,000	3,133,000
Total revenues	658,735,000	546,805,000	459,206,000
Service charges from agents & banks	430,865,000	364,804,000	307,458,000
Salaries & benefits	71,090,000	52,224,000	43,065,000
Other selling, general & administrative expenses	47,979,000	34,394,000	30,334,000
Transaction costs	445,000	3,005,000	1,006,000
Depreciation & amortization	12,866,000	9,470,000	9,491,000
Total operating expenses	563,245,000	463,897,000	391,354,000
Operating income (loss)	95,490,000	82,908,000	67,852,000
Interest expense	10,426,000	5,629,000	4,537,000
Income (loss) before income taxes ..	85,064,000	77,279,000	63,315,000
Current provision for foreign income taxes	532,000	148,000	212,000
Current provision for federal income taxes	18,590,000	14,542,000	11,702,000
Current provision for state income taxes	9,050,000	5,761,000	3,824,000
Total current tax provision	28,172,000	20,451,000	15,738,000
Deferred provision for federal income taxes	(1,811,000)	(423,000)	667,000
Deferred provision for state income taxes	(806,000)	(80,000)	67,000
Foreign	(6,000)
Total deferred tax provision	(2,623,000)	(503,000)	734,000
Income tax provision (benefit) ..	25,549,000	19,948,000	16,472,000
Net income (loss)	59,515,000	57,331,000	46,843,000
Weighted average shares outstanding - basic	35,604,582	37,733,047	38,474,040
Weighted average shares outstanding - diluted	36,429,714	38,625,390	39,103,450
Year end shares outstanding	33,823,237	36,630,970	38,478,700
Net income (loss) per share - basic	\$1.67	\$1.52	\$1.22
Net income (loss) per share - diluted	\$1.63	\$1.48	\$1.20
Number of full time employees	1,110	893	674
Number of part time employees	267	349	210
Total number of employees	1,377	1,242	884
Number of common stockholders	61	[□] 64	[□] 143

[□] Reclassified to conform with 2022 presentation; [□] As of March 8, 2023; [□] As of February 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	239,203,000	149,493,000
Accounts receivable, gross	157,847,000	132,363,000
Allowance for credit losses	2,610,000	2,555,000
Accounts receivable, net	155,237,000	129,808,000
Prepaid wires, net	28,366,000	90,386,000
Prepaid expenses & other current assets	10,068,000	12,749,000
Total current assets	432,874,000	382,436,000
Land	36,000	36,000
Building	663,000	565,000
Computer software & equipment	57,645,000	47,316,000
Office improvements	5,887,000	5,508,000
Furniture & fixtures	3,508,000	2,789,000
Property & equipment, gross	67,739,000	56,214,000
Less: accumulated depreciation	36,083,000	28,054,000
Property & equipment net	31,656,000	28,160,000
Goodwill	53,986,000	49,774,000
Intangible assets, net	18,143,000	19,826,000
Other assets	40,153,000	31,876,000
Total assets	576,812,000	512,072,000
Current portion of long-term debt, net	7,163,000	4,975,000
Accounts payable	36,507,000	25,686,000
Wire transfers & money orders payable, net	125,042,000	112,251,000
Commissions payable to sending agents	19,873,000	19,141,000
Accrued salaries & benefits	8,094,000	5,578,000
Accrued bank charges	1,644,000
Lease liability, current portion	4,955,000	5,258,000
Accrued other professional fees	1,169,000
Accrued taxes	8,613,000	1,329,000
Deferred revenue loyalty program	4,771,000	4,212,000
Contingent consideration liability	1,321,000
Accrued transaction costs	134,000
Other accrued & other current liabilities	2,069,000
Accrued & other liabilities	54,661,000	41,855,000
Accrued and other - Balancing value	8,355,000	...
Total current liabilities	223,373,000	184,767,000
Revolving credit facility	76,000,000
Term loan facility	80,938,000
Total debt	156,938,000
Less: current portion of long term debt	4,975,000
Less: debt origination costs	(1,728,000)
Long-term debt, net	181,073,000	150,235,000
Lease liabilities, net	22,670,000	23,272,000
Deferred tax liabilities, net	659,000	3,892,000
Total long-term liabilities	204,402,000	177,399,000
Common stock	4,000	4,000
Additional paid-in capital	75,686,000	70,210,000
Retained earnings (accumulated deficit)	198,649,000	139,134,000
Accumulated other comprehensive income (loss)	262,000	(142,000)
Treasury stock, at cost	125,564,000	59,300,000
Total stockholders' equity (deficit)	149,037,000	149,906,000
Total Equity	149,037,000	...

Recent Dividends:

1. International Money Express Inc common subject to possible redemption.

No dividends paid.

2. International Money Express Inc common.

No dividends paid.

Annual Dividends:**1. International Money Express Inc common subject to possible redemption.**

No dividends paid.

2. International Money Express Inc common.

No dividends paid.

IOVANCE BIOTHERAPEUTICS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
Product revenue	1,189,000
Total revenues	1,189,000
Cost of sales	10,755,000
Research & development expenses	344,077,000	294,781,000	259,039,000
General & administrative expenses	106,916,000	104,097,000	83,664,000
Total costs & expenses	461,748,000	398,878,000	342,703,000
Income (loss) from operations	(460,559,000)	(398,878,000)	(342,703,000)
Interest income (expense), net	13,043,000	2,985,000	451,000
Income (loss) before income taxes ..	(447,516,000)
Net income (loss)	(444,037,000)	(395,893,000)	(342,252,000)
Weighted average shares outstanding - basic	235,131,000	159,259,000	153,406,000
Weighted average shares outstanding - diluted	235,131,000	159,259,000	153,406,000
Year end shares outstanding	256,135,715	187,812,072	157,004,742
Net income (loss) per share - basic	\$(1.89)	\$(2.49)	\$(2.23)
Net income (loss) per share - diluted	\$(1.89)	\$(2.49)	\$(2.23)
Number of full time employees	557
Total number of employees	557	503	319
Number of common stockholders	17	[□] 17	[□] 14
Income tax benefit	(3,479,000)
Basic EPS Excluding ExtraOrdinary Items ..	\$(1.89)
Diluted EPS Excluding ExtraOrd Items	\$(1.89)

[□] As of December 31, 2022; [□] Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	114,888,000	231,731,000
Short-term investments available for sale	164,979,000	...
Short-term investments	240,114,000
Prepaid expenses & other assets	17,458,000	7,271,000
Trade accounts receivable	151,000	...
Inventory	10,372,000	...
Total current assets	307,848,000	479,116,000
Operating lease right-of-use assets	62,515,000	73,015,000
Lab equipment	23,131,000	22,136,000
Utility equipment	5,990,000	5,951,000
Leasehold improvements	76,804,000	74,305,000
Computer equipment	542,000	695,000
Machinery & equipment	306,000	82,000
Office furniture & equipment	3,297,000	2,927,000
Computer software	7,772,000	6,736,000
Construction in progress	24,101,000	9,118,000
Total property & equipment, cost	141,943,000	121,950,000

Less: accumulated depreciation - property & equipment	27,913,000	...
Less: accumulated depreciation & amortization	...	16,718,000
Property & equipment, net	114,030,000	105,232,000
Restricted cash	66,430,000	6,430,000
Long-term assets	270,000	189,000
Total Intangible Assets, Net	229,258,000	...
Total assets	780,351,000	663,982,000
Accounts payable	33,123,000	26,603,000
Accrued payroll & employee related expenses	34,814,000	19,407,000
Accrued facilities related	2,437,000	6,510,000
Accrued legal & related services	1,610,000	3,015,000
Accrued clinical related	10,911,000	14,812,000
Accrued manufacturing related	10,893,000	4,652,000
Other accrued expenses	6,593,000	3,899,000
Accrued expenses - Balancing value	2,148,000	...
Accrued expenses	69,406,000	52,295,000
Operating lease liabilities	7,777,000	12,587,000
Total current liabilities	110,306,000	91,485,000
Operating lease liabilities - noncurrent	67,085,000	71,859,000
Long-term note payable	1,000,000	1,000,000
Deferred tax liabilities	17,347,000	...
Total non-current liabilities	85,432,000	72,859,000
Total liabilities	195,738,000	164,344,000
Series B convertible preferred stock	3,000	3,000
Common stock	11,000	8,000
Accumulated other comprehensive income (loss)	2,526,000	(902,000)
Additional paid-in capital	2,594,448,000	2,068,867,000
Retained earnings (accumulated deficit)	(2,012,375,000)	(1,568,338,000)
Total stockholders' equity (deficiency)	584,613,000	499,638,000
Total Equity	584,613,000	...

Recent Dividends:**1. Iovance Biotherapeutics Inc series A convertible preferred.**

No dividends paid.

2. Iovance Biotherapeutics Inc common.

No dividends paid.

3. Iovance Biotherapeutics Inc series B convertible preferred.

No dividends paid.

Annual Dividends:**1. Iovance Biotherapeutics Inc series A convertible preferred.**

No dividends paid.

2. Iovance Biotherapeutics Inc common.

No dividends paid.

3. Iovance Biotherapeutics Inc series B convertible preferred.

No dividends paid.

IPOWER INC**Earnings, 6 mos. to Dec 31(Consol. - \$):**

	2023	2022
Total revenues	43,308,496	45,277,263
Cost & expenses	47,129,520	53,953,135
Operating income	(3,821,024)	(8,675,872)
Interest expense	410,977	562,160
Other income (expense), net	59,846	264,032
Net before taxes	(4,172,155)	(8,974,000)
Income taxes	...	(1,495,545)
Net income	(3,207,334)	(7,478,455)
Earnings common share		
Primary	\$(0.11)	\$(0.25)
Fully Diluted	\$(0.11)	\$(0.25)

Common Shares:		
Full Diluted	29,777,378	29,687,878
Year-end	29,710,939	29,572,382

**IRADIMED CORP
Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
			(revised)
Revenue	65,562,296
Revenue	65,562,296	53,303,145	41,814,581
Cost of revenue	15,404,027	12,020,742	9,764,656
Gross profit	50,158,269	41,282,403	32,049,925
General & administrative expenses	15,122,065	10,697,067	9,771,462
Sales & marketing expenses	12,142,090	12,679,610	10,555,738
Research & development expenses	2,858,656	2,278,081	1,905,043
Total operating expenses	30,122,811	25,654,758	22,232,243
Income (loss) from operations	20,035,458	15,627,645	9,817,682
Interest income	1,864,113	581,852	34,806
Realized gains (losses) on maturities of investments	...	8,025	18,593
Foreign currency exchange gains (losses)	(148,842)	(36,773)	(34,794)
Other income (expense)	1,702,798
Disposal of Assets	(12,473)
Other income (expense), net	...	553,104	18,605
Income (loss) before income taxes	21,738,256	16,180,749	9,836,287
Current provision for (benefit from) income taxes - U.S. federal	4,691,517	2,936,394	...
Current provision for (benefit from) income taxes - state	1,273,073	349,669	14,632
Current provision for (benefit from) income taxes - foreign	2,835	1,789	1,439
Current provision for (benefit from) income taxes	5,967,425	3,287,852	16,071
Deferred provision for (benefit from) income taxes - U.S. federal	(1,195,888)	(105,068)	399,512
Deferred provision for (benefit from) income taxes - state	(226,057)	169,478	95,233
Deferred provision for (benefit from) income taxes	(1,421,945)	64,410	494,745
Provision for income tax expense (benefit)	4,545,480	3,352,262	510,816
Net income (loss)	17,192,776	12,828,487	9,325,471
Weighted average shares outstanding - basic	12,602,948	12,562,856	12,346,173
Weighted average shares outstanding - diluted	12,722,530	12,635,971	12,590,853
Year end shares outstanding	12,660,313	12,591,004	12,544,024
Net income (loss) per share - basic	\$1.36	\$1.02	\$0.76
Net income (loss) per share - diluted	\$1.35	\$1.02	\$0.74
Number of full time employees	148	123	110
Number of common			

stockholders	3	□ ₃	□ ₃
Dividends per common share	\$1.53
EPS - Basic - excluding Extraordinary Items	\$1.36
EPS - Diluted - excluding Extraordinary Items	\$1.35
Total number of employees	148

□ As of February 28, 2023; □ As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	49,762,198	57,960,864
Accounts receivable, gross	12,593,108	13,435,019
Less: allowance for doubtful accounts	368,835	160,498
Accounts receivable, net	12,224,273	13,274,521
Raw materials	10,833,004	4,827,113
Work in process	501,191	369,761
Finished goods	1,907,729	411,647
Inventory before allowance for excess & obsolete	12,821,194	5,608,521
Less: allowance for excess & obsolete	420,730	239,288
Inventory, net	...	5,369,233
Prepaid expenses & other current assets	1,193,447	630,960
Prepaid income taxes	...	254,093
Total current assets	76,001,112	77,489,671
Computer software & hardware	1,380,289	1,121,455
Furniture & fixtures	...	1,573,587
Leasehold improvements	270,486	259,146
Machinery & equipment	2,438,922	2,210,181
Tooling in-process	...	665,773
Fixed assets in-process	1,257,844	...
Land	6,253,790	...
Property and equipment, Gross - Balancing value	1,757,129	...
Property & equipment, gross	13,358,460	5,830,142
Less: accumulated depreciation - property & equipment	4,069,835	3,430,330
Property & equipment, net	9,288,625	2,399,812
Intangible assets, net	2,519,053	2,069,439
Operating lease right-of-use asset, net	2,043,043	2,205,286
Deferred tax asset, net	2,122,816	700,867
Other assets	181,449	648,672
Total assets	92,156,098	85,513,747
Accounts payable	1,857,091	1,799,316
Accrued payroll & benefits	2,775,103	2,871,890
Other accrued taxes	103,241	121,919
Warranty reserve	117,463	94,030
Deferred revenue	2,570,407	3,373,122
Current portion of operating lease liability	427,963	293,466
Other current liability	250,000	...
Accrued income taxes	250,041	...
Dividend payable	7,975,997	...
Total current liabilities	16,327,306	8,553,743
Deferred revenue	2,793,548	1,375,197
Operating lease liability, less current portion	1,615,080	1,911,820
Total liabilities	20,735,934	11,840,760
Common stock	1,265	1,259
Additional paid-in capital	28,160,745	26,407,446
Retained earnings	43,258,154	47,264,282
Total stockholders'		

equity.....	71,420,164	73,672,987	
Total Equity	71,420,164	...	

Recent Dividends:

1. iRadimed Corp common.

No dividends paid.

Annual Dividends:

1. iRadimed Corp common.

No dividends paid.

ISPECIMEN INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Sales and marketing ..	3,955,974
Fulfillment	1,788,879
Revenue	9,928,184
Revenue	9,928,184	10,402,303	11,135,303
Cost of revenue	4,820,268	4,756,965	5,249,013
Technology expenses	2,656,287	1,837,882
Sales & marketing expenses	3,566,917	3,445,344	2,422,743
Supply development expenses	1,030,403	801,125	573,913
Fulfillment expenses	1,995,937	1,363,522
General & administrative expenses	5,935,092	6,932,727	5,613,476
Total operating expenses	21,097,533	20,588,385	17,060,549
Income (loss) from operations	(11,169,349)	(10,186,082)	(5,925,246)
Interest expense	16,001	238,963	2,102,681
Change in fair value of derivative liability on convertible notes	(271,000)
Change in fair value of derivative liability on bridge notes & bridge notes, related parties	1,582,700
Gain (loss) on extinguishment of bridge notes & bridge notes, related parties	(2,740,425)
Gain (loss) on extinguishment of convertible notes & convertible notes, related parties	(260,185)
Gain on extinguishment on note payable	788,156
Other income (expense), net	(39,104)	9,778	...
Other expense, net	214,784	...	44,531
Interest income	339,750	169,345	11,397
Total other income (expense), net	69,861	(59,840)	(3,036,569)
Net income (loss) before provision for (benefit) from income taxes	(11,099,488)
Net income (loss)	(11,099,488)	(10,245,922)	(8,961,815)
Weighted average shares outstanding - basic	9,041,341	8,844,307	4,287,424
Weighted average shares outstanding - diluted	9,041,341	8,844,307	4,287,424
Year end shares outstanding	9,083,371	8,925,808	8,733,479
Net income (loss) per share - basic	\$(1.23)	\$(1.16)	\$(2.09)
Net income (loss) per share - diluted	\$(1.23)	\$(1.16)	\$(2.09)
Full-Time Employees (Period End)	53

Total number of employees.....	53	75	59
Number of common stockholders	63	65	67

□ Shares increased due to share-based compensation, conversion of redeemable convertible preferred stock into common stock upon initial public offering and issuance of common stock; □ As of March 16, 2023; □ As of March 18, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash and cash equivalents	2,343,666	...
Cash	15,308,710
Account receivables, gross	1,828,914
Less: allowance for doubtful accounts	520,897	230,999
Accounts receivable - Balancing value	1,249,285	...
Accounts receivable, net	728,388	1,597,915
Accounts receivable-unbilled	2,212,538	2,327,789
Prepaid expenses & other current assets	300,434
Tax credit receivable, current portion	140,873
Prepaid expenses and other current assets	292,079	...
Available-for-sale securities	2,661,932	...
Total current assets	8,238,603	19,675,721
Website	87,184	285,377
Computer equipment & purchased software	96,037	84,589
Equipment	35,449	35,449
Furniture & fixtures	87,184
Leasehold improvements	68,471	60,441
Website	285,377	...
Property & equipment, gross	572,518	553,040
Less: accumulated depreciation - property & equipment	444,731	327,188
Property & equipment, net	127,787	225,852
Internally developed software, net	6,323,034	4,503,787
Operating lease right-of-use asset	193,857	184,692
Security deposits	27,601	27,601
Other intangible assets, net	908,255	...
Total assets	15,819,137	24,617,653
Accounts payable	3,925,438	2,459,063
Accrued expenses	1,540,607	1,531,238
Operating lease - current obligation	167,114	158,451
Deferred revenue	415,771	132,335
Total current liabilities	6,048,930	4,281,087
Operating lease long-term obligation	29,130	27,396
Total liabilities	6,078,060	4,308,483
Common stock	908	892
Additional paid-in capital	69,104,313	68,573,774
Treasury stock	172	172
Retained earnings (accumulated deficit)	(59,364,812)	(48,265,324)
Accumulated other comprehensive income	840	...
Total shareholders' equity (deficit)	9,741,077	20,309,170
Total Equity	9,741,077	...

Recent Dividends:

1. iSpecimen Inc common.

No dividends paid.

Annual Dividends:

1. iSpecimen Inc common.

No dividends paid.

ISPIRE TECHNOLOGY INC

Earnings, 6 mos. to Dec 31 (Consol. - \$):

	2023	2022
Total revenues	84,550,208	58,840,449
Cost & expenses	89,412,117	60,518,105
Operating income	(4,861,909)	(1,677,656)
Interest income	270,865	76,811
Other income (expense), net	7,813	(40,487)
Foreign currency	34,517	(477,582)
Net before taxes	(4,548,714)	(2,118,914)
Net income	(5,396,939)	(2,950,921)
Earnings common share		
Primary	\$(0.10)	\$(0.06)
Fully Diluted	\$(0.10)	\$(0.06)
Common Shares:		
Full Diluted	54,258,224	50,000,000
Year-end	54,279,396	50,000,000

JASPER THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Research & development	51,785,000	34,627,000	25,421,000
General & administrative	17,076,000	16,569,000	11,412,000
Total operating expenses	68,861,000	51,196,000	36,833,000
Income (loss) from operations	(68,861,000)	(51,196,000)	(36,833,000)
Interest earned on marketable securities held in trust account	5,199,000
Change in fair value of earnout liability	18,000	5,725,000	9,277,000
Change in fair value of derivative liability	(3,501,000)
Change in fair value of common stock warrant liability	(575,000)	7,200,000	500,000
Other income (expense), net	(246,000)	586,000	(80,000)
Total other income (expense), net	4,396,000	13,511,000	6,196,000
Income before provision for income taxes	(64,465,000)
Net income (loss) & comprehensive income (loss)	(64,465,000)	(37,685,000)	(30,637,000)
Weighted average shares outstanding			
- basic	10,439,034	3,648,276	1,139,375
Weighted average shares outstanding - diluted	10,439,034	3,648,276	1,139,375
Year end shares outstanding	11,163,896	3,804,568	3,785,511
Net earnings per share - basic	\$(6.18)	\$(10.30)	\$(26.90)
Net earnings per share - diluted	\$(6.18)	\$(10.30)	\$(26.90)
Total number of employees	45
Number of full time employees	45	35	25
Number of common stockholders	15	15	38

□ Reclassified to conform with 2022 presentation; □ Adjusted for 1-for-10 stock split, January 4, 2023; □ As of February 28, 2023; □ As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	86,887,000	38,250,000
Other receivables	663,000
Prepaid insurance	1,362,000
Payroll tax credit		

receivable	250,000	250,000
Other prepaid expenses & current assets	244,000	246,000
Research & development prepaid expenses	615,000	842,000
Other receivables	...	118,000
Other prepaid expenses	877,000	...
Prepaid expenses & other current assets	2,051,000	2,818,000
Other	65,000	...
Total current assets	88,938,000	41,731,000
Leasehold improvements	2,477,000	2,477,000
Lab equipment	1,973,000	1,706,000
Office furniture & fixtures	502,000	502,000
Computer equipment	145,000	145,000
Capitalized software	90,000	90,000
Property & equipment, gross	5,187,000	4,920,000
Less: accumulated depreciation & amortization	2,460,000	1,352,000
Property & equipment, net	2,727,000	3,568,000
Operating lease right-of-use assets	1,467,000	1,886,000
Restricted cash	417,000	417,000
Other non-current assets	1,343,000	759,000
Total assets	94,892,000	48,361,000
Accounts payable	...	1,768,000
Current portion of operating lease liabilities	972,000	865,000
Accounts payable & accrued expenses	4,149,000	...
Research & development accrued expenses	5,169,000	2,651,000
Accrued employee & related compensation expenses	1,767,000	1,587,000
License option liability, current	317,000	...
Other accrued expenses & other current liabilities	...	194,000
Accrued expenses & other current liabilities	7,253,000	4,432,000
Total current liabilities	...	7,065,000
Non-current portion of operating lease liabilities	1,814,000	2,786,000
Common stock warrant liability	...	150,000
Earnout liability	...	18,000
Other non-current liabilities	2,264,000	2,353,000
Total liabilities	16,452,000	12,372,000
Common stock	1,000	4,000
Additional paid-in capital	248,039,000	141,120,000
Retained earnings (accumulated deficit)	(169,600,000)	(105,135,000)
Total stockholders' equity	78,440,000	35,989,000
Total Equity	78,440,000	...

Recent Dividends:**1. Jasper Therapeutics Inc common.**

No dividends paid.

2. Jasper Therapeutics Inc class B common.

No dividends paid.

3. Jasper Therapeutics Inc class A common subject to possible redemption.

No dividends paid.

4. Jasper Therapeutics Inc class A common.

No dividends paid.

Annual Dividends:**1. Jasper Therapeutics Inc common.**

No dividends paid.

2. Jasper Therapeutics Inc class B common.

No dividends paid.

3. Jasper Therapeutics Inc class A common subject to possible redemption.

No dividends paid.

4. Jasper Therapeutics Inc class A common.

No dividends paid.

KAIVAL BRANDS INNOVATIONS GROUP INC**Annual Report****Consolidated Income Statement, Years Ended Oct. 31 (\$):**

	2023	2022	[□] 2021 (revised)
Revenues, net	12,395,134	12,701,539	59,378,208
Revenues - related parties	10,828	68,139	154,560
Royalty revenue	780,929	117,292	...
Excise tax on products	99,873	125,513	756,338
Total revenues, net	13,087,018	12,761,457	58,776,430
Cost of revenue - related party	10,512,423	11,345,912	46,528,501
Cost of revenue - other	...	174,520	314,049
Total cost of revenue	10,512,423	11,520,432	46,842,550
Gross profit	2,574,595	1,241,025	11,933,880
Advertising & promotions expenses	2,450,721	2,679,308	3,195,883
General & administrative expenses	10,787,775	12,950,373	19,207,028
Total operating expenses	13,238,496	15,629,681	22,402,911
Interest income	(466,523)	4	395
Total other income	(466,523)	4	395
Income (loss) before income taxes	(11,130,424)	(14,388,652)	(10,468,636)
Current federal income tax expense (benefit)	(1,301,008)
Current state income tax expense (benefit)	2,348	(18,317)	(134,190)
Total current income tax expense (benefit)	2,348	(18,317)	(1,435,198)
Provision (benefit) for income taxes	2,348	(18,317)	(1,435,198)
Preferred stock dividend	112,500
Net income (loss)	(11,132,772)	(14,370,335)	(9,033,438)
Weighted average shares outstanding - basic	2,721,080	[□] 1,890,971	1,142,869
Weighted average shares outstanding - diluted	2,721,080	[□] 1,890,971	1,142,869
Year end shares outstanding	2,793,386	[□] 2,674,719	[□] 1,437,872
Net earnings (loss) per common share - basic	\$(4.13)	[□] \$(7.56)	\$(7.98)
Net earnings (loss) per common share - diluted	\$(4.13)	[□] \$(7.56)	\$(7.98)
Number of full time employees	18	10	9
Total number of employees	18	10	9
Number of common stockholders	7,400	[□] 7,400	[□] 4,800
Net Income After Extraordinary Items applicable to Common	(11,245,272)
Provision for (benefit from) income taxes	2,348
EPS - Basic - excluding Extraordinary Items	\$(4.13)
EPS - Diluted - excluding Extraordinary Items	\$(4.13)

[□] Reclassified to conform with 2022 presentation; [□] Adjusted for 1-for-21 stock split, January 25, 2024; [□] Shares increased due to issuance of stock for services - restricted stock units, for compensation, exercise of common stock warrants, and converted series A convertible preferred stock; [□] Shares increased due to the effect of common stock issued for cash, net of financing cost; common stock issued for warrant exercise, & common stock issued for compensation; [□] Approximately; [□] As of January 27, 2023; [□] As of February 11, 2022

Consolidated Balance Sheet, Years Ended Oct. 31 (\$):

	2023	2022
Cash	533,659	3,685,893
Accounts receivable, gross	...	574,606
Accounts receivable	1,869,276	574,606
Other receivable - related parties - short term	...	1,539,486
Inventories	4,071,824	1,239,725
Prepaid expenses	430,668	426,407
Income tax receivable	...	1,607,302
Total current assets	6,905,427	9,073,419
Other receivable - related party - net of current portion	...	2,164,646
Right of use asset - operating lease	1,008,428	1,198,969
Fixed assets, Net	2,842	...
Intangible assets, net	11,468,309	...
Total assets	19,385,006	12,437,034
Accounts payable	374,332	40,023
Account payable - related party	2,474,817	...
Accrued expenses	736,194	1,099,157
Customer deposits	...	44,973
Deferred revenue	...	235,274
Operating lease obligation, short term	184,568	166,051
Customer refund due	392,406	...
Loans payable, net	799,471	...
Total current liabilities	4,961,788	1,585,478
Operating lease obligation, net of current portion	866,207	1,050,776
Total liabilities	5,827,995	2,636,254
Series B Convertible Preferred stock	900	...
Common stock	2,793	56,169
Additional paid-in capital	44,317,266	29,375,787
Retained earnings (accumulated deficit)	(30,763,948)	(19,631,176)
Total stockholders' equity (deficit)	13,557,011	9,800,780
Total Stockholders Equity (Deficit)	13,557,011	...

Recent Dividends:**1. Kaival Brands Innovations Group Inc series A convertible preferred.**

No dividends paid.

2. Kaival Brands Innovations Group Inc series B convertible preferred.

No dividends paid.

3. Kaival Brands Innovations Group Inc common.

No dividends paid.

Annual Dividends:**1. Kaival Brands Innovations Group Inc series A convertible preferred.**

No dividends paid.

2. Kaival Brands Innovations Group Inc series B convertible preferred.

No dividends paid.

3. Kaival Brands Innovations Group Inc common.

No dividends paid.

KENILWORTH SYSTEMS CORP.**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	[□] 2021 (revised)
Selling, general & administrative

expenses	29,817
Bank charges & fees	797	108	180
Legal & professional services	...	5,750	4,000
Miscellaneous	165,674	7,500	...
Total operating expenses	196,288	13,358	4,180
Income (loss) from operations	...	(13,358)	(4,180)
Loss from operations	(184,288)
Net income (loss)	(184,288)	(13,358)	(4,180)
Weighted average shares outstanding - basic	63,749,525
Weighted average shares outstanding - diluted	63,749,525
Year end shares outstanding	63,749,525	50,004,185	49,504,185
Net income (loss) per share - basic	\$(0.00)	\$(0.00)	\$0.00
Net income (loss) per share - diluted	\$(0.00)
Number of common stockholders	2,592	2,592	2,592
Revenue	12,000
Total revenue	12,000
Basic EPS Excluding ExtraOrdinary Items	\$(0.00)
Diluted EPS Excluding ExtraOrdinary Items	\$(0.00)

Reclassified to conform with 2022 presentation; Shares increased due to the effect of stock issued in acquisition of subsidiary, and shares issued for services; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):			
	2023	2022	
Bank	19,699	702	
Due from related party	40,000	40,000	
Prepaid expense	3,485	3,485	
Subscription receivable	5,000	5,000	
Total current assets	68,184	49,187	
Trademarks & tradenames	...	30,000,000	
Intellectual property - proprietary databases & technology	...	270,450,011	
Total assets	68,184	300,499,198	
Accruals	...	4,000	
Due to related party	104,168	48,335	
Note payable September 28, 2022	...	300,007,500	
Note Payable	68,900	...	
Total current liabilities	177,068	300,059,835	
Total liabilities	177,068	300,059,835	
Series A convertible preferred stock	125	125	
Common stock	637,495	500,042	
Additional paid-in-capital	38,717,734	39,219,146	
Retained earnings (accumulated deficit)	(39,464,238)	(39,279,950)	
Total stockholders' equity (deficit)	(108,884)	439,363	
Total Equity	(108,884)	...	

Recent Dividends:

- 1. Kenilworth Systems Corp. common.**
No dividends paid.
 - 2. Kenilworth Systems Corp. series A convertible preferred.**
No dividends paid.
- Annual Dividends:**
- 1. Kenilworth Systems Corp. common.**
No dividends paid.
 - 2. Kenilworth Systems Corp. series A convertible preferred.**
No dividends paid.

KINETA INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):			
	2023	2022	2021
Collaboration revenue	442	...	8,044
Licensing revenues	5,000	1,041	...
Grant revenues	...	912	...
Revenue	5,442	1,953	...
Research & development	9,023	15,928	26,410
General & administrative	12,142	8,696	20,379
In-process research & development	...	18,860	...
Total operating expenses	21,165	43,484	46,789
Income (loss) from operations	(15,723)	(41,531)	(38,745)
Interest income	325
Change in fair value measurement of notes payable	(22)	(15,280)	...
Interest expense	337	3,737	1,817
Warrant expense	...	3,309	...
Gain (loss) on extinguishments of debt, net	...	341	1,134
Other income (expense), net	99	63	...
Interest income & other income (expense), net	(75)
Net loss and comprehensive loss	(14,076)
Change in fair value of rights from Private Placement	1,582
Total other income (expense), net	1,647	...	(758)
Net income (loss)	(14,076)	(63,453)	(39,503)
Net income (loss) attributable to noncontrolling interest	(23)	45	...
Net income (loss) attributable to Kineta, Inc.	(14,099)	(63,408)	...
Net income (loss) applicable to common shareholders	(39,503)
Weighted average shares outstanding - basic	11,054	4,926	1,469
Weighted average shares outstanding - diluted	11,054	4,926	1,469
Year end shares outstanding	10,397	8,318	1,521
Net earnings (loss) per share - basic	\$(1.28)	\$(12.87)	\$(26.88)
Net earnings (loss) per share - diluted	\$(1.28)	\$(12.87)	\$(26.88)
Number of full time employees	11	11	40
Number of part time employees	1	1	1
Total number of employees	12
Number of common stockholders	270	684	74

2021 and prior financials for Yumanity Therapeutics, Inc. prior to reverse merger with Kineta Operating, Inc.; Related parties - Interest expense: \$1,659,000; Adjusted for 1-for-7 stock split, December 19, 2022; As is; As of March 28, 2023; As of March 17, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):			
	2023	2022	
Cash	5,783	13,143	

Restricted cash	75	...
Prepaid expenses & other current assets	119	457
Total current assets	5,977	13,600
Laboratory equipment	...	779
Computers & software	...	73
Leasehold improvements	...	14
Property & equipment, gross	...	866
Less: accumulated depreciation & amortization	...	617
Property & equipment, net	...	249
Operating lease right-of-use assets	472	1,211
Rights from private placement	3,832	2,250
Restricted cash	...	125
Total assets	10,281	17,435
Accounts payable	3,694	6,635
Accrued professional fees	97	2,176
Accrued employee compensation & benefits	1,312	745
Accrued clinical trial & preclinical costs	...	404
Accrued interest	...	132
Other accrued expenses	...	70
Accrued Expenses and other current liabilities - Balancing value	2,211	...
Accrued expenses & other current liabilities	802	3,527
Deferred revenue	...	442
Current portion of long-term debt	620	...
Operating lease liability, current portion	547	843
Finance lease liabilities, current portion	...	40
Total current liabilities	7,072	11,487
Notes payable, net of current portion	150	748
Operating lease liabilities, net of current portion	...	547
Finance lease obligation, net of current portion	...	83
Total liabilities	7,222	12,865
Common stock	10	8
Additional paid-in capital	168,669	156,106
Retained earnings (accumulated deficit)	(165,789)	(151,690)
Total stockholders' equity (deficit) attributable to Kineta, Inc.	2,890	4,424
Non-controlling interest	169	146
Total stockholders' equity (deficit)	3,059	4,570

Recent Dividends:

- 1. Kineta Inc common.**
No dividends paid.

Annual Dividends:

- 1. Kineta Inc common.**
No dividends paid.

KINETIC GROUP INC

Earnings, 3 mos. to Dec 31 (Consol. - \$):			
	2023	2022	
Cost & expenses	27,836	16,319	
Operating income	(27,836)	(16,319)	
Net before taxes	(27,836)	...	
Net income	(27,836)	(16,319)	
Earnings common share			
Common Shares:			
Full Diluted	26,320,200	26,320,200	
Year-end	26,320,200	26,320,200	

Consolidated Balance Sheet Items, as of (\$):

Assets:	2023	
Cash & equivalents	129	
Current assets	550,129	
Total assets	550,129	
Liabilities:		
Current liabilities	179,878	
Stockholders' equity	370,251	
Net current assets	370,251	

KING RESOURCES INC

Earnings, 9 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues	51,116	169,580
Net Sales	51,116	
Cost & expenses	329,782	1,047,107
Operating income	(278,666)	(877,527)
Interest expense	302,019	90,903
Other income (expense), net		8,435
Net before taxes	(580,680)	(959,994)
Net income	(580,680)	(959,994)
Earnings common share		
Primary	\$(0.00)	\$
Fully Diluted	\$(0.00)	\$
Common Shares:		
Full Diluted	5,484,167,215,248,165,102	
Year-end	5,484,167,215,484,167,213	

KINGFISH HOLDING CORP

Earnings, 3 mos. to Dec 31(Consol. - \$):

	2023	2022
Cost & expenses	51,805	40,515
Operating income	(56,480)	(44,325)
Interest expense	4,675	3,810
Net before taxes	(56,480)	(44,325)
Net income	(56,480)	(44,325)
Earnings common share		
Common Shares:		
Full Diluted	120,942,987	120,942,987
Year-end	120,942,987	120,942,987

Consolidated Balance Sheet Items, as of (\$):

Assets:	2023	
Cash & equivalents	1,395	
Current assets	1,395	
Total assets	1,395	
Liabilities:		
Current liabilities	639,369	
Long-term debt	200,000	
Stockholders' equity	(857,974)	
Net current assets	(637,974)	

KINTARA THERAPEUTICS INC

Earnings, 6 mos. to Dec 31(Consol. - \$):

	2023	2022
Cost & expenses	3,981,000	8,145,000
Operating income	(3,985,000)	
Foreign currency	(8,000)	11,000
Net before taxes	(3,985,000)	
Net income	(3,985,000)	(8,050,000)
Balance for common	(4,162,000)	(8,416,000)
Earnings common share		
Primary	\$(1.37)	\$(5.42)
Fully Diluted	\$(1.37)	\$(5.42)
Common Shares:		
Full Diluted	3,027,000	1,554,000
Year-end	10,167,000	1,673,000

KNOW LABS INC

Earnings, 3 mos. to Dec 31(Consol. - \$):

	2023	2022
Cost & expenses	3,497,634	3,648,122
Operating income	(3,497,634)	(3,648,122)
Interest income	51,010	
Interest expense	227,170	
Other income (expense), net		52,433
Net before taxes	(3,446,624)	(3,822,859)
Net income	(3,446,624)	(3,822,859)
Balance for common	(3,510,253)	
Earnings common share		
Primary	\$(0.04)	\$(0.08)
Fully Diluted	\$(0.04)	\$(0.08)
Common Shares:		
Full Diluted	81,094,007	48,187,339
Year-end	81,346,524	48,207,937

Consolidated Balance Sheet Items, as of (\$):

Assets:	2023	
Cash & equivalents	4,821,477	
Current assets	4,821,477	
Net property & equip.	75,298	
Total assets	5,013,109	
Liabilities:		
Current liabilities	3,787,220	
Stockholders' equity	1,225,889	
Net current assets	1,034,257	

KOPIN CORP.**Annual Report****Consolidated Income Statement, Years Ended (\$):**

	12/30/23	12/31/22	12/25/21 (revised)
Net component revenues	13,454,866		
Net product revenues	25,937,170	32,420,397	29,882,271
Research & development revenues		14,357,222	14,668,471
License & other revenues		623,571	1,115,375
Other revenues	1,002,141		
Total revenues	40,394,177	47,401,190	45,666,117
Cost of product revenues	24,952,431	32,558,748	25,052,383
Research & development - funded programs	7,177,027	10,279,660	9,976,103
Research & development - internal	3,600,066	8,387,898	6,312,148
Selling, general & administrative expenses	21,842,157	17,965,097	18,100,519
Total operating expenses	57,571,681	69,191,403	59,441,153
Income (loss) from operations	(17,177,504)	(21,790,213)	(13,775,036)
Interest income	829,602	76,877	31,142
Other income (expense), net	245,234	154,357	265,509
Foreign currency transaction gains (losses)	(162,204)	(323,286)	139,014
Gain (loss) on investments	(3,327,347)	2,700,000	
Total non-operating income (expense)	(2,414,715)	2,607,948	435,665
Income (loss) before provision for income taxes & net income (loss) of noncontrolling interest	(19,592,219)	(19,182,265)	(13,339,371)
Current state income tax provision (benefit)			1,000
Current foreign income tax provision (benefit)	156,000	144,000	128,000
Total current income tax provision (benefit)	156,000	144,000	129,000
Deferred federal income tax provision (benefit)	(3,457,000)	1,073,000	(3,367,000)
Deferred state income tax provision (benefit)	(1,063,000)	(1,561,000)	(928,000)
Deferred foreign income tax provision (benefit)	(281,000)	74,000	318,000
Deferred tax credits	4,801,000		
Change in valuation allowance		414,000	3,977,000
Tax provision (benefit)	156,000	144,000	129,000
Net income (loss)	(19,748,219)	(19,326,265)	(13,468,371)
Net loss (income) attributable to the noncontrolling			

interest		348	35,498
Net income (loss) attributable to Kopin Corporation	(19,748,219)	(19,325,917)	(13,432,873)
Weighted average shares outstanding - basic	108,976,245	91,429,106	88,831,532
Weighted average shares outstanding - diluted	108,976,245	91,429,106	88,831,532
Year end shares outstanding	112,251,416	92,883,524	89,988,528
Income (loss) per share from continuing operations - basic	\$(0.18)		
Net income (loss) per share - basic	\$(0.18)	\$(0.21)	\$(0.15)
Income (loss) per share from continuing operations - diluted	\$(0.18)		
Net income (loss) per share - diluted	\$(0.18)	\$(0.21)	\$(0.15)
Number of full time employees	144		181
Total number of employees	144	177	
Number of common stockholders	291	298	320
Foreign currency translation adjustments		(36,478)	
Comprehensive loss attributable to Kopin Corporation	(19,691,993)		

□ Approximately; □ As of March 9, 2023; □ As of March 1, 2022

Consolidated Balance Sheet, Years Ended (\$):

	12/30/23	12/31/22
Cash & cash equivalents	5,710,685	8,258,878
Corporate debt	11,692,000	
Marketable debt securities, at fair value		4,388,778
Accounts receivables, gross	10,731,036	6,840,891
Allowance	1,025,000	303,000
Accounts receivable, net	9,706,036	6,537,891
Contract assets & unbilled receivables	3,409,809	4,068,364
Raw materials	4,785,197	4,285,757
Work-in-process	2,018,421	1,735,454
Finished goods	798,188	405,189
Inventory	7,601,806	6,426,400
Prepaid taxes	85,572	105,495
Prepaid expenses & other current assets	1,124,635	1,074,867
Restricted cash	500,000	
Total current assets	39,830,543	30,860,673
Equipment	14,025,078	13,965,126
Leasehold improvements	3,631,518	3,600,557
Furniture & fixtures	165,636	174,622
Equipment under construction	957,915	550,219
Property, plant & equipment, gross	18,780,147	18,290,524
Accumulated depreciation & amortization	16,616,730	16,458,883
Property, plant & equipment, net	2,163,417	1,831,641
Operating lease right-of-use assets	2,504,909	3,168,520
Equity investments	4,688,522	7,721,206
Total assets	49,312,316	43,752,172
Accounts payable	7,076,759	5,438,980
Accrued payroll & expenses	1,701,506	2,879,139
Accrued warranty	2,160,000	1,966,000
Contract liabilities & billings in excess of revenue earned	916,826	930,500

Operating lease liabilities	651,503	786,928
Accrued post-retirement benefits	790,000
Other accrued liabilities	1,702,681	1,182,346
Customer deposits	408,156	...
Deferred tax liabilities	470,884	482,739
Current liabilities held for sale	790,000	...
Total current liabilities	15,878,315	14,456,632
Noncurrent contract liabilities & asset retirement obligations	278,112	248,284
Operating lease liabilities, net of current portion	1,832,982	2,576,883
Accrued post-retirement benefits, net of current portion	319,996	1,110,000
Other long-term liabilities, net of current portion	1,369,758
Other long term liabilities	1,494,016	...
Total liabilities	19,803,421	19,761,557
Common stock	1,123,220	929,540
Additional paid-in capital	385,411,542	360,567,631
Treasury stock, at cost	103,127	103,127
Cumulative translation adjustment	1,116,319	1,074,292
Unrealized holding gain (loss) on marketable securities	181,695	167,051
Reclassification of gain (loss) of marketable securities in net loss	(65,720)	(65,275)
Accumulated other comprehensive income (loss)	1,232,294	1,176,068
Retained earnings (accumulated deficit)	(358,155,034)	(338,406,815)
Total Kopin Corporation stockholders' equity	29,508,895	24,163,297
Noncontrolling interest	(172,682)
Total stockholders' equity	29,508,895	23,990,615

Recent Dividends:

1. Kopin Corp. common.
No dividends paid.
Annual Dividends:
1. Kopin Corp. common.
No dividends paid.

KOPIN CORP.
Earnings, 9 mos. to (Consol. - \$):

	09/30/23	09/24/22
Total revenues	31,816,544	35,216,833
Cost & expenses	42,206,376	50,783,809
Operating income	(10,389,832)	(15,566,976)
Other income (expense), net	104,403	(7,952)
Gains or losses	(3,327,347)	2,700,000
Foreign currency	(153,442)	(227,294)
Net before taxes	(13,142,247)	(13,061,027)
Income taxes	117,000	108,000
Net income	(13,259,247)	(13,169,027)
Earnings common share		
Primary	\$(0.12)	\$(0.14)
Fully Diluted	\$(0.12)	\$(0.14)
Common Shares:		
Full Diluted	108,436,146	91,317,288
Year-end	114,344,634	92,627,059

LAKE AREA CORN PROCESSORS LLC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
REVENUES	280,440,962
Revenues	280,440,962	282,564,697	258,989,603
Costs of revenues	244,726,671	255,710,981	207,275,615
Gross profit	35,714,291	26,853,716	51,713,988
OPERATING EXPENSES	5,832,995

Operating expenses ..	5,832,995	4,954,621	5,430,294
Income (loss) from operations	29,881,296	21,899,095	46,283,694
Interest & other income	3,606,734	1,789,976	1,360,438
Equity in net income (loss) of investments	9,105,895	3,703,767	10,169,606
Interest expense	212,532	90,881	727,452
Net Income Before Taxes	42,381,393
Total other income (expense)	12,500,097	5,402,862	10,802,592
Net income (loss)	42,381,393	27,301,957	57,086,286
Weighted average units outstanding - basic	29,620,000	29,620,000	29,620,000
Weighted average units outstanding - diluted	29,620,000	29,620,000	29,620,000
Year end units outstanding	29,620,000	29,620,000	29,620,000
Net earnings (loss) per unit - basic	\$1.43	\$0.92	\$1.93
Net earnings (loss) per unit - diluted	\$1.43	\$0.92	\$1.93
Distributions declared per unit	\$1.11	\$0.30
Number of full time employees	47	43	46
Number of common stockholders	1,063	1,058
Basic EPS Excluding ExtraOrdinary Items ..	\$1.43
Diluted EPS Excluding ExtraOrd Items	\$1.43
Total number of employees	47

□ Approximately; □ As of March 9, 2023; □ As of March 3, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	36,773,989	27,004,205
Accounts receivable	6,142,700	1,083,258
Accounts receivable (related party)	1,850,646
Raw materials	12,397,256
Finished goods	10,050,394
Work in process	1,353,715
Parts inventory	1,994,346
Inventory	14,673,710	25,795,711
Derivative financial instruments	1,155,157	2,856,439
Prepaid and other expenses	2,741,191	...
Prepaid expenses	864,810
Total current assets	61,486,747	59,455,069
Land	874,473	874,473
Land improvements	8,763,023	8,763,023
Buildings	9,316,576	9,316,576
Equipment	108,135,828	108,125,289
Construction in progress	890,881	13,366
Property & equipment, gross	127,980,781	127,092,727
Less: accumulated depreciation	69,149,798	63,611,356
Net property & equipment	58,830,983	63,481,371
Goodwill	10,395,766	10,395,766
Investments	55,233,080	17,691,011
Other assets	5,383,310
Total other assets	33,470,087
Other	7,437,578	...
Total assets	193,384,154	156,406,527
Outstanding checks in excess of bank balance	2,670,403	4,200,281
Accounts payable	33,370,759	39,105,845
Accrued liabilities	833,973	719,113
Derivative financial instruments	1,114,590	435,053
Current portion of notes payable	1,000,000

Total current liabilities	37,989,725	45,460,292
Notes payable	20,001,000	2,998,229
Total long-term liabilities	20,001,000	2,998,229
Members' equity	135,393,429	107,948,006
Total Equity	135,393,429	...

Recent Dividends:
1. Lake Area Corn Processors LLC unit.
No dividends paid.

Annual Dividends:
1. Lake Area Corn Processors LLC unit.
No dividends paid.

LANDSEA HOMES CORP
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
			(revised)
Home sales revenue ..	1,169,867,000	1,392,750,000	1,936,400,000
Lot sales & other revenue	40,080,000	53,699,000	86,904,000
Total revenue	1,209,947,000	1,446,449,000	1,023,304,000
Cost of home sales ..	967,034,000	1,108,204,000	1,772,575,000
Cost of lot sales & other	27,939,000	51,321,000	68,131,000
Total cost of sales ..	994,973,000	1,159,525,000	1,840,706,000
Gross margin - home sales	284,546,000	163,825,000
Gross margin - lot sales & other	2,378,000	18,773,000
Total gross margin ..	214,974,000	286,924,000	182,598,000
Sales & marketing expenses	73,248,000	89,305,000	52,840,000
General & administrative expenses	101,442,000	89,325,000	70,266,000
Total operating expenses	174,690,000	178,630,000	123,106,000
Income (loss) from operations	40,284,000	108,294,000	59,492,000
Other income (expense), net	4,261,000	(63,000)	3,886,000
Equity in net income (loss) of unconsolidated joint ventures	149,000	1,262,000
Gain (loss) on remeasurement of warrant liability	(7,315,000)	2,090,000
Pretax income (loss)	44,545,000	101,065,000	66,730,000
Current federal income taxes expense (benefit)	12,418,000	22,350,000	11,507,000
Current state income taxes expense (benefit)	4,394,000	9,350,000	5,314,000
Total current income taxes expense (benefit)	31,700,000	16,821,000
Deferred federal income taxes expense (benefit)	(3,967,000)	(4,681,000)	(2,425,000)
Deferred state income taxes expense (benefit)	(950,000)	(1,619,000)	(401,000)
Total deferred income taxes expense (benefit)	(6,300,000)	(2,826,000)
Income tax expense (benefit)	11,895,000	25,400,000	13,995,000
Net income (loss)	32,650,000	75,665,000	52,735,000
Net income (loss) attributable to noncontrolling interests	(3,414,000)	(2,114,000)	51,000
Net income (loss) attributable to Landsea Homes Corporation	29,236,000	73,551,000	52,786,000
Weighted average shares outstanding - basic	38,885,003	42,052,696	45,198,722

Weighted average shares outstanding - diluted	39,076,322	42,199,462	45,250,718
Year end shares outstanding	36,520,894	40,884,268	46,281,091
Net income (loss) per share - basic	\$0.75	\$1.71	\$1.14
Net income (loss) per share - diluted	\$0.75	\$1.70	\$1.14
Part-Time Employees (Period End)	2
Full-Time Employees (Period End)	497
Total number of employees	499	458	384
Number of common stockholders	9	20	29
EPS - Basic - excluding Extraordinary Items Applicable to Common - Total	\$0.75
EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total	\$0.75

□ Including related parties - homes sales revenue: \$10,751,000;
□ Including to related parties - revenue - lot sales & other revenue: \$3,226,000; □ Including related party interest - Cost of sales - homes sales: \$11,670,000; □ Including cost of sales to related parties - cost of sales - lot sales & other cost of sales: \$2,966,000; □ Including related party interest - Equity in net income (loss) of unconsolidated joint ventures: \$1,250,000; □ As of March 7, 2023; □ As of March 9, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	119,555,000	123,634,000
Cash held in escrow	49,091,000	17,101,000
Prepaid expenses	8,993,000	...
Real estate inventories	1,121,726,000	1,093,369,000
Due from affiliates	4,348,000	3,744,000
Investment in & advances to unconsolidated joint ventures	19,000	41,000
Goodwill	68,639,000	68,639,000
Deferred tax asset, net	18,486,000	13,569,000
Property & equipment, net	12,663,000	9,533,000
Right-of-use asset	11,869,000	15,589,000
Contract assets	5,954,000	7,180,000
Intangible asset, net	...	44,000
Prepaid expenses	...	4,896,000
Project funds in escrow	2,388,000	44,159,000
Warranty & general liability insurance receivables	27,406,000	27,109,000
Other assets	...	11,889,000
Other assets	107,873,000	133,968,000
Other	20,095,000	...
Total assets	1,471,232,000	1,440,496,000
Accounts payable	77,969,000	74,445,000
Beginning warranty reserve and general liability	48,949,000	...
Accrued expenses and other liabilities - Balancing value	160,256,000	...
Franchise tax payable	4,636,000	...
Land development & home construction accrual	...	39,716,000
Warranty accrual	...	46,657,000
Accrued compensation & benefits	26,029,000	18,920,000
Lease liabilities	13,070,000	16,428,000
Sales tax payable	1,646,000	1,448,000
Income tax payable	...	3,420,000
Interest payable	2,775,000	4,351,000
Deferred revenue	180,000	...
Homebuyer deposits	...	15,046,000
Other deposits &

liabilities	...	3,440,000
Accrued expenses & other liabilities	62,971,000	149,426,000
Due to affiliates	881,000	884,000
Construction loans	236,143,000	...
Line of credit facilities	...	514,300,000
Notes & other debts payable	...	514,300,000
Debt issuance costs	...	(8,878,000)
Notes & other debts payable, net	307,631,000	505,422,000
Total liabilities	782,880,000	730,177,000
Common stock	4,000	4,000
Additional paid-in capital	465,290,000	497,598,000
Retained earnings (accumulated deficit)	187,584,000	158,348,000
Total stockholders' equity (deficit)	652,878,000	655,950,000
Noncontrolling interests	35,474,000	54,369,000
Total equity	688,352,000	710,319,000

Recent Dividends:

1. Landsea Homes Corp convertible class B common.

No dividends paid.

2. Landsea Homes Corp class A common subject to possible redemption.

No dividends paid.

3. Landsea Homes Corp class A common.

No dividends paid.

Annual Dividends:

1. Landsea Homes Corp convertible class B common.

No dividends paid.

2. Landsea Homes Corp class A common subject to possible redemption.

No dividends paid.

3. Landsea Homes Corp class A common.

No dividends paid.

LANERN PHARMA INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
General & administrative expenses	5,983,255	5,829,799	5,020,928
Research & development expenses	11,894,315	8,602,954	7,570,580
Total operating expenses (loss) from operations	17,877,570	14,432,753	12,591,508
Interest income	765,388	204,355	67,929
Other income (expense), net	1,150,648	(31,548)	160,550
Net income (loss)	(15,961,534)	(14,259,946)	(12,363,029)
Weighted average shares outstanding - basic	10,842,365	10,850,579	10,904,927
Weighted average shares outstanding - diluted	10,842,365	10,850,579	10,904,927
Year end shares outstanding	10,721,192	10,857,040	11,088,835
Net income (loss) per share - basic	\$(1.47)	\$(1.31)	\$(1.13)
Net income (loss) per share - diluted	\$(1.47)	\$(1.31)	\$(1.13)
Number of full time employees	21	22	14
Number of part time employees	...	1	2
Total number of employees	21	23	16
Number of common stockholders	12	9	15
Foreign currency translation adjustments	...	17,751	183
Income from cont operations before income tax	(15,961,534)

Comprehensive Income - Attributable to Owners of Parent Company - Total	(15,697,608)
---	--------------	-----	-----

□ Shares increased due to exercise of warrants, common stock issued from option exercise and common stock issued from offering; □ As of March 1, 2023; □ As of March 1, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	21,937,749	37,201,786
Restricted cash	...	541,180
Marketable securities	19,364,923	17,994,299
Prepaid expenses & other current assets	2,038,653	2,985,472
Total current assets	43,341,325	58,722,737
Property & equipment, net	52,127	48,008
Operating lease right-of-use assets	228,295	47,687
Other assets	25,869	17,889
Total assets	43,647,616	58,836,321
Accounts payable & accrued expenses	2,505,211	2,745,407
Operating lease liabilities, current	172,975	52,890
Total current liabilities	2,678,186	2,798,297
Operating lease liabilities, net of current portion	61,496	...
Total liabilities	2,739,682	2,798,297
Common stock	1,072	1,086
Additional paid-in capital	96,258,726	95,691,194
Retained earnings (accumulated deficit)	(55,244,404)	(39,282,870)
Accumulated other comprehensive income (loss)	(107,460)	(371,386)
Total stockholders' equity (deficit)	40,907,934	56,038,024
Total Equity	40,907,934	...

Recent Dividends:

1. Lantern Pharma Inc common.

No dividends paid.

Annual Dividends:

1. Lantern Pharma Inc common.

No dividends paid.

LANZATECH GLOBAL INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
General & administrative expenses	50,438,000	5,923,760	951,461
General & administrative expenses - related party	...	120,000	50,000
Capital based tax expense	...	246,182	198,129
Franchise tax expense	...	200,050	188,237
Formation costs	68,142,000
Revenue from collaborative arrangements	5,529,000
Revenue from related party transactions	5,812,000
Revenue from contracts with customers and grants	45,953,000
Revenue from sales of CarbonSmart products	5,337,000
Income (loss) from operations	(106,380,000)	(6,489,992)	(1,387,827)

Total revenues	62,631,000	Total	(24,816,000)	and amortization	32,287,000	...
Change in fair value of derivative warrant liabilities	...	2,969,630	1,905,000	Cost of revenue from collaborative arrangements (exclusive of depreciation shown below)	2,265,000	Property, plant and equipment, net	22,823,000	...
Gain from extinguishment of deferred underwriting commissions on public shares	...	171,700	...	Cost of revenue from related party transactions (exclusive of depreciation shown below)	172,000	Right-of-use assets	18,309,000	...
Offering costs allocated to derivative warrant liabilities	29,388,000	...	476,450	Depreciation expense	5,452,000	Equity method investment	7,066,000	...
Income from investments held in trust account	4,572,000	2,299,536	6,015	Loss from equity method investees, net	(2,902,000)	Other non-current assets	5,736,000	...
Income (loss) before income tax expense	(131,196,000)	(1,049,126)	...	Net Income After Extraordinary Items applicable to Common	(138,215,000)	Total assets	241,624,000	152,493,867
Current federal income taxes	...	309,320	...	Cost of revenue from contracts with customers and grants (exclusive of depreciation shown below)	37,653,000	Accounts payable	4,060,000	2,494,997
Deferred federal income taxes	...	(15,220)	...	Cost of revenue from sales of Carbon Smart products (exclusive of depreciation shown below)	4,889,000	Accrued expenses	...	2,257,059
Valuation allowance	...	15,220	...					Due to related party	...	1,374,000
Income taxes	...	309,320	...					Capital based tax payable	...	394,311
Unpaid cumulative dividends on preferred stock	4,117,000					Franchise tax payable	...	43,552
Net income (loss)	(134,098,000)	(1,358,446)	46,738					Income tax payable	...	309,320
Weighted average per class A common shares outstanding - basic	15,000,000	4,690,909	...					Other accrued liabilities	7,316,000	...
Weighted average per class B common shares outstanding - basic	3,750,000	3,750,000	...					Warrants	7,614,000	...
Weighted average shares outstanding - basic	176,023,219					Contract liabilities	3,198,000	...
Weighted average per class A common shares outstanding - diluted	15,000,000	4,690,909	...					Accrued salaries and wages	5,468,000	...
Weighted average per class B common shares outstanding - diluted	3,750,000	3,750,000	...					Current lease liabilities	126,000	...
Weighted average shares outstanding - diluted	176,023,219					Total current liabilities	27,782,000	6,873,239
Year end shares outstanding	196,642,451	18,750,000	18,750,000					Deferred underwriting commissions	...	200,000
Net earnings (loss) per class A common share - basic	...	\$(0.07)	\$0.01					Derivative warrant liabilities	...	2,640,370
Net earnings (loss) per class B common share - basic	...	\$(0.07)	\$0.01					Non-current lease liabilities	19,816,000	...
Net earnings (loss) per share - basic	\$(0.79)					Non-current contract liabilities	8,233,000	...
Net earnings (loss) per class A common share - diluted	...	\$(0.07)	\$0.01					Fixed Maturity Consideration	7,228,000	...
Net earnings (loss) per class B common share - diluted	...	\$(0.07)	\$0.01					Brookfield SAFE liability	25,150,000	...
Net earnings (loss) per share - diluted	\$(0.79)					Other long-term liabilities	1,421,000	...
Total number of employees	414	...	3					FPA Put Option liability	37,523,000	...
Number of full time employees	414	390	...					Total liabilities	127,153,000	9,713,609
Number of unitholders	51					Class A common stock subject to possible redemption	...	151,113,633
Number of common stockholders	105	142	51					Class B common stock	19,000	375
Number of warrant holders	52					Additional paid-in capital	943,960,000	...
Total cost and operating expenses	169,011,000					Retained earnings (accumulated deficit)	(831,872,000)	(8,333,750)
Non-Operating Income/Expense -					Accumulated other comprehensive income	2,364,000	...
								Total stockholder's equity (deficit)	114,471,000	(8,333,375)
								Total Equity	114,471,000	...

From January 28, 2021 (inception); Non-consolidated; Full-time equivalent; As of February 28, 2023; As of March 16, 2022; As of March 17, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash and cash equivalents	75,585,000	...
Cash	...	6,671
Prepaid expenses - current	...	190,645
Held-to-maturity investment securities	45,159,000	...
Trade and other receivables, net of allowance	11,157,000	...
Contract assets	28,238,000	...
Other current assets	12,561,000	...
Allowance for doubtful accounts	1,751,000	...
Accounts & Notes Receivable - Trade - Gross	12,908,000	...
Inventory	1,750,000	...
Materials and supplies	3,595,000	...
Prepaid assets	3,698,000	...
other	3,518,000	...
Total current assets	172,700,000	197,316
Investments held in trust account	14,990,000	152,296,551
Property, plant and equipment, gross Land	64,000	...
Property, plant and equipment, gross
Leasehold Improvements	4,837,000	...
Property, plant and equipment, gross	40,827,000	...
Machinery And Equipment
Property, plant and equipment, gross	92,000	...
Automobiles
Property, plant and equipment, gross	6,287,000	...
Construction In Progress
Office Equipment and furniture	2,103,000	...
other	900,000	...
Property, plant and equipment, gross	55,110,000	...
accumulated depreciation

Recent Dividends:
1. LanzaTech Global Inc class B common.
 No dividends paid.
2. LanzaTech Global Inc common.
 No dividends paid.
3. LanzaTech Global Inc class A common.
 No dividends paid.
4. LanzaTech Global Inc class A common subject to possible redemption.
 No dividends paid.
Annual Dividends:
1. LanzaTech Global Inc class B common.
 No dividends paid.
2. LanzaTech Global Inc common.
 No dividends paid.
3. LanzaTech Global Inc class A common.
 No dividends paid.
4. LanzaTech Global Inc class A common subject to possible redemption.
 No dividends paid.

LAREDO OIL INC.
Earnings, 6 mos. to Nov 30(Consol. - \$):

	2023	2022
Cost & expenses	2,123,958	1,552,653
Operating income	(2,123,958)	(1,552,653)
Interest expense	194,463	181,056
Other income (expense), net	338,866	109,316
Gains or losses	175,000	...
Net before taxes	(1,804,555)	...
Net income	(1,804,555)	(1,624,393)
Earnings common share		
Primary	\$(0.03)	\$(0.02)
Fully Diluted	\$(0.03)	\$(0.02)
Common Shares:		

LAZDAYS HOLDINGS INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$000):										
	2023	2022	2021 (revised)	(benefit)	(24,307)	1,651	(1,161)	Land	76,291	41,286
Full Diluted.....	66,922,493	55,695,397	55,695,397	(benefit).....	(24,307)	1,651	(1,161)	Building & improvements including leasehold improvements	311,824	113,596
Year-end.....	70,124,809	57,255,381	57,255,381	Total deferred income tax expense (benefit).....	(6,673)	221	(268)	Furniture & equipment	20,364	17,503
Revenues: new vehicle retail.....	...	777,807	725,114	Total deferred income tax expense (benefit).....	...	1,872	(1,429)	Company vehicles.....	2,322	1,691
Revenues: pre-owned vehicle retail.....	323,258	394,582	372,566	Income tax expense (benefit).....	(30,462)	19,183	28,242	Construction in progress	55,384	20,190
Revenues: vehicle wholesale.....	...	21,266	14,241	Net income (loss).....	(110,266)	66,393	82,021	Building and improvements including leasehold improvements	157,463	...
Revenues: finance & insurance.....	62,139	75,482	72,647	Dividends on series A convertible preferred stock.....	4,800	4,801	4,801	Total property & equipment, gross	...	194,266
Revenues: service, body & parts, other.....	57,596	57,824	50,480	Net income (loss) attributable to common stock & participating securities.....	(115,066)	61,592	77,220	Less: accumulated depreciation & amortization	46,098	35,275
New vehicle retail.....	631,748	Weighted average shares outstanding - basic.....	13,689	11,701	11,403	Property & equipment, net.....	265,726	158,991
Vehicle wholesale.....	8,006	Weighted average shares outstanding - diluted.....	13,689	12,798	12,852	Operating lease assets	26,377	26,984
Total revenues.....	1,082,747	1,326,961	1,235,048	Year end shares outstanding.....	14,065	11,112	12,987	Goodwill.....	...	83,460
Cost of revenues: new vehicles.....	...	632,316	586,876	Net earnings (loss) per share - basic.....	\$(8.41)	\$3.47	\$4.43	Intangible assets, net.....	80,546	81,665
Cost of revenues: pre-owned vehicles.....	...	301,565	278,036	Net earnings (loss) per share - diluted.....	\$(8.41)	\$2.42	\$3.93	Deferred tax liability.....	15,444	...
Cost of revenues: vehicle wholesale.....	...	21,620	13,591	Number of full time employees.....	1,300	1,400	1,500	Other assets.....	2,750	2,769
Cost of revenues: parts, service & other.....	552,311	Total number of employees.....	1,300	1,400	1,500	Total assets.....	937,742	830,718
Cost of revenues: finance & insurance.....	...	2,729	2,473	Number of common stockholders.....	47	40	41	Accounts payable.....	15,144	10,843
Cost of revenues: service, body & parts, other.....	...	27,657	25,771	Number of series A preferred stockholders.....	...	4	4	Other accrued expenses.....	...	4,509
Cost of revenues: LIFO.....	...	12,383	4,811	EPS - Basic - excluding Extraordinary Items Applicable to Common - Total.....	\$(8.41)	Customer deposits.....	...	6,000
Pre-owned vehicle.....	259,494	EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total.....	\$(8.41)	Accrued compensation.....	...	6,910
Vehicle wholesale.....	8,178	Impairment - Goodwill.....	117,970	Accrued charge-backs.....	...	8,218
Finance and insurance.....	2,547	Reclassified to conform with 2022 presentation; As is; Approximately; As of February 24, 2023; As of March 9, 2022	Accrued interest.....	...	2,238
Service, body and parts, other.....	27,723	Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):						
LIFO.....	3,752				2023			
Total cost applicable to revenue.....	854,005	998,270	911,558				2022			
Gross profit.....	228,742	Cash.....	58,085	61,687	...	Long term debt, non-current portion, net of debt discount.....	61,429	89,770
Depreciation & amortization.....	18,512	16,758	14,411	Contracts in transit & vehicle receivables.....	...	15,442	...	Term loan & mortgage.....	...	12,538
Selling, general, & administrative expenses.....	198,962	222,218	184,985	Manufacturer receivables.....	...	8,760	...	Acquisition notes payable.....	...	1,200
Income (loss) from operations.....	(106,702)	89,715	124,094	Finance & other receivables.....	...	1,327	...	Total long-term debt.....	...	13,738
PPP loan forgiveness.....	6,626	Receivables, gross.....	23,173	25,529	...	Less: current portion.....	...	3,607
Floorplan interest expense.....	24,820	8,596	1,852	Less: allowance for doubtful accounts.....	479	476	...	Long term debt, non-current portion, net of debt discount.....	...	10,131
Other interest expense.....	10,062	7,996	6,648	Receivables, net.....	22,694	25,053	...	Operating lease liability, non-current portion.....	22,242	22,755
Change in fair value of warrant liabilities.....	856	12,453	(11,711)	New recreational vehicles.....	385,001	342,415	...	Contingent liability, non-current portion.....	49,500	...
Inducement loss on warrant conversion.....	(246)	Pre-owned recreational vehicles.....	86,517	50,457	...	Deferred income tax liability.....	...	15,536
Total other income (expense).....	(34,026)	(4,139)	(13,831)	Parts, accessories & other inventories.....	9,144	6,831	...	Warrant liabilities.....	91,401	906
Income (loss) before income tax expense.....	(140,728)	85,576	110,263	Inventories, gross.....	456,087	399,703	...	Total liabilities.....	724,552	538,723
Current federal income tax expense (benefit).....	539	13,389	23,867	Less: excess of current cost over last-in, first-out ("LIFO").....	24,575	20,822	...	Series A convertible preferred stock.....	56,193	54,983
Current state income tax expense (benefit).....	(21)	3,922	5,804	Inventories.....	...	378,881	...	Additional paid-in capital.....	165,988	130,828
Total current income tax expense (benefit).....	...	17,311	29,671	Income tax receivable.....	7,419	7,912	...	Treasury stock, at cost.....	57,128	57,019
Deferred federal income tax expense	Prepaid expenses & other current assets.....	...	3,316	...	Retained earnings (accumulated deficit).....	48,137	163,203
				Prepaid expenses and other.....	2,614	Common stock.....	2	...
				Total current assets.....	546,899	476,849	...	Total stockholders' equity (deficit).....	156,997	237,012
								Total Equity.....	156,997	...
								Recent Dividends:		
								1. Lazydays Holdings Inc common.		

No dividends paid.
2. Lazydays Holdings Inc series A convertible preferred.
 No dividends paid.
Annual Dividends:
1. Lazydays Holdings Inc common.
 No dividends paid.
2. Lazydays Holdings Inc series A convertible preferred.
 No dividends paid.

LENSAR INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Product	13,902
Lease	2,091
Service	5,064
Revenue - product	4,073	25,959	26,246
Revenue - lease	...	5,915	4,966
Revenue - service	...	3,484	3,247
Product	31,643
Lease	6,448
Total revenue	42,164	35,358	34,459
Cost of revenue - product	...	8,910	11,845
Cost of revenue - lease	...	1,941	1,375
Cost of revenue - service	...	4,552	3,406
Total cost of revenue	...	15,403	16,626
Selling, general & administrative expenses	26,100	27,170	23,887
Research & development expenses	6,139	11,814	12,358
Amortization of intangible assets	1,097	1,148	1,240
Operating income (loss)	(12,229)	(20,177)	(19,652)
Other income, net	698	263	51
Income before income taxes - United States	(14,383)	(19,914)	(19,601)
Income (loss) before income taxes	(14,383)
Net income (loss)	(14,383)	(19,914)	(19,601)
Net income (loss) attributable to common stockholders	...	(19,914)	(19,601)
Weighted average shares outstanding - basic	10,971	10,159	9,374
Weighted average shares outstanding - diluted	10,971	10,159	9,374
Year end shares outstanding	11,327	11,093	10,990
Net earnings (loss) per share - basic	\$(1.31)	\$(1.96)	\$(2.09)
Net earnings (loss) per share - diluted	\$(1.31)	\$(1.96)	\$(2.09)
Full-Time Employees (Period End)	130
Total number of employees	130	110	110
Number of common stockholders	82	113	118
Change in fair value of warrant liabilities	(2,852)
Interest income	698

□ Reclassified to conform with 2022 presentation; □ As is; □ Approximately; □ As of January 31, 2023; □ As of January 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	20,621	14,674
Accounts receivable, gross	4,063	6,096

Net of allowance	62	56
Accounts receivable, net	4,001	6,040
Notes receivable, net	323	200
Finished goods	4,936	4,002
Work-in-progress	2,395	797
Raw materials	8,358	6,941
Inventories	15,689	11,740
Prepaid & other current assets	2,367	1,062
Short-term investments	3,443	...
Total current assets	46,444	33,716
Leasehold improvements	112	112
Manufacturing equipment	987	1,001
Computer & office equipment	97	102
System & laser	1,295	1,204
Software	293	240
Furniture & fixtures	50	50
Transportation equipment	38	38
Property & equipment, gross	2,872	2,747
Less: accumulated depreciation	2,381	2,239
Construction in progress	188	55
Property & equipment, net	679	563
Equipment under lease	...	14,771
Less accumulated depreciation	...	8,455
Equipment under lease, net	7,459	6,316
Notes & other receivables, long-term, net	1,279	442
Intangible assets, net	11,025	12,122
Other assets	2,207	2,685
Long-term investments	492	...
Property, Plant & Equipment Leased Out - Accumulated Depreciation & Impairment	9,510	...
Assets Leased Out under Operating Lease - Gross	16,969	...
Total assets	69,585	55,844
Accounts payable	4,007	5,422
Compensation	3,974	3,348
Professional services	...	437
Customer advances	34	171
Warranty	...	120
Other accrued expenses	...	624
Accrued liabilities - Balancing value	1,709	...
Accrued liabilities	5,717	4,700
Deferred revenue	1,349	768
Operating lease liabilities	559	531
Total current liabilities	11,632	11,421
Long-term operating lease liabilities	1,750	2,272
Series A preferred stock	220	...
Other long-term liabilities	570	167
Deferred Income	350	...
Warrant liabilities	8,457	...
Total liabilities	22,409	13,860
Common stock	113	111
Additional paid-in capital	145,203	139,381
Retained earnings (accumulated deficit)	(111,891)	(97,508)
Series A Redeemable Convertible Preferred Stock, par value \$001 per share, 20 and no shares authorized at 30, 2023 and 31, 2022, respectively; 20 and no shares issued and outstanding at 30, 2023 and 31, 2022, respectively; aggregate liquidation prefer	13,747	...
Accumulated other comprehensive income	4	...

Total stockholders' equity (deficit)	47,176	41,984
Total Equity	47,176	...

□ Net of allowance - notes receivable: \$4,000; □ Net of allowance - notes and other receivables, long-term: \$9,000

Recent Dividends:

1. LENSAR Inc common.

No dividends paid.

Annual Dividends:

1. LENSAR Inc common.

No dividends paid.

LIFE360 INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Subscription revenue	220,794	153,287	86,551
Hardware revenue	...	47,884	952
Partnership revenue	304,518
Data & other revenue	58,178
Other revenue	...	27,134	25,140
Revenue	25,546
Total revenue	304,518	228,305	112,643
Cost of subscription revenue	81,881	30,659	17,807
Cost of hardware revenue	...	45,441	1,340
Cost of other revenue	...	3,607	3,621
Total cost of revenue	81,881	79,707	22,768
Gross profit	222,637	148,598	89,875
Research & development	100,965	102,480	50,994
Sales & marketing	99,072	92,419	47,473
General & administrative	52,583	48,110	23,670
Total operating expenses	...	243,009	122,137
Income (loss) from operations	(29,983)	(94,411)	(32,262)
Convertible notes fair value adjustment	(684)	1,786	(511)
Derivative liability fair value adjustment	(116)	1,295	(733)
Other income (expense), net	3,228	13	(178)
Total other income (expense), net	2,428	3,094	(1,422)
Income (loss) before income taxes	(27,555)	(91,317)	(33,684)
Provision (benefit) for income taxes	616	312	(127)
Net income (loss)	(28,171)	(91,629)	(33,557)
Weighted average shares outstanding - basic	66,749	62,210	51,656
Weighted average shares outstanding - diluted	66,749	62,840	51,656
Year end shares outstanding	68,156	65,240	60,222
Net earning (loss) per share - basic	\$(0.42)	\$(1.47)	\$(0.65)
Net earning (loss) per share - diluted	\$(0.42)	\$(1.50)	\$(0.65)
Number of full time employees	383	400	...
Number of part time employees	...	200	...
Number of common stockholders	...	474	303
EPS - Basic - excluding Extraordinary Items

Annual Report			Consolidated Income Statement, Years Ended Dec. 31 (\$):			Consolidated Income Statement, Years Ended Dec. 31 (\$):			Consolidated Income Statement, Years Ended Dec. 31 (\$):		
			2023	2022	2021	2023	2022	2021	2023	2022	2021
Cost of sales	2,513	gross - Balancing value	146,196	...	Gain (loss) on change in fair value of warrant	1,217,000	14,000
Total revenues	40,502	Property & equipment, gross	9,665,350	6,572,152	liability	2,046,000
Net sales	40,502	Less: accumulated depreciation - property & equipment	4,674,560	4,052,885	Interest income	2,613,000	812,000
Research & development expense	15,903,689	12,805,374	12,476,040	Property & equipment, net	4,990,790	2,519,267	Interest expense	2,613,000
General & administrative expenses	5,359,565	4,334,290	4,520,403	Intangible assets - net	1,254,501	1,030,335	Total other income (expenses)	(1,184,000)	(2,402,000)	(4,513,000)	...
Total cost & expense	21,265,767	17,139,664	16,996,443	Operating lease - right of use - building	2,838,210	358,254	Income (loss) before income taxes	28,100,000	9,608,000	9,477,000	...
Income (loss) from operations	(21,225,265)	(17,139,664)	(16,996,443)	Total other assets	...	1,388,589	Current U.S. federal income tax provision (benefit)	5,851,000	2,613,000	812,000	...
Paycheck Protection Program loan forgiveness	410,700	Total assets	41,783,585	29,263,472	Current state & local income tax provision (benefit)	1,845,000	695,000	194,000	...
Interest income	657,546	91,659	13,826	Accounts payable	1,447,596	791,671	Total current income tax provision (benefit)	7,696,000	3,308,000	1,006,000	...
Commitment fee	673,578	209,709	2,059,464	Accrued bonuses & accrued expenses	...	380,280	Deferred U.S. federal income tax provision (benefit)	(253,000)	(584,000)	1,127,000	...
Realized gain on disposal of assets	215,509	Accounts payable & accrued expenses - related parties	313,483	100,169	Deferred state & local income tax provision (benefit)	(97,000)	85,000	630,000	...
Other income	(12,244)	27,234	...	Deferred lease liability	38,297	41,778	Total deferred income tax provision (benefit)	(350,000)	(499,000)	1,757,000	...
Net income (loss)	(21,038,032)	(17,230,480)	(18,631,381)	Operating lease liability	144,120	190,125	Income tax provision (benefit)	7,346,000	2,809,000	2,763,000	...
Weighted average shares outstanding - basic	115,467,300	111,814,926	105,223,959	Accrued expenses	599,430	...	Net income (loss)	20,754,000	6,799,000	6,714,000	...
Weighted average shares outstanding - diluted	115,467,300	111,814,926	105,223,959	Deferred Revenue	39,875	...	Weighted average shares outstanding - basic	10,773,000	10,425,119	10,013,117	...
Year end shares outstanding	118,137,309	112,882,793	110,555,459	Total current liabilities	2,582,801	1,504,023	Weighted average shares outstanding - diluted	11,812,000	10,676,534	10,231,637	...
Income (loss) per share from continuing operations - basic	\$(0.18)	Deferred lease liability	...	38,297	Year end shares outstanding	11,003,424	10,291,758	10,304,242	...
Net income (loss) per share - basic	\$(0.18)	\$(0.15)	\$(0.18)	Operating lease liability	2,766,970	168,129	Net income (loss) per share - basic	\$1.93	\$0.65	\$0.67	...
Income (loss) per share from continuing operations - diluted	\$(0.18)	Total long term liabilities	2,766,970	206,426	Net income (loss) per share - diluted	\$1.76	\$0.64	\$0.66	...
Net income (loss) per share - diluted	\$(0.18)	\$(0.15)	\$(0.18)	Total liabilities	5,349,771	1,710,449	Number of full time employees	400
Number of full time employees	33	21	19	Common stock	118,137	112,883	Total number of employees	400	1,500	1,650	...
Total number of employees	33	Additional paid-in capital	164,619,363	134,406,825	Number of common stockholders	32	41	44	...
Number of common stockholders	70	80	80	Deferred compensation	432,293	133,324	Recent Dividends: 1. Lightwave Logic Inc common. No dividends paid. Annual Dividends: 1. Lightwave Logic Inc common. No dividends paid.				
Income from cont operations before income tax	(21,038,032)	Retained earnings (accumulated deficit)	(127,871,393)	(106,833,361)	Consolidated Balance Sheet, Years Ended Dec. 31 (\$): 2023 2022 Cash & cash equivalents 59,833,000 36,001,000 Restricted cash 65,000 113,000 Accounts receivable - trade 98,047,000 124,676,000 Retainage 97,755,000 ... Allowance for doubtful accounts 292,000 234,000 Accounts receivable, net ... 124,442,000 Contract assets 51,690,000 61,453,000 Income tax receivable ... 95,000 Advances to & equity in joint ventures, net 12,000 12,000 Other current assets 7,645,000 3,874,000 Total current assets 217,000,000 225,990,000 Land & improvements 400,000 400,000 Buildings & leasehold improvements 54,219,000 10,489,000 Machinery & equipment 31,157,000 26,061,000 Finance leases - vehicles 11,665,000 10,789,000 Buildings and leasehold improvements 10,997,000 ... Gross property & equipment ... 47,739,000 Less: accumulated amortization on finance leases 4,502,000 6,001,000 Less: accumulated				

Approximately; As of February 28, 2023; As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):			Consolidated Balance Sheet, Years Ended Dec. 31 (\$):			Consolidated Balance Sheet, Years Ended Dec. 31 (\$):		
			2023	2022	2023	2022	2023	2022
Cash & cash equivalents	31,432,087	24,102,151	Revenue	516,350,000	...	Revenue	516,350,000	496,782,000
Prepaid insurance	...	218,767	Revenue	516,350,000	496,782,000	490,351,000	Cost of revenue	397,060,000
Other prepaid expenses & other current assets	...	45,675	Cost of revenue	397,060,000	403,041,000	404,441,000	Gross profit	119,290,000
Prepaid rent	...	36,525	Gross profit	119,290,000	93,741,000	85,910,000	Selling, general & administrative	77,879,000
Prepaid license	...	94,195	Selling, general & administrative	77,879,000	71,436,000	Change in fair value of contingent consideration	729,000	2,285,000
Prepaid legal	...	83,941	Change in fair value of contingent consideration	729,000	2,285,000	Amortization of intangibles	1,880,000	1,567,000
Deposit for equipment	...	59,850	Amortization of intangibles	1,880,000	1,567,000	General & administrative costs	87,397,000	...
Prototype devices	...	40,473	General & administrative costs	87,397,000	...	Total operating expenses	90,006,000	81,731,000
Investor relations	...	18,250	Total operating expenses	90,006,000	81,731,000	71,920,000	Operating income (loss)	29,284,000
Loan interest receivable	...	13,669	Operating income (loss)	29,284,000	12,010,000	13,990,000	Interest income (expense), net	(2,144,000)
Prepaid expenses & other current assets	1,237,621	611,345	Interest income (expense), net	(2,144,000)	(2,568,000)	Loss on early termination of operating lease	849,000	...
Accounts receivable	30,376	...	Loss on early termination of operating lease	849,000	...	Gain (loss) on early debt extinguishment	(311,000)	(1,961,000)
Loan receivable	...	642,120	Gain (loss) on early debt extinguishment	(311,000)	(1,961,000)	Gain on change in fair value of interest rate swap	(124,000)	310,000
Total current assets	32,700,084	25,355,616	Gain on change in fair value of interest rate swap	(124,000)	310,000	Gain (loss) on disposition of property & equipment	80,000	281,000
Office equipment	...	119,404	Gain (loss) on disposition of property & equipment	80,000	281,000	2,000
Lab equipment	8,937,847	6,234,777
Furniture	74,119	33,128
Leasehold improvements	396,111	184,843
Property and equipment gross
Software	111,077
Property and equipment

Shares increased due to the effect of issuance of common stock, exercise of warrants, vested restricted stock units; Approximately; As of March 7, 2023; As of March 15, 2022

depreciation	28,887,000	23,514,000	1. Limbach Holdings Inc common stock subject to possible redemption.	stockholders	(49,983,000)	(116,052,000)	(124,665,000)
Property & equipment, net	20,830,000	18,224,000	No dividends paid.	Weighted average shares outstanding			
Intangible assets, net	24,999,000	15,340,000	2. Limbach Holdings Inc cumulative redeemable convertible preferred.	- basic	53,256,513	52,018,987	50,109,426
Goodwill	16,374,000	11,370,000	No dividends paid.	Weighted average shares outstanding			
Right of Use Tangible Assets - Operating Lease			3. Limbach Holdings Inc common.	- diluted	53,256,513	52,018,987	50,109,426
- Accumulated			No dividends paid.	Year end shares outstanding	53,332,150	53,110,132	50,755,546
Depreciation	13,600,000	...	LINDBLAD EXPEDITIONS HOLDINGS INC	Net earnings (loss) per share - basic	\$(0.94)	\$(2.23)	\$(2.41)
Operating lease right-of-use assets - Balancing value	33,327,000	...	Annual Report	Net earnings (loss) per share - diluted	\$(0.94)	\$(2.23)	\$(2.41)
Operating lease right-of-use assets	19,727,000	18,288,000	Consolidated Income Statement, Years Ended Dec. 31 (\$):	Number of shipboard employees		460	390
Deferred tax asset	5,179,000	4,829,000		Number of full time employees	485	400	310
Other assets	330,000	515,000		Number of part time employees	25	20	20
Total assets	304,439,000	294,556,000		Total number of employees	510	880	720
Current portion of long-term debt	2,680,000	9,564,000	Tour revenues	Number of common stockholders	182	180	177
Current operating lease liabilities	3,627,000	3,562,000	Cost of tours	Total Revenue	569,543,000
Accounts payable, including retainage	65,268,000	75,122,000	General & administrative expenses				
Contract liabilities	42,160,000	44,007,000	Selling & marketing expenses				
Accrued income taxes	446,000	1,888,000	Depreciation & amortization expenses				
Accrued payroll & related liabilities	5,561,000	4,545,000	Total operating expenses				
Accrued bonus & commissions	...	9,682,000	Operating income (loss)				
Accrued insurance liabilities	1,007,000	715,000	Interest expense, net				
Accrued job costs	...	1,913,000	Gain (loss) on foreign currency				
Assurance-type warranty liabilities	...	1,581,000	Other income (expense)				
Estimated loss contingency	...	2,182,000	Total other income (expense)				
Earnout payments accrued, current	...	2,859,000	Income (loss) before income taxes - domestic				
Other accrued liabilities	1,566,000	1,465,000	Income (loss) before income taxes - foreign				
Accrued expenses & other current liabilities	22,833,000	24,942,000	Income (loss) before income taxes - current state				
Accrued Expenses and other current liabilities - Balancing value	30,967,000	...	income tax expense (benefit)				
Capitalized Leases - Current Portion	2,680,000	...	Current foreign - other income tax expense (benefit)				
Total current liabilities	145,148,000	159,085,000	Total current income tax expense (benefit)				
State of Ohio loan	9,613,000	...	Deferred federal income tax expense (benefit)				
Term loan	...	21,453,000	Deferred state income tax expense (benefit)				
Finance leases	...	4,954,000	Deferred foreign - other income tax expense (benefit)				
Financing liability	...	5,351,000	Total deferred income tax expense (benefit)				
Capital leases	10,018,000	...	Income tax expense (benefit)				
Total debt	...	31,758,000	Net income (loss)				
Less: current portion	...	9,564,000	Net income (loss) attributable to noncontrolling interest				
Less - unamortized discount & debt issuance costs	...	(666,000)	Net income (loss) attributable to Lindblad Expeditions Holdings, Inc.				
Long-term debt	19,631,000	21,528,000	Series A redeemable convertible preferred stock dividend				
Long-term operating lease liabilities	16,037,000	15,643,000	Non-cash deemed dividend				
Other long-term liabilities	2,708,000	2,858,000	Net income (loss) available to stockholders				
Total liabilities	183,524,000	199,114,000					
Common stock	1,000	1,000					
Additional paid-in capital	92,528,000	87,809,000					
Treasury stock, at cost	2,000,000	2,000,000					
Retained earnings (accumulated deficit)	30,386,000	9,632,000					
Total stockholders' equity	120,915,000	95,442,000					
Total Equity	120,915,000	...					
Recent Dividends:							
1. Limbach Holdings Inc common stock subject to possible redemption.							
No dividends paid.							
2. Limbach Holdings Inc cumulative redeemable convertible preferred.							
No dividends paid.							
3. Limbach Holdings Inc common.							
No dividends paid.							
Annual Dividends:							

□ Approximately; □ As of January 31, 2023; □ As of January 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	156,845,000	87,177,000
Restricted cash	30,499,000	28,847,000
Short-term securities	...	13,591,000
Marine operating supplies	5,438,000	9,961,000
Inventories	...	1,965,000
Prepaid tour expenses	26,123,000	20,605,000
Prepaid other	...	21,173,000
Prepaid expenses & other current assets	25,597,000	41,778,000
Prepaid expenses & other current assets	57,158,000	...
Total current assets	244,502,000	183,319,000
Vessels & improvements	820,101,000	759,981,000
Furniture & equipment	42,055,000	28,732,000
Leasehold improvements	1,424,000	1,426,000
Vessels and improvements	776,622,000	...
Total property & equipment, gross	...	790,139,000
Less: accumulated depreciation	294,099,000	250,733,000
Property & equipment, net	526,002,000	539,406,000
Goodwill	42,017,000	42,017,000
Intangibles, net	9,412,000	11,219,000
Other long-term assets	9,364,000	5,502,000
Deferred tax asset	...	2,167,000
Right-to-use lease assets	...	4,345,000
Total assets	831,297,000	787,975,000
Unearned passenger revenues	252,199,000	245,101,000
Accrued other expense	48,901,000	54,418,000
Accounts payable	16,154,000	16,601,000
New build liability	65,055,000	...
Accounts payable & accrued expenses	...	71,019,000
Lease liabilities - current	1,923,000	1,663,000
Long-term debt - current	47,000	23,337,000
Total current liabilities	319,224,000	341,120,000
Notes payable	621,778,000	351,032,000
First export credit agreement	...	92,965,000
Second export credit agreement	...	107,837,000
Other long-term debt	...	955,000
Total long-term debt	...	552,789,000
Less: current portion	...	23,337,000
Long-term debt, less current portion	...	529,452,000
Deferred tax liabilities	2,118,000	...
Lease liabilities	...	2,961,000
Other long-term liabilities	1,943,000	88,000

Total liabilities	945,063,000	873,621,000
Series A redeemable convertible preferred stock	73,514,000	69,143,000
Redeemable noncontrolling interests	37,784,000	27,886,000
Temporary equity	111,298,000	97,029,000
Common stock	5,000	5,000
Additional paid-in capital	97,139,000	83,850,000
Retained earnings (accumulated deficit)	(322,208,000)	(266,530,000)
Total stockholders' equity (deficit)	(225,064,000)	(182,675,000)

Recent Dividends:

1. Lindblad Expeditions Holdings Inc series A redeemable convertible preferred.

No dividends paid.

2. Lindblad Expeditions Holdings Inc common.

No dividends paid.

Annual Dividends:

1. Lindblad Expeditions Holdings Inc series A redeemable convertible preferred.

No dividends paid.

2. Lindblad Expeditions Holdings Inc common.

No dividends paid.

LINKBANCORP INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2023	2022
Cost & expenses	40,698	24,635
Operating income	1,309	5,872
Net before taxes	1,309	5,872
Income taxes	276	970
Net income	1,033	4,902
Earnings common share		
Primary	\$0.06	\$0.49
Fully Diluted	\$0.06	\$0.48
Common Shares:		
Full Diluted	15,984	10,136,457
Year-end	16,236	14,939,640

LIPELLA PHARMACEUTICALS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Grant revenues	449,617	184,156	259,347
Total revenues	449,617	184,156	259,347
Research & development	3,038,836	2,547,677	1,456,791
General & administrative	2,156,734	226,192	718,384
Total costs & expenses	(5,195,570)	2,773,869	2,175,175
Income (loss) from operations	(4,745,953)	(2,589,713)	(1,915,828)
Other income	...	(45)	57,085
Interest income	137,836	1,678	104
Interest expense related party	10,848	9,612	6,834
Total other income (expense)	126,988	(7,979)	50,355
Income (loss) before income taxes	(4,618,965)	(2,597,692)	(1,865,473)
Net income (loss)	(4,618,965)	(2,597,692)	(1,865,473)
Weighted average common shares outstanding - basic	6,003,074	4,060,624	3,408,051
Weighted average common shares outstanding - diluted	6,003,074	4,060,624	3,408,051
Year end shares outstanding	6,053,956	5,743,945	3,866,625
Net income (loss) per share - basic	\$(0.77)	\$(0.64)	\$(0.55)
Net income (loss) per share - dilutive	\$(0.77)	\$(0.64)	\$(0.55)
Number of full time employees	...	5	4

Number of part time employees	...	2	3
Number of common stockholders	15	15	65

Reclassified to conform with 2022 presentation; Adjusted for 1-for-2.5 stock split, December 19, 2022; Shares increased due to the effect of conversion of series A preferred stock to common stock, related party notes to common stock & issuance of common stock; As of March 27, 2023; As of December 18, 2022; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	3,293,738	5,121,743
Grants receivable	32,286	113,655
Prepaid insurance	...	433,890
Prepaid consulting expense	103,256	130,000
Prepaid expenses	...	563,891
Total current assets	3,429,280	5,799,289
Operating lease right of use asset	135,144	150,821
Furniture, fixtures and equipment - Net	12,750	...
Furniture, fixtures and equipment - Gross	140,294	...
Less: Accumulated depreciation	127,544	...
Property, Plant & Equipment - Net - Total	12,750	...
Total assets	3,577,174	5,950,110
Accounts payable	138,016	384,357
Accrued professional	...	224,871
Accrued clinical expenses	...	164,338
Accrued expenses	77,280	389,209
Operating lease liability	89,223	58,262
Payroll liability	80,836	67,832
Notes payable, current	...	25,000
Related party loan	...	250,000
Related party interest	...	3,596
Total current liabilities	385,355	1,178,256
Operating lease liability, net of current portion	47,371	96,258
Total liabilities	432,726	1,274,514
Common stock	605	574
Additional paid-in capital	13,467,686	10,379,900
Retained earnings (accumulated deficit)	(10,323,843)	(5,704,878)
Total stockholders' equity (deficit)	3,144,448	4,675,596
Total Equity	3,144,448	...

As reported by the Company

Recent Dividends:

1. Lipella Pharmaceuticals Inc common.

No dividends paid.

Annual Dividends:

1. Lipella Pharmaceuticals Inc common.

No dividends paid.

LIPOCINE INC (NEW)

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
License revenue	(2,960,805)
License revenue	109,987
Total revenues	(2,850,818)	500,000	16,140,838
Research & development	10,175,251	8,556,888	7,665,559
General & administrative expenses	4,904,888	4,062,487	5,329,776
Total operating expense	15,080,139	12,619,375	12,995,335
Operating income (loss)	(17,930,957)	(12,119,375)	3,145,503
Interest & investment income	1,366,940	572,578	67,700
Interest expense	...	27,098	203,292

Unrealized gain (loss) on warrant liability	212,690	565,940	355,890
Litigation settlement	...	(250,000)	4,000,000
Total other income (expense), net	1,579,630	1,361,420	(3,779,702)
Income (loss) before income tax expense	(16,351,327)	(10,757,955)	(634,199)
Current state & local income taxes	755	681	200
Income tax expense (benefit)	755	681	200
Issuance of Series B preferred stock dividend	89
Net income (loss)	(16,352,082)	(10,758,636)	(634,399)
Weighted average shares outstanding - basic	5,269,671	5,203,367	5,113,801
Weighted average shares outstanding - diluted	5,269,671	5,227,997	5,154,321
Year end shares outstanding	5,315,830	5,206,517	5,193,568
Net earnings (loss) per share - basic	\$(3.10)	\$(2.04)	\$(0.17)
Net earnings (loss) per share - diluted	\$(3.14)	\$(2.21)	\$(0.17)
Number of full time employees	17	17	13
Total number of employees	17
Number of common stockholders	87	90	96
Net Income After Extraordinary Items applicable to Common	(16,352,171)
Basic EPS Excluding ExtraOrdinary Items	\$(3.10)
Diluted EPS Excluding ExtraOrd Items	\$(3.14)

Reclassified to conform with 2022 presentation; Adjusted for 1-for-17 stock split, May 12, 2023; Shares increased due to the effect of common stock sold through equity and ATM offering and common stock issued for warrant exercises; Approximately; As of March 7, 2023; As of March 7, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	4,771,758	3,148,496
Marketable investment securities	17,263,788	29,381,410
Accrued interest income	52,254	80,427
Contract asset - current	...	579,428
Prepaid & other current assets	773,424	945,319
Total current assets	22,861,224	34,135,080
Computer equipment & software	66,830	53,663
Lab & office equipment	1,180,052	1,180,052
Furniture & fixtures	51,404	51,404
Property, plant & equipment, gross	...	1,285,119
Less: accumulated depreciation	1,182,191	1,153,530
Property and equipment, net - Balancing value	1,298,286	...
Property & equipment, net	116,095	131,589
Contract asset - non-current	...	3,252,500
Other assets	23,753	23,753
Total assets	23,001,072	37,542,922
Accounts payable	1,395,977	600,388
Accrued expenses	1,218,486	1,077,738
Litigation settlement

	2023	2022	2021 (revised)	2021	2022	2023	2022
Interest & other receivables	86	127				292	292
Prepaid expenses & other current assets	450	525					
Total current assets	22,795	19,283	12,734,000	13,067,000	17,576,000		
Investments in debt securities - long term	1,098	5,646		30,393,000			
Land, building, & improvements	11,237	9,610					
Machinery & equipment	1,304	1,304	12,974,000	14,141,000	11,474,000		
Computer equipment	272	272	25,708,000	57,601,000	29,050,000		
Office equipment, furnishings, & improvements	51	51	(25,708,000)	(57,601,000)	(29,050,000)		
Buildings	9,610			1,052,000	151,000		
Total property & equipment		11,237	(186,000)	(155,000)	(75,000)		
Less: accumulated depreciation	3,569	3,257	2,724,000				
Property & equipment, net	7,668	7,980	2,538,000	897,000	76,000		
Patents & trademarks, net	52	73					
Other assets	223	353					
Total assets	31,836	33,335					
Accounts payable	94	88					
Accrued payroll, vacation, & bonuses	138	124		(56,175,000)	(28,974,000)		
Accrued severance	56	56					
Accrued audit fees	106	85					
Accrued liabilities	244	265					
Deferred revenue	6	41					
Total current liabilities	344	394					
Other long-term liabilities	902	902		(529,000)			
Total liabilities	1,246	1,296					
Common stock	917	917					
Warrants	18,179	18,179					
Additional paid-in capital	288,126	288,013					
Retained earnings (accumulated deficit)	(276,743)	(274,696)	(23,170,000)	(56,704,000)	(28,974,000)		
Unrealized gains on available-for-sale securities		(296)	(2,330,000)	(2,479,000)	(1,508,000)		
Accumulated other comprehensive income (loss)	190	(296)	(2,330,000)	(2,479,000)	(1,508,000)		
Non-controlling interest in subsidiary	(79)	(78)	(2,330,000)	(2,479,000)	(1,508,000)		
Total shareholders' equity (deficit)	30,590	32,039	(20,840,000)	(54,225,000)	(27,466,000)		
Total shareholders' (deficit)	30,590						
Recent Dividends:							
1. Liquidmetal Technologies Inc series A-2 convertible redeemable preferred.							
No dividends paid.							
2. Liquidmetal Technologies Inc common.							
No dividends paid.							
3. Liquidmetal Technologies Inc series A-1 convertible redeemable preferred.							
No dividends paid.							
4. Liquidmetal Technologies Inc series A convertible redeemable preferred.							
No dividends paid.							
Annual Dividends:							
1. Liquidmetal Technologies Inc series A-2 convertible redeemable preferred.							
No dividends paid.							
2. Liquidmetal Technologies Inc common.							
No dividends paid.							
3. Liquidmetal Technologies Inc series A-1 convertible redeemable preferred.							
No dividends paid.							
4. Liquidmetal Technologies Inc series A convertible redeemable preferred.							
No dividends paid.							
LISATA THERAPEUTICS INC							
Annual Report							
Consolidated Income Statement, Years Ended Dec. 31 (\$):							
Research & development expenses	12,734,000	13,067,000	17,576,000				
In-process research & development		30,393,000					
General, & administrative expenses	12,974,000	14,141,000	11,474,000				
Operating expenses	25,708,000	57,601,000	29,050,000				
Operating income (loss)	(25,708,000)	(57,601,000)	(29,050,000)				
Investment income, net		1,052,000	151,000				
Other income (expense), net	(186,000)	(155,000)	(75,000)				
Total other income (expense) income	2,724,000						
Total other income (expense), net	2,538,000	897,000	76,000				
Income (loss) from operations before provision for income taxes & noncontrolling interests - United States		(56,175,000)	(28,974,000)				
Income (loss) from operations before provision for income taxes & noncontrolling interests - Australia		(529,000)					
Net income (loss) before provision (benefit) from income taxes & noncontrolling interests	(23,170,000)	(56,704,000)	(28,974,000)				
Deferred state & local provision (benefit) from income taxes	(2,330,000)	(2,479,000)	(1,508,000)				
Total deferred provision (benefit) from income taxes	(2,330,000)	(2,479,000)	(1,508,000)				
Provision (benefit) from income taxes	(2,330,000)	(2,479,000)	(1,508,000)				
Net income (loss)	(20,840,000)	(54,225,000)	(27,466,000)				
Net income (loss) attributable to Lisata Therapeutics, Inc. common stockholders		(54,225,000)	(27,466,000)				
Weighted average shares outstanding - basic	8,073,000	5,180,000	3,688,000				
Weighted average shares outstanding - diluted	8,073,000	5,180,000	3,688,000				
Year end shares outstanding	8,149,897	7,866,061	3,985,981				
Income (loss) per share - continuing operations - basic	\$(2.58)						
Net income (loss) per share - basic	\$(2.58)	\$(10.47)	\$(7.45)				
Income (loss) per share - continuing operations - diluted	\$(2.58)						
Net income (loss) per share - diluted	\$(2.58)	\$(10.47)	\$(7.45)				
Foreign currency translation adjustments		(11,000)					
Number of full time employees	25	27	27				
Total number of employees	25						
Number of common stockholders							
Consolidated Balance Sheet, Years Ended Dec. 31 (\$):							
Cash & cash equivalents	22,593,000	32,154,000					
Marketable securities	27,942,000	37,072,000					
Prepaid & other current assets	3,389,000	2,650,000					
Total current assets	53,924,000	71,876,000					
Furniture & fixtures		25,000					
Computer equipment	589,000	589,000					
Leasehold improvements	72,000	99,000					
Accumulated depreciation	486,000	417,000					
Property & equipment, net	175,000	296,000					
Acquired license-intangible, net	263,000	334,000					
Other assets	332,000	528,000					
Total assets	54,694,000	73,034,000					
Accounts payable	2,421,000	2,655,000					
Salaries, employee benefits & related taxes	2,665,000	2,586,000					
Operating lease liabilities - current	168,000	180,000					
California Institute for Regenerative Medicine ("CIRM") upfront funding - current	1,103,000						
Clinical & research & development related liabilities		785,000					
Warrant liability	4,169,000						
Other accrued liabilities	233,000	177,000					
Total current liabilities	6,590,000	6,383,000					
Other long-term liabilities	210,000	327,000					
Total liabilities	6,800,000	6,710,000					
Common stock	8,000	8,000					
Additional paid-in capital	576,971,000	574,548,000					
Treasury stock, at cost	708,000	708,000					
Retained earnings (accumulated deficit)	(528,081,000)	(507,241,000)					
Accumulated other comprehensive income (loss)	(42,000)	(29,000)					
Total Lisata Therapeutics, Inc. stockholders' equity	48,148,000	66,578,000					
Noncontrolling interests	(254,000)	(254,000)					
Total equity	47,894,000	66,324,000					
Recent Dividends:							
1. Lisata Therapeutics Inc series B convertible redeemable preferred.							
No dividends paid.							
2. Lisata Therapeutics Inc common.							
No dividends paid.							
3. Lisata Therapeutics Inc series E convertible redeemable preferred.							
No dividends paid.							
4. Lisata Therapeutics Inc series A \$0.07 convertible preferred (stated value \$1).							
No dividends paid.							
Annual Dividends:							
1. Lisata Therapeutics Inc series B convertible redeemable preferred.							
No dividends paid.							
2. Lisata Therapeutics Inc common.							
No dividends paid.							
3. Lisata Therapeutics Inc series E convertible redeemable preferred.							

No dividends paid.				Net income (loss)	(100,435)	(225,747)	(124,974)	development costs	181,079	161,633
4. Lisata Therapeutics Inc series A \$0.07 convertible preferred (stated value \$1).				Weighted average shares outstanding				Finance lease right-of-use assets	3,060	3,083
No dividends paid.				- basic	78,593	74,509	69,606	Furniture, equipment, & building improvements	327	506
LIVEPERSON INC				Weighted average shares outstanding				Computer equipment and software	123,580	...
Annual Report				- diluted	78,593	74,509	69,606	Property & equipment, gross	293,428
Consolidated Income Statement, Years Ended Dec. 31 (\$000):				Year end shares outstanding	87,837	75,585	72,234	Less: accumulated depreciation	188,721	155,706
	2023	2022	2021	Income (loss) per share - continuing operations - basic	\$(1.28)	Less assets held for sale	(11,223)
			(revised)	Net income (loss) per share - basic	\$(1.28)	\$(3.03)	\$(1.80)	Property & equipment, net	119,325	126,499
Revenue	401,983	514,800	469,624	Income (loss) per share - continuing operations - diluted	\$(1.28)	Contract acquisition costs	37,354	43,804
Cost of revenue	142,823	184,699	156,880	Net income (loss) per share - diluted	\$(1.28)	\$(3.03)	\$(1.80)	Intangible assets, net	61,625	78,103
Sales & marketing expenses	125,677	214,027	165,421	Number of full time employees	1,095	1,301	1,540	Goodwill	285,631	296,214
General & administrative expenses	91,619	120,625	76,757	Total number of employees	1,095	Deferred tax assets	4,527	4,423
Product development expenses	124,792	193,688	158,390	Number of common stockholders	232	195	197	Investment in joint venture	2,264
Restructuring costs	22,664	19,967	3,397	Foreign currency translation adjustments	(5,113)	(5,644)	Other assets	1,208	2,563
Amortization of purchased intangibles	3,505	3,678	2,045	Net sales	401,983	Total assets	835,513	1,088,940
Goodwill impairment	11,895	Gain on divestiture	17,591	Accounts payable	13,555	25,303
Total costs & expenses	513,358	736,684	562,890	Impairment of intangibles and other assets	7,974	Professional services, consulting & other vendor fees	67,585	51,067
Income (loss) from operations	(111,375)	(221,884)	(93,266)					Payroll & other employee related costs	20,767	19,182
Interest income (expense), net	4,669	(352)	(37,406)					Short-term contingent earn-out	47,819
Other income (expense), net	10,434	(1,784)	3,294					Sales commissions	734	4,402
Total other income (expense), net	15,103	(2,136)	(34,112)					Financing lease liability	3,037	2,569
Income before provision for (benefit from) income taxes - United States	(95,773)	(220,060)	(128,210)					Unrecognized tax benefits	2,196
Income before provision for (benefit from) income taxes - foreign	(499)	(3,960)	832					Restructuring tax	2,076	803
Income (loss) before provision for (benefit from) income taxes	(96,272)	(224,020)	(127,378)					Non income tax	556	...
Current U.S. federal provision for (benefit from) income taxes	(22)					Other accrued expenses & other current liabilities	2,254
Current state & local provision for (benefit from) income taxes	239	431	159					Accrued expenses & other current liabilities	131,440
Current foreign provision for (benefit from) income taxes	2,878	2,458	3,698					Deferred revenue	81,858	84,494
Total current provision for (benefit from) income taxes	3,117	2,889	3,835					Operating lease liabilities	2,719	2,160
Deferred U.S. federal provision for (benefit from) income taxes	651	(1,153)	(2,908)					Liabilities associated with assets held for sale	10,357
Deferred state & local provision for (benefit from) income taxes	488	79	20					Other	2,269	...
Deferred foreign provision for (benefit from) income taxes	(93)	(88)	(3,351)					Convertible senior notes	72,393	...
Total deferred provision for (benefit from) income taxes	1,046	(1,162)	(6,239)					Accrued expenses and other current liabilities - Balancing value	97,024	...
Provision for (benefit from) income taxes	4,163	1,727	(2,404)					Total current liabilities	267,549	253,754
								Deferred revenue, net of current portion	174
								Convertible senior notes, net	511,565	737,423
								Other liabilities	3,158	26,269
								Operating lease liabilities, net of current portion	2,173	682
								Deferred tax liabilities	2,930	2,550
								Total liabilities	787,375	1,020,852
								Common stock	91	78
								Additional paid-in capital	913,522	771,052
								Treasury stock	3	...
								Treasury stock, at cost	3
								Retained earnings (accumulated deficit)	(856,988)	(692,362)
								Accumulated other comprehensive income (loss)	(8,484)	(10,677)
								Total stockholders' equity (deficit)	48,138	68,088
								Total Equity	48,138	...
								Recent Dividends:		
								1. LivePerson Inc common.		
								No dividends paid.		
								Annual Dividends:		
								1. LivePerson Inc common.		
								No dividends paid.		

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022 (revised)	2021 (revised)
Compensation to related parties	...	2,547,615	3,024,113
Patent & licensing legal & filing fees & costs	978,244	1,268,308	729,171
Other costs & expenses	1,495,712	1,146,289	1,230,385
Other general & administrative costs	1,718,180
Research & development costs	898,100	1,349,269	1,736,776
Total costs & expenses	5,090,236	6,311,481	6,720,445
Income (loss) from operations	(5,090,236)	(6,311,481)	(6,720,445)
Interest income	17,486	11,195	626
Interest expense	16,233	8,875	7,414
Foreign currency gain (loss)	1,954	(3,374)	(1,163)
Net income (loss)	(5,087,029)	(6,312,535)	(6,728,396)
Weighted average shares outstanding - basic	1,915,838	1,582,029	1,347,384
Weighted average shares outstanding - diluted	1,915,838	1,582,029	1,347,384
Year end shares outstanding	2,249,290	1,664,706	1,374,659
Net income (loss) per share - basic	\$(2.66)	\$(4.00)	\$(5.00)
Net income (loss) per share - diluted	\$(2.66)	\$(4.00)	\$(5.00)
Number of full time employees	3	3	3
Number of part time employees	1	1	1
Total number of employees	4
Number of common stockholders	46	...	6
Net Income Before Taxes	(5,087,029)
Net loss	(5,087,029)
Basic EPS Excluding ExtraOrdinary Items	\$(2.66)
Diluted EPS Excluding ExtraOrd Items	\$(2.66)

Reclassified to conform with 2022 presentation; As of March 12, 2021; As of March 11, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022 (revised)
Cash	4,203,488	5,353,392
Advances on research & development contract services	78,016	147,017
Prepaid insurance	17,116	49,224
Other prepaid expenses	10,000	11,350
Total current assets	4,308,620	5,560,983
Total assets	4,308,620	5,560,983
Research & development contract liabilities	157,100	165,022
Liquidated damages payable under registration rights agreement	156,758	230,734
Total current liabilities	313,858	395,756
Total liabilities	313,858	395,756
Series A convertible preferred stock	3,500,000	3,500,000
Common stock	225	166
Additional paid-in capital	48,976,265	45,059,760
Retained earnings (accumulated deficit)	(48,481,728)	(43,394,699)

	2023	2022
Total stockholders' equity	3,994,762	5,165,227
Total Equity	3,994,762	5,165,227

Restated to reflect correction of errors

Recent Dividends:
1. Lixte Biotechnology Holdings, Inc. series A convertible preferred (stated value: \$10.00).

No dividends paid.

2. Lixte Biotechnology Holdings, Inc. common.

No dividends paid.

Annual Dividends:
1. Lixte Biotechnology Holdings, Inc. series A convertible preferred (stated value: \$10.00).

No dividends paid.

2. Lixte Biotechnology Holdings, Inc. common.

No dividends paid.

LM FUNDING AMERICA INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Total revenues	8,928,676	613,317
Cost & expenses	13,736,989	16,237,984
Operating income	(8,296,179)	(15,668,385)
Interest income	210,881	264,947
Other income (expense), net	(9,391,215)	10,603,990
Gains or losses	1,917	287,778
Invest. income	1,788	(349,920)
Net before taxes	(17,472,808)	(4,861,590)
Income taxes	...	1,311,678
Income contin. oper.	(17,472,808)	...
Net income	(17,472,808)	(6,173,268)
Earnings common share		
Primary	\$(6.48)	\$(4.38)
Fully Diluted	\$(6.48)	\$(4.38)
Common Shares:		
Full Diluted	2,206,187	2,180,265
Year-end	2,441,981	2,181,981

LONGEVERON INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Grant revenue	41,000	282,000	598,000
Clinical trial revenue	668,000	940,000	708,000
Total revenues	709,000	1,222,000	1,306,000
Cost of revenues	488,000	725,000	716,000
Gross profit	221,000	497,000	590,000
General & administrative	11,401,000	8,119,000	9,740,000
Research & development	9,066,000	9,370,000	7,092,000
Selling & marketing	...	1,051,000	1,214,000
Total operating expenses	21,250,000	18,540,000	18,046,000
Sales expenses	783,000
Income (loss) from operations	(21,029,000)	(18,043,000)	(17,456,000)
Lawsuit expense	...	1,398,000	...
Forgiveness of Paycheck Protection Program loan	23,000	...	300,000
Interest expense	4,000
Other refundable tax credits	(30,000)	306,000	58,000
Other income (expense), net	(377,000)	300,000	57,000
Total other income & (expenses), net	(384,000)	(792,000)	411,000
Net income (loss)	(21,413,000)	(18,835,000)	(17,045,000)
Dividend attributable to warrant down round feature	798,000
Net income to common	(22,211,000)
Weighted average shares outstanding - basic	21,734,901	20,969,032	18,915,086
Weighted average shares outstanding

	2023	2022	2021
- diluted	21,734,901	20,969,032	18,915,086
Year end shares outstanding	25,107,303	21,018,405	20,878,195
Net earnings (loss) per share - basic	\$(1.02)	\$(0.90)	\$(0.90)
Net earnings (loss) per share - diluted	\$(1.02)	\$(0.90)	\$(0.90)
Number of full time employees	23	19	18
Number of part time employees	1	2	2
Number of class A common stockholders	...	12	16
Number of class B common stockholders	...	13	4
Number of common stockholders	27
Total number of employees	24

Reclassified to conform with 2022 presentation; As of March 7, 2023; As of March 10, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	4,949,000	10,503,000
Marketable securities	412,000	9,155,000
National Institutes of Health - grant	...	218,000
Accounts & grants receivable	111,000	218,000
Prepaid expenses & other current assets	376,000	404,000
Total current assets	5,848,000	20,280,000
Leasehold improvements	4,328,000	4,328,000
Furniture or lab equipment	6,969,000	2,264,000
Computer equipment	120,000	46,000
Software or website	38,000	38,000
Furniture/Lab equipment	2,483,000	...
Total property & equipment	...	6,676,000
Less accumulated depreciation & amortization	4,440,000	3,727,000
Property & equipment, net	2,529,000	2,949,000
Intangible assets, net	2,287,000	2,409,000
Right-of-use (ROU) asset	1,221,000	1,531,000
Other assets	193,000	244,000
Total assets	12,078,000	27,413,000
Accounts payable	638,000	1,751,000
Accrued expenses	2,152,000	650,000
Current portion of lease liability	593,000	564,000
Estimated lawsuit liability	...	1,398,000
Deferred revenue	506,000	506,000
Total current liabilities	3,889,000	4,869,000
Lease liability	1,448,000	2,041,000
Total long-term liabilities	1,448,000	2,041,000
Total liabilities	5,337,000	6,910,000
Class A common stock	10,000	6,000
Class B common stock	15,000	15,000
Additional paid-in capital	91,800,000	83,712,000
Stock subscription receivable	(100,000)	(100,000)
Retained earnings (accumulated deficit)	(84,984,000)	(62,773,000)
Accumulated other comprehensive income (loss)	...	(357,000)
Total stockholders' equity	6,741,000	20,503,000
Total Equity	6,741,000	...

Recent Dividends:
1. Longeveron Inc class B common.
No dividends paid.
2. Longeveron Inc class A common.
No dividends paid.

3. Longeveron Inc series A common membership unit.

No dividends paid.

4. Longeveron Inc series B common membership unit.

No dividends paid.

5. Longeveron Inc series C common membership unit.

No dividends paid.

Annual Dividends:**1. Longeveron Inc class B common.**

No dividends paid.

2. Longeveron Inc class A common.

No dividends paid.

3. Longeveron Inc series A common membership unit.

No dividends paid.

4. Longeveron Inc series B common membership unit.

No dividends paid.

5. Longeveron Inc series C common membership unit.

No dividends paid.

LONGEVERON INC**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, Marcum LLP, as it appeared in Co.'s 2023 10-K: "Opinion on the Financial Statements We have audited the accompanying balance sheet of Longeveron, Inc. (the "Company") as of December 31, 2023 and 2022, the related statements of operations, comprehensive loss, stockholders' equity and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America. Explanatory Paragraph **U** Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1, the Company has a significant working capital deficiency, has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations over the next 12 months. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

LULULEMON ATHLETICA INC**Annual Report****Consolidated Income Statement, Years Ended (\$):**

	01/28/24	01/29/23	01/30/22 (revised)
Net revenue	9,619,278,000
Net revenue	9,619,278,000	8,110,518,000	6,256,617,000
Cost of goods sold	4,009,873,000	3,618,178,000	2,648,052,000
Gross profit	5,609,405,000	4,492,340,000	3,608,565,000
Selling, general & administrative expenses	3,397,218,000	2,757,447,000	2,225,034,000
Amortization of intangible assets	5,010,000	8,752,000	8,782,000
Impairment of goodwill & other assets	...	407,913,000	...
Acquisition-related expenses	41,394,000
Gain on disposal of assets	...	10,180,000	...
Provision for impairment & lease exit costs	74,501,000
Income (loss) from operations	2,132,676,000	1,328,408,000	1,333,355,000
Other income (expense), net	43,059,000	4,163,000	514,000
Income (loss) before income tax expense - domestic	...	(98,764,000)	204,350,000
Income (loss) before income tax expense - foreign	...	1,431,335,000	1,129,519,000
Income before income tax expense	2,175,735,000	1,332,571,000	1,333,869,000
Current federal income tax expense (recovery)	140,726,000	34,752,000	25,701,000

Current state income tax expense (recovery)	42,476,000	33,369,000	17,608,000
Current foreign income tax expense (recovery)	469,090,000	400,250,000	322,105,000
Total current income tax expense	652,292,000	468,371,000	365,414,000
Deferred federal income tax expense (recovery)	(14,741,000)	8,932,000	5,858,000
Deferred state income tax expense (recovery)	(3,097,000)	2,363,000	1,045,000
Deferred foreign income tax expense (recovery)	(8,909,000)	(1,895,000)	(13,770,000)
Total deferred income tax expense (recovery)	(26,747,000)	9,400,000	(6,867,000)
Income tax expense	625,545,000	477,771,000	358,547,000
Net income (loss)	1,550,190,000	854,800,000	975,322,000
Weighted average shares outstanding - basic	126,726,000	127,666,000	129,768,000
Weighted average shares outstanding - diluted	127,060,000	128,017,000	130,295,000
Year end shares outstanding	126,222,000	127,321,000	128,500,000
Earnings (loss) per share - continuing operations - basic	\$12.23
Net earnings (loss) per share - basic	\$12.23	\$6.70	\$7.52
Earnings (loss) per share - continuing operations - diluted	\$12.20
Net earnings (loss) per share - diluted	\$12.20	\$6.68	\$7.49
Full-Time Employees (Period End)	38,000
Total number of employees	38,000	34,000	29,000
Number of common stockholders	1,300	1,300	1,000
Foreign currency translation adjustments	...	(65,571,000)	...

[¶] Approximately; ^{¶¶} As of March 22, 2023; ^{¶¶¶} As of March 23, 2022

Consolidated Balance Sheet, Years Ended (\$):

	01/28/24	01/29/23
Cash & cash equivalents	2,243,971,000	1,154,867,000
Accounts receivable, net	124,769,000	132,906,000
Finished goods	1,465,076,000	...
Inventories, at cost	...	1,571,981,000
Provision to reduce inventories to net realizable value	141,474,000	124,614,000
Inventories	1,323,602,000	1,447,367,000
Prepaid & receivable income taxes	183,733,000	185,641,000
Other prepaid expenses & other current assets	184,502,000	...
Prepaid expenses & other current assets	46,652,000	238,672,000
Prepaid expenses	137,203,000	...
Forward currency contract assets	647,000	...
Total current assets	4,060,577,000	3,159,453,000
Land	79,498,000	80,692,000
Buildings	29,032,000	28,850,000
Leasehold improvements	1,006,926,000	818,071,000
Furniture & fixtures	...	144,572,000
Computer hardware	...	166,768,000
Computer software	1,032,567,000	742,295,000
Equipment & vehicles	34,017,000	30,766,000
Work in progress	156,656,000	244,898,000
Property and equipment, gross	176,597,000	...
Computer Equipment	176,597,000	...
Work in progress	247,943,000	...

Property & equipment, gross	2,763,236,000	2,256,912,000
Less: accumulated amortization	...	987,298,000
Accumulated depreciation	1,217,425,000	...
Property & equipment, net	1,545,811,000	1,269,614,000
Right-of-use lease assets	1,265,610,000	969,419,000
Goodwill	24,083,000	24,144,000
Intangible assets, net	...	21,961,000
Deferred income tax assets	9,176,000	6,402,000
Other non-current assets	186,684,000	156,045,000
Other	21,262,000	...
Security deposits	31,825,000	...
Cloud computing arrangement implementation costs	133,597,000	...
Total assets	7,091,941,000	5,607,038,000
Accounts payable	348,441,000	172,732,000
Accrued operating expenses	147,215,000	169,429,000
Accrued freight	...	57,692,000
Sales return allowances	61,634,000	55,528,000
Forward currency contract liabilities	2,872,000	25,625,000
Accrued duty	25,817,000	21,046,000
Sales tax collected	3,088,000	20,183,000
Accrued capital expenditures	31,936,000	19,365,000
Accrued rent	12,522,000	12,223,000
Accrued inventory liabilities	...	4,345,000
Other accrued liabilities & other current liabilities	...	13,787,000
Accrued liabilities and other	348,555,000	...
Accrued liabilities and other	17,447,000	...
Accrued liabilities and other - Balancing value	41,241,000	...
Accrued liabilities & other current liabilities	...	399,223,000
Accrued compensation & related expenses	326,110,000	248,167,000
Current lease liabilities	249,270,000	207,972,000
Accrued inventory liabilities	4,783,000	...
Current income taxes payable	12,098,000	174,221,000
Unredeemed gift card liability	306,479,000	251,478,000
Other current liabilities	40,308,000	38,405,000
Total current liabilities	1,631,261,000	1,492,198,000
Non-current lease liabilities	1,154,012,000	862,362,000
Non-current income taxes payable	15,864,000	28,555,000
Deferred income tax liabilities	29,522,000	55,084,000
Other non-current liabilities	29,201,000	20,040,000
Total liabilities	2,859,860,000	2,458,239,000
Common stock	606,000	611,000
Additional paid-in capital	575,369,000	474,645,000
Retained earnings (accumulated deficit)	3,920,362,000	2,926,127,000
Accumulated other comprehensive income (loss)	(264,256,000)	(252,584,000)
Total stockholders' equity	4,232,081,000	3,148,799,000
Total Equity & Minority Interest	4,232,081,000	...

Recent Dividends:**1. lululemon athletica inc special voting.**

No dividends paid.

2. lululemon athletica inc exchangeable.

No dividends paid.

3. lululemon athletica inc common.

No dividends paid.

Annual Dividends:

- 1. **lululemon athletica inc special voting.**
No dividends paid.
- 2. **lululemon athletica inc exchangeable.**
No dividends paid.
- 3. **lululemon athletica inc common.**
No dividends paid.

LUVU BRANDS INC

Earnings, 6 mos. to Dec 31(Consol. – \$):

	2023	2022
Total revenues	12,912,000	14,661,000
Cost & expenses	12,587,000	14,661,000
Operating income	122,000	1,359,000
Net before taxes	(66,000)	1,188,000
Income taxes	31,000	...
Net income	(97,000)	1,188,000
Earnings common share		
Primary	\$0.02	\$0.02
Fully Diluted	\$0.02	\$0.02
Common Shares:		
Full Diluted	76,547,672	76,371,111
Year-end	76,547,672	76,511,005

MANHATTAN BRIDGE CAPITAL, INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Interest income from loans	6,772,889	5,608,660	...
Origination fees	1,798,075	1,199,230	...
Total revenue	9,796,256	8,570,964	6,807,890
Interest expense on lines of credit used	2,525,935
Interest & amortization of deferred financing costs	1,822,825	1,045,548	7,532
Referral fees	2,153	4,500	...
General & administrative expenses	1,825,227	1,549,251	1,348,838
Total operating costs & expenses	3,376,576	2,401,918	...
Income (loss) from operations	5,442,941	5,194,388	4,405,972
Other income (loss)	33,880	18,000	18,000
Income (loss) before income tax expense	5,476,821	5,212,388	4,423,972
Income tax expense (benefit)	650	650	647
Net income (loss)	5,476,171	5,211,738	4,423,325
Weighted average shares outstanding - basic	11,469,741	11,494,945	10,524,055
Weighted average shares outstanding - diluted	11,469,741	11,494,945	10,524,055
Year end shares outstanding	11,440,651	11,494,945	11,494,945
Net income (loss) per share - basic	\$0.48	\$0.45	\$0.42
Net income (loss) per share - diluted	\$0.48	\$0.45	\$0.42
Number of full time employees	5
Total number of employees	5	5	6
Number of common stockholders	10	11	11
Number of beneficiary stockholders	...	6,400	6,200

[□] As of March 3, 2023; [□] As of March 4, 2022; [□] Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Loans receivable	73,048,403	74,483,463
Interest receivable on

loans	1,395,905	1,363,502
Cash & cash equivalents	104,222	...
Cash - restricted	1,587,773	...
Other assets	63,636	59,566
Operating lease, right-of-use asset	207,364	262,222
Deferred financing costs, net	27,583	7,708
Total assets	76,434,886	76,280,001
Line of credit	...	24,994,234
Senior secured notes	5,827,931	...
Accounts payable & accrued expenses	...	289,868
Operating lease liability	220,527	273,485
Commissions payable	295,292	...
Deferred origination fees	719,019	669,128
Dividends payable	1,287,073	1,436,868
Senior secured notes	...	5,752,845
Line of credit	25,152,338	...
Total liabilities	33,502,180	33,416,428
Common shares	11,757	11,757
Additional paid-in capital	45,548,876	45,535,811
Treasury stock, at cost	1,060,606	798,939
Retained earnings (accumulated deficit)	(1,567,321)	(1,885,056)
Total stockholders' equity (deficit)	42,932,706	42,863,573
Rep Total Equity & Minority Interest	42,932,706	...

[□] Net of deferred financing costs - senior secured notes: \$247,155

Recent Dividends:

1. Manhattan Bridge Capital, Inc. common.

ExDate	Amt	Declared	Record	Payable
12/30/2020	0.11	10/26/2020	12/31/2020	01/15/2021
04/08/2021	0.11	02/08/2021	04/09/2021	04/15/2021
07/08/2021	0.13	04/15/2021	07/09/2021	07/15/2021
10/07/2021	0.13	07/29/2021	10/08/2021	10/15/2021
12/30/2021	0.13	11/09/2021	12/31/2021	01/18/2022
04/07/2022	0.13	02/09/2022	04/08/2022	04/15/2022
07/07/2022	0.13	04/15/2022	07/08/2022	07/15/2022
10/07/2022	0.13	07/28/2022	10/11/2022	10/17/2022
12/29/2022	0.13	12/09/2022	12/30/2022	01/17/2023
04/06/2023	0.11	03/13/2023	04/10/2023	04/17/2023
07/07/2023	0.11	04/17/2023	07/10/2023	07/17/2023
10/09/2023	0.11	07/27/2023	10/10/2023	10/16/2023
12/28/2023	0.11	11/28/2023	12/29/2023	01/16/2024

Annual Dividends:

1. Manhattan Bridge Capital, Inc. common.

2021	0.47	2022	0.50	2023	0.46
2024	0.11

MANITEX INTERNATIONAL INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	[□] 2021 (revised)
Net revenues	291,389,000
Net revenues	291,389,000	273,854,000	211,539,000
Cost of sales	229,037,000	223,835,000	175,377,000
Cost of sales - inventory write-down	3,226,000
Gross profit	62,352,000	50,019,000	32,936,000
Research & development costs	3,388,000	2,989,000	3,332,000
Recruiting expenses	43,122,000
Selling, general & administrative expenses	...	40,417,000	31,948,000
Transaction costs	...	2,236,000	...
Impairment of intangibles & fixed assets	2,078,000
Total operating expenses	46,510,000	45,642,000	37,358,000
Operating income (loss)	15,842,000	4,377,000	(4,422,000)

Interest expense	7,774,000	4,637,000	2,084,000
Interest income	211,000	2,000	43,000
Gain on paycheck protection program loan forgiveness	3,747,000
Foreign currency transaction gain (loss)	(2,539,000)	(108,000)	(543,000)
Other income (expense)	(278,000)	(1,818,000)	(97,000)
Total other income (expense)	(10,380,000)	(6,561,000)	1,066,000
Income (loss) before income taxes - domestic	...	(2,100,000)	(5,467,000)
Income (loss) before income taxes - foreign	...	(84,000)	2,111,000
Income (loss) before income taxes	5,462,000	(2,184,000)	(3,356,000)
Current federal expense (benefit) for income taxes	46,000	1,000	(4,000)
Current state & local expense (benefit) for income taxes	25,000	(1,000)	(58,000)
Current foreign expense (benefit) for income taxes	1,649,000	918,000	1,330,000
Total current expense (benefit) for income taxes	1,720,000	918,000	1,268,000
Deferred federal expense (benefit) for income taxes	(2,713,000)	490,000	...
Deferred state & local expense (benefit) for income taxes	145,000	(343,000)	52,000
Deferred foreign expense (benefit) for income taxes	(1,547,000)	1,049,000	(103,000)
Total deferred expense (benefit) for income taxes	(4,115,000)	1,196,000	(51,000)
Income tax expense (benefit)	(2,395,000)	2,114,000	1,217,000
Net income (loss)	7,857,000	(4,298,000)	(4,573,000)
Net income attributable to noncontrolling interest	(501,000)	(603,000)	...
Net income (loss) attributable to shareholders of Manitex International, Inc.	7,356,000	(4,901,000)	(4,573,000)
Weighted average shares outstanding - basic	20,209,132	20,055,836	19,900,117
Weighted average shares outstanding - diluted	20,223,825	20,055,836	19,900,117
Year end shares outstanding	20,258,194	20,107,014	19,940,487
Earnings (loss) per share from continuing operations - basic	\$0.36
Net earnings (loss) per share - basic	\$0.36	\$(0.21)	\$(0.23)
Earnings (loss) per share from continuing operations - diluted	\$0.36
Net earnings (loss) per share - diluted	\$0.36	\$(0.21)	\$(0.23)
Number of full time employees	705	601	514
Number of part time employees	...	7	12
Total number of

employees.....	705
Number of common stockholders.....	143	[□] 149	[□] 162
Foreign currency translation adjustments.....	...	(1,603,000)	(2,511,000)
Comprehensive income (loss).....	9,009,000

[□] Reclassified to conform with 2022 presentation; [□] As of January 24, 2023; [□] As of February 3, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022	
Cash.....	9,269,000	7,973,000	
Cash - restricted.....	212,000	217,000	
Trade receivables, gross.....	51,304,000	45,804,000	
Allowance for bad debt.....	2,186,000	1,948,000	
Trade receivables, net.....	49,118,000	43,856,000	
Other receivables.....	553,000	1,750,000	
Raw materials & purchased parts.....	57,185,000	47,168,000	
Work in process.....	7,014,000	6,015,000	
Finished goods & replacement parts.....	18,138,000	16,618,000	
Inventory, net.....	82,337,000	69,801,000	
Prepaid expense & other current assets.....	4,084,000	3,832,000	
Assets held for sale.....	...	75,000	
Total current assets.....	145,573,000	127,504,000	
Machinery & equipment.....	11,692,000	9,930,000	
Buildings.....	8,602,000	8,067,000	
Finance lease - building.....	4,606,000	4,606,000	
Land.....	3,484,000	3,709,000	
Furniture & fixtures.....	...	2,437,000	
Computer Equipment.....	1,489,000	1,801,000	
Leasehold improvements.....	2,211,000	2,288,000	
Construction in progress.....	1,724,000	901,000	
Rental fleet.....	1,322,000	37,858,000	
Motor vehicles.....	1,801,000	2,541,000	
Property Plant and Equipment Gross - Balancing value.....	42,380,000	...	
Total property, plant & equipment, gross.....	79,311,000	74,138,000	
Less: accumulated depreciation.....	26,721,000	19,752,000	
Less: accumulated depreciation - finance lease.....	3,030,000	2,689,000	
Total fixed assets, net.....	49,560,000	51,697,000	
Operating lease assets.....	7,416,000	5,667,000	
Intangible assets, net.....	12,225,000	14,367,000	
Goodwill.....	37,354,000	36,916,000	
Deferred tax assets.....	3,603,000	452,000	
Total assets.....	255,731,000	236,603,000	
Notes payable.....	...	22,666,000	
Convertible note-related party, net.....	25,528,000	...	
Current portion of finance lease obligations.....	605,000	509,000	
Current portion of operating lease obligations.....	2,100,000	1,758,000	
Accounts payable.....	47,644,000	45,682,000	
Accounts payable related parties.....	27,000	60,000	
Accrued payroll & benefits.....	5,526,000	4,929,000	
Accrued income tax & other taxes.....	2,505,000	841,000	
Accrued vacation expense.....	1,961,000	1,635,000	
Accrued legal settlement.....	...	1,160,000	
Accrued warranty.....	2,038,000	1,916,000	
Accrued expense other.....	1,603,000	1,898,000	
Accrued bonuses.....	870,000	...	
Accrued expenses.....	14,503,000	12,379,000	
Customer deposits.....	2,384,000	3,407,000	
Total current liabilities.....	92,791,000	86,461,000	
Revolving term credit facilities, net.....	...	41,479,000	
Notes payable, net.....	18,401,000	22,261,000	
Finance lease obligations, net of			

current portion.....	2,777,000	3,382,000	
Non-current operating lease obligations (net of current portion).....	5,315,000	3,909,000	
Convertible note-related party (net).....	47,629,000	...	
Deferred gain on sale of property.....	347,000	427,000	
Deferred tax liability.....	4,145,000	5,151,000	
Other long-term liabilities.....	4,642,000	5,572,000	
Total long-term liabilities.....	83,256,000	82,181,000	
Total liabilities.....	176,047,000	168,642,000	
Common stock.....	134,328,000	133,289,000	
Paid in capital.....	5,440,000	4,266,000	
Retained earnings (deficit).....	(65,982,000)	(73,338,000)	
Accumulated other comprehensive income (loss).....	(4,169,000)	(5,822,000)	
Equity attributable to shareholders of Manitex International, Inc.....	69,617,000	58,395,000	
Equity attributable to noncontrolling interest.....	10,067,000	9,566,000	
Total equity.....	79,684,000	67,961,000	

Recent Dividends:

1. Manitex International Inc common.

No dividends paid.

Annual Dividends:

1. Manitex International Inc common.

No dividends paid.

MARATHON DIGITAL HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	[□] 2022	[□] 2021
Revenues.....	387,508,000	117,753,000	...
Total revenue.....	387,508,000	117,753,000	159,163,000
Cost of revenues - energy, hosting & other.....	223,338,000	72,715,000	27,491,000
Cost of revenues - depreciation & amortization.....	179,513,000	78,709,000	14,904,000
Total cost of revenues.....	402,851,000	151,424,000	42,395,000
General & administrative expenses.....	95,230,000	56,739,000	174,355,000
Legal reserves.....	...	26,131,000	...
Impairment of deposits due to vendor bankruptcy filing.....	...	24,661,000	...
Impairment of digital assets.....	...	182,891,000	30,329,000
Impairment of patents.....	...	919,000	...
Impairment of mining equipment & advances to vendors.....	...	332,933,000	...
Realized & unrealized gains (losses) on digital assets loan receivable & digital assets.....	557,000
Gain on sale of equipment, net of disposals.....	331,484,000	83,879,000	...
Realized & unrealized gains (losses) on digital assets held within investment fund.....	74,696,000
Losses on digital assets held within investment fund.....	...	(85,017,000)	...
Realized gains on digital assets and			

unrealized gains (losses) on digital assets loan receivable.....	...	(14,460,000)	...
Total operating expenses.....	(236,254,000)	639,872,000	129,431,000
Operating income (loss).....	220,911,000	(673,543,000)	(12,663,000)
Gain (loss) from extinguishment of debt.....	82,267,000
Other non-operating income (loss).....	2,809,000	1,283,000	(287,000)
Impairment of loan & investment due to vendor bankruptcy filing.....	...	31,013,000	...
Change in fair value of mining payable.....	(17,421,000)
Interest expense.....	10,350,000	14,981,000	1,570,000
Equity in net earnings of unconsolidated affiliate.....	(617,000)
Income (loss) before income taxes.....	277,599,000	(718,254,000)	(14,520,000)
Current state income tax expense (benefit).....	1,140,000	733,000	2,000
Total current income tax expense (benefit).....	1,140,000	733,000	2,000
Deferred federal income tax expense (benefit).....	66,129,000	(143,598,000)	29,523,000
Deferred state income tax expense (benefit).....	1,659,000	(11,829,000)	7,528,000
Total deferred tax expense (benefit).....	67,788,000	(155,427,000)	37,051,000
Change in valuation allowance.....	(52,502,000)	130,462,000	(14,477,000)
Income tax expense (benefit).....	16,426,000	(24,232,000)	22,576,000
Deemed dividend on Series A Preferred Stock.....	2,121,000
Net income (loss).....	261,173,000	(694,022,000)	(37,096,000)
Net income (loss) attributable to common shareholders.....	259,052,000	(694,022,000)	(37,096,000)
Weighted average shares outstanding - basic.....	183,855,570	113,467,837	99,337,587
Weighted average shares outstanding - diluted.....	192,293,277	113,467,837	99,337,587
Year end shares outstanding.....	242,829,391	145,565,916 [□]	102,733,273
Income (loss) per share from continuing operations - basic.....	\$1.41	\$(6.12)	...
Net income (loss) per share - basic.....	\$1.41	\$(6.12)	\$(0.37)
Income (loss) per share from continuing operations - diluted.....	\$1.06	\$(6.12)	...
Net income (loss) per share - diluted.....	\$1.06	\$(6.12)	\$(0.37)
Number of common stockholders.....	49

[□] Restated to reflect correction of errors; [□] Restated to reflect the correction on revenue recognition, impairment of digital assets, Financial Statement Reclassification, disposal of assets, income tax adjustments and account policy; [□] Shares increased due to stock based compensation, options and warrant exercised, common stock issued for cashless exercise of warrants, service and license agreements

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

No dividends paid.

Annual Dividends:

1. MariMed Inc series B convertible preferred.

No dividends paid.

2. MariMed Inc series C convertible preferred.

No dividends paid.

3. MariMed Inc common.

No dividends paid.

MARINE PETROLEUM TRUST

Earnings, 6 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues	567,589	1,035,579
Cost & expenses	140,294	134,241
Operating income	427,295	901,338
Net before taxes	427,295	901,338
Net income	427,295	901,338
Earnings common share		
Primary	\$0.21	\$0.45
Fully Diluted	\$0.21	\$0.45
Common Shares:		
Full Diluted	2,000,000	2,000,000
Year-end	2,000,000	2,000,000

MARKETWISE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
			(revised)
Net revenue	443,245,000	510,040,000	547,899,000
Related party revenue	4,937,000	2,363,000	1,284,000
Total net revenue	448,182,000	512,403,000	549,183,000
Cost of revenue	56,802,000	62,697,000	239,251,000
Sales & marketing	198,592,000	235,326,000	296,934,000
General & administrative expenses	125,176,000	114,810,000	96,183,000
Depreciation & amortization	3,821,000	3,091,000	2,676,000
Research & development	8,831,000	8,817,000	7,487,000
Related party expense	572,000	379,000	10,245,000
Total operating expenses	396,377,000	425,120,000	1,516,776,000
Income (loss) from operations	51,805,000	87,283,000	(967,593,000)
Other income (expense), net	(611,000)	15,672,000	16,178,000
Interest income (expense), net	4,904,000	(295,000)	(110,000)
Income (loss) before income taxes	56,098,000	102,660,000	(951,525,000)
Deferred income tax expense (benefit) - federal	1,517,000	1,294,000	1,942,000
Deferred income tax expense (benefit) - state	286,000	196,000	416,000
Income tax expense	1,803,000	1,490,000	2,358,000
Net income (loss)	54,295,000	101,170,000	(953,883,000)
Net income (loss) attributable to non-controlling interests	(52,513,000)	(83,180,000)	(59,426,000)
Net income (loss) attributable to MarketWise, Inc.	1,782,000	17,990,000	(1,013,309,000)
Weighted average class A shares outstanding - basic	24,635,000	25,035,000	
Weighted average shares outstanding - basic	31,707,000		
Weighted average class A shares outstanding - diluted	33,312,000	24,747,000	25,035,000
Year end shares outstanding	324,477,284	320,131,958	315,810,705
Net earnings (loss) per class A share - basic	\$0.06	\$0.73	\$0.73

Net earnings (loss) per class A share - diluted	\$0.05	\$0.73	\$0.73
Number of full time employees	581	732	800
Total number of employees	581
Number of class A common stockholders	...	50	32
Number of class B common stockholders	...	27	27
Foreign currency translation adjustments	...	53,000	...
Dividends per common share	\$0.15
Impairment losses	2,583,000
Depreciation	267,000
Amortization of Intangibles	3,554,000
Common Shareholders - Number	69

Total current liabilities	373,893,000	385,506,000	
Derivative liabilities, noncurrent	746,000	1,281,000	
Deferred revenue & other contract liabilities, noncurrent	2,151,000	348,273,000	
Operating lease liabilities, noncurrent	4,366,000	5,831,000	
Deferred revenue and other contract liabilities, noncurrent	304,342,000	...	
Total liabilities	685,498,000	740,891,000	
Class A common stock	4,000	3,000	
Class B common stock	29,000	29,000	
Additional paid-in capital	115,164,000	106,852,000	
Accumulated other comprehensive income (loss)	65,000	44,000	
Retained earnings (accumulated deficit)	(126,343,000)	(128,125,000)	
Total stockholders' equity (deficit) attributable to MarketWise, Inc.	(11,081,000)	(21,197,000)	
Noncontrolling interest	(277,862,000)	(277,186,000)	
Total stockholders' deficit or members' deficit	(288,943,000)	(298,383,000)	

¹ Including stock-based compensation expenses - cost of revenue: \$1,972,000; ² Including stock-based compensation expenses - cost of revenue: \$171,804,000; ³ Including stock-based compensation expenses - sales and marketing: \$2,209,000; ⁴ Including stock-based compensation expenses - sales and marketing: \$48,098,000; ⁵ Including stock-based compensation expenses - general and administrative: \$4,864,000; ⁶ Including stock-based compensation expenses - general and administrative: \$843,449,000; ⁷ From July 22, 2021; ⁸ Shares increased due to the effect of issuance of class A & class B common stock, equity-based compensation and issuance of stock for derivative settlement; ⁹ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	155,174,000	158,575,000
Accounts receivable	4,528,000	4,040,000
Prepaid expenses	9,305,000	11,725,000
Related party receivables	5,182,000	1,512,000
Deferred contract acquisition costs	91,480,000	99,960,000
Other current assets	2,172,000	3,363,000
Total current assets	267,841,000	279,175,000
Furniture & fixtures	960,000	960,000
Computers, software & equipment	1,520,000	1,458,000
Leasehold improvements	1,271,000	1,278,000
Property & equipment, gross	3,751,000	3,696,000
Less: accumulated depreciation & amortization	3,061,000	2,804,000
Property & equipment, net	690,000	892,000
Operating lease right-of-use assets	7,331,000	9,468,000
Intangible assets, net	6,255,000	16,047,000
Goodwill	31,038,000	31,307,000
Deferred contract acquisition costs, noncurrent	73,420,000	97,658,000
Deferred tax assets	9,693,000	7,332,000
Other assets	287,000	629,000
Total assets	396,555,000	442,508,000
Trade & other payables	559,000	686,000
Related party payables, net	1,137,000	1,004,000
Commission & variable compensation	10,941,000	24,207,000
Payroll & benefits	...	5,258,000
Other accrued expenses	...	16,511,000
Accrued expenses - Balancing value	44,100,000	...
Accrued expenses	55,041,000	45,976,000
Deferred revenue & other contract liabilities	287,751,000	315,231,000
Operating lease liabilities	1,446,000	1,484,000
Other current liabilities	27,959,000	21,125,000

Recent Dividends:

1. MarketWise Inc class B ordinary.

No dividends paid.

2. MarketWise Inc class A ordinary.

No dividends paid.

Annual Dividends:

1. MarketWise Inc class B ordinary.

No dividends paid.

2. MarketWise Inc class A ordinary.

No dividends paid.

MARQUIE GROUP INC

Earnings, 6 mos. to Nov 30(Consol. - \$):

	2023	2022
Cost & expenses	244,308	188,114
Operating income	(244,308)	(188,114)
Interest expense	247,924	133,128
Other income (expense), net	711,198	41,194
Net before taxes	218,966	(280,048)
Net income	218,966	(280,048)
Earnings common share		
Common Shares:		
Full Diluted	807,957,041	301,040,848
Year-end	1,154,389,824	756,612,000

MASS MEGAWATTS WIND POWER INC

Earnings, 9 mos. to Jan 31(Consol. - \$):

	2024	2023
Cost & expenses	211,416	187,742
Operating income	(257,802)	
Other income (expense), net	61,387	
Net before taxes	(257,802)	
Net income	(257,802)	(187,742)
Earnings common share		
Common Shares:		
Full Diluted	162,965,122	140,963,943
Year-end	172,214,579	149,139,579

MAYS (J.W.), INC.

Earnings, 6 mos. to Jan 31(Consol. - \$):

	2024	2023
Total revenues	10,738,644	11,607,553
Cost & expenses	10,260,819	10,400,651
Operating income	(379,697)	365,591
Other income (expense), net	66,436	(181,441)
Gains or losses	41,609	...
Net before taxes	(341,603)	134,255
Income taxes	(51,000)	30,000
Net income	(290,603)	104,255
Earnings common share		
Primary	\$(0.14)	\$0.05
Fully Diluted	\$(0.14)	\$0.05
Common Shares:		
Full Diluted	2,015,780	2,015,780
Year-end	2,015,780	2,015,780

MERIT MEDICAL SYSTEMS, INC.
Annual Report

Consolidated Income Statement, Years Ended Dec. 31
(\$000):

	2023	2022	2021 (revised)
Net sales	1,257,366	1,150,981	1,074,751
Cost of sales	673,494	631,882	589,418
Gross profit (loss)	583,872	519,099	485,333
Selling, general & administrative expenses	373,676	342,525	335,690
Research & development expenses	82,728	75,510	71,247
Legal settlement	10,036
Impairment charges	270	2,219	4,283
Contingent consideration expense (benefit)	(1,704)	(4,611)	(3,161)
Acquired in-process research & development expenses	1,550	6,671	...
Income (loss) from operations	123,944	87,563	60,916
Interest income	2,456	439	769
Interest expense	15,511	6,339	5,261
Other income (expense) - net	1,200	966	(2,507)
Total other income (expense) - net	(11,855)	(4,934)	(6,999)
Income (loss) before income taxes - domestic	...	77,562	21,328
Income (loss) before income taxes - foreign	...	5,067	32,589
Income (loss) before income taxes	112,089	82,629	53,917
Current federal income tax expense (benefit)	15,684	9,584	808
Current state income tax expense (benefit)	3,775	3,162	806
Current foreign income tax expense (benefit)	10,862	10,291	8,480
Total current income tax expense (benefit)	30,321	23,037	10,094
Deferred federal income tax expense (benefit)	(11,030)	(10,438)	(468)
Deferred state income tax expense (benefit)	(1,699)	(3,615)	(1,845)
Deferred foreign income tax expense (benefit)	86	(871)	(2,318)
Total deferred income tax expense (benefit)	(12,643)	(14,924)	(4,631)
Income tax expense (benefit)	17,678	8,113	5,463
Net income (loss)	94,411	74,516	48,454
Weighted average shares outstanding - basic	57,593	56,806	56,145
Weighted average shares outstanding - diluted	58,356	57,671	57,359
Year end shares outstanding	57,858	57,306	56,570
Net earnings (loss) per common share - basic	\$1.64	\$1.31	\$0.86
Net earnings (loss) per common share - diluted	\$1.62	\$1.29	\$0.84
Full-Time Employees (Period End)	6,950
Total number of			

employees	6,950	6,846	6,446
Number of common stockholders	91	96	100
Foreign currency translation adjustments	...	(10,491)	...
Basic EPS Excluding ExtraOrdinary Items	\$1.64
Diluted EPS Excluding ExtraOrd Items	\$1.62

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	587,036	58,408
Trade receivables, gross	186,908	173,100
Less: allowance for credit losses	9,023	8,423
Trade receivables - net	177,885	164,677
Other receivables	10,517	12,992
Finished goods	158,893	147,051
Work-in-process	25,420	29,534
Raw materials	119,558	89,406
Inventories	303,871	265,991
Prepaid expenses	4,016	...
Prepaid expenses & other current assets	24,286	22,324
Prepaid income taxes	...	3,913
Income tax refund receivables	859	779
Total current assets	1,108,470	529,084
Land & land improvements	26,017	25,940
Buildings	191,491	189,148
Manufacturing equipment	316,930	299,089
Furniture & fixtures	63,044	61,128
Leasehold improvements	53,638	49,673
Construction-in-progress	61,439	61,269
Total property & equipment	712,559	686,247
Less accumulated depreciation	329,036	303,271
Property & equipment - net	383,523	382,976
Developed technology, gross	...	512,092
Less: accumulated amortization - developed technology	...	274,570
Developed technology - net	283,999	237,522
Other intangible assets, gross	...	108,130
Less: accumulated amortization - other intangible assets	...	69,780
Other intangible assets - net	41,884	38,350
Goodwill	382,240	359,821
Deferred income tax assets	7,288	6,599
Right-of-use operating lease assets	63,047	65,262
Deferred compensation plan assets	...	15,767
Investments in privately held companies	...	15,576
Long-term notes receivable, net	...	2,397
Other assets	...	10,612
Other assets	54,793	44,352
Total assets	2,325,244	1,663,966
Trade payables	65,944	68,504
Accrued payroll & related liabilities	66,929	58,620
Current portion of contingent liabilities	...	15,813
Accrued advances from employees	285	165
Accrued rebates payable	11,005	10,925
Accrued legal settlement	...	1,000
Other accrued expenses	41,820	36,666

Accrued Expenses - Balancing value	120,447	...
Accrued expenses	...	123,189
Current portion of long-term debt	...	11,250
Short-term operating lease liabilities	12,087	11,005
Income taxes payable	5,086	6,697
Liabilities related to unrecognized tax positions	408	...
Total current liabilities	203,564	220,645
Term loans	823,013	124,688
Revolving credit loans	...	73,500
Less unamortized debt issuance costs	...	(179)
Less current portion	...	11,250
Long-term debt	...	186,759
Deferred income tax liabilities	5,547	18,462
Long-term income taxes payable	347	347
Liabilities related to unrecognized tax benefits	1,912	1,912
Deferred compensation payable	17,167	15,264
Deferred credits	1,605	1,708
Long-term operating lease liabilities	56,259	59,736
Other long-term obligations	13,830	14,736
Total liabilities	1,123,244	519,569
Common stock	638,150	675,174
Retained earnings (accumulated deficit)	575,184	480,773
Related to cash flow hedges	...	4,366
Foreign currency translation	(12,996)	(15,916)
Cash Flow Hedges	1,662	...
Accumulated other comprehensive income (loss)	(11,334)	(11,550)
Total stockholders' equity (deficit)	1,202,000	1,144,397
Rep Total Equity & Minority Interest	1,202,000	...

Recent Dividends:
1. Merit Medical Systems, Inc. common.
No dividends paid.
Annual Dividends:
1. Merit Medical Systems, Inc. common.
No dividends paid.

MIMEDX GROUP INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
		(revised)	(revised)
Net sales	321,477,000	267,841,000	258,615,000
Total revenue	321,477,000	267,841,000	...
Cost of sales	54,634,000	48,316,000	43,283,000
Gross profit (loss)	266,843,000	219,525,000	215,332,000
Selling, general & administrative expenses	198,359,000
Investigation, restatement & related expenses	5,176,000	12,177,000	3,791,000
Research & development expenses	12,665,000	12,701,000	17,344,000
Amortization of intangible assets	762,000	701,000	820,000
General & administrative expenses	211,124,000	208,673,000	...
Impairment of intangible assets	53,000
Operating income (loss)	37,116,000	(14,727,000)	(5,035,000)
Interest income (expense), net	(6,457,000)	(5,016,000)	(4,980,000)

Other income (expense), net	(26,000)	(4,000)	(23,000)
Income (loss) before income tax provision	30,633,000	(19,747,000)	(10,038,000)
Current federal income tax expense (benefit)	91,000
Current state income tax expense (benefit)	...	206,000	156,000
Income tax provision expense (benefit)	(36,806,000)	206,000	247,000
Net income (loss) from continuing operations	67,439,000	(19,953,000)	...
Adjustment to net income	(9,211,000)	(10,244,000)	...
Net income (loss)	58,228,000	(30,197,000)	(10,285,000)
Accumulated dividend on series B preferred stock	6,753,000	6,580,000	5,210,000
Accretion of increasing-rate dividend feature	926,000
Accretion of redeemable common stock & common stock with registration rights to fair value	4,890,000
Net income (loss) available to common stockholders	55,796,000	(26,533,000)	(16,421,000)
Weighted average shares outstanding - basic	116,495,810	112,909,266	110,353,406
Weighted average shares outstanding - diluted	145,962,462	112,909,266	110,353,406
Year end shares outstanding	146,227,639	113,705,447	111,925,216
Net income (loss) per common share - basic	\$0.40	\$(0.33)	\$(0.15)
Net income (loss) per common share - diluted	\$0.37	\$(0.33)	\$(0.15)
Number of full time employees	895	...	811
Total number of employees	895	...	811
Number of common stockholders	810	...	869
Net loss per common share - diluted	\$0.48	\$(0.24)	...
Diluted EPS Excluding ExtraOrd Items	\$0.43	\$(0.24)	...
Net (loss) income from discontinued operations	(9,211,000)	(10,244,000)	...
Earn per share-inc from discount opers - diluted	\$(0.06)	\$(0.09)	...
Earning per share-total discount opers - diluted	\$(0.06)	\$(0.09)	...
Earnings per share-inc from discontinued oper	\$(0.08)	\$(0.09)	...
Earnings per share-total discontinued opers	\$(0.08)	\$(0.09)	...

Accounts receivable, gross	57,015,000	46,867,000
Less: allowance for doubtful accounts	3,144,000	3,783,000
Accounts receivable, net	53,871,000	43,084,000
Raw materials	825,000	810,000
Work in process	8,521,000	6,855,000
Finished goods	11,675,000	5,518,000
Inventory	21,021,000	13,183,000
Prepaid expenses	5,624,000	8,646,000
Income tax receivable	...	704,000
Other current assets	1,745,000	2,631,000
Total current assets	164,261,000	134,198,000
Leasehold improvements	8,141,000	9,190,000
Lab & clean room equipment	27,002,000	16,422,000
Furniture & office equipment	1,989,000	15,016,000
Construction in progress	1,791,000	1,983,000
Asset retirement cost	938,000	983,000
Finance lease assets	189,000	189,000
Laboratory and clean room equipment	13,954,000	...
Property & equipment, gross	...	43,783,000
Less accumulated depreciation & amortization - property & equipment	...	35,927,000
Less accumulated depreciation - property & equipment	20,028,000	...
Property & equipment, net	6,974,000	7,856,000
Right of use asset	2,132,000	3,400,000
Goodwill	19,441,000	19,976,000
Intangible assets, net	5,257,000	5,852,000
Deferred tax asset, net	40,777,000	...
Other assets	205,000	148,000
Total assets	239,047,000	171,430,000
Accounts payable	9,048,000	8,847,000
Accrued compensation	22,353,000	21,852,000
Accrued legal costs	...	4,447,000
Accrued estimated returns	...	659,000
Accrued external commisions	...	2,941,000
Accrued clinical trials	...	90,000
Accrued rebates	...	707,000
Accrued Group Purchasing Organization ("GPO") fees	...	638,000
Accrued travel	...	566,000
Other accrued expenses	...	976,000
Accrued expenses	9,361,000	11,024,000
Other current liabilities	3,894,000	1,834,000
Current liabilities of discontinued operations	1,352,000	...
Total current liabilities	46,008,000	43,557,000
Long term debt, net	48,099,000	48,594,000
Other liabilities	2,223,000	4,773,000
Total liabilities	96,330,000	96,924,000
Convertible preferred stock series B	...	92,494,000
Common stock	146,000	114,000
Additional paid-in capital	276,249,000	173,804,000
Retained earnings (accumulated deficit)	(133,678,000)	(191,906,000)
Total stockholders' equity (deficit)	142,717,000	(17,988,000)
Total Equity	142,717,000	...

Recent Dividends:
1. MiMedx Group Inc convertible preferred, series B.
No dividends paid.
2. MiMedx Group Inc common.
No dividends paid.

Annual Dividends:
1. MiMedx Group Inc convertible preferred, series B.
No dividends paid.
2. MiMedx Group Inc common.
No dividends paid.

MINERALYS THERAPEUTICS INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):			
	2023	2022	2021 (revised)
Research & development	70,361	26,250	16,308
General & administrative	14,296	5,229	2,417
Total operating expenses	...	31,479	18,725
Income (loss) from operations	(84,657)	(31,479)	(18,725)
Interest income (expense), net	...	1,676	(27)
Change in fair value of convertible notes	(657)
Other income (expense)	3	4	1
Net Income before Tax	(71,898)
Tax	(71,898)
Interest Income - Non-Bank	12,756
Total other income (expense), net	12,759	1,680	(683)
Net income (loss)	(71,898)	(29,799)	(19,408)
Weighted average shares outstanding - basic	36,188	5,167	4,984
Weighted average shares outstanding - diluted	36,188	5,167	4,984
Year end shares outstanding	41,134	6,419	5,442
Net earnings (loss) per share - basic	\$(1.99)	\$(5.77)	\$(3.89)
Net earnings (loss) per share - diluted	\$(1.99)	\$(5.77)	\$(3.89)
Number of full time employees	28	12	12
Number of common stockholders	29	37	...
Total number of employees	28

Reclassified to conform with 2022 presentation; As is; As of December 15, 2022; Approximately; As of March 3, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):		
	2023	2022
Cash and cash equivalents	643	...
Cash & cash equivalents	49,304	87,701
Marketable securities	...	22,409
Prepaid expenses & other current assets	12,536	2,701
Investments	187,263	...
Cash & Cash Equivalents	48,661	...
Total current assets	249,103	112,811
Other assets	51	1,631
Investments, noncurrent	2,482	...
Total assets	251,636	114,442
Accounts payable	601	1,907
Accrued research & development expenses	7,122	4,846
Accrued compensation & benefits	1,599	665
Other accrued liabilities	...	649
Professional fees and other	1,160	...
Accrued liabilities	9,881	6,160
Total current liabilities	10,482	8,067
Series A convertible preferred stock	...	40,987
Series B convertible preferred stock	...	117,657
Common stock	4	1
Additional paid-in capital	365,858	540
Retained earnings (accumulated deficit)	(124,708)	(52,810)
Total stockholders' deficit	241,154	(52,269)
Total Equity	241,154	...

Restated to reflect discontinued operations; Approximately; As of February 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022 (revised)
Cash & cash equivalents	82,000,000	65,950,000

Recent Dividends:

- 1. Mineralys Therapeutics Inc series B convertible preferred.**
No dividends paid.
- 2. Mineralys Therapeutics Inc series A convertible preferred.**
No dividends paid.
- 3. Mineralys Therapeutics Inc common.**
No dividends paid.

Annual Dividends:

- 1. Mineralys Therapeutics Inc series B convertible preferred.**
No dividends paid.
- 2. Mineralys Therapeutics Inc series A convertible preferred.**
No dividends paid.
- 3. Mineralys Therapeutics Inc common.**
No dividends paid.

MITESCO INC
Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Cost & expenses	2,350,835	3,055,703
Operating income	(2,350,835)	(3,055,703)
Other income (expense), net	(7,609,733)	(184,767)
Gains or losses	8,876	172,573
Net before taxes	(11,885,864)	(6,471,310)
Income contin. oper.	(11,885,864)	(6,471,310)
Income discount. oper.	(2,824,604)	(5,062,920)
Net income	(14,710,468)	(11,534,230)
Balance for common	(15,790,570)	(11,775,426)
Earnings common share		
Primary	\$(2.57)	\$(1.52)
Fully Diluted	\$(2.57)	\$(1.52)
Common Shares:		
Full Diluted	5,048,070	4,408,891
Year-end	5,544,519	4,529,830

MOBILEYE GLOBAL INC
Annual Report
Consolidated Income Statement, Years Ended (\$000):

	12/30/23	12/31/22	¹ 12/25/21
Revenue	2,079,000
Cost of revenue	1,032,000	947,000	731,000
Gross profit	1,047,000	922,000	655,000
Research & development, net	889,000	789,000	544,000
Sales & marketing	118,000	120,000	134,000
General & administrative	73,000	50,000	34,000
Total operating expenses	1,080,000	959,000	712,000
Operating income (loss)	(33,000)	(37,000)	(57,000)
Interest income with a related party	...	18,000	...
Interest expenses with a related party	...	24,000	...
Interest income (expense) with a related party, net	3,000
Other income (expense), net	49,000	11,000	(3,000)
Income (loss) before taxes - U.S.	(13,000)	(49,000)	(96,000)
Income (loss) before taxes - Non-U.S.	29,000	17,000	39,000
Income (loss) before income taxes	16,000	(32,000)	(57,000)
Current provision (benefit) for income taxes - Non-U.S.	58,000	67,000	47,000
Total current provision (benefit) for income taxes	58,000	67,000	47,000
Deferred provision (benefit) for			

income taxes - U.S.	...	28,000	30,000
Deferred provision (benefit) for income taxes - Non-U.S.	(43,000)	(45,000)	(59,000)
Income Taxes - Domestic - Deferred	28,000
Total deferred provision (benefit) for income taxes	(15,000)	(17,000)	(29,000)
Provision (benefit) for income taxes	43,000	50,000	18,000
Net income (loss)	(27,000)	(82,000)	(75,000)
Weighted average shares outstanding - basic	805,000	759,000	...
Weighted average shares outstanding - diluted	805,000	759,000	...
Year end shares outstanding	806,152	801,912	...
Net earnings (loss) per share - basic	\$(0.03)	\$(0.11)	...
Net earnings (loss) per share - diluted	\$(0.03)	\$(0.11)	...
Full-Time Employees (Period End)	3,700
Total number of employees	3,700	¹ 3,500	² 3,100
Number of class A common stockholders	...	³ 2	...
Number of class B common stockholders	...	⁴ 1	...
Common Shareholders - Number	2

¹ December 25, 2021 and prior financials of Mobileye Group;
² Non-consolidated; ³ As is; ⁴ Approximately; ⁵ As of July 2, 2022; ⁶ As of March 1, 2023

Consolidated Balance Sheet, Years Ended (\$000):

	12/30/23	12/31/22
Cash & cash equivalents	1,212,000	1,024,000
Trade account receivables, net	357,000	269,000
Raw materials	46,000	41,000
Work in process	1,000	...
Finished goods	344,000	72,000
Inventories	391,000	113,000
Other current assets	106,000	110,000
Total current assets	2,066,000	1,516,000
Computers, electronic equipment, & software	544,000	124,000
Vehicles	14,000	13,000
Office furniture & equipment	11,000	4,000
Leasehold improvements	37,000	22,000
Construction in process	...	302,000
Computers, electronic equipment, and software	167,000	...
Buildings	315,000	...
Total property & equipment, gross	...	465,000
Less: accumulated depreciation	97,000	81,000
Property & equipment, net	447,000	384,000
Intangible assets, net	2,053,000	2,527,000
Goodwill	10,895,000	10,895,000
Other long-term assets	116,000	119,000
Total non current assets	13,511,000	13,925,000
Total assets	15,577,000	15,441,000
Accounts payable & accrued expenses	229,000	189,000
Employee related accrued expenses	87,000	88,000
Related party payable	39,000	73,000
Other current liabilities	48,000	34,000
Total current liabilities	403,000	384,000
Long-term employee benefits	56,000	56,000
Deferred tax liabilities	148,000	162,000
Other long-term		

liabilities	46,000	45,000
Total non-current liabilities	250,000	263,000
Total liabilities	653,000	647,000
Class A common stock	7,000	1,000
Class B common stock	1,000	8,000
Additional paid-in capital	14,886,000	14,737,000
Accumulated other comprehensive income (loss)	...	(9,000)
Retained earnings (accumulated deficit)	30,000	57,000
Total equity	14,924,000	14,794,000
Total Equity	14,924,000	...

Recent Dividends:

- 1. Mobileye Global Inc class A common.**
No dividends paid.
- 2. Mobileye Global Inc class B common.**
No dividends paid.

Annual Dividends:

- 1. Mobileye Global Inc class A common.**
No dividends paid.
- 2. Mobileye Global Inc class B common.**
No dividends paid.

MOBILEYE GLOBAL INC
Earnings, 9 mos. to (Consol. - \$000):

	09/30/23	10/01/22
Total revenues	1,442,000	1,304,000
Cost & expenses	1,548,000	1,365,000
Operating income	(106,000)	(61,000)
Interest income	9,000	...
Interest expense	20,000	...
Other income (expense), net	38,000	6,000
Net before taxes	(68,000)	(66,000)
Income taxes	22,000	46,000
Net income	(90,000)	(112,000)
Earnings common share		
Primary	\$(0.11)	\$(0.15)
Fully Diluted	\$(0.11)	\$(0.15)
Common Shares:		
Full Diluted	804,000	750,000
Year-end	805,664	51,912

MODULAR MEDICAL, INC
Earnings, 9 mos. to Dec 31(Consol. - \$):

	2023	2022
Cost & expenses	13,210,000	10,306,098
Operating income	(13,210,000)	(10,306,098)
Other income (expense), net	23,000	16
Net before taxes	(13,187,000)	(10,306,082)
Income taxes	2,000	1,600
Net income	(13,189,000)	(10,307,682)
Earnings common share		
Primary	\$(0.64)	\$(0.95)
Fully Diluted	\$(0.64)	\$(0.95)
Common Shares:		
Full Diluted	20,708,000	10,863,082
Year-end	21,299,000	10,932,098

MONTAUK RENEWABLES INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	¹ 2021 (revised)
Total operating revenues	174,904
Total operating revenues	174,904	205,559	148,127
Operating & maintenance expenses	59,762	57,267	49,477
General & administrative expenses	34,403	34,139	42,552
Royalties, transportation, gathering & production fuel	34,861	44,163	28,683
Depreciation & amortization	21,158	20,700	22,869

				2023	2022	¹ 2021 (revised)
Gain on insurance proceeds	...	(313)	(332)	2,819
Impairment loss	...	4,852	1,191	90,175	124,868	...
Transaction costs	178	185	352	423	407	319
Total operating expenses	151,264	160,993	144,792	748	595	319
Operating profit	23,640	44,566	3,335	30,329	29,268	81
Interest expense	5,753	1,792	2,928	255,421	247,631	198
Loss on extinguishment of debt	(154)	35,526	34,526	488
Impairment of tangible assets	902	67,747	20,745	598
Other income (expense)	479	468	(620)	389,771	332,765	5,611
Total other income (expenses)	(5,274)	(1,324)	(3,702)	175,482	156,819	5,341
Income (loss) before income taxes	18,366	43,242	(367)	214,289	175,946	6,579
Current federal income taxes (benefit)	1,006	321	...	18,421	15,755	12,226
Current state income taxes (benefit)	536	1,109	(91)	2,076	3,952	18,443
Total current income taxes (benefit)	1,542	1,430	(91)	470	936	(11,907)
Deferred federal income taxes (benefit)	1,869	6,446	3,368	4,313	4,742	(17,851)
Deferred state income taxes (benefit)	7	172	884	36	96	(17,851)
Total deferred income taxes (benefit)	1,876	6,618	4,252	10,138	...	(17,851)
Income tax expense (benefit)	3,418	8,048	4,161	9,897	5,614	...
Net income (loss)	14,948	35,194	(4,528)	350,238	332,316	(284)
Weighted average shares outstanding - basic	141,728	141,239	141,015	7,916	4,559	...
Weighted average shares outstanding - diluted	142,152	142,579	141,015	3,983	3,221	(761)
Year end shares outstanding	141,986	141,633	141,015	2,355	1,561	(1,252)
Net income (loss) per share - basic	\$0.11	\$0.25	\$(0.03)	...	7,836	...
Net income (loss) per share - diluted	\$0.11	\$0.25	\$(0.03)	...	1,605	(42)
Number of full time employees	151	...	² 132	...	867	(18)
Total number of employees	151	² 137	...	5,550	...	(42)
Number of common stockholders	12	² ³ 11	² ⁴ 11	12,789	15,090	(18,597)
Earnings per share from continuing operations	\$0.11	420	410	(18,597)
Earnings per share from continuing operations	\$0.11	26	71	(25,178)
				313	402	(25,178)
				7,886	7,870	² 216
				901	...	² 216
				29,350	28,402	² 311
				55,614	72,000	³ 161
				...	8,000	...
				...	(495)	...
				...	63,505	...
				4,133	4,341	...
				10	25	...
				5,900	5,493	...
				4,992	3,459	...
				99,999	105,225	...
				1,420	1,416	...
				11,173	11,051	...
				214,378	206,060	...
				45,614	30,666	...
				250,239	227,091	...
				250,239
Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):						
	2023	2022				
Cash & cash equivalents	73,811	105,177				
Restricted cash	8	...				
Other receivables	148	57				
Accounts receivables	12,557	7,148				
Reimbursable expenses	12,752	17				
Accounts & other receivables, net	...	7,222				
Related party receivable	...	9,000				
Current portion of derivative instruments	785	879				
Prepaid expenses & other current assets	47	2,590				
Prepaid expenses and						
Recent Dividends:						
1. Montauk Renewables Inc common.						
No dividends paid.						
Annual Dividends:						
1. Montauk Renewables Inc common.						
No dividends paid.						
MOTUS GI HOLDINGS INC Annual Report						
Consolidated Income Statement, Years Ended Dec. 31 (\$000):						
Revenue	319			
Revenue	319	592	391			
Costs of revenue-sales	81	198	181			
Costs of revenue-impairment of inventory	488	598	443			
Research & development expenses	3,467	5,611	5,341			
Sales & marketing expenses	1,611	4,425	3,077			
General & administrative expenses	6,579	7,611	9,273			
Total costs & expenses	12,226	18,443	18,315			
Operating income (loss)	(11,907)	(17,851)	(17,924)			
Gain (loss) on change in estimated fair value of contingent royalty obligation	103	548	(143)			
Gain (loss) on extinguishment of debt	(284)	...	(237)			
Finance income (expense), net	(761)	(1,252)	(717)			
Other income	5			
Foreign currency gain (loss)	(18)	(42)	(17)			
Income (loss) before income taxes	(12,867)			
Net income (loss)	(12,867)	(18,597)	(19,033)			
Deemed dividends from warrant issuance	6,145			
Net loss attributable to common shareholders	...	(18,597)	(25,178)			
Weighted average shares outstanding - basic	810	² 216	³ 156			
Weighted average shares outstanding - diluted	810	² 216	³ 156			
Year end shares outstanding	1,547	² ³ 311	³ ⁵ 161			
Net earnings (loss) per common share - basic	\$(15.89)	² \$(86.10)	³ \$(161.10)			
Net earnings (loss) per common share - diluted	\$(15.89)	² \$(86.10)	³ \$(161.10)			
Number of full time employees	15	43	³ 30			
Number of part time employees	...	6	...			
Number of common stockholders	289	⁶ ⁸ 122	⁶ ⁷ ⁹ 143			
EPS - Basic - excluding Extraordinary Items			
Applicable to Common - Total	\$(15.89)			
EPS - Diluted - excluding Extraordinary Items			
Applicable to Common - Total	\$(15.89)			
Total number of employees	15			

¹ Reclassified to conform with 2022 presentation; ² As is; ³ As of March 8, 2023; ⁴ As of March 5, 2022

¹ Reclassified to conform with 2022 presentation; ² Adjusted for 1-for-15 stock split, November 2, 2023; ³ Adjusted for 1-for-20 stock split, July 26, 2022; ⁴ Shares increased due to the effect of issuance of common shares pursuant to the market registered offering, issuance of common shares upon vesting of restricted stock units & for board of directors' c; ⁵ Shares increased due to the effect

fect issuance of shares for public offering, exercise of warrants, board of director's compensation, vesting of restricted stock units and to consultants; [□] As is; [□] Approximately; [□] As of February 14, 2023; [□] Unamortized debt discount - long-term debt:

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	4,958	14,042
Accounts receivable	76	59
Raw materials	487	697
Work-in-process	196	155
Finished goods	541	548
Inventory reserve	728	401
Inventory, non-current	(251)	(511)
Inventory, current	245	488
Prepaid expenses & other current assets	478	781
Total current assets	5,757	15,370
Office equipment	171	171
Computers & software	321	321
Machinery	1,155	1,049
Lab & medical equipment	1,489	1,477
Leasehold improvements	200	200
Fixed assets, gross	3,336	3,218
Less: accumulated depreciation & amortization	2,344	1,893
Fixed assets, net	992	1,325
Inventory, non-current	251	511
Right-of-use assets	210	428
Other non-current assets	13	13
Total assets	7,223	17,647
Accounts payable & accrued expenses	1,842	1,969
Operating lease liabilities - current	169	245
Other current liabilities	226	53
Current portion of long-term debt, net	1,033	2,532
Total current liabilities	3,270	4,799
Contingent royalty obligation	...	1,212
Operating lease liabilities - non-current	27	178
Convertible note	...	[□] 3,892
Long-term debt	1,239	[□] 4,589
Total liabilities	4,536	14,670
Common stock	0	...
Additional paid-in capital	156,905	144,328
Retained earnings (accumulated deficit)	(154,218)	(141,351)
Total shareholders' equity (deficit)	2,687	2,977
Total Equity	2,687	...

[□] Unamortized debt discount - convertible note: \$108,000; [□] Unamortized debt discount - convertible note: \$135,000

Recent Dividends:

1. Motus GI Holdings Inc preferred.

No dividends paid.

2. Motus GI Holdings Inc common.

No dividends paid.

Annual Dividends:

1. Motus GI Holdings Inc preferred.

No dividends paid.

2. Motus GI Holdings Inc common.

No dividends paid.

MSC INCOME FUND INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	[□] 2021 (revised)
Interest, fee & dividend income - control investments	...	3,223	2,810
Interest, fee & dividend income - affiliate investments	...	24,057	18,244
Interest, fee &			

dividend income - non-control or non-affiliate investments	76,485	69,074	...	80,269	79,993	79,874	
Non-Control/Non-Affiliate investments	98,480	80,269	79,993	79,874	
Affiliate investments	29,805	80,109	80,106	79,827	
Control investments	3,101	Net investment income per share - basic	\$0.72	\$0.66	\$0.67
Total investment income	131,386	103,765	90,128	Net investment income per share - diluted	\$0.72	\$0.66	\$0.67
Interest expense	36,458	24,423	14,469	Net increase (decrease) in net assets resulting from operations per share - basic	\$0.82	\$0.57	\$0.92
Base management fees	...	19,831	17,316	Net increase (decrease) in net assets resulting from operations per share - diluted	\$0.82	\$0.57	\$0.92
Incentive fees	19,828	2,130	557	Distributions per share	\$0.70	\$0.65	\$0.53
Internal administrative service expenses	8,916	5,147	4,317	Number of common stockholders	14,292	[□] 14,654	^{□□} 14,568
General & administrative expenses	4,254	3,905	4,427	Income tax provision	3,769
Incentive fees	12,569	Full-Time Employees (Period End)	0
Total net unrealized appreciation (depreciation)	46,319	Total number of employees	0
Waiver of internal administrative services expenses	8,308	4,540	4,317				
Total expenses, net of fee and expense waivers	73,717	50,896	36,769				
Net investment income	57,669	52,869	53,359				
Net realized appreciation (depreciation) - control investments	2,223	[□] Reclassified to conform with 2022 presentation; [□] As of March 13, 2023; [□] As is; [□] As of March 14, 2022			
Net realized appreciation (depreciation) - affiliate investments	(7,188)	(7,327)	(2,673)	Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):			
Net realized appreciation (depreciation) - non-control or non-affiliate investments	(29,045)	3,391	2,175				
Realized loss on extinguishment of debt	(2,430)	Investments at fair value - control investments	53,644	[□] 50,303	
Total net realized gain (loss)	(34,010)	(3,936)	(2,928)	Investments at fair value - affiliate investments	291,279	[□] 277,000	
Net unrealized appreciation (depreciation) - control investments	(1,289)	1,503	2,001	Investments at fair value - non-control/non-affiliate investments	747,972	[□] 740,840	
Net unrealized appreciation (depreciation) - affiliate investments	25,116	15,689	10,237	Cash & cash equivalents	30,786	21,312	
Net unrealized appreciation (depreciation) - non-control or non-affiliate investments	22,492	(18,894)	12,857	Interest & dividend receivable	10,541	11,917	
Total net unrealized appreciation (depreciation)	...	(1,702)	25,095	Receivable for securities sold	171	464	
Federal & state income, excise & other taxes	872	(1,281)	(1,890)	Deferred financing costs	3,416	[□] 2,908	
Deferred taxes	2,897	Prepaid & other assets	2,091	2,420	
Deferred taxes	...	(362)	...	Total investments	1,092,895	...	
Net increase (decrease) in net assets resulting from operations	66,209	45,588	73,636	Total assets	1,139,900	1,107,164	
Weighted average shares outstanding				Credit facilities	...	321,688	
				Series A notes due 2026	149,155	[□] 148,856	
				Accounts payable & other liabilities	255	1,142	
				Payable for securities purchased	206	...	
				Interest payable	6,266	5,443	
				Dividends payable	14,019	12,816	
				Management & incentive fees payable	8,745	7,192	
				Deferred tax liability, net	3,259	362	
				Debt	335,688	...	
				Deferred Tax - Credit - Liability	13,558	...	
				Deferred Tax - Debit - Liability	(10,299)	...	
				Total liabilities	517,593	497,499	
				Common stock	80	80	
				Additional paid-in-capital	686,136	684,165	
				Total overdistributed earnings	(63,909)	(74,580)	
				Net assets	...	609,665	
				Net assets value per share	\$7.77	\$7.61	
				Total net assets	622,307	...	
				Total Equity	622,307	...	

□ Cost - control investments: \$31,120,000; □ Cost - affiliate investments: \$241,565,000; □ Cost - non-control or non-affiliate investments: \$787,201,000; □ Net of accumulated amortization - deferred financing costs: \$2,413,000; □ Par - series A notes due 2026: \$150,000,000

Recent Dividends:**1. MSC Income Fund Inc common.**

No dividends paid.

Annual Dividends:**1. MSC Income Fund Inc common.**

No dividends paid.

MSC INCOME FUND INC**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2023	2022
Cost & expenses	53,997	35,021
Net income	42,629	38,770
Earnings common share		
Primary	\$0.53	\$0.48
Fully Diluted	\$0.53	\$0.48
Common Shares:		
Full Diluted	80,246	79,960
Year-end	80,014	80,059

MUELLER (PAUL) CO**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
Net sales	229,156,000	191,520,000	184,613,000
Cost of sales	158,625,000	152,286,000	136,167,000
Gross profit	70,531,000	39,234,000	48,446,000
Selling, general & administrative expenses	88,269,000	35,011,000	43,884,000
Operating income (loss)	(17,738,000)	4,223,000	4,562,000
Interest income	2,535,000	907,000	376,000
Interest expense	350,000	697,000	742,000
PPP loan forgiveness			1,884,000
Other income (expense), net	131,000	208,000	2,468,000
Total other income (expense)			3,986,000
Income (loss) before provision (benefit) for income taxes	(15,422,000)	4,641,000	8,548,000
Current tax expense (benefit)	3,698,000	201,000	(245,000)
Deferred, net	(9,230,000)	831,000	1,792,000
Provision (benefit) for income taxes	(5,532,000)	1,032,000	1,547,000
Net income (loss)	(9,890,000)	3,609,000	7,001,000
Weighted average shares outstanding - basic	1,085,711	1,085,711	1,091,202
Weighted average shares outstanding - diluted	1,085,711	1,085,711	1,091,202
Year end shares outstanding	1,085,711	1,085,711	1,086,661
Earnings (loss) per share from continuing operations - basic	\$(9.11)	\$3.32	
Net earnings (loss) per share - basic	\$(9.11)	\$3.32	\$6.42
Net earnings (loss) per share - diluted	\$(9.11)	\$3.32	\$6.42
Dividends per share	\$0.60	\$0.60	\$0.15
Total number of employees		848	878
Foreign currency translation adjustments			(1,889,000)
Total revenues	229,156,000	191,520,000	
Diluted EPS Excluding ExtraOrd Items	\$(9.11)	\$3.32	
Cost of revenues/COGS	158,625,000		

Average**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2023	2022
Cash in Hand & with Banks	1,883,000	
Cash & cash equivalents		38,176,000
Available-for-sale investments, at market	27,000	24,000
Accounts receivable, gross	25,681,000	21,119,000
Reserve for doubtful accounts	515,000	539,000
Accounts receivable	25,166,000	20,580,000
Inventories - raw materials & components	20,351,000	21,786,000
Inventories - work-in-process	15,923,000	17,910,000
LIFO Reserve	21,774,000	21,691,000
Finished Goods	9,636,000	8,819,000
Inventories (LIFO)	45,910,000	48,515,000
Other Current Assets	3,537,000	3,156,000
Marketable securities	32,042,000	
Total current assets	86,791,000	88,760,000
Land & land improvements	8,126,000	8,005,000
Buildings	28,279,000	27,392,000
Fabrication equipment	87,112,000	80,587,000
Transportation, office & other equipment	145,760,000	18,572,000
Construction-in-progress	3,025,000	5,272,000
Transportation, office and Other Equipment	19,218,000	
Property, plant & equipment, at cost		139,828,000
Less: accumulated depreciation	103,749,000	98,317,000
Net property, plant & equipment	42,011,000	41,511,000
Right of use for operating lease	1,215,000	1,361,000
Deferred tax assets	227,000	2,235,000
Other assets	1,206,000	2,806,000
Long-term net investment in sales-type lease	456,000	312,000
Other Assets	2,363,000	943,000
Total assets	134,269,000	137,928,000
Current maturities of long-term debt	640,000	628,000
Accounts payable	11,041,000	11,802,000
Current lease liability for operating	221,000	263,000
Current lease liability for financing	3,924,000	10,937,000
Accrued expenses - payrolls & benefits		4,521,000
Accrued payrolls & vacations		11,558,000
Other accrued expenses	5,099,000	3,635,000
Advance billings	27,383,000	41,288,000
Vacations	918,000	969,000
Current lease liability for financin	181,000	185,000
Payroll and benefit	8,122,000	
Income taxes payable	1,536,000	
Pension liabilities	32,000	
Total current liabilities	59,097,000	85,786,000
Long-term pension liabilities	233,000	236,000
Note payable	8,880,000	9,349,000
Other long-term liabilities	1,768,000	1,737,000
Operating lease liabilities	493,000	515,000
Capitalized Lease Obligations - Long-Term	282,000	247,000
Common stock	1,508,000	1,508,000
Paid-in surplus	9,708,000	9,708,000
Retained earnings	67,181,000	75,721,000
Treasury Stock	10,787,000	10,787,000
Accumulated other comprehensive income (loss)	(4,094,000)	(36,092,000)
Total shareholders'		

investment	63,516,000	40,058,000
Total Equity	63,516,000	40,058,000

Recent Dividends:**1. Mueller (Paul) Co common.**

ExDate	Amt	Declared	Record	Payable
11/18/2021	0.15	11/04/2021	11/19/2021	12/22/2021
02/24/2022	0.15	02/10/2022	02/25/2022	03/25/2022
05/23/2022	0.15	05/13/2022	05/24/2022	06/24/2022
08/26/2022	0.15	08/18/2022	08/29/2022	09/30/2022
11/21/2022	0.15	11/02/2022	11/22/2022	12/22/2022
02/27/2023	0.15	02/06/2023	02/28/2023	03/31/2023
05/26/2023	0.15	05/12/2023	05/30/2023	06/30/2023
08/28/2023	0.15	08/11/2023	08/29/2023	09/29/2023
11/22/2023	0.15	11/10/2023	11/24/2023	12/22/2023
02/22/2024	0.15	02/09/2024	02/23/2024	03/29/2024

Annual Dividends:**1. Mueller (Paul) Co common.**

2021	0.15	2022	0.60	2023	0.60
2024	0.15				

MULLEN AUTOMOTIVE INC**Earnings, 3 mos. to Dec 31 (Consol. - \$):**

	2023	2022
Cost & expenses	59,404,019	68,823,693
Operating income	(59,404,019)	(73,618,020)
Interest expense	258,023	
Other income (expense), net	(6,133,565)	(302,014,636)
Gains or losses	75,990	
Net before taxes	(65,719,617)	
Income taxes	(1,726,238)	
Net income	(63,993,379)	(378,460,745)
Balance for common	(61,416,201)	(376,914,463)
Earnings common share		
Primary	\$(15.32)	\$(6,300.00)
Fully Diluted	\$(15.32)	\$(6,300.00)
Common Shares:		
Full Diluted	4,007,791	60,470
Year-end	5,884,691	75,274

Consolidated Balance Sheet Items, as of (\$):

	2023
Assets:	
Cash & equivalents	81,512,264
Inventories	30,719,529
Current assets	143,522,220
Net property & equip.	86,916,241
Total assets	381,176,520
Liabilities:	
Current liabilities	96,439,402
Stockholders' equity	210,557,005
Net current assets	47,082,818

MUNCY COLUMBIA FINANCIAL CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2023	2022	2021
Interest & dividend income on interest & fees on loans - taxable		20,604	20,634
Interest & dividend income on interest & fees on loans - tax-exempt		675	725
Interest & dividend income on investment securities - taxable	917	4,321	2,343
Interest & dividend income on investment securities - tax-exempt	318	185	229
Dividend & other interest income on investment securities	5,030	198	213
Interest & dividend income on			

federal funds sold	1	20	1	Currently payable	565	1,560	2,240	mortgages	241,179
Interest & dividend income on deposits in other banks	227	385	128	Deferred tax expense (benefit)	(200)	66	108	Consumer real estate - construction	7,430
Tax-exempt and dividends on investment	969	Income tax provision	365	1,626	2,348	Installment loans to individuals	5,824
Interest and fees on loans-Taxable	30,885	Net income	3,387	9,514	9,405	Loans, net of unearned income	1,068,429	527,729
Total interest & dividend income	38,347	26,388	24,273	Weighted average shares outstanding - basic	2,280	2,078	2,077	Less: allowance for loan losses	9,302	7,279
Interest expense on deposits	4,964	1,773	1,923	Weighted average shares outstanding - diluted	2,280	2,078	2,077	Loans, net	1,059,127	520,450
Interest expenses on short-term borrowings	2,286	322	Year end shares outstanding	3,570	2,079	2,078	Operating lease right-of-use asset	298
Interest expense on long-term borrowings	9,119	2	2	Net income per share - basic	\$1.49	\$4.58	\$4.53	Land	6,684	2,577
Interest expense on junior subordinate debentures	1,002	Net income per share - diluted	\$1.49	\$4.58	\$4.53	Premises	28,846	16,323
Total interest expense	15,085	4,061	2,247	Cash dividends per common share	\$1.71	\$1.67	\$3.13	Furniture & equipment	50,961	11,829
Net interest income (Credit) provision for credit losses - off balance sheet credit exposures	23,262	22,026	22,026	Number of full time employees	270	Leasehold improvements	4
Provision (credit) for loan losses	2,554	(1,810)	120	Number of part time employees	Total Construction In Progress	550	...
Net interest income after provision (credit) for loan losses	20,741	24,137	21,906	Number of common stockholders	788	Improvements	249	...
Service charges & fees	2,117	1,185	Brokerage fees	636	Furniture and equipment	14,632	...
Gain on sale of loans	276	478	1,837	TOTAL PROVISION (CREDIT) FOR CREDIT LOSSES	2,521	Premises & equipment, gross	30,733
Earnings on bank-owned life insurance	503	652	421	Losses on marketable equity securities	(119)	Less: accumulated depreciation & amortization	23,392	18,219
Brokerage income	1,839	597	599	Total number of employees	270	Other premises & equipment, net	27,569	12,514
Trust income	885	845	901	□ As is	Accrued interest receivable	5,362	2,222
Gain (loss) on equity securities	(37)	164	Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):	...	2023	2022	Cash surrender value of bank-owned life insurance	21,859
Investment securities gains (losses)	(1,236)	...	Cash & due from banks	14,614	9,750	9,750	Investment in limited partnerships	5,828	3,745
Gain on sale of premises & equipment	149	Interest-bearing deposits in other banks	3,763	3,333	3,333	Core deposit	11,895	...
Bank card & credit card interchange fees	2,094	Federal funds sold	10,394	1	1	Goodwill	25,609	7,937
Interchange fees	1,720	1,788	Interest-bearing time deposits	979	Other assets	6,663	11,986
Other non-interest income	1,007	935	954	Total cash & cash equivalents	18,377	13,084	13,084	Bank-owned life insurance	40,209	...
Salaries	11,618	7,655	7,411	Obligation of U.S.Government Corporations & Agencies - mortgage-backed	140,358	126,065	126,065	Deferred Tax - Asset - Net	12,634	...
Employee benefits	2,751	2,140	Obligation of U.S.Government Corporations & Agencies - other	200,923	200,923	Foreclosed assets held for sale	170	...
Occupancy expenses	1,391	1,476	1,309	Obligations of state & political subdivisions	84,956	14,063	14,063	Other debt securities	276	...
Furniture & equipment expenses	2,070	1,757	1,504	Local Government Securities - AFS	187,712	Total assets	1,639,779	944,014
State shares tax	412	829	Investment debt securities, available for sale, at fair value	413,302	341,051	341,051	Interest bearing demand deposits	884,654	152,656
Professional fees	1,638	1,390	1,384	Investment equity securities, at fair value	1,077	1,077	Savings	308,570	223,312
Director's fees	326	314	335	Restricted securities	1,295	3,223	3,223	Time deposits	124,512
FDIC assessments	478	262	242	Loans held for sale	366	4,568	4,568	Time Deposits over \$100000	324,131	...
Telecommunications expense	323	351	395	Commercial, financial & agricultural loans	39,573	39,573	Noninterest-bearing deposits	266,015	181,845
Automated teller machine & interchange	340	338	321	Tax-exempt loans	30,679	30,679	Interest Bearing Demand Deposits	251,953	...
Other non-interest expenses	2,533	2,362	2,281	Commercial real estate - commercial mortgages	145,622	145,622	Total deposits	1,150,669	682,325
Pennsylvania shares tax	365	Commercial real estate - other construction & land development loans	18,649	18,649	Short-term borrowings	252,532	171,741
Merger-related expenses	3,028	Commercial real estate - secured by farmland	13,120	13,120	FHLB fixed rate community lending program	70,448	...
Total non-interest expense	24,110	19,068	18,151	Consumer real estate - home equity loans	13,391	13,391	Long-term borrowings	24
Income before income tax provision	3,752	11,140	11,753	Consumer real estate - home equity lines of credit	12,262	12,262	Accrued interest payable	2,358	187
				Consumer real estate - 1-to-4 family residential	Operating lease liability	298
								Other liabilities	9,947	3,497
								Total liabilities	1,485,954	858,072
								Common stock	4,794	2,930
								Surplus	83,343	30,030
								Retained earnings (accumulated deficit)	90,514	90,156
								Unrealized gains (losses) available for sale securities	(15,036)	(27,384)
								Accumulated other comprehensive income (loss)	(15,036)	(27,384)
								Treasury stock, at cost	9,790	9,790
								Total stockholders' equity	153,825	85,942
								Total Equity	153,825	...
								Recent Dividends:		
								1. Muncy Columbia Financial Corp common.		
								No dividends paid.		
								Annual Dividends:		
								1. Muncy Columbia Financial Corp common.		
								No dividends paid.		

NATURAL HEALTH TRENDS CORP.**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

2023 2022 2021

(revised)

Net sales 43,924,000 49,134,000 60,005,000

Revenues 43,924,000

Cost of sales 11,175,000 12,661,000 15,010,000

Gross profit (loss) 32,749,000 36,473,000 44,995,000

Commissions expense 18,414,000 20,747,000 25,578,000

Selling, general & administrative expenses 16,006,000 15,996,000 17,846,000

Total operating expenses 34,420,000 36,743,000 43,424,000

Income (loss) from operations (1,671,000) (270,000) 1,571,000

Other income (expense), net 2,416,000 872,000 (61,000)

Income (loss) before income taxes - domestic ... (982,000) (1,127,000)

Income (loss) before income taxes - foreign ... 1,584,000 2,637,000

Income (loss) before income taxes 745,000 602,000 1,510,000

Current federal income tax provision (benefit) 73,000 (16,000) (207,000)

Current state income tax provision (benefit) 13,000 9,000 9,000

Current foreign income tax provision (benefit) 269,000 195,000 267,000

Total current income tax provision (benefit) 355,000 188,000 69,000

Deferred federal income tax provision (benefit) (4,000) 58,000 309,000

Deferred state income tax provision (benefit) (5,000) 4,000 7,000

Deferred foreign income tax provision (benefit) (169,000) 39,000 40,000

Deferred tax provision (benefit) ... 101,000 356,000

Total deferred taxes (178,000)

Income tax provision (benefit) 177,000 289,000 425,000

Net income (loss) 568,000 313,000 1,085,000

Weighted average shares outstanding - basic 11,436,000 11,362,000 11,017,000

Weighted average shares outstanding - diluted 11,456,000 11,423,000 11,423,000

Year end shares outstanding 11,516,773 11,422,539 11,422,539

Income (loss) per share from continued operations - basic \$0.05

Net income (loss) per share - basic \$0.05 \$0.03 \$0.10

Income (loss) per share from continued operations - diluted \$0.05

Net income (loss) per share - diluted \$0.05 \$0.03 \$0.09

Cash dividends declared per common share \$0.80 \$0.80 \$0.80

Number of full time employees 138 136 138

Number of part time employees ... 4 2

Total number of employees 138 140 140

Number of common stockholders 110 90 90

Foreign currency translation adjustments ... (514,000) ...

Approximately; As of February 27, 2023; As of February 22, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

2023 2022

Cash 8,971,000

Cash & cash equivalents 56,178,000 69,667,000

Finished goods 3,473,000 3,653,000

Raw materials 855,000 890,000

Inventories, gross (35,000)

Less: inventory reserve for obsolescence ... 18,000

Inventories 4,293,000 4,525,000

Other current assets 3,758,000 3,359,000

Cash equivalents 47,207,000

Total current assets 64,229,000 77,551,000

Office equipment 456,000 462,000

Office software 979,000 986,000

Machinery 243,000 20,000

Furniture & fixtures ... 249,000

Leasehold improvements 760,000 981,000

Construction in progress 40,000 30,000

Property & equipment, at cost 2,478,000 2,728,000

Less accumulated depreciation & amortization 2,212,000 2,334,000

Property & equipment, net 266,000 394,000

Operating lease right-of-use assets 3,319,000 3,992,000

Restricted cash 39,000 79,000

Deferred tax assets 369,000 195,000

Other assets 869,000 606,000

Total assets 69,091,000 82,817,000

Accounts payable 990,000 810,000

Income taxes payable ... 2,972,000

Accrued commissions 2,067,000 2,943,000

Accrued sales returns ... 70,000

Accrued employee-related expense ... 737,000

Accrued warehousing, inventory-related & other expense 421,000 374,000

Deferred revenue 6,166,000 5,597,000

Accrued bonus payable 668,000

Amounts held in eWallets 3,945,000 4,895,000

Operating lease liabilities 1,146,000 1,135,000

Other taxes payable 3,716,000

Other current liabilities 784,000 905,000

Sales returns 81,000

Total current liabilities 19,984,000 20,438,000

Income taxes payable 5,054,000 9,098,000

Deferred tax liability 135,000 141,000

Operating lease liabilities 2,318,000 2,989,000

Total liabilities 27,491,000 32,666,000

Common stock 13,000 13,000

Additional paid-in capital 84,695,000 86,102,000

Retained earnings (accumulated deficit) (17,703,000) (9,056,000)

Accumulated other comprehensive income (loss) (1,069,000) (1,004,000)

Accumulated other comprehensive income (loss): foreign currency translation adjustments (1,057,000)

Treasury stock, at cost 24,336,000 25,904,000

Investments - Unrealized Gain/Loss (12,000)

Total Natural Health Trends stockholders' equity (deficit) 41,600,000 50,151,000

Total stockholders' equity (deficit) 41,600,000 50,151,000

equity (deficit) 41,600,000 50,151,000

Recent Dividends:**1. Natural Health Trends Corp. common.**

No dividends paid.

2. Natural Health Trends Corp. series A convertible preferred.

No dividends paid.

Annual Dividends:**1. Natural Health Trends Corp. common.**

No dividends paid.

2. Natural Health Trends Corp. series A convertible preferred.

No dividends paid.

NATURAL RESOURCE HOLDINGS INC (NEW)**Earnings, 9 mos. to Jan 31 (Consol. - \$):**

2024 2023

Cost & expenses 2,022,484 29,394

Operating income (2,022,484) (29,394)

Net before taxes (2,027,693) (35,156)

Net income (2,027,693) (35,156)

Earnings common share

Primary \$(0.42) \$(0.17)

Fully Diluted \$(0.42) \$(0.17)

Common Shares:

Full Diluted 4,811,709 209,502

Year-end 5,709,891 209,502

NATURALSHRIMP INC**Earnings, 9 mos. to Dec 31 (Consol. - \$):**

2023 2022

Total revenues 365,184

Net Sales 365,184 186,004

Cost & expenses 5,892,952 6,343,031

Operating income (7,935,000) (8,609,365)

Other income (expense), net (2,343,303) 3,761,194

Gains or losses 16,014

Net before taxes (10,347,034) (11,552,820)

Net income (10,347,034) (11,552,820)

Balance for common (10,820,775) (13,001,961)

Earnings common share

Primary \$(0.01) \$(0.02)

Fully Diluted \$(0.01) \$(0.02)

Common Shares:

Full Diluted 885,304,007 682,750,957

Year-end 994,965,427 751,322,954

NATURE'S SUNSHINE PRODUCTS, INC.**Annual Report****Consolidated Income Statement, Years Ended Dec. 31**

(\$000): 2023 2022 2021

(revised)

Net sales 445,320 421,910 444,084

Cost of sales 124,193 122,150 115,467

Gross profit 321,127 299,760 328,617

Volume incentives expenses ... 130,377 139,844

Selling, general & administrative expenses 167,058 153,125 154,103

Volume Incentives 135,320

Operating income 18,749 16,258 34,670

Interest & other income (expense), net 552 123 466

Interest expense 69 249 250

Foreign exchange gains (losses), net 970 (917) (3,064)

Total other income (expense) 1,453 (1,043) (2,848)

Income (loss) from continuing operations before provision for income taxes - domestic (15,962) (7,505) 14,932

Income (loss) from continuing operations before provision for income taxes - foreign 36,164 22,720 16,890

				Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):								
				2023		2022		Total shareholders' equity				
								159,540 147,047				
								159,540				
Income (loss) from operations before provision for income taxes	20,202	15,215	31,822	Cash & cash equivalents	82,373	60,032						
Current provision (benefit) for federal income taxes	1,875	2	...	Accounts receivable, gross	8,969	14,226	Recent Dividends:					
Current provision (benefit) for state income taxes	361	(48)	54	Less: allowance for doubtful accounts	142	120	1. Nature's Sunshine Products, Inc. common.					
Current provision (benefit) for foreign income taxes	9,605	6,725	5,690	Accounts receivable, net of allowance for doubtful accounts of \$636 and \$631, respectively	8,827	...	ExDate	Amt	Declared	Record	Payable	
Subtotal current provision (benefit) for income taxes	11,841	6,679	5,744	Accounts receivable, net	...	14,106	03/26/2021	1.00	03/10/2021	03/29/2021	04/09/2021	
Deferred provision (benefit) for federal income taxes	(8,277)	5,792	(5,679)	Raw materials	18,301	23,133	Annual Dividends:					
Deferred provision (benefit) for state income taxes	(490)	(13)	146	Work in process	1,218	1,713	1. Nature's Sunshine Products, Inc. common.					
Deferred provision (benefit) for foreign income taxes	712	2,207	1,404	Finished goods	47,376	43,103	2021.....1.00					
Subtotal deferred provision (benefit) for income taxes	(8,055)	7,986	(4,129)	Inventories	66,895	67,949	NCS MULTISTAGE HOLDINGS INC					
Provision (benefit) for income taxes	3,786	14,665	1,615	Prepaid expenses & other current assets	...	7,420	Annual Report					
Net income (loss)	16,416	550	30,207	Prepaid expenses and other	7,722	...	Consolidated Income Statement, Years Ended Dec. 31 (\$000):					
Net income (loss) attributable to noncontrolling interests	(1,340)	(940)	(1,354)	Total current assets	165,817	149,507	2023	2022	2021	(revised)		
Net income (loss) attributable to common shareholders	15,076	(390)	28,853	Land & improvements	351	668	Revenues - product sales					
Weighted average shares outstanding - basic	19,066	19,326	19,858	Buildings & improvements	32,853	32,055	...	105,859	83,223			
Weighted average shares outstanding - diluted	19,466	19,326	20,327	Machinery & equipment	31,539	31,577	...	49,773	35,279			
Year end shares outstanding	18,875	19,093	19,724	Furniture & fixtures	...	11,669	100,447			
Income (loss) per share from continuing operations - basic	\$0.79	Computer software & hardware	68,887	61,180	42,024			
Net income (loss) per share - basic	\$0.79	\$(0.02)	\$1.45	Property, plant & equipment, gross	139,756	137,149	142,471	155,632	118,502			
Income (loss) per share from continuing operations - diluted	\$0.77	Accumulated depreciation & amortization - property, plant & equipment	94,756	90,987	64,242	68,412	51,897			
Net income (loss) per share - diluted	\$0.77	\$(0.02)	\$1.42	Property, plant & equipment, net	45,000	46,162	Cost of product sales, exclusive of depreciation & amortization expense	22,626	26,816	18,130		
Dividends declared per common share	\$1.00	Operating lease right-of-use assets	13,361	16,145	Cost of services, exclusive of depreciation & amortization expense	86,868	95,228	70,027		
Full-Time Employees (Period End)	814	Restricted investment securities - trading	747	702	Selling, general & administrative expenses	56,518	58,338	49,094		
Total number of employees	814	800	850	Deferred income tax assets	15,064	6,859	Depreciation expenses	3,947	3,650	3,832		
Number of common stockholders	1,224	1,255	1,303	Other assets	9,784	10,403	Amortization expenses	669	669	669		
Foreign currency translation adjustments	...	(3,108)	(250)	Total assets	249,773	229,778	Income (loss) from operations	(5,531)	(2,253)	(5,120)		
Total revenues	445,320	Accounts payable	7,910	6,349	Interest expense, net	...	1,015	733		
Total comprehensive income (loss) attributable to common shareholders	13,042	Accrued volume incentives & service fees	22,922	21,830	Interest (expense) income, net	(586)		
				Salaries & employee benefits	17,053	7,786	Other income (expense), net	4,114	2,950	2,054		
				Sales, use & property tax	3,345	2,754	Foreign currency exchange (loss) gain	462	(283)	283		
				Convention & meeting costs	4,763	5,787	Provision for litigation	1,802		
				Other accrued liabilities	...	9,264	Total other income (expense)	2,188	1,652	1,604		
				Deferred revenue	1,794	2,255	Income (loss) before income tax - U.S. federal	1,256	(1,127)	(9,775)		
				Current installments of long-term debt & revolving credit facility	...	1,174	Income (loss) before income tax - foreign	(4,599)	526	6,259		
				Income taxes payable	6,418	4,117	Income (loss) before income tax - Current U.S. federal tax expense (benefit)	(114)	(291)	37		
				Current portion of operating lease liabilities	4,547	4,266	Current state tax expense (benefit)	54	116	(63)		
				Other	8,001	...	Current foreign tax expense (benefit)	(324)	260	193		
				Total current liabilities	76,753	65,582	Total current tax expense (benefit)	(384)	85	167		
				Liability related to unrecognized tax benefits	747	209	Deferred U.S. federal tax expense (benefit)	103		
				Long-term portion of operating lease liabilities	10,376	13,745						
				Deferred compensation payable	...	702						
				Long-term deferred income tax liabilities	1,401	1,439						
				Other liabilities	644	1,054						
				Liability related to unrecognized tax benefits	312	...						
				Total liabilities	90,233	82,731						
				Common stock	119,694	121,583						
				Retained earnings (accumulated deficit)	49,711	34,635						
				Noncontrolling interests	5,482	4,142						
				Accumulated other comprehensive income (loss)	(15,347)	(13,313)						

Reclassified to conform with 2022 presentation; As is; As of February 24, 2023; As of February 25, 2022

Diluted EPS			
Excluding ExtraOrd			
Items	\$(0.70)
Total number of employees.....	2,100

□ Reclassified to conform with 2022 presentation; □ Approximately; □ Full-time equivalent; □ As of February 20, 2023; □ As of February 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	342,488,000	263,180,000
Marketable securities, at fair value	72,715,000	174,809,000
Accounts receivable, net	131,227,000	119,711,000
Inventories	24,156,000	24,277,000
Prepaid assets	17,987,000	...
Prepaid expenses	15,237,000
Other current assets	8,239,000	8,077,000
Total current assets	596,812,000	605,291,000
Equipment	98,561,000	91,759,000
Leasehold improvements	49,227,000	44,418,000
Furniture & fixtures	12,274,000
Computer hardware & office equipment	32,259,000	32,843,000
Computer software	55,350,000	44,151,000
Construction in progress	3,612,000	8,984,000
Assets not yet placed in service	11,214,000	...
Subtotal property & equipment, gross	250,223,000	234,429,000
Less: accumulated depreciation	158,211,000	131,930,000
Property & equipment, net	92,012,000	102,499,000
Operating lease right-of-use assets	91,769,000	96,109,000
Intangible assets, net	373,128,000	408,260,000
Goodwill	522,766,000	522,766,000
Other assets	4,742,000	5,109,000
Total non-current assets	1,084,417,000	1,134,743,000
Total assets	1,681,229,000	1,740,034,000
Accounts payable	20,334,000	20,510,000
Accrued compensation	53,161,000	40,141,000
Accrued expenses & other liabilities	15,069,000	15,070,000
Current portion of equipment financing obligations	70,000
Current portion of operating lease liabilities	5,610,000	6,584,000
Pharma contract liabilities	2,130,000	7,557,000
Total current liabilities	96,304,000	89,932,000
Convertible senior notes, net	538,198,000	535,322,000
Operating lease liabilities	67,871,000	68,952,000
Other long-term liabilities	13,034,000	13,055,000
Deferred income tax liabilities, net	24,285,000	34,750,000
Total long term liabilities	643,388,000	652,079,000
Total liabilities	739,692,000	742,011,000
Common stock	127,000	127,000
Additional paid-in capital	1,190,139,000	1,160,882,000
Accumulated other comprehensive income (loss)	(1,674,000)	(3,899,000)
Retained earnings (accumulated deficit)	(247,055,000)	(159,087,000)
Total stockholders' equity	941,537,000	998,023,000
Total Equity	941,537,000	...

Recent Dividends:

1. NeoGenomics Inc series A redeemable convertible preferred.
No dividends paid.

2. NeoGenomics Inc common.
No dividends paid.
Annual Dividends:
1. NeoGenomics Inc series A redeemable convertible preferred.
No dividends paid.

2. NeoGenomics Inc common.
No dividends paid.

NEONODE INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	□2021 (revised)
Loss on purchase commitment	362,000
Net technology license sales	620,000
Non-recurring engineering	26,000	205,000	94,000
License revenue	4,470,000	4,787,000
Products revenue	3,803,000	995,000	955,000
Total revenues	4,449,000	5,670,000	5,836,000
Cost of revenues - non-recurring engineering	28,000	33,000
Cost of revenue - products	12,000	776,000	922,000
Cost of revenues - non-recurring revenue	4,168,000
Total cost of revenues	4,542,000	804,000	955,000
Total gross margin	(93,000)	4,866,000	4,881,000
Research & development	3,833,000	3,963,000	3,546,000
Sales & marketing expense	2,455,000	2,034,000	2,839,000
General & administrative expense	4,363,000	4,155,000	5,603,000
Total operating expenses	10,651,000	10,152,000	11,988,000
Operating income (loss)	(10,744,000)	(5,286,000)	(7,107,000)
Interest income (expense), net	730,000	100,000	(15,000)
Other income	6,000	21,000	...
Total other income (expense)	736,000	121,000	(15,000)
Income (loss) before income taxes - domestic	(4,453,000)	(5,570,000)
Income (loss) before income taxes - foreign	(712,000)	(1,552,000)
Income (loss) before provision for income taxes	(10,008,000)	(5,165,000)	(7,122,000)
Current foreign income tax expense (benefit)	115,000	118,000	146,000
Domestic Tax - Domestic	(1,054,000)
Income Taxes - Foreign - Deferred	(2,094,000)
Foreign valuation allowance	3,148,000
Provision for (benefit from) income taxes	115,000	118,000	146,000
Net income (loss) including noncontrolling interests	(10,123,000)	(5,283,000)	(7,268,000)
Less: net income (loss) attributable to noncontrolling interests	400,000	818,000
Net income (loss) attributable to Neonode Inc.	(10,123,000)	(4,883,000)	(6,450,000)
Weighted average shares outstanding - basic	15,322,000	13,632,000	11,907,000

Weighted average shares outstanding - diluted	15,322,000	13,632,000	11,907,000
Year end shares outstanding	15,359,481	14,455,765	13,575,952
Earnings (loss) per share from continuing operations - basic	\$(0.66)
Net income (loss) per share - basic	\$(0.66)	\$(0.36)	\$(0.54)
Net income (loss) per share - diluted	\$(0.66)	\$(0.36)	\$(0.54)
Number of full time employees	53	45	45
Number of part time employees	10	10
Total number of employees	53	55	...
Number of common stockholders	55	□37	□50
Foreign currency translation adjustments	68,000	...
Earnings per share from continuing operations	\$(0.66)

□ Reclassified to conform with 2022 presentation; □ As of February 8, 2023; □ As of February 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	16,155,000	...
Cash	14,816,000
Accounts receivable, net	917,000	...
Accounts receivable & unbilled revenue, gross	1,478,000
Less: allowance for doubtful accounts	□30,000
Accounts receivable & unbilled revenues, net	1,448,000
Raw materials	319,000	3,177,000
Work-in-process	192,000	414,000
Finished goods	99,000	236,000
Inventories, gross	610,000	...
Inventory	3,827,000
Prepaid insurance	140,000
Prepaid rent	108,000	91,000
VAT receivable	410,000	297,000
Advances to suppliers	114,000	...
Other prepaid expenses & other current assets	306,000	179,000
Total current assets	18,620,000	20,798,000
Computers, software, furniture & fixtures	1,336,000
Equipment	2,732,000	2,639,000
Computer Software & Equipment - Tangible Assets - Gross	1,513,000	...
Less: accumulated depreciation	3,905,000	...
Less: accumulated depreciation & amortization	3,693,000
Property & equipment, net	340,000	282,000
Operating lease right-of-use assets, net	54,000	118,000
Total assets	19,014,000	21,198,000
Accounts payable	334,000
Accrued payroll & employee benefits	941,000	951,000
Accrued returns & warranty	30,000	49,000
Accrued consulting fees	324,000	...
Accrued consulting fees & other accrued expenses	151,000
Accrued expenses	200,000
Contract liabilities	10,000	36,000
Trade accounts payable	440,000	...
Current portion of finance lease obligations	33,000	95,000

Current portion of operating lease obligations	54,000	83,000	discontinued operations	(2,829,000)	(1,083,000)	development	43,000	103,000	
Accrued product warranties	354,000	...	Income (loss) before income taxes	(1,575,000)	...	Computer equipment	...	43,000	
Total current liabilities	1,832,000	1,699,000	Net income (loss)	(1,575,000)	(7,106,000)	Furniture & fixtures	37,000	37,000	
Finance lease obligations, net of current portion	19,000	46,000	Less: undeclared deemed dividend attributable to noncontrolling interest	...	(276,000)	Leasehold Improvements	88,000	13,000	
Operating lease obligations, net of current portion	...	35,000	Net loss attributable to Nephros, Inc. shareholders	(1,575,000)	(7,382,000)	Computer Software & Equipment - Tangible Assets - Gross	103,000	...	
Total liabilities	...	1,780,000	Weighted average shares outstanding - basic	10,386,018	10,297,134	Property & equipment, gross	1,114,000	1,039,000	
Common stock	15,000	14,000	Weighted average shares outstanding - diluted	10,386,018	10,297,134	Less: accumulated depreciation	962,000	923,000	
Additional paid-in-capital	235,158,000	227,235,000	Year end shares outstanding	10,543,675	10,297,429	Property & equipment, net	152,000	116,000	
Accumulated other comprehensive income (loss)	(396,000)	(340,000)	Net income (loss) per share - continuing operations - basic	\$(0.15)	\$(0.42)	Lease right-of-use assets	1,807,000	984,000	
Retained earnings (accumulated deficit)	(217,614,000)	(207,491,000)	Net income (loss) per share - discontinued operations - basic	\$0.00	\$(0.28)	Intangible assets, net	381,000	423,000	
Total Neonode Inc. stockholders' equity (deficit)	17,163,000	19,418,000	Net income (loss) per share - diluted	\$(0.15)	\$(0.70)	Goodwill	759,000	759,000	
Total stockholders' equity	17,163,000	19,418,000	Net income (loss) per share - discontinued operations - diluted	\$0.00	\$(0.28)	License & supply agreement, net	271,000	402,000	
□ Approximately			Net income (loss) per share - continuing operations - diluted	\$(0.15)	\$(0.70)	Other asset	86,000	54,000	
Recent Dividends:			Number of full time employees	31	27	Total assets	11,861,000	10,999,000	
1. Neonode Inc series B preferred.			Total number of employees	31	...	Current portion of secured note payable	...	71,000	
No dividends paid.			Number of common stockholders	44	44	Accounts payable	...	740,000	
2. Neonode Inc series A preferred.			Number of beneficiary stockholders	...	1,600	Accrued bonus	...	76,000	
No dividends paid.			Foreign currency translation adjustments	...	(14,000)	Accrued directors' fees	...	126,000	
3. Neonode Inc common.			Earnings per share-inc from discontinued oper	\$0.00	...	Accrued legal	...	4,000	
No dividends paid.			Earn per share-inc from discont oper - diluted	\$0.00	...	Accrued sales commission	...	36,000	
Annual Dividends:			Comprehensive loss	(1,575,000)	...	Accrued sales tax payable	...	7,000	
1. Neonode Inc series B preferred.			□ Restated to reflect the discontinued operations of Pathogen Detection Systems business; □ Approximately			Accrued franchise tax	...	10,000	
No dividends paid.			Consolidated Balance Sheet, Years Ended Dec. 31 (\$):			Accrued other	...	26,000	
2. Neonode Inc series A preferred.						Accounts payable & accrued expenses	873,000	...	
No dividends paid.						Current portion of lease liabilities	442,000	316,000	
3. Neonode Inc common.						Capitalized Leases - Current Portion	4,000	...	
No dividends paid.						Current portion of lease liabilities	446,000	...	
NEPHROS INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$):						Total current liabilities	2,113,000	1,412,000	
	2023	2022	□2021 (revised)			Equipment financing, net of current portion	...	1,000	
Product revenues	14,110,000	9,929,000	10,065,000	31	27	Lease liabilities, net of current portion	1,390,000	705,000	
Royalty & other revenues	128,000	46,000	152,000	44	44	Lease Liabilities - Unspecified - Long -Term	1,390,000	...	
Total net revenues	14,238,000	9,975,000	10,217,000	...	1,600	Total liabilities	3,503,000	2,118,000	
Cost of goods sold	5,833,000	5,244,000	4,584,000	Common stock	10,000	10,000	
Gross margin (loss)	8,405,000	4,731,000	5,633,000	Additional paid-in capital	152,754,000	148,413,000	
Research & development expenses	873,000	1,255,000	1,498,000	...	(14,000)	Retained earnings (accumulated deficit)	(144,406,000)	(142,831,000)	
Depreciation & amortization expense	214,000	218,000	192,000	Subtotal of stockholders' equity	8,358,000	5,592,000	
Selling, general & administrative expenses	8,911,000	7,593,000	7,195,000	Noncontrolling interest	...	3,289,000	
Total operating expenses	9,998,000	9,066,000	8,885,000	Total stockholders' equity	8,358,000	8,881,000	
Operating income (loss) from continuing operations	(1,593,000)	(4,335,000)	(3,252,000)	Recent Dividends:			
Interest expense	2,000	20,000	41,000	1. Nephros Inc common.			
Interest income	64,000	14,000	10,000	No dividends paid.			
Extinguishment of PPP loan	482,000	Annual Dividends:			
Other income (expense), net	(44,000)	64,000	17,000	1. Nephros Inc common.			
Interest expense & amortization of debt discount	2,000	No dividends paid.			
Total other income (expense)	18,000	58,000	468,000	NET POWER INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$):			
Loss from continuing operations	(1,575,000)	(4,277,000)	(2,784,000)		2023	2022	□2021
Loss from discontinued operations				Cash & cash equivalents	4,307,000	3,634,000	...
				Accounts receivable, net	1,496,000	1,286,000	...
				Finished goods	2,144,000	2,709,000	...
				Raw materials	326,000	422,000	...
				Work in process	...	22,000	...
				Total gross inventory	2,470,000
				Inventory, net	...	3,153,000	...
				Prepaid expenses & other current assets	132,000
				Total current assets	8,405,000	8,261,000	...
				Manufacturing & research equipment	843,000	843,000	...
				Capitalized internal use software and website
				General & administrative expenses	53,944,000	5,796,015	632,131
				General & administrative expenses - related party	261,000	120,000	65,000
				Income (loss) from operations	(227,660,000)	(5,916,015)	(697,131)
				Change in fair value of derivative warrant liabilities	...	5,245,310	(6,742,750)
				Interest earned on investments held in trust account	...	4,898,432	18,341

Offering costs associated with derivative warrant liabilities	592,641	(Expense)	19,477,000	Total liabilities	41,572,572	
Loss upon issuance of private placement warrants	2,175,000	Other Income (Expense)	(31,000)	Class A ordinary shares subject to possible redemption	349,816,773	
Revenue	175,000	Gross profit (loss)	172,000	Class B ordinary shares	7,000	863	
Net income (loss)	(175,992,000)	4,227,727	(10,189,181)	Change in Earnout Shares liability and Warrant liability	26,515,000	Additional paid-in capital	851,841,000	...	
Total revenues	175,000	Net other income (expense)	45,961,000	Retained earnings (accumulated deficit)	(39,310,765)	
Net income (loss) attributable to non-controlling interest in subsidiary	...	(162,605)	391,892	Total operating expenses	227,832,000	Class B Common Stock	14,000	...	
Net income (loss) attributable to Rice Acquisition Corp. II	...	4,065,122	(9,797,289)	Project development	1,104,000	Shareholders equity	(66,853,000)	...	
Cost of Revenue	3,000	Shares used to calculate Diluted EPS - Total	213,065,335	Total Rice Acquisition Corp. II equity (deficit)	785,009,000	(39,309,902)	
Weighted average shares outstanding of class A ordinary shares - basic	...	34,502,500	20,412,350	Provision for Income Tax	(5,707,000)	Non-controlling interest in subsidiary	(228,287)	
Weighted average shares outstanding of class B ordinary shares - basic	...	8,625,000	7,984,399	EPS - Basic - including Extraordinary Items Applicable to Common - Total	\$(0.82)	Total shareholder's equity (deficit)	785,009,000	(39,538,189)	
Weighted average shares outstanding of class A ordinary shares - diluted	...	34,502,500	20,412,350	EPS - Diluted - including Extraordinary Items Applicable to Common - Total	\$(0.82)	Redeemable non-controlling interests in subsidiary	1,545,905,000	...	
Sales and marketing	2,660,000	Comprehensive Income - Attributable to Owners of Parent Company - Total	(98,760,000)	Recent Dividends:			
Option settlement - related party	79,054,000	Common Shareholders - Number	53	1. NET Power Inc class A ordinary.			
Weighted average shares outstanding of class B ordinary shares - diluted	...	8,625,000	7,984,399	□ From February 2, 2021 (date of inception); □ As of February 15, 2023; □ As of March 30, 2022							
Year end shares outstanding	213,065,335	43,127,500	43,127,500	Consolidated Balance Sheet, Years Ended Dec. 31 (\$):							
Net income (loss) per class A ordinary share - basic	...	\$0.09	\$(0.35)	Cash and cash equivalents	536,927,000	Consolidated Income Statement, Years Ended (\$000):			
Net income (loss) per class B ordinary share - basic	...	\$0.09	\$(0.35)	Cash	1,627,877	12/30/23	12/31/22	01/01/22 (revised)	
Net income (loss) per class A ordinary share - diluted	...	\$0.09	\$(0.35)	Due from related party	7,960	Net product sales	69,205	161,637	102,355
Net income (loss) per class B ordinary share - diluted	...	\$0.09	\$(0.35)	Prepaid expenses	1,777,000	272,546	2023	License fee	40,000
Full-Time Employees (Period End)	43	Other Current Assets	93,000	...	2022	Net sales	161,637	142,355
Total number of employees	43	2	2	Interest receivable	1,942,000	Total net revenues	69,205
Number of class A common stockholders	...	2	2	Short-Term Investments	100,000,000	Cost of sales	66,812	149,745	93,458
Number of class B common stockholders	...	4	4	Accounts receivables, net	58,000	Gross profit (loss)	2,393	11,892	48,897
Income from cont operations before income tax	(181,699,000)	Total current assets	640,797,000	1,908,383	...	Research & development expenses	9,164	10,624	7,241
Weighted average shares outstanding	213,065,335	Investments held in trust account	349,942,773	...	Intellectual property legal fees	42,572	20,421	19,494
Earnings per share from continuing operations	\$(0.82)	Intangible Assets, net	1,307,265,000	Selling, general & administrative expenses	12,414	14,347	10,779
Earnings per share from continuing operations	\$(0.82)	Property, Plant and Equipment, net	96,856,000	Total operating expenses	64,150	45,392	37,514
Research and development	27,080,000	Lease Right-of-Use Asset	2,212,000	Operating income (loss)	(61,757)	(33,500)	11,383
Research and development - related party	12,886,000	Goodwill	423,920,000	Interest income (expense), net	1,300	57	(568)
Depreciation and amortization	50,843,000	Total long-term assets	1,830,253,000	Other income (expense), net	60	74	643
Interest Income	Total assets	2,471,050,000	351,851,156	...	Total other income (expense), net	1,360	131	75
				Accounts payable	617,000	31,780	...	Income (loss) before provision (benefit) for income taxes - U.S.	(32,857)	12,016
				Accrued Liabilities	10,915,000	Income (loss) before provision (benefit) for income taxes - foreign	(512)	(558)
				Accrued Incentive Compensation	2,016,000	Income (loss) before provision (benefit) for income taxes	(60,397)	(33,369)	11,458
				Other Accrued Liabilities	1,465,000	Current state provision (benefit) for income taxes	1	1	27
				Accrued Liabilities - Balancing value	7,434,000	Current foreign provision (benefit) for income taxes	6,600
				Accrued expenses	4,986,852	Total current provision (benefit) for income taxes	1	1	6,627
				Due to related parties	142,000	Deferred federal
				Lease Liability	347,000				
				Total current liabilities	12,021,000	5,018,632	...				
				Deferred underwriting commissions in connection with the initial public offering	11,721,500	...				
				Derivative warrant liabilities	24,832,440	...				
				Asset retirement obligation	2,060,000				
				Lease Liability	1,808,000				
				Earnout shares liability	1,671,000				
				Warrant liability	55,920,000				
				Tax Receivable Agreement liability	8,937,000				
				Deferred taxes	57,719,000				

provision (benefit) for income taxes	(12,833)	(7,822)	(1,897)	Operating Lease Liabilities - Current Portion/Short-Term	617	...	unrealized gain (loss) on marketable securities	(1,351,000)	(173,000)	
Deferred state provision (benefit) for income taxes	(1,189)	(1,006)	(1,913)	Accrued expenses and other current liabilities - Balancing value	2,569	...	Total other income, net	3,823,000	154,000	
Deferred foreign provision (benefit) for income taxes	4	17	15	Capitalized Leases - Current Portion	90	...	Income (loss) before income taxes & equity in net income (losses) of equity method investee	158,000	(80,000)	19,740,000	
Change in valuation allowance	14,018	8,811	3,795	Total current liabilities	47,590	38,073	Current state & local income taxes provision (benefit)	144,000	
Provision (benefit) for income taxes	1	1	6,627	Note payable	447	Current federal income taxes provision (benefit)	2,808,000	
Net income (loss)	(60,398)	(33,370)	4,831	Less: current portion	(447)	Current income taxes provision (benefit)	11,000	...	2,952,000	
Weighted average shares outstanding - basic	244,118	231,487	218,171	Operating lease liabilities	1,213	1,744	Deferred state & local income taxes provision (benefit)	(39,000)	56,000	83,000	
Weighted average shares outstanding - diluted	244,118	231,487	225,589	Other liabilities	237	270	Deferred federal income taxes provision (benefit)	(360,000)	551,000	1,425,000	
Year end shares outstanding	253,593	232,557	230,113	Total liabilities	49,040	40,087	Deferred income taxes provision (benefit)	(399,000)	607,000	1,508,000	
Net income (loss) per common share - basic	\$(0.25)	\$(0.14)	\$0.02	Common stock	254	233	(LOSS) INCOME BEFORE SHARE OF NET LOSS OF EQUITY METHOD INVESTEE	546,000	
Net income (loss) per common share - diluted	\$(0.25)	\$(0.14)	\$0.02	Additional paid-in capital	307,328	250,428	Total income taxes provision (benefit)	(388,000)	607,000	4,460,000	
Number of full time employees	96	Retained earnings (accumulated deficit)	(283,823)	(223,425)	Share of net income (losses) of equity method investee	(2,003,000)	(1,639,000)	(999,000)	
Total number of employees	96	100	120	Total stockholders' equity (deficit)	23,759	27,236	Net income (loss)	(1,457,000)	(2,326,000)	14,281,000	
Number of common stockholders	16	13	14	Total Equity	23,759	...	Weighted average shares outstanding - basic	23,791,287	23,825,917	24,136,821	
Basic EPS Excluding ExtraOrdinary Items	\$(0.25)	Recent Dividends:				Weighted average shares outstanding - diluted	23,791,287	23,825,917	24,530,568
Diluted EPS Excluding ExtraOrd Items	\$(0.25)	1. Netlist Inc common.				Year end shares outstanding	23,553,908	23,863,639	23,792,212
As is; [2] Approximately; [3] As of February 21, 2023; [4] As of February 21, 2022				No dividends paid.				Earnings (loss) per share from continued operations - basic	\$(0.06)
Consolidated Balance Sheet, Years Ended (\$000):				Annual Dividends:				Net earnings (loss) per share - basic	\$(0.06)	\$(0.10)	\$0.59
	12/30/23	12/31/22		1. Netlist Inc common.				Earnings (loss) per share from continued operations - diluted	\$(0.06)
				No dividends paid.				Net earnings (loss) per share - diluted	\$(0.06)	\$(0.10)	\$0.58
Cash & cash equivalents	40,445	25,011		NETSOL TECHNOLOGIES INC				Cash dividends declared per share	\$0.10	\$0.10	\$0.10
Restricted cash	12,400	18,600		Earnings, 6 mos. to Dec 31(Consol. - \$):				Number of full time employees	2	2	3
Accounts receivable, gross	4,630	8,379			2023	2022	Number of consultants employees	2	2	
Less: allowances	68	137		Total revenues	29,480,122	25,096,477	Total number of employees	2	
Accounts receivable, net	4,562	8,242		Cost & expenses	28,102,661	29,650,006	Number of common stockholders	37	39	38	
Raw materials	4,133	8,223		Operating income	1,377,461	(4,942,705)	Number of beneficiary stockholders	1,200	1,300	
Work in process	274	185		Interest income	882,998	741,763	Reclassified to conform with 2022 presentation; [2] As of March 28, 2022; [3] As is; [4] As of March 23, 2023; [5] Approximately				
Finished goods	7,624	2,278		Interest expense	566,339	323,973	Consolidated Balance Sheet, Years Ended Dec. 31 (\$):				
Inventories	12,031	10,686		Other income (expense), net	576	97,113	2023 2022				
Prepaid expenses & other current assets	441	1,308		Gains or losses	28,344	28,344	Cash & cash equivalents				
Total current assets	69,879	63,847		Foreign currency	(148,870)	1,972,928	16,896,000 13,448,000				
Machinery & equipment	7,684	7,881		Net before taxes	1,545,826	(2,426,530)					
Computer equipment & software	614	2,477		Income taxes	271,948	413,404					
Leasehold improvements	770	781		Net income	1,273,878	(2,839,934)					
Furniture & fixtures	620		Earnings common share					
Construction in progress	8	6		Primary	\$0.04	\$(0.24)					
Computer Equipment and Software	2,015	...		Fully Diluted	\$0.04	\$(0.24)					
Property & equipment, gross	11,091	11,765		Common Shares:					
Less: accumulated depreciation & amortization	10,321	10,627		Full Diluted	11,359,338	11,263,869					
Property & equipment, net	770	1,138		Year-end	11,390,888	11,283,954					
Operating lease right-of-use assets	1,590	2,043		NETWORK-1 TECHNOLOGIES, INC							
Other assets	560	295		Annual Report							
Total assets	72,799	67,323		Consolidated Income Statement, Years Ended Dec. 31 (\$):							
Accounts payable	39,831	28,468			2023	2022					
Revolving line of credit	3,844	4,935									
Accrued payroll & related liabilities	1,346	1,588		Licenses revenue	2,601,000	...					
Accrued expenses & other current liabilities	1,862	2,635		Revenue	2,601,000	...					
Long-term debt due within one year	447		Costs of licenses	874,000	...					

Marketable securities, at fair value	28,571,000	34,991,000
Prepaid taxes	...	177,000
Other current assets	206,000	348,000
Total current assets	45,673,000	48,964,000
Patents, net of accumulated amortization	1,326,000	1,592,000
Equity investment	5,249,000	7,252,000
Operating leases right-of-use asset	16,000	161,000
Security deposits	13,000	...
Total other assets	6,604,000	9,005,000
Total assets	52,277,000	57,969,000
Accounts payable	125,000	507,000
Income taxes payable	...	115,000
Accrued payroll	378,000	317,000
Operating lease obligations - current	23,000	79,000
Other accrued expenses	297,000	587,000
Total current liabilities	823,000	1,605,000
Deferred tax liability	762,000	1,161,000
Operating lease obligation, non-current	...	94,000
Total liabilities	1,585,000	2,860,000
Common stock	235,000	239,000
Additional paid-in capital	67,446,000	66,939,000
Retained earnings (accumulated deficit)	(16,989,000)	(12,055,000)
Accumulated other comprehensive income (loss)	...	(14,000)
Total stockholders' equity	50,692,000	55,109,000
Total Equity	50,692,000	...

Recent Dividends:
1. Network-1 Technologies, Inc common.

ExDate	Amt	Declared	Record	Payable
03/15/2021	0.05	02/23/2021	03/16/2021	03/31/2021
09/20/2021	0.05	09/10/2021	09/21/2021	09/30/2021
03/08/2022	0.05	02/23/2022	03/09/2022	03/24/2022
09/19/2022	0.05	09/09/2022	09/20/2022	09/30/2022
03/14/2023	0.05	03/03/2023	03/15/2023	03/31/2023
09/18/2023	0.05	09/08/2023	09/19/2023	09/29/2023
03/14/2024	0.05	02/23/2024	03/15/2024	03/29/2024

Annual Dividends:
1. Network-1 Technologies, Inc common.

2021	0.10	2022	0.10	2023	0.10
2024	0.05				

NEUROGENE INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Research & development expense	44,394,000	41,129,000	39,162,000
General & administrative expense	11,189,000	17,968,000	21,536,000
Total operating expenses	55,583,000	59,097,000	...
Income (loss) from operations	(55,583,000)	(59,097,000)	(60,698,000)
Interest Expense on Financial Lease Liabilities	12,000
Interest expense	12,000
Interest income	2,951,000	1,582,000	...
Interest income	19,000
Foreign exchange gains (losses)	(1,000)
Other expenses	12,000
Other income (loss), net	(28,000)	(42,000)	6,000
Bargain purchase gain	(16,355,000)
Income before income taxes - U.S.	...	(57,557,000)	(60,692,000)
Net loss before

income taxes	(36,317,000)
Net income (loss)	(36,317,000)	(57,557,000)	(60,692,000)
Weighted average shares outstanding - basic	12,823,665	11,044,232	11,008,332
Weighted average shares outstanding - diluted	12,823,665	11,044,232	11,008,332
Year end shares outstanding	12,823,665	8,529,669	8,491,494
Net earnings (loss) per common share - basic	\$(2.83)	\$(5.20)	\$(5.50)
Net earnings (loss) per common share - diluted	\$(2.83)	\$(5.20)	\$(5.50)
Number of full time employees	91	56	...
Total number of employees	91	...	91
Number of common stockholders	...	6	5

□ Non-consolidated; □ Adjusted for 1-for-5 stock split, September 25, 2023; □ As of March 16, 2023; □ As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	148,210,000	37,887,000
Short-term investments	48,947,000	58,497,000
Other current assets	...	2,750,000
Prepaid expenses and other current assets	3,191,000	...
Total current assets	200,348,000	99,134,000
Leasehold improvements, cost	15,376,000	...
Laboratory equipment, cost	3,144,000	6,773,000
Less: accumulated amortization - laboratory equipment	...	1,926,000
Laboratory equipment, net	...	4,847,000
Furniture, fixtures, & IT equipment, cost	...	2,342,000
Less: accumulated amortization - furniture, fixtures, & IT equipment	...	1,026,000
Office furniture & equipment, gross	19,000	...
Total property and equipment, cost	268,000	...
And Software Development Costs
Total property and equipment, cost	234,000	...
Construction In Progress	6,142,000	...
Manufacturing equipment - Gross
Property & equipment, cost	25,183,000	9,115,000
Less: total accumulated amortization	...	2,952,000
Acc Depr/Imp of Property/Plant/Equipment	8,009,000	...
Property & equipment, net	17,174,000	6,163,000
Operating lease right-of-use asset	3,681,000	9,715,000
Long-term prepayments & deposits	98,000	...
Other non-current assets	764,000	936,000
Restricted cash	508,000	...
Total assets	222,573,000	115,948,000
Trade accounts payable	...	478,000
Accrued clinical & preclinical expenses	...	4,360,000
Accrued compensation & vacation	...	3,539,000
Other accrued liabilities	...	1,170,000
Operating lease liability	2,559,000	1,375,000
Finance lease liability	42,000	140,000
Other current liabilities	281,000	...
Accrued expenses and

other current liabilities	17,495,000	...
Total current liabilities	22,973,000	11,062,000
Non-current operating lease liability	12,302,000	10,322,000
Non-current finance lease liability	65,000	233,000
Other liabilities	203,000	...
Lease contingent value rights liability, non-current	1,006,000	...
Total liabilities	36,549,000	21,617,000
Additional paid-in capital	373,178,000	545,407,000
Retained earnings (accumulated deficit)	(187,154,000)	(451,055,000)
Accumulated other comprehensive income (loss)	...	(21,000)
Common stock	13	...
Total stockholders' equity	186,024,000	94,331,000
Total Equity	186,024,000	...

□ Non-consolidated

Recent Dividends:

1. Neurogene Inc common.

No dividends paid.

Annual Dividends:

1. Neurogene Inc common.

No dividends paid.

NEUROMETRIX INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Revenues	5,901,425
Revenues	5,901,425	8,256,073	8,253,493
Cost of revenues	1,954,012	2,505,833	2,331,833
Gross profit	3,947,413	5,750,240	5,921,660
Research & development	2,777,960	3,239,725	2,596,415
Sales & marketing	3,365,265	2,865,615	1,619,711
General & administrative	4,955,709	4,386,666	3,990,141
Total operating expenses	11,098,934	10,492,006	8,206,267
Income (loss) from operations	(7,151,521)	(4,741,766)	(2,284,607)
Total other income	364,929
Interest income	257,105	325,157	3,150
Net income (loss) before taxes	(6,529,487)
Net income (loss)	(6,529,487)	(4,416,609)	(2,281,457)
Net income (loss) applicable to common stockholders	...	(4,416,609)	(2,281,457)
Weighted average shares outstanding - basic	1,041,991	891,267	638,881
Weighted average shares outstanding - diluted	1,041,991	891,267	638,881
Year end shares outstanding	1,524,939	973,219	835,060
Income (loss) per common share from continuing operations - basic	\$(6.27)
Net income (loss) per common share - basic	\$(6.27)	\$(4.96)	\$(3.60)
Income (loss) per common share from continuing operations - diluted	\$(6.27)
Net income (loss) per common share - diluted	\$(6.27)	\$(4.96)	\$(3.60)
Number of full time employees	26	27	23
Total number of

employees.....	26
Number of common stockholders.....	42	[□] 45	[□] 48

[□] Reclassified to conform with 2022 presentation; [□] Adjusted for 1- for -8 stock split, November 22, 2023; [□] Shares increased due to the effect of issuance of common stock and vesting of restricted stock; [□] As of March 21, 2023; [□] Approximately; [□] As of January 27, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):			
	2023	2022	
Cash & cash equivalents.....	1,731,946	4,253,268	
Held-to-maturity securities.....	...	16,946,459	
Accounts receivable, gross.....	543,824	671,771	
Less: allowances - accounts receivable.....	25,000	25,000	
Accounts receivable, net.....	518,824	646,771	
Purchased components.....	1,151,381	982,129	
Finished goods.....	408,047	632,858	
Inventories.....	1,559,428	1,614,987	
Prepaid expenses & other current assets.....	779,039	645,502	
Available-for-sale securities.....	16,265,205	...	
Total current assets.....	20,854,442	24,106,987	
Computer & laboratory equipment.....	33,104	459,218	
Furniture & equipment.....	...	33,104	
Production equipment.....	296,180	296,180	
Leasehold improvements.....	70,918	58,128	
Computer and laboratory equipment.....	629,970	...	
Fixed assets, gross.....	1,030,172	846,630	
Less: accumulated depreciation.....	736,723	681,011	
Fixed assets, net.....	293,449	165,619	
Right to use asset.....	250,150	370,609	
Other long-term assets.....	26,400	26,400	
Total assets.....	21,424,441	24,669,615	
Accounts payable.....	215,509	368,082	
Accrued professional services.....	...	155,000	
Accrued compensation.....	298,534	249,224	
Accrued warranty.....	876,739	16,700	
Accrued sales tax.....	...	131,621	
Other accrued expenses.....	...	37,394	
Accrued expenses & compensation.....	...	589,939	
Other.....	41,888	...	
Compensation.....	346,245	...	
Warranty.....	9,400	...	
Sales tax.....	141,672	...	
Clinical.....	39,000	...	
Lease obligation, current portion.....	148,391	148,391	
Total current liabilities.....	1,240,639	1,106,412	
Lease obligation, net of current portion.....	92,485	207,516	
Total liabilities.....	1,333,124	1,313,928	
Convertible preferred stock.....	1	1	
Common stock.....	152	778	
Additional paid-in capital.....	229,960,346	226,934,774	
Retained earnings (accumulated deficit).....	(210,109,353)	(203,579,866)	
Accumulated other comprehensive income (loss).....	240,171	...	
Total stockholders' equity (deficit).....	20,091,317	23,355,687	
Rep Total Equity & Minority Interest.....	20,091,317	...	

Recent Dividends:

1. NeuroMetrix Inc series C convertible preferred. No dividends paid.
2. NeuroMetrix Inc series D convertible preferred. No dividends paid.
3. NeuroMetrix Inc series A1 Ū A4 convertible preferred.

No dividends paid.			
4. NeuroMetrix Inc common.			
No dividends paid.			
5. NeuroMetrix Inc series E convertible preferred.			
No dividends paid.			
6. NeuroMetrix Inc series F convertible preferred.			
No dividends paid.			
7. NeuroMetrix Inc series B convertible preferred.			
No dividends paid.			
Annual Dividends:			
1. NeuroMetrix Inc series C convertible preferred.			
No dividends paid.			
2. NeuroMetrix Inc series D convertible preferred.			
No dividends paid.			
3. NeuroMetrix Inc series A1 Ū A4 convertible preferred.			
No dividends paid.			
4. NeuroMetrix Inc common.			
No dividends paid.			
5. NeuroMetrix Inc series E convertible preferred.			
No dividends paid.			
6. NeuroMetrix Inc series F convertible preferred.			
No dividends paid.			
7. NeuroMetrix Inc series B convertible preferred.			
No dividends paid.			

NEUROONE MEDICAL TECHNOLOGIES CORP**Earnings, 3 mos. to Dec 31(Consol. - \$):**

	2023	2022
Total revenues.....	977,649	...
Cost & expenses.....	4,368,124	3,354,119
Operating income.....	(3,390,475)	(1,784,352)
Other income (expense), net.....	45,575	51,583
Net before taxes.....	(3,344,900)	(1,732,769)
Net income.....	(3,344,900)	(1,732,769)
Earnings common share		
Primary.....	\$(0.14)	\$(0.11)
Fully Diluted.....	\$(0.14)	\$(0.11)
Common Shares:		
Full Diluted.....	23,995,610	16,230,997
Year-end.....	24,831,090	16,238,464

Consolidated Balance Sheet Items, as of (\$):

	2023	2022
Assets:		
Cash & equivalents.....	2,680,985	...
Inventories.....	1,608,657	...
Current assets.....	5,093,007	...
Net property & equip.....	505,175	...
Total assets.....	5,822,378	...
Liabilities:		
Current liabilities.....	1,383,240	...
Stockholders' equity.....	4,418,156	...
Net current assets.....	3,709,767	...

NEXIEN BIOPHARMA INC**Earnings, 6 mos. to Dec 31(Consol. - \$):**

	2023	2022
Cost & expenses.....	75,431	147,347
Operating income.....	(99,436)	...
Net before taxes.....	(99,436)	...
Net income.....	(99,436)	(188,466)
Earnings common share		
Common Shares:		
Full Diluted.....	64,840,502	61,493,507
Year-end.....	65,272,196	62,022,196

NEXT MEATS HOLDINGS INC**Earnings, 6 mos. to Oct 31(Consol. - \$):**

	2023	2022
Total revenues.....	475,624	871,315
Cost & expenses.....	1,061,778	2,500,324
Operating income.....	(681,784)	(1,646,990)
Other income (expense), net.....	(57,379)	(78,213)
Net before taxes.....	(660,027)	(1,728,896)
Income taxes.....	...	341
Net income.....	(660,027)	(1,729,238)
Earnings common share		
Common Shares:		
Full Diluted.....	502,562,280	...
Year-end.....	462,705,290	...

NEXTDECADE CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022
Total revenues.....	475,624	871,315
Cost & expenses.....	1,061,778	2,500,324
Operating income.....	(681,784)	(1,646,990)
Other income (expense), net.....	(57,379)	(78,213)
Net before taxes.....	(660,027)	(1,728,896)
Income taxes.....	...	341
Net income.....	(660,027)	(1,729,238)
Earnings common share		
Common Shares:		
Full Diluted.....	502,562,280	...
Year-end.....	462,705,290	...

	2023	2022	[□] 2021 (revised)
General & administrative expenses.....	111,468,000	49,093,000	16,803,000
Development expense, net.....	4,891,000	4,101,000	1,615,000
Lease expense.....	6,141,000	1,119,000	905,000
Depreciation expense.....	168,000	162,000	184,000
Total operating expenses.....	122,668,000	54,475,000	19,507,000
Total operating income (loss).....	(122,668,000)	(54,475,000)	(19,507,000)
Gain (loss) on common stock warrant liabilities.....	(44,803,000)	(5,747,000)	(2,533,000)
Other income (expense), net.....	7,526,000	151,000	1,000
Loss on common stock warrant liabilities.....	(1,879,000)
Interest Expense - Net of Capitalized Interest.....	50,285,000
Loss on debt extinguishment.....	(9,531,000)
Total other income (expense).....	(98,972,000)	(5,596,000)	(2,532,000)
Net income attributable to non-controlling interest.....	59,379,000
Net income (loss).....	(221,640,000)	(60,071,000)	(22,039,000)
Net income (loss) attributable to NextDecade Corporation.....	...	(60,071,000)	(22,039,000)
Preferred stock dividends.....	20,484,000	24,282,000	18,294,000
Deemed dividends on convertible preferred stock.....	63,000
Net income (loss) attributable to common stockholders.....	(182,745,000)	(84,353,000)	(40,396,000)
Weighted average shares outstanding - basic.....	194,595,000	130,136,000	119,201,000
Weighted average shares outstanding - diluted.....	194,595,000	130,136,000	119,201,000
Year end shares outstanding.....	256,500,000	143,549,000	120,838,000
Net earnings (loss) per common share - basic.....	\$(0.94)	\$(0.65)	\$(0.34)
Net earnings (loss) per common share - diluted.....	\$(0.94)	\$(0.65)	\$(0.34)
Number of full time employees.....	147	102	57
Number of part time employees.....	...	7	4
Total number of employees.....	147
Number of common stockholders.....	68	[□] 66	[□] 71
Income from cont operations before income tax.....	(221,640,000)
Earnings per share from continuing operations.....	\$(0.94)
Earnings per share from continuing operations.....	\$(0.94)

[□] Reclassified to conform with 2022 presentation; [□] Approximately; [□] As of March 2, 2023; [□] As of March 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

2023 2022

Cash & cash equivalents	38,241,000	62,789,000
Prepaid subscriptions	...	423,000
Prepaid insurance	...	619,000
Other prepaid expenses & other current assets	...	107,000
Prepaid expenses & other current assets	2,089,000	1,149,000
Restricted cash	256,237,000	...
Derivative asset	17,958,000	...
Total current assets	314,525,000	63,938,000
Cash, cash equivalents & securities held in Trust	389,695,000	...
Computers	...	780,000
Furniture, fixtures & equipment	...	610,000
Leasehold improvements	...	101,000
Total fixed assets	...	1,491,000
Less: accumulated depreciation	1,174,000	1,006,000
Total fixed assets, net	...	485,000
Terminal & pipeline assets (not placed in service) - terminal	...	197,144,000
Terminal & pipeline assets (not placed in service) - pipeline	...	21,017,000
Total terminal & pipeline assets	...	218,161,000
Property, Plant & Equipment - Gross - Total	2,438,907,000	...
Corporate and other	7,518,000	...
Rio Grande LNG Facility	2,431,389,000	...
Property, plant & equipment, net	2,437,733,000	218,646,000
Operating lease right-of-use assets, net	170,827,000	1,474,000
Other non current assets	11,021,000	28,372,000
Total assets	3,323,801,000	312,430,000
Accounts payable	243,129,000	1,084,000
Employee compensation expense	9,270,000	6,650,000
Terminal asset costs	...	12,046,000
Permitting costs	...	279,000
Accrued legal services	...	3,124,000
Share-based compensation liability	6,851,000	182,000
Other accrued liabilities	781,000	903,000
Accrued liabilities & other current liabilities	...	23,184,000
Current operating lease liabilities	3,143,000	1,093,000
Accrued and other current liabilities - Balancing value	299,264,000	...
Rio Grande LNG Facility costs	268,821,000	...
Accrued interest payable	20,392,000	...
Total current liabilities	552,387,000	25,361,000
Note payable to stockholder	1,816,301,000	...
Non-current common stock warrant liabilities	1,818,000	6,790,000
Non-current operating lease liabilities	145,962,000	465,000
Other non-current liabilities	...	23,000,000
Non-current derivative liability	66,899,000	...
Total liabilities	2,583,367,000	55,616,000
Series A convertible preferred stock	...	73,026,000
Series B convertible preferred stock	...	73,408,000
Series C convertible preferred stock	...	56,009,000
Common stock	26,000	14,000
Treasury stock	14,214,000	4,587,000
Additional paid-in-capital	693,883,000	289,084,000
Retained earnings (accumulated deficit)	(391,772,000)	(230,140,000)
Total stockholders' equity (deficit)	287,923,000	54,371,000
Equity Minority

Interests/Equity	...
Non-Controlling Interests	452,511,000
Total Equity	740,434,000

Recent Dividends:

1. **NextDecade Corp common.**
No dividends paid.
 2. **NextDecade Corp series B convertible preferred.**
No dividends paid.
 3. **NextDecade Corp series A convertible preferred.**
No dividends paid.
 4. **NextDecade Corp series C convertible preferred.**
No dividends paid.
- Annual Dividends:**
1. **NextDecade Corp common.**
No dividends paid.
 2. **NextDecade Corp series B convertible preferred.**
No dividends paid.
 3. **NextDecade Corp series A convertible preferred.**
No dividends paid.
 4. **NextDecade Corp series C convertible preferred.**
No dividends paid.

NFINITI INC

Earnings, 3 mos. to Jan 31 (Consol. - \$):

	2024	2023
Cost & expenses	11,567	6,198
Operating income	(11,567)	(6,198)
Net before taxes	(11,567)	...
Net income	(11,567)	(6,198)
Earnings common share
Common Shares:
Full Diluted	120,000,000	120,000,000
Year-end	120,000,000	120,000,000

Consolidated Balance Sheet Items, as of (\$):

	2024
Assets:	...
Liabilities:	...
Current liabilities	145,593
Stockholders' equity	(145,593)
Net current assets	(145,593)

NI HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

	2023	2022	2021 (revised)
Net premiums earned	351,137	328,290	299,589
Fee & other income	...	1,453	1,775
Fixed income securities	11,506	9,226	8,489
Equity securities	1,118	1,485	1,221
Real estate	622	595	625
Cash & cash equivalents	579	30	4
Total gross investment income	13,825	11,336	10,339
Investment expenses	(3,369)	(3,516)	(3,208)
Net investment income	10,456	7,820	7,131
Net investment gains (losses)	2,124	(13,126)	15,479
Fee and other income	1,978
Direct Premium	401,945
Ceded Premium	(54,378)
Assumed Premium	3,570
Total revenues	365,695	324,437	323,974
Losses & loss adjustment expenses	244,412	294,432	216,379
Amortization of deferred policy acquisition costs	82,991	66,803	64,574
Other underwriting & general expenses	35,799	32,231	31,715
Goodwill impairment charge	6,756
Total expenses	369,958	393,466	312,668
Income (loss) before income taxes	(4,263)	(69,029)	11,306
Current tax provision (benefit) - federal	2,567	(11,280)	3,930
Current tax

provision (benefit) - state	278	(2)	354
Current income tax (benefit) provision	2,845	(11,282)	4,284
Deferred income tax expense (benefit)	(1,882)
Deferred tax (benefit) provision	...	(3,972)	(1,310)
Income tax expense (benefit)	963	(15,254)	2,974
Net income (loss)	(5,226)	(53,775)	8,332
Net income (loss) attributable to non-controlling interest	(250)	679	84
Net income attributable to NI Holdings, Inc.	(5,476)	(53,096)	8,416
Weighted average shares outstanding - basic	21,159	21,333	21,424
Weighted average shares outstanding - diluted	21,159	21,333	21,656
Year end shares outstanding	20,600	21,076	21,220
Net earnings (loss) per common share - basic	\$(0.26)	\$(2.49)	\$0.39
Net earnings (loss) per common share - diluted	\$(0.26)	\$(2.49)	\$0.39
Number of full time employees	219	230	204
Number of part time employees	...	3	3
Total number of employees	219	233	207
Common Shareholders - Number	533
Number of stockholders	...	558	575
EPS - Basic - excluding Extraordinary Items
Applicable to Common - Total	\$(0.26)
EPS - Diluted - excluding Extraordinary Items
Applicable to Common - Total	\$(0.26)

As is; Approximately; As of February 28, 2023; As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	56,693	47,002
Fixed income securities, at fair value	347,731	303,324
Equity securities, at fair value	27,767	52,393
Other investments	2,006	2,005
Total cash & investments	...	404,724
Premiums & agents' balances receivable	...	62,173
Deferred policy acquisition costs	34,120	29,768
Reinsurance premiums receivable	...	1,647
Reinsurance recoverables on losses	...	37,575
Income tax recoverable	...	13,964
Accrued investment income	2,763	2,456
Land	1,403	1,403
Building improvements	14,538	14,271
Electronic data processing equipment	1,441	1,310
Furniture & fixtures	2,953	2,919
Automobiles	1,319	1,310
Gross property & equipment, cost	21,654	21,213

Less: accumulated depreciation	11,757	11,370	equipment	15,000	141,000
Property & equipment, net	9,897	9,843	Total operating expenses	17,151,000	16,592,000	13,592,000
Deferred income taxes	8,413	9,005	Income (loss) from operations	5,953,000	3,888,000	2,272,000
Receivable from Federal Crop Insurance Corporation	17,404	15,462	Interest expense	487,000	411,000	430,000
Goodwill & other intangibles	17,250	PPP loan forgiveness gain	6,171,000
Other assets	10,965	10,365	Total other income (expense)	(411,000)	5,741,000
Premiums and agents balances receivable	74,058	...	Income (loss) before income taxes - domestic	990,000	6,072,000
Reinsurance recoverables on losses	48,969	...	Income (loss) before income taxes - foreign	2,487,000	1,941,000
Reinsurance premiums receivable	4,061	...	Income (loss) before income taxes ..	5,466,000	3,477,000	8,013,000
Total cash and investments	434,197	...	Current income tax expense (benefit) - federal	388,000	855,000	401,000
Goodwill and other intangibles	10,039	...	Current income tax expense (benefit) - state	75,000	55,000	17,000
Total assets	654,886	614,232	Current income tax expense (benefit) - foreign	491,000	557,000	441,000
Unpaid losses & loss adjustment expenses	190,459	Deferred income tax expense (benefit) - federal	(2,360,000)
Unearned premiums	148,513	Deferred income tax expense (benefit) - state	(241,000)
Accrued expenses & other liabilities	22,053	Deferred income tax expense (benefit) - foreign	239,000
Unpaid losses and loss adjustment expenses	217,119	...	Income tax expense (benefit)	(1,408,000)	1,467,000	859,000
Unearned Premiums	164,100	...	Net income (loss)	6,874,000	2,010,000	7,154,000
Accrued expenses and other liabilities	23,180	...	Weighted average shares outstanding-basic	2,722,135	2,685,378	2,664,586
Income tax payable	88	...	Weighted average shares outstanding-diluted ..	2,885,879	2,891,285	2,821,523
Lease Liabilities	1,837	...	Year end shares outstanding	2,690,633	2,690,633	2,672,064
Accrued expenses and other liabilities -	Earnings (loss) per share-continuing operations-basic	\$2.53
Balancing value	21,343	...	Net earnings (loss) per share-basic	\$2.53	\$0.75	\$2.68
Total liabilities	404,487	361,025	Earnings (loss) per share-continuing operations-diluted	\$2.38
Common stock	230	230	Net earnings (loss) per share-diluted	\$2.38	\$0.70	\$2.54
Additional paid-in capital	96,294	95,671	Number of full-time employees	733	782	782
Unearned employee stock ownership plan shares	698	941	Number of part-time employees	42	50	25
Retained earnings (accumulated deficit)	208,376	214,121	Number of common stockholders	590	^① 611	^② 628
Accumulated other comprehensive income (loss), net of income taxes	(21,384)	(29,286)	Total revenues	139,332,000
Treasury stock, at cost	35,177	28,818	Foreign currency translation adjustments	(426,000)	93,000
Non-controlling interest	2,758	2,230	Total number of employees	775
Total shareholders' equity	250,399	253,207	Net earnings (loss) per share-diluted	\$2.38
Total shareholders equity	250,399	...				

Recent Dividends:**1. NI Holdings Inc common.**

No dividends paid.

Annual Dividends:**1. NI Holdings Inc common.**

No dividends paid.

NORTECH SYSTEMS INC.**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
Net sales	139,332,000	134,123,000	115,168,000
Cost of goods sold	116,228,000	113,643,000	99,304,000
Gross profit	23,104,000	20,480,000	15,864,000
Selling expenses	3,598,000	3,719,000	2,361,000

	2023	2022	2021
General & administrative expenses	12,354,000	11,425,000	10,002,000

	2023	2022	2021
Restructuring expenses	327,000

	2023	2022	2021
Research & development expenses	1,199,000	1,463,000	483,000

	2023	2022	2021
Loss (gain) on abandonment of intangible asset	560,000

	2023	2022	2021
Gain (loss) on sale of property &

Raw materials	20,863,000	21,673,000
Work in process	1,033,000	1,238,000
Finished goods	934,000	671,000
Reserves	1,170,000	1,144,000
Other STOCKS	21,660,000	...
Inventories, net	22,438,000
Contract assets	14,481,000	9,982,000
Prepaid assets	1,334,000
Prepaid assets & other current assets	1,698,000	...
Total current assets	58,793,000	54,860,000
Land	148,000	148,000
Building & leasehold improvements	6,041,000	5,289,000
Manufacturing equipment	19,877,000	19,128,000
Office & other equipment	7,385,000	6,822,000
Accumulated depreciation	26,938,000	...
Less: accumulated depreciation & amortization	24,979,000
Property & equipment, net	6,513,000	6,408,000
Operating lease assets	6,917,000	7,850,000
Other intangible assets, net	263,000	422,000
Deferred taxes	2,641,000	...
Total assets	75,127,000	69,540,000
Current portion of finance lease obligations	356,000	390,000
Current portion of operating leases	1,033,000	1,155,000
Accounts payable	15,924,000	14,792,000
Accrued payroll & commissions	4,138,000	4,803,000
Other accrued liabilities	1,063,000	5,258,000
Customer Deposits	4,068,000	...
Total current liabilities	26,582,000	26,398,000
Long-term line of credit	6,853,000
Long-term finance lease obligations, net of current portion	209,000	565,000
Line of Credit	5,815,000	...
Long-tem operating lease obligations, net of current portion	6,763,000	7,549,000
Other long-term liabilities	414,000	95,000
Total long-term liabilities	13,201,000	15,062,000
Total liabilities	39,783,000	41,460,000
Preferred stock	250,000	250,000
Common stock	27,000	27,000
Additional paid-in capital	16,929,000	16,347,000
Accumulated other comprehensive income (loss)	(532,000)	(370,000)
Retained earnings (accumulated deficit)	18,670,000	11,826,000
Total shareholders' equity (deficit)	35,344,000	28,080,000
Total Equity	35,344,000	...

Recent Dividends:**1. Nortech Systems Inc. preferred.**

No dividends paid.

2. Nortech Systems Inc. common.

No dividends paid.

Annual Dividends:**1. Nortech Systems Inc. preferred.**

No dividends paid.

2. Nortech Systems Inc. common.

No dividends paid.

NORTHWEST BIOTHERAPEUTICS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
Research material sales	1,932,000
Research & other revenues	1,683,000	1,005,000
Total revenues	1,932,000	1,683,000	1,005,000

As of March 6, 2023; As of March 9, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	960,000	1,027,000
Restricted cash	715,000	1,454,000

	2023	2022
Accounts receivable, gross	19,637,000	16,309,000
Less allowances	358,000	334,000
Accounts receivable	15,975,000

	2023	2022
Accounts receivable - shareholder	19,279,000	...
Employee retention credit receivable	2,650,000

Research & development expenses	27,730,000	35,511,000	20,308,000
General & administrative expenses	29,710,000	33,353,000	33,399,000
Total operating costs & expenses	57,440,000	68,864,000	53,707,000
Income (loss) from operations	(55,508,000)	(67,181,000)	(52,702,000)
Change in fair value of derivative liabilities	3,644,000	(25,821,000)	239,347,000
Change in fair value of share liabilities	...	33,000	...
Gain on sale of intellectual property & equipment	(78,000)
Gain (loss) from extinguishment of debt	(5,403,000)	(2,691,000)	(165,000)
Interest expense related to outstanding notes - contractual interest	2,560,000	2,890,000	2,347,000
Interest expense related to outstanding notes - amortization of debt premium	287,000
Interest expense related to outstanding notes - amortization of debt discount	2,372,000	2,771,000	2,301,000
Total interest expenses related to outstanding notes	5,219,000	5,661,000	4,648,000
Interest expenses related to payable to Advent BioServices	140,000
Other interest expenses	22,000	407,000	223,000
Interest expense	5,241,000	6,068,000	5,011,000
Inducement expense	647,000
Foreign currency transaction gain (loss)	2,008,000	(3,304,000)	(1,696,000)
Change in fair value of convertible notes	(2,021,000)
Total other income (expense)	...	(37,851,000)	231,828,000
Net income (loss)	(62,599,000)	(105,032,000)	179,126,000
Deemed dividend related to warrant modification	1,774,000
Net income (loss) applicable to common stockholders	(64,373,000)
Weighted average shares outstanding - basic	1,119,191,000	1,015,852,000	873,517,000
Weighted average shares outstanding - diluted	1,119,191,000	1,015,852,000	873,517,000
Year end shares outstanding	1,175,500,000	1,068,394,000	948,445,000
Net income (loss) per common share - basic	\$(0.06)	\$(0.10)	\$0.21
Net income (loss) per common share - diluted	\$(0.06)	\$(0.10)	\$(0.06)
Number of full time employees	22	20	20
Total number of employees	22
Number of common

stockholders	46,111	45,152	41,900
Income from cont operations before income tax	(62,599,000)
Earnings per share from continuing operations	\$(0.06)
Earnings per share from continuing operations	\$(0.06)
Deferred Tax - Federal	(9,859,000)
Deferred Tax - State	(3,927,000)
Deferred Tax - Foreign	19,000
Change in valuation allowance	13,767,000

Full-time equivalent; Approximately; As of February 15, 2023; As of February 15, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	2,126,000	6,965,000
Prepaid expenses & other current assets	1,999,000	2,460,000
Total current assets	4,125,000	9,425,000
Computer and manufacturing equipment and software	2,776,000	...
Leasehold improvements	17,785,000	13,070,000
Office furniture & equipment	487,000	300,000
Computer & manufacturing equipment & software	21,134,000	2,238,000
Land in the U.K.	86,000	82,000
Property, plant & equipment, gross	...	15,690,000
Less: accumulated depreciation	3,856,000	2,272,000
Property, plant & equipment, net	17,278,000	13,418,000
Construction in progress	...	2,028,000
Right-of-use asset, net	4,183,000	4,189,000
Indefinite-lived intangible asset	1,292,000	1,292,000
Goodwill	626,000	626,000
Other assets	361,000	345,000
Total non-current assets	23,740,000	21,898,000
Total assets	27,865,000	31,323,000
Accounts payable & accrued expenses	...	10,687,000
Accounts payable & accrued expenses to related parties & affiliates	3,544,000	6,955,000
Convertible notes, net	...	135,000
Notes payable, net	3,944,000	15,403,000
Contingent payable derivative liability	9,188,000	8,668,000
Warrant liability	944,000	80,559,000
Investor advances	7,000	2,566,000
Share liability	483,000	678,000
Lease liabilities	314,000	354,000
Shares payable	10,244,000	...
Mortgage loan, net	3,765,000	...
Convertible notes at fair value	12,771,000	...
Total current liabilities	45,204,000	126,005,000
Notes payable, net of current portion, net	20,312,000	5,991,000
Lease liabilities, net of current portion	4,454,000	4,370,000
Contingent payment obligation	4,950,000	...
Total non-current liabilities	29,716,000	10,361,000
Total liabilities	74,920,000	136,366,000
Series C convertible preferred stock	18,718,000	23,060,000
Common stock	1,175,000	1,068,000
Additional paid-in capital	1,291,316,000	1,164,885,000

Stock subscription receivable	(79,000)	(79,000)
Retained earnings (accumulated deficit)	(1,359,721,000)	(1,297,122,000)
Accumulated other comprehensive income (loss)	1,536,000	3,145,000
Total stockholders' equity (deficit)	(65,773,000)	(128,103,000)
Total Equity	(65,773,000)	...

Recent Dividends:

- Northwest Biotherapeutics Inc series A convertible preferred. No dividends paid.
 - Northwest Biotherapeutics Inc series C convertible preferred. No dividends paid.
 - Northwest Biotherapeutics Inc series B convertible preferred. No dividends paid.
 - Northwest Biotherapeutics Inc series A-1 convertible preferred. No dividends paid.
 - Northwest Biotherapeutics Inc series A preferred. No dividends paid.
 - Northwest Biotherapeutics Inc common. No dividends paid.
- Annual Dividends:**
- Northwest Biotherapeutics Inc series A convertible preferred. No dividends paid.
 - Northwest Biotherapeutics Inc series C convertible preferred. No dividends paid.
 - Northwest Biotherapeutics Inc series B convertible preferred. No dividends paid.
 - Northwest Biotherapeutics Inc series A-1 convertible preferred. No dividends paid.
 - Northwest Biotherapeutics Inc series A preferred. No dividends paid.
 - Northwest Biotherapeutics Inc common. No dividends paid.

NOVACCESS GLOBAL INC

Earnings, 3 mos. to Dec 31(Consol. - \$):

	2023	2022
Cost & expenses	257,546	517,118
Operating income	(257,546)	(517,118)
Interest expense	71,814	300,454
Other income (expense), net	1,632,953	(1,813,834)
Net before taxes	1,303,593	...
Net income	1,303,593	(2,631,406)
Balance for common	...	(2,631,406)
Earnings common share		
Primary	\$0.06	\$(0.14)
Fully Diluted	\$0.01	\$(0.14)
Common Shares:		
Full Diluted	95,937,820	18,979,871
Year-end	23,955,540	20,326,276

Consolidated Balance Sheet Items, as of (\$):

	2023	2022
Assets:		
Cash & equivalents	1,505	17,338
Current assets	17,338	17,338
Total assets	17,338	17,338
Liabilities:		
Current liabilities	6,446,514	(6,429,176)
Stockholders' equity	(6,429,176)	(6,429,176)
Net current assets	(6,429,176)	(6,429,176)

NUVECTIS PHARMA INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Employee compensation & benefits	...	4,648	1,164
Clinical expense	...	3,714	670
License fee	...	2,297	7,111
Manufacturing	...	2,170	424

Professional services & other	398	176	No dividends paid.	Net income (loss) per share - basic	\$(0.63)	\$1.41	\$2.35
Research & development expense	15,380	13,227	9,545	Net income (loss) per share - diluted	\$(0.63)	\$1.41	\$2.35
Professional & consulting services	2,381	2,574	2,574	Dividends per share	...	\$0.56	\$0.55
Employee compensation & benefits	1,756	414	414	Total number of employees	...	213	213
Insurance	1,183	Number of common stockholders	1,227	1,240	1,253
Other general & administrative expense	687	361	361	Number of beneficiary stockholders	...	905	977
General & administrative expense	7,517	6,007	3,349	Basic EPS Excluding ExtraOrdinary Items	\$(0.63)
Operating income (loss)	(22,897)	(19,234)	(12,894)	Diluted EPS Excluding ExtraOrdinary Items	\$(0.63)
Finance income	637	149	4	Approximately; As of March 1, 2023; As of March 1, 2022
Net income (loss) attributable to common shareholder	(22,260)	(19,085)	(12,890)	Consolidated Balance Sheet, Years Ended Dec. 31 (\$):			
Weighted average shares outstanding - basic	15,557	12,658	4,268	2023 2022			
Weighted average shares outstanding - diluted	15,557	12,658	4,268	Cash	...	310,556	...
Year end shares outstanding	17,419	14,642	4,506	Cash & cash equivalents	1,259,904
Net income (loss) per common share - basic	\$(1.43)	\$(1.51)	\$(3.02)	Receivables, gross	3,561,892	3,865,422	...
Net income (loss) per common share - diluted	\$(1.43)	\$(1.51)	\$(3.02)	Allowance for doubtful accounts	150,000	140,000	...
Number of full time employees	11	11	8	Receivables, Net of Allowance for Doubtful Accounts of \$175,705 and \$300,000	3,411,892
Number of common stockholders	45	45	43	Receivables, net	...	3,725,422	...
Income from cont operations before income tax	(22,260)	Income taxes receivable	...	283,665	...
				Materials, supplies & inventories	34,438,857	23,617,800	...
				Prepaid expenses & other current assets	2,245,160	1,886,480	...
				Total current assets	41,355,813	29,823,923	...
				Goodwill	40,603,029	49,903,029	...
				Intangibles	14,488,608	16,363,192	...
				Other investments	8,322,252	11,016,246	...
				Right of use asset	1,348,290	1,341,029	...
				Financial derivative instruments	1,342,628	2,214,462	...
				Other assets	884,122	461,445	...
				Land	707,648	712,503	...
				Buildings	11,007,636	10,918,490	...
				Other support assets	24,419,429	22,980,859	...
				Central office & circuit equipment	63,323,590	61,046,604	...
				Cable & wire facilities	154,273,968	118,171,835	...
				Other plant & equipment	404,883	404,883	...
				Plant under construction	23,220,217	5,655,876	...
				Other property & equipment	32,433,191	29,836,775	...
				Video plant	18,848,612	16,096,032	...
				Total property, plant & equipment	328,639,174	265,823,857	...
				Less accumulated depreciation	173,088,602	159,632,293	...
				Net property, plant & equipment	155,550,572	106,191,564	...
				Total assets	263,895,314	217,314,890	...
				Accounts payable	12,803,435	7,012,264	...
				Accrued income taxes	581,098
				Other accrued taxes	253,490	243,965	...
				Deferred compensation	45,797	62,765	...
				Accrued compensation	1,562,115	2,051,316	...
				Other accrued liabilities	1,059,163	2,291,630	...
				Checks Written in Excess of Cash Balance	2,270,832
				Operating Lease Liabilities - Current	352,969
				Portion/Short-Term Other Accrued Liabilities
				- Balancing value	706,194
				Total current liabilities	18,575,930	11,661,940	...
				Secured reducing credit facilities	...	60,000,000	...
				Secured revolving credit facilities	...	19,885,082	...
				Less: unamortized loan

Recent Dividends:**1. Nuvectis Pharma Inc convertible preferred stock A.**

No dividends paid.

2. Nuvectis Pharma Inc common.

No dividends paid.

Annual Dividends:**1. Nuvectis Pharma Inc convertible preferred stock A.**

No dividends paid.

2. Nuvectis Pharma Inc common.

fees	...	(1,332,885)	
Long-term debt, net of unamortized loan fees	122,891,638	78,552,197	
Loan guarantees	...	169,565	
Deferred income taxes	23,032,099	22,737,530	
Unrecognized tax benefit	...	23,304	
Other accrued liabilities	1,132,799	1,236,949	
Deferred compensation	256,605	351,553	
Common stock	8,555,345	8,488,689	
Accumulated other comprehensive income (loss)	959,442	1,582,455	
Unearned compensation	...	(79,892)	
Retained earnings (accumulated deficit)	88,491,456	92,430,816	
Total stockholders' equity (deficit)	98,006,243	102,581,852	
Total Equity	98,006,243	...	

preferred stockholders	2,297	...	75
Net income (loss) after deemed dividend	(22,627)	(14,525)	[Ⓐ] (19,620)
Weighted average shares outstanding - basic	1,964	174	[Ⓐ] 69
Weighted average shares outstanding - diluted	1,964	174	[Ⓐ] 69
Year end shares outstanding	5,682	[Ⓐ] 536	[Ⓐ] [Ⓐ] 105
Net earnings (loss) per share - basic	\$(11.52)	\$(83.55)	[Ⓐ] \$(285.36)
Net earnings (loss) per share - diluted	\$(11.52)	\$(83.55)	[Ⓐ] \$(285.36)
Number of full time employees	59	[Ⓐ] [Ⓐ] 35	[Ⓐ] [Ⓐ] 75
Total number of employees	59
Number of common stockholders	3	[Ⓐ] [Ⓐ] 3	[Ⓐ] [Ⓐ] 3
Foreign currency translation adjustments	...	(7)	...
Basic and diluted loss per share	\$(11.52)
Diluted EPS
Excluding ExtraOrd Items	\$(11.52)

Operating lease liability	544	760
Total liabilities	6,559	12,316
Common stock	1	...
Additional paid-in capital	290,646	279,736
Accumulated other comprehensive income - foreign currency translation adjustment	(31)	(18)
Accumulated other comprehensive income - unrealized gain (loss) on marketable securities	...	56
Retained earnings (accumulated deficit)	(287,626)	(267,417)
Mezzanine Equity Series J Convertible Preferred Stock as of 31, 2023 and 31, 2022, par value \$00001 per share; authorized 600,000 and outstanding 11,950 and none, issued and outstanding 11,950 and none, respectively	221	...
Total stockholders' equity	3,211	12,357
Total Equity	3,211	...

Recent Dividends:

1. Nuvera Communications Inc common.

ExDate	Amt	Declared	Record	Payable
03/04/2021	0.13	02/23/2021	03/05/2021	03/15/2021
06/04/2021	0.14	05/26/2021	06/07/2021	06/15/2021
09/09/2021	0.14	08/31/2021	09/10/2021	09/17/2021
12/09/2021	0.14	11/30/2021	12/10/2021	12/17/2021
03/04/2022	0.14	02/24/2022	03/07/2022	03/15/2022
06/03/2022	0.14	05/25/2022	06/06/2022	06/15/2022
09/08/2022	0.14	08/30/2022	09/09/2022	09/16/2022
12/08/2022	0.14	11/29/2022	12/09/2022	12/16/2022
03/03/2023	0.14	02/23/2023	03/06/2023	03/15/2023
06/02/2023	0.14	05/24/2023	06/05/2023	06/15/2023

Annual Dividends:

1. Nuvera Communications Inc common.

2021	0.55	2022	0.56	2023	0.28
------	------	------	------	------	------

NUWELLIS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

	2023	2022	[Ⓐ] 2021 (revised)
Total revenues	8,864
Net sales	8,864	8,543	7,921
Cost of goods sold	3,881	3,788	3,430
Gross profit	4,983	4,755	4,491
Selling, general & administrative expense	17,191	17,584	19,039
Research & development expense	5,422	4,342	4,978
Total operating expenses	22,613	21,926	24,017
Income (loss) from operations	(17,630)	(17,171)	(19,526)
Interest expense	3,483
Other income (expense), net	154	75	(19)
Financing expense	...	9,247	...
Change in fair value of warrant liability	758	11,827	...
Income (loss) before income taxes - domestic	(20,233)	(14,551)	(19,582)
Income (loss) before income taxes - foreign	32	35	37
Income (loss) before income taxes	(20,201)	(14,516)	(19,545)
Current foreign income tax expense (benefit), net	8	9	9
Income tax expense (benefit)	8	9	9
Dividend on Series J Convertible Preferred Stock	121
Net income (loss)	(20,209)	(14,525)	(19,554)
Deemed dividend to

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

2023 2022

	2023	2022
Cash & cash equivalents	3,800	17,737
Marketable securities	...	569
Accounts receivable	1,951	1,406
Finished goods	393	993
Work in process	207	204
Raw materials	1,472	1,609
Inventory reserves	75	145
Inventories - Balancing value	1,997	...
Inventories, net	...	2,661
Other current assets	461	396
Total current assets	8,209	22,769
Production equipment	1,360	1,360
Loaners & demo equipment	1,534	1,444
Computer software & equipment	...	719
Office furniture & fixtures	375	375
Leasehold improvements	253	253
Software	688	...
Property, plant & equipment, gross	4,210	4,151
Less: accumulated depreciation	3,482	3,171
Property, plant & equipment, net	728	980
Operating lease right-of-use asset	713	903
Other assets	120	21
Total assets	9,770	24,673
Accounts payable & accrued liabilities	2,380	2,245
Accrued compensation	525	2,161
Current portion of operating lease liability	216	196
Current portion of finance lease liability	...	28
Other current liabilities	51	58
Total current liabilities	3,172	4,688
Common stock warrant liability	2,843	6,868

Recent Dividends:

1. Nuwellis Inc common.

No dividends paid.

2. Nuwellis Inc series F convertible preferred.

No dividends paid.

3. Nuwellis Inc series D convertible preferred.

No dividends paid.

4. Nuwellis Inc series C convertible preferred.

No dividends paid.

5. Nuwellis Inc series B-1 convertible preferred.

No dividends paid.

6. Nuwellis Inc series J convertible preferred.

No dividends paid.

Annual Dividends:

1. Nuwellis Inc common.

No dividends paid.

2. Nuwellis Inc series F convertible preferred.

No dividends paid.

3. Nuwellis Inc series D convertible preferred.

No dividends paid.

4. Nuwellis Inc series C convertible preferred.

No dividends paid.

5. Nuwellis Inc series B-1 convertible preferred.

No dividends paid.

6. Nuwellis Inc series J convertible preferred.

No dividends paid.

NV5 GLOBAL INC

Annual Report

Consolidated Income Statement, Years Ended (\$000):

	12/30/23	12/31/22	01/01/22 (revised)
Gross revenues	861,739	786,778	706,706
Direct costs - salaries & wages	215,608	186,806	175,047
Direct costs - sub-consultant services	150,681	153,641	124,998
Direct costs - other direct costs	65,088	60,357	47,347
Total direct costs	431,377	400,804	347,392
Gross profit	430,362	385,974	359,314
Salaries & wages, payroll taxes & benefits	226,137	193,488	176,838
General & administrative expenses	67,668	66,114	53,986
Facilities & facilities related expenses	22,891	21,252	20,193
Depreciation & amortization expenses	52,486	38,938	39,953
Total operating expenses	369,182	319,792	290,970

Income (loss) from operations	61,180	66,182	68,344	Survey & field equipment	62,553	49,985	equity	775,795	...	
Interest expense	12,970	3,808	6,239	Leasehold improvements	6,881	6,546				
Income (loss) before income tax expense	48,210	62,374	62,105	Total property & equipment, gross	104,920	85,768	Recent Dividends:			
Current federal income tax expense (benefit)	22,085	20,977	14,251	Less: accumulated depreciation - property & equipment	54,652	44,128	1. NV5 Global Inc common.			
Current state income tax expense (benefit)	5,633	9,040	7,353	Property & equipment, net	50,268	41,640	No dividends paid.			
Current foreign income tax expense (benefit)	1,583	943	400	Right-of-use lease asset, net - Balancing value	79,327	...	Annual Dividends:			
Total current income tax expense (benefit)	29,301	30,960	22,004	Right of Use Tangible Assets - Operating Lease - Accumulated Depreciation	42,491	...	1. NV5 Global Inc common.			
Deferred federal income tax expense (benefit)	(23,235)	(15,401)	(3,740)	Right-of-use lease assets, net	36,836	39,314	No dividends paid.			
Deferred state income tax expense (benefit)	(2,487)	(3,161)	(3,238)	Intangible assets, net	226,702	160,431	OBLONG INC			
Deferred income taxes (benefit) - foreign	18	3	(68)	Goodwill	524,573	400,957	Annual Report			
Total deferred income tax expense (benefit)	(25,704)	(18,559)	(7,046)	Other assets	3,149	2,705	Consolidated Income Statement, Years Ended Dec. 31 (\$):			
Income tax expense (benefit)	3,597	12,401	14,958	Total assets	1,170,592	935,723	2023	2022	2021	
Net income (loss)	44,613	49,973	47,147	Accounts payable	54,865	57,771	(revised)			
Weighted average shares outstanding - basic	15,086	14,754	14,135	Current portion of lease liability	13,972	13,081	Video solutions revenue - equipment ..	3,810,000	...	
Weighted average shares outstanding - diluted	15,474	15,260	14,656	Accrued vacation	7,295	12,467	Revenue	3,810,000	5,476,000	7,739,000
Year end shares outstanding	15,895	15,523	15,414	Accrued payroll & related taxes	8,782	6,616	Cost of revenue (exclusive of depreciation & amortization & casualty loss)	2,899,000	3,930,000	5,021,000
Earnings (loss) per share from continuing operations - basic	\$2.96	Accrued benefits	5,160	Gross profit	911,000	1,546,000	2,718,000
Net earnings (loss) per share - basic	\$2.96	\$3.39	\$3.34	Accrued operating expenses	8,701	4,540	Research & development	20,000	1,699,000	2,913,000
Earnings (loss) per share from continuing operations - diluted	\$2.88	Other accrued liabilities	2,449	Sales & marketing ...	309,000	1,431,000	2,195,000
Net earnings (loss) per share - diluted	\$2.88	\$3.27	\$3.22	Income tax payable and other liabilities	3,240	...	General & administrative	4,870,000	5,278,000	6,363,000
Number of full time employees	3,813	3,323	3,139	Accrued liabilities	47,423	44,313	Impairment charges ..	262,000	12,740,000	305,000
Number of part time employees	321	289	Billings in excess of costs & estimated earnings on uncompleted contracts	41,679	31,183	Casualty loss, net	(400,000)	483,000	...
Total number of employees	3,813	3,644	3,428	Other current liabilities	2,263	1,597	Depreciation & amortization	345,000	1,903,000	2,736,000
Number of common stockholders	2,649	2,499	2,735	Current portion of contingent consideration	3,922	10,854	Total operating expenses	5,406,000	23,534,000	14,512,000
				Current portion of notes payable & other obligations	9,267	...	Income (loss) from operations	(4,495,000)	(21,988,000)	(11,794,000)
				Capitalized Leases - Current Portion	1,220	...	Interest & other income (expense)	(28,000)	(19,000)	(22,000)
				Total current liabilities	159,419	160,894	Gain (loss) on extinguishment of debt	2,448,000
				Contingent consideration, less current portion	143	4,481	Interest & other income	59,000	227,000
				Other long-term liabilities	26,930	29,542	Other income	166,000
				Long-term lease liabilities	1,176	...	Total interest & other income, net	138,000	40,000	2,653,000
				Senior credit facility	33,750	Income (loss) before income taxes - United States	(21,948,000)	(9,340,000)
				Uncollateralized promissory notes	18,492	Income (loss) before income taxes - foreign	199,000
				Finance leases	3,188	3,465	Income (loss) before income taxes ..	(4,357,000)	(21,948,000)	(9,141,000)
				Other obligations	1,814	Current income tax expense (benefit) - foreign	15,000	(4,000)	(75,000)
				Debt issuance costs, net of amortization	(2,672)	Current income tax expense (benefit) - state	12,000	(3,000)	(15,000)
				Current portion of notes payable & other obligations	(15,176)	Total current income tax expense (benefit)	27,000	(7,000)	(90,000)
				Deferred income tax liabilities, net	2,837	6,893	Income tax expense (benefit)	27,000	(7,000)	(90,000)
				Notes payable, less current portion	205,468	...	Net income (loss)	(4,384,000)	(21,941,000)	(9,051,000)
				Operating lease liability	25,754	...	Loss (gain) on redemption of preferred stock	751,000
				Total liabilities	394,797	241,483	Preferred stock dividends	343,000	...	1,000
				Common stock	159	155	Undeclared dividends	366,000
				Additional paid-in capital	508,256	471,300	Induced conversion of series A-2 preferred stock	300,000
				Retained earnings (accumulated deficit)	267,398	222,785	Warrant modification	25,000	...	37,000
				Accumulated other comprehensive income (loss)	(18)	...	Net income (loss) attributable to common stockholders ..	(5,503,000)	(21,941,000)	(9,755,000)
				Total stockholders' equity (deficit)	775,795	694,240	Weighted average shares outstanding - basic	5,595,000	2,065,000	1,779,000
				Total stockholders' equity	775,795	694,240

As is; As of February 17, 2023; As of February 23, 2022

Consolidated Balance Sheet, Years Ended (\$000):

	12/30/23	12/31/22	
Cash & cash equivalents	44,824	38,541	
Billed receivables, gross	155,988	149,082	
Less: allowance for doubtful accounts	2,274	3,445	
Billed receivables, net	152,593	145,637	
Unbilled receivables, gross	115,545	95,104	
Less: allowance for doubtful accounts	3,395	2,242	
Unbilled receivables, net	113,271	92,862	
Prepaid expenses & other current assets	18,376	13,636	
Total current assets	329,064	290,676	
Office furniture & equipment	3,487	3,421	
Computer equipment	31,999	25,816	

Weighted average shares outstanding			
- diluted	5,595,000	2,065,000	[Ⓜ] 1,779,000
Year end shares outstanding	16,685,000	2,063,308	[Ⓜ] [Ⓜ] 2,054,403
Income (loss) per common share from continuing operations - basic	\$(0.98)
Net income (loss) per common share - basic	\$(0.98)	\$(10.62)	[Ⓜ] \$(5.48)
Income (loss) per common share from continuing operations - diluted	\$(0.98)
Net income (loss) per common share - diluted	\$(0.98)	\$(10.62)	[Ⓜ] \$(5.48)
Depreciation & amortization	345,000
Number of full time employees	17	20	47
Number of part time employees	...	2	2
Total number of employees	17	22	49
Number of common stockholders	147	[Ⓜ] 152	[Ⓜ] 162

[Ⓜ] Reclassified to conform with 2022 presentation; [Ⓜ] Adjusted for 1-for-15 stock split, January 4, 2023; [Ⓜ] Shares increased due to the effect of issuance of shares from private placement, from preferred stock conversions, stock compensation and for fees; [Ⓜ] As of March 20, 2023; [Ⓜ] As of March 23, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash and cash equivalents	5,990,000	...
Cash	...	3,085,000
Accounts receivable, gross	577,000	624,000
Less: allowance for doubtful accounts	...	209,000
Accounts receivable, net	424,000	415,000
Inventory before reserve for obsolescence	239,000	...
Inventory, net	...	723,000
Prepaid expenses	...	131,000
Employee retention credit receivable	...	316,000
Other current assets	...	90,000
Prepaid software licenses	...	112,000
Provision - Doubtful
Accounts	153,000	...
Total current assets	6,896,000	4,872,000
Network equipment & software	...	1,913,000
Computer equipment & software	...	294,000
Accumulated depreciation	...	2,204,000
Property & equipment, net	...	3,000
Intangibles, net	...	604,000
Operating lease, right-of-use assets, net	17,000	142,000
Other assets	12,000	40,000
Total assets	6,925,000	5,661,000
Accounts payable	211,000	184,000
Compensation costs	448,000	707,000
Taxes & regulatory fees	22,000	59,000
Customer deposits	...	128,000
Professional fees	104,000	57,000
Accrued dividends on series A-2 preferred stock	136,000	...
Other accrued expenses & liabilities	8,000	123,000
Customer deposits	118,000	...
Current portion deferred revenue	132,000	436,000
Operating lease

liabilities, current	17,000	219,000
Accrued rent	202,000	...
Total current liabilities	1,398,000	1,913,000
Operating lease liabilities, non-current	...	17,000
Deferred revenue, net of current portion	26,000	114,000
Total long-term liabilities	26,000	131,000
Total liabilities	1,424,000	2,044,000
Common stock	2,000	...
Treasury stock	181,000	181,000
Additional paid-in capital	233,911,000	227,645,000
Retained earnings (accumulated deficit)	(228,231,000)	(223,847,000)
Total stockholders' equity (deficit)	5,501,000	3,617,000
Total Equity	5,501,000	...

- Recent Dividends:**
- 1. Oblong Inc series E convertible preferred (stated value: \$28.50).**
No dividends paid.
 - 2. Oblong Inc series A-2 convertible preferred (stated value: \$7,500).**
No dividends paid.
 - 3. Oblong Inc series B convertible preferred (stated value: \$1,000).**
No dividends paid.
 - 4. Oblong Inc series B-1 non-convertible preferred (stated value: \$100,000).**
No dividends paid.
 - 5. Oblong Inc common.**
No dividends paid.
 - 6. Oblong Inc series C convertible preferred (stated value: \$1,000).**
No dividends paid.
 - 7. Oblong Inc series D convertible preferred (stated value: \$28.50).**
No dividends paid.
 - 8. Oblong Inc series C convertible preferred (stated value: \$10,000).**
No dividends paid.
 - 9. Oblong Inc series F convertible preferred.**
No dividends paid.

OCULUS VISIONTECH INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	[Ⓜ] 2021
Consulting expense	43,269	135,000	24,021
Research & development expenses	95,884	1,137,883	818,269
Selling, general & administrative

expenses	274,498	399,467	430,691
Share-based compensation	84,034	396,520	713,684
Income (loss) from operations	...	(2,068,870)	(1,986,665)
Interest income	11,704	5,153	...
Gain on reduction of commitment to issue shares	...	414,128	...
Loss before taxes for the year	(591,212)
Net income (loss)	(591,212)	(1,649,589)	(1,986,665)
Weighted average shares outstanding - basic	91,422,569	91,422,569	89,968,723
Weighted average shares outstanding - diluted	91,422,569	91,422,569	89,968,723
Year end shares outstanding	91,422,569	91,422,569	91,422,569
Net income (loss) per share - basic	\$(0.01)	\$(0.02)	\$(0.02)
Net income (loss) per share - diluted	\$(0.01)	\$(0.02)	\$(0.02)
Total number of employees	...	3	3
Number of common stockholders	1,285	1,285	[Ⓜ] 1,285
Foreign currency translation adjustments	...	41,046	...
Loss from operations	602,916
Consulting	148,500
Basic EPS Excluding ExtraOrdinary Items	\$(0.01)
Diluted EPS Excluding ExtraOrd Items	\$(0.01)
Filing and regulatory fees	32,862
Professional fees	78,089
Office and administration	120,278

[Ⓜ] Reclassified to conform with 2022 presentation; [Ⓜ] As of March 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	156,574	687,602
Prepaid expense	16,014	28,028
Taxes receivable - Canadian GST	11,367	2,210
Prepaid expenses & other current assets	27,381	30,238
Total current assets	183,955	717,840
Total assets	183,955	717,840
Accounts payable	87,422	224,716
Accrued fees & expenses	48,826	51,869
Accounts payable & accrued expenses	136,248	276,585
Accounts payable & accrued expenses - related parties	137,475	25,838
Total current liabilities	273,723	302,423
Common stock	46,850,710	...
Common stock & additional paid-in capital	...	46,850,710
Additional paid-in capital	1,479,031	1,394,997
Accumulated other comprehensive income	(32,863)	(34,856)
Retained earnings (accumulated deficit)	(48,386,646)	(47,795,434)
Totla stockholders' equity (deficit)	(89,768)	415,417
Total Equity	(89,768)	...

- Recent Dividends:**
- 1. Oculus Visiontech Inc common.**
No dividends paid.

Annual Dividends:

1. Oculus Visiontech Inc common.
No dividends paid.

OCUPHIRE PHARMA INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
Collaborations revenue	589,000
License & collaborations revenue	...	39,850,000	...
Total revenue	19,049,000
General & administrative	11,959,000	7,269,000	8,121,000
Research & development	17,653,000	14,355,000	15,173,000
Total operating expenses	29,612,000	21,624,000	23,294,000
Income (loss) from operations	(10,563,000)	18,226,000	(22,705,000)
Interest expense on short-term loan	2,000
Interest expense	1,328,000	9,000	2,000
Fair value change in derivative & warrant liabilities	80,000	...	(33,829,000)
Other expense, net	(1,837,000)	14,000	...
Other income (expense), net	(157,000)
Income (loss) before provision for income taxes	(9,974,000)	18,203,000	(56,693,000)
Current federal income taxes	2,000	279,000	...
Current state income taxes	10,000	36,000	...
Current income taxes	12,000	315,000	...
Provision for income taxes	12,000	315,000	...
Net income (loss)	(9,986,000)	17,888,000	(56,693,000)
Weighted average shares outstanding - basic	21,589,821	19,931,080	14,852,745
Weighted average shares outstanding - diluted	21,589,821	20,597,212	14,852,745
Year end shares outstanding	23,977,491	20,861,315	18,845,828
Net income (loss) per share - basic	\$(0.46)	\$0.90	\$(3.82)
Net income (loss) per share - diluted	\$(0.46)	\$0.87	\$(3.82)
Number of full time employees	17	9	8
Total number of employees	17
Number of common stockholders	75	83	85
Basic EPS Excluding ExtraOrdinary Items	\$(0.46)
Diluted EPS Excluding ExtraOrdinary Items	\$(0.46)

□ Non-consolidated; □ Shares increased due to the effect of issuance of common stock and warrants, exercise of series B warrants, share-based compensation, and exercise of stock options; □ Approximately; □ As of March 27, 2023; □ As of March 23, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	50,501,000	42,634,000
Accounts receivable	926,000	1,298,000
Contract asset	...	3,552,000
Marketable securities	15,000	...
Prepays	997,000	1,373,000
Other prepaids & other assets	...	80,000
Prepays & other current assets	1,099,000	1,453,000

Short-term investments	...	49,000
Other	102,000	...
Contract assets and unbilled receivables	1,407,000	...
Total current assets	53,948,000	48,986,000
Equipment	20,000	20,000
Furniture	...	5,000
Lab & computer equipment	5,000	...
Equipment, gross	25,000	25,000
Less accumulated depreciation	25,000	19,000
Property & equipment, net	...	6,000
Total assets	53,948,000	48,992,000
Accounts payable	...	1,069,000
Income taxes	...	315,000
R&D services & supplies	...	212,000
Payroll	753,000	782,000
Professional services	591,000	208,000
Other accrued expenses	71,000	167,000
Accrued expenses - Balancing value	400,000	...
Accrued expenses	...	1,684,000
Accrued expenses	1,815,000	...
Derivative liability	74,000	...
Total current liabilities	4,042,000	2,753,000
Total liabilities	4,042,000	2,753,000
Common stock	2,000	2,000
Additional paid-in capital	131,370,000	117,717,000
Retained earnings (accumulated deficit)	(81,466,000)	(71,480,000)
Total stockholders' equity (deficit)	49,906,000	46,239,000
Total Equity	49,906,000	...

Recent Dividends:

1. Ocuphire Pharma Inc common.

No dividends paid.

Annual Dividends:

1. Ocuphire Pharma Inc common.

No dividends paid.

ONCTERNAL THERAPEUTICS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2023	2022	2021
Grant revenue	785	1,490	4,315
Total revenues	785
Research & development expenses	29,753	32,980	24,086
General & administrative expenses	12,746	13,457	11,595
Total operating expenses	42,499	46,437	35,681
Income (loss) from operations	(41,714)	(44,947)	(31,366)
Interest income	2,235	777	33
Income (loss) from operations before income taxes	(39,479)
Net income (loss)	(39,479)	(44,170)	(31,333)
Weighted average shares outstanding - basic	2,940	2,630	2,466
Weighted average shares outstanding - diluted	2,940	2,630	2,466
Year end shares outstanding	2,948	2,873	2,471
Income (loss) per share from continuing operations - basic	\$(13.43)
Net income (loss) per share - basic	\$(13.43)	\$(16.80)	\$(12.80)
Income (loss) per share from continuing operations -

diluted
Net income (loss) per share - diluted	\$(13.43)	\$(16.80)	\$(12.80)
Number of full time employees	...	30	26
Number of part time employees	...	2	...
Number of common stockholders	88	112	117

□ Reclassified to conform with 2022 presentation; □ Adjusted for 1- for -20 stock split, January 8, 2024; □ As is; □ As of March 3, 2023; □ As of March 4, 2022; □ Approximately; □ As of March 3, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	6,697	37,142
Short-term investments	27,558	26,582
Prepaid & other current assets	...	3,566
Prepaid and other	1,804	...
Total current assets	36,059	67,290
Right-of-use asset	258	87
Other assets	412	1,274
Total assets	36,729	68,651
Accounts payable	1,148	2,917
Accrued research & development	...	972
Accrued clinical trials	...	868
Accrued legal fees	...	138
Accrued compensation	1,579	2,691
Other accrued liabilities	...	9
Accrued liabilities - Balancing value	2,298	...
Accrued liabilities	3,877	4,678
Lease, current	173	87
Total current liabilities	5,198	7,682
Lease, net of current	145	...
Other long-term liabilities	1,334	...
Total Liabilities	6,677	...
Common stock	3	57
Additional paid-in capital	227,825	219,203
Accumulated other comprehensive income	3	9
Retained earnings (accumulated deficit)	(197,779)	(158,300)
Total stockholders' equity (deficit)	30,052	60,969
Total Equity	30,052	...

Recent Dividends:

1. Oncternal Therapeutics Inc convertible preferred.

No dividends paid.

2. Oncternal Therapeutics Inc common.

No dividends paid.

Annual Dividends:

1. Oncternal Therapeutics Inc convertible preferred.

No dividends paid.

2. Oncternal Therapeutics Inc common.

No dividends paid.

ONE GROUP HOSPITALITY INC (THE)**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
Owned restaurant net revenue	317,366,000	300,859,000	264,404,000
Management & incentive fee revenue	15,403,000
Management, license & incentive fee revenue	...	15,779,000	12,774,000
Total revenues	332,769,000	316,638,000	277,178,000
Owned restaurant cost of sales	75,727,000	75,365,000	67,468,000
Owned restaurant operating expenses	...	174,689,000	144,529,000
Total owned

operating expenses	250,054,000	211,997,000	
General & administrative expenses	30,751,000	29,081,000	25,573,000
Depreciation & amortization	15,664,000	12,134,000	10,790,000
COVID-19 related expenses	207,000	2,534,000	5,821,000
Other expenses	1,021,000		
Transaction costs		123,000	160,000
Lease termination expenses		257,000	1,912,000
Agreement restructuring expenses			503,000
Pre-opening expenses		5,519,000	1,037,000
Write-off of trademark costs & other expenses		630,000	
Interest expense, net of interest income	7,028,000		
General & administrative expenses & taxes	191,250,000		
Total costs & expenses	(323,475,000)	300,332,000	257,793,000
Operating income	9,294,000	16,306,000	19,385,000
Interest expense, net of interest income		2,113,000	3,780,000
Gain (loss) on early debt extinguishment			(600,000)
Gain on CARES Act Loan Forgiveness			18,529,000
Total other income (expenses), net	(7,028,000)	2,113,000	(14,149,000)
Income (loss) before provision for income taxes - domestic	2,077,000	14,051,000	33,331,000
Income (loss) before provision for income taxes - foreign	189,000	142,000	203,000
Income (loss) before provision for income taxes	2,266,000	14,193,000	33,534,000
Current state & local income taxes		808,000	564,000
Current foreign income taxes	35,000	75,000	110,000
Current Tax - State and local	638,000		
Total current tax expense	673,000	883,000	674,000
Deferred federal income taxes	(2,550,000)	(429,000)	(195,000)
Deferred state & local income taxes		420,000	1,107,000
Deferred Tax - State and local	117,000		
Total deferred provision for (benefit from) income taxes	(2,433,000)	(9,000)	912,000
Provision for income taxes	(1,760,000)	874,000	1,586,000
Net income (loss)	4,026,000	13,319,000	31,948,000
Less: net income (loss) attributable to noncontrolling interest	692,000	215,000	(600,000)
Net income (loss) attributable to The ONE Group Hospitality, Inc.	4,718,000	13,534,000	31,348,000
Weighted average shares outstanding - basic	31,556,437	32,400,515	31,155,224
Weighted average shares outstanding			

- diluted	32,287,864	33,871,797	33,794,344
Year end shares outstanding	31,283,975	31,735,423	32,125,762
Net income (loss) per share from continuing operations - basic	\$0.15		
Net income (loss) per share - basic	\$0.15	\$0.42	\$1.01
Net income (loss) per share from continuing operations- diluted	\$0.15		
Net income (loss) per share - diluted	\$0.15	\$0.40	\$0.93
Full-Time Employees (Period End)	257		
Total number of employees	257	3,700	3,784
Number of common stockholders	70	76	85
Foreign currency translation adjustments		(224,000)	
Pre-opening Expenses	8,855,000		

□ Include stock-based compensation - General & administrative: \$3,985,000; □ Include stock-based compensation - General & administrative: \$3,618,000; □ Approximately; □ As of February 28, 2023; □ As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	21,047,000	55,121,000
Accounts receivable	17,264,000	15,220,000
Inventory	6,184,000	5,728,000
Other current assets	376,000	
Other current assets	1,809,000	2,091,000
Due from related parties		376,000
Total current assets	46,680,000	78,536,000
Furniture, fixtures & equipment		33,372,000
Leasehold improvements	130,136,000	89,121,000
Less: accumulated depreciation & amortization	60,128,000	47,528,000
Construction in progress	17,044,000	16,276,000
Restaurant smallwares	3,103,000	2,846,000
Restaurant supplies	49,753,000	
Property & equipment, net	139,908,000	94,087,000
Operating lease right-of-use assets	95,075,000	85,161,000
Deferred tax assets, net	14,757,000	12,323,000
Intangibles, net	15,306,000	15,290,000
Other assets	4,636,000	4,774,000
Security deposits	883,000	853,000
Total assets	317,245,000	291,024,000
Accounts payable	19,089,000	13,055,000
Accrued payroll & related	5,655,000	5,249,000
VAT & sales taxes	4,238,000	4,118,000
Amounts due to landlords	2,753,000	2,949,000
Income taxes & related	30,000	156,000
Accrued construction on new restaurants	6,318,000	1,903,000
Accrued insurance		742,000
Legal, professional & other services	1,364,000	626,000
Accrued interest		268,000
Other accrued expenses		6,398,000
Other	5,034,000	
Insurance	545,000	
Accrued expenses	28,333,000	22,409,000
Deferred license revenue	2,077,000	
Deferred gift card revenue & other current liabilities		2,115,000
Current portion of operating lease liabilities	6,897,000	6,336,000
Current portion of		

long-term debt	1,500,000	1,500,000
Other current liabilities	266,000	256,000
Interest	2,396,000	
Total current liabilities	58,162,000	45,671,000
Other long-term liabilities	832,000	972,000
Operating lease liabilities, net of current portion	120,481,000	105,247,000
Term loan agreements		24,250,000
Delayed draw term facility		50,000,000
Total debt		74,250,000
Less: current portion of long-term debt		1,500,000
Less: debt issuance costs		(2,206,000)
Long-term debt, net of current portion	70,410,000	70,544,000
Total liabilities	249,885,000	222,434,000
Common stock	3,000	3,000
Treasury stock	15,051,000	7,169,000
Additional paid-in capital	58,270,000	55,583,000
Retained earnings (accumulated deficit)	28,884,000	24,166,000
Accumulated other comprehensive income (loss)	(2,930,000)	(2,869,000)
Total stockholders' equity (deficit)	69,176,000	69,714,000
Noncontrolling interests	(1,816,000)	(1,124,000)
Total equity	67,360,000	68,590,000

Recent Dividends:

1. ONE Group Hospitality Inc (The) common.
No dividends paid.
Annual Dividends:
1. ONE Group Hospitality Inc (The) common.
No dividends paid.

ONE STOP SYSTEMS INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Revenue	60,896,797		
Revenue	60,896,797	72,421,345	61,982,104
Cost of revenue	42,942,175	52,023,736	42,342,815
Gross margin (loss)	17,954,622	20,397,609	19,639,289
General & administrative	9,264,447	7,279,401	7,658,418
Impairment of goodwill	5,630,788		
Marketing & selling	6,651,516	6,806,306	6,201,228
Research & development	4,331,024	4,743,574	4,032,616
Total operating expenses	25,877,775	18,829,281	17,892,262
Income (loss) from operations	(7,923,153)	1,568,328	1,747,027
Interest income	544,958	237,751	244,382
Interest expense	117,774	162,391	527,139
Gain on forgiveness of Paycheck Protection Program (PPP) loan & interest	(1,716,727)		(1,514,354)
Other income (expense), net	(9,806)	550,854	(40,176)
Total other income (expense), net	2,134,105	626,214	1,191,421
Income (loss) before provision for income taxes - domestic operations		(292,325)	1,248,943
Income (loss) before provision for income taxes - foreign operations		2,486,867	1,689,505
Income (loss) before income taxes	(5,789,048)	2,194,542	2,938,448
Current federal provision (benefit)			

for income taxes	24,641	Less: accumulated depreciation & amortization	6,183,000	5,069,208	Cost of service & other	28,715	25,330	25,350
Current state provision (benefit)				Property & equipment, net	2,370,224	2,570,124	Total cost of goods sold	...	70,436	71,546
for income taxes	23,153	29,695	2,763	Operating lease right-of-use assets	1,922,784	731,043	Gross profit	157,715	148,570	142,935
Current international provision (benefit)				Deposits & other assets	38,093	60,243	Sales & marketing	70,235	60,949	62,730
for income taxes	974,830	612,198	548,062	Goodwill	1,489,722	7,120,510	Research & development	38,420	41,735	47,414
Total current provision (benefit)				Intangible assets, net	...	42,154	General & administrative	58,267	55,552	53,031
for income taxes	1,022,624	641,893	550,825	Total assets	48,265,652	56,364,571	Impairment of intangible assets	...	3,828	...
Deferred federal provision (benefit)				Accounts payable	1,201,781	4,592,713	Restructuring & other related charges	17,311	9,482	...
for income taxes	(95,496)	2,345,612	(81,341)	Accrued compensation & related liabilities	1,023,902	989,478	Amortization of intangible assets	2,353	4,139	5,888
Deferred state provision (benefit)				Deferred revenue	299,514	378,952	Total operating costs	186,586	175,685	169,063
for income taxes	...	1,436,092	136,191	Customer deposits	27,447	61,696	Operating income (loss)	(28,871)	(27,115)	(26,128)
Total deferred provision (benefit)				Warranty reserve	607,809	584,268	Interest income net	2,090
for income taxes	(95,496)	3,781,704	54,850	Trade & other taxes	392,336	225,743	Interest income (expense), net	...	595	(1)
Provision (benefit)				Other accrued expenses	851,511	773,732	Other income (expense), net	(532)	14,827	(14)
for income taxes	927,128	4,423,597	605,675	Accrued expenses & other liabilities	3,202,519	3,013,869	Income (loss) before income taxes	...	(9,569)	(15,056)
Net income (loss)	(6,716,176)	(2,229,055)	2,332,773	Current portion of operating lease obligation	390,926	536,588	- U.S.	...	(2,124)	(11,087)
Weighted average shares outstanding - basic	20,854,777	19,730,698	18,305,878	Current portion of related-party notes payable, net	2,077,895	...	Income (loss) before income taxes - non U.S.	...	(11,693)	(26,143)
Weighted average shares outstanding - diluted	20,854,777	19,730,698	19,503,737	Current portion of notes payable	...	2,952,447	Current provision (benefit) for income taxes - federal	2	122	(11)
Year end shares outstanding	20,661,341	20,084,528	18,772,214	Total current liabilities	6,873,121	11,095,617	Current provision (benefit) for income taxes - state	54	32	(23)
Net income (loss) per share - basic	\$(0.32)	\$(0.11)	\$0.13	Long-term debt, net of current portion	...	409,294	Current provision (benefit) for income taxes - foreign	2,473	1,665	2,478
Net income (loss) per share - diluted	\$(0.32)	\$(0.11)	\$0.12	Deferred tax liability, net	44,673	138,662	Total current provision (benefit) for income taxes	2,529	1,819	2,444
Number of full time employees	96	104	103	Operating lease obligation, net	1,765,536	397,249	Deferred provision (benefit) for income taxes - federal	361	(349)	3,774
Number of part time employees	10	8	6	Total liabilities	8,683,330	12,040,822	Deferred provision (benefit) for income taxes - state	(47)	35	(3)
Total number of employees	106	112	109	Common stock	2,066	2,008	Deferred provision (benefit) for income taxes - foreign	(357)	1,236	(1,774)
Number of common stockholders	5,800	60	60	Additional paid-in capital	47,323,673	45,513,807	Total deferred provision (benefit) for income taxes	(43)	922	1,997
Foreign currency translation adjustments	...	331,109	...	Accumulated other comprehensive income (loss)	675,310	510,485	Provision (benefit) for income taxes	2,486	2,741	4,441

□ Approximately; □ As of February 28, 2023; □ As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	4,048,948	3,112,196
Short-term investments	7,771,820	10,123,535
Accounts receivable	8,368,279	11,372,598
Less: allowance for doubtful accounts	50,032	45,354
Accounts receivable, net	8,318,247	11,327,244
Raw materials	12,975,235	9,370,162
Sub-assemblies	...	892,123
Work-in-process	344,685	1,343,239
Finished goods	9,824,987	10,357,452
Inventory, gross	454,181	21,962,976
Less: allowances for obsolete & slow-moving inventories	1,904,340	1,187,610
Inventories, net	21,694,748	20,775,366
Prepaid expenses & other current assets	611,066	502,156
Total current assets	42,444,829	45,840,497
Computers & computer equipment	1,146,490	825,086
Furniture & office equipment	503,180	469,060
Manufacturing equipment & engineering tools	8,553,224	2,713,137
ERP financial system	3,081,805	2,585,357
Leasehold improvements	1,045,483	1,036,947
Vehicles	37,746	9,745
Manufacturing equipment and engineering tools	2,738,520	...
Property & equipment, gross	...	7,639,332

Recent Dividends:

1. One Stop Systems Inc series B preferred.

No dividends paid.

2. One Stop Systems Inc series A preferred.

No dividends paid.

3. One Stop Systems Inc series C preferred.

No dividends paid.

4. One Stop Systems Inc common.

No dividends paid.

Annual Dividends:

1. One Stop Systems Inc series B preferred.

No dividends paid.

2. One Stop Systems Inc series A preferred.

No dividends paid.

3. One Stop Systems Inc series C preferred.

No dividends paid.

4. One Stop Systems Inc common.

No dividends paid.

ONESPAN INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

	2023	2022	2021
		(revised)	(revised)
Product & license revenue	130,848	121,426	120,358
Service & other revenue	...	97,580	94,123
Services and other	104,258
Total revenue	235,106	219,006	214,481
Cost of products sold	48,676
Cost of product & license	...	45,106	46,196

Weighted average shares outstanding - basic	40,193	40,143	39,614
Weighted average shares outstanding - diluted	40,193	40,143	39,614
Year end shares outstanding	37,519	39,726	40,001
Net income (loss) per share - basic	\$(0.74)	\$(0.36)	\$(0.77)
Net income (loss) per share - diluted	\$(0.74)	\$(0.36)	\$(0.77)
Number of full time employees	676
Total number of employees	676	...	879
Number of common

stockholders	111	...	153
Number of beneficiary			
stockholders	...	10,799	9,860
Basic EPS Excluding ExtraOrdinary Items	\$(0.74)
Diluted EPS Excluding ExtraOrd Items	\$(0.74)

Recent Dividends:
1. OneSpan Inc common.
 No dividends paid.
Annual Dividends:
1. OneSpan Inc common.
 No dividends paid.

OPAL FUELS INC

Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2023	2022
Total revenues	169,100,000	168,814,000
Cost & expenses	173,938,000	159,640,000
Operating income	(15,772,000)	(642,000)
Interest expense	4,482,000	7,184,000
Other income (expense), net	122,230,000	8,386,000
Gains or losses	4,955,000	...
Net before taxes	106,931,000	560,000
Net income	106,931,000	560,000
Balance for common	15,945,000	(1,125,000)
Earnings common share		
Primary	\$0.59	\$(0.04)
Fully Diluted	\$0.58	\$(0.06)
Common Shares:		
Full Diluted	27,683,855	25,823,772
Year-end	27,696,550	170,070,427

OPEN LENDING CORP
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Program fees	80,611,000	75,630,000	...
Profit share	43,301,000	90,056,000	133,215,000
Claims administration service fees	64,092,000
Claims administration & other service fees	10,067,000	8,927,000	6,810,000
Total revenue	117,460,000	179,594,000	215,655,000
Cost of services	22,282,000	19,968,000	18,621,000
Gross profit (loss)	95,178,000	159,626,000	197,034,000
General & administrative expenses	43,043,000	35,950,000	30,393,000
Selling & marketing expenses	17,485,000	17,856,000	12,000,000
Research & development expenses	5,575,000	8,205,000	4,352,000
Total operating expenses	66,103,000	62,011,000	46,745,000
Operating income (loss)	29,075,000	97,615,000	150,289,000
Gain on extinguishment of tax receivable agreement	55,422,000
Loss on extinguishment of debt	(8,778,000)
Interest expense	10,661,000	5,832,000	5,859,000
Interest income	10,335,000	1,995,000	213,000
Other expense, net	(109,000)	238,000	119,000
Income (loss) before income taxes	28,858,000	93,540,000	191,168,000
Current federal income tax expense (benefit)	10,091,000	22,029,000	19,537,000
Current state income taxes	1,682,000	4,516,000	5,494,000
Deferred federal income tax expense (benefit)	(2,821,000)	(4,165,000)	16,098,000
Deferred state income tax expense (benefit)	(2,164,000)	4,540,000	3,957,000
Provision (benefit) for income taxes	6,788,000	26,920,000	45,086,000
Net income (loss)	22,070,000	66,620,000	146,082,000
Net income (loss) attributable to common stockholders	...	66,620,000	146,082,000

Weighted average shares outstanding - basic	120,826,644	126,108,329	126,354,597
Weighted average shares outstanding - diluted	121,474,880	126,261,614	126,390,435
Year end shares outstanding	118,819,795	123,646,059	126,212,876
Net income (loss) per share - basic	\$0.18	\$0.53	\$1.16
Net income (loss) per share - diluted	\$0.18	\$0.53	\$1.16
Full-Time Employees (Period End)	210
Total number of employees	210	180	132
Number of common stockholders	23	24	28
EPS - Basic - excluding Extraordinary Items
Applicable to Common - Total	\$0.18
EPS - Diluted - excluding Extraordinary Items
Applicable to Common - Total	\$0.18

As is; As of February 18, 2022; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022	(revised)
Cash & cash equivalents	42,493	96,167	66,732
Short term investments	...	2,328	1,600
Restricted cash	1,037	1,208	65,132
Accounts receivable, gross	65,923	66,732	64,387
Less: allowances	1,536	1,600	8,511
Accounts receivable, net	64,387	65,132	6,762
Component parts	8,511	6,762	7,042
Work-in-process & finished goods	7,042	5,292	15,553
Inventories, net	15,553	12,054	6,575
Prepaid expenses	6,575	6,222	5,139
Contract assets	5,139	4,520	11,159
Other current assets	11,159	10,757	146,343
Total current assets	146,343	198,387	3,658
Office equipment & software	3,658	4,260	7,459
Leasehold improvements	7,459	9,927	12,560
Capitalized software	12,560	4,007	8,574
Office equipment and software	8,574	14,451	32,251
Total property & equipment	32,251	32,645	13,529
Accumulated depreciation	13,529	19,964	18,722
Property & equipment, net	18,722	12,681	6,171
Operating lease right-of-use assets	6,171	8,022	93,684
Goodwill	93,684	90,514	10,832
Intangible assets, net of accumulated amortization	10,832	12,482	1,721
Deferred income taxes	1,721	1,901	11,718
Other assets	11,718	11,095	289,191
Total assets	289,191	335,082	17,452
Accounts payable	17,452	17,357	69,331
Deferred revenue	69,331	64,637	14,335
Accrued wages & payroll taxes	14,335	18,345	2,646
Short-term income taxes payable	2,646	2,438	10,684
Other accrued expenses	10,684	7,664	382
Deferred compensation	382	373	2,027
Operating lease liabilities	2,027	2,258	8,657
Other Accrued Expenses - Balancing value	8,657	5,406	114,830
Total current liabilities	114,830	110,814	4,152
Long-term deferred revenue	4,152	6,269	6,824
Long-term lease liabilities	6,824	8,442	3,177
Other long-term liabilities	3,177	2,484	...
Long-term income taxes payable	...	2,565	1,067
Deferred income taxes	1,067	1,197	130,050
Total liabilities	130,050	131,771	38
Common stock	38	40	118,620
Additional paid-in capital	118,620	107,305	47,377
Treasury stock, at cost	47,377	18,222	98,939
Retained earnings (accumulated deficit)	98,939	128,738	(11,079)
Accumulated other comprehensive income (loss)	(11,079)	(14,550)	159,141
Total stockholders' equity (deficit)	159,141	203,311	159,141
Rep Total Equity & Minority Interest	159,141	203,311	...

Reclassified to conform with 2022 presentation; As of February 27, 2023; As of February 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	240,206,000	204,450,000
Restricted cash	6,463,000	4,069,000
Accounts receivable	4,616,000	5,721,000
Current contract assets	28,704,000	54,429,000
Income tax receivable	7,035,000	9,714,000
Other current assets	2,852,000	2,361,000
Total current assets	289,876,000	280,744,000
Property & equipment, net	3,913,000	2,573,000
Operating lease right-of-use asset	5,911,000	...
Accumulated amortization	1,921,000	...
Operating lease right-of-use assets, net	3,990,000	4,610,000
Contract assets, net	610,000	21,001,000
Deferred tax asset, net	70,113,000	65,128,000
Other assets	5,535,000	5,575,000
Total assets	374,037,000	379,631,000
Accounts payable & accrued expenses	375,000	...
Accounts payable	...	288,000
Accrued expenses	8,131,000	6,388,000
Current portion of debt	...	3,750,000
Current notes payable	4,688,000	...
Third-party claims administration liability	6,464,000	4,055,000
Other current liabilities	932,000	626,000
Total current liabilities	20,590,000	15,107,000
Term loan	...	149,063,000
Less: current portion of debt	...	3,750,000
Less: unamortized deferred financing costs	...	(1,630,000)
Long-term debt, net of deferred financing costs	139,357,000	143,683,000
Operating lease liabilities	3,450,000	4,082,000
Other non-current liabilities	5,060,000	3,935,000
Total liabilities	168,457,000	166,807,000
Common stock	1,282,000	1,282,000
Additional paid-in capital	502,032,000	499,625,000
Retained earnings (accumulated deficit)	(193,749,000)	(215,819,000)
Treasury stock at cost	103,985,000	72,264,000
Total stockholders' equity (deficit)	205,580,000	212,824,000
Total Equity	205,580,000	...

Recent Dividends:**1. Open Lending Corp class B common.**

No dividends paid.

2. Open Lending Corp class A common subject to possible redemption.

No dividends paid.

3. Open Lending Corp class A common.

No dividends paid.

Annual Dividends:**1. Open Lending Corp class B common.**

No dividends paid.

2. Open Lending Corp class A common subject to possible redemption.

No dividends paid.

3. Open Lending Corp class A common.

No dividends paid.

OPENLOCKER HOLDINGS INC**Earnings, 6 mos. to Jan 31(Consol. - \$):**

	2024	2023
Total revenues	16,310	11,089
Cost & expenses	603,643	1,337,892
Operating income	(587,333)	(1,326,803)
Net before taxes	(612,978)	(1,326,803)
Net income	(612,978)	(1,326,803)
Earnings common share		
Primary	\$(0.01)	\$(0.03)
Fully Diluted	\$(0.01)	\$(0.03)
Common Shares:		
Full Diluted	41,455,308	38,910,468
Year-end	41,604,650	39,150,006

OPPENHEIMER HOLDINGS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021 (revised)
Commissions	349,248,000	370,382,000	401,607,000
Advisory fees	415,679,000	425,615,000	451,197,000
Investment banking	117,665,000	127,529,000	435,870,000
Bank deposit sweep income	172,807,000	104,558,000	15,557,000
Interest income	104,550,000	60,713,000	36,482,000
Principal transactions, net	65,347,000	21,031,000	23,984,000
Other revenue	23,529,000	1,113,000	29,338,000
Total revenue	1,248,825,000	1,110,941,000	1,394,035,000
Compensation & related expenses	782,396,000	740,827,000	886,840,000
Communications & technology	91,321,000	85,474,000	80,520,000
Occupancy & equipment costs	66,002,000	59,897,000	60,069,000
Clearing & exchange fees	24,928,000	25,566,000	22,306,000
Interest expense	68,599,000	23,846,000	9,855,000
Other expenses	168,809,000	129,777,000	109,804,000
Total expenses	1,202,055,000	1,065,387,000	1,169,394,000
Pre-tax income	46,770,000	45,554,000	224,641,000
Current U.S. federal tax (benefit)	6,967,000	18,862,000	47,880,000
Current state & local tax (benefit)	...	8,068,000	18,331,000
Current non-U.S. operations (benefit)	937,000	1,129,000	258,000
Current Tax - Local	2,137,000
Current income taxes (benefit)	10,041,000	28,059,000	66,469,000
Deferred U.S. federal tax (benefit)	5,207,000	(10,420,000)	(1,745,000)
Deferred state & local tax (benefit)	...	(4,538,000)	790,000
Deferred non-U.S. operations (benefit)	331,000	343,000	163,000
Deferred Tax - Local	919,000
Deferred income taxes (benefit)	6,457,000	(14,615,000)	(792,000)
Income tax expense (benefit)	16,498,000	13,444,000	65,677,000
Net income (loss)	30,272,000	32,110,000	158,964,000

Less net loss (income) attributable to non-controlling interest, net of tax	(93,000)	241,000	...
Net income (loss) attributable to Oppenheimer Holdings Inc.	30,179,000	32,351,000	158,964,000
Weighted average shares outstanding - basic	10,736,166	11,666,194	12,642,306
Weighted average shares outstanding - diluted	11,645,708	12,607,752	13,582,828
Year end shares outstanding	10,286,448	10,968,221	12,546,701
Net earnings (loss) per share-basic	\$2.81	\$2.77	\$12.57
Net earnings (loss) per share-diluted	\$2.59	\$2.57	\$11.70
Dividends per share	...	\$0.60	\$1.54
Number of full time employees	2,903	2,868	2,868
Number of part time employees	39	44	45
Number of employees	2,942	2,912	2,913
Number of class A stockholders	...	90	72
Number of class B stockholders	...	31	32
Number of common stockholders	118
Comprehensive income attributable to Oppenheimer Holdings Inc	29,677,000

Reclassified to conform with 2022 presentation; As of February 28, 2023; As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	28,835,000	112,433,000
Deposits with clearing organizations	78,706,000	77,691,000
Restricted cash	...	25,534,000
Receivable from brokers, dealers & clearing organizations	284,696,000	206,077,000
Receivable from customers, gross	1,060,237,000	1,203,114,000
Allowance for credit losses	345,000	350,000
Receivable from customers, net	1,059,892,000	1,202,764,000
Income tax receivable	7,199,000	...
Securities purchased under agreements to resell	5,842,000	...
Securities owned	...	498,594,000
Notes receivable, net	62,640,000	57,495,000
Furniture, fixtures & equipment	63,473,000	76,070,000
Leasehold improvements	...	58,423,000
Furniture, equipment & leasehold improvements, gross	126,606,000	134,493,000
Less: accumulated depreciation	82,732,000	97,751,000
Furniture, equipment & leasehold improvements, net	43,874,000	36,742,000
Accumulated Amortization
Operating Lease, Right-of-Use	99,716,000	...
Operating Lease, Right-of-Use Asset - Balancing value	240,270,000	...
Right-of-use lease assets, net	140,554,000	142,630,000
Intangible assets	34,340,000	32,100,000

Goodwill	142,162,000	137,889,000
Other assets	190,764,000	184,443,000
Securities owned, including amounts pledged	795,312,000	...
Total assets	2,874,816,000	2,714,392,000
Payable to brokers, dealers & clearing organizations	9,002,000	550,006,000
Payable to customers	369,287,000	456,475,000
Securities sold under agreements to repurchase	640,382,000	161,009,000
Securities sold, but not yet purchased, at fair value	31,676,000	52,768,000
Accrued compensation	256,244,000	239,136,000
Accounts payable & other liabilities	82,810,000	102,202,000
Lease liabilities	183,273,000	182,570,000
Income tax payable	...	4,130,000
Senior secured notes, net	112,658,000	113,434,000
Deferred tax liabilities, net	38,355,000	32,241,000
Payable to brokers, dealers and clearing organizations	361,890,000	...
Deferred Tax - Debit - Liability	(47,830,000)	...
Deferred tax liabilities, net of deferred tax assets - Balancing value	84,165,000	...
Deferred tax liabilities, net of deferred tax assets - Balancing value	2,020,000	...
Total liabilities	2,085,577,000	1,893,971,000
Redeemable noncontrolling interests	...	25,466,000
Common stock	10,000	11,000
Additional paid-in capital	31,774,000	28,628,000
Retained earnings (accumulated deficit)	756,468,000	764,178,000
Accumulated other comprehensive income (loss)	914,000	1,416,000
Total Oppenheimer Holdings Inc. stockholders' equity	789,166,000	794,233,000
Non-controlling interest	73,000	722,000
Total stockholders' equity	789,239,000	794,955,000

Including amounts pledged - securities owned, at fair value: \$175,724,000; Net of accumulated amortization - right-of-use lease assets: \$82,449,000; Net of debt issuance costs - senior secured notes: \$616,000; Net of deferred tax assets - deferred tax liabilities: \$55,628,000

Recent Dividends:**1. Oppenheimer Holdings Inc class B voting common.**

ExDate	Amt	Declared	Record	Payable
01/20/2021	0.12	01/20/2021	02/12/2021	02/26/2021
03/09/2021	0.12	03/09/2021	05/14/2021	05/28/2021
07/29/2021	0.15	07/29/2021	08/12/2021	08/26/2021
12/23/2021	1.00	12/14/2021	12/27/2021	12/31/2021

2. Oppenheimer Holdings Inc class A non-voting common.

ExDate	Amt	Declared	Record	Payable
02/11/2021	0.12	01/29/2021	02/12/2021	02/26/2021
05/13/2021	0.12	04/30/2021	05/14/2021	05/28/2021
08/11/2021	0.15	07/29/2021	08/12/2021	08/26/2021
11/10/2021	0.15	10/29/2021	11/12/2021	11/26/2021
12/23/2021	1.00	12/14/2021	12/27/2021	12/31/2021
02/10/2022	0.15	01/28/2022	02/11/2022	02/25/2022
05/12/2022	0.15	04/29/2022	05/13/2022	05/27/2022
08/11/2022	0.15	07/29/2022	08/12/2022	08/26/2022
11/09/2022	0.15	10/28/2022	11/11/2022	11/25/2022
02/09/2023	0.15	01/27/2023	02/10/2023	02/24/2023
05/11/2023	0.15	04/28/2023	05/12/2023	05/26/2023
08/10/2023	0.15	07/28/2023	08/11/2023	08/25/2023
11/09/2023	0.15	10/27/2023	11/10/2023	11/24/2023
02/08/2024	0.15	01/26/2024	02/09/2024	02/23/2024

Annual Dividends:
1. Oppenheimer Holdings Inc class B voting common.
 2021.....1.39
2. Oppenheimer Holdings Inc class A non-voting common.
 2021.....1.54 2022.....0.60 2023.....0.60
 2024.....0.15

Net income (loss) 267,090 150,556 139,898
 Weighted average shares outstanding
 - basic 178,973 181,105 179,855
 Weighted average shares outstanding
 - diluted 180,375 182,075 181,205
 Year end shares outstanding 174,576 181,958 179,926
 Earnings per share (loss) from continuing operations-basic \$1.49 ...
 Net earnings (loss) per common share - basic \$1.49 \$0.83 \$0.78
 Earnings per share (loss) from continuing operations-diluted \$1.48 ...
 Net earnings (loss) per common share - diluted \$1.48 \$0.83 \$0.77
 Number of full time employees 5,809 5,597 5,430
 Number of part time employees 1,993 2,461 1,808
 Total number of employees 7,802 ... 7,238
 Number of common stockholders 96 118 122

Deferred income taxes 34,920 22,154
 Other noncurrent liabilities 9,683
 Total noncurrent liabilities 1,177,054 1,161,482
 Total liabilities 1,795,363 1,726,833
 Common stock 18 18
 Treasury stock 255,107 2,403
 Paid-in capital 1,204,270 1,176,906
 Retained earnings (accumulated deficit) 457,513 190,423
 Accumulated other comprehensive income (loss) 14,978 21,159
 Total stockholders' equity (deficit) 1,421,672 1,386,103
 Rep Total Equity & Minority Interest 1,421,672 ...

OPTEX SYSTEMS HOLDINGS INC
Earnings, 3 mos. to (Consol. - \$):

	12/31/23	01/01/23
Total revenues	6,968,000	4,040,000
Cost & expenses	6,415,000	4,322,000
Operating income	553,000	(282,000)
Interest expense	7,000	
Net before taxes	546,000	(282,000)
Income taxes	115,000	(59,000)
Net income	431,000	(223,000)
Earnings common share		
Primary	\$0.06	\$(0.03)
Fully Diluted	\$0.06	\$(0.03)
Common Shares:		
Full Diluted	6,721,661	6,537,808
Year-end	6,823,693	6,763,070

Consolidated Balance Sheet Items, as of (\$):

	2023
Assets:	
Cash & equivalents	2,373,000
Inventories	12,685,000
Current assets	17,900,000
Net property & equip.	964,000
Total assets	22,389,000
Liabilities:	
Current liabilities	4,856,000
Stockholders' equity	15,377,000
Net current assets	13,044,000

As is; As of February 20, 2023; As of February 18, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	343,849	294,186
Accounts receivable, net	...	377,542
Receivables, net	377,658	...
Inventories	274,004	224,281
Prepaid expenses & other current assets	98,744	98,330
Total current assets	1,094,255	994,339
Infusion pumps	36,943	34,942
Equipment, furniture & other property & equipment	23,593	31,929
Leasehold improvements	99,725	99,085
Computer software, purchased & internally developed	50,572	34,922
Assets under development	33,668	29,411
Property & equipment, gross	244,501	230,289
Less: accumulated depreciation	123,871	121,968
Property & equipment, net	120,630	108,321
Operating lease right-of-use asset	84,159	72,424
Goodwill	1,540,246	1,533,424
Intangible assets, net	20,092	22,371
Referral sources, net	315,304	341,744
Other noncurrent assets	42,349	40,313
Total noncurrent assets	2,122,780	2,118,597
Total assets	3,217,035	3,112,936
Current portion of long-term debt	6,000	6,000
Accounts payable	426,513	378,763
Accrued compensation & employee benefits	92,508	76,906
Accrued expenses & other current liabilities	75,010	84,302
Current portion of operating lease liability	18,278	19,380
Total current liabilities	618,309	565,351
First lien term loan	...	574,164
Senior unsecured notes	1,056,650	490,040
Total debt	...	1,064,204
Less: current portion	...	6,000
Operating lease liability, net of current portion	85,484	71,441

Recent Dividends:
1. Option Care Health Inc series C convertible preferred.
 No dividends paid.
2. Option Care Health Inc series A convertible preferred.
 No dividends paid.
3. Option Care Health Inc common.
 No dividends paid.
Annual Dividends:
1. Option Care Health Inc series C convertible preferred.
 No dividends paid.
2. Option Care Health Inc series A convertible preferred.
 No dividends paid.
3. Option Care Health Inc common.
 No dividends paid.

ORAMED PHARMACEUTICALS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
SALES AND MARKETING	87,000
REVENUES	1,340,000
Revenues	1,340,000	2,703,000	904,000
Research & development expenses	8,971,000	27,639,000	9,037,000
Selling & marketing expenses	...	1,851,000	898,000
General & administrative expenses	8,425,000	13,811,000	3,295,000
Operating income (loss)	(15,769,000)	(40,598,000)	(12,326,000)
Changes in fair value of warrants	(1,514,000)
Income from interest on deposits	8,016,000	3,473,000	114,000
Exchange rate differences, net	...	176,000	...
Income from interest on corporate bonds	10,000	100,000	43,000
Gain from securities, net	16,461,000
Other financial income	...	5,000	1,000
Interest expense	2,037,000
Exchange rate differences	(124,000)	...	(11,000)
Bank & broker commissions	29,000	14,000	2,000
Gain (loss) from securities, net	(69,000)	(43,000)	...
Revaluation of securities, net	...	(763,000)	(72,000)
Other financial expenses	2,000
Income (loss) before tax expenses - United States (U.S.)	11,604,000	(11,164,000)	(3,639,000)
Income (loss) before tax expenses - outside U.S.	(6,516,000)	(26,500,000)	(8,616,000)

OPTION CARE HEALTH INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021
Net revenue	4,302,324
Net revenue	4,302,324	3,944,735	3,438,640
Cost of revenue	3,321,101	3,077,817	2,659,034
Gross profit (loss)	981,223	866,918	779,606
Selling, general & administrative expenses	...	566,122	525,707
General & administrative expenses	607,427
Depreciation & amortization expense	59,201	60,565	63,058
Total operating expenses	666,628	626,687	588,765
Operating income (loss)	314,595	240,231	190,841
Interest expense, net	51,248	53,806	67,003
Equity in earnings of joint ventures	5,530	5,125	6,030
Other income (expense), net	89,865	14,218	(13,374)
Total other income (expense)	...	(34,463)	(74,347)
Income (loss) before income taxes	358,742	205,768	116,494
Current income tax provision (benefit) - federal	56,474	4,103	...
Current income tax provision (benefit) - state	20,253	9,182	6,817
Deferred income tax provision (benefit) - federal	18,739	38,810	(30,411)
Deferred income tax provision (benefit) - state	(3,814)	3,117	190
Income tax expense (benefit)	91,652	55,212	(23,404)

Income (loss)			
before tax expenses ..	5,088,000	(37,664,000)	(12,255,000)
Current taxes on income - outside U.S.	100,000
Tax expenses	100,000
Net income (loss) for the period	5,088,000	(37,764,000)	(12,255,000)
Net income (loss) attributable to non-controlling interests	437,000	1,203,000	587,000
Net income (loss) attributable to stockholders	5,525,000	(36,561,000)	(11,668,000)
Weighted average shares outstanding - basic	40,315,068	38,997,649	37,113,137
Weighted average shares outstanding - diluted	40,566,901	38,997,649	37,113,137
Year end shares outstanding	40,338,979	39,563,888	38,158,792
Net income (loss) per share - basic	\$0.14	\$(0.94)	\$(0.31)
Net income (loss) per share - diluted	\$0.14	\$(0.94)	\$(0.31)
Full-Time Employees (Period End)	15
Total number of employees	15	17	...
Number of common stockholders	38	34	...
FINANCIAL INCOME (EXPENSE), NET ..	22,894,000
Basic EPS Excluding ExtraOrdinary Items ..	\$0.14
Diluted EPS Excluding ExtraOrd Items	\$0.14

□ For 4 months due to fiscal year end change; □ Reclassified to conform with 2022 presentation; □ Approximately; □ As of March 6, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	9,055,000	40,464,000
Short term deposits	95,279,000	111,513,000
Investment in equity securities - D.N.A		
Biomedical Solutions Ltd.	352,000
Investment in equity securities - Entera Bio Ltd.	85,000
Held to maturity bonds	3,306,000
Marketable securities	3,743,000
Prepaid expenses & other current assets	1,389,000
Investments at fair value	57,713,000	...
Total current assets	162,584,000	157,109,000
Lease car deposits	7,000
Long term deposits	7,000	7,000
Marketable securities	1,807,000	...
Long-term investment	2,700,000
Amounts funded in respect of employee rights upon retirement	27,000	24,000
Property & equipment, net	873,000	815,000
Operating lease right of use assets	694,000	987,000
Other non-marketable equity securities	3,524,000	...
Investments at fair value	51,035,000	...
Total long term assets	57,967,000	4,533,000
Total assets	220,551,000	161,642,000
Accounts payable	551,000	2,175,000
Payroll & related accruals	453,000	529,000
Institutions	11,000
Accrued liabilities	605,000	1,443,000
Due to shareholder	325,000	...
Deferred revenues	1,340,000

Payable to related parties	1,000
Operating lease liabilities	267,000	247,000
Short-term borrowings	51,013,000	...
Total current liabilities	53,214,000	5,746,000
Long-term deferred revenues	4,000,000	4,000,000
Employee rights upon retirement	28,000	21,000
Provision for uncertain tax position	11,000	11,000
Operating lease liabilities	342,000	647,000
Other liabilities	63,000	61,000
Total long term liabilities	4,444,000	4,740,000
Common stock	485,000	476,000
Additional paid-in capital	320,892,000	314,417,000
Retained earnings (accumulated deficit)	(157,556,000)	(163,081,000)
Total stockholders' equity	163,821,000	151,812,000
Non-controlling interests	(928,000)	(656,000)
Total equity	162,893,000	151,156,000

Recent Dividends:

1. Oramed Pharmaceuticals Inc common.

No dividends paid.

Annual Dividends:

1. Oramed Pharmaceuticals Inc common.

No dividends paid.

ORAMED PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Total revenues	1,340,000	2,022,000
Cost & expenses	13,232,000	32,880,000
Operating income	(11,892,000)	(30,858,000)
Interest income	4,510,000	...
Interest expense	826,000	...
Net before taxes	(8,208,000)	(28,928,000)
Income taxes	100,000	...
Net income	(8,208,000)	(29,028,000)
Earnings common share		
Primary	\$(0.19)	\$(0.72)
Fully Diluted	\$(0.19)	\$(0.72)
Common Shares:		
Full Diluted	40,246,515	38,856,514
Year-end	40,282,688	39,113,236

ORGANOGENESIS HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	□2021
Net revenue	433,140,000
Net revenue	433,140,000	450,893,000	467,359,000
Cost of goods sold	106,481,000	105,019,000	114,199,000
Gross profit (loss)	326,659,000	345,874,000	353,160,000
Selling, general & administrative expenses	269,754,000	283,808,000	250,200,000
Research & development expenses	44,380,000	39,762,000	30,742,000
Total operating expenses	314,134,000	323,570,000	280,942,000
Income (loss) from operations	12,525,000	22,304,000	72,218,000
Interest expense	2,190,000	2,009,000	7,236,000
Gain (loss) on the extinguishment of debt	(1,883,000)
Other income (loss), net	57,000	(13,000)	(13,000)
Total other income (expense), net	(2,133,000)	(2,022,000)	(9,132,000)
Net income (loss) before income taxes ..	10,392,000	20,282,000	63,086,000
Current federal income tax expense (benefit)	1,275,000	178,000	...

Current state income tax expense (benefit)	2,157,000	2,575,000	899,000
Current foreign income tax expense (benefit)	3,000	17,000	(39,000)
Total current income tax expense (benefit)	3,435,000	2,770,000	860,000
Deferred federal income tax expense (benefit)	3,311,000	5,446,000	(30,506,000)
Deferred state income tax expense (benefit)	(1,312,000)	(3,466,000)	(1,470,000)
Deferred foreign income tax expense (benefit)	13,000
Total deferred income tax expense (benefit)	2,012,000	1,980,000	(31,976,000)
Income tax expense (benefit)	5,447,000	4,750,000	(31,116,000)
Net income (loss)	4,945,000	15,532,000	94,202,000

Weighted average shares outstanding

- basic

Weighted average shares outstanding

- diluted

Year end shares outstanding

Net income (loss) per share - basic

Net income (loss) per share - diluted

Number of full time employees

Total number of employees

Number of class A common shareholders

EPS - Basic - excluding ExtraOrdinary Items

Applicable to Common - Total

EPS - Diluted - excluding ExtraOrdinary Items

Applicable to Common - Total

□ Reclassified to conform with 2022 presentation; □ Approxi-

mately; □ As of February 15, 2023; □ As of February 15, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	103,840,000	102,478,000
Restricted cash	498,000	812,000
Accounts receivable, gross	95,812,000
Less - allowance for doubtful accounts	6,362,000
Accounts & Notes Receivable - Trade - Net	81,999,000	...
Accounts & Notes Receivable - Trade - Net - Balancing value	88,859,000	...
Accounts receivable, net	89,450,000
Raw materials	12,988,000	12,282,000
Work in process	810,000	1,022,000
Finished goods	14,455,000	11,479,000
Inventory	28,253,000	24,783,000
Prepaid subscriptions	4,211,000
Prepaid conferences & marketing expenses	106,000
Deposits	635,000
Prepaid insurance	54,000
Other prepaid expenses & current assets	80,000
Prepaid expenses & current assets	10,454,000	5,086,000

- allowance for credit losses	6,860,000	...
Total current assets	225,044,000	222,609,000
Leasehold improvements	60,819,000	37,607,000
Building	4,943,000	4,943,000
Furniture, computers & equipment	64,585,000	57,147,000
Property & equipment, gross	...	99,697,000
Accumulated depreciation & amortization	...	62,798,000
Construction in progress	59,067,000	65,564,000
Accumulated depreciation	73,186,000	...
Property & equipment, net	116,228,000	102,463,000
Intangible assets, net	15,871,000	20,789,000
Goodwill	28,772,000	28,772,000
Operating lease right-of-use assets, net	40,118,000	43,192,000
Deferred tax asset, net	28,002,000	30,014,000
Other assets	5,990,000	1,520,000
Total assets	460,025,000	449,359,000
Current portion of term loan	5,486,000	4,538,000
Current portion of finance lease obligations	1,081,000	...
Current portion of operating lease obligations	10,004,000	11,708,000
Accounts payable	30,724,000	32,330,000
Accrued personnel costs	...	17,113,000
Accrued royalties	...	3,320,000
Accrued but unpaid lease obligations & interest	...	2,463,000
Accrued taxes	...	2,625,000
Other accrued expenses & other current liabilities	...	926,000
Accrued expenses & other current liabilities	30,074,000	26,447,000
Current portion of operating lease obligations - related party	3,140,000	...
Total current liabilities	80,509,000	75,023,000
Term loan	...	71,250,000
Less debt discount & debt issuance cost	60,745,000	(481,000)
Less current maturities	...	(4,538,000)
Term loan, net of current portion	...	66,231,000
Finance lease obligations, net of current portion	1,888,000	...
Operating lease obligations, net of current portion	19,780,000	41,314,000
Other liabilities	1,213,000	1,122,000
Operating lease obligations, net of current portion - related party	17,227,000	...
Total liabilities	181,362,000	183,690,000
Common stock	13,000	13,000
Additional paid-in capital	319,621,000	310,957,000
Retained earnings (accumulated deficit)	(40,971,000)	(45,301,000)
Total stockholders' equity (deficit)	278,663,000	265,669,000
Total Equity	278,663,000	...

Recent Dividends:

1. Organogenesis Holdings Inc Class A ordinary shares subject to possible redemption.

No dividends paid.

2. Organogenesis Holdings Inc class A common.

No dividends paid.

3. Organogenesis Holdings Inc class A ordinary shares.

No dividends paid.

4. Organogenesis Holdings Inc class B ordinary shares.

No dividends paid.

5. Organogenesis Holdings Inc redeemable class A common.

No dividends paid.

Annual Dividends:

1. Organogenesis Holdings Inc Class A ordinary shares subject to possible redemption.

No dividends paid.

2. Organogenesis Holdings Inc class A common.

No dividends paid.

3. Organogenesis Holdings Inc class A ordinary shares.

No dividends paid.

4. Organogenesis Holdings Inc class B ordinary shares.

No dividends paid.

5. Organogenesis Holdings Inc redeemable class A common.

No dividends paid.

ORIGIN MATERIALS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
			(revised)
Products	23,896,000
Services	4,909,000
Total revenues	28,805,000
Cost of revenues (exclusive of depreciation and amortization shown separately below)	23,591,000
Research & development	21,351,000	14,141,000	9,124,000
General & administrative	35,382,000	24,095,000	17,265,000
Depreciation & amortization	3,363,000	711,000	544,000
Total operating expenses	...	38,947,000	26,933,000
Income (loss) from operations	(54,882,000)	(38,947,000)	(26,933,000)
Interest income	6,303,000	8,825,000	1,413,000
Interest expense, net of capitalized interest	131,000	...	2,838,000
Change in fair value of derivatives	69,000	(443,000)	(1,326,000)
Change in fair value of warrants liability	...	21,988,000	(4,525,000)
Change in fair value of earnout liability	40,983,000	85,437,000	75,488,000
Other income, net	838,000	1,709,000	811,000
Unrealized gain on marketable securities held in trust account	29,531,000
Income before income tax benefits	22,711,000
Total other (income) expenses, net	77,593,000	117,516,000	69,023,000
Net income (loss)	23,798,000	78,569,000	42,090,000
Weighted average shares outstanding - basic	139,718,385	137,563,877	101,221,781
Weighted average shares outstanding - diluted	142,658,423	142,146,767	106,237,754
Year end shares outstanding	145,706,531	143,034,225	141,301,569
Net income (loss) per share - basic	\$0.17	\$0.57	\$0.42
Net income (loss) per share - diluted	\$0.17	\$0.55	\$0.40
Number of full time employees	162	201	86
Number of common stockholders	37	43	97
Number of warrant holders	...	1	...
Total number of employees	162
Foreign currency translation adjustments	...	(6,688,000)	77,000
State	20,000
Foreign	139,000
Total current tax

expenses	159,000
Foreign	(1,246,000)
Income tax expenses	(1,087,000)

□ Approximately; □ As of February 16, 2023; □ As of February 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	75,502,000	107,858,000
Restricted cash	...	490,000
Marketable securities	82,761,000	215,464,000
Other receivables	3,449,000	4,346,000
Prepaid expenses & other current assets	8,360,000	3,341,000
Accounts receivable	16,128,000	...
Finished goods	24,000	...
Inventory	912,000	...
Raw materials	888,000	...
Total current assets	187,112,000	331,499,000
Land	11,356,000	11,358,000
Pilot plant	116,754,000	4,599,000
Lab equipment	3,468,000	2,526,000
Machinery & equipment	1,094,000	948,000
Computer & other equipment	1,629,000	598,000
Construction in process	54,023,000	138,847,000
Property, plant and equipment, gross	187,112,000	331,499,000
Land Improvements	62,930,000	...
Property, plant & equipment, gross	...	158,876,000
Less: accumulated depreciation & amortization	8,136,000	4,693,000
Property, plant & equipment, net	243,118,000	154,183,000
Operating lease right-of-use asset	4,468,000	2,779,000
Intangible assets, net	121,000	160,000
Other long-term assets	25,754,000	5,079,000
Deferred tax assets	1,261,000	...
Total assets	461,834,000	493,700,000
Accounts payable	1,858,000	10,384,000
Accrued expenses	7,689,000	8,414,000
Operating lease liability, current	367,000	619,000
Other liabilities, current	918,000	51,000
Derivative liability	300,000	344,000
Stockholder convertible notes payable	1,730,000	...
Total current liabilities	12,862,000	19,812,000
Earnout liability	1,783,000	42,533,000
Canadian government research & development program liability	7,348,000	7,185,000
Assumed common stock warrants liability	1,341,000	30,872,000
Stockholder note	3,459,000	5,847,000
Related party other liabilities, long-term	...	5,395,000
Operating lease liability	4,207,000	2,249,000
Other liabilities, long-term	...	2,902,000
Other Non-Current Liabilities	8,327,000	...
Total liabilities	39,327,000	116,795,000
Common stock	15,000	14,000
Additional paid-in capital	382,854,000	371,072,000
Retained earnings (accumulated deficit)	45,570,000	21,772,000
Accumulated other comprehensive income (loss)	(5,932,000)	(15,953,000)
Total stockholders' equity	422,507,000	376,905,000
Total Equity	422,507,000	...

Recent Dividends:

1. Origin Materials Inc common.

No dividends paid.

2. Origin Materials Inc class B common. No dividends paid.				Number of full time employees	1,078	liabilities	65,272	63,288
3. Origin Materials Inc class A common. No dividends paid.				Total number of employees	1,078	² 1,023	³ 953	Current portion of finance lease liabilities	4,000
Annual Dividends:				Number of class A common stockholders	73	² 102	³ 116	Total current liabilities	169,488	145,927
1. Origin Materials Inc common. No dividends paid.				Basic EPS Excluding ExtraOrdinary Items ..	\$0.80	Reserve for uncertain tax positions	285	175
2. Origin Materials Inc class B common. No dividends paid.				Diluted EPS	Term loan	422,973
3. Origin Materials Inc class A common. No dividends paid.				Excluding ExtraOrd Items	\$0.77	Unsecured senior notes	357,406	390
								Less current installments of long-term debt	23,733
								Deferred income taxes, net	79,373	70,233
OVERSEAS SHIPHOLDING GROUP INC (NEW)								Noncurrent operating lease liabilities	107,911	149,960
Annual Report								Noncurrent finance lease liabilities	16,456
Consolidated Income Statement, Years Ended Dec. 31 (\$000):								Other liabilities	10,368	16,997
	2023	2022	¹ 2021 (revised)	Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):	2023	2022		Total liabilities	724,831	799,378
Net sales	359,543	Cash & cash equivalents	76,257	78,732		Common stock - class A	895	883
Time charter revenues	327,329	254,744	Voyage receivables, gross	22,338	31,062		Paid-in additional capital	588,361	597,455
Voyage charter revenues	139,471	104,318	Less: unbilled	4,976	11,364		Retained earnings (accumulated deficit)	(174,825)	(233,023)
Net shipping revenues	92,328	Voyage receivables	19,698		Treasury stock, at cost	64,380	29,040
Total shipping revenues	451,871	466,800	359,062	Income tax recoverable	1,914	1,914		Items not yet recognized as a component of net periodic benefit cost (pension & other postretirement benefit plans)	4,002	3,410
Voyage expenses	28,344	40,472	66,467	Other receivables	3,140	5,334		Accumulated other comprehensive income (loss)	4,002	3,410
Vessel expenses	166,246	176,666	140,413	Receivables, net	17,362	...		Total equity (deficit)	339,685
Charter hire expenses	64,971	88,849	90,166	Prepaid expenses	662	385		Total equity (deficit)	354,053	339,685
Depreciation & amortization expenses	67,164	70,637	61,823	Inventories & other current assets	1,860	2,283				
General & administrative	28,223	26,985	24,097	Investment security to be held to maturity	14,900	...				
Bad debt expense (recovery)	(1,080)	Total current assets	114,588	108,346				
Gain (loss) on disposal of vessels & other property, including impairments, net	(6,276)	Vessels, at cost	1,092,950	1,082,822				
Operating income (loss)	96,923	63,191	(29,100)	Accumulated depreciation - vessels	427,508	385,242				
Gain (loss) on extinguishment of debt, net	(8,031)	Construction in progress	33,482	10,406				
Interest income	3,959	840	5	Finance lease right-of-use asset, at cost	26,940	26,940				
Change in investment value	611	60	(241)	Accumulated amortization	(10,706)	(8,856)				
Pension & post retirement items	(1,290)	(2,582)	(2,157)	Finance lease right-of-use asset, net	(16,234)	18,084				
Gain on prepayment of deferred payment obligations	912	Other property, at cost	5,616	5,578				
Miscellaneous - net ..	(106)	(155)	64	Accumulated depreciation & amortization - other property	5,508	5,469				
Interest expense, net	31,216	33,060	29,203	Accumulated depreciation	427,508	...				
Income (loss) before income taxes ..	72,373	33,458	(64,349)	Vessels & other property, less accumulated depreciation	699,032	...				
Current - federal income taxes	12	9	8	Vessels & other property, less accumulated depreciation & amortization	726,179				
Current - state income taxes	933	538	131	Deferred drydock expenditures, net	44,827	38,976				
Deferred - federal income taxes	12,544	4,630	(15,275)	Intangible assets, less accumulated amortization	13,417	18,017				
Deferred - state income taxes	(3,570)	1,717	(2,961)	Operating lease right-of-use assets	172,703	206,797				
Income tax expense (benefit)	9,919	6,894	(18,097)	Investment security to be held to maturity	14,803				
Net income (loss)	62,454	26,564	(46,252)	Other assets	34,317	25,945				
Weighted average common shares outstanding - basic	78,486	Total assets	1,078,884	1,139,063				
Year end shares outstanding	70,946	78,297	87,170	Accounts payable	5,172	5,962				
Net income (loss) per class A share - basic	\$0.80	\$0.30	\$(0.51)	Payroll & benefits	16,891	10,397				
Net income (loss) per class A share - diluted	\$0.77	\$0.29	\$(0.51)	Dividends payable	4,256	...				
Cash dividends declared & paid	\$0.06	Interest	2,322	2,437				
				Insurance	748	520				
				Accrued drydock & repair costs	3,988	957				
				Bunkers & lubricants	710	370				
				Charter revenues received in advance	15,752	21,778				
				Accrued vessel expenses	8,598	10,888				
				Accrued general & administrative, primarily professional fees	978	985				
				Other accounts payable, accrued expenses & other current liabilities	1,496	612				
				Current installments of long-term debt	43,305	23,733				
				Current portion of operating lease						

Recent Dividends:**1. Overseas Shipholding Group Inc (New) Class A common.**

No dividends paid.

2. Overseas Shipholding Group Inc (New) common.

No dividends paid.

3. Overseas Shipholding Group Inc (New) Class B common.

No dividends paid.

Annual Dividends:**1. Overseas Shipholding Group Inc (New) Class A common.**

No dividends paid.

2. Overseas Shipholding Group Inc (New) common.

No dividends paid.

3. Overseas Shipholding Group Inc (New) Class B common.

No dividends paid.

PACCAR FINANCIAL CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2023	2022	2021 (revised)
Interest & fee income	477,900	318,500	300,500
Operating lease & rental revenues	235,400	306,100	333,800
Used truck sales & other revenues	20,800	18,300	81,700
Total interest & other revenues	734,100	642,900	716,000
Interest & other borrowing costs	275,700	138,800	124,500
Depreciation & other rental expenses	189,100	179,600	268,700
Cost of used truck sales & other expenses	15,000	8,600	71,400
Selling, general & administrative expenses	64,500	60,700	57,300
Provision for losses on receivables	8,100	(4,700)	(2,200)
Total expenses	552,400	383,000	519,700
Income (loss) before income taxes ..	181,700	259,900	196,300
Current federal provision (benefit)			

for income taxes	19,100	34,700	219,800
Current state provision (benefit) for income taxes	11,900	12,800	30,300
Total current provision (benefit) for income taxes	31,000	47,500	250,100
Deferred federal provision (benefit) for income taxes	18,000	17,600	(180,400)
Deferred state provision (benefit) for income taxes	(6,800)	(2,000)	(21,500)
Total deferred provision (benefit) for income taxes	11,200	15,600	(201,900)
Income taxes expense (benefit)	42,200	63,100	48,200
Net income (loss)	139,500	196,800	148,100
Year end shares outstanding	145	145	145
Number of full time employees	354	349	343
Number of common stockholders	1	1	1

As is

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash	175,100	48,800
Retail loans	5,028,200	4,627,000
Retail financing leases	1,710,400	1,433,500
Dealer wholesale financing	1,953,300	1,093,200
Dealer master notes	509,200	377,000
Operating lease receivables & other finance & other receivables	65,300	49,400
Less: allowance for losses: loans & leases	58,600	59,700
Less: allowance for losses: dealer wholesale financing	1,000	1,000
Less: allowance for losses: operating lease & other finance & other receivables	1,400	1,000
Finance & other receivables, net	9,205,400	7,518,400
Due from PACCAR Inc ("PACCAR") & affiliates	1,750,700	1,905,300
Equipment on operating leases, gross	...	1,479,900
Less: accumulated amortization - equipment on operating lease	...	625,900
Equipment on operating leases, net	528,000	854,000
Other assets	337,800	223,900
Total assets	11,997,000	10,550,400
Accounts payable, accrued expenses & other liabilities	603,100	528,300
Due to PACCAR & affiliates	58,600	21,800
Commercial paper	2,842,400	1,657,700
Medium-term notes	6,071,700	5,814,500
Deferred taxes & other liabilities	490,000	486,000
Total liabilities	10,065,800	8,508,300
Preferred stock	31,000	31,000
Common stock	14,500	14,500
Additional paid-in capital	171,600	164,600
Retained earnings	1,703,100	1,813,600
Accumulated other comprehensive income (loss)	11,000	18,400
Total stockholder's equity	1,931,200	2,042,100

Recent Dividends:

1. Paccar Financial Corp common.
No dividends paid.

2. Paccar Financial Corp 6% noncumulative nonvoting preferred.
No dividends paid.

Annual Dividends:

1. Paccar Financial Corp common.
No dividends paid.

2. Paccar Financial Corp 6% noncumulative nonvoting preferred.
No dividends paid.

PACCAR FINANCIAL CORP
Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2023	2022
Total revenues	540,500	473,300
Cost & expenses	253,400	142,200
Operating income	148,300	193,600
Net before taxes	148,300	193,600
Income taxes	36,700	47,700
Net income	111,600	145,900
Earnings common share		
Common Shares:		
Year-end	145	145

PACIFIC GREEN TECHNOLOGIES INC
Earnings, 9 mos. to Dec 31 (Consol. - \$):

	2023	2022
Total revenues	88,315,459	6,859,221
Cost & expenses	91,189,385	14,204,755
Operating income	(2,991,187)	(7,496,194)
Other income (expense), net	(951)	...
Gains or losses	18,567,829	...
Minority interest	...	20,165
Net before taxes	12,245,057	...
Income taxes	1,165,639	...
Income contin. oper.	(7,705,115)	...
Net income	11,079,418	(7,725,280)
Earnings common share		
Primary	\$0.22	\$(0.16)
Fully Diluted	\$0.22	\$(0.16)
Common Shares:		
Full Diluted	50,616,766	47,339,386
Year-end	52,345,724	47,026,886

PALTALK INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Subscription revenue	10,662,691	12,368,008	...
Advertising revenue	333,144	326,854	451,337
Technology service revenue	10,646,700	...	454,504
Total revenue	10,979,844	10,989,545	13,273,849
Costs of revenue	3,238,243	2,823,570	2,720,189
Sales & marketing expense	878,657	1,571,275	1,170,386
Product development expense	4,860,607	5,934,433	5,391,819
General & administrative expenses	4,072,580	4,311,815	2,706,733
Impairment loss on digital tokens	...	7,262	765,232
Total costs & expenses	13,050,087	14,648,355	12,754,359
Income (loss) from operations	(2,070,243)	(3,658,810)	519,490
Other income	343,045
Interest income (expense), net	639,611	74,895	133
Gain (loss) on extinguishment of term debt	506,500
Realized gain (loss) from the sale of digital tokens	307,934
Income (loss) from operations before provision for income taxes

(benefit)	(1,087,587)	(3,583,915)	1,334,057
Current state & local income taxes (benefit)	6,579	15,685	9,951
Income Taxes - Foreign - Current	76,031
Total current income taxes (benefit)	82,610	15,685	9,951
Deferred foreign income taxes (benefit)	(102,862)	(187,350)	...
Total deferred income taxes (benefit)	(102,862)	(187,350)	...
Income tax expense (benefit)	(20,252)	(171,665)	9,951
Net income (loss)	(1,067,335)	(3,412,250)	1,324,106
Weighted average shares outstanding - basic	9,222,206	9,638,567	7,766,111
Weighted average shares outstanding - diluted	9,222,206	9,638,567	7,809,132
Year end shares outstanding	9,222,157	9,227,349	9,832,157
Net income (loss) per share - continuing operations - basic	\$(0.12)
Net income (loss) per common share - basic	\$(0.12)	\$(0.35)	\$0.17
Net income (loss) per share - continuing operations - diluted	\$(0.12)
Net income (loss) per common share - diluted	\$(0.12)	\$(0.35)	\$0.17
Number of full time employees	...	19	21
Number of part time employees	...	0	1
Number of common stockholders	52	52	53

Shares increased due to issuance of common stock and treasury stock received from cashless option exercises. As of March 15, 2023; As of March 21, 2022; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	13,568,049	14,739,933
Credit card holdback receivable	114,212	...
Accounts receivable, gross	116,030	125,945
Less: allowances	23,326	3,648
Less: reserve for future chargebacks	92,704	...
Accounts receivable, net	...	122,297
Prepaid expense & other current assets	990,634	543,199
Total current assets	14,765,599	15,405,429
Operating lease right-of-use asset	77,005	159,181
Goodwill	6,326,250	6,326,250
Intangible assets, net	2,704,477	3,526,811
Other assets	13,937	13,937
Total assets	23,887,268	25,431,608
Accounts payable	792,053	1,013,637
Accrued compensation, benefits & payroll taxes	91,250	114,000
Other accrued expenses	134,870	111,193
Contingent consideration	...	85,000
Operating lease liabilities, current portion	77,005	82,176
Deferred subscription revenue	2,043,362	2,257,452
Total current liabilities	3,138,540	3,663,458

Operating lease liabilities, non-current portion	77,005	
Deferred tax liability	614,041	716,903
Total liabilities	3,752,581	4,457,366
Common stock	9,864	9,864
Treasury stock	1,199,337	1,192,124
Additional paid-in capital	36,208,728	35,973,735
Retained earnings (accumulated deficit)	(14,884,568)	(13,817,233)
Total stockholders' equity (deficit)	20,134,687	20,974,242
Total Equity	20,134,687	...

Recent Dividends:**1. Paltalk Inc common.**

No dividends paid.

Annual Dividends:**1. Paltalk Inc common.**

No dividends paid.

PANAMERA HOLDINGS CORP**Earnings, 6 mos. to Jan 31(Consol. - \$):**

	2024	2023
Total revenues	50,000	...
Cost & expenses	154,273	64,820
Operating income	(104,273)	(14,819)
Interest income	978	...
Interest expense	1,344	1,798
Net before taxes	(104,639)	(16,617)
Net income	(104,639)	(16,617)
Earnings common share		
Common Shares:		
Full Diluted	35,410,000	37,361,351
Year-end	35,410,000	33,210,000

PARKERVISION INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021 (revised)
Product revenue	25,000,000
Licensing revenue	...	925,000	144,000
Total revenue	25,000,000
Cost of sales	227,000	10,000	5,000
Gross margin	24,773,000	915,000	139,000
Selling, general & administrative expenses	14,744,000	7,773,000	8,088,000
Total operating expenses	14,744,000	7,773,000	8,088,000
Interest & other income	58,000	103,000	242,000
Interest & other expense	...	(324,000)	(251,000)
Interest expense	424,000
Change in fair value of contingent payment obligations	(148,000)	(2,734,000)	(4,372,000)
Total interest & other income (expense)	...	(2,955,000)	(4,381,000)
Net income (loss) before income taxes	9,515,000	(9,813,000)	(12,330,000)
Net income (loss)	9,515,000	(9,813,000)	(12,330,000)
Weighted average shares outstanding - basic	85,732,000	78,395,000	71,299,000
Weighted average shares outstanding - diluted	119,888,000	78,395,000	71,299,000
Year end shares outstanding	87,681,000	81,246,000	76,992,000
Earnings (loss) per share - continuing operations - basic	\$0.11
Net earnings (loss) per share - basic	\$0.11	\$(0.13)	\$(0.17)
Earnings (loss) per share - continuing operations - diluted	\$0.08
Net earnings (loss)

per share - diluted	\$0.08	\$(0.13)	\$(0.17)
Number of full time employees	7	7	7
Number of part time employees	1	1	1
Total number of employees	8
Number of common stockholders	6,500	82	83
Number of beneficial stockholders	...	6,850	7,200

□ Shares increased due to th effect of issuance of common stock for private and public offerings, exercised options and warrants services, conversion of debt and share-based compensation; □ Approximately; □ As of March 24, 2023; □ As of March 15, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	2,560,000	109,000
Prepaid services	31,000	202,000
Prepaid licenses, software tools & support	16,000	15,000
Prepaid insurance	12,000	25,000
Other prepaid expenses	2,000	...
Other prepaid expenses & current assets	...	2,000
Prepaid expenses	61,000	244,000
Other current assets	34,000	30,000
Total current assets	2,655,000	383,000
Intangible assets, net	1,055,000	1,359,000
Operating lease right-of-use assets	...	4,000
Other assets, net	313,000	5,000
Total assets	4,023,000	1,751,000
Accounts payable	573,000	901,000
Accrued salaries & wages	23,000	23,000
Accrued warranty reserves	67,000	...
Accrued professional fees	...	79,000
Other accrued expenses	6,000	486,000
Related party note payable, current portion	...	139,000
Convertible notes, current portion	1,045,000	625,000
Lease payable, current portion	...	4,000
Current portion of long-term subordinated debentures	134,000	...
Other accrued expenses	447,000	...
Customer Advances - Short-Term	375,000	...
Interest Payable - Short-Term Debt	66,000	...
Total current liabilities	2,289,000	2,257,000
Note payable, net of current portion	7,618,000	...
Secured contingent payment obligation	...	40,708,000
Unsecured contingent payment obligations	...	5,089,000
Convertible notes, net of current portion	3,893,000	3,913,000
Related party note payable, net of current portion	340,000	473,000
Lease payable, net of current portion	29,402,000	...
Total long-term liabilities	41,253,000	50,183,000
Total liabilities	43,542,000	52,440,000
Common stock	877,000	812,000
Additional paid-in capital	393,314,000	391,724,000
Retained earnings (accumulated deficit)	(433,710,000)	(443,225,000)
Total shareholders' equity (deficit)	(39,519,000)	(50,689,000)
Total Equity	(39,519,000)	...

Recent Dividends:**1. ParkerVision Inc common.**

No dividends paid.

Annual Dividends:**1. ParkerVision Inc common.**

No dividends paid.

PARKS! AMERICA INC**Earnings, 3 mos. to (Consol. - \$):**

	12/31/23	01/01/23
Total revenues	1,897,625	...
Net Sales	...	1,861,379
Cost & expenses	2,133,319	1,798,632
Deprec., depl. & amort.	...	217,184
Operating income	(458,897)	(154,437)
Interest expense	51,445	58,736
Other income (expense), net	35,887	29,613
Net before taxes	(474,455)	(183,560)
Income taxes	(105,200)	(30,600)
Net income	(369,255)	(152,960)

Earnings common share

Common Shares:

Full Diluted	75,579,000	75,227,000
Year-end	75,726,851	75,227,058

Consolidated Balance Sheet Items, as of (\$):

Assets:	2023
Cash & equivalents	2,595,974
Inventories	431,546
Current assets	4,677,674
Net property & equip.	14,900,272
Total assets	19,640,058
Liabilities:	
Current liabilities	1,462,949
Long-term debt	3,262,159
Stockholders' equity	14,682,621
Net current assets	3,214,725

PAVMED INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021 (revised)
Revenue	2,452,000
Revenue	2,452,000	377,000	500,000
Cost of revenue	6,420,000	3,614,000	585,000
Sales & marketing expense	17,583,000	19,318,000	8,895,000
General & administrative expenses	30,947,000	41,041,000	25,420,000
Amortization of acquired intangible assets	2,021,000	1,784,000	146,000
Research & development expenses	14,276,000	25,547,000	19,847,000
Total operating expenses	...	91,304,000	54,893,000
Net income (loss) from operations	...	(90,927,000)	(54,393,000)
Interest expense	589,000	1,272,000	...
Change in fair value - senior secured convertible notes & senior convertible note	...	(1,273,000)	1,682,000
Loss on issue & offering costs - senior secured convertible note	1,186,000	4,332,000	...
Debt extinguishments gain (loss) - senior secured convertible notes	(3,782,000)	(5,434,000)	(3,715,000)
Debt forgiveness	300,000
Change in fair value - senior secured convertible note	6,026,000
Change in fair value - series A warrants derivative liability	(390,000)
Gain on sale of intellectual property	1,000,000

Interest income	505,000
Other income (expense), net	(10,468,000)	(12,311,000)	(1,733,000)
Income (loss) before provision for income tax	(79,263,000)	(103,238,000)	(56,126,000)
Deemed Dividend on Series Z warrant modification	1,791,000
Net income (loss) before noncontrolling interests	(79,263,000)	(103,238,000)	(56,126,000)
Net income (loss) attributable to the noncontrolling interests	15,088,000	14,255,000	5,779,000
Net income (loss) attributable to PAVmed Inc.	...	(88,983,000)	(50,347,000)
Less: series B convertible preferred stock dividends earned	304,000	281,000	283,000
Net income (loss) attributable to PAVmed Inc. common stockholders	(66,270,000)	(89,264,000)	(50,630,000)
Weighted average shares outstanding - basic	7,231,546	[□] 5,938,405	5,167,718
Weighted average shares outstanding - diluted	7,231,546	[□] 5,938,405	5,167,718
Year end shares outstanding	8,578,505	[□] 6,300,702	[□] 5,757,856
Net earnings (loss) per share - basic	\$(9.16)	[□] \$(15.00)	\$(9.75)
Net earnings (loss) per share - diluted	\$(9.16)	[□] \$(15.00)	\$(9.75)
Number of full time employees	...	[□] 124	[□] 89
Number of beneficiary stockholders	225	[□] 214	[□] 17,000
State and Local Income Taxes - Domestic - Deferred	(16,789,000)
Income Taxes - Total - Deferred	(36,112,000)
Valuation allowance reserve	36,112,000

[□] Reclassified to conform with 2022 presentation; [□] As reported by the Company; [□] Adjusted for 1- for -15 stock split, December 7, 2023; [□] Shares increased due to the effect of conversion of preferred stock and notes, issuance of common stock, restricted stock awards vests, exercised warrants and options, employee stock purchase plan; [□] As of March 9, 2023; [□] As of March 29, 2022; [□] Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	19,639,000	39,744,000
Accounts receivable	61,000	17,000
Prepaid expenses, deposits, & other current assets	261,000	4,165,000
Deposits	2,672,000	...
Advanced payments to suppliers	848,000	...
Advanced payments to service providers & suppliers	739,000	...
Prepaid expenses & other current assets	4,520,000	...
Inventory	278,000	...
Total current assets	24,498,000	43,926,000
Computer & office equipment	835,000	784,000
Laboratory equipment	...	2,064,000
Furniture & fixtures	394,000	379,000

Leasehold improvements	2,000	2,000
Assets under construction	16,000	30,000
Research & development equipment	2,255,000	...
Total fixed assets	3,502,000	3,259,000
Less: accumulated depreciation	1,719,000	808,000
Fixed assets, net	1,783,000	2,451,000
Operating lease, right-of-use assets	4,267,000	3,037,000
Intangible assets, net	1,424,000	3,445,000
Other assets	1,147,000	1,121,000
Total assets	33,119,000	53,980,000
Accounts payable	1,786,000	2,704,000
EsoCheck license agreement fee	96,000	...
Accrued compensation & employee benefits	2,507,000	1,947,000
CWRU Amended License Agreement - Royalty fee	...	10,000
Accrued operating expenses	3,246,000	1,748,000
Accrued expenses and other current liabilities	6,626,000	...
Operating lease liabilities, current portion	1,565,000	1,141,000
Senior secured convertible notes - at fair value	...	33,650,000
Senior secured convertible notes - at fair value	44,200,000	...
Other current liabilities	777,000	...
Total current liabilities	54,177,000	41,200,000
Operating lease liabilities, less current portion	2,960,000	1,846,000
Total liabilities	57,137,000	43,046,000
Series B convertible preferred stock	2,993,000	...
Preferred stock	...	2,695,000
Common stock	9,000	95,000
Additional paid-in capital	237,600,000	216,106,000
Retained earnings (accumulated deficit)	(294,433,000)	(228,169,000)
Treasury stock	...	408,000
Total PAVmed Inc. stockholders' equity	(53,831,000)	(9,681,000)
Noncontrolling interests	29,813,000	20,615,000
Total stockholders' equity (deficit)	(24,018,000)	10,934,000

Recent Dividends:

- 1. PAVmed Inc series A convertible preferred.**
No dividends paid.
 - 2. PAVmed Inc series B convertible preferred.**
No dividends paid.
 - 3. PAVmed Inc common.**
No dividends paid.
 - 4. PAVmed Inc series A-1 convertible preferred.**
No dividends paid.
- Annual Dividends:**
- 1. PAVmed Inc series A convertible preferred.**
No dividends paid.
 - 2. PAVmed Inc series B convertible preferred.**
No dividends paid.
 - 3. PAVmed Inc common.**
No dividends paid.
 - 4. PAVmed Inc series A-1 convertible preferred.**
No dividends paid.

PAXMEDICA INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
General & administrative expenses	12,230,292	8,816,940	4,973,245

Research & development expenses	3,914,979	1,787,488	2,224,555
Total operating expenses	16,145,271	10,604,428	7,197,800
Income (loss) from operations	(16,145,271)	(10,604,428)	(7,197,800)
Interest expense	9,165	5,237	2,805,856
Gain on conversion of notes	59,890
Loss on conversion of simple agreement for future equity ("SAFE")	...	5,338,808	...
Loss on issuance of debt	...	391,246	...
Loss on extinguishment of debt	(45,585)	(161,563)	...
Change in fair value of notes	1,819,009	272,202	...
Change in fair value of SAFE	(270,695)	163,025	175,783
Change in fair value warrant liability	...	1,873,192	(458,558)
Other income (expense)	...	64,500	2,430
Total other income (expense)	(2,144,454)	(4,197,339)	(3,031,171)
Net income (consolidated)	(18,289,725)	(14,801,767)	(10,228,971)
Weighted average shares outstanding - basic	1,662,795	[□] 514,216	392,118
Weighted average shares outstanding - diluted	1,662,795	[□] 514,216	392,118
Year end shares outstanding	7,401,242	[□] 707,976	406,676
Net earnings (loss) per share - basic	\$(11.00)	[□] \$(28.73)	\$(26.01)
Net earnings (loss) per share - diluted	\$(11.00)	[□] \$(28.73)	\$(26.01)
Number of full time employees	6	3	...
Number of part time employees	1	2	...
Total number of employees	7	5	...
Common Shareholders - Number	10
Number of stockholders	...	[□] 12	...
Income from cont operations before income tax	(18,289,725)

[□] Adjusted for 1- for -17 stock split, October, 31, 2023; [□] Shares increased due to the effect issuance of shares for commitment fees consulting fees, warrants, conversion of notes payable, series seed & series X preferred stock and warrants exchange; [□] As of March 10, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	4,710,642	1,901,887
Prepaid & other current assets	...	302,431
Prepaid administration	390,400	...
Prepaid contractors	579,363	...
Total current assets	5,680,405	2,204,318
Total assets	5,680,405	2,204,318
Accounts payable	811,733	721,955
Accounts payable - related party	18,500	20,000
Accrued expenses	...	1,019,071
Notes payable - fair value	...	173,543
Shares settled liability	...	160,949
Professional fees	91,750	...
Accrued expenses - Compensation	873,349	...

Accrued expenses -			discontinued				Equipment	22,809	21,242
Balancing value	965,099	...	operations	(605)	(421)		Vehicles	434	442
Total current liabilities	1,795,332	2,095,518	Total income (loss)				Leasehold improvements	8	23
Deferred revenue	500,000	...	from discontinued				Office furniture &		
Total liabilities	2,295,332	2,095,518	operations	(433)	...		equipment	1,130	1,299
Series X preferred shares	...	5	Net income (loss)	485	(3,816)	671	Construction-in-progress	1,010	727
Common stock	740	1,204	Net income (loss)				Buildings and land	24,311	...
Additional paid-in capital	55,414,069	33,847,607	attributable to				Total property &		
Retained earnings (accumulated deficit)	(52,029,741)	(33,740,016)	non-controlling				equipment	...	47,754
Preferred shares	5	...	interest	164	Less accumulated	30,693	28,797
Total stockholder's equity (deficit)	3,385,073	108,800	Net income (loss)				depreciation	19,009	18,957
Total Equity	3,385,073	...	attributable to				Net property & equipment		
			Perma-Fix				Property & equipment		
			Environmental				related to discontinued		
			Services, Inc.				operations	81	81
			common stockholders	...	(3,816)	835	Operating lease		
			Weighted average				right-of-use assets	1,990	1,971
			shares outstanding	13,506	13,280	12,433	Permits	9,905	9,610
			- basic				Other intangible assets -		
			Weighted average				net	461	629
			shares outstanding				Finite risk sinking fund		
			- diluted	13,739	13,280	12,673	(restricted cash)	12,074	11,570
			Year end shares				Deferred tax assets	4,299	4,116
			outstanding	13,647	13,325	13,215	Other assets	370	438
			Income (loss) per				Total assets	78,749	70,898
			share - continuing				Accounts payable	9,582	10,325
			operations - basic	\$0.07	\$(0.24)	\$0.10	Accrued salaries &		
			Income (loss) per				employee benefits	4,120	2,629
			share -				Accrued sales, property		
			discontinued				& other tax	477	240
			operations - basic	\$(0.03)	\$(0.05)	\$(0.03)	Accrued interest payable	...	8
			Net income (loss)				Accrued insurance payable	1,390	1,253
			per share - basic	\$0.04	\$(0.29)	\$0.07	Other accrued expenses	...	463
			Income (loss) per				Other	550	...
			share - continuing				Disposal or		
			operations -				transportation accrual	1,198	887
			diluted	\$0.07	\$(0.24)	\$0.10	Deferred revenue	6,815	4,813
			Income (loss) per				Billing in excess of		
			share -				costs & estimated		
			discontinued				earning earning	6,815	...
			operations -				Accrued closure costs -		
			diluted	\$(0.03)	\$(0.05)	\$(0.03)	current	79	682
			Net income (loss)				Notes payable	23	...
			per share - diluted	\$0.04	\$(0.29)	\$0.07	Current portion of		
			Number of full time				long-term debt	773	476
			employees	288	287	275	Current portion of		
			Number of part time				operating lease		
			employees	9	9	11	obligations	380	416
			Total number of				Current portion of		
			employees	297	296	286	finance lease obligations	291	154
			Number of common				Current liabilities		
			stockholders	121	128	134	related to discontinued		
			Earnings per				operations	269	362
			share-total				Total current liabilities	25,947	22,708
			discontinued opers	\$(0.03)	Accrued closure costs	8,051	7,284
			Earning per				Term loan	...	552
			share-total discount				Capital line	...	463
			opers-diluted	\$(0.03)	Note payable	1,975	24
			Foreign currency				Less current portion of		
			translation				long-term debt	...	476
			adjustments	...	(137)	...	Long-term debt, less		
							current portion	...	563
							Long-term operating lease		
							obligations, less current		
							portion	1,670	1,584
							Long-term capital lease		
							obligations, less current		
							portion	776	...
							Long-term finance lease		
							obligations, less current		
							portion	...	318
							Long-term liabilities		
							related to discontinued		
							operations	953	908
							Total long-term		
							liabilities	13,425	10,657
							Total liabilities	39,372	33,365
							Common stock	14	13
							Additional paid-in		
							capital	116,502	115,209
							Retained earnings		
							(accumulated deficit)	(76,951)	(77,436)
							Accumulated other		
							comprehensive income		

Recent Dividends:**1. PaxMedica Inc series X preferred.**

No dividends paid.

2. PaxMedica Inc common.

No dividends paid.

Annual Dividends:**1. PaxMedica Inc series X preferred.**

No dividends paid.

2. PaxMedica Inc common.

No dividends paid.

PERMA-FIX ENVIRONMENTAL SERVICES, INC.**Annual Report****Consolidated Income Statement, Years Ended Dec. 31****(\$000):**

	2023	2022	2021
			(revised)
Services	89,735
Net revenues	89,735	70,599	72,191
Cost of goods sold	73,366	60,990	65,367
Gross profit	16,369	9,609	6,824
Selling, general & administrative expenses	14,975	14,652	12,845
Research & development	561	336	746
Gain (loss) on disposal of property & equipment	(77)	(18)	(2)
Income (loss) from operations	756	(5,397)	(6,769)
Interest income	606	99	26
Interest expense	323	175	247
Interest expense - financing fees	93	61	41
Other income (expense)	(11)	1,945	(86)
Gain (loss) on extinguishment of debt	5,381
Loss on deconsolidation of subsidiary	1,062
Income (loss) from continuing operations before taxes	935	(3,589)	(2,798)
Federal income tax expense (benefit) - deferred	(28)	(331)	(3,503)
State income tax expense (benefit) - current	7	12	(56)
Foreign income tax expense - current	26
State income tax expense (benefit) - deferred	(38)	(59)	(357)
Income Taxes - Foreign - Current	76
Income tax expense (benefit)	17	(378)	(3,890)
Income (loss) from continuing operations, net of taxes	918	(3,211)	1,092
Income (loss) from			

discontinued operations	...	(605)	(421)
Total income (loss) from discontinued operations	(433)
Net income (loss)	485	(3,816)	671
Net income (loss) attributable to non-controlling interest	164
Net income (loss) attributable to Perma-Fix Environmental Services, Inc. common stockholders	...	(3,816)	835
Weighted average shares outstanding - basic	13,506	13,280	12,433
Weighted average shares outstanding - diluted	13,739	13,280	12,673
Year end shares outstanding	13,647	13,325	13,215
Income (loss) per share - continuing operations - basic	\$0.07	\$(0.24)	\$0.10
Income (loss) per share - discontinued operations - basic	\$(0.03)	\$(0.05)	\$(0.03)
Net income (loss) per share - basic	\$0.04	\$(0.29)	\$0.07
Income (loss) per share - continuing operations - diluted	\$0.07	\$(0.24)	\$0.10
Income (loss) per share - discontinued operations - diluted	\$(0.03)	\$(0.05)	\$(0.03)
Net income (loss) per share - diluted	\$0.04	\$(0.29)	\$0.07
Number of full time employees	288	287	275
Number of part time employees	9	9	11
Total number of employees	297	296	286
Number of common stockholders	121	128	134
Earnings per share - total discontinued opers	\$(0.03)
Earning per share - total discount opers-diluted	\$(0.03)
Foreign currency translation adjustments	...	(137)	...

□ Approximately; □ As of February 14, 2023; □ As of February 14, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash	...	1,866
Cash & cash equivalents	7,500	...
Accounts receivable, gross	9,752	9,421
Allowance for doubtful accounts	30	57
Accounts receivable, net	9,722	9,364
Unbilled receivables	...	6,062
Insurance claim receivable	8,432	...
Inventories	1,155	814
Prepaid & other assets	3,738	5,405
Current assets related to discontinued operations	13	15
Total current assets	30,560	23,526
Buildings & land	49,702	24,021

(loss)	(100)	(165)
Less common stock in treasury, at cost	88	88
Total Perma-Fix Environmental Services, Inc. stockholders' equity	39,377	37,533
Total stockholders' equity	39,377	37,533

Recent Dividends:

1. Perma-Fix Environmental Services, Inc. series B preferred stock of subsidiary.

No dividends paid.

2. Perma-Fix Environmental Services, Inc. common.

No dividends paid.

Annual Dividends:

1. Perma-Fix Environmental Services, Inc. series B preferred stock of subsidiary.

No dividends paid.

2. Perma-Fix Environmental Services, Inc. common.

No dividends paid.

PERMIAN RESOURCES CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Oil sales	2,696,777,000	1,622,035,000	...
Natural gas sales	142,077,000	276,957,000	...
Oil & gas sales	1,029,892,000
NGL sales	282,039,000	232,273,000	...
Total revenues	3,120,893,000	2,131,265,000	...
Lease operating expenses	373,772,000	171,867,000	106,419,000
Severance & ad valorem taxes	240,762,000	155,724,000	67,140,000
Gathering, processing & transportation expenses	89,282,000	97,915,000	85,896,000
Depreciation, depletion & amortization expense	1,007,576,000	444,678,000	289,122,000
Impairment & abandonment expenses	125,331,000	77,424,000	32,511,000
Exploration & other expenses	19,337,000	11,378,000	7,883,000
General & administrative expenses	161,855,000	159,554,000	110,454,000
Total operating expenses	(2,024,596,000)	(1,122,415,000)	699,425,000
Net gain (loss) on sale of long-lived assets	211,000	...	34,168,000
Proceeds from terminated sale of assets	5,983,000
Income (loss) from operations	370,618,000
Gain (loss) on sale of oil & natural gas properties	(1,314,000)	...
Credit facility	30,049,000	15,974,000	10,771,000
Senior secured notes	2,908,000
Senior notes	132,341,000	61,515,000	40,056,000
Convertible senior notes	5,525,000	5,525,000	4,315,000
Amortization of debt issuance costs & debt discount	16,078,000	15,652,000	4,992,000
Interest capitalized	7,813,000	3,021,000	1,754,000
Other interest expense	1,029,000
Interest expense	177,209,000	95,645,000	61,288,000
Gain (loss) on extinguishment of debt	(22,156,000)
Net gain (loss) on derivative			

instruments	114,016,000	(42,368,000)	(148,825,000)
Other income (expense)	2,333,000	...	395,000
Total	609,000	...
Total other income (expense)	(60,860,000)	...	(231,874,000)
Income (loss) before income taxes ..	1,035,648,000	870,132,000	138,744,000
Current income tax expense - state	2,893,000	2,796,000	569,000
Income Taxes - Domestic - Current ..	(104,000)
Total current income tax expense	569,000
Deferred income tax expense (benefit) - federal	132,039,000	106,011,000	...
Deferred income tax expense (benefit) - state	21,117,000	11,485,000	...
Income Taxes - Total - Current	2,789,000
Income Taxes - Total - Deferred	153,156,000
Income tax expense (benefit)	155,945,000	120,292,000	569,000
Net income (loss)	879,703,000	749,840,000	138,175,000
Less: net income (loss) attributable to noncontrolling interest	(403,397,000)	(234,803,000)	...
Net income attributable to class A common stock	476,306,000	515,037,000	138,175,000
Weighted average shares outstanding - basic	349,213,000	286,160,000	280,871,000
Weighted average shares outstanding - diluted	389,096,000	322,816,000	310,170,000
Year end shares outstanding	771,752,591	557,832,257	284,696,972
Income (loss) per share of class A common stock - basic	\$1.36	\$1.80	\$0.49
Income (loss) per share of class A common stock - diluted	\$1.24	\$1.61	\$0.46
Number of full time employees	461	218	147
Total number of employees	461
Number of class A common stock	17	17
Number of class C common stock	87	...
Impairment and abandonment expense	6,681,000	3,875,000	...
Dividends Per Share - Common - Gross - by Period End Date ..	\$0.37	\$0.05	...
EPS - Basic - excluding Extraordinary Items Applicable to Common - Total	\$1.36
EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total	\$1.24
Common Shareholders - Number	295

As of February 18, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Accrued oil & gas sales receivable, net	345,982,000	...
Cash & cash equivalents	73,290,000	59,545,000

Joint interest billings, net	123,160,000	58,375,000
Other accounts receivable	481,060,000	206,266,000
Accounts receivable, net	282,846,000
Derivative instruments	70,591,000	100,797,000
Prepaid & other current assets	25,451,000	20,602,000
Other	3,690,000	1,206,000
Accrued derivative settlements receivable	8,228,000	16,999,000
Total current assets	650,392,000	463,790,000
Oil & natural gas properties, successful efforts method	14,036,109,000	...
Accumulated depreciation, depletion & amortization	3,401,895,000	2,419,692,000
Total oil & natural gas properties, net	7,874,226,000
Other property & equipment, net	43,647,000	15,173,000
Proved properties	15,036,687,000	8,869,174,000
Unproved properties	2,401,317,000	1,424,744,000
Total property & equipment, net	14,079,756,000	7,889,399,000
Operating lease, right-of-use asset	59,359,000	64,792,000
Other noncurrent assets	176,071,000	74,611,000
Total assets	14,965,578,000	8,492,592,000
Accounts payable	94,533,000	51,443,000
Accrued capital expenditures	271,569,000	133,854,000
Revenues payable	527,470,000	250,120,000
Accrued employee compensation & benefits	29,836,000	33,897,000
Accrued interest	100,882,000	45,627,000
Payable to Silverback Exploration, LLC & Silverback Operating, LLC	1,167,525,000	...
Accrued derivative settlements payable	2,342,000
Accrued expenses & other payable	143,235,000	44,873,000
Accounts payable & accrued expenses	562,156,000
Derivative instruments	1,998,000
Operating lease liabilities	33,006,000	29,759,000
Other current liabilities	41,022,000	11,656,000
Total current liabilities	1,241,553,000	605,569,000
Long-term debt, net	3,848,781,000	2,140,798,000
Asset retirement obligations	121,417,000	40,947,000
Deferred income taxes	422,627,000	4,430,000
Operating lease liabilities	28,302,000	41,341,000
Other noncurrent liabilities	73,150,000	3,211,000
Total liabilities	5,735,830,000	2,836,296,000
Additional paid-in capital	5,766,881,000	2,698,465,000
Retained earnings (accumulated deficit)	569,139,000	237,226,000
Class C common stock	23,000	27,000
Class A: 298,640,260 shares issued and 288,52,257 shares outstanding at , 2022 and 294,260,62 shares issued and 284,696,972 sha	54,000	30,000
Total shareholders' equity (deficit)	6,336,097,000	2,935,748,000
Noncontrolling interest	2,893,651,000	2,720,548,000
Total equity	9,229,748,000	5,656,296,000

Recent Dividends:

- 1. Permian Resources Corp class C common.**
No dividends paid.
- 2. Permian Resources Corp class A common.**
No dividends paid.
- 3. Permian Resources Corp class B common.**
No dividends paid.
- 4. Permian Resources Corp series A preferred.**
No dividends paid.

5. Permian Resources Corp series B preferred.

No dividends paid.

Annual Dividends:**1. Permian Resources Corp class C common.**

No dividends paid.

2. Permian Resources Corp class A common.

No dividends paid.

3. Permian Resources Corp class B common.

No dividends paid.

4. Permian Resources Corp series A preferred.

No dividends paid.

5. Permian Resources Corp series B preferred.

No dividends paid.

PETRO USA INC**Earnings, 6 mos. to Dec 31(Consol. - \$):**

	2023	2022
Cost & expenses	24,979	15,461
Operating income	(24,979)	(15,461)
Interest expense	140	140
Net before taxes	(25,119)	(15,601)
Net income	(25,119)	(15,601)
Earnings common share		
Common Shares:		
Full Diluted	200,080,920	200,030,920
Year-end	200,130,920	200,033,920

PHARMA-BIO SERV INC**Earnings, 3 mos. to Jan 31(Consol. - \$):**

	2024	2023
Total revenues	2,380,187	4,238,356
Net Sales	2,380,187	2,380,187
Cost & expenses	2,818,487	3,909,724
Operating income	(438,300)	328,632
Other income (expense), net	180,529	246,545
Net before taxes	(257,771)	575,177
Income taxes	12,948	148,745
Net income	(270,719)	426,432
Earnings common share		
Primary	\$(0.01)	\$0.02
Fully Diluted	\$(0.01)	\$0.02
Common Shares:		
Full Diluted	22,962,460	22,957,755
Year-end	22,963,143	22,950,321

Consolidated Balance Sheet Items, as of (\$):

	2024
Assets:	
Cash & equivalents	6,413,550
Current assets	18,775,013
Net property & equip.	26,383
Total assets	19,231,246
Liabilities:	
Current liabilities	3,678,369
Stockholders' equity	14,156,377
Net current assets	15,096,644

PHOTOZOU HOLDINGS INC**Annual Report****Consolidated Income Statement, Years Ended Nov. 30 (\$):**

	2023	2022	2021 (revised)
Revenue from cameras sold	57,436	139,974	159,662
Service revenue	16,465	46,017	48,935
Total revenues	73,901	185,991	208,597
Cost of revenue from cameras sold	41,992	109,301	118,229
Cost of service revenue	37,354	41,337	28,756
Total cost of revenues	79,346	150,638	146,985
Gross profit (loss)	(5,445)	35,353	61,612
General & administrative expenses	259,504	199,022	263,986
Total operating expenses	259,504	199,022	263,986
Other income	1,454	8,544	3,243
Other expenses	342	161	251
Net income (loss) before taxes	(263,837)	(155,286)	(199,382)
Net income (loss)	(263,837)	(155,286)	(199,382)
Weighted average shares outstanding - basic	8,000,000	8,000,000	8,000,000
Weighted average			

shares outstanding - diluted	8,000,000	8,000,000	8,000,000
Year end shares outstanding	8,000,000	8,000,000	8,000,000
Net income (loss) per common share - basic	\$(0.03)	\$(0.02)	\$(0.02)
Net income (loss) per common share - diluted	\$(0.03)	\$(0.02)	\$(0.02)
Number of common stockholders	125	125	125
Full-Time Employees (Period End)	0
Total number of employees	0

As of March 17, 2023; As of March 17, 2022

Consolidated Balance Sheet, Years Ended Nov. 30 (\$):

	2023	2022
Cash & cash equivalents	11,562	19,104
Accounts receivable	4,594	7,981
Prepaid & other current assets	1,709	2,657
Sales tax recoverable	14,771	10,978
Inventories - Total	68,466	58,780
Inventories	...	58,780
Total current assets	101,102	99,500
Software, net	55,311	5,401
Advance payments	...	25,084
Total assets	156,413	129,985
Accrued expenses	13,419	823
Due to related party	794,757	651,999
Long-term loan payable, current portion	9,628	10,197
Total current liabilities	817,804	663,019
Long-term loan payable, non-current portion	6,419	16,994
Total liabilities	824,223	680,013
Common stock	800	800
Additional paid in capital	50,030	50,030
Retained earnings (accumulated deficit)	(938,784)	(674,947)
Accumulated other comprehensive income (loss)	220,144	74,089
Total stockholders' equity (deficit)	(667,810)	(550,028)
Total Equity	(667,810)	...

Recent Dividends:**1. Photozou Holdings Inc common.**

No dividends paid.

Annual Dividends:**1. Photozou Holdings Inc common.**

No dividends paid.

PHUNWARE INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021 (revised)
Net revenues	4,832,000	6,521,000	...
Net revenues	4,832,000	6,521,000	10,643,000
Cost of revenues	3,146,000	3,012,000	7,030,000
Gross profit (loss)	1,686,000	3,509,000	3,613,000
Sales & marketing expenses	3,329,000	4,114,000	3,022,000
General & administrative expenses	13,780,000	17,277,000	13,256,000
Research & development expenses	4,449,000	6,149,000	4,179,000
Impairment of goodwill	25,819,000
Total operating expenses	47,377,000	27,540,000	20,457,000
Operating income (loss)	(45,691,000)	(24,031,000)	(16,844,000)
Promissory note	203,000
Convertible notes	1,111,000

Accretion of debt discount - issuance costs	1,913,000
Accretion of debt discount - warrants	1,029,000
All other debt & financing obligations	1,733,000	2,406,000	225,000
Interest expense	4,481,000
Gain (loss) on extinguishment of debt	(237,000)	...	(7,952,000)
Impairment of digital assets	50,000	22,911,000	9,383,000
Fair value adjustment for warrant liabilities	256,000	3,349,000	(18,139,000)
Gain on forgiveness of Paycheck Protection Program ("PPP") loan	2,850,000
Other income (expense), net	230,000	211,000	1,000
Gain on sale of digital assets	5,310,000	367,000	...
Total other income (expense)	(37,104,000)
Income (loss) before taxes	(41,915,000)	(45,421,000)	(53,948,000)
Current state provision expense (benefit) for income taxes	29,000	4,000	11,000
Total current provision expense (benefit) for income taxes	29,000	4,000	11,000
Deferred federal provision expense (benefit) for income taxes	(416,000)
Deferred state provision expense (benefit) for income taxes	(21,000)
Total deferred provision expense (benefit) for income taxes	(437,000)
Income tax expense (benefit)	29,000	4,000	(426,000)
Net income (loss)	(52,785,000)	(50,894,000)	(53,522,000)
Weighted average shares outstanding - basic	2,379,972	1,979,634	1,508,940
Weighted average shares outstanding - diluted	2,379,972	1,979,634	1,508,940
Year end shares outstanding	3,851,448	2,063,067	1,935,032
Net income (loss) per share - basic	\$(22.18)	\$(25.71)	\$(35.50)
Net income (loss) per share - diluted	\$(22.18)	\$(25.71)	\$(35.50)
Full-Time Employees (Period End)	25
Total number of employees	25	...	120
Number of common stockholders	171	...	177
Net loss from discontinued operation, net of \$0 taxes	(10,841,000)	(5,469,000)	...
EPS - Basic - excluding Extraordinary Items Applicable to Common - Total	\$(17.62)	\$(22.95)	...
EPS - Diluted - excluding Extraordinary Items Applicable to

Common - Total	Ⓐ\$(17.62)	\$(22.95)	...
Discontinued Operations - Net - Income/Expense	(10,841,000)	(5,469,000)	...
Net Income Before Extraordinary and Preferred Dividends	(41,944,000)	(45,425,000)	...
Earn per share-inc from discount opers - diluted	Ⓐ\$(4.56)	\$(2.76)	...
Earning per share-total discount opers - diluted	Ⓐ\$(4.56)	\$(2.76)	...
Earnings per share-inc from discontinued oper	Ⓐ\$(4.56)	\$(2.76)	...
Earnings per share-total discontinued opers	Ⓐ\$(4.56)	\$(2.76)	...

Ⓐ Restated to reflect discontinued operations; Ⓑ Adjusted for 1-for-50 stock split, February 27, 2024; Ⓒ Shares increased due to the effect of exercise of stock option, release of restricted stock, stock purchase plan, payment of board of director fees and warrant exercises; Ⓓ Approximately; Ⓔ As of March 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
		(revised)
Cash on hand and in Bank	3,934,000	...
Cash	...	1,955,000
Accounts receivable, gross	636,000	1,156,000
Less allowances for doubtful accounts	86,000	198,000
Accounts receivable, net	550,000	958,000
Inventory	...	2,780,000
Digital assets	75,000	10,137,000
Prepaid expenses	374,000	...
Prepaid expenses & other current assets	...	1,033,000
Current assets of discontinued operation	28,000	...
Total current assets	4,961,000	16,863,000
Property & equipment, net	40,000	221,000
Goodwill	...	31,113,000
Intangible assets, net	...	2,524,000
Right-of-use asset	1,451,000	3,712,000
Other assets	276,000	402,000
Total assets	6,728,000	54,835,000
Accounts payable	7,836,000	7,699,000
Accrued expenses - payroll related expenses	15,000	899,000
Accrued expenses - interest payable	...	618,000
Accrued expenses - accounts payable settlement	...	231,000
Accrued expenses - taxes	...	457,000
Accrued expenses - other	...	690,000
Accrued expenses	...	2,895,000
Lease liability	629,000	954,000
Deferred revenue	1,258,000	2,904,000
PhunCoin, Inc. deposits	...	1,202,000
Current maturities of long-term debt, net	4,936,000	9,667,000
Warrant liability	1,202,000	256,000
Income Taxes	110,000	...
Current liabilities of discontinued operation	205,000	...
Accrued expenses - Balancing value	437,000	...
Other	312,000	...
Total current liabilities	16,503,000	25,577,000
Deferred revenue	651,000	1,274,000
Lease liability	1,031,000	3,103,000
Total liabilities	18,185,000	29,954,000
Common stock	385	10,000
Additional paid-in capital	292,467,000	275,562,000
Accumulated other comprehensive income (loss)	(418,000)	(472,000)

Retained earnings (accumulated deficit)	(303,004,000)	(250,219,000)
Treasury stock at cost; 461,500 and 0 shares at 31, 2023 and 31, 2022, respectively	502,000	...
Total stockholders' equity (deficit)	(11,457,000)	24,881,000
Total Equity	(11,457,000)	...

Recent Dividends:

1. Phunware Inc common subject to possible redemption.

No dividends paid.

2. Phunware Inc common.

No dividends paid.

3. Phunware Inc series A convertible preferred.

No dividends paid.

Annual Dividends:

1. Phunware Inc common subject to possible redemption.

No dividends paid.

2. Phunware Inc common.

No dividends paid.

3. Phunware Inc series A convertible preferred.

No dividends paid.

PIEDMONT LITHIUM INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	Ⓐ2021
			(revised)
Costs of sales	34,138,000
Revenue	39,817,000
Total revenues	39,817,000
Exploration & mine development costs	1,929,000	1,939,498	9,628,803
General & administrative expenses	43,319,000	29,448,567	10,956,005
Total operating expenses	45,248,000	31,388,065	20,584,808
Gain (loss) from equity method investments in unconsolidated affiliates	194,000	(8,352,290)	(642,135)
Income (loss) from operations	(39,375,000)	(39,740,355)	(21,226,943)
Interest income	3,859,000	1,153,012	...
Interest expense	39,000	115,029	112,869
Gain (loss) from foreign currency exchange	(91,000)	(87,931)	(8,543)
Gain on dilution of equity method investments in unconsolidated affiliates	16,975,000	28,954,893	...
Total other income (expense)	...	29,904,945	(121,412)
Income (loss) before income taxes - domestic	(30,116,000)	(31,650,816)	(20,656,738)
Income (loss) before income taxes - foreign	11,445,000	21,815,406	(691,617)
Income (loss) before taxes	(18,671,000)	(9,835,410)	(21,348,355)
Income taxes	3,106,000	3,139,264	...
Net income (loss)	(21,777,000)	(12,974,674)	(21,348,355)
Weighted average shares outstanding - basic	19,033,000	17,517,678	15,868,521
Weighted average shares outstanding - diluted	19,033,000	17,517,678	15,868,521
Year end shares outstanding	19,272,000	18,073,367	15,894,395
Net income (loss) per share - basic	\$(1.14)	\$(0.74)	\$(1.35)
Net income (loss) per share - diluted	\$(1.14)	\$(0.74)	\$(1.35)
Full-Time Employees (Period End)	63
Total number of

employees	63	40	28
Number of common stockholders	11	Ⓐ9	Ⓐ196
Gross profit	5,679,000
Basic EPS Excluding ExtraOrdinary Items	\$(1.14)
Diluted EPS Excluding ExtraOrd Items	\$(1.14)

Ⓐ For 6 months due to fiscal year end change ; Ⓑ Reclassified to conform with 2022 presentation; Ⓒ As of February 24, 2023; Ⓓ As of February 19, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

2023 2022

Cash & cash equivalents	71,730,000	99,246,963
Investments in equity securities	484,000	483,836
Prepaid assets & other receivables	3,345,000	2,128,005
Other current assets	3,829,000	2,611,841
Accounts receivable	595,000	...
Total current assets	76,154,000	101,858,804
Mining interests	401,000	56,119,627
Mine development	6,255,000	3,050,239
Land	3,259,000	720,033
Leasehold improvements	401,000	281,008
Facilities & equipment	916,000	675,795
Construction in process	35,101,000	10,779,566
Property, plant, & equipment, gross	127,413,000	71,626,268
Less: accumulated depreciation	327,000	85,470
Property, plant & equipment, net	127,086,000	71,540,798
Advances on exploration project	...	17,316,440
Other non-current assets	30,353,000	263,845
Operating lease right-of-use assets	1,371,000	1,293,394
Asset retirement obligation	414,000	...
Non-current prepaid assets	28,189,000	...
Other non-current assets	379,000	18,873,679
Equity investments in unconsolidated affiliates	147,662,000	95,647,802
Total assets	381,255,000	287,921,083
Accounts payable & accrued expenses	11,754,000	12,861,514
Current portion of long-term debt	149,000	425,187
Operating lease liabilities	312,000	...
Other current liabilities	29,463,000	124,464
Accrued provisional revenue adjustment	29,151,000	...
Total current liabilities	41,366,000	13,411,165
Long-term debt, net of current portion	14,000	163,425
Operating lease liabilities, net of current portion	1,091,000	1,176,709
Deferred tax liabilities	6,023,000	2,881,123
Other non-current liabilities	431,000	...
Asset retirement obligation liability	431,000	...
Total liabilities	48,925,000	17,632,422
Common stock	2,000	1,807
Additional paid-in capital	462,899,000	381,241,814
Retained earnings (accumulated deficit)	(126,844,000)	(105,657,674)
Accumulated other comprehensive income (loss)	(3,727,000)	(5,297,286)
Total stockholders' equity (deficit)	332,330,000	270,288,661
TOTAL EQUITY	332,330,000	...

Recent Dividends:

1. Piedmont Lithium Inc common.				2. Piedmont Lithium Inc CHESSE depositary interests.			
No dividends paid.				No dividends paid.			
Annual Dividends:				Annual Dividends:			
1. Piedmont Lithium Inc common.				2. Piedmont Lithium Inc CHESSE depositary interests.			
No dividends paid.				No dividends paid.			
PLUG POWER INC				PLUG POWER INC			
Annual Report				Annual Report			
Consolidated Income Statement, Years Ended Dec. 31 (\$):				Consolidated Balance Sheet, Years Ended Dec. 31 (\$):			
	2023	2022	2021		2023	2022	
			(revised)				
Impairment of tangible assets	20,014,000	Interest Expense on Financial Lease	7,500,000
Sales of fuel cell systems & related infrastructure	63,731,000	Liabilities	8,200,000
Sales of fuel cell systems, related infrastructure & equipment	711,433,000	558,932,000	392,777,000	Interest Capitalized	45,901,000
Services performed on fuel cell systems & related infrastructure	39,093,000	35,280,000	26,706,000	Interest expense - Gross Balancing value	(986,000)
Power purchase agreements	47,183,000	35,153,000	...	Gain (loss) on extinguishment of debt	(12,806,000)	(20,166,000)	(5,704,000)
Fuel delivered to customers & related equipment	66,246,000	57,196,000	46,917,000	Gain (loss) on equity method investments	(131,000)	1,168,000	159,000
Other revenues	2,849,000	789,000	...	Other gain	55,829,000	37,259,000	4,040,000
Other	10,837,000	Interest income	45,201,000	39,037,000	43,225,000
Net revenue	891,340,000	701,440,000	502,342,000	Interest expense	...	2,303,000	765,000
Power Purchase Agreements	218,936,000	Other expense, net	...	(1,395,000)	(81,000)
Fuel delivered to customers	246,318,000	Realized loss on investments, net	11,421,000	(18,159,000)	6,738,000
Other Product And Services	6,544,000	Change in fair value of equity securities	...	(697,342,000)	(466,825,000)
Cost of revenue - sales of fuel cell systems, related infrastructure & equipment	765,575,000	468,057,000	307,157,000	Income (loss) before income taxes - United States	...	(25,827,000)	(9,337,000)
Cost of revenue - services performed on fuel cell systems & related infrastructure	75,412,000	59,365,000	63,729,000	Income (loss) before income taxes - Foreign	(1,376,197,000)	(723,169,000)	(476,162,000)
Cost of revenue - provision (benefit) for loss contracts related to service	86,346,000	26,801,000	71,988,000	Income (loss) before income taxes - U.S income taxes (benefit)	...	(868,000)	(16,540,000)
Cost of revenue - power purchase agreements	144,696,000	102,417,000	...	Foreign income taxes (benefit)	...	1,707,000	343,000
Cost of revenue - fuel delivered to customers & related equipment	194,255,000	127,196,000	...	Income tax expense (benefit)	(7,364,000)	839,000	(16,197,000)
Cost of revenue - other	2,622,000	1,165,000	...	Net income (loss)	(1,368,833,000)	(724,008,000)	(459,965,000)
Total cost of revenue	1,399,131,000	895,796,000	673,652,000	Net income (loss) attributable to company	...	(724,008,000)	(459,965,000)
Gross profit (loss)	(507,791,000)	(194,356,000)	(171,310,000)	Net income (loss) attributable to common shareholders	...	(724,008,000)	(459,965,000)
Research & development expense	113,745,000	99,579,000	64,762,000	Weighted average shares outstanding - basic	595,468,419	579,716,708	558,182,177
Selling, general & administrative expenses	422,469,000	363,929,000	179,852,000	Weighted average shares outstanding - diluted	595,468,419	579,716,708	558,182,177
Impairment of long-lived assets	5,218,000	10,224,000	...	Year end shares outstanding	606,135,659	590,345,658	577,654,900
Change in fair value of contingent consideration	16,468,000	11,176,000	...	Net earnings (loss) per share - basic	\$(2.30)	\$(1.25)	\$(0.82)
Gain on sale of assets	(30,024,000)	Net earnings (loss) per share - diluted	\$(2.30)	\$(1.25)	\$(0.82)
Goodwill impairment	249,480,000	Number of full time employees	3,868
Total operating expenses	835,732,000	485,194,000	266,014,000	Total number of employees	3,868	3,353	2,449
Operating income (loss)	(1,343,523,000)	(679,550,000)	(437,324,000)	Number of common stockholders	1,514	1,467	1,094
				Number of beneficiary stockholders	...	901	837
				Foreign currency translation adjustments	...	(4,468,000)	...
				Loss on equity method investments	(41,786,000)
				Basic EPS Excluding ExtraOrdinary Items	\$(2.30)
				Diluted EPS Excluding ExtraOrd Items	\$(2.30)
					\$(2.30)
				Approximately; As of February 17, 2023; As of February 18, 2022			
				Consolidated Balance Sheet, Years Ended Dec. 31 (\$):			
					2023	2022	
				Cash & cash equivalents	135,033,000	690,630,000	...
				Restricted cash	216,552,000	158,958,000	...
				Available-for-sale securities, at fair value	...	1,332,943,000	...
				Equity securities	...	134,836,000	...
				Accounts receivable, gross	252,609,000
				Less: allowance for doubtful accounts	8,798,000
				Accounts receivable	243,811,000	129,450,000	...
				Raw materials & supplies - production locations	564,818,000	450,432,000	...
				Raw materials & supplies - customer locations	20,751,000	18,860,000	...
				Work-in-process	149,574,000	112,231,000	...
				Finished goods	226,110,000	64,113,000	...
				Inventory - Balancing value	961,253,000
				Inventory	...	645,636,000	...
				Contract assets	126,248,000	62,456,000	...
				Prepaid expenses & other current assets	104,068,000	150,389,000	...
				Total current assets	1,786,965,000	3,305,298,000	...
				Restricted cash	817,559,000	699,756,000	...
				Land	6,049,000	1,772,000	...
				Software, machinery & equipment	229,352,000	169,633,000	...
				Construction in progress	1,109,896,000	575,141,000	...
				Hydrogen production plants	77,107,000
				Leasehold improvements	95,229,000	21,363,000	...
				Property, plant & equipment	1,517,633,000	767,909,000	...
				Less accumulated depreciation	81,456,000	48,116,000	...
				Property, plant & equipment, net	1,436,177,000	719,793,000	...
				Right of use assets related to finance leases, net	57,281,000	53,742,000	...
				Right of use assets related to operating leases, net	399,969,000	360,287,000	...
				Equipment related to power purchase agreements and fuel delivered to customers	139,651,000
				Less: accumulated depreciation	28,390,000
				Equipment related to power purchase agreements & fuel delivered to customers, net	111,261,000	89,293,000	...
				Contract assets	29,741,000	41,831,000	...
				Goodwill	...	248,607,000	...
				Intangible assets, net	188,886,000	207,725,000	...
				Investments in non-consolidated entities & non-marketable equity securities	63,783,000	31,250,000	...
				Other assets	11,116,000	6,694,000	...
				Total assets	4,902,738,000	5,764,276,000	...
				Accounts payable	257,828,000	191,895,000	...
				Accrued payroll & compensation related costs	32,584,000	18,231,000	...
				Accrual for capital expenditures	83,781,000	53,089,000	...
				Accrued accounts payable	64,767,000	53,899,000	...
				Accrued sales & other taxes	17,207,000	15,112,000	...
				Accrued interest	562,000	421,000	...
				Other accrued liabilities	...	15,678,000	...
				Accrued other	1,643,000
				Accrued expenses - Balancing value	200,544,000
				Accrued expenses	...	156,430,000	...
				Deferred revenue & other contract liabilities	...	131,813,000	...
				Deferred revenue	204,139,000
				Operating lease liabilities	63,691,000	48,861,000	...
				Finance lease liabilities	9,441,000	8,149,000	...
				Finance obligations	84,031,000	58,925,000	...
				Current portion of long term debt	2,716,000	5,142,000	...
				Contingent consideration,

loss accrual for service contracts & other current liabilities	142,410,000	34,060,000
Total current liabilities	964,800,000	635,275,000
Deferred revenue	84,163,000	...
Deferred revenue & other contract liabilities	...	98,085,000
Operating lease liabilities	292,002,000	271,504,000
Finance lease liabilities	36,133,000	37,988,000
Finance obligations	284,363,000	270,315,000
Convertible senior notes, net	195,264,000	193,919,000
Long-term debt	1,209,000	3,925,000
Contingent consideration, loss accrual for service contracts & other liabilities	146,679,000	193,051,000
Total liabilities	2,004,613,000	1,704,062,000
Common stock	6,254,000	6,084,000
Additional paid-in capital	7,494,685,000	7,297,306,000
Accumulated other comprehensive income (loss)	(6,802,000)	(26,004,000)
Retained earnings (accumulated deficit)	(4,489,744,000)	(3,120,911,000)
Less common stock in treasury	106,268,000	96,261,000
Total stockholders' equity	2,898,125,000	4,060,214,000
Total Equity	2,898,125,000	...

□ Amortized cost - available-for-sale securities, at fair value: \$1,355,614,000

Recent Dividends:

- 1. Plug Power Inc series E redeemable convertible preferred.**
No dividends paid.
- 2. Plug Power Inc common.**
No dividends paid.
- 3. Plug Power Inc series D redeemable convertible preferred.**
No dividends paid.
- 4. Plug Power Inc class B convertible preferred.**
No dividends paid.
- 5. Plug Power Inc series C redeemable convertible preferred.**
No dividends paid.

Annual Dividends:

- 1. Plug Power Inc series E redeemable convertible preferred.**
No dividends paid.
- 2. Plug Power Inc common.**
No dividends paid.
- 3. Plug Power Inc series D redeemable convertible preferred.**
No dividends paid.
- 4. Plug Power Inc class B convertible preferred.**
No dividends paid.
- 5. Plug Power Inc series C redeemable convertible preferred.**
No dividends paid.

PLUS THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):			
	2023	□2022	2021
Grant revenue	4,913,000	224,000	...
Total revenues	4,913,000
Research & development	9,690,000	9,698,000	5,323,000
General & administrative	8,544,000	10,238,000	6,853,000
In process research & development acquired	250,000
Gain (loss) on disposal of property & equipment	(66,000)
Operating income (loss)	(13,321,000)	(19,712,000)	(12,492,000)
Interest income	400,000	147,000	19,000
Interest expense	395,000	711,000	932,000

Change in fair value of liability instruments	...	1,000	6,000
Total other income (expense)	5,000	(563,000)	(907,000)
Net income (loss)	(13,316,000)	(20,275,000)	(13,399,000)
Weighted average shares outstanding - basic	3,140,925	□1,750,350	805,946
Weighted average shares outstanding - diluted	3,140,925	□1,750,350	805,946
Year end shares outstanding	4,444,097	□2,240,092	□1,034,002
Earnings (loss) per share - continuing operations - basic	\$(4.24)
Net income (loss) per share - basic	\$(4.24)	□\$(11.55)	\$(16.65)
Earnings (loss) per share - continuing operations - diluted	\$(4.24)
Net income (loss) per share - diluted	\$(4.24)	□\$(11.55)	\$(16.65)
Number of full time employees	20	17	14
Total number of employees	20
Number of common stockholders	4	□□16	□□20
Income from cont operations before income tax	(13,316,000)

□ Non-consolidated; □ Adjusted for 1-for-15 stock split, May 1, 2023; □ Shares increased due to the effect of sale of common shares; □ Shares increased due to the effect of the sale of common shares, issuance of common shares for exercise of warrants and conversion of series B convertible preferred shares to common shares; □ Approximately; □ As of February 17, 2023; □ As of February 14, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	□2022
Cash & cash equivalents	8,554,000	18,120,000
Prepaid services	644,000	2,999,000
Prepaid insurance	636,000	698,000
Total current assets	9,834,000	21,817,000
Office & computer equipment	1,632,000	1,474,000
Leasehold improvements	1,810,000	1,810,000
Property & equipment, gross	3,442,000	3,284,000
Less accumulated depreciation	2,536,000	1,960,000
Property & equipment, net	906,000	1,324,000
Operating lease right-use-of assets	202,000	248,000
Intangible assets, net	42,000	94,000
Goodwill	372,000	372,000
Total assets	11,388,000	23,867,000
Accounts payable	4,758,000	8,364,000
Accrued payroll & bonuses	370,000	989,000
Accrued professional fees	128,000	147,000
Accrued vacation & compensation	...	325,000
Accrued research & development studies	...	309,000
Deferred rent	6,631,000	...
Warranty reserve	987,000	...
Operating lease liability	120,000	110,000
Term loan obligation, current	...	1,608,000
Term loan obligations, net of discount	3,976,000	...
Accrued R&D studies	388,000	...
Total current liabilities	10,727,000	11,852,000
Noncurrent operating lease liability	85,000	141,000
Term loan obligation	...	3,786,000

Deferred grant liability	...	1,643,000
Warrant liability	1,924,000	...
Total liabilities	12,736,000	17,422,000
Common stock	5,000	34,000
Additional paid-in capital	479,274,000	473,596,000
Retained earnings (accumulated deficit)	(480,501,000)	(467,185,000)
Treasury stock, at cost	126,000	...
Total stockholders' equity (deficit)	(1,348,000)	6,445,000
Total Equity	(1,348,000)	...

□ Non-consolidated

Recent Dividends:

- 1. Plus Therapeutics Inc series A 3.6% convertible preferred.**
No dividends paid.
- 2. Plus Therapeutics Inc common.**
No dividends paid.
- 3. Plus Therapeutics Inc series C preferred.**
No dividends paid.
- 4. Plus Therapeutics Inc series B convertible preferred.**
No dividends paid.

Annual Dividends:

- 1. Plus Therapeutics Inc series A 3.6% convertible preferred.**
No dividends paid.
- 2. Plus Therapeutics Inc common.**
No dividends paid.
- 3. Plus Therapeutics Inc series C preferred.**
No dividends paid.
- 4. Plus Therapeutics Inc series B convertible preferred.**
No dividends paid.

PORCH GROUP INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	□2021
Revenue	430,302,000
Revenue	430,302,000	275,948,000	192,433,000
Cost of revenue	220,243,000	107,577,000	□58,725,000
Product and technology	58,502,000
Selling & marketing expenses	144,307,000	113,848,000	□84,273,000
Product & technology	37,180,000	□59,565,000	□47,005,000
General & administrative	103,192,000	110,619,000	□85,795,000
Impairment loss on intangible assets & goodwill	57,232,000	61,386,000	...
Total operating expenses	620,656,000	452,995,000	275,798,000
Income (loss) from operations	(190,354,000)	(177,047,000)	(83,365,000)
Interest expense	31,828,000	8,723,000	5,757,000
Change in fair value of earnout liability	...	13,822,000	(18,519,000)
Change in fair value of private warrant liability	...	14,486,000	(15,389,000)
Gain (loss) on extinguishment of debt	81,354,000	...	5,110,000
Investment income & realized gains, net of investment expenses	8,285,000	1,174,000	701,000
Interest income	3,895,000	717,000	33,000
Transaction costs - recapitalization	444,000
Gain on settlement of accounts payable	44,000	...	175,000
Other income (expenses)	(2,000)	(146,000)	132,000
Other income (expenses), net	3,893,000	571,000	340,000
Change in fair value of

derivatives	(4,261,000)
Total other income (expense)	57,043,000	21,330,000	(33,514,000)
Income (loss) before income tax expense	(133,311,000)	(155,717,000)	(116,879,000)
Current federal income tax expense	...	483,000	(1,065,000)
Current state income taxes	399,000	644,000	205,000
Total current income taxes	399,000	1,127,000	(860,000)
Deferred federal income taxes	66,000	(285,000)	(8,561,000)
Deferred state income taxes	157,000	...	(852,000)
Total deferred income taxes	223,000	(285,000)	(9,413,000)
Income tax (benefit) expense	622,000	842,000	(10,273,000)
Net income (loss)	(133,933,000)	(156,559,000)	(106,606,000)
Net income (loss) attributable to common stockholders	...	(156,559,000)	(106,606,000)
Weighted average shares outstanding - basic	96,057,000	97,351,241	93,884,566
Weighted average shares outstanding - diluted	96,057,000	97,351,241	93,884,566
Year end shares outstanding	97,100,000	98,455,838	97,961,597
Net earnings (loss) per share - basic	\$(1.39)	\$(1.61)	\$(1.14)
Net earnings (loss) per share - diluted	\$(1.39)	\$(1.61)	\$(1.14)
Number of full time employees	864	911,800	911,700
Total number of employees	864
Number of common stockholders	554	126,685	133,686
EPS - Basic - excluding Extraordinary Items Applicable to Common - Total	\$(1.39)
EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total	\$(1.39)

[¶] Reclassified to conform with 2022 presentation; ^{¶¶} Include stock-based compensation expense - cost of revenue: \$1,000; ^{¶¶¶} Include stock-based compensation expense - selling & marketing expenses: \$4,855,000; ^{¶¶¶¶} Include stock-based compensation expense - selling & marketing expenses: \$5,584,000; ^{¶¶¶¶¶} Include stock-based compensation expense - product & technology expenses: \$5,435,000; ^{¶¶¶¶¶¶} Include stock-based compensation expense - product & technology expenses: \$7,223,000; ^{¶¶¶¶¶¶¶} Include stock-based compensation expense - general & administrative expenses: \$16,751,000; ^{¶¶¶¶¶¶¶¶} Include stock-based compensation expense - general & administrative expenses: \$25,784,000; ^{¶¶} Approximately; ^{¶¶¶} As of February 1, 2023; ^{¶¶¶¶} As of January 1, 2022; ^{¶¶¶¶¶} As of March 10, 2023; ^{¶¶¶¶¶¶} As of March 11, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	258,418,000	215,060,000
Accounts receivable, gross	24,888,000	26,938,000
Less: allowance for uncollectible receivables	600,000	500,000
Accounts & Notes Receivable - Trade - Net	24,288,000	...
Accounts receivable, net	...	26,438,000
Short-term investments	35,588,000	36,523,000
Reinsurance balance due	83,582,000	299,060,000
Prepaid expenses & other current assets	13,214,000	20,009,000
Restricted cash	...	13,545,000

Restricted cash and cash equivalents	38,814,000	...
Deferred policy acquisition costs	27,174,000	...
Total current assets	481,078,000	610,635,000
Software & computer equipment	35,615,000	8,326,000
Furniture, office equipment, & other	1,573,000	2,118,000
Internally developed software	24,526,000	17,128,000
Leasehold improvements	1,176,000	1,178,000
Software and computer equipment	8,340,000	...
Property, equipment & software, gross	...	28,750,000
Less: accumulated depreciation & amortization	18,754,000	16,510,000
Property, equipment & software, net	16,861,000	12,240,000
Operating lease right-of-use assets	...	4,201,000
Goodwill	191,907,000	244,697,000
Long-term investments	103,588,000	55,118,000
Intangibles assets, net	87,216,000	108,255,000
Long-term insurance commissions receivable	13,429,000	12,265,000
Other assets	5,314,000	1,646,000
Total assets	899,393,000	1,049,057,000
Accounts payable	8,761,000	6,268,000
Accrued expenses & other current liabilities	248,683,000	39,742,000
Accrued expenses and other current liabilities	59,396,000	...
Accrued expenses and other current liabilities - Balancing value	57,727,000	...
Deferred revenues	...	270,690,000
Refundable customer deposits	17,980,000	20,142,000
Current debt	...	16,455,000
Current portion of long-term debt	244,000	...
Losses & loss adjustment expense reserves	95,503,000	100,632,000
Other insurance liabilities, current	31,585,000	61,710,000
Operating Lease Liabilities - Current Portion/Short-Term	1,669,000	...
Total current liabilities	462,152,000	515,639,000
Long-term debt	435,495,000	425,310,000
Operating lease liabilities, non-current	...	2,536,000
Earnout liability, at fair value	...	44,000
Private warrant liability, at fair value	...	707,000
Other liabilities	37,429,000	25,468,000
Total liabilities	935,076,000	969,704,000
Common stock	10,000	10,000
Additional paid-in capital	690,223,000	670,537,000
Accumulated other comprehensive income (loss)	(3,860,000)	(6,171,000)
Retained earnings (accumulated deficit)	(722,056,000)	(585,023,000)
Total stockholders' equity	(35,683,000)	79,353,000
Total Equity	(35,683,000)	...

^{¶¶} Includes fair value - Other liabilities: \$24,546,000

Recent Dividends:

- 1. Porch Group Inc class B common.**
No dividends paid.
- 2. Porch Group Inc common.**
No dividends paid.
- 3. Porch Group Inc class A common subject to possible redemption.**
No dividends paid.
- 4. Porch Group Inc class A common.**

No dividends paid.

Annual Dividends:

- 1. Porch Group Inc class B common.**
No dividends paid.
- 2. Porch Group Inc common.**
No dividends paid.
- 3. Porch Group Inc class A common subject to possible redemption.**
No dividends paid.
- 4. Porch Group Inc class A common.**
No dividends paid.

PORTSMOUTH SQUARE, INC.

Earnings, 6 mos. to Dec 31 (Consol. - \$):

	2023	2022
Cost & expenses	21,101,000	20,120,000
Operating income	217,000	2,082,000
Gains or losses	(34,000)	97,000
Net before taxes	(4,125,000)	(2,050,000)
Income taxes	1,000	(721,000)
Net income	(4,126,000)	(1,329,000)
Earnings common share		
Primary	\$(5.62)	\$(1.81)
Fully Diluted	\$(5.62)	\$(1.81)
Common Shares:		
Full Diluted	734,187	734,187
Year-end	734,187	734,187

POWER SOLUTIONS INTERNATIONAL INC (DE)

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
			(revised)
Total revenues	458,973,000
Net sales	458,973,000	481,333,000	456,255,000
Cost of sales	353,109,000	392,770,000	414,984,000
Gross profit (loss)	105,864,000	88,563,000	41,271,000
Research, development & engineering expenses	19,457,000	18,896,000	22,435,000
Selling, general & administrative expenses	40,386,000	42,941,000	57,871,000
Amortization of intangible assets	1,746,000	2,124,000	2,535,000
Total operating expenses	61,589,000	63,961,000	82,841,000
Operating income (loss)	44,275,000	24,602,000	(41,570,000)
Interest expense	17,069,000	13,028,000	7,307,000
Other income (expense), net	(1,000)
Total other income (expense), net	...	(13,028,000)	(7,308,000)
Income (loss) before income taxes	27,206,000	11,574,000	(48,878,000)
Current federal tax expense (benefit)	61,000	204,000	(418,000)
Current state tax expense (benefit)	639,000	(89,000)	(17,000)
Total current tax expense (benefit)	700,000	115,000	(435,000)
Deferred federal tax expense (benefit)	64,000	(71,000)	(106,000)
Deferred state tax expense (benefit)	136,000	260,000	135,000
Retained earnings (accumulated deficit)	200,000	189,000	29,000
Income tax expense (benefit)	900,000	304,000	(406,000)
Net income (loss)	26,306,000	11,270,000	(48,472,000)
Weighted average shares outstanding - basic	22,960,000	22,938,000	22,908,000
Weighted average shares outstanding - diluted	22,973,000	22,948,000	22,908,000
Year end shares outstanding	22,968,000	22,951,000	22,926,000
Net earnings (loss) per common share - basic	\$1.15	\$0.49	\$(2.12)
Net earnings (loss)			

per common share - diluted	\$1.15	\$0.49	\$(2.12)
Number of full time employees	700	800	700
Total number of employees	700
Number of common stockholders	50	53	51
Basic EPS Excluding ExtraOrdinary Items	\$1.15
Diluted EPS Excluding ExtraOrd Items	\$1.15

□ Approximately; □ As of April 10, 2023; □ As of March 28, 2021

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	22,758,000	24,296,000
Restricted cash	3,836,000	3,604,000
Accounts receivable, gross	72,954,000	94,202,000
Allowances	5,975,000	4,308,000
Accounts receivable, net	66,979,000	89,894,000
Income tax receivable	550,000	555,000
Raw materials	68,273,000	101,566,000
Work in process	1,166,000	3,073,000
Finished goods	21,238,000	19,825,000
Total inventories	84,947,000	124,464,000
Inventory allowance	5,730,000	3,904,000
Inventories, net	...	120,560,000
Prepaid expenses & other current assets	26,312,000	16,364,000
Total current assets	205,382,000	255,273,000
Leasehold improvements	6,987,000	7,107,000
Machinery & equipment	46,964,000	45,747,000
Construction in progress	1,654,000	467,000
Total property, plant & equipment, at cost	55,605,000	53,321,000
Accumulated depreciation	40,677,000	39,477,000
Property, plant & equipment, net	14,928,000	13,844,000
Right-of-use assets, net	27,145,000	13,282,000
Intangible assets, net	3,914,000	5,660,000
Goodwill	29,835,000	29,835,000
Other noncurrent assets	3,099,000	2,019,000
Total assets	284,303,000	319,913,000
Accounts payable	67,355,000	76,430,000
Current maturities of long-term debt	139,000	130,000
Revolving line of credit	50,000,000	130,000,000
Finance lease liability, current	76,000	90,000
Operating lease liability, current	3,912,000	2,894,000
Other short-term financing	94,820,000	75,614,000
Warrant liability	2,741,000	...
Accrued product warranty	11,290,000	13,037,000
Litigation reserves	3,929,000	2,102,000
Contract liabilities	...	2,256,000
Accrued compensation & benefits	8,469,000	7,299,000
Accrued interest expense	1,913,000	5,257,000
Other accrued liabilities	...	4,158,000
Other accrued liabilities	...	34,109,000
Other	3,657,000	...
Other accrued liabilities (from related parties \$1,833 and \$5,232 as of 31, 2023 and 2022, respectively)	31,999,000	...
Total current liabilities	248,301,000	319,267,000
Deferred income taxes	1,478,000	1,278,000
Long-term debt, net of current maturities	90,000	5,029,000
Finance lease liability, long-term	94,000	170,000
Operating lease liability, long-term	25,070,000	10,971,000
Noncurrent contract liabilities	2,401,000	3,199,000

Other noncurrent liabilities	10,786,000	10,371,000
Total liabilities	288,220,000	350,285,000
Common stock	23,000	23,000
Additional paid-in capital	157,770,000	157,673,000
Retained earnings (accumulated deficit)	(160,790,000)	(187,096,000)
Treasury stock, at cost	920,000	972,000
Total stockholders' equity (deficit)	(3,917,000)	(30,372,000)
Total Equity	(3,917,000)	...

□ From related parties: \$2,325,000; □ From related parties: \$23,358,000; □ From related parties: \$75,020,000; □ From related parties: \$5,232,000; □ From related parties: \$4,800,000

Recent Dividends:

I. Power Solutions International Inc (DE) common.
No dividends paid.

Annual Dividends:

I. Power Solutions International Inc (DE) common.
No dividends paid.

PRECISION OPTICS CORP INC (MA)

Earnings, 6 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues	9,145,544	10,972,262
Cost & expenses	10,254,999	10,502,999
Operating income	(1,109,455)	469,263
Interest expense	113,762	119,319
Net before taxes	(1,223,217)	349,944
Net income	(1,223,217)	349,944
Earnings common share		
Primary	\$(0.20)	\$0.06
Fully Diluted	\$(0.20)	\$0.06
Common Shares:		
Full Diluted	6,066,545	5,937,471
Year-end	6,067,518	5,683,302

PRESTO AUTOMATION INC

Earnings, 6 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues	9,778,000	14,709,000
Cost & expenses	42,943,000	42,474,000
Operating income	(33,165,000)	(27,765,000)
Interest expense	7,315,000	6,406,000
Other income (expense), net	27,794,000	51,936,000
Net before taxes	(12,686,000)	17,765,000
Income taxes	(4,000)	5,000
Net income	(12,682,000)	17,760,000
Earnings common share		
Primary	\$(0.23)	\$0.44
Fully Diluted	\$(0.23)	\$0.35
Common Shares:		
Full Diluted	60,721,231	50,775,172
Year-end	70,335,628	51,231,608

PRIME MERIDIAN HOLDING CO

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

	2023	2022	2021 (revised)
Interest income - loans	35,291	26,221	23,050
Interest income - debt securities	3,698	2,938	1,086
Other interest income	937	1,581	268
Total interest income	39,926	30,740	24,404
Interest expense on savings, NOW & money-market deposits	...	2,315	1,653
Interest expense on time deposits	...	264	369
Interest expense on deposits	9,492	2,579	2,022
Interest expense from other borrowings	1,086	200	58
Total interest expense	10,578	2,779	2,080

Net interest income	29,348	27,961	22,324
Provision (credit) for loan losses	1,450	890	(104)
Net interest income after provision (credit) for loan losses	27,898	27,071	22,428
Service charges & fees on deposit amounts	...	302	245
Debit card or ATM revenue, net	...	540	470
Mortgage banking revenue	352	473	1,174
Income from bank-owned life insurance	389	379	271
Gain (loss) on sale of securities available for sale	108
Other noninterest income	...	240	238
Salaries & employee benefits	11,172	9,627	8,093
Occupancy & equipment expenses	2,490	1,621	1,546
Professional fees	559	514	483
Advertising expenses	903	793	707
FDIC assessment	360	360	316
Software maintenance	1,214
Software maintenance, amortization & other	...	1,162	975
Other noninterest expenses	...	2,191	1,950
Occupancy and Equipment	1,647
Total noninterest expenses	18,345	16,268	14,070
Earnings (loss) before income taxes	11,448	12,737	10,864
Current federal income taxes	2,434	2,699	2,109
Current state income taxes	696	685	356
Total current income taxes	3,130	3,384	2,465
Deferred federal income taxes	(305)	(257)	41
Deferred state income taxes	(85)	(71)	11
Total deferred income taxes	(390)	(328)	52
Income taxes	2,740	3,056	2,517
Net earnings (loss)	8,708	9,681	8,347
Weighted average shares outstanding - basic	3,210	3,155	3,127
Weighted average shares outstanding - diluted	3,251	3,194	3,142
Year end shares outstanding	3,260	3,164	3,129
Net earnings (loss) per share - basic	\$2.71	\$3.07	\$2.67
Net earnings (loss) per share - diluted	\$2.68	\$3.03	\$2.66
Number of full time employees	110	107	94
Number of common stockholders	350	311	318
Deposit Account	357
Other Income	224
Dividends Per Share - Common - Gross - by Period End Date	\$0.22
Debit Card	573
Total number of employees	110

□ Reclassified to conform with 2022 presentation; □ As is; □

Full time equivalent employees; [□] As of February 28, 2023; [□] As of February 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & due from banks	9,003	8,119
Federal funds sold	14,856	19,259
Interest bearing deposits	4,557	12,410
Total cash & cash equivalents	28,416	39,788
Debt securities available for sale	124,475	129,436
Debt securities held to maturity	11,850	[□] 11,805
Loans held for sale	5,288	7,058
Real estate mortgage loans - commercial	...	202,263
Real estate mortgage loans - residential & home equity	...	224,211
Real estate mortgage loans - construction	81,640	75,151
Residential and home equity	254,574	...
Total real estate mortgage loans	...	501,625
Commercial	223,795	...
Commercial loans	85,983	86,308
Consumer & other loans	5,936	7,698
Total loans	651,928	595,631
Net deferred loan (fees) costs	192	(229)
Less: Allowance for loan losses	5,609	7,145
Loans, net	646,127	588,715
Federal Home Loan Bank stock	1,283	463
Land	1,704	1,704
Building	5,111	5,089
Leasehold improvements	...	1,584
Furniture, fixtures & equipment	...	2,360
Computer & software	3,720	3,642
Leasehold improvements	1,584	...
Furniture fixtures and equipment - Other - Gross	2,438	...
Total, at cost	14,557	14,379
Less: accumulated depreciation & amortization	...	6,357
accumulated depreciation and amortization	7,081	...
Premises & equipment, net	7,476	8,022
Right of use lease asset	2,823	3,044
Deferred tax asset	3,529	4,533
Accrued interest receivable	3,114	2,385
Bank-owned life insurance	...	16,532
Capitalized offering costs	16,921	...
Other assets	3,226	3,391
Total assets	854,528	815,172
Noninterest-bearing demand deposits	189,426	197,987
Savings, NOW & money-market deposits	476,826	493,439
Time deposits	...	40,109
Time Deposits	82,436	...
Total deposits	748,688	731,535
Other borrowings	...	4,275
Official checks	2,377	4,090
Operating lease liability	3,013	3,208
Other liabilities	5,474	5,011
Federal Home Loan Bank advances	15,000	...
Total liabilities	774,552	748,119
Common stock	33	32
Additional paid-in capital	40,522	39,718
Retained earnings (accumulated deficit)	47,234	37,278
Accumulated other comprehensive income

(loss)	(7,813)	(9,975)
Total stockholders' equity	79,976	67,053
Total Equity	79,976	...

[□] Fair value - Debt securities held to maturity: \$9,917,000

Recent Dividends:

1. Prime Meridian Holding Co common.

No dividends paid.

Annual Dividends:

1. Prime Meridian Holding Co common.

No dividends paid.

PRIORITY TECHNOLOGY HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
REVENUES	755,612,000
Revenues	755,612,000	663,641,000	514,901,000
Costs of services (excludes depreciation & amortization)	480,307,000	436,753,000	359,885,000
Salary & employee benefits	79,974,000	65,077,000	43,818,000
Depreciation	11,494,000
Amortization of Intangibles excluding Goodwill	56,901,000
Depreciation & amortization expense	68,395,000	70,681,000	49,697,000
Selling, general & administrative expenses	45,412,000	34,965,000	28,408,000
Total operating expenses	674,088,000	607,476,000	481,808,000
Operating income	81,524,000	56,165,000	33,093,000
Interest expense	76,108,000	53,554,000	36,485,000
Debt extinguishment & modification expenses	8,322,000
Gain on sale of business & investment	7,643,000
Other income (expense), net	1,736,000	589,000	202,000
Total other income (expense), net	(74,372,000)	(52,965,000)	(36,962,000)
Income (loss) before income taxes	7,152,000	3,200,000	(3,869,000)
U.S. current income tax expense (benefit) - federal	10,624,000	10,411,000	(2,321,000)
U.S. current income tax expense (benefit) - state & local	...	2,546,000	(379,000)
U.S. current income tax expense (benefit) - foreign	738,000	349,000	1,000
State and local	3,187,000
Total U.S. current income tax expense (benefit)	14,549,000	13,306,000	(2,699,000)
U.S. deferred income tax expense (benefit) - federal	(5,149,000)	(5,001,000)	(1,343,000)
U.S. deferred income tax expense (benefit) - state & local	...	(2,970,000)	(1,213,000)
U.S. deferred income tax expense (benefit) - foreign	(225,000)	15,000	(3,000)
Income Taxes - Local - Deferred	(712,000)
Total U.S. deferred income tax expense (benefit)	(6,086,000)	(7,956,000)	(2,559,000)
Income tax expense (benefit)	8,463,000	5,350,000	(5,258,000)
Net income (loss)	(1,311,000)	(2,150,000)	1,389,000

Less: dividends & accretion attributable to redeemable senior preferred stockholders	47,744,000	36,880,000	18,009,000
Less: non-controlling interest ("NCI") preferred unit redemptions, net of deferred tax benefit	8,021,000
Net income (loss) attributable to common stockholders	(49,055,000)	(39,030,000)	(24,641,000)
Weighted average shares outstanding - basic	78,333,000	78,233,000	71,902,000
Weighted average shares outstanding - diluted	78,333,000	78,233,000	71,902,000
Year end shares outstanding	76,956,889	76,044,629	[□] 76,739,896
Net income (loss) per share - basic	\$(0.63)	\$(0.50)	\$(0.34)
Net income (loss) per share - diluted	\$(0.63)	\$(0.50)	\$(0.34)
Number of full time employees	974	863	783
Number of part time employees	...	7	7
Total number of employees	974	870	790
Number of common stockholders	69	[□] 85	[□] 64

[□] Shares increased due to vesting of stock-based compensation, issuance of common stock, exercise of stock options and fair value of common shares issued for non-controlling interest redemption; [□] As of March 17, 2023; [□] As of March 10, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	39,604,000	18,454,000
Restricted cash	11,923,000	10,582,000
Accounts receivable, gross	63,840,000	79,256,000
Less: allowances	5,289,000	1,143,000
Accounts receivable, net	58,551,000	78,113,000
Prepaid expenses & other current assets	13,273,000	11,832,000
Current portion of notes receivable	1,468,000	1,471,000
Settlement assets & customer/subscriber account balances	756,475,000	532,018,000
Total current assets	881,294,000	652,470,000
Notes receivable, less current portion	3,728,000	3,191,000
Computer software	78,492,000	64,197,000
Equipment	10,377,000	13,302,000
Leasehold improvements	1,535,000	6,990,000
Furniture & fixtures	1,442,000	2,909,000
Property, equipment & software, gross	91,846,000	87,398,000
Less: accumulated depreciation - property, equipment & software	56,442,000	58,409,000
Capital work in-progress	9,276,000	5,698,000
Property, equipment & software, net	44,680,000	34,687,000
Goodwill, net	376,103,000	369,337,000
Intangible assets, net	273,350,000	288,794,000
Deferred income tax assets, net	22,533,000	16,447,000
Other non-current assets	13,649,000	8,437,000
Total assets	1,615,337,000	1,373,363,000
Accrued expenses	12,621,000	17,742,000
Accrued card network fees	14,320,000	14,243,000
Accrued compensation	8,748,000	7,287,000
Contingent consideration	...	6,079,000
Accounts payable	11,003,000	6,513,000

Accounts payable & accrued expenses	52,643,000	51,864,000
Accrued residual commissions	33,025,000	35,979,000
Customer deposits & advance payments	3,934,000	2,618,000
Current portion of long-term debt	6,712,000	6,200,000
Settlement & customer/subscriber account obligations	755,754,000	533,340,000
Accounts Payable and Accrued Expenses - Balancing value	5,951,000	...
Operating Lease Liabilities - Current Portion/Short-Term	1,582,000	...
Accrued Expenses - Balancing value	11,039,000	...
Total current liabilities	852,068,000	630,001,000
Term facility	...	610,700,000
Revolving credit facility	...	12,500,000
Less: current portion of long-term debt	...	6,200,000
Less: unamortized debt discounts & deferred financing costs	...	(18,074,000)
Long-term debt, net of current portion, discounts & debt issuance costs	631,965,000	598,926,000
Other noncurrent liabilities	18,763,000	11,643,000
Total liabilities	1,502,796,000	1,240,570,000
Redeemable senior preferred stock	258,605,000	235,579,000
Common stock	77,000	76,000
Additional paid-in capital	...	9,650,000
Treasury stock, at cost	12,815,000	11,559,000
Retained earnings (accumulated deficit)	(134,951,000)	(102,208,000)
Accumulated other comprehensive income	(29,000)	...
Total stockholders' equity (deficit) attributable to stockholders of Priority Technology Holdings, Inc. ("PRTH")	(147,718,000)	(104,041,000)
Non-controlling interest	1,654,000	1,255,000
Total stockholders' equity (deficit)	(146,064,000)	(102,786,000)

Recent Dividends:

1. Priority Technology Holdings Inc redeemable senior preferred.

No dividends paid.

2. Priority Technology Holdings Inc common.

No dividends paid.

3. Priority Technology Holdings Inc common subject to possible conversion.

No dividends paid.

Annual Dividends:

1. Priority Technology Holdings Inc redeemable senior preferred.

No dividends paid.

2. Priority Technology Holdings Inc common.

No dividends paid.

3. Priority Technology Holdings Inc common subject to possible conversion.

No dividends paid.

PROCYON CORP.

Earnings, 6 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues	2,373,160	2,359,640
Net Sales	2,373,160	2,359,640
Cost & expenses	2,531,966	2,402,638
Operating income	(158,806)	(42,998)
Interest income	10,826	...
Other income (expense), net	18,534	2,844
Gains or losses	(1,214)	...
Net before taxes	(130,660)	(37,067)

Income taxes	(8,802)	...
Net income	(276,328)	(28,265)
Balance for common	(284,133)	(36,620)
Earnings common share
Primary	\$(0.04)	...
Fully Diluted	\$(0.04)	...
Common Shares:
Full Diluted	8,108,388	8,087,388
Year-end	8,108,388	...

PROFIRE ENERGY, INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
			(revised)
Sales of goods, net	54,284,295	42,318,263	23,690,994
Sales of services, net	3,923,765	3,618,380	2,665,182
Total revenues	58,208,060	45,936,643	26,356,176
Cost of sales - services	3,147,697
Cost of sales - products	24,528,345
Cost of goods sold - product	...	21,425,176	12,825,906
Cost of goods sold - services	...	2,860,077	2,129,255
Total cost of goods sold	...	24,285,253	14,955,161
Gross profit	30,532,018	21,651,390	11,401,015
General & administrative expenses	17,184,917	14,396,763	11,533,496
Research & development expenses	917,123	1,432,000	1,120,080
Depreciation expense	369,703
Depreciation & amortization expense	575,878	628,019	762,439
Amortization of Intangibles excluding Goodwill	206,175
Total operating expenses	18,677,918	16,456,782	13,416,015
Income (loss) from operations	11,854,100	5,194,608	(2,015,000)
Interest expense	9,449
Gain (loss) on sale of fixed assets	268,817	318,075	192,183
Other income (expense)	(57,088)	(3,626)	8,715
Interest income	390,031	177,125	133,201
Total other income (expense)	592,311	491,574	334,099
Income (loss) before income taxes	12,446,411	5,686,182	(1,680,901)
U.S federal federal income taxes - current	2,164,032	887,732	(492,757)
State & local income taxes - current	334,390	176,700	25,374
Foreign income taxes - current	159,381	...	(179,939)
Total current income taxes	2,657,803	1,064,432	(647,322)
U.S federal income taxes - deferred	(900,847)	435,603	15,831
State & local income taxes - deferred	(139,385)	85,670	2,133
Foreign income taxes - deferred	52,126	152,717	...
Total deferred income taxes	(988,106)	673,990	17,964
Income tax expense (benefit)	1,669,697	1,738,422	(629,358)
Net income (loss)	10,776,714	3,947,760	(1,051,543)
Net income available to common stockholders	...	3,947,760	(1,051,543)
Weighted average shares outstanding

- basic	47,355,978	47,161,101	48,070,581
Weighted average shares outstanding
- diluted	49,127,558	48,447,342	48,070,581
Year end shares outstanding	46,803,868	47,105,771	47,643,233
Net earnings per share - basic	\$0.23	\$0.08	\$(0.02)
Net earnings per share - diluted	\$0.22	\$0.08	\$(0.02)
Number of full time employees	118	103	90
Number of part time employees	...	4	8
Total number of employees	118	107	98
Number of common stockholders	75	81	81
Foreign currency translation adjustments	...	(670,167)	...
FULLY DILUTED EARNINGS PER SHARE	\$0.23
FULLY DILUTED EARNINGS PER SHARE	\$0.22

□ Approximately; □ As of March 7, 2023; □ As of March 7, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	10,767,519	7,384,578
Short-term investments	2,799,539	1,154,284
Accounts receivable, gross	14,379,134	11,106,890
Less: allowance for doubtful accounts	365,394	220,745
Accounts receivable, net	14,013,740	10,886,145
Raw materials	338,539	166,927
Finished goods	14,171,616	10,452,930
Subtotal	14,059,656	10,619,857
Reserve for obsolescence	450,499	325,877
Inventories, net	...	10,293,980
Prepaid inventory	1,944,942	784,420
Accrued receivables	119,035	881,176
Prepaid insurance	351,273	240,785
Interest receivables	81,868	72,761
Tax credits	740	118,035
Other prepaid expenses & current assets	...	217,462
Prepaid expenses & other current assets	2,832,262	2,314,639
Other	334,404	...
Total current assets	44,472,716	32,033,626
Long term investments	6,425,582	7,503,419
Financing right-of-use asset	106,402	120,239
Furniture & fixtures	...	623,086
Computers	...	223,626
Software	299,706	...
Machinery & equipment	549,584	541,036
Leased equipment	...	22,462
Vehicles	2,567,005	2,038,581
Land & buildings	734,736	11,240,356
Land and buildings	11,375,748	...
Total property & equipment	15,526,779	14,689,147
Less: accumulated depreciation	4,744,407	4,265,183
Property & equipment, net	10,782,372	10,423,964
Net deferred tax asset	496,785	...
Goodwill	2,579,381	2,579,381
Intangible assets, net	1,104,102	1,268,907
Operating lease right-of-use assets	326,505	...
Lease right-of-use asset	432,907	...
Total long-term assets	21,821,129	21,895,910
Total assets	66,293,845	53,929,536
Accounts payable	2,699,556	2,955,506
Income taxes payable	1,723,910	205,169
Employee-related payables	2,910,801	2,404,848
Deferred revenue	780,428	420,827
Inventory-related

payables	400,701	285,109	income taxes - deferred		(75,000)	64,000	Total assets	34,384,000	31,047,000
Other tax-related payables	119,188	54,762	Total state provision (benefit) for income taxes		33,000	129,000	Accounts payable	2,931,000	2,812,000
Warranty liabilities	108,930	74,103	Current Tax - Federal	848,000			Accrued contributions to retirement plans	730,000	687,000
Other accrued liabilities		334,345	Current Tax - State	126,000			Accrued self-insurance reserves	263,000	210,000
Accrued liabilities		3,573,994	Deferred Tax - Federal	111,000			Accrued salaries & wages	226,000	205,000
Current financing lease liability	47,492	53,646	Deferred Tax - State	8,000			Other accrued expenses		637,000
Other	221,772		Current income tax expense	974,000			Other	537,000	
Accrued liabilities - Balancing value	4,541,820		Deferred income taxes	119,000			Current portion of long-term debt	17,000	36,000
Current lease liability	130,184		Income tax expense	1,093,000	668,000	1,148,000	Current portion of operating lease liabilities	361,000	359,000
Operating current lease liability	82,692		Net earnings	4,349,000	2,918,000	4,412,000	Income taxes	217,000	226,000
Total current liabilities	9,095,470	6,788,315	Weighted average shares outstanding - basic	3,320,000	3,379,000	3,447,000	Total current liabilities	5,282,000	5,172,000
Net deferred income tax liability	52,621	488,858	Weighted average shares outstanding - diluted	3,320,000	3,379,000	3,447,000	Deferred income taxes	764,000	575,000
Long-term financing lease liability	63,393	67,883	Year end shares outstanding	3,294,000	3,324,000	3,418,400	Self-insurance reserves	263,000	268,000
Operating long-term lease liability	244,135		Net earnings per share - basic	\$1.31	\$0.86	\$1.28	Long-term debt	42,000	43,000
Long-term lease liability	307,528		Net earnings per share - diluted	\$1.31	\$0.86	\$1.28	Operating lease liabilities	2,624,000	2,573,000
Total liabilities	9,455,619	7,345,056	Number of full time employees	253,000			Finance lease liabilities	536,000	423,000
Common stock	53,048	52,144	Total number of employees	253,000	242,000	232,000	Other noncurrent liabilities	202,000	141,000
Treasury stock, at cost	9,324,272	7,336,323	Number of common stockholders	235,000	226,000	214,000	Total liabilities	9,713,000	9,195,000
Additional paid-in capital	32,751,749	31,737,843	Basic EPS Excluding ExtraOrdinary Items	\$1.31			Common stock related to employee stock ownership plan (ESOP)	4,220,000	4,029,000
Accumulated other comprehensive income (loss)	(2,844,702)	(3,294,873)	Diluted EPS Excluding ExtraOrd Items	\$1.31			Common stock	3,294,000	3,324,000
Retained earnings	36,202,403	25,425,689	Interest and dividend income	379,000			Additional paid-in capital	2,005,000	1,687,000
Total stockholders' equity	56,838,226	46,584,480	Fair value adjustment	398,000			Retained earnings	19,741,000	17,413,000
Total Equity	56,838,226		Net (gain) loss on sale of equity securities previously recognized through fair value adjustment	(48,000)			Investments	(412,000)	(618,000)

Recent Dividends:**1. Profire Energy, Inc common.**

No dividends paid.

Annual Dividends:**1. Profire Energy, Inc common.**

No dividends paid.

PUBLIX SUPER MARKETS, INC.**Annual Report****Consolidated Income Statement, Years Ended (\$000):**

	12/30/23	12/31/22	12/25/21 (revised)
Sales	57,096,000	54,534,000	47,997,000
Other operating income	438,000	408,000	397,000
Total revenues	57,534,000	54,942,000	48,394,000
Total costs and expenses	42,089,000		
Cost of merchandise sold		39,938,000	34,828,000
Operating & administrative expenses	10,972,000	10,245,000	9,413,000
Total costs & expenses	53,061,000	50,183,000	44,241,000
Operating profit	4,473,000	4,759,000	4,153,000
Investment income (loss)	863,000	(1,262,000)	1,330,000
Investment income	134,000		
Other nonoperating income, net	106,000	89,000	77,000
Earnings before income tax expense	5,442,000	3,586,000	5,560,000
Federal provision for income taxes - current		810,000	755,000
Federal provision (benefit) for income taxes - deferred		(175,000)	264,000
Total federal provision for income taxes		635,000	1,019,000
State provision (benefit) for income taxes - current		108,000	65,000
State provision (benefit) for			

Reclassified to conform with 2022 presentation; Adjusted for 5-for-1 stock split, April 14, 2022; As is; Approximately; As of February 7, 2023; As of February 1, 2022

Consolidated Balance Sheet, Years Ended (\$000):

	12/30/23	12/31/22
Cash & cash equivalents	865,000	1,336,000
Short-term investments	1,899,000	566,000
Trade receivables	1,174,000	1,106,000
Inventories	2,462,000	2,341,000
Prepaid expenses	82,000	74,000
Total current assets	6,482,000	5,423,000
Long-term investments	11,867,000	10,992,000
Other noncurrent assets	730,000	561,000
Operating lease right-of-use assets	3,121,000	2,979,000
Land	2,491,000	2,319,000
Buildings & improvements	7,660,000	7,130,000
Furniture, fixtures & equipment	7,114,000	6,567,000
Leasehold improvements	1,999,000	1,875,000
Finance lease right-of-use assets	752,000	582,000
Construction in progress	377,000	215,000
Property, plant & equipment, gross	20,393,000	18,688,000
Accumulated depreciation	8,209,000	7,596,000
Net property, plant & equipment	12,184,000	11,092,000

Recent Dividends:**1. Publix Super Markets, Inc. common.**

ExDate	Amt	Declared	Record	Payable
01/14/2021	0.32	01/04/2021	01/15/2021	02/01/2021
04/14/2021	0.37	04/01/2021	04/15/2021	05/03/2021
07/14/2021	0.37	07/01/2021	07/15/2021	08/02/2021
10/14/2021	0.37	10/01/2021	10/15/2021	11/01/2021
01/13/2022	0.37	01/03/2022	01/14/2022	02/01/2022
04/13/2022	0.90	04/01/2022	04/15/2022	05/02/2022
07/14/2022	0.90	07/01/2022	07/15/2022	08/01/2022
10/13/2022	0.90	10/03/2022	10/14/2022	11/01/2022
	0.90	01/03/2023	01/13/2023	02/01/2023
	0.10	04/03/2023	04/14/2023	05/01/2023
	0.10	07/03/2023	07/14/2023	08/01/2023
	0.10	10/02/2023	10/13/2023	11/01/2023
	0.10	01/02/2024	01/15/2024	02/01/2024

Annual Dividends:**1. Publix Super Markets, Inc. common.**

2021	1.43	2022	3.07	2023	1.20
2024	0.10				

PURE BIOSCIENCE INC**Earnings, 6 mos. to Jan 31(Consol. - \$):**

	2024	2023
Total revenues	1,048,000	868,000
Net Sales	1,043,000	863,000
Cost & expenses	2,723,000	2,912,000
Operating income	(1,675,000)	(2,044,000)
Interest expense	62,000	4,000
Other income (expense), net		(5,000)
Net before taxes	(1,737,000)	
Net income	(1,737,000)	(2,053,000)
Earnings common share		
Primary	\$(0.02)	\$(0.02)
Fully Diluted	\$(0.02)	\$(0.02)
Common Shares:		
Full Diluted	111,856,473	111,356,473
Year-end	111,856,473	111,356,473

PUREBASE CORP**Annual Report****Consolidated Income Statement, Years Ended Nov. 30 (\$):**

	2023	2022	2021 (revised)
Revenue	325,875
Revenue, net	325,875	471,608	369,450
Selling, general & administrative expenses	1,541,238	32,883,673	8,500,338
Product fulfillment expenses	96,148	132,247	107,928
Stock based compensation	7,391,278
Total operating expenses	...	33,015,920	8,608,266
Income (loss) from operations	(8,702,789)	(32,544,312)	(8,238,816)
Other income (expense)	310,401	2,007	23,200
Interest expense	76,941	40,120	91,581
Loss on conversion of related party debt & payables	618,000
Net Income Before Tax	(9,087,329)
Total other income (expense)	(384,540)	(38,113)	(68,381)
Net income (loss)	(9,087,329)	(32,582,425)	(8,307,197)
Weighted average shares outstanding - basic	230,731,334	228,296,555	215,173,902
Weighted average shares outstanding - diluted	230,731,334	228,296,555	215,173,902
Year end shares outstanding	230,863,005	230,753,005	215,380,751
Net earnings (loss) per common share - basic	\$(0.04)	\$(0.14)	\$(0.04)
Net earnings (loss) per common share - diluted	\$(0.04)	\$(0.14)	\$(0.04)
Number of full time employees	7	4	3
Number of part time employees	...	1	2
Total number of employees	7
Number of common stockholders	99	197	93
Basic EPS Excluding ExtraOrdinary Items	\$(0.04)
Diluted EPS Excluding ExtraOrd Items	\$(0.04)

As of February 28, 2023; As of March 11, 2022

Consolidated Balance Sheet, Years Ended Nov. 30 (\$):

	2023	2022
Cash & cash equivalents	5,572	19,055
Prepaid expenses & other assets	15,434	4,731
Total current assets	21,006	23,786
Property & equipment	130,716	...
Furniture & equipment	6,952	6,952
Machinery & equipment	35,151	35,151
Automobiles & trucks	25,061	25,061
Construction in process	620,000	620,000
Total property & equipment	817,880	687,164
Less: accumulated depreciation - property & equipment	67,164	67,164
Property & equipment, net	750,716	620,000
Right of use assets	39,799	79,599
Total assets	811,521	723,385
Accounts payable	314,502	30,078
Accrued interest - related party	120,011	47,120
Accrued compensation	39,080	28,134
Accounts payable &		

accrued expenses	7,431	115,478	...
Settlement liability	618,000	400,000	...
Lease liability	40,880	38,882	...
Note payable to officer	8,716	28,716	...
Convertible notes payable - related party, net	...	36,000	...
Notes payable, related party	...	25,000	...
Accounts Payable and Accrued Expenses	481,024
Convertible notes payable - affiliated entity, net of discount of \$38,231	19,000
Line of credit, current	346,735
Total current liabilities	1,514,355	644,076	...
Lease liability, net of current portion	...	40,880	...
Convertible notes payable - related party, net of current portion	1,525,676	610,889	...
Total liabilities	...	1,295,845	...
Common stock	230,863	160,350	...
Additional paid in capital	60,271,605	52,910,839	...
Retained earnings (accumulated deficit)	(62,730,978)	(53,643,649)	...
Total Purebase Corp. stockholders' equity (deficit)	(2,228,510)	(572,460)	...
Total stockholders' equity (deficit)	(2,228,510)	(572,460)	...

As reported by the Company

Recent Dividends:**1. PureBase Corp common.**

No dividends paid.

Annual Dividends:**1. PureBase Corp common.**

No dividends paid.

PURECYCLE TECHNOLOGIES INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021 (revised)
Operating costs	52,392,000	26,559,000	10,554,000
Research & development expenses	6,607,000	1,090,000	1,411,000
Selling, general & administrative expenses	54,902,000	53,669,000	57,615,000
Total operating costs & expenses	113,901,000	81,318,000	69,580,000
Interest earned on marketable securities held in trust account	10,863,000
Interest expense	31,368,000
Interest income (expense)	...	2,641,000	(6,652,000)
Change in fair value of warrants	33,824,000	(5,842,000)	(1,476,000)
Other income (expense)	(483,000)	(227,000)	206,000
Total other income (expense)	...	(3,428,000)	(7,922,000)
Net income (loss)	(101,715,000)	(84,746,000)	(77,502,000)
Net income (loss) attributable to common stockholder	...	(84,746,000)	(77,502,000)
Weighted average shares outstanding - basic	163,865,000	155,957,000	102,913,000
Weighted average shares outstanding - diluted	163,865,000	155,957,000	102,913,000
Year end shares outstanding	164,279,000	163,550,000	127,647,000
Net income (loss) per share - basic	\$(0.62)	\$(0.54)	\$(0.75)
Net income (loss) per share - diluted	\$(0.62)	\$(0.54)	\$(0.75)
Full-Time Employees			

(Period End)	146
Total number of employees	146	177	119
Number of common stockholders	142	145	149
Income from cont operations before income tax	(101,065,000)
Income Taxes - Domestic - Deferred	650,000
Income Taxes - Total - Deferred	650,000
Provision for income taxes	650,000

Reclassified to conform with 2022 presentation; Shares increased due to the effect issuance of common stock and equity based compensation; As of March 13, 2023; As of March 18, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	...	63,892,000
Debt securities available for sale	48,226,000	98,592,000
Restricted cash - current	25,692,000	68,850,000
Prepaid expenses & other current assets	15,316,000	4,883,000
Cash and cash equivalents	73,411,000	...
Total current assets	162,645,000	236,217,000
Restricted cash - non-current	...	94,781,000
Prepaid expenses & other non-current assets	4,772,000	5,483,000
Operating lease right-of-use assets	29,799,000	19,136,000
Building	81,593,000	12,534,000
Machinery & equipment	329,381,000	23,728,000
Leasehold improvements	1,525,000	2,957,000
Fixtures & furnishings	711,000	529,000
Land improvements	150,000	150,000
Land	1,150,000	1,150,000
Construction in process	226,885,000	473,269,000
Land net	1,150,000	...
Machinery and equipment	349,796,000	...
Land improvements	118,000	...
Buildings - Net	79,153,000	...
Leasehold Improvements - Gross	2,972,000	...
Total property, plant & equipment, cost	...	514,317,000
Accumulated Depreciation Machinery And Equipment	20,415,000	...
Accumulated Depreciation Furniture And Fixtures	177,000	...
Buildings - Accumulated Depreciation & Impairment	2,440,000	...
Leasehold Improvements - Accumulated Depreciation & Impairment	1,447,000	...
Less: accumulated depreciation	...	8,598,000
Furniture And Fixtures Net	534,000	...
Construction In Progress
Net	226,885,000	...
Property, plant & equipment, net	638,746,000	505,719,000
Restricted cash and cash equivalents - non-current	203,411,000	...
Accumulated Depreciation Land Improvements	32,000	...
Total assets	1,039,373,000	861,336,000
Accounts payable	2,881,000	1,667,000
Accrued expenses	35,391,000	35,102,000
Notes payable - current	9,148,000	...
Accrued interest	8,190,000	1,532,000
Operating Lease Liabilities - Current Portion/Short-Term	2,535,000	...
Accrued expenses - Balancing value	32,856,000	...
Total current liabilities	55,610,000	38,301,000

Deferred revenue	5,000,000	5,000,000
Bonds payable - non-current	467,708,000	233,513,000
Warrant liability	22,059,000	55,883,000
Operating lease right-of-use liabilities	27,253,000	16,620,000
Other non-current liabilities	1,811,000	1,136,000
Related party note payable	39,696,000	...
Total liabilities	619,137,000	350,453,000
Common stock	164,000	164,000
Additional paid-in capital	764,344,000	753,885,000
Accumulated other comprehensive income (loss)	(32,000)	(641,000)
Retained earnings (accumulated deficit)	(344,240,000)	(242,525,000)
Total stockholders' equity (deficit)	420,236,000	510,883,000
Total Equity	420,236,000	...

Recent Dividends:**1. PureCycle Technologies Inc common stock subject to possible redemption.**

No dividends paid.

2. PureCycle Technologies Inc common.

No dividends paid.

Annual Dividends:**1. PureCycle Technologies Inc common stock subject to possible redemption.**

No dividends paid.

2. PureCycle Technologies Inc common.

No dividends paid.

QDM INTERNATIONAL INC**Earnings, 9 mos. to Dec 31(Consol. - \$):**

	2023	2022
Total revenues	5,446,729	47,020
Net Sales	5,446,729	...
Cost & expenses	3,845,334	287,793
Operating income	1,601,395	(240,773)
Interest expense	829	...
Other income (expense), net	35,690	3,235
Gains or losses	33,165	...
Net before taxes	1,669,421	(238,495)
Income taxes	266,028	...
Net income	1,403,393	(238,495)
Earnings common share		
Primary	\$0.05	\$(1.14)
Fully Diluted	\$0.05	\$(1.14)
Common Shares:		
Full Diluted	29,155,920	209,520
Year-end	29,155,920	209,521

QUEST RESOURCE HOLDING CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
Revenue	288,377,652
Revenue	288,377,652	284,037,823	155,715,373
Cost of revenue	238,312,950	235,182,337	127,009,706
Gross profit (loss)	50,064,702	48,855,486	28,705,667
Selling, general, & administrative expenses	37,669,419	37,800,161	21,728,886
Depreciation & amortization expenses	9,570,538	9,649,966	2,469,425
Amortization of Intangibles excluding Goodwill	9,142,589
Depreciation	427,949
Total operating expenses	47,239,957	47,450,127	24,198,311
Operating income (loss)	2,824,745	1,405,359	4,507,356
Interest expense	9,729,098	7,280,741	2,495,130
Income (loss) before taxes	(6,904,353)	(5,875,382)	2,012,226
Current income tax expense (benefit)	386,932	172,604	321,169

Income tax expense (benefit)	386,932	172,604	321,169
Net income (loss)	(7,291,285)	(6,047,986)	1,691,057
Weighted average shares outstanding - basic	20,123,221	19,473,786	18,885,714
Weighted average shares outstanding - diluted	20,123,221	19,473,786	20,735,017
Year end shares outstanding	20,161,400	19,696,006	19,045,988
Net income (loss) per share - basic	\$(0.36)	\$(0.31)	\$0.09
Net income (loss) per share - diluted	\$(0.36)	\$(0.31)	\$0.08
Number of full time employees	195	197	188
Number of part time employees	...	6	5
Total number of employees	195	203	193
Number of common stockholders	90	95	105
Basic EPS Excluding ExtraOrdinary Items	\$(0.36)
Diluted EPS Excluding ExtraOrd Items	\$(0.36)

Reclassified to conform with 2022 presentation; Approximately; As of March 1, 2023; As of March 1, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	324,014	9,563,709
Accounts receivable, gross	59,728,653	48,067,154
Less: allowance for doubtful accounts	1,581,595	2,176,010
Accounts receivable	58,147,058	45,891,144
Prepaid expenses & other current assets	2,142,071	2,310,423
Total current assets	60,613,143	57,765,276
Goodwill	85,828,238	84,258,206
Intangible assets, net	26,051,428	33,556,340
Machinery & equipment	3,321,220	3,159,483
Office furniture & fixtures	573,686	568,040
Leasehold improvements	715,312	719,781
Computer equipment	451,329	676,197
Property & equipment, gross	5,061,547	5,123,501
Accumulated depreciation - property & equipment	2,932,371	2,499,797
Property & equipment, net	4,626,090	2,623,704
Right-of-use operating lease assets	1,862,455	2,385,870
Security deposits & other assets	...	901,653
Security deposits & other assets	634,459	...
Total assets	177,118,899	181,491,049
Accounts payable	38,600,461	28,744,858
Accrued taxes	484,854	331,936
Employee compensation	1,478,826	1,812,028
Operating lease liability - current portion	493,928	489,938
Other accounts payable & accrued liabilities	...	828,701
Accounts payable & accrued liabilities	41,296,166	32,207,461
Other current liabilities	...	4,688,605
Deferred revenues	2,469,690	...
Current portion of notes payable	...	1,158,800
Long-term debt & capital lease obligations - current portion	1,158,800	...
Miscellaneous	238,097	...
Total current liabilities	44,924,656	38,054,866
Monroe Capital Management advisors, LLC term loan	...	61,073,151
Green Remedies Waste &

Recycling, Inc. promissory note	...	1,637,970
PNC Bank, National Association ("PNC") ABL facility	64,638,180	12,238,034
Total notes payable	...	74,949,155
Less: current portion of long-term debt	...	1,158,800
Less: unamortized debt issuance costs	...	(2,122,715)
Less: unamortized OID	...	(288,643)
Less: unamortized OID warrant	...	(806,106)
Notes payable, net	...	70,572,891
Other long-term liabilities, net	1,274,691	1,724,244
Other long-term liabilities	1,274,691	...
Total liabilities	110,837,527	110,352,001
Common stock	20,161	19,696
Additional paid-in capital	176,309,463	173,876,319
Retained earnings (accumulated deficit)	(110,048,252)	(102,756,967)
Total stockholders' equity (deficit)	66,281,372	71,139,048
Total Equity	66,281,372	...

Recent Dividends:**1. Quest Resource Holding Corp common.**

No dividends paid.

Annual Dividends:**1. Quest Resource Holding Corp common.**

No dividends paid.

RED CAT HOLDINGS INC**Earnings, 9 mos. to Jan 31(Consol. - \$):**

	2024	2023
Total revenues	11,526,930	3,541,846
Cost & expenses	25,546,954	18,555,715
Operating income	(14,020,024)	(15,013,869)
Other income (expense), net	(28,144)	94,357
Gains or losses	(733,697)	257,244
Net before taxes	(14,838,925)	(14,759,107)
Income contin. oper.	(14,838,925)	(14,759,107)
Income discont. oper.	(2,141,289)	(962,971)
Net income	(16,980,214)	(15,722,078)
Earnings common share		
Primary	\$(0.31)	\$(0.29)
Fully Diluted	\$(0.31)	\$(0.29)
Common Shares:		
Full Diluted	55,409,930	54,050,127
Year-end	74,171,106	54,385,461

RED VIOLET INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31****(\$000):**

	2023	2022	2021
Revenue	60,204
Revenue	60,204	53,318	44,022
Cost of revenue (exclusive of depreciation & amortization)	13,069	12,211	11,195
Sales & marketing expenses	13,833	10,834	8,932
General & administrative expenses	22,446	23,237	19,811
Amortization of Intangibles excluding Goodwill	8,119
Depreciation	233
Depreciation & amortization	8,352	6,675	5,399
Total costs & expenses	57,700	52,957	45,337
Income (loss) from operations	2,504	361	(1,315)
Interest (expense) income, net	1,334	351	(7)
Gain on

extinguishment of debt	...	2,175	costs	116	Basic EPS Excluding ExtraOrdinary Items..	\$(1.58)
Income (loss) before income taxes	3,838	712	Sales tax payable	50	Diluted EPS
Current income taxes expense (benefit) - state	94	7	Miscellaneous expenses payable	91	Excluding ExtraOrd Items	\$(1.58)
Current income taxes expense (benefit) - federal	16	...	Current portion of operating lease liabilities	569				
Total current income taxes expense (benefit)	110	...	Deferred revenue	690				
Deferred income taxes expense (benefit) - federal	(2,139)	1,149	Accrued expenses and other current liabilities	1,989				
Deferred income taxes expense (benefit) - state	371	392	Accrued expenses and other current liabilities - Balancing value	131				
valuation allowance	(8,033)	(1,452)	Income Taxes - Payable - Short-Term	16				
Income Taxes - Total - Deferred	(9,801)	...	Total current liabilities	4,879				
Income tax expense (benefit)	(9,691)	96	Noncurrent operating lease liabilities	1,999				
Net income (loss)	13,529	616	Deferred tax liabilities	6,878				
Weighted average shares outstanding - basic	13,974	13,759	Total liabilities	6,321				
Weighted average shares outstanding - diluted	14,134	14,107	Common stock	14				
Year end shares outstanding	13,971	13,956	Treasury stock, at cost	188				
Net income (loss) per share - basic	\$0.97	\$0.04	Additional paid-in capital	94,159				
Net income (loss) per share - diluted	\$0.96	\$0.04	Retained earnings (accumulated deficit)	(7,873)				
Number of full time employees	183	186	Total shareholders' equity	86,112				
Number of part time employees	...	1	Total Equity	86,112				
Number of common stockholders	25	28						
Total number of employees	183	...						

¹ As is; ² As of March 3, 2023; ³ As of March 4, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):								
	2023	2022		2021 (revised)			2023	2022
Cash & cash equivalents	32,032	31,810					23,767	24,228
Accounts receivable	7,294	5,595					...	14,932
Less: allowance for doubtful accounts	159	60					62	62
Accounts receivable, net	7,135	5,535					3,010	3,010
Prepaid expenses & other current assets	1,113	771					1,340	1,847
Total current assets	40,280	38,116					28,179	44,079
Computer & network equipment	1,127	1,082					4,687	4,359
Furniture, fixtures & office equipment	787	776						
Leasehold improvements	53	53					12	470
Total property & equipment cost	1,967	1,911					...	12
Less: accumulated depreciation - property & equipment	1,375	1,202					115	115
Property & equipment, net	592	709					126	...
Intangible assets, net	34,403	31,647					Computer Equipment and Software	...
Goodwill	5,227	5,227					367	...
Right-of-use assets	2,457	1,114					Property & equipment, gross	5,307
Other noncurrent assets	517	601					Less accumulated depreciation & amortization	4,246
Deferred tax assets	9,514	...					Property & equipment, net	1,061
Total assets	92,990	77,414					Intangibles, net	33
Accounts payable	1,631	2,229					Right of use asset	1,477
Accrued payroll & related expenses	1,685	1,600					Total assets	30,750
Accrued data acquisition					Accounts payable	204

REGULUS THERAPEUTICS INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$000):									
	2023	2022	2021 (revised)						
Research & development	21,152	18,410	17,794						
General & administrative	9,957	9,829	10,022						
Total operating expenses	31,109	28,239	27,816						
Income (loss) from operations	(31,109)	(28,239)	(27,816)						
Interest & other income	1,677	605	864						
Interest & other expense	604	688	855						
Income (loss) before income taxes	(30,036)	(28,322)	(27,807)						
Current state income tax expense (benefit)	1	...	1						
Total current income tax expense (benefit)	1	...	1						
Income tax expense	1	1	1						
Net income (loss)	(30,037)	(28,323)	(27,808)						
Weighted average shares outstanding - basic	18,960	15,260	14,570						
Weighted average shares outstanding - diluted	18,960	15,260	14,570						
Year end shares outstanding	20,223	16,840	14,597						
Net income (loss) per share - basic	\$(1.58)	\$1.86	\$3.24						
Net income (loss) per share - diluted	\$(1.58)	\$1.86	\$3.24						
Number of full time employees	30	30	26						
Total number of employees	30						
Number of common stockholders	36	11	13						

Recent Dividends:								
1. Red Violet Inc common.								
No dividends paid.								
Annual Dividends:								
1. Red Violet Inc common.								
No dividends paid.								
REGULUS THERAPEUTICS INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$000):								
Recent Dividends:								
1. Regulus Therapeutics Inc class A-2 convertible preferred.								
No dividends paid.								
2. Regulus Therapeutics Inc class A-4 convertible preferred.								
No dividends paid.								
3. Regulus Therapeutics Inc common.								
No dividends paid.								
4. Regulus Therapeutics Inc class A-1 convertible preferred.								
No dividends paid.								
5. Regulus Therapeutics Inc class A-3 convertible preferred.								
No dividends paid.								
Annual Dividends:								
1. Regulus Therapeutics Inc class A-2 convertible preferred.								
No dividends paid.								

2. Regulus Therapeutics Inc class A-4 convertible preferred.
No dividends paid.
3. Regulus Therapeutics Inc common.
No dividends paid.
4. Regulus Therapeutics Inc class A-1 convertible preferred.
No dividends paid.
5. Regulus Therapeutics Inc class A-3 convertible preferred.
No dividends paid.

REMARK HOLDINGS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2023	2022
Total revenues	4,176,000	10,037,000
Cost & expenses	15,129,000	24,784,000
Operating income	(11,131,000)	(14,868,000)
Other income (expense), net	(6,712,000)	
Gains or losses	(14,000)	(26,698,000)
Net before taxes	(21,208,000)	(46,891,000)
Income taxes		(9,000)
Net income	(21,208,000)	(46,882,000)
Earnings common share		
Primary	\$(1.38)	\$(4.50)
Fully Diluted	\$(1.38)	\$(4.50)
Common Shares:		
Full Diluted	15,355,583	10,529,055
Year-end	19,711,855	10,640,777

REPAY HOLDINGS CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021 (revised)
Processing & service fees	296,627,000		
Revenue	296,627,000	279,227,000	219,258,000
Cost of services	69,703,000	64,826,000	55,484,000
Selling general & administrative	148,653,000	149,061,000	120,053,000
Depreciation & amortization	103,857,000	107,751,000	89,692,000
Change in fair value of contingent consideration		3,300,000	(5,846,000)
Impairment loss	75,800,000	8,090,000	2,180,000
Total operating expenses	408,040,000	326,428,000	273,255,000
Loss on business disposition	(10,027,000)		
Amortization of Computer Software	19,789,000		
Amortization of Intangibles excluding Goodwill	81,642,000		
Depreciation	2,426,000		
Income (loss) from operations	(111,413,000)	(47,201,000)	(53,997,000)
Interest expense	1,048,000	4,375,000	3,679,000
Gain (loss) on extinguishment of debt			(5,941,000)
Change in fair value of tax receivable liability		66,871,000	(14,109,000)
Other income (expense)	(455,000)	(135,000)	97,000
Other gains (loss)	(6,619,000)	(245,000)	(9,099,000)
Income (loss) before income taxes - Domestic		13,305,000	(87,353,000)
Income (loss) before income taxes - Foreign		1,610,000	625,000
Income (loss) before income tax expense (benefit)	(119,535,000)	14,915,000	(86,728,000)
Current federal tax expense (benefit)	591,000	1,300,000	35,000
Current state tax expense (benefit)	332,000	263,000	2,000
Current foreign tax expense (benefit)	556,000	419,000	
Current tax expense (benefit)	1,479,000	1,982,000	37,000
Deferred tax			

expense (benefit) - federal	(1,858,000)	1,421,000	(18,113,000)
Deferred tax expense (benefit) - state	(1,736,000)	2,755,000	(12,800,000)
Deferred tax expense (benefit) - foreign		16,000	185,000
Total deferred tax expense (benefit)	(3,594,000)	4,192,000	(30,728,000)
Income tax expense (benefit)	(2,115,000)	6,174,000	(30,691,000)
Net income (loss)	(117,420,000)	8,741,000	(56,037,000)
Less: net income (loss) attributable to non-controlling interests	6,930,000	4,095,000	5,953,000
Net income (loss) attributable to the company	(110,490,000)	12,836,000	(50,084,000)
Weighted average shares outstanding - basic	90,048,638	88,792,453	83,318,189
Weighted average shares outstanding - diluted	90,048,638	110,671,731	83,318,189
Year end shares outstanding	90,804,084	88,276,713	88,502,721
Net earnings (loss) per class A share - basic	\$(1.23)	\$0.14	\$(0.60)
Net earnings (loss) per class A share - diluted	\$(1.23)	\$0.12	\$(0.60)
Number of full time employees	512	579	552
Total number of employees	512		
Number of common stockholders	33		
Number of class A stockholders		12	12
Number of class V stockholders		24	24
Foreign currency translation adjustments		(2,000)	
Comprehensive Income - Attributable to Owners of Parent Company - Total	(110,490,000)		

[□] Reclassified to conform with 2022 presentation; [□] Shares increased due to the effect issuance of shares, exchange of post-merger repay units and release of share awards vested under Incentive Plan; [□] Approximately; [□] As of February 22, 2023; [□] As of February 22, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	118,096,000	64,895,000
Accounts receivable	36,017,000	33,544,000
Prepaid expenses & other current assets		18,213,000
Prepaid expenses and other	15,209,000	
Total current assets	169,322,000	116,652,000
Furniture, fixtures & office equipment	4,905,000	4,014,000
Computers		4,889,000
Leasehold improvements	663,000	659,000
Computer Software & Equipment - Tangible Assets - Gross	4,813,000	
Property, plant & equipment, gross	10,381,000	9,562,000
Less: accumulated depreciation & amortization	7,248,000	5,187,000
Property, plant & equipment, net	3,133,000	4,375,000
Restricted cash	26,049,000	28,668,000

Intangible assets, net	447,141,000	500,575,000
Goodwill	716,793,000	827,813,000
Operating lease right-of-use assets, net	8,023,000	9,847,000
Deferred tax assets	146,872,000	136,370,000
Other assets	2,500,000	2,500,000
Total noncurrent assets	1,350,511,000	1,510,148,000
Total assets	1,519,833,000	1,626,800,000
Accounts payable & accrued expenses	22,030,000	
Accounts payable		21,781,000
Related party payable		1,000,000
Accrued expenses	32,906,000	29,016,000
Current operating lease liabilities	1,629,000	2,263,000
Current tax receivable agreement	580,000	24,454,000
Other current liabilities	318,000	3,593,000
Total current liabilities	57,463,000	82,107,000
Revolving credit facility		20,000,000
Convertible senior debt		440,000,000
Total borrowings under credit facility		460,000,000
Less: long-term loan debt issuance cost		(8,681,000)
Long-term debt	434,166,000	451,319,000
Noncurrent operating lease liabilities	7,247,000	8,295,000
Tax receivable agreement, net of current portion	188,331,000	154,673,000
Other liabilities	1,838,000	2,113,000
Total noncurrent liabilities	631,582,000	616,400,000
Total liabilities	689,045,000	698,507,000
Class A ordinary	10	
Class A common stock	9,000	9,000
Treasury stock	12,528,000	10,000,000
Additional paid-in capital	1,151,327,000	1,117,736,000
Accumulated other comprehensive income (loss)	(3,000)	(3,000)
Retained earnings (accumulated deficit)	(323,670,000)	(213,180,000)
Total Repay Holdings Corporation stockholders' equity	815,135,000	894,562,000
Non-controlling interests	15,653,000	33,731,000
Total equity	830,788,000	928,293,000

Recent Dividends:**1. Repay Holdings Corp class A common.**

No dividends paid.

2. Repay Holdings Corp class V common.

No dividends paid.

3. Repay Holdings Corp class B common.

No dividends paid.

4. Repay Holdings Corp ordinary shares subject to possible redemption.

No dividends paid.

Annual Dividends:**1. Repay Holdings Corp class A common.**

No dividends paid.

2. Repay Holdings Corp class V common.

No dividends paid.

3. Repay Holdings Corp class B common.

No dividends paid.

4. Repay Holdings Corp ordinary shares subject to possible redemption.

No dividends paid.

RESEARCH FRONTIERS INC.**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021 (revised)
Fee income	909,598	539,686	1,263,034
Gross operating revenues	909,598		
Operating expenses	2,359,634	2,555,689	2,521,849
Research & development	583,266	609,127	580,000
Total expenses	2,942,900	3,164,816	3,101,849
Operating income			

(loss)	(2,033,302)	(2,625,130)	(1,838,815)
Net investment income (loss)	124,938	(44,219)	(7,537)
Income (loss) before income tax expense (benefit)	(1,908,364)
Net income (loss)	(1,908,364)	(2,669,349)	(1,846,352)
Weighted average shares outstanding - basic	33,453,627	32,070,233	31,646,520
Weighted average shares outstanding - diluted	33,453,627	32,070,233	31,646,520
Year end shares outstanding	33,509,287	33,150,396	31,650,396
Net income (loss) per common share - basic	\$(0.06)	\$(0.08)	\$(0.06)
Net income (loss) per common share - diluted	\$(0.06)	\$(0.08)	\$(0.06)
Number of full time employees	□ ₆	□ ₆
Number of common stockholders	7,100	□ ₃₁₂	□ ₂₈₃
Number of beneficiary stockholders	□ _{7,100}	□ _{7,100}
Earnings per share from continuing operations	\$(0.06)
Earnings per share from continuing operations	\$(0.06)

□ As of March 9, 2023; □ As of March 9, 2022; □ Approximately; □ As of March 8, 2023; □ As of March 8, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	2,475,958	4,230,916
Royalty receivables, Gross	2,256,854	...
Royalties receivable, net	1,003,404	□ _{589,599}
Prepaid expenses & other current assets	96,784	100,973
Doubtful Accounts	1,253,450	...
Total current assets	3,576,146	4,921,488
Equipment & furniture	1,393,923	1,392,365
Trade show materials	775,654	775,654
Autos	53,764	53,764
Leasehold improvements	584,967	584,967
Fixed assets, gross	2,808,308	2,806,750
Less accumulated depreciation	2,768,710	2,741,362
Fixed assets, net	39,598	65,388
Operating lease right of use ("ROU") assets	178,715	323,509
Deposits & other assets	56,066	56,066
Total assets	3,850,525	5,366,451
Current portion of operating lease liability	212,359	196,405
Accounts payable	50,880	71,079
Payroll, bonuses & related benefits	9,032	29,219
Professional services	4,800	4,800
Other accrued expenses & current liabilities	360
Accrued Expenses and Other	14,192	...
Other	360	...
Total current liabilities	277,431	301,863
Operating lease liability, net of current portion	55,363	267,723
Total liabilities	332,794	569,586
Common stock	3,351	3,315
Additional paid-in capital	127,779,221	127,150,027
Retained earnings (accumulated deficit)	(124,264,841)	(122,356,477)
Total shareholders' equity	3,517,731	4,796,865
Total Equity	3,517,731	...

□ Net of reserves - royalties receivable: \$1,158,450

Recent Dividends:
1. Research Frontiers Inc. common.
 No dividends paid.

Annual Dividends:
1. Research Frontiers Inc. common.
 No dividends paid.

RIDGEWOOD ENERGY T FUND LLC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	□ ₂₀₂₁
Oil & gas revenue	5,526,000	3,212,000
Other revenue	184,000	310,000	368,000
Other revenue from affiliate	2,953,000
Total revenue	3,137,000	5,836,000	3,580,000
Depletion & amortization	1,726,000	2,084,000	2,365,000
Lease operating expense	220,000	315,000	143,000
Transportation & processing expense	172,000	132,000
Insurance expense	49,000	61,000	73,000
Accretion expense	27,000	27,000
Workover expense	25,000	15,000	(25,000)
Operating expenses - General & administrative	463,000	590,000	350,000
Other general expense	127,000
Accretion expense and other	42,000
Total expenses	2,430,000	2,912,000	2,947,000
Income (loss) from operations	707,000	2,924,000	633,000
Interest income (expense)	6,000	(86,000)
Net Income before Tax	765,000
Total other income (loss)	58,000
Interest income	58,000
Net income (loss)	765,000	2,930,000	547,000
Net income (loss) - manager interest	354,000	734,000	429,000
Net income (loss) - shareholder interest	411,000	2,196,000	118,000
Year end shares outstanding	972	972	972
Net income (loss) per share	\$423.00	\$2,260.00	\$121.00
Number of common stockholders	1,754	□ _{1,753}	□ _{1,737}
Shares used to calculate Basic EPS - Total	972
Shares used to calculate Diluted EPS - Total	972
EPS - Diluted - including Extraordinary Items Applicable to Common - Total	\$423.00
Full-Time Employees (Period End)	0
Total number of employees	0

□ Reclassified to conform with 2022 presentation; □ As of January 31, 2023; □ As of January 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	806,000	641,000
Salvage fund	247,000	121,000
Production receivable	209,000	369,000
Due from affiliate	7,000	9,000
Other current assets	27,000	39,000

Total current assets	1,296,000	1,179,000
Salvage fund	1,109,000	1,274,000
Proved oil & gas properties	18,256,000	18,142,000
Less: accumulated depletion & amortization	15,996,000	14,351,000
Total oil & gas properties, net	3,791,000
Other assets	2,260,000	...
Total assets	4,665,000	6,244,000
Due to operators	43,000	24,000
Accrued accounting & legal fees	50,000	64,000
Accrued royalty	57,000
Accrued expenses	50,000	121,000
Asset retirement obligations	247,000	121,000
Total current liabilities	340,000	266,000
Asset retirement obligations	614,000	739,000
Total liabilities	954,000	1,005,000
Manager - distributions	(9,336,000)
Manager - retained earnings	9,023,000
Manager's total	(303,000)	(313,000)
Shareholders - capital contributions	144,529,000	144,529,000
Shareholders - syndication costs	(16,990,000)
Shareholders - distributions	(55,413,000)
Shareholders - retained earnings (accumulated deficit)	(9,680,000)	(66,574,000)
Retained earnings	9,377,000	...
Syndication costs	(16,990,000)	...
Distributions	(57,362,000)	...
Accumulated deficit	(66,163,000)	...
Shareholders' total	3,711,000	5,552,000
Total members' capital	3,711,000	5,239,000

Recent Dividends:
1. Ridgewood Energy T Fund LLC membership interest.
 No dividends paid.

Annual Dividends:
1. Ridgewood Energy T Fund LLC membership interest.
 No dividends paid.

RIGETTI COMPUTING INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	□ ₂₀₂₁
Revenue	12,008,000
Revenue	12,008,000	13,102,000	...
Cost of revenue	2,800,000	2,873,000	...
Total gross profit	9,208,000	10,229,000	...
Research & development	52,768,000	59,952,000	...
Sales & marketing	6,348,000	...
General & administrative expenses	27,744,000	47,632,000	4,904,921
Goodwill impairment	5,377,000	...
Restructuring	991,000
Total operating expenses	81,503,000	119,309,000	...
Income (loss) from operations	(72,295,000)	(109,080,000)	(4,904,921)
Interest expense	5,779,000	5,286,000	...
Interest income	5,076,000	2,433,000	...
Change in fair value of derivative warrant liabilities	(1,160,000)	22,132,000	(17,782,000)
Change in fair value of earn-out liability	(949,000)	19,207,000	...
Transaction costs	927,000	...
Offering costs associated with derivative warrant liabilities	502,450
Income from investments held in

trust account	19,271	- Balancing value	1,246,000	...	Engineering	64,303,000
Total other income				Total property & equipment	77,785,000	65,390,000	Total revenue	280,678,000	259,171,000	213,243,000
(expense), net	(2,812,000)	37,559,000	...	Less: accumulated depreciation & amortization	33,302,000	25,860,000	Cost of revenues - bitcoin mining	...	74,335,000	45,513,000
Net income (loss) before provision for income taxes	(75,107,000)	(71,521,000)	...	Property & equipment, net	44,483,000	39,530,000	Cost of revenues - data center hosting	97,122,000	61,906,000	32,998,000
Net income (loss)	(75,107,000)	(71,521,000)	(23,170,100)	Operating lease right-of-use assets, net	7,634,000	9,316,000	Cost of revenues - engineering	60,614,000	57,455,000	3,582,000
Weighted average class A shares outstanding - basic	28,639,726	Other assets	129,000	129,000	Acquisition-related costs	...	78,000	21,198,000
Weighted average class B shares outstanding - basic	8,433,904	Total assets	159,913,000	203,442,000	Selling, general & administrative expense	100,346,000	67,452,000	87,429,000
Weighted average shares outstanding - basic	...	102,300,852	...	Accounts payable	5,772,000	1,938,000	Depreciation & amortization	252,354,000	107,950,000	26,324,000
Weighted average class A shares outstanding - diluted	28,639,726	Accrued expenses and other current liabilities	8,563,000	...	Change in fair value of derivative asset	...	(71,418,000)	(12,112,000)
Weighted average class B shares outstanding - diluted	8,625,000	- Balancing value	...	1,818,000	Power curtailment credits	71,215,000	27,345,000	6,514,000
Weighted average shares outstanding - diluted	131,977,000	102,300,852	...	Utilities	Change in fair value of contingent consideration	...	(159,000)	975,000
Year end shares outstanding	147,066,336	125,257,233	43,125,000	Professional & subscription fees	...	2,044,000	Realized gain on sale or exchange of cryptocurrencies	184,734,000
Net earnings (loss) per class A share basic	\$(0.62)	Property & other taxes	...	1,161,000	Realized gain on sale or exchange of Bitcoin	6,721,000	30,346,000	253,000
Net earnings (loss) per class B share basic	\$(0.62)	Subcontractor cost	...	804,000	Gain on exchange of equipment	(5,336,000)	16,281,000	...
Net earnings (loss) per share - basic	\$(0.57)	\$(0.70)	...	Payroll & other payroll costs	1,654,000	781,000	Casualty-related charges (recoveries), net	(5,974,000)	9,688,000	...
Net earnings (loss) per class A share - diluted	\$(0.62)	Property & equipment	...	639,000	Impairment of Bitcoin	...	147,365,000	43,973,000
Net earnings (loss) per class B share - diluted	\$(0.62)	Other accrued expenses & other current liabilities	...	626,000	Impairment of goodwill	...	335,648,000	...
Net earnings (loss) per share - diluted	\$(0.57)	\$(0.70)	...	Accrued interest	297,000	314,000	Impairment of miners	...	55,544,000	...
Total number of employees	...	144	4	Deferred offering costs	...	18,000	Total cost & expenses	343,725,000	771,872,000	243,113,000
Number of class A common stockholders	...	1	1	Accrued expenses & other current liabilities	6,326,000	8,205,000	Operating income (loss)	(63,047,000)	(512,701,000)	(29,870,000)
Number of class B common stockholders	...	7	7	Deferred revenue	343,000	961,000	Interest income (expense), net	8,222,000	454,000	(296,000)
Number of common stockholders	168	209	...	Debt - current portion	12,164,000	8,303,000	Realized gain (loss) on sale of marketable equity securities	...	(8,996,000)	...
Foreign currency translation adjustments	...	101,000	...	Operating lease liabilities - current	2,210,000	2,345,000	Realized gain on sale or exchange of long-term investment	26,260,000
Weighted average shares outstanding	131,977,000	liabilities - noncurrent	6,297,000	7,858,000	Unrealized loss on marketable equity securities	(13,655,000)
				Derivative warrant liabilities	2,927,000	1,767,000	Other income (expense)	260,000	(59,000)	2,378,000
				Earn-out liabilities	2,155,000	1,206,000	Total other income (expense)	8,482,000	(8,601,000)	14,687,000
				Total liabilities	50,325,000	53,218,000	Income (loss) before taxes - domestic	(54,565,000)	(521,302,000)	(15,183,000)
				Common stock	14,000	12,000	Net income (loss) before taxes	(54,565,000)	(521,302,000)	(15,183,000)
				Additional paid-in capital	463,089,000	429,025,000	Current income tax expense - US state	(48,000)	789,000	254,000
				Accumulated other comprehensive gain (loss)	244,000	(161,000)	Current income tax expense	(48,000)	789,000	254,000
				Retained earnings (accumulated deficit)	(353,759,000)	(278,652,000)	Deferred income tax expense (benefit) - US federal	(5,045,000)	(12,538,000)	...
				Total shareholders' equity (deficit)	109,588,000	150,224,000	Deferred income tax expense (benefit)	(5,045,000)	(12,538,000)	...
				Total Equity	109,588,000	...	Total income tax benefit (expense)	(5,093,000)	(11,749,000)	254,000
							Net income (loss)	(49,472,000)	(509,553,000)	(15,437,000)
							Net income (loss) attributable to Riot Blockchain, Inc.	...	(509,553,000)	(15,437,000)
							Weighted average shares outstanding

Recent Dividends:**1. Rigetti Computing Inc class A ordinary.**

No dividends paid.

2. Rigetti Computing Inc common.

No dividends paid.

3. Rigetti Computing Inc class B ordinary.

No dividends paid.

Annual Dividends:**1. Rigetti Computing Inc class A ordinary.**

No dividends paid.

2. Rigetti Computing Inc common.

No dividends paid.

3. Rigetti Computing Inc class B ordinary.

No dividends paid.

RIOT PLATFORMS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
			(revised)
Mining	96,597,000
Revenue - Bitcoin mining	188,996,000	156,870,000	184,422,000
Revenue - data center hosting	...	36,862,000	24,546,000
Revenue - engineering	...	65,342,000	4,178,000
Other revenue	97,000	97,000	97,000
Data Center Hosting	27,282,000

¹ December 31, 2021 and prior periods are for Supernova Partners Acquisition Company II, Ltd. prior to reverse recapitalization with Rigetti Holdings Inc.; ² Shares increased due to the effect of initial public offering; ³ As of March 1, 2023; ⁴ As of February 2, 2022; ⁵ As of March 22, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	21,392,000	57,888,000
Available-for-sale investments	78,537,000	84,923,000
Accounts receivable	5,029,000	6,235,000
Prepaid expenses & other current assets	2,709,000	2,450,000
Forward contract - assets	...	2,229,000
Deferred offering costs	...	742,000
Total current assets	107,667,000	154,467,000
Quantum computing fridges	39,801,000	30,218,000
Process equipment	25,121,000	23,330,000
Leasehold improvements	8,372,000	7,561,000
IT hardware	3,245,000	3,035,000
Furniture & other assets	...	1,246,000
Property, Plant & Equipment - Gross - Total

- basic	175,026,051	139,433,901	93,452,764
Weighted average shares outstanding			
- diluted	175,026,051	139,433,901	93,452,764
Year end shares outstanding	230,836,624	167,751,112	116,748,472
Income (loss) per share from continuing operations - basic	\$(0.28)
Net income (loss) per share - basic	\$(0.28)	\$(3.65)	\$(0.17)
Income (loss) per share from continuing operations - diluted	\$(0.28)
Net income (loss) per share - diluted	\$(0.28)	\$(3.65)	\$(0.17)
Number of full time employees	534
Total number of employees	534	489	...
Number of common stockholders	1,815	1,253	...

Restated to reflect the correction of misstatement regarding calculation of impairment of Bitcoin; Shares increased due to the effect of issuance of restricted stock, issuance of common stock or at-the-market offering and conversion of preferred stock to common stock; Shares increased due to the effect of issuance of the common stock underlying restricted stock units, market offering, exercise of warrants, warrants settlement, Whinstone & ESS Metron acquisitions; Shares increased due to the effect of the conversion of preferred stock and stock option exercise; Approximately; As of March 1, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	597,169,000	230,328,000
Accounts receivable, gross	26,206,000	28,832,000
Allowance for doubtful accounts	1,500,000	1,900,000
Accounts receivable, net	24,706,000	26,932,000
Costs & estimated earnings in excess of billings	...	19,743,000
Prepaid expenses & other current assets	29,107,000	32,661,000
Cryptocurrencies	15,359,000	...
Bitcoin	311,178,000	109,420,000
Future power credits, current portion	271,000	24,297,000
Derivative asset, current portion	30,781,000	...
Total current assets	1,008,571,000	443,381,000
Buildings & improvements	2,108,000	...
Buildings & building improvements	348,865,000	229,685,000
Land rights & land improvements	10,320,000	10,164,000
Miners & mining equipment	496,230,000	441,324,000
Machinery & facility equipment	39,144,000	35,125,000
Office & computer equipment	...	1,206,000
Construction in progress	166,970,000	97,231,000
Total cost of property & equipment	1,063,637,000	814,735,000
Less: accumulated depreciation	359,443,000	122,180,000
Less: accumulated depreciation & amortization	...	0
Property & equipment, net	704,194,000	692,555,000
Deposits	215,009,000	42,433,000
Long-term investments	13,121,000	...
Finite-lived intangible assets, net	15,697,000	21,477,000

Derivative asset	73,437,000	97,497,000
Operating lease right-of-use assets	20,413,000	21,673,000
Future power credits, less current portion	...	638,000
Other long term assets	...	310,000
Future power credits	638,000	...
Total assets	2,051,080,000	1,319,964,000
Accounts payable	23,157,000	18,445,000
Accrued compensation	14,888,000	...
Billings in excess of costs & estimated earnings	4,073,000	8,446,000
Construction in progress	...	16,621,000
Power related costs & remittances	...	32,632,000
Accrued compensation	...	8,582,000
Accrued insurance	...	3,660,000
Other accrued expenses	...	3,969,000
Accrued expenses	62,628,000	65,464,000
Deferred revenue, current portion	2,458,000	2,882,000
Contingent consideration liability - future power credits, current portion	271,000	24,297,000
Operating lease liability, current portion	2,421,000	2,009,000
Accrued expenses - Balancing value	47,740,000	...
Deferred gain on acquisition post-close dispute settlement	26,007,000	...
Total current liabilities	121,015,000	121,543,000
Deferred revenue, less current portion	15,801,000	17,869,000
Operating lease liability, less current portion	18,924,000	20,242,000
Contingent consideration liability - future power credits, less current portion	638,000	638,000
Other long-term liabilities	6,680,000	8,230,000
Total liabilities	163,058,000	168,522,000
Common stock	2,687,692,000	1,907,784,000
Retained earnings (accumulated deficit)	(799,820,000)	(756,342,000)
Accumulated other comprehensive income (loss), net	150,000	...
Total Riot Platforms Inc. stockholders' equity	1,888,022,000	1,151,442,000
Total stockholders' equity	1,888,022,000	1,151,442,000

Recent Dividends:

- Riot Platforms Inc common.**
No dividends paid.
- Riot Platforms Inc 0% series B convertible preferred.**
No dividends paid.

Annual Dividends:

- Riot Platforms Inc common.**
No dividends paid.
- Riot Platforms Inc 0% series B convertible preferred.**
No dividends paid.

RISKON INTERNATIONAL INC

Earnings, 9 mos. to Dec 31(Consol. - \$):

	2023	2022
Cost & expenses	28,599,483	3,551,885
Operating income	(28,666,000)	(3,551,885)
Other income (expense), net	(4,170,295)	(3,923)
Gains or losses	21,866,277	9,017,305
Net before taxes	(15,780,508)	5,384,144
Income contin. oper.	(15,780,508)	5,384,144
Net income	(24,598,945)	(33,032,049)
Balance for common	(23,564,185)	(30,873,703)
Earnings common share		
Primary	\$(8.62)	\$(36.21)
Fully Diluted	\$(8.62)	\$(36.21)
Common Shares:		
Full Diluted	2,854,949	912,320
Year-end	10,734,744	981,878

RISKON INTERNATIONAL INC

Earnings, 9 mos. to Dec 31(Consol. - \$):

	2023	2022
Cost & expenses	28,599,483	3,551,885
Operating income	(28,666,000)	(3,551,885)
Other income (expense), net	(4,170,295)	(3,923)
Gains or losses	21,866,277	9,017,305
Net before taxes	(15,780,508)	5,384,144
Income contin. oper.	(15,780,508)	5,384,144
Net income	(24,598,945)	(33,032,049)
Balance for common	(23,564,185)	(30,873,703)
Earnings common share		
Primary	\$(8.62)	\$(36.21)
Fully Diluted	\$(8.62)	\$(36.21)
Common Shares:		
Full Diluted	2,854,949	912,320
Year-end	10,734,744	981,878

RMR GROUP INC (THE)

Earnings, 3 mos. to Dec 31(Consol. - \$000):

	2023	2022
Total revenues	261,671	250,740
Cost & expenses	250,641	230,204
Operating income	10,607	20,268
Other income (expense), net	...	(5,314)
Gains or losses	4,049	...
Net before taxes	18,164	16,724
Income taxes	2,638	2,484
Net income	15,526	14,240
Balance for common	...	6,256
Earnings common share		
Primary	\$0.42	\$0.38
Fully Diluted	\$0.41	\$0.37
Common Shares:		
Full Diluted	31,512	31,413
Year-end	31,711	31,605

Consolidated Balance Sheet Items, as of (\$000):

	2023
Assets:	
Cash & equivalents	202,428
Current assets	325,705
Net property & equip.	14,728
Total assets	625,443
Liabilities:	
Current liabilities	126,078
Long-term debt	4,730
Stockholders' equity	240,967
Net current assets	199,627

ROCKET LAB USA INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
			(revised)
Revenues	244,592,000
Revenues	244,592,000	210,996,000	62,237,000
Cost of revenues	193,183,000	192,006,000	64,130,000
Gross profit (loss)	51,409,000	18,990,000	(1,893,000)
Research & development, net	119,054,000	65,168,000	41,765,000
Selling, general & administrative	110,273,000	89,026,000	58,395,000
Total operating expenses	229,327,000	154,194,000	100,160,000
Operating income (loss)	(177,918,000)	(135,204,000)	(102,053,000)
Interest income (expense), net	(4,248,000)	(7,799,000)	(6,128,000)
Gain (loss) on foreign exchange	(470,000)	(4,435,000)	(567,000)
Change in fair value of liability classified warrants	...	(13,482,000)	15,294,000
Other income (expense), net	(3,715,000)	(1,010,000)	798,000
Total other income (expense), net	(1,003,000)	2,258,000	(22,787,000)
Income before income taxes - United States	...	(186,121,000)	(132,585,000)
Income before income taxes - Foreign	...	53,175,000	7,745,000
Income (loss) before income taxes	(178,921,000)	(132,946,000)	(124,840,000)

Current provision (benefit) for income taxes - state	(18,000)	(39,000)	2,000
Current provision (benefit) for income taxes - foreign	3,270,000	3,802,000	2,377,000
Total current provision (benefit) for income taxes	3,252,000	3,763,000	2,379,000
Deferred provision (benefit) for income taxes - federal	114,000	(2,073,000)	(5,957,000)
Deferred provision (benefit) for income taxes - state	452,000	(173,000)	(339,000)
Deferred provision (benefit) for income taxes - foreign	(168,000)	1,481,000	(3,603,000)
Total deferred provision (benefit) for income taxes	398,000	(765,000)	(9,899,000)
Benefit (provision) for income taxes	3,650,000	2,998,000	(7,520,000)
Net income (loss)	(182,571,000)	(135,944,000)	(117,320,000)
Net income attributable to common shareholders	...	(135,944,000)	(117,320,000)
Weighted average shares outstanding - basic	481,768,060	466,214,095	209,895,135
Weighted average shares outstanding - diluted	481,768,060	466,214,095	209,895,135
Year end shares outstanding	488,923,055	475,356,517	450,180,479
Net earnings (loss) per share - basic	\$(0.38)	\$(0.29)	\$(0.56)
Net earnings (loss) per share - diluted	\$(0.38)	\$(0.29)	\$(0.56)
Number of full time employees	1,650	1,400	758
Total number of employees	1,650
Number of common stockholders	38	40	60
Foreign currency translation adjustments	...	600,000	...
EPS - Basic - excluding Extraordinary Items Applicable to Common - Total	\$(0.38)
EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total	\$(0.38)

□ Approximately; □ As of March 3, 2023; □ As of March 17, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):		
	2023	2022
Cash & cash equivalents	162,518,000	242,515,000
Marketable securities	82,255,000	229,276,000
Accounts receivable, net	35,176,000	36,572,000
Contract assets	12,951,000	9,451,000
Raw materials	45,062,000	33,376,000
Work in process	53,628,000	50,661,000
Finished goods	9,167,000	8,242,000
Inventories	107,857,000	92,279,000
Prepaid expenses & deposits	48,031,000	43,126,000
Government grant receivables	9,940,000	1,443,000
Other current assets	5,245,000	7,632,000
Prepays & other current assets	66,949,000	52,201,000

Assets held for sale	9,016,000	...
Customer financing receivables	3,733,000	...
Total current assets	476,722,000	662,294,000
Buildings & improvements	59,730,000	36,493,000
Machinery, equipment, vehicles & office furniture	82,973,000	54,300,000
Computer equipment, hardware & software	11,624,000	7,517,000
Launch site assets	14,193,000	12,822,000
Construction in process	25,999,000	26,771,000
Property, plant & equipment, gross	194,519,000	137,903,000
Less accumulated depreciation & amortization	49,110,000	36,389,000
Property, plant & equipment, net	145,409,000	101,514,000
Intangible assets, net	68,094,000	79,692,000
Goodwill	71,020,000	71,020,000
Right-of-use assets - operating leases	59,401,000	35,239,000
Right-of-use assets - finance leases	14,987,000	15,614,000
Marketable securities, non-current	...	9,193,000
Restricted cash	3,916,000	3,356,000
Deferred income tax assets, net	3,501,000	3,898,000
Investment held in trust account	79,247,000	...
Other non-current assets	18,914,000	7,303,000
Total assets	941,211,000	989,123,000
Trade payables	29,303,000	12,084,000
Accrued expenses	5,590,000	8,723,000
Employee benefits payable	16,342,000	8,634,000
Contract liabilities	139,338,000	108,344,000
Current installments of long-term borrowings	17,764,000	2,906,000
Other current liabilities	15,036,000	22,249,000
Total current liabilities	223,373,000	162,940,000
Long-term borrowings, excluding current installments	87,587,000	100,043,000
Non-current operating lease liabilities	56,099,000	34,266,000
Non-current finance lease liabilities	15,238,000	15,568,000
Deferred tax liabilities	426,000	95,000
Other non-current liabilities	3,944,000	3,005,000
Total liabilities	...	315,917,000
Common stock	49,000	48,000
Additional paid-in capital	1,176,484,000	1,112,977,000
Retained earnings (accumulated deficit)	(623,526,000)	(440,955,000)
Accumulated other comprehensive income	1,537,000	1,136,000
Total stockholders' equity (deficit)	554,544,000	673,206,000
Total Equity	554,544,000	...

Recent Dividends:

- 1. Rocket Lab USA Inc common.**
No dividends paid.
- 2. Rocket Lab USA Inc class A ordinary.**
No dividends paid.
- 3. Rocket Lab USA Inc class B ordinary.**
No dividends paid.

Annual Dividends:

- 1. Rocket Lab USA Inc common.**
No dividends paid.
- 2. Rocket Lab USA Inc class A ordinary.**
No dividends paid.
- 3. Rocket Lab USA Inc class B ordinary.**
No dividends paid.

ROCKY MOUNTAIN INDUSTRIALS INC

Earnings, 9 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues	453,085	714,884
Cost & expenses	3,658,892	6,420,815

Operating income	(3,205,807)	(5,705,931)
Other income (expense), net	30,000	...
Gains or losses	8,191,610	(5,909)
Net before taxes	3,963,485	(6,408,657)
Income contin. oper.	...	(6,408,657)
Net income	3,963,485	(6,408,657)
Earnings common share		
Primary	\$0.48	\$(1.02)
Fully Diluted	\$0.48	\$(1.02)
Common Shares:		
Full Diluted	7,387,157	6,655,598
Year-end	6,763,125	40,652,690

S&W SEED CO.

Earnings, 6 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues	27,297,275	32,803,667
Cost & expenses	32,655,809	39,862,776
Deprec., depl. & amort.	2,145,042	2,590,338
Operating income	(7,503,576)	(9,649,447)
Other income (expense), net	96,896	43,724
Gains or losses	...	1,828,282
Equity earnings	1,538,225	4,015
Foreign currency	(616,486)	(367,539)
Net before taxes	(11,668,516)	(10,885,741)
Income taxes	(755,778)	(383,960)
Net income	(12,450,963)	(10,505,796)
Earnings common share		
Primary	\$(0.29)	\$(0.25)
Fully Diluted	\$(0.29)	\$(0.25)
Common Shares:		
Full Diluted	43,050,329	42,627,645
Year-end	43,292,044	42,763,423

SANUWAVE HEALTH INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	□2021
		(revised)	(revised)
Product	19,255,000
Rental income	1,143,000
Revenue	20,398,000	16,742,000	13,010,000
Cost of revenues - product	6,035,000
Cost of revenues	...	4,331,000	4,986,000
Gross margin	14,363,000	12,411,000	8,024,000
General & administrative	8,674,000	12,556,000	11,690,000
Selling & marketing	4,898,000	7,474,000	8,591,000
Research & development	579,000	567,000	1,101,000
Depreciation & amortization	752,000	766,000	784,000
Total operating expenses	14,903,000	21,363,000	22,166,000
Operating income (loss)	(540,000)	(8,952,000)	(14,142,000)
Interest expense	12,946,000	12,771,000	6,883,000
Interest expense, related party	2,677,000	1,361,000	212,000
Change in fair value of derivative liabilities	(9,621,000)	16,654,000	(2,622,000)
Gain (loss) on issuance of debt	...	(3,434,000)	(3,572,000)
Gain (loss) on extinguishment of debt	...	(418,000)	204,000
Gain (loss) on foreign currency exchange	...	(9,000)	(4,000)
Other expense	(19,000)
Total other income (expense)	(25,263,000)	(1,339,000)	(13,089,000)
Income (loss) before income taxes - domestic	...	(10,279,000)	(27,208,000)
Income (loss) before income taxes - foreign	...	(12,000)	(23,000)
Net income (loss) before income taxes	(25,803,000)	(10,291,000)	(27,231,000)
Current state			

income tax expense (benefit).....	4,000	2,000	28,000	compensation	2,298,000	4,585,000	initial issuance of private warrants	(512,000)	...	(2,599,200)
Total current income tax expense (benefit).....	4,000	2,000	28,000	Warrant liability	14,447,000	1,416,000	Change in fair value of conversion option liability	11,835
Deferred federal income tax expense (benefit).....	(3,564,000)	(5,657,000)	(5,038,000)	Current portion of small business administration ("SBA") loans	5,404,000	16,713,000	Transaction costs allocated to warrant liabilities	30,212
Deferred state income tax expense (benefit).....	(459,000)	753,000	(869,000)	Accrued interest	5,444,000	4,052,000	Interest earned on investments held in trust account	30,739
Deferred foreign income tax expense (benefit).....	(3,000)	(1,000)	4,000	Interest payable, related parties	669,000	788,000	Change in fair value of debt and liability instruments	(7,189,000)
Change in valuation allowance	4,026,000	4,905,000	5,903,000	Current portion of contract liabilities	92,000	60,000	Total other income (expense), net	(8,887,000)	27,274,000	1,788,935
Income tax expense (benefit).....	4,000	2,000	28,000	Short term loan, net	18,278,000	...	Income (loss) before income taxes ..	(114,318,000)	(23,360,000)	...
Net income (loss)	(25,807,000)	(10,293,000)	(27,259,000)	Notes payable, related parties, net	1,705,000	7,409,000	Current income tax expense - state	13,000	4,000	...
Weighted average shares outstanding - basic	793,850,994	549,470,787	518,355,642	Other current liabilities	947,000	319,000	Total current income tax expense ..	13,000	4,000	...
Weighted average shares outstanding - diluted	793,850,994	549,470,787	518,355,642	Accrued other	284,000	1,037,000	Deferred income tax expense (benefit) - federal	(16,514,000)	(10,396,000)	...
Year end shares outstanding	1,140,559,527	548,737,651	481,619,621	Asset-backed secured promissory notes	3,117,000	...	Deferred income tax expense (benefit) - state	(11,247,000)	(1,851,000)	...
Income (loss) per share from continuing operations - basic	\$(0.03)	Asset-backed secured promissory notes, related parties	1,458,000	...	Total deferred income tax expense (benefit)	(27,761,000)	(12,247,000)	...
Net income (loss) per share - basic	\$(0.03)	\$(0.02)	\$(0.05)	Total current liabilities	64,755,000	60,215,000	Changes in tax rate	(1,471,000)	1,347,000	...
Income (loss) per share from continuing operations - diluted	\$(0.03)	Contract liabilities	347,000	230,000	Changes in valuation allowance ..	29,232,000	10,900,000	...
Net income (loss) per share - diluted	\$(0.03)	\$(0.02)	\$(0.05)	Operating leases	492,000	438,000	Income tax expense (benefit)	13,000	4,000	...
Number of full time employees	31	38	40	Total non-current liabilities	839,000	668,000	Distribution for Preferred Shares	52,645,000
Total number of employees	31	Total liabilities	65,594,000	60,883,000	Net income (loss)	(114,331,000)	(23,364,000)	783,438
Number of common stockholders	238	201	198	Common stock	1,140,000	549,000	Net income (loss) attributable to common stockholders	(166,976,000)	(23,364,000)	...
Foreign currency translation adjustments	6,000	...	Additional paid-in capital	175,842,000	152,750,000	Weighted average shares outstanding - basic	130,298,000	134,226,000	16,820,548
				Retained earnings (accumulated deficit)	(220,049,000)	(194,242,000)	Weighted average shares outstanding - diluted	130,298,000	134,226,000	16,834,110
				Accumulated other comprehensive income (loss)	(111,000)	(67,000)	Year end shares outstanding	100,015,665	141,348,856	17,250,000
				Total stockholders' equity (deficit)	(43,178,000)	(41,010,000)	Net income (loss) per share - basic	\$(1.28)	\$(0.17)	\$0.05
				Total Equity	(43,178,000)	(41,010,000)	Net income (loss) per share - diluted	\$(1.28)	\$(0.17)	\$0.05

Reclassified to conform 2023 presentation

Recent Dividends:

- Sanuwave Health Inc series A convertible preferred.**
No dividends paid.
- Sanuwave Health Inc common.**
No dividends paid.

Annual Dividends:

- Sanuwave Health Inc series A convertible preferred.**
No dividends paid.
- Sanuwave Health Inc common.**
No dividends paid.

SCILEX HOLDING COMPANY

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Net revenue	46,743,000	38,034,000	...
Cost of revenue	15,681,000	10,797,000	...
Research & development	9,054,000	...
Operating & formation costs	12,746,000	...	1,005,498
Selling, general & administrative expense	119,641,000	64,895,000	...
Intangible amortization	4,106,000	3,922,000	...
Total operating costs & expenses	152,174,000	88,668,000	...
Income (loss) from operations	(105,431,000)	(50,634,000)	(1,005,498)
Gain (loss) on derivative liability	8,310,000	...
Gain (loss) on debt extinguishment, net	28,634,000	...
Interest expense	1,068,000	9,604,000	...
Interest expense - debt discount	1,826
Gain (loss) on foreign currency exchange	(118,000)	(66,000)	...
Change in fair value of warrants	4,377,600
Gain (loss) on			

Non-consolidated; As reported by the Company; Shares increased due to initial public offering of shares; Approximately; As of March 3, 2023; As of February 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	3,921,000	2,184,000
Accounts receivable, net	34,597,000	21,236,000
Inventory	4,214,000	1,378,000
Prepaid expenses & other current assets	4,810,000
Prepaid expenses and other	4,049,000	...
Total current assets	46,781,000	29,608,000
Computers & equipment	5,000	77,000
Furniture	118,000
Leasehold improvements	50,000	55,000
Construction in progress	689,000	689,000
Computers and equipment	36,000	...

Reclassified to conform with 2022 presentation; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	1,797,000	1,153,000
Accounts receivable, gross	3,598,000	5,066,000
Less: allowance for doubtful accounts	284,000	1,037,000
Accounts receivable, net	3,314,000	4,029,000
Finished goods	416,000	570,000
Parts & accessories	2,882,000	641,000
Gross inventory	2,951,000	868,000
Provision (reserve) for slow moving inventory	347,000	343,000
Prepaid expenses & other current assets	1,722,000	570,000
Total current assets	9,784,000	6,620,000
Property, equipment & right of use assets, net	938,000	856,000
Intangible assets, net	4,434,000	5,137,000
Goodwill	7,260,000	7,260,000
Total non-current assets	12,632,000	13,253,000
Total assets	22,416,000	19,873,000
Senior secured promissory note payable, in default	14,416,000
Factoring liabilities	1,490,000	2,130,000
Accounts payable	5,705,000	4,400,000
Registration penalties	1,583,000	1,583,000
License fees	892,000	892,000
Board of directors fees	942,000	415,000
Warranty reserve	5,999,000	8,512,000
Accrued employee		

Property & equipment, gross	780,000	939,000
Less: accumulated depreciation	58,000	167,000
Property & equipment, net	722,000	772,000
Operating lease right-of-use asset	2,943,000	1,131,000
Intangibles, net	36,485,000	40,591,000
Goodwill	13,481,000	13,481,000
Other long-term assets	897,000	944,000
Total assets	101,309,000	86,527,000
Accounts payable	40,954,000	8,450,000
Accrued payroll	2,681,000	1,354,000
Accrued rebates & fees	89,658,000	30,893,000
Accrued expenses	7,408,000	3,136,000
Current portion of deferred consideration	491,000	264,000
Current portion of operating lease liabilities	759,000	745,000
Convertible debentures	108,429,000	...
Total current liabilities	250,380,000	44,842,000
Long-term portion of deferred consideration	2,895,000	3,387,000
Derivative liabilities	1,518,000	1,231,000
Operating lease liabilities	2,237,000	665,000
Other long-term liabilities	179,000	163,000
Long-term debt, net	17,038,000	...
Total liabilities	274,247,000	50,288,000
Preferred stock	...	3,000
Common stock	16,000	14,000
Additional paid-in capital	407,813,000	412,136,000
Retained earnings (accumulated deficit)	(490,245,000)	(375,914,000)
Treasury stock, at cost; 60,068,585 shares and nil shares as of 30, 2023 and 31, 2022, respectively	90,522,000	...
Total shareholders' equity (deficit)	(172,938,000)	36,239,000
Total Equity	(172,938,000)	...

Recent Dividends:
1. Scilex Holding Company preferred.
 No dividends paid.
2. Scilex Holding Company ordinary.
 No dividends paid.
Annual Dividends:
1. Scilex Holding Company preferred.
 No dividends paid.
2. Scilex Holding Company ordinary.
 No dividends paid.

SEELOS THERAPEUTICS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Contract service revenue	2,203,000
Total revenue	2,203,000
Research & development expense	30,117,000	58,620,000	46,649,000
General & administrative expense	12,585,000	12,296,000	15,020,000
Total operating expense	42,702,000	70,916,000	61,669,000
Income (loss) from operations	(40,499,000)	(70,916,000)	(61,669,000)
Interest income	198,000	121,000	113,000
Interest expense	75,000	14,000	1,598,000
Change in fair value of derivative liability	(369,000)
Change in fair value of warrant liabilities	17,995,000	292,000	(517,000)
Change in fair			

value of convertible notes	(2,049,000)	(3,017,000)	230,000
Net gain (loss) on extinguishment of debt	(9,151,000)	...	(2,387,000)
Gain on forgiveness of debt	149,000
Other income, net	(4,301,000)
Total other income (expense)	2,617,000	(2,618,000)	(4,379,000)
Income (loss) from continuing operations before income tax expense	(37,882,000)
Net income (loss)	(37,882,000)	(73,534,000)	(66,048,000)
Weighted average shares outstanding - basic	4,900,222	□3,544,739	3,029,669
Weighted average shares outstanding - diluted	4,900,222	□3,544,739	3,029,669
Year end shares outstanding	9,794,594	□3,572,275	□3,516,682
Income (loss) per share from continuing operations - basic	\$(7.73)
Net income (loss) per share - basic	\$(7.73)	□\$(20.70)	\$(21.90)
Income (loss) per share from continuing operations - diluted	\$(7.73)
Net income (loss) per share - diluted	\$(7.73)	□\$(20.70)	\$(21.90)
Number of full time employees	...	□15	□15
Number of part time employees	1	□1	□1
Total number of employees	1	□16	□16
Number of common stockholders	104	□□110	□□109
Number of beneficiary stockholders	...	□1	□1

□ Adjusted for 1-for-30 stock split, November 28, 2023; □ Shares increased due to the effect of issuance of common stock, securities purchase agreements and warrant exercised; □ As of February 24, 2023; □ As of February 25, 2022; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	2,996,000	15,533,000
Note receivable	763,000	...
Prepaid insurance	...	104,000
Prepaid clinical costs	...	6,837,000
Other prepaid expenses	...	200,000
Prepaid expenses & other current assets	77,000	7,141,000
Prepayments - Short-Term	1,567,000	...
Prepaid expenses and other current assets	1,644,000	...
Total current assets	5,403,000	22,674,000
Operating lease right-of-use asset	15,000	72,000
Operating lease right-of-use asset	15,000	...
Total assets	5,418,000	22,746,000
Accounts payable	16,403,000	3,626,000
Professional fees	...	278,000
Personnel related	56,000	1,288,000
Outside research & development services	...	5,627,000
Other accrued expenses	...	89,000
Accrued expenses	2,516,000	7,282,000
Short-term portion of convertible notes payable, at fair value	...	11,865,000
Licenses payable	...	2,195,000

Convertible debt	14,213,000	...
Warrant liabilities, at fair value	5,781,000	132,000
Operating lease liability	15,000	58,000
Accrued Expenses - Balancing value	2,460,000	...
Total current liabilities	38,928,000	25,158,000
Convertible notes payable, at fair value	...	8,184,000
Operating lease liability, long-term	...	15,000
Total liabilities	38,928,000	33,357,000
Common stock	10,000	107,000
Additional paid-in-capital	219,106,000	204,026,000
Retained earnings (accumulated deficit)	(252,626,000)	(214,744,000)
Total stockholders' equity (deficit)	(33,510,000)	(10,611,000)
Rep Total Equity & Minority Interest	(33,510,000)	...

Recent Dividends:
1. Seelos Therapeutics Inc common.
 No dividends paid.
Annual Dividends:
1. Seelos Therapeutics Inc common.
 No dividends paid.

SEMLER SCIENTIFIC INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021
Strategic streamlining	734
Revenues	68,184	56,686	53,027
Total revenue	68,184
Cost of revenues	6,984	4,252	6,122
Engineering & product development	5,773	4,809	3,780
Sales & marketing	18,147	17,685	14,445
General & administrative	14,290	12,737	9,235
Total operating expenses	45,928	39,483	33,582
Income (loss) from operations	22,256	17,203	19,445
Interest income	2,471	494	10
Other income (expense)	17	(5)	...
Change in fair value of notes held for investment	(307)
Impairment of investments	337
Total other income (expense)	1,844	489	10
Pre-tax net income (loss)	24,100	17,692	19,455
Current federal income taxes	3,576	3,201	1,397
Current state tax provision (benefit)	605	517	428
Total current tax provision (benefit)	4,181	3,718	1,825
Deferred federal tax provision (benefit)	(680)	(373)	456
Deferred state tax provision (benefit)	16	22	(48)
Total deferred tax provision (benefit)	(664)	(351)	408
Income tax provision (benefit)	3,517	3,367	2,233
Net income (loss)	20,583	14,325	17,222
Weighted average shares outstanding - basic	6,733	6,727	6,732
Weighted average shares outstanding - diluted	7,819	8,000	8,139
Year end shares			

outstanding	6,885	6,692	6,758
Net income (loss) per share - basic	\$3.06	\$2.13	\$2.56
Net income (loss) per share - diluted	\$2.63	\$1.79	\$2.12
Number of full time employees	92	127	124
Total number of employees	92
Number of common stockholders	30	33	29
Basic EPS - Net Income excl Extra Items applicable to Common - (Company Level)	\$3.06
Diluted EPS - Net Income excl Extra Items applicable to Common - (Company Level)	\$2.63

As is; Approximately; As of March 16, 2023; As of February 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	57,200	23,014
Short-term investments	20,073
Restricted cash	132	...
Trade accounts receivable, gross	6,412	3,993
Allowance for doubtful accounts	287	109
Trade accounts receivable, net	6,125	3,884
Inventory	445	...
Inventory, net	469
Prepaid expenses & other current assets	2,042	1,468
Total current assets	65,944	48,908
Assets for lease, net	2,285	2,478
Capital assets	1,544	1,206
Less: accumulated depreciation	824	539
Property & equipment, net	720	667
Other non-current assets	270	2,842
Long-term investments	512	821
Notes held for investment	5,372	4,679
Long-term deferred tax assets	2,962	2,298
Assets for Lease	3,375	...
Accumulated depreciation Assets for Lease	1,090	...
Total assets	78,065	62,693
Accounts payable	402	835
Compensation	2,008	2,467
Accrued taxes	1,991	1,923
Miscellaneous accruals	503	358
Accrued expenses	4,502	4,748
Deferred revenue	1,120	1,160
Other short-term liabilities	176	114
Total current liabilities	6,200	6,857
Other long-term liabilities	70	160
Other long-term liabilities	70	...
Total long-term liabilities	70	160
Common stock	7	7
Additional paid-in capital	11,985	16,449
Retained earnings (accumulated deficit)	59,803	39,220
Total stockholders' equity (deficit)	71,795	55,676
Total Equity	71,795	...

Recent Dividends:
1. Semler Scientific Inc common.
No dividends paid.

Annual Dividends:
1. Semler Scientific Inc common.
No dividends paid.

**SENESTECH INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31
(\$000):**

	2023	2022	2021 (revised)
Product sales, net	1,193	1,019	576
Grant revenue	24
Total revenues	1,193	1,019	600
Cost of sales	654	555	356
Gross profit	539	464	244
Research & development	1,228	1,859	1,954
Selling, general & administrative	7,043	8,279	7,224
Total operating expenses	8,271	10,138	9,178
Operating income (loss)	(7,732)	(9,674)	(8,934)
Interest income	26	7	4
Interest expense	4	2	11
Payroll protection program loan forgiveness	651
Miscellaneous income (expense)	(26)	22
Total other income (expense)	22	(21)	666
Net income (loss) & comprehensive income (loss)	(7,710)	(9,695)	(8,268)
Net income (loss) attributable to common shareholders	(9,695)	(8,268)
Weighted average shares outstanding - basic	670	52	47
Weighted average shares outstanding - diluted	670	52	47
Year end shares outstanding	5,140	67	51
Net income (loss) per common share - basic	\$(11.51)	\$(186.00)	\$(177.24)
Net income (loss) per common share - diluted	\$(11.51)	\$(186.00)	\$(177.24)
Number of full time employees	25	29	26
Number of part time employees	0	1	1
Number of common stockholders	694	696
Income from cont operations before income tax	(7,710)
Earnings per share from continuing operations	\$(11.51)
Earnings per share from continuing operations	\$(11.51)

Reclassified to conform with 2022 presentation; Adjusted for 1-for-12 stock split, November 15, 2023; Adjusted for 1-for-20 stock split, November 16, 2022; Shares increased due to the effect of exercise of warrants, services, fractional shares in the 20:1 reverse stock split, and net proceeds received for stock issued and prefunding of warrants; Shares increased due to the effect issuance of shares for cash and exercised of warrants; As is; Approximately; As of March 15, 2023; As of March 29, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	5,395	4,775
Accounts receivables, gross	99	119

Allowance for uncollectible accounts	4	6
Accounts receivable, net	95	113
Software licenses	152	157
Marketing programs & conferences	1	74
Insurance	64	61
Patents	14	39
Professional services	30	41
Other prepaid expenses	388	6
Other	16	...
Prepaid inventory	111	...
Prepaid expenses	378
Raw materials	747	772
Finished goods	53	99
Total inventory	795	871
Reserve for obsolescence	5	18
Inventory, net	853
Total current assets	6,673	6,119
Right to use assets, operating leases	210	347
Research & development equipment	1,763	1,558
Office & computer equipment	808	800
Autos	54	54
Furniture & fixtures	41	41
Leasehold improvements	141	119
Construction in progress	5
Property & equipment, gross	2,577
Less: accumulated depreciation & amortization	2,419	2,283
Property & equipment, net	388	294
Other noncurrent assets	22	22
Total assets	7,293	6,782
Current portion of long-term debt	33	...
Accounts payable	150	540
Compensation, severance & related benefits	232	497
Legal services	121	36
Product warranty	15	18
Personal property & franchise tax	6
Other accrued expenses	3
Accrued Expenses - Balancing value	368	...
Accrued expenses	560
Current portion of operating lease liability	217	180
Deferred revenue	18	44
Total current liabilities	786	1,324
Other unsecured promissory notes	156	...
Operating lease liability, less current portion	179
Total liabilities	942	1,503
Common stock	5	1
Additional paid-in capital	136,259	127,481
Retained earnings (accumulated deficit)	(129,913)	(122,203)
Total stockholders' equity (deficit)	6,351	5,279
Total Equity	6,351	...

Recent Dividends:
1. SenesTech Inc common.
No dividends paid.

Annual Dividends:
1. SenesTech Inc common.
No dividends paid.

**SENSUS HEALTHCARE INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021 (revised)
Revenues	24,405,000
Revenues	24,405,000	44,532,000	27,042,000

EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total \$(0.17)

□ December 31, 2021 financials for SES AI Corporation prior to Business Combination with SES Holdings Pte. Ltd.; □ Approximately; □ As of March 28, 2022; □ As of March 10, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):		
	2023	2022
Cash in Hand & with Banks	10,674,000	...
Cash	60,315,000
Money market funds	74,997,000	46,308,000
Cash & cash equivalents	85,671,000	106,623,000
Short-term investments	246,775,000	283,460,000
Receivable from related party	3,911,000	2,383,000
Inventories	558,000	383,000
Prepaid expenses & other current assets	11,712,000	3,792,000
Total current assets	348,627,000	396,641,000
Laboratory machinery & equipment	21,762,000	18,133,000
Office & computer equipment	1,169,000	358,000
Leasehold improvements	18,228,000	11,443,000
Construction in progress	9,773,000	5,422,000
Total property & equipment	50,932,000	35,356,000
Less: accumulated depreciation	12,973,000	7,600,000
Property & equipment, net	37,959,000	27,756,000
Intangible assets, net	1,345,000	1,473,000
Right-of-use assets, net	13,099,000	11,363,000
Other assets	4,723,000	3,206,000
Deferred tax assets	1,057,000	...
Total assets	406,810,000	440,439,000
Accounts payable	4,830,000	6,187,000
Operating lease liabilities, current	2,404,000	1,899,000
Accrued expenses and other current liabilities - Balancing value	5,811,000	...
Advance payments received under joint development agreements	4,189,000
Employee compensation & related costs	7,022,000	3,115,000
Income taxes payable	288,000	1,422,000
Professional & consulting services	1,566,000
Other accrued expenses & other current liabilities	979,000
Accrued expenses & other current liabilities	13,121,000	11,271,000
Total current liabilities	20,355,000	19,357,000
Sponsor earn-out liability	4,166,000	10,961,000
Operating lease liabilities, non-current	11,316,000	10,165,000
Unearned government grant	6,657,000
Other liabilities	2,753,000	1,760,000
Accrued liabilities	9,270,000	...
Total liabilities	47,860,000	48,900,000
Class B shares	35,000	35,000
Additional paid-in capital	559,214,000	538,041,000
Retained earnings (accumulated deficit)	(198,686,000)	(145,286,000)
Accumulated other comprehensive income (loss)	(1,613,000)	(1,251,000)
Total stockholders' equity (deficit)	358,950,000	391,539,000
Total Equity	358,950,000	...

Recent Dividends:

1. SES AI Corp class B ordinary.
No dividends paid.

2. SES AI Corp class A ordinary.
No dividends paid.
Annual Dividends:
1. SES AI Corp class B ordinary.
No dividends paid.
2. SES AI Corp class A ordinary.
No dividends paid.

SHARING SERVICES GLOBAL CORP Earnings, 9 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues	8,172,469	12,737,673
Net Sales	8,172,469	12,737,673
Cost & expenses	11,705,805	24,571,002
Operating income	(3,533,336)	(11,833,329)
Interest expense	3,006,440	9,761,622
Other income (expense), net	1,769,586	(10,165,925)
Gains or losses	207,210
Net before taxes	(4,770,190)	(31,553,666)
Income taxes	3,554	(789,803)
Net income	(4,773,744)	(30,763,863)
Earnings common share		
Primary	\$(0.01)	\$(0.12)
Fully Diluted	\$(0.01)	\$(0.12)
Common Shares:		
Full Diluted	374,543,761	267,956,183
Year-end	376,328,885	262,832,833

SIGMATRON INTERNATIONAL INC. Earnings, 9 mos. to Jan 31(Consol. - \$):

	2024	2023
Total revenues	292,741,928	306,147,772
Net Sales	292,741,928	306,147,772
Cost & expenses	283,615,920	289,498,098
Operating income	9,126,008	16,649,674
Other income (expense), net	27,224	568,137
Net before taxes	1,156,634	11,881,285
Income taxes	267,267	2,948,323
Income contin. oper.	889,367	8,932,962
Net income	889,367	(20,829,117)
Earnings common share		
Primary	\$0.15	\$(3.44)
Fully Diluted	\$0.14	\$(3.44)
Common Shares:		
Full Diluted	6,152,073	6,067,161
Year-end	6,094,288	6,071,288

SIGN THERAPEUTICS INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):			
	2023	2022	2021 (revised)
Marketing expenses ..	392	457	...
Research & development expense ..	798,165	657,657	734,014
General & administrative expense	1,656,760	1,489,151	1,274,203
Total operating expenses	2,455,317	2,147,265	2,008,217
Income (loss) from operations	(2,455,317)	(2,147,265)	(2,008,217)
Impairment of assets	536,047
Interest expense	2,402	438	30,867
Interest expense - debt discount	1,755,995	646,302	368,205
Interest expense - original issuance costs	285,187	135,812	61,283
Modification of warrants	352,965
Total other income (expense), net	(1,690,619)	(782,552)	(996,402)
Income (loss) before income taxes ..	(4,145,936)	(2,929,817)	(3,004,619)
Net income (loss)	(4,145,936)	(2,929,817)	(3,004,619)
Weighted average shares outstanding - basic	1,100,372	37,396,591	36,396,594
Weighted average shares outstanding - diluted	1,100,372	37,396,591	36,396,594
Year end shares outstanding	1,288,415	38,263,813	37,295,803

Net income (loss) per share from continuing operations - basic	\$(3.77)
Net income (loss) per share - basic	\$(3.77)	\$(0.08)	\$(0.08)
Net income (loss) per share from continuing operations - diluted	\$(3.77)
Net income (loss) per share - diluted	\$(3.77)	\$(0.08)	\$(0.08)
Number of full time employees	5	4	□5
Number of common stockholders	111	108	108
Total number of employees	5

□ As of March 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	11,690	8,356
Inventories	50,000	50,000
Other current assets	56,373	11,942
Total current assets	118,063	70,298
Office equipment	29,041	29,041
Computer equipment	3,157
Less: accumulated depreciation	16,902	10,146
Computer Software & Equipment - Tangible Assets - Gross	3,157	...
Property, Plant & Equipment - Gross - Total	32,198	...
Property & equipment, net	15,296	22,052
Intangible assets, net	2,100
Operating lease right-of-use assets	167,736	217,718
Other assets	20,711	20,711
Total assets	321,806	332,879
Accounts payable	327,517
Accrued payroll & payroll taxes	791,754	30,124
Accounts payable - related party	461,646	...
Short-term convertible notes payable, net	□1,636,656
Current portion of operating lease liabilities	61,123	53,200
Estimated fair value of contingent payments, net	80,000	...
Other current liabilities	3,182	1,197
Short term notes payable, less unamortized debt issuance costs of \$70,000	2,210,299	...
Total current liabilities	3,608,004	2,048,694
Operating lease liabilities, net of current portion	126,302	187,425
Total long-term liabilities	126,302	187,425
Total liabilities	3,734,306	2,236,119
Common stock	129	3,826
Additional paid-in-capital	7,928,883	5,288,510
Retained earnings (accumulated deficit)	(11,341,512)	(7,195,576)
Total stockholders' equity (deficit)	(3,412,500)	(1,903,240)
Total Equity	(3,412,500)	...

□ Less unamortized debt issuance costs - short-term convertible notes payable: \$642,660

Recent Dividends:

1. Signy Therapeutics Inc common.
No dividends paid.
2. Signy Therapeutics Inc series A preferred.

No dividends paid.
Annual Dividends:
1. Sigyn Therapeutics Inc common.
 No dividends paid.
2. Sigyn Therapeutics Inc series A preferred.
 No dividends paid.

Year end shares outstanding 5,315,581 5,256,177 5,136,177
 Earnings (loss) per share - continuing operations - basic \$(0.20) ...
 Net income (loss) per common share - basic \$(0.20) \$(0.05) \$(0.03)
 Earnings (loss) per share - continuing operations - diluted \$(0.20) ...
 Net income (loss) per common share - diluted \$(0.20) \$(0.05) \$(0.03)

(accumulated deficit) (1,946,685) (876,590)
 Total stockholders' equity (deficit) 7,472,610 9,552,464
 Total equity (deficit) 7,472,610 ...

SILVERSUN TECHNOLOGIES INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Software product revenues, net	14,110,773	11,781,362	7,863,387
Service revenues, net	40,406,168	33,203,914	33,837,993
Total revenues, net ...	54,516,941	44,985,276	41,701,380
Product	8,512,767
Service	24,390,365
Cost of revenues:			
product	7,077,804	4,575,386
Cost of revenues:			
service	19,946,736	19,917,936
Total cost of revenues	32,903,132	27,024,540	24,493,322
Gross profit (loss)	21,613,809	17,960,736	17,208,058
Selling & marketing expenses ..	8,852,739	7,745,265	6,719,909
General & administrative expenses	10,217,157	9,471,625	9,402,259
Share-based compensation expenses	41,497	180,260	441,310
Depreciation & amortization expenses	828,157	948,965	875,566
Total selling, general & administrative expenses	18,346,115	17,439,044
Total operating expenses	19,939,550
Income (loss) from operations	1,674,259	(385,379)	(230,986)
Gain from bargain purchase	71,359
Gain on sale of product line	250,000
Interest expense, net	55,666	89,024	46,802
Deal costs	(2,986,107)
Total other income (expense), net	(89,024)	274,557
Income (loss) before taxes	(1,367,514)	(474,403)	43,571
Current federal provision (benefit) for income taxes	25,505	(105,826)	92,334
Current state & local provision (benefit) for income taxes	14,913	22,410	37,545
Total current provision (benefit) for income taxes	40,418	(83,416)	129,879
Deferred federal provision (benefit) for income taxes	(240,485)	(78,677)	51,207
Deferred state & local provision (benefit) for income taxes	(97,352)	(30,091)	(3,081)
Total deferred provision (benefit) for income taxes	(337,837)	(108,768)	48,126
Provision (benefit) for income taxes	(297,419)	(192,184)	178,005
Net income (loss)	(1,070,095)	(282,219)	(134,434)
Weighted average shares outstanding - basic	5,259,595	5,167,081	5,026,420
Weighted average shares outstanding - diluted	5,259,595	5,167,081	5,026,420

□ Approximately; □ As of February 6, 2022; □ As of March 25, 2022; □ As of February 26, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	6,143,298	8,008,633
Accounts receivable, gross	3,479,087	2,723,271
Less: allowances for doubtful accounts	510,212	490,311
Accounts receivable, net	2,968,875	2,232,960
Unbilled services	194,407	367,165
Deferred charges	735,908	1,516,895
Prepaid expenses & other current assets	1,753,849	1,573,615
Total current assets	11,796,337	13,699,268
Leasehold improvements	165,701	165,701
Equipment, furniture, & fixtures	3,942,502	3,821,575
Property & equipment, gross	4,108,203	3,987,276
Less: accumulated depreciation & amortization - property & equipment	3,604,856	3,275,962
Property & equipment, net	503,347	711,314
Operating lease right-of-use assets, net	521,866	328,562
Intangible assets, net	4,918,849	4,265,353
Goodwill	1,139,952	1,139,952
Deferred tax assets, net	1,443,902	1,106,065
Deposits & other assets	171,448	187,553
Total assets	20,495,701	21,438,067
Accounts payable	4,563,248	3,272,555
Accrued expenses	2,654,920	2,432,703
Accrued interest	24,507	23,757
Long term debt - current portion	701,749	680,146
Long term debt - related party - current portion	103,333
Finance lease obligations - current portion	154,336	214,990
Operating lease liabilities - current portion	262,733	268,345
Deferred revenue	3,161,082	3,757,090
Total current liabilities	11,522,575	10,752,919
Long-term debt net of current portion	994,266	671,014
Finance lease obligations net of current portion	247,117	401,453
Operating lease liabilities net of current portion	259,133	60,217
Total liabilities	13,023,091	11,885,603
Common stock	53	53
Additional paid-in capital	9,419,242	10,429,001
Retained earnings

Recent Dividends:

- SilverSun Technologies Inc series A preferred.**
No dividends paid.
 - SilverSun Technologies Inc class A common.**
No dividends paid.
 - SilverSun Technologies Inc series B preferred.**
No dividends paid.
 - SilverSun Technologies Inc series B preferred.**
No dividends paid.
- Annual Dividends:**
- SilverSun Technologies Inc series A preferred.**
No dividends paid.
 - SilverSun Technologies Inc class A common.**
No dividends paid.
 - SilverSun Technologies Inc series B preferred.**
No dividends paid.
 - SilverSun Technologies Inc series B preferred.**
No dividends paid.

SINCLAIR INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021 (revised)
Station broadcast revenues, net of agency commissions ..	3,106,000
Media revenues	3,894,000	6,083,000
Non-media revenues ..	28,000	34,000	51,000
Total revenues	3,134,000	3,928,000	6,134,000
Media programming & production expenses	49,000	1,942,000	4,291,000
Media selling, general & administrative expenses	747,000	812,000	908,000
Amortization of program contract costs	80,000	90,000	93,000
Non-media expenses	44,000	57,000
Depreciation of property & equipment	105,000	100,000	114,000
Corporate general & administrative expenses	694,000	160,000	170,000
Amortization of definite-lived intangible & other assets	166,000	221,000	477,000
Gain on deconsolidation of subsidiary	(10,000)	3,357,000	...
Gain (loss) on asset dispositions	(3,000)
Gain (loss) on asset dispositions & other, net of impairment	64,000	71,000
Total operating expenses (gains)	3,465,000	(52,000)	6,039,000
Operating income (loss)	(331,000)	3,980,000	95,000
Interest expense including amortization of debt discount & deferred financing costs	305,000	296,000	618,000
Gain (loss) on extinguishment of debt	15,000	3,000	(7,000)
Income (loss) from equity method investments	29,000	56,000	45,000
Other income (expense), net	(45,000)	(129,000)	(14,000)

Total other income (expense), net	(306,000)	(366,000)	(594,000)	gross	620,000	617,000	affiliated, current portion	...	(3,000)
Income (loss) before income taxes	(637,000)	3,614,000	(499,000)	Less allowance for doubtful accounts	4,000	5,000	Operating lease liabilities, less current portion	152,000	154,000
Current federal provision (benefit) for income taxes	5,000	6,000	(78,000)	Accounts receivable, net	616,000	612,000	Notes payable, capital leases & commercial bank financing, less current portion	4,139,000	...
Current state provision (benefit) for income taxes	(5,000)	3,000	2,000	Income taxes receivable	8,000	5,000	Program contracts payable, less current portion	14,000	10,000
Deferred federal provision (benefit) for income taxes	...	9,000	(76,000)	Prepaid expenses & other current assets	189,000	182,000	Deferred tax liabilities	252,000	610,000
Deferred state provision (benefit) for income taxes	(342,000)	868,000	(93,000)	Total current assets	1,475,000	1,683,000	Other long-term liabilities	204,000	220,000
Deferred federal provision (benefit) for income taxes	(16,000)	36,000	(4,000)	Land & improvements	72,000	72,000	Capitalized Lease Obligations - Long-Term	25,000	...
Deferred state provision (benefit) for income taxes	(358,000)	904,000	(97,000)	Real estate held for development & sale	19,000	19,000	Total liabilities	...	5,829,000
NET (LOSS) INCOME	(279,000)	Buildings & improvements	309,000	300,000	Redeemable noncontrolling interests	...	194,000
Income tax provision (benefit)	(358,000)	913,000	(173,000)	Operating equipment	...	873,000	Class A common stock	1,000	1,000
Net income (loss) attributable to the redeemable noncontrolling interests	4,000	(20,000)	(18,000)	Station equipment	879,000	...	Class B common stock	237	...
Net income (loss) attributable to the noncontrolling interests	(16,000)	(29,000)	(70,000)	Office furniture & equipment	149,000	130,000	Additional paid-in capital	517,000	624,000
Net income (loss) attributable to Sinclair Broadcast Group	(291,000)	2,652,000	(414,000)	Leasehold improvements	47,000	45,000	Retained earnings (accumulated deficit)	(234,000)	122,000
Weighted average shares outstanding - basic	65,125	70,653	75,050	Automotive equipment	64,000	63,000	Accumulated other comprehensive income (loss)	1,000	1,000
Weighted average shares outstanding - diluted	65,125	70,656	75,050	Finance lease assets	61,000	61,000	Total Sinclair Broadcast Group shareholders' equity (deficit)	285,000	748,000
Year end shares outstanding	63,513	69,623	73,089	Construction in progress	90,000	74,000	Noncontrolling interests	(64,000)	(67,000)
Earnings (loss) per share-continuing operations-basic	\$(4.46)	Gross property & equipment	1,690,000	1,637,000	Total equity (deficit)	221,000	681,000
Net earnings (loss) per common share - basic	\$(4.46)	\$37.54	\$(5.51)	Less: accumulated depreciation	975,000	909,000			
Earnings (loss) per share-continuing operations-diluted	\$(4.46)	Property & equipment, net	715,000	728,000			
Net earnings (loss) per common share - diluted	\$(4.46)	\$37.54	\$(5.51)	Operating lease assets	142,000	145,000			
Dividends declared per share	\$1.00	\$1.00	\$0.80	Restricted cash	182,000	...			
Number of full time employees	7,300	Goodwill	2,082,000	2,088,000			
Total number of employees	7,300	7,900	11,500	Indefinite-lived intangible assets	150,000	150,000			
Number of common stockholders	40	Customer relationships, net	369,000	444,000			
Number of class A common stockholders	36	34	...	Other definite-lived intangible assets, net	410,000	502,000			
Media programming and production expenses	1,611,000	Equity method investments	128,000	113,000			
Comprehensive (loss) income attributable to SBG	(291,000)	Other investments	387,000	442,000			
				Post-retirement plan assets	45,000	41,000			
				Note receivable	...	193,000			
				Other assets	...	175,000			
				Total assets	6,085,000	6,704,000			
				Compensation & employee benefits	98,000	100,000			
				Interest	12,000	11,000			
				Programming related obligations	156,000	151,000			
				Legal, litigation, & regulatory	505,000	10,000			
				Accounts payable & other operating expenses	142,000	125,000			
				Accounts payable & accrued liabilities	913,000	397,000			
				Capital leases payable	2,000	...			
				Current portion of notes payable, finance leases, & commercial bank financing	34,000	38,000			
				Current portion of operating lease liabilities	21,000	23,000			
				Current portion of notes payable & capital leases payable to affiliates	36,000	...			
				Current portion of program contracts payable	...	83,000			
				Other current liabilities	57,000	67,000			
				Liabilities held for sale	76,000	...			
				Total current liabilities	1,103,000	608,000			
				Bank credit agreement, term loans	...	2,733,000			
				Unsecured notes	4,114,000	782,000			
				Senior secured notes	...	750,000			
				Debt of variable interest entities	...	8,000			
				Debt of non-media subsidiaries	...	16,000			
				Finance leases	...	23,000			
				Finance leases - affiliate	...	9,000			
				Less: deferred financing costs & discount	...	(56,000)			
				Less: current portion	...	(35,000)			
				Less: finance leases -			

As is; [□] Approximately; [□] As of February 23, 2022; [□] As of February 27, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	662,000	884,000
Accounts receivable,		

[□] Include total assets of variable interest entities - Total assets: \$115,000,000; [□] Include total liabilities of variable interest entities - Total liabilities: \$18,000,000

Recent Dividends:

- 1. Sinclair Inc class B common.**
No dividends paid.
- 2. Sinclair Inc series D convertible exchangeable preferred.**
No dividends paid.
- 3. Sinclair Inc class A common.**

ExDate	Amt	Declared	Record	Payable
08/31/2023	0.25	08/02/2023	09/01/2023	09/15/2023
11/30/2023	0.25	11/01/2023	12/01/2023	12/15/2023
03/08/2024	0.25	02/28/2024	03/11/2024	03/25/2024

Annual Dividends:

- 1. Sinclair Inc class B common.**
No dividends paid.
- 2. Sinclair Inc series D convertible exchangeable preferred.**
No dividends paid.
- 3. Sinclair Inc class A common.**

2023 0.50 2024 0.25

SINGULARITY FUTURE TECHNOLOGY LTD

Earnings, 6 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues	1,857,166	...
Cost & expenses	5,419,425	9,186,422
Operating income	(3,562,259)	(6,474,287)
Other income (expense), net	(83,664)	(119,480)
Gains or losses	62,384	...
Net before taxes	(3,583,539)	(6,593,767)
Income taxes	...	103,426
Net income	(3,583,539)	(6,697,193)
Earnings common share		
Primary	\$(1.90)	\$(3.20)
Fully Diluted	\$(1.90)	\$(3.20)
Common Shares:		
Full Diluted	1,755,683	2,122,782
Year-end	1,751,553	2,224,433

SKYWATER TECHNOLOGY INC

Annual Report

Consolidated Income Statement, Years Ended (\$000):

	12/31/23	01/01/23	01/02/22
Revenue	286,682	212,941	162,848
Cost of revenue,			

before inventory				Revenue	286,682	issuance costs	22,765	55,817
write-down	186,974	156,878		EPS - Basic -				Current portion of		
Inventory				excluding				contingent consideration	1,319	...
write-down	...	13,442		Extraordinary Items				Current portion of		
Cost of revenue	227,390	...		Applicable to				foundry services		
Total cost of				Common - Total	\$(0.68)	obligation	44,883	...
revenue	227,390	186,974	170,320	EPS - Diluted -				Deferred revenue -		
Gross profit (loss)	59,292	25,967	(7,472)	excluding				current	49,551	28,186
Research &				Extraordinary Items				Current portion of		
development	10,169	9,431	8,747	Applicable to				finance lease liabilities	645	...
General &				Common - Total	\$(0.68)	Current portion of		
administrative								operating lease		
expenses	63,911	□ As is; □ As of March 10, 2023; □ As of March 7, 2022; □				liabilities	48	...
Selling, general &				Approximately				Deferred revenue current		
administrative								- Balancing value	4,668	...
expenses	...	46,303	43,595	Consolidated Balance Sheet, Years Ended (\$000):				Total current liabilities	144,197	132,172
Change in fair					12/31/23	01/01/23		Revolver	...	60,093
value of contingent				Cash & cash equivalents	18,382	30,025		Financing (by VIE)	...	36,826
consideration	...	(2,710)		Trade accounts receivable	65,961	29,683		Tool financing loan	...	3,037
Operating income				Unbilled revenue	...	34,625		Unamortized debt issuance		
(loss)	(14,788)	(29,767)	(57,104)	(contract assets)		costs	...	(7,103)
Paycheck Protection				Allowance for doubtful	...	1,638		Total long-term debt	36,098	92,853
Program loan				accounts		Less: current portion of		
forgiveness	...	6,453		Accounts receivable -	...	66,141		long-term debt	...	57,672
Gain (loss) on debt				Balancing value	66,141	...		Finance lease obligations	9,275	...
extinguishment	...	(1,101)	...	Accounts receivable, net	...	62,670		Long-term debt, less		
Interest expense	10,826	5,194	3,542	Raw materials	4,775	3,991		current portion & net of		
Total other income				Work-in-process	19	359		unamortized debt issuance		
(expense)	(10,826)	(6,295)	2,911	Supplies & spare parts	10,547	9,047		costs	...	35,181
Income (loss)				Inventory - Balancing	...	15,341		Long-term incentive plan	...	1,643
before income taxes	(25,614)	(36,062)	(54,193)	value	...	13,397		Deferred revenue -		
Current federal				Inventories	...	2,395		long-term	65,754	67,967
income taxes	8	562	379	Prepaid expenses	2,663	...		Deferred income tax		
Current state				Equipment purchased for	...	12,737	5,669	liability, net	679	1,239
income taxes	41	3	(106)	customers	...	1,453	2,097	Other long-term		
Total current tax				Deferred contract costs	129	liabilities	9,327	13,585
expense	49	565	273	Prepaid inventory	...	16,853	10,290	Contract Liabilities	63,810	...
Deferred federal				Prepaid expenses & other	...	172	169	Deferred revenue		
income taxes	(570)	148	(6,794)	current assets	...	29,666	...	long-term - Balancing		
(benefit)				Income tax receivable	...	180	...	value	1,944	...
Deferred state				Contract assets	...	146,375	116,551	Operating lease liability	52	...
income taxes	...	96	(269)	Allowance for credit	...	5,396	5,396	Total long-term		
(benefit)				losses	...	297,134	88,141	liabilities	111,858	119,615
Total deferred tax				Total current assets	146,375	116,551	116,551	Total liabilities	256,055	251,787
(benefit)	(570)	244	(7,063)	Land	...	193,977	187,276	Common stock	470	437
Income tax expense				Buildings & improvements	...	8,979	9,746	Additional paid-in		
(benefit)	(521)	809	(6,790)	Machinery & equipment	...	88,782	...	capital	178,473	147,304
Net income (loss)	(25,093)	(36,871)	(47,403)	Fixed assets not yet in	Retained earnings		
Less: net income				service	(accumulated deficit)	(125,203)	(94,072)
attributable to				Buildings and	Total shareholders'		
non-controlling				improvements	equity, SkyWater		
interests	(5,663)	(2,722)	(3,293)	Total property &	Technology, Inc.	53,740	53,669
Net income (loss)				equipment, at cost	...	290,559	...	Non-controlling interests	6,961	308
attributable to				Less: accumulated	...	137,767	110,644	Total shareholder' equity		
SkyWater				depreciation	...	159,367	179,915	(deficit)	60,701	53,977
Technology, Inc.	(30,756)	(39,593)	(50,696)	Property & equipment,	...	5,672	5,608			
Undistributed				net	...	3,293	2,605	Recent Dividends:		
preferred return to				Intangible assets, net	...	96	141	1. SkyWater Technology Inc common.		
Class B preferred				Supplies & spare parts	...	1,953	944	No dividends paid.		
unitholders	398	Operating lease	...	5,342	3,690	Annual Dividends:		
Net income (loss)				right-of-use assets	...	316,756	305,764	1. SkyWater Technology Inc common.		
attributable to				Other assets	No dividends paid.		
common shareholders				Other assets	SMARTMETRIC INC		
Weighted average				Total assets	316,756	305,764		Earnings, 6 mos. to Dec 31(Consol. - \$):		
common shares				Current portion of	...	3,976	1,855	2023	2022	
outstanding - basic	45,507	40,835	29,038	long-term debt	...	19,614	21,102	Cost & expenses	341,441	394,088
Weighted average				Accounts payable	5,705	Operating income	(370,639)	(394,088)
common shares				Accrued compensation	1,500	Other income (expense), net	...	(251,618)
outstanding -				Licensed technology	30	Net before taxes	(370,639)	...
diluted	45,507	40,835	29,038	Accrued commissions	20	Net income	(370,639)	(671,662)
Year end units				Accrued fixed asset	4,734	Balance for common	(370,639)	(671,662)
outstanding	47,028	43,705	39,836	expenditures	786	Earnings common share		
Net earnings (loss)				Accrued royalties	1,294	Common Shares:		
per common share -				Finance lease obligations	11,143	Full Diluted	2,453,949,756,010,411,250	
basic	\$(0.68)	\$(0.97)	\$(1.76)	Accrued inventory	Year-end	2,822,719,707,487,909,032	
Net earnings (loss)				Other accrued expenses			
per common share -				Accrued expenses -	SMITH MICRO SOFTWARE INC		
diluted	\$(0.68)	\$(0.97)	\$(1.76)	Balancing value	13,776	Annual Report		
Number of full time				Accrued commissions	488	Consolidated Income Statement, Years Ended Dec. 31		
employees	731	Other accrued expenses -	(\$000):		
Total number of				Balancing value	21,068	2023	2022	2021
employees	731	□706	□590	Accrued expenses	48,291	25,212				(revised)
Number of common				Short-term financing, net				
stockholders	1	□□2	□□□3	of unamortized debt		Products revenue	40,862	...

Revenues	40,862	48,513	58,422
Cost of revenues	10,559	14,210	12,698
Gross profit	30,303	34,303	45,724
Selling & marketing	11,089	12,887	11,581
Research & development	17,145	29,870	26,197
General & administrative	12,779	16,161	17,920
Change in fair value of contingent consideration	12,864
Amortization of intangible assets	...	6,312	8,100
Depreciation and amortization	7,345
Total operating expenses	48,358	65,230	76,662
Operating income (loss)	(18,055)	(30,927)	(30,938)
Change in fair value of warrant & derivative liabilities	...	4,669	...
Gain (loss) on debt extinguishment	(3,991)
Gain on sale of software products	4,214
Interest Expense - Net of Capitalized Interest	6,354
Interest income (expense), net	...	(2,680)	34
Other income (expense), net	(52)	(115)	76
Income (loss) before income taxes - domestic	...	(29,539)	(31,301)
Income (loss) before income taxes - foreign	...	486	473
Income (loss) before provision for income taxes	(24,238)	(29,053)	(30,828)
Current income tax expense (benefit) - state	14	8	5
Current income tax expense - foreign	154	157	152
Total current income tax expense (benefit)	168	165	157
Deferred income tax expense (benefit) - federal	9	24	24
Deferred income tax expense (benefit) - state	(19)	37	35
Deferred income tax expense (benefit) - foreign	(1)
Total deferred income tax expense (benefit)	(10)	61	58
Provision for income tax expense (benefit)	158	226	215
Net income (loss)	(24,396)	(29,279)	(31,043)
Weighted average shares outstanding - basic	64,916	55,422	51,232
Weighted average shares outstanding - diluted	64,916	55,422	51,232
Year end shares outstanding	74,784	56,198	54,259
Net income (loss) per share - basic	\$(0.38)	\$(0.53)	\$(0.61)
Net income (loss) per share - diluted	\$(0.38)	\$(0.53)	\$(0.61)
Full-Time Employees (Period End)	231
Total number of employees	231	315	373

Number of common stockholders 81 89 92
 Depreciation & amortization 7,345 ...
 Earnings per share from continuing operations \$(0.38) ...
 Earnings per share from continuing operations \$(0.38) ...
 As is; Approximately; As of March 15, 2023; As of March 1, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	7,125	14,026
Accounts receivable, gross	7,915	10,504
Less: allowances for doubtful accounts & other adjustments	3	3
Accounts receivable, net	7,912	10,501
Prepaid expenses & other current assets	1,843	1,983
Total current assets	16,880	26,510
Computer hardware, software & equipment	803	10,347
Leasehold improvements	1,440	3,381
Office furniture & fixtures	...	828
Computer hardware, software, and equipment	6,653	...
Equipment & improvements, gross	8,896	14,556
Less: accumulated depreciation & amortization	8,013	13,058
Equipment & improvements, net	883	1,498
Right-of-use assets	2,759	3,722
Other assets	482	490
Intangible assets, net	29,532	36,320
Goodwill	35,041	35,041
Total assets	85,577	103,581
Accounts payable	2,522	3,236
Accrued payroll & benefits	2,500	3,883
Current operating lease liabilities	1,483	1,441
Other current liabilities	1,137	1,589
Current portion of convertible notes payable	...	9,007
Derivative liabilities	...	1,575
Total current liabilities	7,642	20,731
Warrant liabilities	...	3,317
Operating lease liabilities	1,780	2,976
Deferred rent & other long term liabilities	597	...
Deferred tax liabilities, net	168	178
Total non-current liabilities	2,545	6,471
Common stock	75	56
Additional paid-in capital	381,263	357,875
Accumulated comprehensive earnings (deficit)	(305,948)	(281,552)
Total stockholders' equity	75,390	76,379
Total Equity	75,390	...

Recent Dividends:
 1. Smith Micro Software Inc common. No dividends paid.
 2. Smith Micro Software Inc series B 10% convertible preferred. No dividends paid.
Annual Dividends:
 1. Smith Micro Software Inc common. No dividends paid.

2. Smith Micro Software Inc series B 10% convertible preferred.
 No dividends paid.

SOCIETAL CDMO INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Cost of sales	76,497,000
Revenue	94,635,000
Revenue	94,635,000	90,214,000	75,360,000
Cost of sales (excluding amortization of intangible assets)	...	67,076,000	55,537,000
Selling, general & administrative expenses	21,024,000	21,954,000	18,374,000
Amortization of intangible assets	687,000	905,000	1,037,000
Total operating expenses	98,208,000	89,935,000	74,948,000
Operating income (loss)	(3,573,000)	279,000	412,000
Interest income	394,000
Interest expense	9,963,000	14,059,000	15,134,000
Gain (loss) on extinguishment of debt	...	(4,996,000)	3,352,000
Income (loss) before income taxes	(13,142,000)	(18,776,000)	(11,370,000)
Current federal income tax expense (benefit)	...	33,000	...
Current state & local income tax expense (benefit)	...	57,000	...
Income Taxes - Local - Current	43,000
Total current income tax expense (benefit)	43,000	90,000	...
Deferred federal income tax expense (benefit)	(2,092,000)	1,399,000	(2,396,000)
Deferred state & local income tax expense (benefit)	...	4,266,000	(677,000)
Income Taxes - Local - Deferred	(1,164,000)
Total deferred income tax expense (benefit)	(3,256,000)	5,665,000	(3,073,000)
Change in valuation allowance	3,345,000	(4,650,000)	3,073,000
Income tax expense (benefit)	132,000	1,105,000	...
Net income (loss)	(13,274,000)	(19,881,000)	(11,370,000)
Weighted average shares outstanding - basic	95,229,192	57,877,920	44,117,473
Weighted average shares outstanding - diluted	95,229,192	57,877,920	44,117,473
Year end shares outstanding	104,856,247	84,588,868	46,681,453
Income (loss) per share from continuing operations - basic	\$(0.14)
Net income (loss) per share - diluted	\$(0.14)	\$(0.34)	\$(0.26)
Number of full time employees	258	275	258
Total number of employees	258
Number of common

stockholders	6	^⑥	^⑮	(accumulated deficit)	(278,909,000)	(265,635,000)
				Total shareholders' equity (deficit)	58,663,000	59,859,000
				Total Equity	58,663,000	...

^⑥ Reclassified to conform with 2022 presentation; ^⑮ Shares increased due to the effect of issuance of shares, vesting of restricted share units and exercise of share options; ^⑮ Shares increased due to the effect of issuance of common stock, vesting of restricted stock units and exercise of stock options; ^⑮ As of February 22, 2023; ^⑮ As of February 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	8,095,000	14,995,000
Accounts receivable, net	16,576,000	15,950,000
Raw materials	5,337,000	4,318,000
Work in process	3,310,000	3,689,000
Finished goods	1,615,000	2,294,000
Inventory	10,262,000	10,301,000
Contract assets	12,837,000	8,724,000
Prepaid expenses & other current assets	2,878,000	2,848,000
Assets held for sale	...	2,768,000
Current assets of discontinued operation	2,813,000	...
Total current assets	53,461,000	55,586,000
Land	604,000	604,000
Building & improvements	22,913,000	22,751,000
Furniture, office & computer equipment	6,845,000	6,388,000
Manufacturing equipment	68,002,000	58,039,000
Construction in process	3,973,000	7,024,000
Property, plant & equipment, gross	102,337,000	94,806,000
Less: accumulated depreciation	52,542,000	44,441,000
Property, plant & equipment, net	49,795,000	50,365,000
Operating lease asset	5,004,000	5,491,000
Intangible assets, net	2,241,000	2,928,000
Goodwill	41,077,000	41,077,000
Other assets	1,896,000	1,996,000
Total assets	153,474,000	157,443,000
Accounts payable	1,312,000	1,466,000
Accrued payroll & related costs	5,807,000	4,276,000
Accrued transaction costs	25,000	3,653,000
Contract liabilities	543,000	2,211,000
Accrued property, plant & equipment	696,000	934,000
Accrued professional & consulting fees	869,000	356,000
Other accrued expenses & other current liabilities	...	1,029,000
Accrued interest	511,000	227,000
Other	2,363,000	...
Accrued expenses & other current liabilities	10,814,000	12,686,000
Current portion of operating lease liability	1,105,000	1,079,000
Current portion of debt	36,756,000	7,577,000
Total current liabilities	49,987,000	22,808,000
Term loan under credit agreement	...	36,900,000
Note with former equity holder of IriSys	339,000	4,078,000
Other debt	...	339,000
Less: unamortized deferred issuance costs	...	(2,476,000)
Less: unamortized original discount	...	(297,000)
Less: current portion of debt	...	7,577,000
Debt, net of current portion	...	30,967,000
Operating lease liability, net of current portion	4,153,000	4,584,000
Other liabilities	40,332,000	39,225,000
Total liabilities	94,811,000	97,584,000
Convertible preferred stock	...	4,350,000
Common stock	1,049,000	846,000
Additional paid-in capital	336,523,000	320,298,000
Retained earnings		

Recent Dividends:

1. Societal CDMO Inc series A convertible preferred.

No dividends paid.

2. Societal CDMO Inc common.

No dividends paid.

Annual Dividends:

1. Societal CDMO Inc series A convertible preferred.

No dividends paid.

2. Societal CDMO Inc common.

No dividends paid.

SOLENO THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	^⑮ 2021
			(revised)
Research & development expenses	...	15,265,000	21,453,000
General & administrative expenses	13,481,000	9,844,000	10,806,000
Change in fair value of contingent consideration	25,189,000	(712,000)	(731,000)
Change in fair value of contingent consideration	(2,714,000)
Total operating expenses	41,384,000	24,397,000	31,528,000
Operating income (loss)	(41,384,000)	(24,397,000)	(31,528,000)
Change in fair value of warrant liability	(182,000)	30,000	508,000
Interest income	2,578,000	300,000	110,000
Total other income (expense)	2,396,000	330,000	618,000
Income (loss) before income taxes - United States	(39,180,000)	(24,173,000)	(30,453,000)
Income (loss) before income taxes - foreign	192,000	106,000	(457,000)
Income (loss) from continuing operations before provision for income tax benefit	(38,988,000)	(24,067,000)	(30,910,000)
Net income (loss)	(38,988,000)	(24,067,000)	(30,910,000)
Weighted average shares outstanding - basic	16,492,132	8,397,088	^⑮ 5,318,022
Weighted average shares outstanding - diluted	16,492,132	8,397,088	^⑮ 5,318,022
Year end shares outstanding	31,678,159	8,159,382	^⑮ 5,324,287
Income (loss) per common share from continuing operations - basic	\$(2.36)
Net income (loss) per common share - basic	\$(2.36)	\$(2.87)	\$(5.81)
Income (loss) per common share from continuing operations - diluted	\$(2.36)
Net income (loss) per common share - diluted	\$(2.36)	\$(2.87)	^⑮ \$(5.81)
Number of full time employees	33	25	20
Number of part time employees	9	7	11
Total number of employees	42	...	31

Number of common stockholders	37	^⑮ 40	^⑮ 47
-------------------------------	----	-----------------	-----------------

^⑮ Reclassified to conform with 2022 presentation; ^⑮ Adjusted for 1-for-15 stock split, August 29, 2022; ^⑮ As of March 9, 2023; ^⑮ As of March 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	169,681,000	14,602,000
Prepaid expenses & other current assets	1,677,000	1,045,000
Total current assets	171,358,000	15,647,000
Computer hardware	29,000	72,000
Computer software	72,000	...
Furniture & fixtures	...	29,000
Property & equipment, gross	...	101,000
Less accumulated depreciation & amortization	89,000	75,000
Property & equipment, net	12,000	26,000
Operating lease right-of-use assets	407,000	131,000
Intangible assets, net	8,749,000	10,693,000
Other long-term assets	165,000	...
Total assets	180,691,000	26,497,000
Accounts payable, net	3,149,000	1,777,000
Accrued compensation	3,135,000	1,675,000
Accrued clinical trial site costs	3,393,000	3,222,000
Operating lease liabilities	273,000	155,000
Other current liabilities	1,555,000	484,000
Total current liabilities	11,505,000	7,313,000
2018 PIPE warrant liability	...	1,000
Contingent liability for Essentialis, Inc. ("Essentialis") purchase price	11,549,000	8,835,000
Long-term lease liabilities	130,000	...
Total liabilities	...	16,149,000
Common stock	32,000	8,000
Additional paid-in capital	433,885,000	247,762,000
Retained earnings (accumulated deficit)	(276,410,000)	(237,422,000)
Total stockholders' equity (deficit)	157,507,000	10,348,000
Total equity	157,507,000	...

Recent Dividends:

1. Soleno Therapeutics Inc series B convertible preferred.

No dividends paid.

2. Soleno Therapeutics Inc series A convertible preferred.

No dividends paid.

3. Soleno Therapeutics Inc common.

No dividends paid.

Annual Dividends:

1. Soleno Therapeutics Inc series B convertible preferred.

No dividends paid.

2. Soleno Therapeutics Inc series A convertible preferred.

No dividends paid.

3. Soleno Therapeutics Inc common.

No dividends paid.

SOLIGENIX INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	^⑮ 2021
			(revised)
Licensing revenue	...	250,000	...
Contract revenue	33,351
Grant revenue	839,359	698,911	790,917
Total revenues	839,359	948,911	824,268
Cost of revenues	742,048	550,822	728,640
Gross profit	97,311	398,089	95,628
Research & development	3,312,699	7,944,089	8,185,850
General &			

administrative	4,482,552	6,692,904	5,008,738
Income (loss) from operations	(7,697,940)	(14,238,904)	(13,098,960)
Gain on forgiveness of Paycheck Protection Program loan	(393,791)	...	421,584
Foreign currency transaction gain (loss)	1,483	(30,549)	(39,361)
Research & development incentives	23,784	132,869	174,770
Interest income (expense)	(49,129)
Interest expense, net	...	822,611	904,502
Other income (expense), principally net proceeds from QTDP grant	120,771
Other income	43,223	5,921	30,754
Change in fair value of convertible debt	43,066
Total other income (expense)	(210,593)	(714,370)	(316,755)
Net income (loss) before income taxes	(7,908,533)	(14,953,274)	(13,415,715)
State income taxes	...	(1,154,935)	(864,742)
Income tax expense (benefit)	(1,767,803)	(1,154,935)	(864,742)
Net income (loss) applicable to common stockholders	...	(13,798,339)	(12,550,973)
Weighted average common shares outstanding - basic	7,758,036	2,871,345	2,675,488
Weighted average common shares outstanding - diluted	7,758,036	2,871,345	2,675,488
Year end shares outstanding	10,378,238	2,908,578	2,858,230
Net income (loss) per share - basic	\$(0.79)	2\$(4.81)	2\$(4.69)
Net income (loss) per share - diluted	\$(0.79)	2\$(4.81)	2\$(4.69)
Number of full time employees	13	13	13
Number of part time employees	2	2	2
Total number of employees	15	15	15
Number of common stockholders	112	108	111
Foreign currency translation adjustments	...	(17,195)	66,279
Basic EPS Excluding ExtraOrdinary Items	\$(0.79)
Diluted EPS Excluding ExtraOrd Items	\$(0.79)

[□] Reclassified to conform with 2022 presentation; [■] Adjusted for 1-for-15 stock split, February 10, 2023; [▣] Shares increased due to the effect issuance of common shares for pursuant to B. Riley At Market issuance sales agreements, to vendors, exercise of warrants and exercise of stock options; [▤] As of March 24, 2023; [▥] As of March 22, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022	2021
Cash & cash equivalents	8,446,158	13,359,615	...
Contracts & grants receivable	...	115,130	...
UK research & development incentives receivable	23,894

Research & development incentives receivable, current	...	104,198	...
Prepaid expenses & other current assets	866,014	274,209	...
Unbilled revenue	171,254
Total current assets	9,507,320	13,853,152	...
Security deposit	22,777	22,777	...
Accumulated depreciation	121,320
Office furniture & equipment, gross	133,247	133,247	...
Less: accumulated depreciation - office furniture & equipment	...	114,766	...
Office furniture & equipment, net	11,927	18,481	...
Deferred issuance cost	...	20,206	...
Right-of-use lease assets	229,834	340,987	...
Research & development incentives receivable, net of current portion	...	24,114	...
Other assets	25,468
Total assets	9,797,326	14,279,717	...
Clinical trial expenses	1,993,784	1,884,117	...
Other accrued expenses	...	423,629	...
Accrued expenses	...	2,307,746	...
Accounts payable	1,111,226	3,865,796	...
Accrued compensation	251,115	336,692	...
Lease liabilities, current	121,765	108,948	...
Convertible debt, net	2,250,000	9,897,691	...
Other	424,218
Accrued expenses - Balancing value	2,418,002
Total current liabilities	6,152,108	16,516,873	...
Convertible debt, net	1,010,934
Lease liabilities, net of current portion	111,862	233,627	...
Total liabilities	7,274,904	16,750,500	...
Series D preferred stock	...	43	...
Common stock	10,378	2,909	...
Additional paid-in capital	228,193,977	217,064,964	...
Retained earnings (accumulated deficit)	(225,704,176)	(219,563,446)	...
Accumulated other comprehensive income (loss)	22,243	24,747	...
Total shareholders' equity (deficiency)	2,522,422	(2,470,826)	...
Total Equity	2,522,422

[□] Debt discount - convertible debt: \$102,309

Recent Dividends:
1. Soligenix Inc common.
 No dividends paid.

Annual Dividends:
1. Soligenix Inc common.
 No dividends paid.

SOUTHLAND HOLDINGS INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
General & administrative costs	67,195,000	1,281,634	162,602
Income (loss) from operations	(31,381,000)	(1,281,634)	(162,602)
Investment income on trust account	23,580,000	4,013,841	24,163
Income (loss) before income tax provision	(27,242,000)	2,732,207	(138,439)
Current provision for federal income taxes	...	800,905	...
Deferred provision for federal income taxes	...	(227,143)	...
Change in valuation allowance	...	227,143	...
Federal	710,000

State	620,000
Foreign	2,633,000
Federal	(6,394,000)
State	(2,616,000)
Foreign	(319,000)
Income Taxes - Total - Current	3,963,000
Valuation allowance	(3,161,000)
Income Taxes - Total - Deferred	(12,490,000)
Provision for income taxes	(8,527,000)	800,905	...
Revenue	1,160,417,000
Net income attributable to noncontrolling interests	(538,000)
Net Income After Extraordinary Items applicable to Common	(19,253,000)
Net income (loss)	(18,715,000)	1,931,302	(138,439)
Total revenues	1,160,417,000
Weighted average public shares outstanding - basic	...	28,771,000	6,260,292
Weighted average founders shares outstanding - basic	...	7,140,000	6,413,684
Cost of construction	1,124,603,000
Weighted average shares outstanding - basic	47,088,813
Weighted average public shares outstanding - diluted	...	28,771,000	6,260,292
Weighted average founders shares outstanding - diluted	...	7,140,000	6,413,684
Weighted average shares outstanding - diluted	47,088,813
Year end shares outstanding	47,891,984	35,911,000	35,911,000
Net earnings (loss) per public share - basic	...	\$0.05	\$(0.01)
Net earnings (loss) per founders share - basic	...	\$0.05	\$(0.01)
Net earnings (loss) per share - basic	\$(0.41)
Net earnings (loss) per public share - diluted	...	\$0.05	\$(0.01)
Net earnings (loss) per founders share - diluted	...	\$0.05	\$(0.01)
Net earnings (loss) per share - diluted	\$(0.41)
Full-Time Employees (Period End)	2,500
Total number of employees	2,500	2,500	...
Number of units stockholders	27
Number of common stockholders	1,461	1,399	31
Number of warrants stockholder	1
Gain on investments, net	30,000
Interest expense	19,471,000
Gross profit	35,814,000
Comprehensive income (loss) attributable to Southland Stockholders	(18,137,000)

[□] From July 14, 2021 (date of inception); [■] Non-consolidated;

□ Approximately; □ As of February 27, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):	
2023	2022
Cash	231,519
Prepaid expenses	200,117
Cash and cash equivalents	49,176,000
Restricted cash	14,644,000
Accounts receivable, net	194,869,000
Retainage receivables	109,562,000
Contract assets	554,202,000
Other current assets	20,083,000
Provision - Accounts & Notes Receivable - Trade	1,300,000
Accounts receivable, net - Balancing value	196,169,000
Total current assets	942,536,000
Cash held in Trust	431,636
Account	283,319,605
Land	6,170,000
Buildings	30,904,000
Machinery and equipment	305,068,000
Assets in progress	7,209,000
Office and safety equipment	1,258,000
Property, Plant & Equipment - Gross - Total	383,401,000
accumulated depreciation	281,251,000
Auto and trucks	32,792,000
Property and equipment, net	102,150,000
Right-of-use assets	12,492,000
Investments - unconsolidated entities	121,648,000
Investments - limited liability companies	2,590,000
Investments - private equity	3,235,000
Goodwill	1,528,000
Intangible assets, net	1,682,000
Other noncurrent assets	1,711,000
Deferred tax asset	11,496,000
Total noncurrent assets	258,532,000
Total assets	1,201,068,000
Accounts payable & accrued expenses	162,464,000
Franchise tax payable	137,884
Income taxes payable	82,206
Retainage payable	40,950,000
Accrued liabilities	124,667,000
Current portion of long-term debt	48,454,000
Short-term lease liabilities	14,081,000
Contract liabilities	193,351,000
Short-term operating lease liabilities	8,862,000
Short-term lease liabilities	5,219,000
Total current liabilities	223,035
Deferred underwriting commissions	9,660,000
Long-term debt	251,906,000
Long-term lease liabilities	5,246,000
Deferred tax liabilities	2,548,000
Other noncurrent liabilities	47,728,000
Long-term operating lease liabilities	3,526,000
Long-term accrued liabilities	49,109,000
Long-term lease liabilities	1,720,000
Total long-term liabilities	356,537,000
Total liabilities	940,504,000
Common stock subject to possible redemption	283,195,442
Common stock	5,000
Additional paid-in capital	270,330,000
Retained earnings (accumulated deficit)	(19,253,000)

Accumulated other comprehensive loss	(1,460,000)	...
Total stockholders' equity (deficit)	249,622,000	(9,327,236)
Noncontrolling interest	10,942,000	...
Total Equity	260,564,000	...

Recent Dividends:

1. Southland Holdings Inc common subject to possible conversion.

No dividends paid.

2. Southland Holdings Inc common.

No dividends paid.

Annual Dividends:

1. Southland Holdings Inc common subject to possible conversion.

No dividends paid.

2. Southland Holdings Inc common.

No dividends paid.

SPAR GROUP, INC.

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2023	2022
Total revenues	197,649	196,626
Net Sales	197,649	...
Cost & expenses	189,387	188,959
Deprec., depl. & amort.	1,574	1,524
Operating income	6,688	6,143
Other income (expense), net	347	363
Net before taxes	5,787	5,911
Income taxes	1,806	1,942
Net income	3,981	3,969
Earnings common share		
Primary	\$0.08	\$0.08
Fully Diluted	\$0.08	\$0.08
Common Shares:		
Full Diluted	23,350	22,010
Year-end	23,241	22,480

SPROUT SOCIAL INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	□2021 (revised)
Subscription	330,458	251,213	185,726
Professional services & other revenue	3,185	2,615	2,133
Total revenue	333,643	253,828	187,859
Cost of revenues - subscription	...	58,767	45,791
Cost of revenues - professional services & other revenue	...	1,091	997
Subscription	75,076
Professional services and other	1,192
Total cost of revenue	...	59,858	46,788
Gross profit (loss)	257,375	193,970	141,071
Research & development expenses	79,550	61,436	40,049
Selling & marketing expenses	168,091	123,695	84,182
General & administrative expenses	79,011	60,515	44,929
Total operating expenses	326,652	245,646	169,160
Income (loss) from operations	(69,277)	(51,676)	(28,089)
Interest expense	2,754	153	300
Interest income	7,021	2,535	259
Other income (expense), net	(768)	(580)	(361)
Income before income taxes - domestic	...	(49,177)	(27,097)
Income before income taxes - foreign	...	(697)	(1,394)

Income (loss) before income taxes	(65,778)	(49,874)	(28,491)
Income tax expense (benefit)	649	366	211
Net income (loss)	(66,427)	(50,240)	(28,702)
Net income (loss) attributable to common shareholders	...	(50,240)	(28,702)
Weighted average shares outstanding - basic	55,664	54,612	53,768
Weighted average shares outstanding - diluted	55,664	54,612	53,768
Year end shares outstanding	56,236	55,023	54,154
Net income (loss) per share - basic	\$(1.19)	\$(0.92)	\$(0.53)
Net income (loss) per share - diluted	\$(1.19)	\$(0.92)	\$(0.53)
Number of full time employees	1,383	□1,141	□887
Number of class A common stockholders	...	□□8	□□9
Number of class B common stockholders	...	□□14	□□14
EPS - Basic - excluding Extraordinary Items
Applicable to Common - Total	\$(1.19)
EPS - Diluted - excluding Extraordinary Items
Applicable to Common - Total	\$(1.19)
Common Shareholders - Number	19
Total number of employees	1,383

□ Reclassified to conform with 2022 presentation; □ As is; □ As of February 17, 2023; □ As of February 22, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	49,760	79,917
Marketable securities	44,645	92,929
Accounts receivable, gross	65,666	37,622
Less: allowances	2,177	1,789
Accounts receivable, net	63,489	35,833
Deferred commissions	27,725	20,369
Prepaid expenses & other assets	10,324	6,418
Total current assets	195,943	235,466
Marketable securities, noncurrent	3,699	12,995
Leasehold improvements	18,336	18,308
Furniture & fixtures	4,114	4,015
Computer equipment & hardware	4,539	4,528
Internal-use software	2,165	774
Total property & equipment	29,154	27,625
Less: accumulated depreciation	17,747	15,676
Property & equipment, net	11,407	11,949
Deferred commissions, net of current portion	26,240	19,638
Operating lease, right-of-use asset	8,729	9,503
Goodwill	121,404	2,299
Intangible assets, net	28,065	2,006
Other assets, net	1,098	64
Total assets	396,585	293,920
Accounts payable	6,933	4,988
Deferred revenue	140,536	95,740
Operating lease liability	3,948	3,499
Accrued wages & payroll related benefits	18,362	14,257
Accrued expenses & other

current liabilities	14,322	
Accrued expenses and other	11,260	
Total current liabilities	181,039	132,806
Deferred revenue, net of current portion	920	490
Long-term debt	55,000	
Operating lease liability, net of current portion	15,083	18,287
Other noncurrent liabilities	351	
Total liabilities	252,393	151,583
Class A common stock	4	4
Class B common stock	1	1
Additional paid-in capital	471,789	401,419
Treasury stock, at cost	35,113	32,733
Accumulated other comprehensive income (loss)	(77)	(369)
Retained earnings (accumulated deficit)	(292,412)	(225,985)
Total stockholders' equity (deficit)	144,192	142,337
Total Equity	144,192	

Recent Dividends:

- 1. Sprout Social Inc class B.**
No dividends paid.
- 2. Sprout Social Inc class A.**
No dividends paid.

Annual Dividends:

- 1. Sprout Social Inc class B.**
No dividends paid.
- 2. Sprout Social Inc class A.**
No dividends paid.

STABILLIS SOLUTIONS INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Liquefied natural gas ("LNG") product revenue	73,114,000		
Revenues	73,114,000	98,823,000	69,171,000
Cost of revenue		77,694,000	55,216,000
Change in unrealized loss on natural gas derivatives	(541,000)	878,000	
Cost of LNG product	54,919,000		
Selling, general & administrative	12,893,000	13,191,000	13,792,000
Gain from disposal of fixed assets	1,223,000	34,000	24,000
Depreciation expense	7,878,000	8,664,000	8,894,000
Impairment of right-of-use lease asset			376,000
Total operating expenses	73,926,000	100,393,000	78,254,000
Income (loss) from operations before equity income		(1,570,000)	(9,083,000)
Income from equity investment in foreign joint venture	1,897,000	1,881,000	2,146,000
Foreign joint venture operating related expenses		283,000	363,000
Net equity income from foreign joint venture operations	(206,000)	1,598,000	1,783,000
Interest expense, net	256,000	591,000	324,000
Interest expense, net - related parties		179,000	577,000

Other income (expense)	(176,000)	(185,000)	1,058,000
Interest income (expense) & other income (expense), net	(78,000)		
Total other income (expense)	(510,000)	(955,000)	157,000
Income (loss) from continuing operations before income tax expense	369,000	(927,000)	(7,143,000)
Current state income tax expense (benefit)	118,000	(108,000)	267,000
Current foreign income tax expense (benefit)	126,000	373,000	220,000
Income tax expense (benefit)	244,000	265,000	487,000
Net income (loss) from continuing operations	125,000	(1,192,000)	(7,630,000)
Income (loss) from discontinued operations, net		(1,994,000)	(168,000)
Net income (loss)	125,000	(3,186,000)	(7,798,000)
Weighted average shares outstanding - basic	18,496,376	18,289,839	17,504,190
Weighted average shares outstanding - diluted	18,508,700	18,289,839	17,504,190
Year end shares outstanding	18,573,391	18,420,067	17,691,268
Earnings (loss) per share from continuing operations - basic	\$0.01	\$(0.07)	\$(0.44)
Earnings per share-inc from discontinued oper	\$0.00		
Earnings (loss) per share from discontinued operations - basic	\$0.00	\$(0.11)	\$(0.01)
Net earnings (loss) per share - basic	\$0.01	\$(0.17)	\$(0.45)
Earnings (loss) per share from continuing operations - diluted	\$0.01	\$(0.07)	\$(0.44)
Earn per share-inc from discount oper - diluted	\$0.00		
Earnings (loss) per share from discontinued operations - diluted	\$0.00	\$(0.11)	\$(0.01)
Net earnings (loss) per share - diluted	\$0.01	\$(0.17)	\$(0.45)
Number of full time employees	104	99	
Number of part time employees		1	
Total number of employees	104	100	
Number of common stockholders	26	23	
Foreign currency translation adjustments		(895,000)	413,000

Restated to reflect the discontinued operations of Brazil Operations; As of March 9, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	5,374,000	11,451,000
Accounts receivable, other	7,752,000	
Total	169,000	

Inventories, net		205,000
Prepaid liquefied natural gas ("LNG")	1,012,000	
Prepaid insurance		990,000
Prepaid supplier expenses	132,000	286,000
Other receivables	159,000	254,000
Natural gas derivatives at fair value, current		347,000
Deposits	237,000	236,000
Other prepaid expenses & current assets	137,000	73,000
Prepaid expenses & other current assets	1,677,000	2,186,000
Assets held for sale		2,049,000
Total current assets	14,972,000	32,217,000
Liquefaction plants & systems		47,636,000
Real property & buildings	2,066,000	2,057,000
Vehicles & tanker trailers & equipment		52,647,000
Automobiles & trucks	49,689,000	
Machinery & shop equipment	48,523,000	
Computer & office equipment	458,000	470,000
Construction in progress	9,879,000	527,000
Leasehold improvements	31,000	31,000
Less accumulated depreciation	61,167,000	55,699,000
Property, plant & equipment, net	49,479,000	47,669,000
Goodwill	4,314,000	4,314,000
Investments in foreign joint ventures		11,606,000
Right-of-use assets	525,000	
Right-of-use assets & other noncurrent assets		774,000
Advances to & investments in foreign joint ventures	12,009,000	
Total assets	81,299,000	96,580,000
Accounts payable		4,474,000
Compensation & benefits	3,276,000	3,111,000
Professional fees	511,000	454,000
LNG fuel & transportation	3,632,000	6,549,000
Accrued interest	46,000	33,000
Customer deposits & prepayments		8,456,000
Other taxes payable	354,000	701,000
Other accrued liabilities	139,000	338,000
Accrued liabilities	8,355,000	19,642,000
Current portion of long-term notes payable	1,682,000	848,000
Current portion of long-term notes payable - related parties		2,435,000
Current portion of finance & operating lease obligations	164,000	133,000
Current portion of finance lease obligation	44,000	
Current portion of operating lease obligations	120,000	
Other accounts payable	1,518,000	
Customer Deposits	397,000	
Total current liabilities	11,719,000	27,532,000
Long-term notes payable, net of current portion & debt issuance costs	7,747,000	8,650,000
Long-term portion of finance & operating lease obligations	21,000	183,000
Long-term portion of operating lease obligations	21,000	
Other noncurrent liabilities		348,000
Total liabilities	19,487,000	36,713,000
Common stock	19,000	19,000
Additional paid-in capital	102,057,000	100,137,000

			Total operating expenses			Consolidated Balance Sheet, Years Ended Dec. 31 (\$):			
			2023	2022	2021	2023	2022	2021	
Accumulated other comprehensive income (loss)	(18,000)	82,000	182,979,000	164,213,000	84,321,000	Cash & cash equivalents	105,375,000	87,903,000	
Retained earnings (accumulated deficit)	(40,246,000)	(40,371,000)	(179,314,000)	(131,121,000)	(83,074,000)	Short-term investments	8,219,000	162,074,000	
Total stockholders' equity	61,812,000	59,867,000	14,977,000	10,468,000	17,395,000	Accounts receivable, gross	303,499,000	227,098,000	
Total Equity	61,812,000	...	59,121,000	...	(5,064,000)	Less: allowance for doubtful accounts	4,904,000	3,879,000	
Recent Dividends:			Change in fair value of warrants & embedded derivatives	(7,731,000)	...	3,424,000	Accounts receivable, net	302,848,000	223,219,000
1. Stabillis Solutions Inc series A redeemable convertible preferred.			Other income (expense), net	2,921,000	2,374,000	898,000	Work in process inventory	23,074,000	3,374,000
No dividends paid.			Total other income (expense), net	39,334,000	(8,094,000)	(18,137,000)	Raw materials	2,961,000	4,623,000
2. Stabillis Solutions Inc common.			Income (loss) before income taxes - domestic	(138,934,000)	(137,164,000)	(101,211,000)	Finished goods	629,000	376,000
No dividends paid.			Income (loss) before income taxes - foreign	(1,046,000)	(2,051,000)	...	Batteries	1,000	1,000
Annual Dividends:			Income (loss) before provision for (benefit from) income taxes	(139,980,000)	(139,215,000)	(101,211,000)	Inventory, net	26,665,000	8,374,000
1. Stabillis Solutions Inc series A redeemable convertible preferred.			Current income taxes - federal	...	(24,000)	...	Deferred costs with suppliers	...	43,159,000
No dividends paid.			Current income taxes - state	490,000	184,000	...	Deferred costs with suppliers	20,555,000	...
2. Stabillis Solutions Inc common.			Current income taxes - foreign	381,000	188,000	...	Prepaid expenses	5,971,000	5,676,000
No dividends paid.			Total current income taxes	...	348,000	...	Utility program deposits	153,000	80,000
STAR ALLIANCE INTERNATIONAL CORP			Deferred income taxes - federal	(294,000)	(12,448,000)	...	Due from related parties	73,000	74,000
Earnings, 6 mos. to Dec 31(Consol. - \$):			Deferred income taxes - state	(41,000)	(3,021,000)	...	Other current assets	3,106,000	2,196,000
	2023	2022	Deferred income taxes - foreign	(103,000)	(40,000)	...	Other current assets	9,303,000	8,026,000
Cost & expenses	311,356	8,137,095	Total deferred income taxes	...	(15,509,000)	...	Financing obligation receivables	4,253,000	...
Operating income	(311,356)	(8,137,095)	Provision for (benefit from) income taxes	433,000	(15,161,000)	...	Total current assets	472,965,000	532,755,000
Interest expense	175,121	203,510	Net income (loss)	(140,413,000)	(124,054,000)	(101,211,000)	Energy storage systems, net	74,418,000	90,757,000
Other income (expense), net	(480,386)	(1,218,806)	Net income (loss) attributable to common stockholders	...	(124,054,000)	(101,211,000)	Contract origination costs, net	11,119,000	11,697,000
Net before taxes	(966,863)	(9,559,411)	Weighted average shares outstanding - basic	155,583,957	153,413,743	105,561,139	Goodwill	547,205,000	546,649,000
Net income	(966,863)	(9,559,411)	Weighted average shares outstanding - diluted	155,583,957	153,413,743	105,561,139	Intangible assets, net	157,146,000	162,265,000
Earnings common share			Year end shares outstanding	155,932,880	154,540,197	144,671,624	Operating lease right-of-use assets	12,255,000	12,431,000
Primary	\$ (0.05)	\$ (0.05)	Net earnings (loss) per share - basic	\$(0.90)	\$(0.81)	\$(0.96)	Prepaid warranties & maintenance	...	33,686,000
Fully Diluted	\$ (0.05)	\$ (0.05)	Net earnings (loss) per share - diluted	\$(0.90)	\$(0.81)	\$(0.96)	Unbilled receivables, net	...	9,409,000
Common Shares:			Full-Time Employees (Period End)	624	Deferred costs with suppliers	...	7,720,000
Full Diluted	331,583,394	177,936,989	Total number of employees	624	660	213	Receivable from special purpose entities ("SPEs")	...	2,543,000
Year-end	471,086,221	191,849,360	Number of common stockholders	93	108	176	Self-generation incentive program deposits	...	688,000
STEEL CONNECT INC			EPS - Basic - excluding Extraordinary Items	Investment in variable interest entities ("VIEs")	...	1,971,000
Earnings, 6 mos. to Jan 31(Consol. - \$000):			EPS - Diluted - excluding Extraordinary Items	Energy storage systems, gross	145,336,000	...
	2024	2023	Applicable to Common - Total	\$(0.90)	Energy storage systems-Accumulated depreciation	70,918,000	...
Total revenues	84,386	102,140	Applicable to Common - Total	\$(0.90)	Property & equipment, net	...	2,158,000
Cost & expenses	79,091	95,658	Reclassified to conform with 2022 presentation; Shares increased due to merger and PIPE financing, conversion of warrants and convertible notes into common stock upon merger, exchange of warrants into common stock, public warrants exercises; As of February 9, 2023; As of February 17, 2022	Project assets	...	3,208,000
Operating income	3,527	6,482					Other noncurrent assets	...	3,956,000
Interest income	6,718	476					Other noncurrent assets	81,869,000	65,339,000
Interest expense	496	1,674					Total assets	1,356,977,000	1,421,893,000
Other income (expense), net	898	(74)					Accounts payable	78,277,000	83,831,000
Net before taxes	10,647	5,210					Accrued payables	67,543,000	83,022,000
Income taxes	865	779					Accrued interest - notes payable	...	311,000
Income contin. oper.	4,431	4,431					Other accrued liabilities	6,656,000	1,925,000
Net income	19,564	4,431					Accrued liabilities	76,873,000	85,258,000
Balance for common	2,077	3,357					Accrued payroll	14,372,000	12,466,000
Earnings common share							Financing obligation, current portion	...	15,720,000
Primary	\$0.33	\$0.56					Deferred revenue, current portion	53,997,000	64,311,000
Fully Diluted	\$0.33	\$0.56					System advances	...	266,000
Common Shares:							Lease liabilities - current portion	...	2,574,000
Full Diluted	26,075	6,497					Due to related parties	...	687,000
Year-end	6,286	6,513					Other current liabilities	...	1,885,000
STEM INC							Other current liabilities	12,726,000	5,412,000
Annual Report							Financial Liabilities - Short-Term	14,835,000	...
Consolidated Income Statement, Years Ended Dec. 31 (\$):							Accrued interest	2,674,000	...
	2023	2022					Total current liabilities	251,080,000	266,998,000
							Deferred revenue, noncurrent	88,650,000	73,763,000
Services & other revenue	62,548,000	52,143,000					Asset retirement obligation	4,052,000	4,262,000
Hardware revenue	398,967,000	310,837,000					Notes payable, noncurrent	523,633,000	1,603,000
Total revenue	461,515,000	362,980,000							
Service revenue	50,298,000	...							
Cost of services & other revenue	43,153,000	28,177,000							
Cost of hardware revenue	407,552,000	286,735,000							
Total cost of revenue	457,850,000	329,888,000							
Gross margin	3,665,000	33,092,000							
Sales & marketing expenses	51,556,000	48,882,000							
Research & development expenses	56,508,000	38,303,000							
General & administrative expenses	74,915,000	77,028,000							

Convertible notes, noncurrent	447,909,000		extinguishment of debt		2,183,000	& benefits	1,222,000	1,381,000	
Financing obligation, noncurrent	63,867,000		Deferred income taxes expenses (benefit) - federal	(2,108,000)		Accrued licenses & maintenance fees	484,000	484,000	
Lease liabilities, noncurrent	10,455,000	10,962,000	Deferred income taxes expenses (benefit) - state & local	(773,000)		Accrued warranties	107,000	163,000	
Other liabilities	416,000	362,000	Valuation allowance	2,881,000		Accrued taxes		47,000	
Financial Liabilities - Long-Term	52,010,000		Net income (loss)	(20,713,000)	(18,292,000)	(10,716,000)	Accrued investigational sites		101,000
Total liabilities	930,296,000	869,726,000	Cumulative dividend on convertible preferred stock	1,343,000	1,343,000	1,345,000	Deferred contract obligation	1,045,000	1,045,000
Common stock	16,000	15,000	Net income (loss) available to common stockholders	(22,056,000)	(19,635,000)	(12,061,000)	Other accrued liabilities		136,000
Additional paid-in capital	1,198,716,000	1,185,364,000	Weighted average shares outstanding - basic	80,702,358	76,061,183	75,558,233	Less: long term accrued liabilities		(51,000)
Accumulated other comprehensive income (loss)	(42,000)	(1,672,000)	Weighted average shares outstanding - diluted	80,702,358	76,061,183	75,558,233	Accrued liabilities - Balancing value	114,000	
Retained earnings (accumulated deficit)	(772,494,000)	(632,081,000)	Year end shares outstanding	80,945,682	74,870,444	74,614,225	Accrued liabilities	2,972,000	3,306,000
Total Stem, Inc.'s stockholders' equity	551,626,000	552,167,000	Net income (loss) per share - basic	\$(0.27)	\$(0.26)	\$(0.16)	Deferred revenue	6,657,000	7,342,000
Non-controlling interests	541,000		Net income (loss) per share - diluted	\$(0.27)	\$(0.26)	\$(0.16)	Current portion of operating lease liabilities	428,000	373,000
Total stockholders' equity	426,681,000		Full-Time Employees (Period End)	122			Total current liabilities	13,247,000	14,291,000

□ Includes due from related parties - other current assets: \$74,000

Recent Dividends:

1. Stem Inc class B common.

No dividends paid.

2. Stem Inc common.

No dividends paid.

3. Stem Inc class A common.

No dividends paid.

Annual Dividends:

1. Stem Inc class B common.

No dividends paid.

2. Stem Inc common.

No dividends paid.

3. Stem Inc class A common.

No dividends paid.

STEREOTAXIS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Systems	8,058,000		
Disposables Service And Accessories	3,853,000		
Systems revenue	6,845,000	11,168,000	
Disposables, service & accessories revenue	18,032,000	21,302,000	22,867,000
Sublease revenue			986,000
Systems	8,739,000		
Total revenue	26,771,000	28,147,000	35,021,000
Cost of revenue - systems	5,802,000	7,527,000	
Cost of revenue - disposables, service & accessories	3,875,000	3,276,000	
Cost of revenue - sublease			986,000
Total cost of revenue	11,911,000	9,677,000	11,789,000
Gross margin	14,860,000	18,470,000	23,232,000
Research & development	10,273,000	10,558,000	10,199,000
Sales & marketing	12,376,000	12,325,000	11,948,000
General & administrative	14,050,000	14,363,000	13,973,000
Total operating expenses	36,699,000	37,246,000	36,120,000
Operating income (loss)	(21,839,000)	(18,776,000)	(12,888,000)
Other income (expense)	30,000		
Interest income (expense), net	1,096,000		
Interest income	484,000		(11,000)
Gain on			

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	19,818,000	8,586,000
Restricted cash - current	525,000	525,000
Short-term investments		19,844,000
Accounts receivable, gross	4,494,000	5,325,000
Less: allowance	672,000	235,000
Accounts receivable, net	3,822,000	5,090,000
Raw materials	5,918,000	6,556,000
Work in process	1,034,000	530,000
Finished goods	3,413,000	2,697,000
Reserve for excess & obsolescence	1,939,000	1,907,000
Inventories, net	8,426,000	7,876,000
Prepaid expenses		605,000
Prepaid commissions		187,000
Deposits		669,000
Other assets		72,000
Less: noncurrent prepaid expenses & other assets		(208,000)
Total current assets	33,267,000	43,246,000
Equipment	4,269,000	4,393,000
Leasehold improvements	2,911,000	2,692,000
Construction in process		204,000
Property & equipment, gross	7,180,000	7,289,000
Less: accumulated depreciation	3,876,000	3,458,000
Property & equipment, net	3,304,000	3,831,000
Restricted cash	219,000	744,000
Operating lease right-of-use assets	4,982,000	5,384,000
Prepaid & other non-current assets	137,000	208,000
Total assets	41,909,000	53,413,000
Accounts payable	3,190,000	3,270,000
Accrued salaries, bonus		

□ Reclassified to conform with 2022 presentation; □ Approximately; □ As of February 28, 2023; □ As of February 28, 2022

Accrued licenses & maintenance fees	484,000	484,000
Accrued warranties	107,000	163,000
Accrued taxes		47,000
Accrued investigational sites		101,000
Deferred contract obligation	1,045,000	1,045,000
Other accrued liabilities		136,000
Less: long term accrued liabilities		(51,000)
Accrued liabilities - Balancing value	114,000	
Accrued liabilities	2,972,000	3,306,000
Deferred revenue	6,657,000	7,342,000
Current portion of operating lease liabilities	428,000	373,000
Total current liabilities	13,247,000	14,291,000
Long-term deferred revenue	1,637,000	1,654,000
Operating lease liabilities	5,062,000	5,488,000
Other liabilities	43,000	51,000
Total liabilities	19,989,000	21,484,000
Convertible preferred stock, series A		5,583,000
Convertible preferred stock, series B	5,577,000	6,000
Common stock	81,000	75,000
Additional paid in capital	554,148,000	543,438,000
Treasury stock	206,000	206,000
Retained earnings (accumulated deficit)	(537,680,000)	(516,967,000)
Total stockholders' equity (deficit)	21,920,000	26,346,000
Total Equity	21,920,000	

Recent Dividends:

1. Stereotaxis Inc common.

No dividends paid.

2. Stereotaxis Inc series A convertible preferred.

No dividends paid.

3. Stereotaxis Inc series B convertible preferred.

No dividends paid.

Annual Dividends:

1. Stereotaxis Inc common.

No dividends paid.

2. Stereotaxis Inc series A convertible preferred.

No dividends paid.

3. Stereotaxis Inc series B convertible preferred.

No dividends paid.

SUNDANCE STRATEGIES, INC

Earnings, 9 mos. to Dec 31 (Consol. - \$):

	2023	2022
Cost & expenses	371,839	524,649
Operating income	(371,839)	(524,649)
Interest expense	316,480	281,303
Other income (expense), net	(213,920)	(418,436)
Net before taxes	(902,239)	(1,224,388)
Net income	(902,239)	(1,224,388)
Earnings common share		
Primary	\$(0.02)	\$(0.03)
Fully Diluted	\$(0.02)	\$(0.03)
Common Shares:		
Full Diluted	41,693,714	41,408,441
Year-end	42,258,441	41,408,441

SUNHYDROGEN INC

Earnings, 6 mos. to Dec 31 (Consol. - \$):

	2023	2022
Cost & expenses	2,241,832	5,679,214
Deprec., depl. & amort.		21,440
Operating income	(2,263,612)	(5,700,654)
Interest expense	3,405	45,050
Other income (expense), net	(1,021,762)	9,048,972
Gains or losses	(188,040)	397,727
Net before taxes	(3,476,819)	
Net income	(3,476,819)	3,700,995
Balance for common		3,700,995
Earnings common share		

Number of full time employees.....	984	921	823
Number of common stockholders.....	11	11	19
Foreign currency translation adjustments.....	...	(112,000)	...
Total number of employees.....	984

□ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents.....	103,929,000	181,673,000
Accounts receivable, gross.....	67,642,000	42,157,000
Less: allowance for doubtful accounts.....	550,000	4,000
Accounts & Notes Receivable - Trade - Net.....	67,092,000	...
Accounts receivable, net.....	...	42,153,000
Prepaid expenses & other assets.....	9,479,000	12,553,000
Total current assets.....	180,500,000	236,379,000
Specialty rental assets, net.....	349,064,000	357,129,000
Land.....	31,111,000	28,483,000
Buildings & leasehold improvements.....	901,000	769,000
Machinery & office equipment.....	1,820,000	1,581,000
Other property, plant & equipment.....	...	7,341,000
Software & other.....	8,589,000	...
Specialty rental assets, net - Balancing value.....	754,846,000	...
Total other property, plant & equipment, gross.....	42,421,000	38,174,000
Less: accumulated depreciation - other property, plant & equipment.....	7,790,000	6,276,000
Right of Use Tangible Assets - Capital/Finance Lease - Accumulated Depreciation.....	405,782,000	...
Other property, plant & equipment, net.....	34,631,000	31,898,000
Operating lease right-of-use assets, net.....	19,698,000	27,298,000
Goodwill.....	41,038,000	41,038,000
Other intangible assets, net.....	66,282,000	75,182,000
Deferred financing costs revolver, net.....	2,479,000	896,000
Other non-current assets.....	661,000	1,907,000
Total assets.....	694,353,000	771,727,000
Accounts payable.....	20,926,000	17,563,000
Employee accrued compensation expense.....	9,583,000	11,873,000
Other accrued liabilities.....	20,656,000	18,230,000
Accrued interest on debt.....	3,413,000	9,539,000
Accrued liabilities.....	33,652,000	39,642,000
Deferred revenue & customer deposits.....	675,000	120,040,000
Current portion of operating lease obligations.....	11,914,000	12,516,000
Current portion of finance lease & other financing obligations.....	1,369,000	1,135,000
Deferred revenue and customer deposits.....	1,794,000	...
Total current liabilities.....	70,330,000	190,896,000
Deferred underwriting compensation.....	3,675,000	...
Long-term debt - principal amount.....	178,093,000	334,500,000
Less: unamortized original issue discount.....	...	(971,000)
Less: unamortized term loan deferred financing costs.....	...	(4,681,000)

Long-term debt, net.....	328,848,000	...
Long-term finance lease & other financing obligations.....	1,024,000	1,088,000
Long-term operating lease obligations.....	8,426,000	11,104,000
Other non-current liabilities.....	...	6,309,000
Deferred revenue & customer deposits.....	...	5,479,000
Deferred tax liability.....	53,074,000	15,172,000
Asset retirement obligations.....	2,424,000	2,247,000
Warrant liabilities.....	...	9,737,000
Total liabilities.....	317,046,000	570,880,000
Common stock.....	10,000	10,000
Common stock in treasury at cost.....	23,559,000	23,559,000
Additional paid-in capital.....	142,379,000	139,287,000
Accumulated other comprehensive income (loss).....	(2,638,000)	(2,574,000)
Retained earnings (accumulated deficit).....	261,115,000	87,683,000
Total stockholders' equity.....	377,307,000	200,847,000
Total Equity.....	377,307,000	...

Recent Dividends:

1. Target Hospitality Corp class A ordinary subject to possible redemption.

No dividends paid.

2. Target Hospitality Corp class B ordinary.

No dividends paid.

3. Target Hospitality Corp common.

No dividends paid.

4. Target Hospitality Corp class A ordinary.

No dividends paid.

Annual Dividends:

1. Target Hospitality Corp class A ordinary subject to possible redemption.

No dividends paid.

2. Target Hospitality Corp class B ordinary.

No dividends paid.

3. Target Hospitality Corp common.

No dividends paid.

4. Target Hospitality Corp class A ordinary.

No dividends paid.

TECHPRECISION CORP

Earnings, 6 mos. to Sep 30 (Consol. - \$):

	2023	2022
Net Sales.....	15,341,326	15,599,004
Cost & expenses.....	16,518,479	16,244,436
Operating income.....	(1,177,153)	(645,432)
Interest expense.....	242,639	167,375
Other income (expense), net.....	40,876	664,381
Net before taxes.....	(1,378,916)	(148,426)
Net income.....	(1,055,788)	(110,221)
Earnings common share		
Primary.....	\$(0.12)	\$.....
Fully Diluted.....	\$(0.12)	\$.....
Common Shares:		
Full Diluted.....	8,667,298	8,580,707
Year-end.....	8,737,432	8,610,990

TEMPEST THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):	2023	2022	2021
			(revised)
Research & development outside services.....	17,498	14,745	11,355
Compensation expense.....	...	4,084	2,869
Stock-based compensation expense.....	...	517	303
Consulting & professional services.....	...	1,448	1,634

Other expenses.....	1,733	1,005
Research & development expenses.....	22,527	17,166
General & administrative.....	11,659	12,113
Income (loss) from operations.....	(29,157)	(34,640)
Interest income.....	1,115	...
Interest expense.....	1,449	1,618
Other income (expense), net.....	1,115	...
Interest income & other income (expenses), net.....	...	549
Total other income (expenses), net.....	(334)	(1,069)
Income (loss) before income tax.....	(29,491)	...
Loss from operations.....	(29,491)	...
Net income (loss).....	(29,491)	(35,709)
Weighted average shares outstanding - basic.....	15,416	11,549
Weighted average shares outstanding - diluted.....	15,416	11,549
Year end shares outstanding.....	22,045	10,519
Net earnings (loss) per share - basic.....	\$(1.91)	\$(3.09)
Net earnings (loss) per share - diluted.....	\$(1.91)	\$(3.09)
Number of full time employees.....	17	...
Total number of employees.....	17	19
Number of Common Shareholders.....	78	...
Number of stockholders.....	...	83
Earnings per share from continuing operations.....	\$(1.91)	...
Earnings per share from continuing operations.....	\$(1.91)	...

□ Reclassified to conform with 2022 presentation; □ Shares increased due to the effect issuance of shares for exercised of options; □ Shares increased due to the effect issuance of shares for stock options exercised, conversion of preferred stock, for cash and Millendo shareholders; □ As is; □ As of March 16, 2023; □ Reclassified to conform with 2019 presentation

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents.....	39,230	31,230
Insurance recovery of legal settlement.....	...	450
Prepaid expenses.....	700	703
Prepaid research & development costs.....	337	304
Other current assets.....	96	263
Prepaid expenses & other current assets.....	1,133	1,270
Total current assets.....	40,363	32,950
Computer equipment & software.....	328	168
Furniture & fixtures.....	...	310
Lab equipment.....	1,133	1,061
Leasehold improvements.....	235	882
Computer equipment and software.....	169	...
Property & equipment.....	1,865	2,421
Less: accumulated depreciation.....	1,025	1,361
Property & equipment - net.....	840	1,060
Operating lease right-of-use assets.....	9,952	11,650
Other noncurrent assets.....	448	429

Total assets	51,603	46,089	
Current portion of debt	4,285	...	
Accounts payable	845	1,108	
Accrued legal settlement	...	450	
Accrued professional & consultant fees	1,673	...	
Accrued other liabilities	...	756	
Accrued clinical trial liability	...	2,205	
Accrued expenses	...	2,961	
Current operating lease liabilities	952	1,413	
Accrued compensation	1,543	1,248	
Interest payable	113	97	
Total current liabilities	9,411	7,277	
Loan payable	6,264	10,371	
Operating lease liabilities, less current portion	9,160	10,330	
Total liabilities	24,835	27,978	
Common stock	22	11	
Additional paid-in capital	192,009	153,872	
Retained earnings (accumulated deficit)	(165,263)	(135,772)	
Total stockholders' equity (deficit)	26,768	18,111	
Total stockholders' equity (deficit)	26,768	...	

[□] Net of discount and issuance costs - loan payable: \$454,000

Recent Dividends:

1. Tempest Therapeutics Inc common.

No dividends paid.

Annual Dividends:

1. Tempest Therapeutics Inc common.

No dividends paid.

TG THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Product revenue, net	92,005,000	2,633,000	6,537,000
License revenue	141,657,000	152,000	152,000
Total revenue	233,662,000	2,785,000	6,689,000
Cost of product revenue	14,131,000	265,000	790,000
Research & development - noncash compensation	13,010,000	13,224,000	24,047,000
Research & development - other research & development	63,182,000	112,128,000	198,532,000
Total research & development	76,192,000	125,352,000	222,579,000
Selling, general & administrative - noncash compensation	24,923,000	5,961,000	37,227,000
Other selling, general & administrative	97,783,000	64,046,000	90,863,000
Total selling, general & administrative	122,706,000	70,007,000	128,090,000
Total costs & expenses	213,029,000	195,624,000	351,459,000
Operating income (loss)	20,633,000	(192,839,000)	(344,770,000)
Interest expense	12,615,000	10,191,000	5,638,000
Other income	5,044,000	4,695,000	2,307,000
Total other income (expense), net	(7,571,000)	(5,496,000)	(3,331,000)
Income taxes	390,000
Net income (loss)	12,672,000	(198,335,000)	(348,101,000)
Weighted average shares outstanding - basic	141,955,112	135,411,258	132,222,753
Weighted average shares outstanding			

- diluted	148,508,465	135,411,258	132,222,753
Year end shares outstanding	151,424,289	146,385,388	143,250,734
Net income (loss) per share - basic	\$0.09	\$(1.46)	\$(2.63)
Net income (loss) per share - diluted	\$0.09	\$(1.46)	\$(2.63)
Number of full time employees	...	226	286
Number of common stockholders	214	218	220
Earnings per share from continuing operations	\$0.09
Earnings per share from continuing operations	\$0.09

[□] As of February 16, 2023; [□] As of February 25, 2022; [□] As of February 17, 2023; [□] As of February 23, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	92,933,000	102,304,000
Accounts receivable, net	51,093,000	...
Short-term investment, available for sale, at market	124,575,000	...
Short-term investment securities	...	59,374,000
Prepaid research & development	4,183,000	4,237,000
Other current assets	5,336,000	2,359,000
Work in Process	31,243,000	...
Finished Goods	1,999,000	...
Raw Materials	6,582,000	...
Inventories	39,823,000	...
Total current assets	317,943,000	168,274,000
Restricted cash	1,285,000	1,273,000
Long-term investment securities	...	12,404,000
Leasehold interest, net	...	1,627,000
Equipment, net	...	307,000
Right of use assets	8,050,000	8,888,000
Leasehold interest, net	1,415,000	...
Property, plant & equipment, net	95,000	...
Goodwill	799,000	799,000
Total assets	329,587,000	193,572,000
Accounts payable & accrued expenses	38,471,000	42,019,000
Other current liabilities	1,631,000	1,169,000
Lease liability - current portion	1,446,000	1,581,000
Accrued compensation	12,172,000	8,432,000
Total current liabilities	53,720,000	53,201,000
Deferred revenue, net of current portion	6,016,000	305,000
Loan payable - non-current	100,118,000	71,135,000
Lease liability - non current	9,231,000	10,344,000
Total liabilities	169,085,000	134,985,000
Common stock	151,000	146,000
Additional paid-in capital	1,674,946,000	1,585,708,000
Treasury stock, at cost	234,000	234,000
Retained earnings (accumulated deficit)	...	(1,527,033,000)
Accumulated deficit	(1,514,361,000)	...
Total stockholders' equity (deficiency)	160,502,000	58,587,000
Total equity	160,502,000	...

Recent Dividends:

1. TG Therapeutics Inc common.

No dividends paid.

2. TG Therapeutics Inc series A convertible preferred.

No dividends paid.

3. TG Therapeutics Inc preferred.

No dividends paid.

Annual Dividends:

1. TG Therapeutics Inc common.

No dividends paid.

2. TG Therapeutics Inc series A convertible preferred.

No dividends paid.

3. TG Therapeutics Inc preferred.

No dividends paid.

THARIMMUNE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
			(revised)
Research & development	3,559,635	2,278,424	1,842,803
General & administrative	5,895,585	4,603,514	1,365,214
Total operating expenses	9,455,220	6,881,938	3,208,017
Income (loss) from operations	(9,455,220)	(6,881,938)	(3,208,017)
Interest expense	16,505	1,591,244	831,277
Change in redemption value	1,832,651
Interest income	152,631
Total other income (expenses), net	136,126	(1,591,244)	1,001,374
Net income (loss)	(9,319,094)	(8,473,182)	(2,206,643)
Weighted average shares outstanding - basic	1,305,437	452,672	254,293
Weighted average shares outstanding - diluted	1,305,437	452,672	254,293
Year end shares outstanding	11,739,676	460,566	254,293
Net income (loss) per share - basic	\$(7.14)	\$(18.75)	\$(8.75)
Net income (loss) per share - diluted	\$(7.14)	\$(18.75)	\$(8.75)
Number of full time employees	...	1	1
Number of part time employees	...	1	1
Number of common stockholders	22	21	25
Income from cont operations before income tax	(9,319,094)

[□] Adjusted for 1- for -25 stock split, November 21, 2023; [□] Shares increased due to the effect of stock options exercised, services agreement, initial public offering, and conversion of related-party convertible notes; [□] As of March 10, 2023; [□] As of March 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash and cash equivalents	10,935,352	...
Cash	...	6,510,534
Prepaid expenses & other current assets	11,041	178,094
Total current assets	10,946,393	6,688,628
Total assets	10,946,393	6,688,628
Accounts payable	908,577	954,505
Accrued expenses	906,469	190,468
Total current liabilities	1,815,046	1,144,973
Total liabilities	1,815,046	1,144,973
Common stock	1,175	1,160
Additional paid-in capital	33,903,663	20,996,892
Retained earnings (accumulated deficit)	(24,703,526)	(15,384,432)
Treasury stock, at cost	69,965	69,965
Total stockholders' equity (deficit)	9,131,347	5,543,655
Total Equity	9,131,347	...

Recent Dividends:

1. Tharimmune Inc common.

No dividends paid.

Annual Dividends:

1. Tharimmune Inc common.

No dividends paid.

THC THERAPEUTICS INC (NEW)

Annual Report

Consolidated Income Statement, Years Ended Jul. 31 (\$):

	2023	2022	2021 (revised)
Professional fees	148,496	178,897	253,838
Consulting fees	87,170	966,533	205,170
Salaries & wages	187,749	462,317	267,975
General & administrative	70,497	138,281	212,994
Total operating expenses	493,912	1,746,028	939,977
Income (loss) from operations	(493,912)	(1,746,028)	(939,977)
Gain (loss) on derivative liability	184,143	327,501	(393,718)
Impairment expense	(2,310)
Interest expense	79,577	100,402	551,750
Total other income (expense)	106,876	227,099	(945,468)
Income (loss) before provision for income taxes	(387,036)
Net income (loss)	(387,036)	(1,518,929)	(1,885,445)
Weighted average shares outstanding - basic	32,806,009	33,244,334	23,659,514
Weighted average shares outstanding - diluted	32,806,009
Year end shares outstanding	34,146,149	33,891,671	29,287,337
Net income (loss) per common share - basic	\$(0.01)	\$(0.05)	\$(0.08)
Net income (loss) per common share - diluted	\$(0.01)
Number of full time employees	1	1	1
Total number of employees	1
Number of common shareholders	37	37	37
Basic EPS Excluding ExtraOrdinary Items	\$(0.01)
Diluted EPS Excluding ExtraOrd	\$(0.01)

□ Shares increased due to the effect of shares issued for conversion of convertible debt and common stock issued for cash

Consolidated Balance Sheet, Years Ended Jul. 31 (\$):

	2023	2022
Cash	10	32
Prepaid expenses	970	40,656
Inventory	...	25
Total current assets	980	40,713
Physical silver assets	...	152,785
Hydrinator prototype	27,100	27,100
Float spa & associated equipment	60,000	60,000
Office furniture & equipment	532	532
Less accumulated depreciation	87,632	87,632
Intangible assets, net	12,010	13,403
Total assets	12,990	206,901
Accounts payable & accrued liabilities	1,936,637	1,580,689
Accrued expenses - related party	5,180	16,807
Advances from related parties	59,648	144,632
Notes payable	25,000	...
Notes payable, net	...	25,000
Convertible notes payable	576,028	576,028
Convertible notes payable - related party	130,761	200,000
Derivative liability	489,569	673,712
Total current liabilities	3,222,823	3,216,868
License fee payable, net

of current portion	100,000	...
Total liabilities	...	3,216,868
Commitments & contingencies	...	100,000
Common stock	32,746	32,492
Preferred A stock	226	226
Stock payable	752,228	622,278
Stock receivable	(6,902,000)	(6,902,000)
Additional paid-in capital	41,230,912	41,173,946
Retained earnings (accumulated deficit)	(38,423,945)	(38,036,909)
Total stockholders' equity (deficit)	(3,309,833)	(3,109,967)
Total stockholders' equity (deficit)	(3,309,833)	...

Recent Dividends:

1. THC Therapeutics Inc (New) series A preferred.

No dividends paid.

2. THC Therapeutics Inc (New) common.

No dividends paid.

3. THC Therapeutics Inc (New) series C preferred.

No dividends paid.

4. THC Therapeutics Inc (New) series B preferred.

No dividends paid.

Annual Dividends:

1. THC Therapeutics Inc (New) series A preferred.

No dividends paid.

2. THC Therapeutics Inc (New) common.

No dividends paid.

3. THC Therapeutics Inc (New) series C preferred.

No dividends paid.

4. THC Therapeutics Inc (New) series B preferred.

No dividends paid.

THC THERAPEUTICS INC (NEW)

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, Gries & Associates, LLC, as it appeared in Co.'s 2023 10-K: "Opinion on the Financial Statements We have audited the accompanying balance sheets of THC Therapeutics, Inc. (the Company), as of July 31, 2023 and 2022, and the related consolidated statements of operations, statements of stockholders' deficit, and cash flows for each of the two years then ended, and the related notes and schedules (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of July 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America. Going Concern Uncertainty As shown in the financial statements, the Company incurred net loss of \$387,036 during the year ended July 31, 2023 and accumulated losses of \$38,423,945. These factors create an uncertainty as to the Company's ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the success of raising additional capital through the issuance of common stock and the ability to generate sufficient operating revenue. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern."

THRYV HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

	2023	2022	2021 (revised)
Revenues	916,961	1,202,388	1,113,382
Revenue	916,961
Gross profit	578,247	780,382	705,339
Cost of services	338,714	422,006	408,043
Sales & marketing expense	300,538	362,432	357,813
General & administrative expense	208,880	216,406	153,902
Impairment charges	...	102,222	3,611
Impairment charges-Goodwill	268,846
Total operating expenses	778,264	681,060	515,326
Operating income (loss)	(200,017)	99,322	190,013
Interest expense	61,728	56,902	48,867

Interest expense, related party	...	3,505	17,507
Other components of net periodic pension benefit (cost)	2,719	44,612	14,829
Other income (expense)	(1,518)	15,448	(4,154)
Income (loss) before income tax expense (benefit) - U.S.	(278,741)	68,706	168,965
Income (loss) before income tax expense (benefit) - foreign	18,197	30,269	(34,651)
Income (loss) before income tax expense (benefit)	(260,544)	98,975	134,314
Current federal income taxes	1,870	42,065	31,690
Current state & local income taxes	1,542	6,579	5,852
Current foreign income taxes	8,238	11,096	14,494
Total current income taxes	11,650	59,740	52,036
Deferred federal income taxes	(7,789)	(9,096)	4,378
Deferred state & local income taxes	826	3,439	(2,560)
Deferred foreign income taxes	(5,936)	(9,456)	(21,117)
Total deferred income taxes	(12,899)	(15,113)	(19,299)
Income tax expense (benefit)	(1,249)	44,627	32,737
Net income (loss)	(259,295)	54,348	101,577

Weighted average shares outstanding - basic	34,723	34,336	33,607
Weighted average shares outstanding - diluted	34,723	36,506	36,496
Year end shares outstanding	35,303	34,594	34,145
Earnings (loss) per common share - basic	\$(7.47)	\$1.58	\$3.02
Earnings (loss) per common share - diluted	\$(7.47)	\$1.49	\$2.78
Part-Time Employees (Period End)	61
Full-Time Employees (Period End)	2,988
Total number of employees	3,049	2,955	2,630
Number of common stockholders	41	50	51
Foreign currency translation adjustments	...	(8,214)	(8,047)
Basic EPS Excluding ExtraOrdinary Items	\$(7.47)
Diluted EPS Excluding ExtraOrd	\$(7.47)

□ As is; □ As of February 21, 2023; □ As of March 11, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	18,216	16,031
Accounts receivable, gross	220,429	299,464
Less: allowance for credit losses	14,926	14,766
Accounts Receivable, net - Balancing value	205,503	...
Accounts receivable, net	...	284,698
Contract assets, net	2,909	2,583
Taxes receivable	3,085	11,553

Prepaid expenses	17,771	25,092	2023	2022	2021	Mining equipment	...	58,646	
Indemnification asset	...	26,495			(revised)	Property & equipment, gross	...	182,605	
Other current assets	2,662	11,864	Gain on mineral interest	...	500,000	Less: accumulated depreciation	...	182,053	
Deferred costs	16,722	...	Management service income	...	300,000	Equipment, net	...	552	
Total current assets	266,868	378,316	Total revenues	...	300,000	Total property & equipment	332,509	280,885	
Capitalized software	154,590	129,086	Exploration expenses	87,702	156	9,842	Right to use asset	21,629	...
Computer & data processing equipment	39,077	40,765	Legal & accounting expense	115,763	113,717	85,309	Total assets	986,388	1,722,328
Other fixed assets & capitalized software	194,981	1,345	Management & administrative expense	410,674	630,844	428,982	Accounts payable & other accrued liabilities	39,050	27,599
Other	1,314	...	Depreciation	552	1,553	2,849	Accrued related party liability	...	146,685
Fixed assets & capitalized software, gross	...	171,196	Total operating expenses	614,691	746,270	526,982	Operating lease liability
Less accumulated depreciation & amortization	156,382	128,862	Net operating income (loss)	(614,691)	(446,270)	273,018	- current	18,612	...
Fixed assets & capitalized software, net	38,599	42,334	Interest expense, related parties	634	Advance from BeMetals	...	5,433
Goodwill	302,400	566,004	Unrealized gain (loss) on investment	(179,604)	(782,072)	(941,079)	Deferred compensation	1,104,625	1,041,500
Intangible assets, net	18,788	34,715	Reclamation expense	(27,495)	16,250	...	Accrued legal fees	136,685	...
Deferred tax assets	128,051	113,859	Gain (loss) on sale of investment	(47,091)	...	92,685	Total current liabilities	1,298,972	1,221,217
Other assets	28,464	42,649	Other income (expenses)	1,664	790	9,214	Operating lease liability - long-term	3,532	...
Total assets	783,170	1,177,877	Total other income (expense)	(197,536)	(797,532)	(839,814)	Accrued reclamation costs	81,250	81,250
Accrued taxes	8,832	...	Net income (loss) before income taxes	(812,227)	(1,243,802)	(566,796)	Total liabilities	1,383,754	1,302,467
Accrued expenses	37,889	...	Net loss	(812,227)	Common stock	60,856	60,856
Accounts payable	10,348	18,972	Net income (loss) - noncontrolling interest in Owyhee Gold Trust	(5,000)	(937)	(5,000)	Additional paid-in capital	6,564,947	6,564,947
Accrued salaries & related expenses	57,357	60,784	Net income (loss) - Thunder Mountain Gold, Inc.	(817,227)	(1,244,739)	(571,796)	Less treasury stock, at cost	24,200	24,200
Accrued severance	...	1,260	Weighted average shares outstanding - basic	60,855,579	60,855,579	60,384,839	Retained earnings (accumulated deficit)	(7,168,608)	(6,351,381)
Accrued taxes	...	9,799	Weighted average shares outstanding - diluted	60,855,579	60,855,579	60,384,839	Total Thunder Mountain Gold, Inc stockholders' equity (deficit)	(567,005)	250,222
Accrued expenses	...	52,313	Year end shares outstanding	60,855,579	60,855,579	60,855,579	Non-controlling interests	169,639	169,639
Accrued service credits	1,825	2,654	Net income (loss) per common share - basic	\$(0.01)	\$(0.02)	\$(0.01)	Total stockholders' equity (deficit)	(397,366)	419,861
Accrued liabilities	...	126,810	Net income (loss) per common share - diluted	\$(0.01)	\$(0.02)	\$(0.01)			
Current portion of unrecognized tax benefits	23,979	31,919	Full-Time Employees (Period End)	3			
Contract liabilities	44,558	41,854	Total number of employees	3	3	3			
Current portion of long-term debt	70,000	70,000	Number of common stockholders	1,168	1,272	1,272			
Other current liabilities	8,402	10,937	Basic EPS Excluding ExtraOrdinary Items	\$(0.01)			
Accrued liabilities - Balancing value	105,903	...	Diluted EPS			
Total current liabilities	263,190	300,492	Excluding ExtraOrd Items	\$(0.01)			
Term loan, net	...	345,256							
Asset-based lending facility	48,845	54,554							
Pension obligations, net	69,388	72,590							
Deferred tax liabilities	...	513							
Other liabilities	18,995	22,205							
Total long-term liabilities	367,280	495,118							
Common stock, net	627	613							
Additional paid-in capital	1,151,259	1,105,701							
Treasury stock	485,793	468,879							
Retained earnings (deficit)	(498,202)	(238,907)							
Accumulated other comprehensive loss-Foreign currency translation adjustment	(15,191)	...							
Accumulated other comprehensive income (loss)	...	(16,261)							
Total shareholders' equity (deficit)	152,700	382,267							
Total Equity	152,700	...							

□ Net of allowance - contract assets: \$33,000

□ Approximately

Recent Dividends:

1. Thryv Holdings Inc common. No dividends paid.
2. Thryv Holdings Inc common. No dividends paid.

Annual Dividends:

1. Thryv Holdings Inc common. No dividends paid.
2. Thryv Holdings Inc common. No dividends paid.

THUNDER MOUNTAIN GOLD, INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022	2021
Cash & cash equivalents	170,628	682,718	...
Investment in BeMetals, at fair value	...	738,612	...
Prepaid expenses & other assets	33,786	20,113	...
Available-for-sale investments	427,836
Total current assets	632,250	1,441,443	...
Land	332,509	280,333	...
Vehicles	...	22,441	...
Buildings	...	65,071	...
Construction equipment	...	36,447	...

Recent Dividends:

1. Thunder Mountain Gold, Inc. common.

No dividends paid.

Annual Dividends:

1. Thunder Mountain Gold, Inc. common.

No dividends paid.

TIANCI INTERNATIONAL INC

Earnings, 6 mos. to Jan 31(Consol. - \$):

	2024	2023
Total revenues	4,220,776	...
Cost & expenses	4,139,155	162,286
Operating income	81,621	(162,286)
Other income (expense), net	24,953	...
Net before taxes	106,574	(162,286)
Income taxes	11,972	...
Net income	94,602	(162,286)
Earnings common share		
Primary	\$0.01	\$(0.07)
Fully Diluted	\$0.01	\$(0.07)
Common Shares:		
Full Diluted	6,363,163	2,450,148
Year-end	14,781,803	2,450,148

TILE SHOP HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Net sales	377,146,000	394,702,000	370,700,000
Cost of sales	134,085,000	135,765,000	117,570,000
Gross profit	243,061,000	258,937,000	253,130,000
Selling, general & administrative expenses	226,903,000	236,328,000	232,520,000
Income (loss) from operations	16,158,000	22,609,000	20,610,000
Interest expense	2,164,000	1,579,000	656,000
Income (loss) before income taxes	13,994,000	21,030,000	19,954,000
Current provision for (benefit from) income taxes - federal	2,087,000	3,870,000	5,397,000
Current provision for (benefit from)

income taxes - state	556,000	1,040,000	1,390,000
Current provision for (benefit from) income taxes - international	4,000
Total current provision for (benefit from) income taxes - federal	794,000	91,000	(1,698,000)
Deferred provision for (benefit from) income taxes - state	486,000	281,000	131,000
Deferred provision for (benefit from) income taxes - international	...	45,000	(44,000)
Total deferred provision for (benefit from) income taxes	1,280,000	417,000	(1,611,000)
Provision for (benefit from) income taxes	3,923,000	5,327,000	5,180,000
Net income (loss)	10,071,000	15,703,000	14,774,000
Weighted average shares outstanding - basic	43,424,089	48,855,701	50,393,980
Weighted average shares outstanding - diluted	43,620,790	49,247,047	51,085,463
Year end shares outstanding	44,510,779	44,377,445	51,963,377
Income (loss) per common share - basic	\$0.23	\$0.32	\$0.29
Income (loss) per common share - diluted	\$0.23	\$0.32	\$0.29
Dividends per common share	\$0.65
Number of full time employees	1,136	1,233	1,247
Number of part time employees	...	154	96
Total number of employees	1,136	1,387	1,343
Number of common stockholders	246	391	420
Foreign currency translation adjustments	...	(64,000)	24,000
Basic EPS Excluding ExtraOrdinary Items	\$0.23
Diluted EPS Excluding ExtraOrd Items	\$0.23
Total Revenue	377,146,000

□ Approximately; □ As of February 27, 2023; □ As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	8,620,000	5,948,000
Restricted cash	...	1,811,000
Receivables, gross	3,182,000	3,711,000
Allowance for doubtful accounts	300,000	300,000
Receivables, net	...	3,411,000
Trade receivables, net	2,882,000	...
Finished goods	92,205,000	119,517,000
Raw materials	1,474,000	1,435,000
Inventories	93,679,000	120,952,000
Income tax receivable	129,000	3,859,000
Other current assets	9,248,000	10,422,000
Total current assets	114,558,000	146,403,000
Land	...	904,000
Building & building

improvements	25,979,000	25,835,000
Leasehold improvements	102,244,000	99,949,000
Furniture & fixtures	...	148,298,000
Machinery & equipment	32,263,000	31,261,000
Computer equipment & software	146,033,000	49,313,000
Purchased computer software	50,878,000	...
Vehicles	8,428,000	8,064,000
Construction in progress	2,873,000	1,648,000
Land, Gross	904,000	...
Total property, plant & equipment	369,602,000	365,272,000
Less: accumulated depreciation	305,285,000	294,177,000
Property, plant & equipment, net	64,317,000	71,095,000
Right of use asset	129,092,000	118,501,000
Deferred tax assets	5,256,000	6,536,000
Other assets	3,449,000	3,287,000
Total assets	316,672,000	345,822,000
Accounts payable	23,345,000	23,506,000
Income tax payable	...	3,000
Current portion of lease liability	27,265,000	27,866,000
Accrued wages & salaries	2,129,000	...
Accrued customer deposits	10,719,000	11,315,000
Accrued sales return reserve	...	4,993,000
Accrued wages & salaries	5,523,000	6,040,000
Accrued taxes	1,135,000	...
Accrued payroll & sales taxes	...	2,286,000
Other current liabilities	4,989,000	7,282,000
Deferred compensation	3,640,000	...
Total current liabilities	78,745,000	83,291,000
Long-term lease liability, net	112,697,000	103,353,000
Other long-term liabilities	5,543,000	5,009,000
Total liabilities	196,985,000	237,053,000
Common stock	4,000	4,000
Additional paid-in-capital	128,861,000	127,997,000
Retained earnings (accumulated deficit)	...	(19,180,000)
Accumulated other comprehensive income (loss)	(69,000)	(52,000)
Accumulated deficit	(9,109,000)	...
Total stockholders' equity	119,687,000	108,769,000
Total Stockholders Equity	119,687,000	...

Recent Dividends:
1. Tile Shop Holdings Inc common.
 No dividends paid.

Annual Dividends:
1. Tile Shop Holdings Inc common.
 No dividends paid.

TOURMALINE BIO INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	2021
Research & development	32,368	57,005	34,245
General & administrative expenses	13,041	19,472	13,262
Total operating expenses	45,409	76,477	47,507
Income (loss) from operations	(45,409)	(76,477)	(47,507)
Interest & other income (expense), net	...	2,583	(326)
Net income (loss)	(42,124)	(73,894)	(47,833)
Net income (loss) attributable to common stockholders	...	(73,894)	(47,833)
Weighted average

shares outstanding - basic	4,747	4,125	2,913
Weighted average shares outstanding - diluted	4,747	4,125	2,913
Year end shares outstanding	20,338	4,163	4,091
Net earnings (loss) per share - basic	\$(8.87)	\$(17.90)	\$(16.40)
Net earnings (loss) per share - diluted	\$(8.87)	\$(17.90)	\$(16.40)
Number of full time employees	...	129	112
Number of part time employees	...	13	15
Number of common stockholders	...	20	28
Dividends per common share	\$15.12
Net Income before Tax	(42,124)
Other income, net	3,285
Non-Operating Income/Expense - Total	3,285

□ Adjusted for 1-for-10 stock split, October 20, 2023; □ Shares increased due to the effect issuance of common shares for conversion of convertible preferred stock, contingent common stock, exercise of stock options and 2021 employee stock purchase plan; □ As is; □ As of March 1, 2023; □ As of March 1, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash & cash equivalents	140,726	13,670
Marketable securities	62,225	167,612
Prepaid insurance	...	1,037
Prepaid research & development expenses	...	2,426
Other current assets	...	868
Prepaid expenses & other current assets	5,923	4,331
Total current assets	208,874	185,613
Equipment	...	6,562
Leasehold improvements	...	1,191
Computer equipment	...	859
Furniture & fixtures	...	674
Construction in progress	...	242
Property & equipment, gross	...	9,528
Less: accumulated depreciation	38	4,180
Property, Plant & Equipment - Net - Balancing value	123	...
Property & equipment, net	85	5,348
Right-of-use assets	362	2,643
Other assets	747	111
Restricted Cash	227	...
Total assets	210,295	193,715
Accounts payable	1,071	3,887
Accrued compensation & benefit costs	...	3,566
Accrued research & development expenses	...	1,978
Accrued professional fees, consulting & other	...	1,121
Accrued expenses	...	6,665
Lease liability, current	221	910
Accrued expenses and other current liabilities	3,710	...
Total current liabilities	5,002	11,462
Share repurchase liability	...	208
Other liabilities	57	16
Lease liability, net of current	194	1,974
Total liabilities	5,253	13,660
Common stock	2	4
Additional paid-in capital	267,024	345,513

equity (deficit).....	(276,422)	759,202
Total Equity	(276,422)	...

Recent Dividends:

1. Trex Acquisition Corp common.

No dividends paid.

Annual Dividends:

1. Trex Acquisition Corp common.

No dividends paid.

TREX ACQUISITION CORP

Earnings, 3 mos. to Sep 30(Consol. – \$):

	2023	2022
Total revenues	12,912	25,829
Cost & expenses	356,778	849,778
Operating income	(343,866)	(823,949)
Net before taxes	(343,866)	(823,949)
Net income	(343,866)	(823,949)

Earnings common share

Primary	\$(0.02)	\$(0.04)
Fully Diluted	\$(0.02)	\$(0.04)

Common Shares:

Full Diluted	18,223,953	19,840,618
Year-end	18,223,953	19,840,618

Consolidated Balance Sheet Items, as of (\$):

Assets:	2023	
Current assets	159,213	
Total assets	273,373	
Liabilities:		
Current liabilities	793,190	
Stockholders' equity	(519,817)	
Net current assets	(633,977)	

U S GOLDMINING INC

Annual Report

Consolidated Income Statement, Years Ended Nov. 30 (\$):

	2023	2022	2021
Other exploration expenses	366,855
Exploration expenses	5,054,500	543,322	565,813
General & administrative expenses	4,670,248	1,172,810	113,882
Depreciation & accretion	19,255	17,616
Depreciation	30,959
Accretion	21,051
Total operating expenses	9,776,758	1,735,387	697,311
Income (loss) from operations	(9,776,758)	(1,735,387)	(697,311)
Foreign exchange gain (loss)	(1,801)	(3,270)	...
Income (loss) before income taxes ..	(9,351,640)	(1,738,657)	(697,311)
Net income (loss)	(9,356,577)	(1,738,657)	(697,311)
Weighted average shares outstanding - basic	11,480,346	9,937,248	9,500,001
Weighted average shares outstanding - diluted	11,480,346	9,937,248	9,500,001
Year end shares outstanding	12,398,709	10,135,001	9,500,001
Drilling	1,694,952
Consulting fees	1,499,000
Land fee, camp maintenance expenses	945,751
Transportation and travel	547,942
Office, consulting, investor relations, insurance and travel	2,101,872
Professional fees	1,665,183
Filing, listing, dues and subscriptions	178,595
Share-based compensation	423,831
Management fees,			

salaries and benefits	300,767
Net income (loss) per common share - basic	\$(0.82)	\$(0.17)	Ⓜ\$(0.07)
Net income (loss) per common share - diluted	\$(0.82)	\$(0.17)	Ⓜ\$(0.07)
Number of full time employees	6	Ⓜ2	...
Number of part time employees	Ⓜ2	...
Current income tax expense	4,937
Interest income	426,919
Total number of employees	6

Ⓜ Adjusted for 2.714286-for-1 stock split, September 22, 2022;

Ⓜ As of April 19, 2023

Consolidated Balance Sheet, Years Ended Nov. 30 (\$):

	2023	2022
Cash and cash equivalents	11,401,338	...
Cash	54,508
Income tax receivable	68,000
Prepaid technical consulting services	17,353	...
Prepaid dues & subscriptions	186,014	5,129
Prepaid insurance	7,000
Deferred financing costs	94,932
Other repaid expenses & deferred costs	50
Prepaid expenses & deferred costs	375,933	107,111
Other receivables	115,113	...
Restricted Cash	86,870	...
Inventories	27,249	...
Prepaid corporate development expenses	172,566	...
Total current assets	12,006,503	229,619
Exploration & evaluation assets	31,392	...
Right of Use assets	135,728	...
Property and equipment, net Vehicles	58,519	...
Property, Plant and Equipment, Cost Vehicles	60,537	...
Property, Plant and Equipment, Accumulated Depreciation Vehicles	2,018	...
Exploration equipment -Gross	52,846	...
Property, Plant & Equipment - camp structures - Accumulated Depreciation & Impairment	27,179	...
Property, Plant & Equipment - camp structures- Net	740,527	...
Property, Plant & Equipment - camp structures - Gross	767,706	...
Property and equipment, net	850,130	...
Exploration equipment - Net	51,084	...
Exploration Equipment - Accumulated Depreciation & Impairment	1,762	...
Total assets	13,023,753	229,619
Accounts payable	197,978	466,127
Accrued liabilities	112,048	26,922
Withholdings taxes payable	4,918	116,187
Due to Parent	677,783
Withholdings taxes payable	180,863	...
Current portion of lease liabilities	17,268	...
Total current liabilities	513,075	1,287,019

Asset retirement obligations	179,880	225,871
Lease liabilities	118,087	...
Total liabilities	811,042	1,512,890
Common stock	12,399	10,135
Retained earnings (accumulated deficit)	(14,477,940)	(5,121,363)
Additional paid-in capital	26,678,252	3,827,957
Total stockholders' equity (deficit)	12,212,711	(1,283,271)
Total Equity	12,212,711	...

Recent Dividends:

1. U S GoldMining Inc common.

No dividends paid.

Annual Dividends:

1. U S GoldMining Inc common.

No dividends paid.

UFP TECHNOLOGIES INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	Ⓜ2021
Net sales	400,072,000	353,792,000	206,320,000
Cost of sales	287,847,000	263,532,000	155,206,000
Gross profit (loss)	112,225,000	90,260,000	51,114,000
Selling, general & administrative expenses	50,889,000	45,796,000	29,480,000
Acquisition costs	1,027,000	430,000
Change in fair value of contingent consideration	3,527,000	9,837,000	...
Gain on sale of Molded Fiber business	15,651,000	...
Gain (loss) on sales of property, plant & equipment ...	(145,000)	6,149,000	14,000
Operating income (loss)	57,664,000	55,400,000	21,218,000
Interest Expense on Financial Lease Liabilities	4,000
Interest expense - Balancing value	3,641,000
Interest expense, net	3,645,000	2,763,000	39,000
Other income (expense)	(117,000)	81,000	26,000
Income (loss) before income tax provision (benefit) ...	53,902,000	52,718,000	21,205,000
Current federal income tax expense (benefit)	6,099,000	11,238,000	5,793,000
Current state income tax expense (benefit)	1,784,000	2,309,000	1,320,000
Current foreign income tax expense (benefit)	272,000	1,863,000	...
Total current income tax expense (benefit)	8,155,000	15,410,000	7,113,000
Deferred federal income tax expense (benefit)	841,000	(3,856,000)	(1,399,000)
Deferred state income tax expense (benefit)	2,000	(624,000)	(395,000)
Deferred foreign income tax expense (benefit)	(20,000)	(1,000)	...
Total deferred income tax expense (benefit)	823,000	(4,481,000)	(1,794,000)
Income tax expense (benefit)	8,978,000	10,929,000	5,319,000
Net income	44,924,000	41,789,000	15,886,000
Weighted average shares outstanding			

Right-of-use - finance leases	49,074	58,421
Restricted cash	320,000	320,000
Other non-current assets	90,045	88,832
Total non-current assets	7,969,938	9,472,924
Total assets	29,972,871	46,145,055
Accounts payable	1,240,902	268,074
Legal, tax & accounting fees	...	527,523
Salary & related costs	...	387,047
Research & development costs	...	3,586,251
Patent fees	...	421,759
Inventory purchases	...	345,563
Other accrued expenses	...	620,237
Accrued expenses	2,056,929	5,888,380
Contingent consideration	...	2,214,022
Other liabilities	...	3,023,767
Contract liabilities	36,132	29,851
Lease liability - operating leases	825,475	755,125
Lease liability - finance leases	9,236	8,814
Lease liability - finance leases	46,397	55,633
Employee entitlements liabilities	869,195	831,730
Short-term loan - unsecured	...	65,768
Short-term loan	911,082	...
Total current liabilities	5,948,951	13,085,531
Asset retirement obligations	1,214,255	2,920,630
Employee entitlements liabilities	76,165	48,273
Lease liability - operating leases	3,179,294	3,943,517
Total non-current liabilities	4,516,111	6,968,053
Total liabilities	10,465,062	20,053,584
Common stock	21,237	21,184
Additional paid-in capital	119,239,087	119,040,784
Current year loss	(6,741,564)	...
Retained earnings (accumulated deficit)	(92,678,783)	(65,824,231)
Current year income (loss)	...	(26,854,552)
Accumulated other comprehensive income (loss)	(332,168)	(291,714)
Total stockholders' equity	19,507,809	26,091,471
Total stockholders equity	19,507,809	...

Recent Dividends:
1. Universal Biosensors Inc common.
 No dividends paid.
Annual Dividends:
1. Universal Biosensors Inc common.
 No dividends paid.

UNIVERSAL BIOSENSORS INC

Earnings, 9 mos. to Sep 30(Consol. - A\$):

	2023	2022
Total revenues	4,514,413	3,763,763
Cost & expenses	16,528,645	18,695,294
Operating income	(12,721,542)	(16,954,925)
Interest income	600,562	172,304
Other income (expense), net	7,329,189	2,772,576
Foreign currency	(45,967)	(81,372)
Net before taxes	(4,990,443)	(14,204,516)
Net income	(4,990,443)	(14,204,516)
Earnings common share		
Primary	A\$(0.02)	A\$(0.07)
Fully Diluted	A\$(0.02)	A\$(0.07)
Common Shares:		
Full Diluted	212,369,435	194,303,678
Year-end	212,369,435	211,844,435

UPEXI INC

Earnings, 6 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues	49,175,469	37,960,361

Cost & expenses	49,146,191	39,770,095
Operating income	(2,929,275)	(4,077,854)
Other income (expense), net	7,562,593	7,562,593
Net before taxes	(4,880,544)	1,261,962
Income taxes	(1,167,174)	47,052
Income contin. oper.	1,214,910	1,214,910
Income discont. oper.	(1,376,332)	(1,376,332)
Net income	(3,794,307)	(161,422)
Earnings common share		
Primary	\$(0.18)	\$0.00
Fully Diluted	\$(0.18)	\$0.00
Common Shares:		
Full Diluted	20,275,745	17,220,564
Year-end	20,397,779	17,960,748

US GLOBAL INVESTORS INC

Annual Report

Consolidated Income Statement, Years Ended Jun. 30 (\$):

	2023	2022 (revised)	2021 (revised)
Advisory fees	14,940,000	24,525,000	21,445,000
Administration services fees	134,000	189,000	209,000
Total operating revenues	15,074,000	24,714,000	21,654,000
Employee compensation & benefits	4,798,000	6,059,000	7,369,000
General & administrative	6,122,000	6,911,000	5,704,000
Advertising	382,000	405,000	220,000
Depreciation	243,000	226,000	...
Depreciation & amortization expenses	196,000
Total operating expenses	11,549,000	13,601,000	13,489,000
Total interest expense	4,000
Operating income (loss)	3,525,000	11,113,000	8,165,000
Investment income (loss)	316,000	(6,174,000)	28,338,000
Income (loss) from equity method investments	...	(206,000)	347,000
Gain on forgiveness of Paycheck Protection Program ("PPP") loan	444,000
Other income	242,000	235,000	144,000
Total other income (loss)	29,273,000
Income (loss) before income taxes	4,083,000	4,968,000	37,438,000
Current tax expense - U.S. Federal	1,245,000	3,859,000	2,004,000
Current tax expense - Non-U.S.	2,418,000
Deferred tax expense (benefit) - U.S. Federal	(442,000)	(2,657,000)	576,000
Deferred tax expense (benefit) - Non-U.S.	479,000
Income Taxes - Foreign - Current	(2,000)	154,000	...
Income Taxes - Foreign - Deferred	2,000	(234,000)	...
Income Taxes - Local - Current	131,000	406,000	...
Tax expense (benefit)	934,000	1,528,000	5,477,000
Net income (loss)	3,149,000	3,440,000	31,961,000
Weighted average shares outstanding - basic	14,638,833	15,010,138	15,067,044
Weighted average shares outstanding - diluted	14,639,069	15,011,128	15,067,953
Year end shares outstanding	14,565,223	14,957,499	15,036,595
Net income (loss) per share - basic	\$0.22	\$0.23	\$2.12
Net income (loss)			

per share - diluted	\$0.22	\$0.23	\$2.12
Number of full time employees	21	...	22
Number of part time employees	3	...	1
Total number of employees	24
Number of class A common stockholders	170
Number of class C common stockholders	24
Number of class A beneficiary stockholders	208
Foreign currency translation adjustments	(5,000)

□ Restated to reflect correction of errors; □ Reclassified to conform with 2022 presentation; □ Approximately; □ As of November 9, 2021

Consolidated Balance Sheet, Years Ended Jun. 30 (\$):

	2023	2022 (revised)
Cash & cash equivalents	25,401,000	22,314,000
Restricted cash	...	1,000,000
Investments in securities at fair value	11,642,000	12,138,000
Restricted certificate of deposit	1,000,000	...
Accounts & other receivables	1,245,000	1,796,000
Tax receivable	576,000	384,000
Prepaid expenses	510,000	400,000
Total current assets	40,374,000	38,032,000
Building & land	4,616,000	4,606,000
Furniture, equipment, & other property & equipment	981,000	987,000
Gross property & equipment	5,597,000	5,593,000
Accumulated depreciation	4,459,000	4,223,000
Net property & equipment	1,138,000	1,370,000
Deferred tax asset	1,920,000	252,000
Investments in equity securities at fair value, non-current	1,563,000	4,290,000
Investments in available-for-sale debt securities at fair value	7,008,000	11,449,000
Investments in held-to-maturity debt securities	1,000,000	1,000,000
Other investments	2,388,000	3,992,000
Financing lease, right of use assets	65,000	93,000
Other assets, non-current	217,000	216,000
Total assets	55,673,000	60,694,000
Accounts payable	143,000	73,000
Accrued compensation & related costs	1,165,000	1,864,000
Dividends payable	329,000	337,000
Financing lease liability, short-term	28,000	27,000
Professional fees	697,000	889,000
Vendors payable	157,000	460,000
ETF operating & distribution expenses	344,000	385,000
Other taxes payable	76,000	97,000
Total current liabilities	2,939,000	4,132,000
Deferred tax liability	4,000	...
Financing lease liability, long-term	38,000	66,000
Reserve for uncertain tax positions	496,000	...
Total long-term liabilities	538,000	66,000
Total liabilities	3,477,000	4,198,000
Common stock - class A	52,000	347,000
Convertible common stock - class C	347,000	52,000
Additional paid-in-capital	16,442,000	16,438,000
Treasury stock, class A

shares at cost	3,740,000	2,599,000
Unrealized gains (losses) on available-for-sale investments	1,348,000	4,276,000
Accumulated other comprehensive income (loss), net of tax	1,348,000	4,276,000
Retained earnings (accumulated deficit)	37,747,000	37,982,000
Total shareholders' equity	52,196,000	56,496,000
Total shareholders' equity (deficit)	52,196,000	...

Recent Dividends:**1. US Global Investors Inc class A common.**

ExDate	Amt	Declared	Record	Payable
01/08/2021	0.00	12/03/2020	01/11/2021	01/25/2021
02/05/2021	0.00	12/03/2020	02/08/2021	02/22/2021
02/12/2021	0.00	02/08/2021	02/16/2021	02/26/2021
03/12/2021	0.01	12/03/2020	03/15/2021	03/29/2021
04/09/2021	0.01	03/18/2021	04/12/2021	04/26/2021
05/07/2021	0.01	03/18/2021	05/10/2021	05/24/2021
06/11/2021	0.01	03/18/2021	06/14/2021	06/28/2021
07/09/2021	0.01	06/02/2021	07/12/2021	07/26/2021
08/13/2021	0.01	06/02/2021	08/16/2021	08/30/2021
09/10/2021	0.01	06/02/2021	09/13/2021	09/27/2021
10/07/2021	0.01	09/30/2021	10/11/2021	10/25/2021
11/12/2021	0.01	09/30/2021	11/15/2021	11/29/2021
12/10/2021	0.01	09/30/2021	12/13/2021	12/27/2021
01/07/2022	0.01	12/08/2021	01/10/2022	01/24/2022
02/11/2022	0.01	12/08/2021	02/14/2022	02/28/2022
03/11/2022	0.01	12/08/2021	03/14/2022	03/28/2022
04/08/2022	0.01	03/17/2022	04/11/2022	04/25/2022
05/06/2022	0.01	03/17/2022	05/09/2022	05/23/2022
06/10/2022	0.01	03/17/2022	06/13/2022	06/27/2022
07/08/2022	0.01	06/16/2022	07/11/2022	07/25/2022
08/05/2022	0.01	06/16/2022	08/08/2022	08/22/2022
09/09/2022	0.01	06/16/2022	09/12/2022	09/26/2022
10/14/2022	0.01	10/05/2022	10/17/2022	10/31/2022
11/10/2022	0.01	10/05/2022	11/14/2022	11/28/2022
12/09/2022	0.01	10/05/2022	12/12/2022	12/27/2022
01/06/2023	0.01	12/21/2022	01/09/2023	01/23/2023
02/10/2023	0.01	12/21/2022	02/13/2023	02/27/2023
03/10/2023	0.01	12/21/2022	03/13/2023	03/27/2023
04/06/2023	0.01	03/10/2023	04/10/2023	04/24/2023
05/05/2023	0.01	03/10/2023	05/08/2023	05/22/2023
06/09/2023	0.01	03/10/2023	06/12/2023	06/26/2023
07/07/2023	0.01	06/22/2023	07/10/2023	07/24/2023
08/11/2023	0.01	06/22/2023	08/14/2023	08/28/2023
09/08/2023	0.01	06/22/2023	09/11/2023	09/25/2023
10/05/2023	0.01	09/18/2023	10/09/2023	10/23/2023
11/09/2023	0.01	09/18/2023	11/13/2023	11/27/2023
12/08/2023	0.01	09/18/2023	12/11/2023	12/26/2023
01/05/2024	0.01	12/08/2023	01/08/2024	01/22/2024
02/09/2024	0.01	12/08/2023	02/12/2024	02/26/2024
03/08/2024	0.01	12/08/2023	03/11/2024	03/25/2024

2. US Global Investors Inc class C convertible common.

No dividends paid.

Annual Dividends:**1. US Global Investors Inc class A common.**

2021	0.07	2022	0.09	2023	0.09
2024	0.02				

2. US Global Investors Inc class C convertible common.

No dividends paid.

VALUE LINE INC

Earnings, 9 mos. to Jan 31(Consol. - \$000):

	2024	2023
Total revenues	28,484	29,977
Net Sales	19,174	...
Cost & expenses	20,831	21,264
Operating income	7,653	8,713
Interest income	1,387	...
Other income (expense), net	9,772	8,516
Gains or losses	(133)	1,276
Net before taxes	18,679	18,505
Income taxes	...	4,469
Net income	14,232	14,036
Earnings common share		
Primary	\$1.51	\$1.48

Fully Diluted Common Shares:	\$1.51	\$1.48
Full Diluted	9,430	9,466
Year-end	9,427	9,439

Number of common stockholders	2,264	2,355	2,462
[□] Reclassified to conform with 2022 presentation; [■] As is; [▣] Approximately; [▤] As of March 14, 2023; [▥] As of February 23, 2022			

VAXART INC Annual Report**Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2023	2022	2021 (revised)
Revenue from customer service contracts	3,459	...	13
Non-cash royalty revenue related to the sale of future royalties	3,920	107	879
Total revenue	7,379	107	892
Research & development expenses	68,142	81,054	48,749
General & administrative expenses	22,584	29,386	21,890
Impairment of intangible assets	...	4,254	3,005
Total operating expenses	90,726	114,694	73,644
Operating income (loss)	(83,347)	(114,587)	(72,752)
Interest income	2,652	1,247	81
Non-cash interest expense related to sale of future royalties	1,447	1,305	1,480
Gain on remeasurement of future royalty liability	...	6,960	3,789
Foreign exchange gain (loss), net	(62)	(6)	(1)
Income (loss) before provision for income taxes	(82,204)	(107,691)	(70,363)
Current provision for (benefit from) state income taxes	3	3	1
Current provision for (benefit from) foreign income taxes	258	64	106
Total current provision for (benefit from) income taxes	261	67	107
Provision for income taxes	261	67	107
Net income (loss)	(82,465)	(107,758)	(70,470)

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2023	2022
Cash at Banks	3,352	...
Cash & cash equivalents	31,403	...
Cash, cash equivalents & restricted cash	34,755	46,013
Marketable securities	4,958	...
Royalties receivable	3,008	...
Accounts receivable	...	20
Short-term investments	4,958	49,704
Prepaid expenses & other current assets	2,815	3,714
Royalties receivable	3,008	...
Total current assets	45,536	99,451
Laboratory equipment	1,105	12,035
Office & computer equipment	...	1,078
Leasehold improvements	3,985	1,760
Machinery & equipment	13,448	...
Construction in progress	24	3,984
Property & equipment, gross	18,562	18,857
Less: accumulated depreciation	6,831	3,272
Property & equipment, net	11,731	15,585
Right-of-use assets, net	24,840	25,715
Goodwill	4,508	4,508
Intangible assets, net	4,289	5,020
Other long-term assets	926	3,568
Total assets	91,830	153,847
Accounts payable	1,584	5,514
Deferred grant revenue	...	2,000
Current portion of operating lease liability	2,703	2,228
Current portion of liability related to sale of future royalties	535	95
Accrued compensation	4,576	3,112
Accrued clinical & manufacturing expenses	312	2,413
Accrued professional & consulting services	211	691
Other accrued current liabilities	...	1,868
Other accrued current liabilities	5,634	8,084
2.875% convertible senior notes, net	3,803	...
Total current liabilities	13,724	17,921
Operating lease liability, net of current portion	17,385	19,477
Liability related to sale of future royalties, net of current portion	...	5,621
Notes payable, net & capital lease obligations, net	2,623	...
Other long-term liabilities, net of current portion	...	231
Other long-term liabilities	293	...
Total liabilities	34,025	43,250
Common stock	15	13
Treasury stock at cost, 13,553 shares and none as of 31, 2023 and 31, 2022, respectively	366	...
Additional paid-in capital	467,731	437,992
Accumulated other comprehensive income (loss)	(1)	(299)
Retained earnings (accumulated deficit)	(409,574)	(327,109)

Total stockholders' equity (deficit)	57,805	110,597
Total Equity	57,805	...

Recent Dividends:**1. Vaxart Inc common.**

No dividends paid.

Annual Dividends:**1. Vaxart Inc common.**

No dividends paid.

VAXART INC**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2023	2022
Total revenues	4,134	85
Cost & expenses	70,581	83,534
Operating income	(66,447)	(83,449)
Foreign currency	(59)	(2)
Net before taxes	(65,003)	(83,789)
Income taxes	87	51
Net income	(65,090)	(83,840)
Earnings common share		
Primary	\$(0.45)	\$(0.66)
Fully Diluted	\$(0.45)	\$(0.66)
Common Shares:		
Full Diluted	145,810	126,374
Year-end	152,037	128,331

VERDE RESOURCES INC**Earnings, 6 mos. to Dec 31 (Consol. - \$):**

	2023	2022
Total revenues	41,874	107,452
Cost & expenses	1,119,543	1,752,117
Operating income	(1,077,669)	(1,644,665)
Interest expense	84,923	1,879,660
Other income (expense), net	86,793	7,653
Net before taxes	(1,075,799)	(3,516,672)
Net income	(1,075,799)	(3,516,672)
Earnings common share		
Fully Diluted	1,179,634,810	867,178,851
Year-end	1,193,046,422	1,173,576,654

VERICEL CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
Product sales, net	197,516,000	163,698,000	153,075,000
Other revenue	667,000	3,109,000
Total revenue	197,516,000	164,365,000	156,184,000
Cost of product sales	61,940,000	54,577,000	50,159,000
Gross profit (loss)	135,576,000	109,788,000	106,025,000
Research & development expense	21,042,000	19,943,000	16,287,000
Selling, general & administrative expense	120,998,000	106,903,000	97,592,000
Total operating expenses	142,040,000	126,846,000	113,879,000
Income (loss) from operations	(6,464,000)	(17,058,000)	(7,854,000)
Interest income	4,632,000	1,341,000	224,000
Interest expense	600,000	366,000	4,000
Other income (expense)	64,000	95,000	52,000
Total other income (expense)	4,096,000	1,070,000	272,000
Income (loss) before income taxes	(15,912,000)	(7,367,000)
Income (loss) before income taxes - U.S.	(15,912,000)	(7,367,000)
Income (loss) before income taxes - foreign	(76,000)	(104,000)
Income (loss) before income taxes	(2,368,000)	(15,988,000)	(7,582,000)
Income tax expense (benefit)	814,000	721,000	(111,000)
Net income (loss)	(3,182,000)	(16,709,000)	(7,471,000)
Weighted average shares outstanding - basic	47,590,000	47,130,000	46,472,000
Weighted average			

shares outstanding - diluted	47,590,000	47,130,000	46,472,000
Year end shares outstanding	47,829,000	47,253,000	46,880,000
Net income (loss) per share - basic	\$(0.07)	\$(0.35)	\$(0.16)
Net income (loss) per share - diluted	\$(0.07)	\$(0.35)	\$(0.16)
Number of full time employees	314	305	281
Number of common stockholders	170	170	169
Basic EPS Excluding ExtraOrdinary Items	\$(0.07)
Diluted EPS Excluding ExtraOrd Items	\$(0.07)
Total number of employees	314

Reclassified to conform with 2022 presentation; Approximate; As of January 31, 2023; As of January 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	69,088,000	51,067,000
Short-term investments	68,471,000
Short-term investments	40,469,000	...
Account receivable, gross	58,399,000	46,586,000
Allowance for doubtful accounts	43,000	47,000
Accounts receivable, net	58,356,000	46,539,000
Raw materials	11,348,000	15,101,000
Work-in-process	1,210,000	832,000
Finished goods	529,000	53,000
Inventory	13,087,000	15,986,000
Other current assets	6,853,000	4,803,000
Restricted cash	17,778,000	...
Total current assets	205,631,000	186,866,000
Machinery & equipment	5,562,000	5,041,000
Furniture, fixtures & office equipment	1,731,000	1,710,000
Computer equipment & software	9,116,000	8,224,000
Leasehold improvements	14,901,000	13,689,000
Construction in process	32,531,000	5,438,000
Financing right-of-use lease	63,841,000	37,000
Total property & equipment, gross	34,139,000
Less: accumulated depreciation	22,206,000	18,302,000
Property & equipment, net	41,635,000	15,837,000
Right-of-use assets	73,462,000	41,535,000
Other long-term assets	771,000	1,303,000
Long-term investments	25,283,000	19,962,000
Intangible assets, net	6,875,000	7,500,000
Total assets	353,657,000	273,003,000
Accrued expenses	17,215,000	...
Accounts payable	22,347,000	16,930,000
Accrued bonus related compensation	9,757,000	7,132,000
Employee related accruals	3,503,000	3,101,000
Insurance reimbursement-related liabilities	3,591,000	5,030,000
Other accrued expenses	364,000	927,000
Current portion of operating lease liabilities	6,187,000	4,302,000
Other liabilities	41,000
Total current liabilities	45,749,000	37,463,000
Operating lease liabilities	81,856,000	43,268,000
Capital lease obligations	100,000	...
Total liabilities	127,705,000	80,731,000
Common stock	629,229,000	593,245,000
Accumulated other comprehensive income (loss)	(978,000)
Other comprehensive income (loss)	(100,000)	...

Retained earnings (accumulated deficit)	(403,177,000)	(399,995,000)
Total shareholders' equity (deficit)	225,952,000	192,272,000
Total Equity	225,952,000	...

Recent Dividends:**1. Vericel Corp series B-2 voting convertible preferred.**

No dividends paid.

2. Vericel Corp common.

No dividends paid.

3. Vericel Corp series A non-voting convertible preferred.

No dividends paid.

Annual Dividends:**1. Vericel Corp series B-2 voting convertible preferred.**

No dividends paid.

2. Vericel Corp common.

No dividends paid.

3. Vericel Corp series A non-voting convertible preferred.

No dividends paid.

VERITEC, INC.**Earnings, 6 mos. to Dec 31 (Consol. - \$):**

	2023	2022
Total revenues	165,000	208,000
Cost & expenses	438,000	549,000
Operating income	(273,000)	(341,000)
Net before taxes	(541,000)	...
Net income	(541,000)	(583,000)
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	39,988,007	39,988,007
Year-end	39,988,007	39,988,007

VERRA MOBILITY CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
Service revenue	783,595,000	695,218,000	492,846,000
Product sales	33,715,000	46,380,000	57,744,000
Total revenue	817,310,000	741,598,000	550,590,000
Cost of service revenue	18,232,000	16,330,000	5,337,000
Cost of product sales	25,231,000	30,932,000	29,809,000
Operating expenses	273,288,000	226,324,000	163,370,000
Selling, general & administrative expenses	198,550,000	163,133,000	123,407,000
Depreciation, amortization & loss (gain) on disposal of assets, net	113,195,000	140,174,000	116,801,000
Income (loss) from operations	188,814,000	164,705,000	111,866,000
Interest expense, net	86,701,000	69,372,000	44,942,000
Change in fair value of private placement warrants	(24,966,000)	14,400,000	(7,600,000)
Tax receivable agreement liability adjustment	3,077,000	720,000	1,016,000
Gain on interest rate swap	(817,000)	996,000	...
Gain (loss) on extinguishment of debt	(3,533,000)	3,005,000	(5,334,000)
Other income, net	11,123,000	12,654,000	12,895,000
Total other income (expenses)	(101,817,000)	(37,597,000)	(43,965,000)
Income (loss) before income taxes - U.S.	92,425,000	140,858,000	77,101,000
Income (loss) before income taxes - foreign	(5,428,000)	(13,750,000)	(9,200,000)
Income (loss) before income taxes	86,997,000	127,108,000	67,901,000
Current federal			

income tax provision (benefit) ...	38,109,000	34,071,000	25,361,000
Current state income tax provision (benefit) ...	15,794,000	14,779,000	10,523,000
Current foreign income tax provision (benefit) ...	3,113,000	1,777,000	160,000
Total current income tax provision (benefit) ...	57,016,000	50,627,000	36,044,000
Deferred federal income tax provision (benefit) ...	(16,522,000)	(8,069,000)	(7,434,000)
Deferred state income tax provision (benefit) ...	(6,335,000)	(4,863,000)	(1,627,000)
Deferred foreign income tax provision (benefit) ...	(4,177,000)	(3,062,000)	(531,000)
Total deferred income tax provision (benefit) ...	(27,034,000)	(15,994,000)	(9,592,000)
Income tax provision (benefit) ...	29,982,000	34,633,000	26,452,000
Net income (loss) ...	57,015,000	92,475,000	41,449,000
Weighted average shares outstanding - basic	158,777,000	152,848,000	159,983,000
Weighted average shares outstanding - diluted	160,017,000	159,026,000	163,778,000
Year end shares outstanding	166,555,000	148,962,000	156,079,000
Net income (loss) per share - basic	\$0.36	\$0.61	\$0.26
Net income (loss) per share - diluted	\$0.36	\$0.50	\$0.25
Number of full time employees	1,788	1,396	1,306
Number of part time employees	207	174	127
Total number of employees	1,995	1,570	...
Number of common stockholders	8	6	8
Foreign currency translation adjustments	...	(7,771,000)	(5,305,000)
EPS - Basic - excluding Extraordinary Items	\$0.36
EPS - Diluted - excluding Extraordinary Items	\$0.36

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

2023 2022

Cash & cash equivalents	136,309,000	105,204,000
Restricted cash	3,413,000	3,911,000
Accounts receivable, gross	216,324,000	179,686,000
Less: allowance for credit losses	18,500,000	15,900,000
Accounts receivable, net	197,824,000	163,786,000
Unbilled receivables	37,065,000	30,782,000
Inventory	17,966,000	19,307,000
Deferred offering costs associated with proposed public offering	757,000	...
Prepaid assets	6,775,000	...
Prepaid tolls	9,174,000	9,978,000
Prepaid services	10,496,000	9,171,000
Prepaid income taxes	9,830,000	4,629,000
Prepaid computer maintenance	1,755,000	5,492,000
Costs to fulfill a customer contract	5,852,000	3,193,000
Prepaid insurance	...	3,112,000

Deposits	2,322,000	2,057,000
Other prepaid expenses & other current assets	...	1,972,000
Prepaid expenses & other current assets	46,961,000	39,604,000
Total current assets	439,538,000	362,594,000
Installation & service parts, net	22,895,000	22,923,000
Software	37,415,000	30,288,000
Leasehold improvements	10,031,000	9,806,000
Computer equipment	21,415,000	20,274,000
Furniture	2,651,000	2,648,000
Automobiles	14,422,000	12,933,000
Construction in progress	17,781,000	19,357,000
Equipment installed at customer sites	159,151,000	...
Property & equipment, gross	...	217,813,000
Less: accumulated depreciation	139,618,000	108,038,000
Property & equipment, net	123,248,000	109,775,000
Operating lease assets	33,523,000	37,593,000
Intangible assets, net	301,025,000	377,420,000
Goodwill	835,835,000	833,480,000
Other non-current assets	33,919,000	12,484,000
Total assets	1,789,983,000	1,756,269,000
Accounts payable	78,749,000	79,869,000
Deferred revenue	28,788,000	31,164,000
Accrued salaries & wages	27,905,000	19,109,000
Current deferred tax liabilities	7,574,000	7,559,000
Current portion of operating lease liabilities	7,133,000	6,355,000
Accrued interest payable	4,594,000	4,459,000
Restricted cash due to customers	2,835,000	3,541,000
Payroll liabilities	3,214,000	2,136,000
Advanced deposits	2,308,000	1,029,000
Current portion of interest rate swap liability	...	977,000
Other accrued liabilities	...	3,682,000
Other	4,254,000	...
Accrued legal settlement	31,500,000	...
Accrued liabilities	93,119,000	48,847,000
Tax receivable agreement liability, current portion	1,802,000	4,994,000
Current portion of long-term debt	9,019,000	21,935,000
Payable to related party pursuant to tax receivable agreement, current portion	5,098,000	...
Total current liabilities	214,773,000	186,809,000
2021 term loan, due 2028	...	886,106,000
Senior notes, due 2029	1,029,113,000	350,000,000
Less: original issue discounts	...	(5,637,000)
Less: unamortized deferred financing costs	...	(18,489,000)
Total long-term debt	...	1,211,980,000
Less: current portion of long-term debt	...	21,935,000
Long-term debt, net of current portion	...	1,190,045,000
Operating lease liabilities, net of current portion	29,124,000	33,362,000
Tax receivable agreement liability, net of current portion	48,369,000	50,900,000
Private placement warrant liabilities	...	24,066,000
Asset retirement obligations	14,580,000	12,993,000
Deferred tax liabilities, net	18,360,000	21,149,000
Other long-term liabilities	14,197,000	5,875,000
Total liabilities	1,368,516,000	1,525,199,000
Common stock	17,000	15,000

Common stock contingent consideration	...	36,575,000
Additional paid-in capital	557,513,000	305,423,000
Retained earnings (accumulated deficit)	(125,887,000)	(98,078,000)
Accumulated other comprehensive income (loss)	(10,176,000)	(12,865,000)
Total stockholders' equity (deficit)	421,467,000	231,070,000
Total Equity	421,467,000	...

Recent Dividends:

- Verra Mobility Corp class F common.**
No dividends paid.
- Verra Mobility Corp class A common subject to possible redemption.**
No dividends paid.
- Verra Mobility Corp class A common.**
No dividends paid.

Annual Dividends:

- Verra Mobility Corp class F common.**
No dividends paid.
- Verra Mobility Corp class A common subject to possible redemption.**
No dividends paid.
- Verra Mobility Corp class A common.**
No dividends paid.

VERTEX ENERGY INC.
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Net sales	3,177,187,000
Revenues	...	2,791,715,000	207,760,000
Total revenues	3,177,187,000
Disposal of rejects	3,005,996,000
Cost of revenues	...	2,598,276,000	178,786,000
Depreciation & amortization attributable to costs of revenues	27,018,000	13,429,000	4,043,000
Gross profit (loss)	144,173,000	180,010,000	24,931,000
Selling, general & administrative expenses	168,640,000	127,782,000	30,606,000
Loss on assets impairment	2,124,000
Depreciation & amortization attributable to operating expenses	4,146,000	3,673,000	1,681,000
Total operating expenses	172,786,000	131,455,000	34,411,000
Income (loss) from operations	(28,613,000)	48,555,000	(9,480,000)
Other income (expense)	633,000	(306,000)	4,158,000
Gain (loss) on change in value of derivative warrant liability	7,992,000	7,821,000	(15,685,000)
Interest expense	119,567,000	79,911,000	3,832,000
Total other income (expense)	(110,942,000)	(72,396,000)	(15,359,000)
Income (loss) from continuing operations before income tax	(139,555,000)	(23,841,000)	(24,839,000)
Current state tax expense (benefit)	...	9,000	...
Deferred federal tax expense (benefit)	...	(5,313,000)	...
Deferred state tax expense (benefit)	...	(1,867,000)	...
Federal tax benefit	(10,214,000)
State tax expense	24,000
State tax benefit	(3,195,000)
Income tax expense (benefit)	(13,385,000)	(7,171,000)	...
Income (loss) from

continuing operations	(126,170,000)	(16,670,000)	(24,839,000)
Income (loss) from discontinued operations, net of tax	18,667,000	17,178,000	
Net income (loss)	(71,973,000)	1,997,000	(7,661,000)
Net income (loss) attributable to non-controlling interest & redeemable non-controlling interest from continuing operations	487,000	63,000	(207,000)
Net income (loss) attributable to non-controlling interest & redeemable non-controlling interest from discontinued operations	(6,882,000)	(10,496,000)	
Net income (loss) attributable to Vertex Energy, Inc.	(71,486,000)	(4,822,000)	(18,364,000)
Accretion of redeemable noncontrolling interest to redemption value	428,000	1,992,000	
Accretion of discount on series B & B-1 preferred stock		507,000	
Dividends on series B & B-1 preferred stock		(258,000)	
Net income (loss) available to common stockholders	(5,250,000)	(20,605,000)	
Weighted average shares outstanding - basic	85,596,000	70,686,000	56,303,000
Weighted average shares outstanding - diluted	85,596,000	70,686,000	56,303,000
Year end shares outstanding	93,514,346	75,668,826	63,287,965
Income (loss) per common share from continuing operations - basic	\$(1.47)	\$(0.24)	\$(0.48)
Income (loss) per common share from discontinued operations - basic	\$0.63	\$0.17	\$0.12
Net income (loss) per common share - basic	\$(0.84)	\$(0.07)	\$(0.36)
Income (loss) per common share from continuing operations - diluted	\$(1.47)	\$(0.24)	\$(0.48)
Income (loss) per common share from discontinued operations - diluted	\$0.63	\$0.17	\$0.12
Net income (loss) per common share - diluted	\$(0.84)	\$(0.07)	\$(0.36)
Number of full time employees		497	282
Number of common stockholders	296	296	246
Number of series A preferred stockholders			71
Discontinued operations	54,197,000		

Restated to reflect the discontinued operations of Heartland Assets and Operations; Shares increased due to conversion of A, B and B1 preferred stock to common stock, exercise of B1 warrants and options; As of February 15, 2023; As of February 21, 2022; Approximately; As is; As of March 1, 2023; As of March 11, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	76,967,000	141,258,000
Restricted cash	3,606,000	4,929,000
Accounts receivable trade	37,473,000	36,098,000
Allowance for doubtful accounts	1,309,000	1,550,000
Accounts receivable, net	36,164,000	34,548,000
Inventory	182,120,000	135,473,000
Prepaid insurance		8,356,000
Commodity derivative advance		5,472,000
Renewable volume obligation (RVO) assets		2,001,000
Other prepaid expenses		5,160,000
Independent deposit		10,329,000
Other current assets		5,342,000
Prepaid expenses & other current assets		36,660,000
Assets held for sale		20,560,000
Inventory financing deposit	53,174,000	
Total current assets	352,031,000	373,428,000
Other property & equipment	46,000	
Equipment	276,331,000	97,120,000
Furniture & fixtures		86,000
Leasehold improvements	2,852,000	2,852,000
Office equipment	1,400,000	1,433,000
Vehicles	15,087,000	9,212,000
Construction in progress	53,467,000	96,765,000
Building	3,663,000	2,334,000
Turnarounds	21,100,000	18,964,000
Land		9,168,000
Land, Gross	9,793,000	
Fixed assets, at cost	383,739,000	237,934,000
Less: accumulated depreciation	57,628,000	36,185,000
Fixed assets, net	326,111,000	201,749,000
Finance lease right-of-use assets, net		44,081,000
Operating lease right-of-use assets, net	96,394,000	53,557,000
Intangible assets, net	11,541,000	11,827,000
Deferred tax assets		2,498,000
Deposits, long-term	64,499,000	
Other assets	4,048,000	2,245,000
Total non-current assets	502,593,000	315,957,000
Total assets	854,624,000	689,385,000
Accrued purchases	17,685,000	21,185,000
Accrued interest	460,000	1,488,000
Accrued compensation & benefits	7,605,000	6,530,000
Accrued income, real estate, sales & other taxes		1,102,000
RINS liabilities		51,355,000
Environmental liabilities - current		51,000
Accrued expenses and other current liabilities	73,636,000	
Accrued taxes other than payroll taxes	826,000	
Accrued expenses and other current liabilities - Balancing value	46,735,000	
Accrued expenses		81,711,000
Accounts payable	75,004,000	20,997,000
Finance lease - current	2,435,000	1,363,000
Operating lease - current	20,296,000	9,012,000
Current portion of long-term debt, net	16,362,000	13,911,000
Obligations under inventory financing agreements, net		117,939,000

Derivative commodity liability		242,000
Liabilities held for sale, current	141,093,000	3,424,000
Unearned revenue	325,000	
Total current liabilities	328,826,000	248,599,000
Convertible senior note		95,178,000
Term loan	170,701,000	165,000,000
SBA loan		59,000
Various institutions		5,602,000
Principal amount of long-term debt		265,839,000
Less: unamortized discount & deferred financing costs		(81,918,000)
Total debt, net of unamortized discount & deferred financing costs		183,921,000
Less: current maturities, net of unamortized discount & deferred financing costs		13,911,000
Long-term debt, net		170,010,000
Finance lease - non-current	66,206,000	45,164,000
Operating lease - non-current	74,444,000	44,545,000
Deferred federal income tax	2,776,000	
Derivative warrant liability	9,907,000	14,270,000
Other liabilities	1,377,000	1,377,000
Total liabilities	654,237,000	523,965,000
Common stock	94,000	76,000
Additional paid-in capital	383,632,000	279,552,000
Retained earnings (accumulated deficit)	(187,379,000)	(115,893,000)
Total Vertex Energy, Inc. stockholders' equity (deficit)	196,347,000	163,735,000
Non-controlling interest	4,040,000	1,685,000
Total equity	200,387,000	165,420,000

Recent Dividends:

- Vertex Energy Inc. 8% series B cumulative redeemable convertible participating preferred.**
No dividends paid.
 - Vertex Energy Inc. series B1 preferred.**
No dividends paid.
 - Vertex Energy Inc. series B mandatorily redeemable preferred.**
No dividends paid.
 - Vertex Energy Inc. series C convertible preferred.**
No dividends paid.
 - Vertex Energy Inc. series B preferred.**
No dividends paid.
 - Vertex Energy Inc. common.**
No dividends paid.
 - Vertex Energy Inc. series A convertible preferred.**
No dividends paid.
- Annual Dividends:**
- Vertex Energy Inc. 8% series B cumulative redeemable convertible participating preferred.**
No dividends paid.
 - Vertex Energy Inc. series B1 preferred.**
No dividends paid.
 - Vertex Energy Inc. series B mandatorily redeemable preferred.**
No dividends paid.
 - Vertex Energy Inc. series C convertible preferred.**
No dividends paid.
 - Vertex Energy Inc. series B preferred.**
No dividends paid.
 - Vertex Energy Inc. common.**
No dividends paid.
 - Vertex Energy Inc. series A convertible preferred.**
No dividends paid.

VIPER ENERGY INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2023	2022	[□] 2021 (revised)	per unit - diluted	\$2.69	\$2.00	\$0.85	
Other operating expense	356	Distributions per common unit	\$1.99	\$2.09	\$1.43	
Royalty income	717,110	837,976	501,534	Number of common unitholders	8	^{□□} 10	^{□□} 13	
Lease bonus income	1,855	27,791	2,763	Depletion	146,118	
Lease bonus income - related party	107,823	EPS - Basic - excluding	
Other operating income	909	700	620	Extraordinary Items	
Total operating income	827,697	866,467	504,917	Applicable to Common - Total	\$2.69	
Production & ad valorem taxes	50,401	56,372	32,558	EPS - Diluted - excluding	
Depletion expense	121,071	102,987	Extraordinary Items	
General & administrative expenses	10,603	8,542	7,800	Applicable to Common - Total	\$2.69	
Total costs & expenses	207,478	185,985	143,345					
Income (loss) from operations	620,219	680,482	361,572					
Interest expense, net	48,222	40,409	34,044					
Gain (loss) on derivative instruments, net	(25,793)	(18,138)	(69,409)					
Other income, net	1,774	416	79					
Interest expense, net	(48,907)					
Other fees and expenses	(836)					
Total other income (expense), net	(72,926)	(58,131)	(103,374)					
Income (loss) before income taxes	547,293	622,351	258,198					
Current income tax provision (benefit) - federal	50,414	15,929	1,218					
Current income tax provision (benefit) - state	2,538	1,074	303					
Total current income tax provision (benefit)	52,952	17,003	1,521					
Deferred income tax provision (benefit) - federal	(6,532)	(49,656)	...					
Income Taxes - Local - Deferred	(468)					
Total deferred income tax provision (benefit)	(7,000)	(49,656)	...					
Provision for (benefit from) income taxes	45,952	(32,653)	1,521					
Net income (loss) attributable to non-controlling interest	(301,253)	(503,331)	(198,738)					
Net income (loss) attributable to Viper Energy Partners LP	200,088	151,673	57,939					
Less: net income (loss) allocated to participating securities	299	365	193					
Net income (loss) attributable to common unitholders	151,308	57,746					
Weighted average units outstanding - basic	74,176	75,612	68,319					
Weighted average units outstanding - diluted	74,176	75,679	68,391					
Year end units outstanding	176,854	163,940	169,256					
Net income (loss) per unit - basic	\$2.69	\$2.00	\$0.85					
Net income (loss)								

	2023	2022	[□] 2021 (revised)
Cash & cash equivalents	25,869	18,179	...
Royalty income receivable (net of allowance for credit losses)	108,681	81,657	...
Royalty income receivable - related party	3,329	6,260	...
Derivative instruments	358	9,328	...
Other current assets	3,196	...
Prepaid expenses and other current assets	4,467
Income tax receivable	813
Total current assets	143,517	118,620	...
Oil & natural gas interests, full cost method of accounting	[□] 3,464,819	...
Land	5,688	5,688	...
Accumulated depletion & impairment	866,352	720,234	...
Oil and natural gas interests- Gross	4,628,983
Property, net	2,750,273	...
Funds held in escrow	3,768,319
Derivative instruments	92	442	...
Deferred tax asset (net of allowance)	56,656	49,656	...
Other assets	5,509	1,382	...
Total assets	3,974,093	2,920,373	...
Accounts payable	19	1,129	...
Accounts payable-related party	1,330	306	...
Interest payable	11,036	3,972	...
Ad valorem taxes payable	13,299	12,492	...
Derivatives instruments payable	2,961	1,684	...
Other accrued liabilities	1,452	...
Accrued liabilities	27,021	19,600	...
Derivative instruments	1,279
Income taxes payable	1,925	911	...
Other	1,407
Total current liabilities	33,256	21,946	...
Senior notes	1,083,082	430,350	...
Revolving credit facility	152,000	...
Unamortized debt issuance costs	(1,306)	...
Unamortized discount	(4,149)	...
Long-term debt, net	576,895	...
Derivative instruments	201	7	...
Total liabilities	1,116,539	598,848	...
General partner	649	...
Common units	689,178	...
Class B units	832	...
Total Viper Energy Partners LP unitholders' equity	690,659	...
Non-controlling interest	1,843,262	1,630,866	...
Additional paid-in capital	1,031,078
Retained earnings (accumulated deficit)	(16,786)
Total unitholders' equity	1,014,292
Total equity	2,857,554	2,321,525	...

	2023	2022	[□] 2021 (revised)
Collaboration revenue - related party	314,000	1,772,000	2,963,000
Total revenue	314,000
Research & development expenses	159,765,000 [□]	100,894,000	56,886,000
General & administrative expenses	94,999,000	35,182,000	25,805,000
Total operating expenses	254,764,000	136,076,000	82,691,000
Income (loss) from operations	(254,450,000)	(134,304,000)	(79,728,000)
Interest & other income	18,563,000	4,916,000	318,000
Interest & other expense	1,847,000	486,000	3,000
Net Income Before Tax	(237,734,000)
Tax	16,716,000
Other income (expense), net	4,430,000	315,000
Net income (loss)	(237,734,000)	(129,874,000)	(79,413,000)
Weighted average shares outstanding - basic	44,755,475	32,087,293	11,918,712
Weighted average shares outstanding - diluted	44,755,475	32,087,293	11,918,712
Year end shares outstanding	53,986,112	[□] 41,305,947	[□] 23,924,004
Net earnings (loss) per share - basic	\$(5.31)	\$(4.05)	\$(6.66)
Net earnings (loss) per share - diluted	\$(5.31)	\$(4.05)	\$(6.66)
Number of full time employees	94	[□] 86	[□] 50
Total number of employees	94
Number of common stockholders	31	^{□□} 20	^{□□} 29
EPS - Basic - excluding Extraordinary Items
Applicable to Common - Total	\$(5.31)
EPS - Diluted - excluding Extraordinary Items
Applicable to Common - Total	\$(5.31)

[□] Amount excluded from depletion - Oil & natural gas interests, full cost method of accounting: \$1,297,221,000

Recent Dividends:

1. Viper Energy Inc common units.

No dividends paid.

2. Viper Energy Inc class B units.

No dividends paid.

3. Viper Energy Inc class A.

No dividends paid.

4. Viper Energy Inc general partner.

No dividends paid.

5. Viper Energy Inc class B.

No dividends paid.

Annual Dividends:

1. Viper Energy Inc common units.

No dividends paid.

2. Viper Energy Inc class B units.

No dividends paid.

3. Viper Energy Inc class A.

No dividends paid.

4. Viper Energy Inc general partner.

No dividends paid.

5. Viper Energy Inc class B.

No dividends paid.

VIRIDIAN THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	[□] 2021 (revised)
--	------	------	--------------------------------

Collaboration revenue - related party	314,000	1,772,000	2,963,000
Total revenue	314,000
Research & development expenses	159,765,000 [□]	100,894,000	56,886,000
General & administrative expenses	94,999,000	35,182,000	25,805,000
Total operating expenses	254,764,000	136,076,000	82,691,000
Income (loss) from operations	(254,450,000)	(134,304,000)	(79,728,000)
Interest & other income	18,563,000	4,916,000	318,000
Interest & other expense	1,847,000	486,000	3,000
Net Income Before Tax	(237,734,000)
Tax	16,716,000
Other income (expense), net	4,430,000	315,000
Net income (loss)	(237,734,000)	(129,874,000)	(79,413,000)
Weighted average shares outstanding - basic	44,755,475	32,087,293	11,918,712
Weighted average shares outstanding - diluted	44,755,475	32,087,293	11,918,712
Year end shares outstanding	53,986,112	[□] 41,305,947	[□] 23,924,004
Net earnings (loss) per share - basic	\$(5.31)	\$(4.05)	\$(6.66)
Net earnings (loss) per share - diluted	\$(5.31)	\$(4.05)	\$(6.66)
Number of full time employees	94	[□] 86	[□] 50
Total number of employees	94
Number of common stockholders	31	^{□□} 20	^{□□} 29
EPS - Basic - excluding Extraordinary Items
Applicable to Common - Total	\$(5.31)
EPS - Diluted - excluding Extraordinary Items
Applicable to Common - Total	\$(5.31)

□ Reclassified to conform with 2022 presentation; □ Including related party expenses - research and development: \$5,619,000; □ Shares increased due to the effect of issuance of shares upon the conversion of convertible preferred shares, exercises of warrants and share options and cash under employee share purchase plan; □ Shares increased due to issuance of common stock upon conversion of convertible preferred stock, exercises of warrants and stock options, and common stock upon vesting of restricted stock units; □ As is; □ As of March 3, 2023; □ As of March 7, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):		
	2023	2022
Cash & cash equivalents	102,827,000	155,579,000
Short-term investments	374,543,000	268,971,000
Prepaid expenses & other current assets	9,006,000	6,521,000
Unbilled revenue - related party	102,000	102,000
Total current assets	486,478,000	431,173,000
Lab equipment	1,145,000	1,160,000
Laboratory & computer equipment	417,000	...
Leasehold improvements	670,000	1,113,000
Computer hardware & software	489,000	725,000
Furniture & fixtures	...	332,000
Property & equipment, gross	2,721,000	3,330,000
Less: accumulated depreciation & amortization - property & equipment	1,049,000	2,004,000
Property & equipment, net	1,672,000	1,326,000
Operating lease right-of-use asset, net	1,670,000	1,610,000
Other assets	604,000	982,000
Total assets	490,424,000	435,091,000
Accounts payable	2,239,000	14,234,000
Accrued outsourced clinical trials & preclinical studies	10,724,000	12,576,000
Accrued employee compensation & related taxes	10,513,000	4,772,000
Operating lease liability, short-term	843,000	613,000
Accrued legal fees & expenses	399,000	177,000
Accrued other professional service fees	473,000	392,000
Accrued value of liability-classified stock purchase warrants	100,000	100,000
Accrued interest payable	154,000	...
Other accrued liabilities	902,000	197,000
Accrued liabilities and other	24,108,000	...
Accrued liabilities	...	18,827,000
Current portion of deferred revenue - related party	288,000	288,000
Total current liabilities	26,635,000	33,349,000
Long-term debt, net	20,205,000	4,645,000
Deferred revenue - related party	573,000	861,000
Other liabilities	989,000	1,172,000
Total liabilities	48,402,000	40,027,000
Series B redeemable convertible preferred stock	128,281,000	...
Preferred stock	78,235,000	...
Preferred stock, series A non-voting convertible preferred stock	...	85,470,000
Preferred stock, series B non-voting convertible preferred stock	...	56,677,000
Common stock	540,000	414,000
Additional paid-in capital	960,536,000	741,067,000
Accumulated other comprehensive income (loss)	338,000	(390,000)

Retained earnings (accumulated deficit)	(725,908,000)	(488,174,000)
Total stockholders' equity	442,022,000	395,064,000
Total Equity	442,022,000	...

Recent Dividends:

1. Viridian Therapeutics Inc series A non-voting convertible preferred.

No dividends paid.

2. Viridian Therapeutics Inc series B non-voting convertible preferred.

No dividends paid.

3. Viridian Therapeutics Inc common.

No dividends paid.

Annual Dividends:

1. Viridian Therapeutics Inc series A non-voting convertible preferred.

No dividends paid.

2. Viridian Therapeutics Inc series B non-voting convertible preferred.

No dividends paid.

3. Viridian Therapeutics Inc common.

No dividends paid.

VISIUM TECHNOLOGIES INC

Earnings, 6 mos. to Dec 31 (Consol. - \$):

	2023	2022
Cost & expenses	1,639,117	995,533
Operating income	(1,639,117)	(995,533)
Interest expense	178,544	166,940
Other income (expense), net	20,654	(596,926)
Net before taxes	(1,797,007)	...
Net income	(1,797,007)	(1,759,399)
Balance for common	(2,281,467)	...
Earnings common share		
Primary	\$(0.04)	\$(0.57)
Fully Diluted	\$(0.04)	\$(0.57)
Common Shares:		
Full Diluted	57,608,052	3,085,138
Year-end	96,501,142	3,986,103

VISTAGEN THERAPEUTICS INC

Earnings, 9 mos. to Dec 31 (Consol. - \$):

	2023	2022
Total revenues	866,700	(402,900)
Cost & expenses	22,528,700	46,626,000
Operating income	(21,662,000)	(47,028,900)
Interest income	...	34,000
Net before taxes	(19,838,100)	(47,015,200)
Income taxes	2,500	5,500
Net income	(19,840,600)	(47,020,700)
Balance for common	(47,020,700)	...
Earnings common share		
Primary	\$(1.27)	\$(6.90)
Fully Diluted	\$(1.27)	\$(6.90)
Common Shares:		
Full Diluted	15,632,451	6,891,641
Year-end	27,025,209	6,897,212

VIVID SEATS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021 (revised)
Revenues	712,879,000
Revenues	712,879,000	600,274,000	443,038,000
Cost of revenues (exclusive of depreciation & amortization shown separately below)	182,184,000	140,508,000	90,617,000
Marketing & selling	274,096,000	248,375,000	181,358,000
General & administrative expenses	159,081,000	127,619,000	92,170,000
Depreciation & amortization	17,178,000	7,732,000	2,322,000
Change in fair value of contingent consideration	(998,000)	(2,065,000)	...
Income (loss) from operations	81,338,000	78,105,000	76,571,000

Interest expense - net	13,505,000	12,858,000	58,179,000
Gain (loss) on extinguishment of debt	...	(4,285,000)	(35,828,000)
Other (income) expense	3,109,000	8,227,000	(1,389,000)
Income before income taxes - U.S.	...	68,416,000	(17,859,000)
Income before income taxes - foreign	...	773,000	(966,000)
Income (loss) before income taxes	70,942,000	69,189,000	(18,825,000)
Current income taxes - U.S. federal	1,084,000	15,000	...
Current income taxes - state & local	326,000	248,000	304,000
Current - Foreign	1,250,000
Total current income tax expense (benefit)	2,660,000	263,000	304,000
Deferred income taxes - foreign	(372,000)	(1,853,000)	...
Deferred - US Federal	(38,915,000)
Deferred - State & Local	(5,572,000)
Total deferred income tax expense (benefit)	(44,859,000)	(1,853,000)	...
Income tax expense	(42,199,000)	(1,590,000)	304,000
Net Income After Extraordinary Items applicable to Common	74,536,000
Net income (loss)	113,141,000	70,779,000	(19,129,000)
Net loss attributable to Hoya Intermediate, LLC shareholders prior to reverse recapitalization	12,836,000
Net loss attributable to redeemable noncontrolling interests	(38,605,000)	(42,117,000)	3,010,000
Net income (loss) attributable to class A common stockholders	...	28,662,000	(3,283,000)
Weighted average class A shares outstanding - basic	92,678,514	80,257,247	77,498,775
Weighted average class A shares outstanding - diluted	198,877,441	198,744,381	77,498,775
Year end shares outstanding	210,100,814	200,610,774	197,291,871
Net earnings (loss) per class A share - basic	\$0.80	\$0.36	\$(0.04)
Net earnings (loss) per class A share - diluted	\$0.26	\$0.36	\$(0.04)
Full-Time Employees (Period End)	768
Total number of employees	768	575	430
Number of common stockholders	57	79	76
Comprehensive income (loss) attributable to Class A Common Stockholders	75,283,000

□ As of February 28, 2023; □ As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

2023 2022

Cash & cash equivalents	125,484,000	251,542,000
Restricted cash	6,950,000	748,000
Accounts receivables, gross	41,431,000	4,900,000
Less: write off
Accounts receivable - net	58,481,000	36,531,000
Inventory, gross	17,783,000	...
Less: inventory write down	...	(5,000,000)
Inventory - net	21,018,000	12,783,000
Recovery of future customer compensation	25,750,000	23,311,000
Prepaid expenses	8,218,000	6,032,000
Other current assets	93,000	569,000
Prepaid expenses & other current assets	34,061,000	29,912,000
Total current assets	245,994,000	331,516,000
Computer equipment	2,792,000	1,935,000
Furniture	...	1,625,000
Leasehold improvements	7,655,000	7,467,000
Furniture and Fixtures	1,705,000	...
Total property & equipment	12,152,000	11,027,000
Less: accumulated depreciation	1,996,000	596,000
Property & equipment - net	10,156,000	10,431,000
Right-of-use assets - net	9,826,000	7,859,000
Intangible assets - net	241,155,000	81,976,000
Goodwill	947,359,000	715,258,000
Other non-current assets	3,052,000	4,391,000
Deferred tax assets	85,564,000	...
Investments	6,993,000	...
Total assets	1,550,099,000	1,151,431,000
Accounts payable	257,514,000	161,312,000
Accrued marketing expense	20,828,000	26,873,000
Accrued taxes	...	542,000
Accrued customer credits	64,318,000	88,167,000
Accrued future customer compensation	33,010,000	30,181,000
Accrued contingencies	...	5,898,000
Accrued payroll	17,381,000	10,660,000
Other current liabilities	16,895,000	19,649,000
Accrued expenses & other current liabilities	...	181,970,000
Deferred revenue	34,674,000	31,983,000
Current maturities of long-term debt	3,933,000	2,750,000
Accrued expenses and other current liabilities - Balancing value	191,642,000	...
Accrued operating expenses	39,210,000	...
Operating Lease Liabilities - Current Portion/Short-Term	2,059,000	...
Accrued operating expenses - Balancing value	18,769,000	...
Total current liabilities	487,763,000	378,015,000
First lien loan	264,632,000	272,938,000
Total long-term debt, gross	...	272,938,000
Less: unamortized debt issuance costs	...	(5,290,000)
Total long-term debt, net of issuance costs	...	267,648,000
Less: Current portion-other (long-term debt)	...	2,750,000
Long-term debt - net	...	264,898,000
Long-term lease liabilities	16,215,000	14,911,000
Other liabilities	29,031,000	13,445,000
Tax Receivable Agreement liability	165,699,000	...
Total long-term liabilities	475,577,000	293,254,000
Redeemable noncontrolling interests	...	862,860,000
Class A common stock	14,000	8,000
Class B common stock	8,000	12,000
Additional paid in capital	1,096,430,000	663,908,000

Treasury stock, at cost, 97.55 shares at 0, 2022; no shares at , 202	52,586,000	...
Treasury stock	...	32,494,000
Retained earnings (accumulated deficit)	(939,596,000)	(1,014,132,000)
Accumulated other comprehensive income (loss)	747,000	...
Redeemable noncontrolling interests	481,742,000	...
Total shareholder's equity	586,759,000	(382,698,000)
Total Equity	586,759,000	...

Recent Dividends:**1. Vivid Seats Inc class A common.**

No dividends paid.

2. Vivid Seats Inc class B common.

No dividends paid.

Annual Dividends:**1. Vivid Seats Inc class A common.**

No dividends paid.

2. Vivid Seats Inc class B common.

No dividends paid.

VIVOS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021
Revenues, net	19,500	36,499	14,887
Revenues	19,500
Cost of goods sold	...	28,779	12,000
Cost of materials	...	25,536	...
Gross profit	(6,036)	7,720	2,887
Professional fees	1,606,923
Professional fees, including stock-based compensation	...	1,755,316	1,838,323
Payroll expenses	281,716	275,240	267,477
Research & development expense	732,698	343,802	286,848
General & administrative expense	165,773	151,111	112,037
Total operating expenses	2,787,110	2,525,469	2,504,685
Operating income (loss)	(2,793,146)	(2,517,749)	(2,501,798)
Interest expense	25,375
Forgiveness of debt	136,445
Gain (loss) on on debt extinguishment	...	47,588	(137,038)
Interest income	49,577
Loss on issuance of shares	(151,184)
Total non-operating income (expenses)	(101,607)	47,588	(25,968)
Net income (loss) before provision for income taxes	(2,894,753)	(2,470,161)	(2,527,766)
Net income (loss)	(2,894,753)	(2,470,161)	(2,527,766)
Weighted average shares outstanding - basic	368,805,214	351,425,912	325,851,906
Weighted average shares outstanding - diluted	368,805,214	351,425,912	325,851,906
Year end shares outstanding	387,894,033	362,541,528	343,530,678
Net income (loss) per share - basic	\$(0.01)	\$(0.01)	\$(0.01)
Net income (loss) per share - diluted	\$(0.01)	\$(0.01)	\$(0.01)
Number of full time employees	...	1	1
Total number of employees	1
Number of common stockholders	223	223	230
Basic EPS Excluding ExtraOrdinary Items	\$(0.01)

Diluted EPS Excluding ExtraOrd Items	\$(0.01)
--------------------------------------	----------	-----	-----

Reclassified to conform with 2022 presentation; Approximately: As of March 1, 2023; As of March 1, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	1,592,287	1,706,065
Accounts receivable - trade	7,000	...
Accounts receivable	...	11,000
Prepaid expenses	10,837	25,671
Total current assets	1,610,124	1,742,736
Total assets	1,610,124	1,742,736
Accounts payable & accrued expenses	245,004	81,692
Total current liabilities	245,004	81,692
Total liabilities	245,004	81,692
Preferred Stock - Redeemable - Convertible Series A	2,071	...
Preferred Stock - Redeemable - Convertible Series B	200	...
Preferred Stock - Redeemable - Convertible Series C	385	...
Series A convertible preferred stock	...	2,071
Additional paid in capital - series A convertible preferred stock	8,842,458	8,842,458
Series B convertible preferred stock	...	200
Additional paid in capital - series B convertible preferred stock	290,956	290,956
Series C convertible preferred stock	...	385
Additional paid in capital - Series C Convertible preferred stock	500,507	500,507
Common stock	387,894	362,541
Additional paid in capital - common stock	73,791,430	71,217,954
Retained earnings (accumulated deficit)	(82,450,781)	(79,556,028)
Total stockholders' equity (deficit)	1,365,120	1,661,044
Total Equity	1,365,120	...

Recent Dividends:**1. Vivos Inc common.**

No dividends paid.

2. Vivos Inc series C convertible preferred.

No dividends paid.

3. Vivos Inc series A convertible preferred.

No dividends paid.

4. Vivos Inc series B convertible preferred.

No dividends paid.

Annual Dividends:**1. Vivos Inc common.**

No dividends paid.

2. Vivos Inc series C convertible preferred.

No dividends paid.

3. Vivos Inc series A convertible preferred.

No dividends paid.

4. Vivos Inc series B convertible preferred.

No dividends paid.

WALLY WORLD MEDIA, INC**Earnings, 3 mos. to Dec 31(Consol. - \$):**

	2023	2022
Cost & expenses	504	10,448
Operating income	(504)	(10,448)
Net before taxes	(504)	(10,448)
Net income	(504)	(10,448)
Earnings common share
Common Shares:

Full Diluted	330,483,033	330,483,033
Year-end	330,483,033	330,483,033

Consolidated Balance Sheet Items, as of (\$):

Assets:	2023	2022
Current assets	1,125	1,125
Total assets	1,125	1,125
Liabilities:		
Current liabilities	92,934	92,934
Stockholders' equity	(91,809)	(91,809)
Net current assets	(91,809)	(91,809)

WB BURGERS ASIA INC

Earnings, 3 mos. to Oct 31(Consol. - \$):

	2023	2022
Total revenues	142,992	106,138
Cost & expenses	416,785	1,379,876
Operating income	(273,793)	(1,276,425)
Other income (expense), net	84,834	13,179
Foreign currency	(266,810)	2,546
Net before taxes	(455,769)	(1,263,246)
Net income	(455,769)	(1,263,246)
Earnings common share		
Common Shares:		
Full Diluted	1,876,251,800	1,049,388,026
Year-end	2,072,642,444	1,057,340,752

Consolidated Balance Sheet Items, as of (\$):

Assets:	2023	2022
Cash & equivalents	37,889	37,889
Inventories	5,294	5,294
Current assets	139,108	139,108
Net property & equip.	521,708	521,708
Total assets	963,583	963,583
Liabilities:		
Current liabilities	319,102	319,102
Stockholders' equity	644,481	644,481
Net current assets	(179,994)	(179,994)

WEARABLE HEALTH SOLUTIONS INC

Earnings, 6 mos. to Dec 31(Consol. - \$):

	2023	2022
Total revenues	269,662	414,499
Cost & expenses	670,518	1,688,120
Operating income	(407,430)	(1,279,452)
Interest income	1,500	1,500
Other income (expense), net	637,334	19,500
Net before taxes	144,133	(1,288,558)
Net income	144,133	(1,288,558)
Balance for common	209,208	209,208
Earnings common share		
Primary	\$(0.00)	\$(0.00)
Fully Diluted	\$(0.00)	\$(0.00)
Common Shares:		
Full Diluted	2,238,555,908	1,524,691,793
Year-end	1,826,705,108	1,531,592,608

WEBCO INDUSTRIES INC.

Earnings, 6 mos. to Jan 31(Consol. - \$000):

	2024	2023
Total revenues	303,822	361,901
Net Sales	303,822	361,901
Cost & expenses	294,323	344,870
Operating income	9,499	17,031
Net before taxes	7,152	13,807
Income taxes	1,727	1,865
Net income	5,425	11,943
Earnings common share		
Primary	\$6.86	\$15.68
Fully Diluted	\$6.69	\$14.97
Common Shares:		
Full Diluted	811	798
Year-end	769	769

WHERE FOOD COMES FROM INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Verification & certification service revenue	19,413,000	17,610,000	16,058,000
Product sales	4,001,000	4,364,000	3,830,000
Software & related consulting revenue	1,721,000	2,871,000	2,044,000

Total revenues	25,135,000	24,845,000	21,932,000
Costs of verification & certification services	10,986,000	9,748,000	8,402,000
Costs of products	...	2,333,000	2,441,000
Costs of software license, maintenance & support services	1,355,000
Cost of software & related consulting	2,272,000	2,296,000	1,352,000
Total costs of revenues	14,613,000	14,377,000	12,195,000
Gross profit	10,522,000	10,468,000	9,737,000
Selling, general & administrative expenses	7,825,000	7,816,000	7,434,000
Income (loss) from operations	2,697,000	2,652,000	2,303,000
Dividend income from Progressive Beef, LLC	320,000	250,000	200,000
Gain (loss) on sale of assets	...	12,000	95,000
Loan forgiveness of note payable from paycheck protection program	1,037,000
Other income, net	53,000	5,000	2,000
Gain (loss) on foreign currency exchange	(7,000)	(38,000)	(11,000)
Impairment expense	...	62,000	...
Interest expense	5,000
Interest expense	5,000	3,000	6,000
Gain (loss) on sale of property & equipment	7,000
Income (loss) before income taxes	3,065,000	2,816,000	3,620,000
Current international income taxes expense (benefit)	5,000
Current federal income taxes expense (benefit)	697,000	708,000	534,000
Current state income taxes expense (benefit)	186,000	172,000	140,000
Total current income taxes expense (benefit)	883,000	880,000	679,000
Deferred federal income taxes expense (benefit)	26,000	(50,000)	(17,000)
Deferred state income taxes expense (benefit)	4,000	(8,000)	(3,000)
Total deferred income taxes expense (benefit)	30,000	(58,000)	(20,000)
Income tax expense (benefit)	913,000	822,000	659,000
Net income (loss)	2,152,000	1,994,000	2,961,000
Weighted average shares outstanding - basic	5,485,000	5,955,000	6,098,000
Weighted average shares outstanding - diluted	5,548,000	6,035,000	6,185,000
Year end shares outstanding	5,503,000	5,775,000	6,071,000
Net income (loss) per share - basic	\$0.39	\$0.34	\$0.49
Net income (loss) per share - diluted	\$0.39	\$0.33	\$0.48
Number of full time employees	89	88	80
Number of part time employees	...	5	7
Total number of employees	89	93	87

Number of common stockholders	63	87	121
Basic EPS Excluding ExtraOrdinary Items	\$0.39
Diluted EPS Excluding ExtraOrd Items	\$0.39

□ Approximately; □ As of February 16, 2023; □ As of February 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	2,641,000	4,368,000
Accounts receivable, gross	57,128,000	2,227,000
Less: allowance for doubtful accounts	55,000,000	55,000
Accounts receivable, net of allowance	2,128,000	2,172,000
Inventories	1,109,000	888,000
Prepaid expenses & other current assets	335,000	463,000
Total current assets	6,213,000	7,891,000
Automobiles	137,000	137,000
Furniture & office equipment	579,000	582,000
Software & tools	1,466,000	1,927,000
Website development & other enhancements	189,000	189,000
Building & leasehold improvements	812,000	811,000
Property & equipment, gross	3,183,000	3,646,000
Less accumulated depreciation	2,339,000	2,648,000
Property & equipment, net	844,000	998,000
Right-of-use assets, net	2,296,000	2,607,000
Investment in Progressive Beef, LLC	...	991,000
Intangible & other assets, net	2,303,000	2,340,000
Goodwill, net	2,946,000	2,946,000
Deferred tax assets, net	493,000	523,000
Equity investments	1,191,000	...
Total assets	16,286,000	18,296,000
Accounts payable	567,000	640,000
Income & sales taxes payable	62,000	14,000
Payroll related accruals	341,000	326,000
Customer deposits	...	35,000
Professional fees & other expenses	171,000	394,000
Accrued expenses & other current liabilities	615,000	769,000
Customer deposits	41,000	...
Deferred revenue	1,485,000	1,278,000
Current portion of finance lease obligations	14,000	9,000
Current portion of operating lease obligations	298,000	341,000
Total current liabilities	2,979,000	3,037,000
Finance lease obligations, net of current portion	41,000	37,000
Operating lease obligation, net of current portion	2,447,000	2,745,000
Total liabilities	5,467,000	5,819,000
Common stock	7,000	6,000
Additional paid-in-capital	12,290,000	12,145,000
Treasury stock	11,219,000	7,263,000
Retained earnings (accumulated deficit)	9,741,000	7,589,000
Total Where Food Comes From, Inc. equity (deficit)	10,819,000	12,477,000
Total equity	10,819,000	12,477,000

□ Approximately

Recent Dividends:**1. Where Food Comes From Inc common.**

No dividends paid.

Annual Dividends:**1. Where Food Comes From Inc common.**

No dividends paid.

WILLSCOT MOBILE MINI HOLDINGS CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021 (revised)
Delivery and installation	317,117,000
New units	26,439,000
Rental units	23,141,000
Leasing	398,467,000
Leasing & services revenue: leasing	...	1,621,690,000	1,252,490,000
Leasing & services revenue: delivery & installation	...	429,152,000	321,129,000
Sales revenue: new units	...	40,338,000	46,993,000
Sales revenue: rental units	...	51,443,000	52,368,000
Modular Leasing	1,833,935,000
Modular Delivery And Installation	437,179,000
Rental units	45,524,000
New units	48,129,000
Total revenues	2,364,767,000	2,142,623,000	1,672,980,000
Costs of leasing & services: leasing	...	376,868,000	282,576,000
Costs of leasing & services: delivery & installation	...	322,636,000	267,533,000
Costs of sales: new units	...	24,011,000	31,348,000
Costs of sales: rental units	...	26,907,000	28,030,000
Depreciation of rental equipment	265,733,000	256,719,000	218,790,000
Gross profit (loss)	1,333,870,000	1,135,482,000	844,703,000
Selling, general & administrative expenses	596,090,000	567,214,000	464,278,000
Transaction costs	(15,354,000)	25,000	1,375,000
Other depreciation & amortization expenses	72,921,000	62,380,000	61,777,000
Lease impairment expense & other related charges	...	254,000	2,888,000
Restructuring costs	...	(86,000)	11,866,000
Currency gains (losses), net	(6,754,000)	(886,000)	(427,000)
Other income (expense), net	...	6,673,000	(1,715,000)
Operating income (loss)	673,459,000	511,482,000	300,377,000
Interest expense	205,040,000	146,278,000	116,358,000
Fair value gain (loss) on common stock warrant liabilities	(26,597,000)
Gain (loss) on extinguishment of debt	(5,999,000)
Income before income taxes - U.S.	...	341,412,000	137,922,000
Income before income taxes - non-U.S.	...	23,792,000	13,501,000
Income (loss) from continuing operations before income tax expense (benefit)	468,419,000	365,204,000	151,423,000
Current state income tax expense (benefit)	12,250,000	11,327,000	4,645,000
Current foreign income tax expense (benefit)	7,382,000	6,204,000	1,795,000
Deferred federal			

income tax expense (benefit)	80,698,000	63,585,000	23,707,000
Deferred state income tax expense (benefit)	27,276,000	8,917,000	(2,671,000)
Deferred foreign income tax expense (benefit)	(1,031,000)	(1,170,000)	9,052,000
Income tax expense (benefit) from continuing operations	126,575,000	88,863,000	36,528,000
Income (loss) from continuing operations	341,844,000	276,341,000	114,895,000
Income from discontinued operations before income tax	4,003,000	63,468,000	58,267,000
Gain on sale of discontinued operations	176,078,000	35,456,000	...
Income tax expense from discontinued operations	(45,468,000)	(35,725,000)	(13,018,000)
Income from discontinued operations, net of tax	134,613,000	63,199,000	45,249,000
Net income (loss)	476,457,000	339,540,000	160,144,000
Income (loss) from continuing operations attributable to WillScot Mobile Mini Holdings Corp. common shareholders	...	276,341,000	114,895,000
Income (loss) from discontinued operations attributable to WillScot Mobile Mini Holdings Corp. common shareholders	...	63,199,000	45,249,000
Net income (loss) attributable to common shareholders	...	339,540,000	160,144,000
Weighted average shares outstanding - basic	198,554,885	216,808,577	226,518,931
Weighted average shares outstanding - diluted	201,849,836	221,399,162	232,793,902
Year end shares outstanding	189,967,135	207,951,682	223,939,527
Net income (loss) per share from continuing operations - basic	\$1.72	\$1.27	\$0.51
Net income (loss) per share from discontinued operations - basic	\$0.68	\$0.30	\$0.20
Net earnings (loss) per share - basic	\$2.40	\$1.57	\$0.71
Net income (loss) per share from continuing operations - diluted	\$1.69	\$1.25	\$0.49
Net income (loss) per share from discontinued operations - diluted	\$0.67	\$0.28	\$0.20
Net earnings (loss) per share - diluted	\$2.36	\$1.53	\$0.69
Full-Time Employees (Period End)	5,000
Total number of employees	5,000	4,500	...
Number of common stockholders	...	42	...
Foreign currency			

translation adjustments	...	(44,548,000)	...
Restated to reflect the discontinued operation of Tank and Pump Solutions and UK Storage Solutions; ⁽²⁾ Approximately			
Consolidated Balance Sheet, Years Ended Dec. 31 (\$):			
	2023	2022	
Cash & cash equivalents	10,958,000	7,390,000	
Trade receivables, gross	532,786,000	466,814,000	
Less: allowance for credit losses	81,656,000	57,048,000	
Trade receivables, net of allowances for doubtful accounts	451,130,000	...	
Trade receivables, net	...	409,766,000	
Raw materials	43,071,000	38,611,000	
Work in process	4,335,000	...	
Finished units	...	2,419,000	
Inventories	47,406,000	41,030,000	
Prepaid expenses & other current assets	57,492,000	31,635,000	
Assets held for sale - current	2,110,000	31,220,000	
Total current assets	569,096,000	521,041,000	
Rental equipment, gross	4,755,443,000	4,250,416,000	
Less: accumulated depreciation	180,483,000	1,173,129,000	
Rental equipment, net	...	3,077,287,000	
Buildings & leasehold improvements	178,117,000	...	
Land, buildings, & leasehold improvements	...	174,322,000	
Vehicles & equipment	233,793,000	167,337,000	
Office furniture, fixtures & software	109,460,000	106,747,000	
Total property, plant & equipment, gross	521,370,000	448,406,000	
Less: accumulated depreciation	1,374,128,000	143,747,000	
Property, plant & equipment, net	340,887,000	304,659,000	
Operating lease assets	245,647,000	219,405,000	
Goodwill	1,176,635,000	1,011,429,000	
Intangible assets, net	419,709,000	419,125,000	
Other non-current assets	4,626,000	6,683,000	
Assets held for sale - non-current	...	268,022,000	
Value added products	204,933,000	...	
Modular space units	3,541,451,000	...	
Portable storage units	1,009,059,000	...	
Rental equipment, net - Balancing value	3,381,315,000	...	
Total long-term assets	5,568,819,000	5,306,610,000	
Total assets	6,137,915,000	5,827,651,000	
Accounts payable & accrued offering expenses	86,123,000	...	
Accounts payable	...	108,071,000	
Accrued expenses	129,621,000	110,820,000	
Accrued employee benefits	45,564,000	56,340,000	
Deferred revenue & customer deposits	...	203,793,000	
Operating lease liabilities - current	57,408,000	50,499,000	
Current portion of long-term debt	18,786,000	13,324,000	
Liabilities held for sale - current	...	19,095,000	
Deferred underwriting compensation	224,518,000	...	
Total current liabilities	562,020,000	561,942,000	
Secured notes	...	1,013,820,000	
ABL facility	...	1,988,176,000	
Finance leases	117,099,000	74,370,000	
Total debt	3,421,417,000	3,076,366,000	
Less: current portion of long-term debt	...	13,324,000	
Long-term debt	3,538,516,000	3,063,042,000	
Deferred tax liabilities	554,268,000	401,453,000	
Operating lease liabilities - non-current	187,837,000	169,618,000	
Other non-current liabilities	34,024,000	18,537,000	
Liabilities held for sale			

- non-current	47,759,000	
Total ong-term liabilities	4,314,645,000	3,700,409,000
Total liabilities	4,876,665,000	4,262,351,000
Common stock	20,000	21,000
Additional paid-in-capital	2,089,091,000	2,886,951,000
Foreign currency translation adjustment	(56,031,000)	(70,122,000)
Unrealized gains (losses) on hedging activities	3,263,000	...
Accumulated other comprehensive income (loss)	(52,768,000)	(70,122,000)
Retained earnings (accumulated deficit)	(775,093,000)	(1,251,550,000)
Total shareholders' equity (deficit)	1,261,250,000	1,565,300,000
Total equity (deficit)	1,261,250,000	...

Recent Dividends:

- WillScot Mobile Mini Holdings Corp class B common.**
No dividends paid.
- WillScot Mobile Mini Holdings Corp common.**
No dividends paid.
- WillScot Mobile Mini Holdings Corp class A ordinary shares subject to possible redemption.**
No dividends paid.
- WillScot Mobile Mini Holdings Corp class A common.**
No dividends paid.

Annual Dividends:

- WillScot Mobile Mini Holdings Corp class B common.**
No dividends paid.
- WillScot Mobile Mini Holdings Corp common.**
No dividends paid.
- WillScot Mobile Mini Holdings Corp class A ordinary shares subject to possible redemption.**
No dividends paid.
- WillScot Mobile Mini Holdings Corp class A common.**
No dividends paid.

WORKHORSE GROUP INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Total revenues	13,094,752
Sales, net of returns & allowances	13,094,752	5,023,072	(851,922)
Cost of sales	38,350,545	37,672,308	132,492,110
Gross profit (loss)	(25,255,793)	(32,649,236)	(133,344,032)
Selling, general & administrative	55,574,740	73,220,088	40,160,795
Research & development	24,467,933	23,213,540	11,610,027
Total operating expenses	80,042,673	96,433,628	51,770,822
Loss from operations	...	(129,082,864)	(185,114,854)
Interest expense, net	8,731,247	1,837,882	12,644,164
Other loss (income)	(10,000,000)	13,646,528	(225,432,884)
Income (loss) before provision (benefit) for income taxes	(124,029,713)	(117,274,218)	(423,191,902)
Current state & local income taxes	(110,524)	...	(13,159)
Total current taxes	(110,524)	...	(13,159)
Deferred federal income taxes	(21,864,569)
Deferred state & local income taxes	30,639
Total deferred taxes	(21,833,930)
Provision (benefit) for income taxes	(110,524)	...	(21,847,089)
Net income (loss)	(123,919,189)	(117,274,218)	(401,344,813)
Weighted average shares outstanding - basic	207,293,249	158,576,305	128,676,131
Weighted average shares outstanding			

- diluted	207,293,249	158,576,305	128,676,131
Year end shares outstanding	285,980,843	165,605,355 [□]	151,915,455
Net income (loss) per common share - basic	\$(0.60)	\$(0.74)	\$(3.12)
Net income (loss) per common share - diluted	\$(0.60)	\$(0.74)	\$(3.12)
Number of full time employees	298	331	221
Total number of employees	298
Number of common stockholders	150	200 ^{□□}	200 ^{□□}
Basic EPS Excluding ExtraOrdinary Items	\$(0.60)
Diluted EPS Excluding ExtraOrd Items	\$(0.60)
Impairment - Financial Investments	10,000,000

[□] Shares increased due to the effect of stock options and warrants exercised, vesting of restricted shares, and conversion of convertible notes; ^{□□} Approximately; ^{□□} As of February 1, 2023; ^{□□} As of February 1, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	25,845,915	99,276,301
Accounts and lease receivable	4,470,209	...
Accounts receivable - Balancing value	4,670,209	...
Accounts receivable	...	2,079,343
Other receivable	...	15,000,000
Raw materials	32,682,324	42,500,878
Work in process	2,892,329	25,210,131
Finished goods	18,309,829	301,645
Total inventory before inventory reserve	45,408,192	68,012,654
Less: inventory reserve	8,476,290	59,162,512
Inventory, net	...	8,850,142
Prepaid purchase	...	34,611,649
Less: prepaid purchase reserve	...	(22,163,338)
Prepaid purchase, net	...	12,448,311
Prepaid insurance	...	1,198,769
Other prepaid expenses & other current assets	...	505,401
Prepaid expenses & other current assets	8,101,162	14,152,481
Restricted cash	10,000,000	...
allowance for doubtful accounts	200,000	...
Total current assets	93,825,478	139,358,267
Buildings	12,677,544	...
Construction in progress	1,104,010	9,027,020
Land & improvements	2,130,542	875,182
Buildings & improvements	...	8,167,736
Equipment & vehicles	...	8,183,089
Tooling	23,081,818	689,286
Tooling	8,044,563	...
Property, plant & equipment, gross	47,038,477	26,942,313
Less: accumulated depreciation	9,161,522	5,441,218
Property, plant & equipment, net	37,876,955	21,501,095
Lease right-of-use assets	9,795,981	11,706,803
Other assets	4,174,800	176,310
Investment in Tropos Technologies, Inc. ("Tropos")	...	10,000,000
Other assets	176,310	...
Operating leases	5,621,181	...
Total assets	141,674,724	182,742,475
Accounts payable	12,456,272	11,891,279
Legal reserve	...	35,000,000
Compensation & related costs	2,083,808	4,967,187

Other accrued liabilities & other current liabilities	...	4,584,310
Accrued liabilities & other current liabilities	...	44,551,497
Deferred revenue, current	4,714,331	3,375,000
Warranty liability	4,862,740	2,207,674
Current portion of lease liability	1,012,428	1,285,032
Warrant liability	1,902,647	...
Duke Energy Corporation financing obligation	5,605,325	...
Current portion of convertible note, at fair value	20,180,100	...
Current portion of lease liability	3,560,612	...
Current Portion of finance lease liability	2,548,184	...
Accrued liabilities and other - Balancing value	2,778,932	...
Total current liabilities	53,282,027	63,310,482
Deferred revenue, long-term	...	2,005,000
Lease liability, long-term	5,280,526	8,840,062
Lease Liabilities - Unspecified - Long -Term	5,280,526	...
Total liabilities	58,562,553	74,155,544
Common stock	285,981	165,605
Additional paid-in capital	834,394,441	736,070,388
Retained earnings (accumulated deficit)	(751,568,251)	(627,649,062)
Total stockholders' equity (deficit)	83,112,171	108,586,931
Total Equity	83,112,171	...

Recent Dividends:

- Workhorse Group Inc common.**
No dividends paid.
 - Workhorse Group Inc series A preferred.**
No dividends paid.
 - Workhorse Group Inc mandatory redeemable series B preferred.**
No dividends paid.
- Annual Dividends:**
- Workhorse Group Inc common.**
No dividends paid.
 - Workhorse Group Inc series A preferred.**
No dividends paid.
 - Workhorse Group Inc mandatory redeemable series B preferred.**
No dividends paid.

X4 PHARMACEUTICALS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

	2023	2022	2021 (revised)
Research & development	72,017	61,058	50,647
Selling, general & administrative	35,505	27,020	24,702
Goodwill impairment	9,758
Gain on sale of nonfinancial assets	...	509	...
Total operating expenses	...	87,569	85,107
Income (loss) from operations	(107,522)	(87,569)	(85,107)
Interest income	4,582	219	10
Interest expense	5,777	3,993	3,642
Change in fair value of warrant & derivative liabilities	7,074	1,701	(366)
Other income (expense), net	554	(4,197)	426
Total other income (expense), net	6,433	(6,270)	(3,572)
Income (loss) before income taxes

- U.S.	(94,742)	(89,865)	
Income (loss) before income taxes			
- foreign (Austria)	903	1,186	
Income (loss) before provision for (benefit from) income taxes	(101,089)	(93,839)	(88,679)
Provision for (benefit from) income taxes	78	28	17
Net income (loss)	(101,167)	(93,867)	(88,696)
Deemed dividend on class B warrant price set	2,546	13,943	
Net income (loss) attributable to common stockholders	(101,167)	(96,413)	(102,639)
Weighted average shares outstanding - basic	177,812	63,526	25,749
Weighted average shares outstanding - diluted	177,812	63,526	25,749
Year end shares outstanding	167,435	121,667	28,128
Net income (loss) per share - basic	\$(0.57)	\$(1.52)	\$(3.99)
Net income (loss) per share - diluted	\$(0.57)	\$(1.52)	\$(3.99)
Number of full time employees	93	70	83
Number of common stockholders	60	66	77
EPS - Basic - excluding Extraordinary Items Applicable to Common - Total	\$(0.57)		
EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total	\$(0.57)		
Total number of employees	93		

¹ Reclassified to conform with 2022 presentation; ² Shares increased due to issuance of stock, warrants and pre-funded warrants, vesting of restricted stock units, exercise of stock options and pre-funded warrants and employee stock purchase plan; ³ Shares increased due to issuance of stock, redeemable common stock and pre-funded warrants, employee stock purchase plan, and exercise of stock options and pre-funded warrants; ⁴ As is; ⁵ As of March 1, 2023; ⁶ As of March 1, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):			
	2023	2022	
Cash & cash equivalents	99,216	121,718	
Research & development incentive receivable	562	1,152	
Prepaid expenses & other current assets	7,298	5,807	
Marketable securities	15,000		
Total current assets	122,076	128,677	
Leasehold improvements	228	228	
Furniture & fixtures	1,301	1,268	
Computer equipment	160	173	
Software	24	24	
Lab equipment	651	639	
Total property & equipment, gross	2,364	2,332	
Less: accumulated depreciation & amortization - property & equipment		1,228	
Accumulated depreciation and amortization	1,619		
Property & equipment, net	745	1,104	
Goodwill	17,351	17,351	
Right-of-use assets	5,650	7,229	
Other assets	1,436	1,225	

Total assets	147,258	155,586	
Accounts payable	8,947	7,777	
Accrued employee compensation & benefits	8,195	6,592	
Accrued external research & development expenses	2,804	3,906	
Accrued professional fees	1,195	571	
Accrued deferred financing fees		591	
Other accrued expenses		374	
Accrued other	622		
Accrued expenses	12,816	12,034	
Current portion of long-term debt		1,315	
Current portion of lease liability	1,099	1,198	
Total current liabilities	22,862	22,324	
Long-term debt		32,500	
Principal amount of long-term debt		32,500	
Debt premium (discount), net of accretion		(196)	
Cumulative accrual of end of term payments		1,315	
Less: Current portion of long-term debt		1,315	
Long-term debt, including accretion, net of discount	54,570	32,304	
Lease liabilities	2,612	3,603	
Warrant liability	15,683	23,131	
Other liabilities	432	173	
Total liabilities	96,159	81,535	
Common stock	167	122	
Additional paid-in capital	528,956	450,786	
Accumulated other comprehensive income (loss)	(119)	(119)	
Retained earnings (accumulated deficit)	(477,905)	(376,738)	
Total stockholders' equity (deficit)	51,099	74,051	
Total Equity	51,099		

Recent Dividends:

- X4 Pharmaceuticals Inc common.**
No dividends paid.
 - X4 Pharmaceuticals Inc series B convertible preferred.**
No dividends paid.
 - X4 Pharmaceuticals Inc series seed convertible preferred.**
No dividends paid.
 - X4 Pharmaceuticals Inc redeemable common.**
No dividends paid.
 - X4 Pharmaceuticals Inc series A convertible preferred.**
No dividends paid.
- Annual Dividends:**
- X4 Pharmaceuticals Inc common.**
No dividends paid.
 - X4 Pharmaceuticals Inc series B convertible preferred.**
No dividends paid.
 - X4 Pharmaceuticals Inc series seed convertible preferred.**
No dividends paid.
 - X4 Pharmaceuticals Inc redeemable common.**
No dividends paid.
 - X4 Pharmaceuticals Inc series A convertible preferred.**
No dividends paid.

XERIANT INC**Earnings, 6 mos. to Dec 31(Consol. - \$):**

	2023	2022	
Cost & expenses	658,833	1,275,004	
Operating income	(658,833)	(1,275,004)	
Other income (expense), net	(20,298)	(4,375,037)	
Gains or losses	(2,448)		
Net before taxes	(1,548,907)		
Net income	(1,548,907)	(6,111,883)	
Earnings common share			
Primary	\$	\$(0.02)	
Fully Diluted	\$	\$(0.02)	
Common Shares:			
Full Diluted	408,569,551	369,415,435	
Year-end	445,044,644	376,933,144	

XPEL INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	2021 (revised)
Product revenue	311,406,000	258,174,000	217,283,000
Service revenue	84,887,000	65,819,000	41,980,000
Total revenue	396,293,000	323,993,000	259,263,000
Cost of product sales	198,008,000	169,905,000	151,286,000
Cost of service	35,871,000	26,576,000	15,300,000
Total cost of sales	233,879,000	196,481,000	166,586,000
Gross margin (loss)	162,414,000	127,512,000	92,677,000
Sales & marketing expenses		25,367,000	18,273,000
General & administrative expenses	63,654,000	48,208,000	34,288,000
Selling, general & administrative expense	31,788,000		
Total operating expenses	95,442,000	73,575,000	52,561,000
Operating income (loss)	66,972,000	53,937,000	40,116,000
Interest expense	1,248,000	1,410,000	303,000
Foreign currency exchange gain (loss)	307,000	(562,000)	(373,000)
Income (loss) before income taxes - domestic		48,574,000	35,647,000
Income (loss) before income taxes - international		3,391,000	3,793,000
Income (loss) before income taxes	66,031,000	51,965,000	39,440,000
Current federal income tax expense (benefit)	11,104,000	9,006,000	5,051,000
Current foreign income tax expense (benefit)	1,372,000	1,025,000	1,158,000
Current state income tax expense (benefit)	1,671,000	1,036,000	664,000
Total current income tax expense (benefit)	14,147,000	11,067,000	6,873,000
Deferred federal income tax expense (benefit)	(533,000)	(196,000)	968,000
Deferred foreign income tax expense (benefit)	(354,000)	(249,000)	3,000
Deferred state income tax expense (benefit)	(29,000)	(38,000)	29,000
Total deferred income tax expense (benefit)	(916,000)	(483,000)	1,000,000
Income tax expense	13,231,000	10,584,000	7,873,000
Net income (loss)	52,800,000	41,381,000	31,567,000
Weighted average shares outstanding - basic	27,622,000	27,614,000	27,613,000
Weighted average shares outstanding - diluted	27,634,000	27,616,000	27,613,000
Year end shares outstanding	27,630,025	27,616,064	27,612,597
Net earnings (loss) per share - basic	\$1.91	\$1.50	\$1.14
Net earnings (loss) per share - diluted	\$1.91	\$1.50	\$1.14
Full-Time Employees (Period End)	1,054		
Total number of employees	1,054	818	709
Number of common stockholders	11	11	16
Foreign currency translation adjustments		(1,613,000)	656,661

Basic EPS Excluding ExtraOrdinary Items . . .	\$1.91
Diluted EPS Excluding ExtraOrd Items	\$1.91
Stockholders of the Company	53,794,000

(accumulated deficit)	168,624,000	115,824,000
Equity attributable to stockholders of the Company	179,989,000	124,722,000
Total stockholders' equity	179,989,000	124,722,000

Related party, net	236	3,611	...
Total net sales	457,433	463,292	1,014,600
Cost of products sold	381,600
Related party cost of products sold	4,200
Intangible asset amortization	26,512	26,982	86,200
Research & development	26,162	31,147	61,300
Selling, general & administrative	248,964	253,158	554,400
Restructuring	4,489	2,559	3,300

Ⓔ Reclassified to conform with 2022 presentation; Ⓕ Approximately; Ⓖ Full-time equivalent; Ⓗ As of February 28, 2023; Ⓘ As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	11,609,000	8,056,000
Accounts receivable, gross	24,111,000	14,926,000
Less: allowance for doubtful accounts	0	200,000
Accounts receivable, net	24,111,000	14,726,000
Raw materials	22,308,000	10,416,000
Work in process	6,230,000	6,756,000
Finished goods	77,971,000	63,403,000
Inventories	106,509,000	...
Inventory, net	80,575,000
Prepaid expenses & other current assets	3,529,000	3,464,000
Income tax receivable	696,000	...
Total current assets	146,454,000	106,821,000
Furniture & fixtures	3,844,000	2,667,000
Computer equipment	4,743,000	3,455,000
Vehicles	1,141,000	838,000
Equipment	5,685,000	4,728,000
Leasehold improvements	10,921,000	7,081,000
Plotters	4,315,000	2,980,000
Construction in progress	201,000	1,745,000
Total property & equipment, gross	30,850,000	23,494,000
Less accumulated depreciation	13,870,000	9,291,000
Property & equipment, net	16,980,000	14,203,000
Right-of-use lease assets	15,459,000	15,309,000
Intangible assets, net	34,905,000	29,294,000
Other non-current assets	782,000	972,000
Goodwill	37,461,000	26,763,000
Total assets	252,041,000	193,362,000
Current portion of notes payable	62,000	77,000
Current portion lease liabilities	3,966,000	3,885,000
Trade payables	24,233,000	16,689,000
Payroll liabilities	4,296,000	3,596,000
Contract liabilities	761,000	261,000
Acquisition holdback payments	868,000	191,000
Other liabilities	2,286,000	2,233,000
Accounts payable & accrued liabilities	22,970,000
Income tax payable	470,000
Accounts payable and accrued liabilities - Balancing value	32,444,000	...
Total current liabilities	27,402,000
Deferred tax liability, net	2,658,000	2,049,000
Other long-term liabilities	890,000	1,070,000
Borrowings on line of credit	26,000,000
Non-current portion of lease liabilities	12,715,000	12,119,000
Notes payable	317,000	77,000
Less: current portion	77,000
Non-current portion of notes payable	19,000,000	...
Total liabilities	72,052,000	68,640,000
Common stock	28,000	28,000
Additional paid-in-capital	12,546,000	11,073,000
Accumulated other comprehensive income (loss)	(1,209,000)	(2,203,000)
Retained earnings

Recent Dividends:

1. XPEL Inc common.

No dividends paid.

Annual Dividends:

1. XPEL Inc common.

No dividends paid.

YIJIA GROUP CORP

Earnings, 9 mos. to Jan 31(Consol. - \$):

	2024	2023
Total revenues	26,100	35,000
Cost & expenses	53,154	54,842
Operating income	(27,054)	(19,842)
Net before taxes	(27,054)	(19,842)
Net income	(27,054)	(19,842)
Earnings common share		
Common Shares:		
Full Diluted	25,012,270	5,871,250
Year-end	25,012,270	5,871,250

YINFU GOLD CORP

Earnings, 9 mos. to Dec 31(Consol. - \$):

	2023	2022
Cost & expenses	51,230	343,614
Operating income	(51,230)	(343,614)
Other income (expense), net	9,038	977
Net before taxes	(42,192)	(342,635)
Net income	(42,192)	(342,635)
Earnings common share		
Primary	\$	\$(0.17)
Fully Diluted	\$	\$(0.17)
Common Shares:		
Full Diluted	121,983,993	1,983,993
Year-end	121,983,993	1,983,993

ZEIUS INC

Earnings, 3 mos. to Dec 31(Consol. - \$):

	2023	2022
Cost & expenses	192,179	148,082
Operating income	(243,997)	(148,082)
Interest expense	45,353	25,690
Net before taxes	(289,350)	(173,772)
Net income	(289,350)	(173,772)
Earnings common share		
Common Shares:		
Full Diluted	105,515,460	105,515,460
Year-end	105,515,460	105,515,460

Consolidated Balance Sheet Items, as of (\$):

Assets:	2023
Cash & equivalents	42,327
Current assets	114,463
Net property & equip.	235,802
Total assets	1,025,265
Liabilities:	
Current liabilities	2,394,357
Stockholders' equity	(1,369,092)
Net current assets	(2,279,894)

ZIMVIE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):	2023	Ⓔ2022 (revised)	Ⓕ2021
Cost of products sold, excluding intangible asset amortization	166,819	165,960	...
Related party cost of products sold, excluding intangible asset amortization	231	3,386	...
Net sales - third party, net	457,197	459,681	1,008,800
Net sales - related party, net	5,800

related	15,195	26,587	24,100
Operating expenses	488,372	509,779	1,115,100
Operating income (loss)	(30,939)	(46,487)	(100,500)
Other income (expense), net	326	2,857	(500)
Interest expense, net	20,234	10,870	300
Income before income taxes - U.S. operations	(60,674)	(96,110)	(19,000)
Income before income taxes - foreign operations	9,827	41,610	82,300
Income (loss) before income taxes	(50,847)	(54,500)	(101,300)
Current federal income taxes provision (benefit)	1,616	(2,556)	3,500
Current state income taxes provision (benefit)	(875)	483	1,600
Current foreign income taxes provision (benefit)	5,875	16,407	10,800
Current income taxes provision (benefit)	6,616	14,334	15,900
Deferred federal income taxes provision (benefit)	(11,464)	(4,200)
Deferred state income taxes provision (benefit)	(5,127)	(1,500)
Deferred foreign income taxes provision (benefit)	(1,414)	(5,339)	(16,200)
Deferred income taxes provision (benefit)	(1,414)	(21,930)	(21,900)
Provision (benefit) for income taxes	5,202	(7,596)	(6,000)
Net income (loss)	(393,282)	(63,881)	(95,300)
Net income (loss)	(95,300)
Weighted average shares outstanding - basic	26,454	26,083	...
Weighted average shares outstanding - diluted	26,454	26,083	...
Year end shares outstanding	27,076	26,222	...
Net income (loss) per common share - basic	\$(14.87)	\$(2.45)	...
Net income (loss) per common share - diluted	\$(14.87)	\$(2.45)	...
Full-Time Employees (Period End)	2,600
Total number of employees	2,600	...	ⒺⒻ2,700
Number of common stockholders	10,900	...	ⒺⒻ12,000
Income from continuing operations	(56,049)	(46,904)	...
Loss from

discontinued operations before income taxes	(62,127)	(55,419)	...	Total current liabilities	173,614	217,309	Year end shares outstanding	640,002,580 [□]	524,231,493 [□]	364,322,883
Write-down of spine disposal group to fair value	(289,456)	Deferred income taxes	265	98,062	Net earnings (loss) per share - basic	\$(0.01)	\$(0.12)	\$(0.04)
Benefit for income taxes from discontinued operations	14,350	38,442	...	Lease liability	9,080	22,287	Net earnings (loss) per share - diluted	\$(0.01)	\$(0.12)	\$(0.04)
Discontinued operations	(337,233)	(16,977)	...	Other long-term liabilities	9,055	13,561	Number of full time employees	22	2	2
Earnings per share from continuing operations	\$(2.12)	\$(1.80)	...	Term loan	508,797	536,456	Number of part time employees	...	21	22
Earnings per share-total discontinued opers	\$(12.75)	\$(0.65)	...	Debt issuance costs	...	(4,223)	Total number of employees	22	23	24
Earnings per share from continuing operations	\$(2.12)	\$(1.80)	...	Total debt	...	532,233	Number of common stockholders	19,891	19,522 [□]	19,300 [□]
Earning per share-total discont opers - diluted	\$(12.75)	\$(0.65)	...	Non-current portion of debt	...	532,233	Foreign currency translation adjustments	...	(93,000)	...
				Noncurrent liabilities of discontinued operations	95,041	...	Basic EPS Excluding ExtraOrdinary Items	\$(0.01)
				Total liabilities	795,852	883,452	Diluted EPS Excluding ExtraOrd Items	\$(0.01)
				Common stock	271	262				
				Additional paid in capital	922,996	897,028				
				Retained earnings (accumulated deficit)	(440,814)	(47,532)				
				Accumulated other comprehensive income (loss)	(72,960)	(91,154)				
				Total stockholders' equity	409,493	758,604				
				Total equity	409,493	758,604				

[□] Restated to reflect discontinued operations; [□] 2021 and prior financial of the Spine and Dental Businesses of Zimmer Biomet Holdings, Inc.; [□] Non-consolidated; [□] As is; [□] Approximately; [□] As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):		
	2023	2022
Cash & cash equivalents	71,511	89,601 (revised)
Accounts receivable, gross	68,390	183,987
Allowance for expected credit losses	3,222	15,026
Accounts receivable, less allowance for credit losses	65,168	168,961
Related party receivable	...	8,483
Finished goods	54,456	200,098
Work in progress	20,659	21,199
Raw materials	4,485	12,557
Inventories	79,600	233,854
Prepaid expenses	...	28,359
Income tax receivable	...	7,311
Other assets	...	1,294
Prepaid expenses & other current assets	23,825	36,964
Current assets of discontinued operations	242,773	...
Total current assets	482,877	537,863
Land	...	7,235
Building & equipment	146,287	210,305
Capitalized software costs	19,626	36,881
Instruments	...	270,041
Construction in progress	8,178	16,865
Land - Gross	6,700	...
Property, plant & equipment, gross	180,791	541,327
Less: accumulated depreciation	126,624	392,888
Property, plant & equipment, net	54,167	148,439
Goodwill	262,111	259,999
Intangible assets, net	114,354	654,965
Other assets	26,747	40,790
Noncurrent assets of discontinued operations	265,089	...
Total assets	1,205,345	1,642,056
Accounts payable	27,785	43,998
Related party payable	...	13,176
Income taxes payable	2,863	14,356
License & service agreements	39,884	25,337
Salaries, wages & benefits	23,171	47,812
Lease liabilities	4,053	9,617
Accrued liabilities	...	63,013
Other current liabilities	67,108	145,779
Current liabilities of discontinued operations	75,858	...

Recent Dividends:

1. ZimVie Inc common.

No dividends paid.

Annual Dividends:

1. ZimVie Inc common.

No dividends paid.

ZIMVIE INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2023	2022
Total revenues	653,195	...
Net Sales	...	684,742
Cost & expenses	645,532	695,396
Operating income	(54,124)	(70,832)
Other income (expense), net	(372)	977
Net before taxes	(81,676)	(81,702)
Income taxes	(23,246)	(48,165)
Net income	(58,430)	(33,537)
Earnings common share		
Primary	\$(2.21)	\$(1.29)
Fully Diluted	\$(2.21)	\$(1.29)
Common Shares:		
Full Diluted	26,406	26,074
Year-end	26,534	26,088

ZION OIL & GAS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2023	2022	2021
Other	2,627,000
General & administrative expenses	5,193,000	6,243,000	7,594,000
Other expenses	...	3,092,000	3,287,000
Impairment of unproved oil & gas properties	135,000	45,615,000	...
Total general & administrative expenses	7,955,000
Income (loss) from operations	...	(54,950,000)	(10,881,000)
Gain (loss) on derivative liability	431,000
Foreign exchange gain (loss)	(4,000)	(93,000)	(31,000)
Financial income (expenses), net	2,000	(34,000)	(240,000)
Income (loss) before income taxes	(7,957,000)	(55,077,000)	(10,721,000)
Net income (loss)	(7,957,000)	(55,077,000)	(10,721,000)
Weighted average shares outstanding - basic	568,351,000	468,639,000	277,457,000
Weighted average shares outstanding - diluted	568,351,000	468,639,000	277,457,000

[□] Shares increased due to the effect of funds received from sale of DSPP units and shares; exercise of warrants; and option exercises; [□] Shares increased due to funds received from sale of DSPP units & shares & exercise of warrants, conversion of bonds, bond interest paid in shares, & options exercised; [□] Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash & cash equivalents	615,000	1,735,000
Fixed short term bank & escrow deposits - restricted	1,020,000	1,379,000
Prepaid expenses & other	515,000	600,000
Other deposits	...	483,000
Governmental receivables	18,000	267,000
Other receivables	123,000	143,000
Total current assets	2,291,000	4,607,000
Drilling costs, & other operational related costs	...	2,362,000
Capitalized salary costs	...	2,342,000
Capitalized interest costs	...	1,418,000
Legal & seismic costs, license fees & other preparation costs	...	9,728,000
Other costs	...	39,000
Drilling rig & related equipment, gross	(2,215,000)	7,736,000
Less: accumulated depreciation - drilling rig & related equipment	...	1,455,000
Drilling rig & related equipment, net	5,510,000	6,281,000
Property & equipment, gross	...	759,000
Less: accumulated depreciation-property & equipment	...	647,000
Property, Plant & Equipment - Other - Accumulated Depreciation & Impairment	686,000	...
Drilling rig and related equipment - Balancing value	7,725,000	...
Property, Plant & Equipment - Other - Net - Balancing value	760,000	...
Property & equipment at cost	5,584,000	6,393,000
Right of use lease assets	194,000	202,000
Assets held for severance benefits	475,000	424,000
Total assets	25,181,000	27,515,000
Accounts payable	777,000	2,147,000
Lease obligation - current	167,000	196,000
Asset retirement obligation	571,000	571,000
Accrued drilling

provisions	...	495,000
Employees related	157,000	...
Accrued employee related	...	250,000
Accrued audit & legal costs	328,000	168,000
Other accrued liabilities	...	119,000
Deferred officers' compensation - short-term	208,000	...
Insurance financing	432,000	...
Total current liabilities	2,640,000	3,946,000
Lease obligation - non-current	24,000	12,000
Provision for severance pay	499,000	457,000
Total long-term liabilities	523,000	469,000
Total liabilities	3,163,000	4,415,000
Common stock	6,400,000	5,242,000
Additional paid-in capital	302,177,000	296,460,000
Retained earnings (accumulated deficit)	(286,559,000)	(278,602,000)
Total stockholders' equity	22,018,000	23,100,000
Total Equity	22,018,000	...

Recent Dividends:**1. Zion Oil & Gas Inc common.**

No dividends paid.

Annual Dividends:**1. Zion Oil & Gas Inc common.**

No dividends paid.

ZIVO BIOSCIENCE INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2023	2022	¹ 2021 (revised)
Product and other costs	16,040
Cost of goods sold	16,040
Total revenues	27,650
General & administrative	5,897,594	6,491,704	6,694,619
Research & development	1,377,028	2,240,270	1,950,500
Total costs & expenses	7,274,622	8,731,974	8,645,119
Income (loss) from operations	(7,263,012)	(8,731,974)	(8,645,119)
Gain on forgiveness of debt & accrued interest	(439,594)	...	122,520
Interest expense - related parties	50,785	...	188,605
Interest expense	23,793	13,319	44,677
Total other income (expense)	(514,172)	(13,319)	(110,762)
Income (loss) before provision for income taxes - domestic	...	(8,745,293)	(8,755,881)
Income (loss) before provision for income taxes	(7,777,184)	(8,745,293)	(8,755,881)
Net income (loss)	(7,777,184)	(8,745,293)	(8,755,881)
Weighted average shares outstanding			
- basic	1,690,009	² 1,569,943	1,271,512
Weighted average shares outstanding			
- diluted	1,690,009	² 1,569,943	1,271,512
Year end shares outstanding	2,382,356	² 1,569,943	1,569,943
Net income (loss) per share - basic	\$(4.60)	² \$(5.58)	\$(6.90)
Net income (loss) per share - diluted	\$(4.60)	² \$(5.58)	\$(6.90)
Number of full time employees	8	8	10
Number of common stockholders	209	³ 224	⁴ 235
GROSS MARGIN	11,610

Earnings per share from continuing operations	\$(4.60)
Earnings per share from continuing operations	\$(4.60)
Total number of employees	8

¹ Restated to reflect adjustment made to revise errors made in its historical financial statements related to the valuation and expense of equity-based compensation.; ² Adjusted for 1- for -6 stock split, October 27, 2023; ³ Approximately; ⁴ As of March 1, 2023; ⁵ As of April 20, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2023	2022
Cash	274,380	1,799,263
Prepaid expenses	147,262	102,416
Accounts Receivable	3,735	...
Total current assets	425,377	1,901,679
Operating lease - right of use asset	98,280	189,282
Security deposit	32,058	32,058
Total assets	555,715	2,123,019
Accounts payable - related party	172,670	...
Accounts payable	993,090	490,670
Current portion of long-term operating lease	106,342	99,259
Convertible debentures payable	240,000	240,000
Deferred R&D obligations - participation agreements	...	525,904
Deferred R&D obligations - participation agreements related parties	...	175,427
Accrued interest	100,686	98,286
Accrued liabilities - payroll & directors fees	...	398,176
Accrued liabilities - employee bonus	1,148,770	...
Total current liabilities	2,761,558	2,027,722
Long-term operating lease, net of current portion	...	105,919
Total long-term liabilities	...	105,919
Total liabilities	2,761,558	2,133,641
Common stock	2,383	9,420
Additional paid-in capital	121,373,488	115,784,488
Retained earnings (accumulated deficit)	(123,581,714)	(115,804,530)
Total stockholders' equity (deficit)	(2,205,843)	(10,622)
Total Equity	(2,205,843)	...

Recent Dividends:**1. Zivo Bioscience Inc common.**

No dividends paid.

Annual Dividends:**1. Zivo Bioscience Inc common.**

No dividends paid.

*

MERGENT OTC UNLISTED News Reports 0895-3252 is published weekly online on Tuesdays and printed the last Friday of the month by Mergent, Inc., 444 Madison Ave., New York, NY 10022. The News Reports are part of the OTC UNLISTED Manual and provide periodic updates. Send address changes to MERGENT OTC UNLISTED, 580 Kingsley Park Drive, Fort Mill, SC 29715.

Copyright©2024 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.